<SEC-DOCUMENT>0001682852-20-000010.txt : 20200507
<SEC-HEADER>0001682852-20-000010.hdr.sgml : 20200507
<ACCEPTANCE-DATETIME>20200507160356
ACCESSION NUMBER:		0001682852-20-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200507
DATE AS OF CHANGE:		20200507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moderna, Inc.
		CENTRAL INDEX KEY:			0001682852
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				813467528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38753
		FILM NUMBER:		20856237

	BUSINESS ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6177146500

	MAIL ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Moderna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>moderna10-q3312020.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:17760cfcaef544b7b54f31033681d964,x:46d5a60915d04c1194f25b77923770e2-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:mrna="http://www.modernatx.com/20200331" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:AmendmentFlag" id="Fact-31B3957CB3FD149B37B8B8937FDA62EE-wk-Fact-31B3957CB3FD149B37B8B8937FDA62EE" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-67A1CA98180DB9A6F703B8937FD3FDBA-wk-Fact-67A1CA98180DB9A6F703B8937FD3FDBA">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-CEF44D7B60C5D837F80EB8937FCD1224-wk-Fact-CEF44D7B60C5D837F80EB8937FCD1224">Q1</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalYearFocus" id="Fact-BB833D2DCB33AFDE1757B8937FD81D3D-wk-Fact-BB833D2DCB33AFDE1757B8937FD81D3D">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:EntityCentralIndexKey" id="Fact-C4F85CF7AC1855137752B8937FCAE50A-wk-Fact-C4F85CF7AC1855137752B8937FCAE50A">0001682852</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2019Q4_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" id="Fact-AE164D7AF8FFECDE0D04B8937FF7BF3C-wk-Fact-AE164D7AF8FFECDE0D04B8937FF7BF3C">243000000</ix:nonFraction><ix:nonNumeric contextRef="D2015Q4Dec31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod" id="Fact-2ADE5F30DEC8C5F1D44BB91A4211B80A-wk-Fact-2ADE5F30DEC8C5F1D44BB91A4211B80A">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q2May31Merck_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod" id="Fact-2BE76D7A2ACDD82162B7B91B8BB2D293-wk-Fact-2BE76D7A2ACDD82162B7B91B8BB2D293">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod" id="Fact-67515B79C5E8A44864C3B90888E1263E-wk-Fact-67515B79C5E8A44864C3B90888E1263E">P12M</ix:nonNumeric><ix:nonNumeric contextRef="D2017Q4Oct31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod" id="Fact-F29864B0880F6E7BB2B5B908F98C1D67-wk-Fact-F29864B0880F6E7BB2B5B908F98C1D67">P12M</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod" id="Fact-F2FDC441B2B6A540FE90B930B047EC74-wk-Fact-F2FDC441B2B6A540FE90B930B047EC74">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected" id="Fact-30FF93B66A96CECA1260B932A982A4C0-wk-Fact-30FF93B66A96CECA1260B932A982A4C0">P6M</ix:nonNumeric><ix:nonNumeric contextRef="D2015Q4Dec31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" id="Fact-E51931C93B14F13A3FE0B91A8DF6C335-wk-Fact-E51931C93B14F13A3FE0B91A8DF6C335">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="D2016Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" id="Fact-759A6C7946BAA1890DCDB931C72019BB-wk-Fact-759A6C7946BAA1890DCDB931C72019BB">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q2May31Merck_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" id="Fact-DD51807AA4B2A919C094B91C6AB15AE2-wk-Fact-DD51807AA4B2A919C094B91C6AB15AE2">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" id="Fact-48933DE20FC152D7B9E8B9302DC1089A-wk-Fact-48933DE20FC152D7B9E8B9302DC1089A">P3Y</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2019Q4_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember" name="mrna:RevenueFromGrantsCurrentFundingCapacity" id="Fact-9D5B6F2A48C784ECEF42B8937FF44315-wk-Fact-9D5B6F2A48C784ECEF42B8937FF44315">19700000</ix:nonFraction><ix:nonNumeric contextRef="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member" name="mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod" id="Fact-331C3B2E83BCB4F6E7B0B959EE0A4E3E-wk-Fact-331C3B2E83BCB4F6E7B0B959EE0A4E3E">P6M</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-66C6D930F2A12B1C0F70B8938009493D-wk-Fact-66C6D930F2A12B1C0F70B8938009493D">0.0001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-04175EA856DC4BF88E90B893800E749D-wk-Fact-04175EA856DC4BF88E90B893800E749D">0.0001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-D77088086B1ABDD53A64B893800922C2-wk-Fact-D77088086B1ABDD53A64B893800922C2">1600000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesAuthorized" id="Fact-BA919DF4BDFFD4C56636B893800DEE39-wk-Fact-BA919DF4BDFFD4C56636B893800DEE39">1600000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-CE94331CFA137CD5A9B3B89380123AFE-wk-Fact-CE94331CFA137CD5A9B3B89380123AFE">336536985</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesIssued" id="Fact-762C3359AAB42FD26C6AB8938008D420-wk-Fact-762C3359AAB42FD26C6AB8938008D420">370102805</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-1F64D099C01CD649037AB89380108271-wk-Fact-1F64D099C01CD649037AB89380108271">336536985</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesOutstanding" id="Fact-61C93BD998EFEBF06F40B893800C3972-wk-Fact-61C93BD998EFEBF06F40B893800C3972">370102805</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" name="us-gaap:ContractWithCustomerLiability" id="Fact-71995AEA8D55E9171452B8937FF128D9-wk-Fact-71995AEA8D55E9171452B8937FF128D9">0</ix:nonFraction><ix:nonNumeric contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-20F64D1B7CBAEBE77C96B983BB638A00-wk-Fact-20F64D1B7CBAEBE77C96B983BB638A00">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="I2015Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact-3BD6DCAD174C4D0A0B7EB982AA5C515A-wk-Fact-3BD6DCAD174C4D0A0B7EB982AA5C515A">P6Y</ix:nonNumeric><ix:nonNumeric contextRef="I2017Q2Apr30_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_LandAdjacentToNorwoodMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact-3637C2CFFD9424D4B480B9837E07CDE2-wk-Fact-3637C2CFFD9424D4B480B9837E07CDE2">P35Y</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q1YTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-66752301688B0DE17B93B8937FD96B17-wk-Fact-66752301688B0DE17B93B8937FD96B17">540000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q1YTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-1CE20C57408CDFCA47CAB8937FD99274-wk-Fact-1CE20C57408CDFCA47CAB8937FD99274">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q1YTD" name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact-3CF32CA797658B19E0D5B8AFD4E65652-wk-Fact-3CF32CA797658B19E0D5B8AFD4E65652">1108000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-C93697D4C8EA59183EDFB893800F07DB-wk-Fact-C93697D4C8EA59183EDFB893800F07DB">0.0001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-ED4FC7F2EB2F1268DE99B893800E9EE5-wk-Fact-ED4FC7F2EB2F1268DE99B893800E9EE5">0.0001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-57EE37F22F9BE97E99A2B893800F4C99-wk-Fact-57EE37F22F9BE97E99A2B893800F4C99">162000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-17927E649323BF4555BBB893800DE19F-wk-Fact-17927E649323BF4555BBB893800DE19F">162000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-0D0F7B4CB610979C09FCB893800C1EB9-wk-Fact-0D0F7B4CB610979C09FCB893800C1EB9">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesIssued" id="Fact-B203F3741A79C8A3736EB8938011A20E-wk-Fact-B203F3741A79C8A3736EB8938011A20E">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-2E1B62FE052983734293B893800A6784-wk-Fact-2E1B62FE052983734293B893800A6784">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-E6EA1290E67EDE6CD90CB8938008B8CC-wk-Fact-E6EA1290E67EDE6CD90CB8938008B8CC">0</ix:nonFraction><ix:nonNumeric contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Fact-C9B4B7CDE5A93FC60529CBE482A9CACA-wk-Fact-C9B4B7CDE5A93FC60529CBE482A9CACA">P8Y9M</ix:nonNumeric><ix:nonNumeric contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2028-01-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Fact-65B7E827A4605E09C871CBE4A8BA8558-wk-Fact-65B7E827A4605E09C871CBE4A8BA8558">P9M</ix:nonNumeric><ix:nonNumeric contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Fact-41E277A6D1789753DA03CBE70B32F551-wk-Fact-41E277A6D1789753DA03CBE70B32F551">P3Y9M</ix:nonNumeric><ix:nonNumeric contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Fact-6D3EF974EBB69D3E7835CBE7F0126CF8-wk-Fact-6D3EF974EBB69D3E7835CBE7F0126CF8">P1Y6M</ix:nonNumeric><ix:nonNumeric contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Fact-94D33FF9A3F2E9C07077CBE62F52B109-wk-Fact-94D33FF9A3F2E9C07077CBE62F52B109">P4Y9M</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" name="us-gaap:Revenues" id="Fact-EF9CF300F2C43F439459B8937FF0012E-wk-Fact-EF9CF300F2C43F439459B8937FF0012E">0</ix:nonFraction><ix:nonNumeric contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-1DC140A9B67101BC0130B95A3DD482B0-wk-Fact-1DC140A9B67101BC0130B95A3DD482B0">P4Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mrna-20200331.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2April30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborativeArrangementWithRelatedPartyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborativeArrangementWithRelatedPartyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborativeArrangementWithRelatedPartyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborativeArrangementWithRelatedPartyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_MerckMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_MajorCustomersAxis_us-gaap_OtherCustomerMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_us-gaap_OtherCustomerMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_AstraZenecaMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_AstraZenecaMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_VertexMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:VertexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_VertexMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:VertexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_MerckMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ClinicalSupplyReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:ClinicalSupplyReimbursementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:RegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Jun30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_SeparateAgreementsWithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:SeparateAgreementsWithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2028-01-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ClinicalSupplyReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:ClinicalSupplyReimbursementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:VariableConsiderationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_KRASPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:KRASPerformanceObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q1Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_FixedPaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:FixedPaymentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesSubsequentProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:RegulatoryMilestonesSubsequentProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q1Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_DevelopmentMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:DevelopmentMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ResearchAndDevelopmentFundingMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:ResearchAndDevelopmentFundingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesHPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_EstimatedReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:EstimatedReimbursementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_SeparateAgreementsWithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:SeparateAgreementsWithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:VariableConsiderationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan31az_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2016StrategicAllianceWithAstraZenecaIL12Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:RegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_CommercialMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:CommercialMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan31az_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2016StrategicAllianceWithAstraZenecaIL12Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2016StrategicAllianceWithAstraZenecaIL12Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_OncologyDevelopmentTargetPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:OncologyDevelopmentTargetPerformanceObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ResearchAndDevelopmentFundingMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:ResearchAndDevelopmentFundingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_SublicenseReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:SublicenseReimbursementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_ToxicityMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:ToxicityMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May31Merck_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May31Merck_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1Jan31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_Combined2018AZAgreementPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:Combined2018AZAgreementPerformanceObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_CompetitionMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:CompetitionMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_OptionExerciseFeeMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:OptionExerciseFeeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_VEGFAProductAZD8601Member_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:VEGFAProductAZD8601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:VariableConsiderationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_PCVPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:PCVPerformanceObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_IL12PerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:IL12PerformanceObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2Jun30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_DevelopmentMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:DevelopmentMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentResearchAndDevelopmentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_SublicenseReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:SublicenseReimbursementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q4Dec31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q4Oct31_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialProjectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialProjectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialBaseAwardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialBaseAwardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Mar31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_FollowOnProjectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:FollowOnProjectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrna_RightOfUseAssetFinancingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:RightOfUseAssetFinancingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrna_RightOfUseAssetFinancingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:RightOfUseAssetFinancingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:FiveHundredTechnologySquareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:OfficeLaboratoryAndLightManufacturingSpaceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:TwoHundredTechnologySquareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:TwoHundredTechnologySquareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:TwoHundredTechnologySquareSubleaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:OfficeLaboratoryAndLightManufacturingSpaceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:FiveHundredTechnologySquareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2May_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:TwoHundredTechnologySquareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-01</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Apr30_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_LandAdjacentToNorwoodMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:LandAdjacentToNorwoodMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_mrna_ClinicalOperationsAndSupportCommitmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_us-gaap_PurchaseCommitmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_mrna_ClinicalOperationsAndSupportCommitmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-11</xbrli:startDate>
			<xbrli:endDate>2018-12-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Dec11">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-02-14</xbrli:startDate>
			<xbrli:endDate>2020-02-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Dec11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-02-14</xbrli:startDate>
			<xbrli:endDate>2020-02-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2May7">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrna_StockOptionAndGrantPlan2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndGrantPlan2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Nov30_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Nov30_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-11-30</xbrli:startDate>
			<xbrli:endDate>2018-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2May1_srt_CounterpartyNameAxis_mrna_LonzaLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:LonzaLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-05-01</xbrli:startDate>
			<xbrli:endDate>2020-05-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2April16_srt_CounterpartyNameAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="milestone">
		<xbrli:measure>mrna:milestone</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="candidate">
		<xbrli:measure>mrna:candidate</xbrli:measure>
	</xbrli:unit><xbrli:unit id="option">
		<xbrli:measure>mrna:option</xbrli:measure>
	</xbrli:unit><xbrli:unit id="campus">
		<xbrli:measure>mrna:campus</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="extension_period">
		<xbrli:measure>mrna:extension_period</xbrli:measure>
	</xbrli:unit><xbrli:unit id="USD_PER_sqft">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>utreg:sqft</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="installment">
		<xbrli:measure>mrna:installment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="contract_option">
		<xbrli:measure>mrna:contract_option</xbrli:measure>
	</xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e3051-wk-Fact-0468755339101634CF3BB893800565B3" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1742-wk-Fact-06331F9217E917C083EEB89380103D9E" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e900-wk-Fact-13B91B25EEEA209A05DDB8937FF9A56A" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e1219-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52 d8108495e748-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e1016-wk-Fact-156AE2DD85FA9D77014AB893801275AF d8093385e1160-wk-Fact-156AE2DD85FA9D77014AB893801275AF" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8086815e661-wk-Fact-16C6E45D368ABF511BFCB8937FCB92FD" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2620-wk-Fact-171B54BA2BAC4D6F68F9B89380150DE5" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8086815e786-wk-Fact-27C8D3886673A4C3D82AB8937FC91677" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8086815e701-wk-Fact-280EF1911DA26D907515B8937FE3FF22" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2396-wk-Fact-28368F1B02540394CB54B8938018EDC2" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1222-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED d8093385e2083-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e779-wk-Fact-2E84575AAA5FF3FC9F78B8937FF58F76" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e976-wk-Fact-326EE1AA525F98E1FA63B8938009353C" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e856-wk-Fact-388AA200DC25E9066B99B893800C8ED9 d8093385e963-wk-Fact-388AA200DC25E9066B99B893800C8ED9" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2508-wk-Fact-393E94D668BA5E8C9C9DB89380111236" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e3171-wk-Fact-3C6E0C87B7DA52EDD9B4B8938007040F" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e941-wk-Fact-3D792C328A7A9FAF77F0B8937FD8E780" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e740-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA d8093385e1760-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1101-wk-Fact-5061953B1C2C59733B33B8937FE3BCE5" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1385-wk-Fact-57606C3B8D696B7B20FBB8938013667B" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e936-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB d8093385e1093-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e3191-wk-Fact-63A2E5079CEFCAF5726EB89380070257" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e659-wk-Fact-66360CB5AE1A1B5E4ABEB8938010E740" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1664-wk-Fact-68DBC17D0B4E10977736B8938009AD08 d8093385e2281-wk-Fact-68DBC17D0B4E10977736B8938009AD08" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e982-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE d8093385e1824-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e737-wk-Fact-6C01246797B7AC79E810B893800D7458" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2713-wk-Fact-6E98F6850B8815FC9558B893800F1738" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1262-wk-Fact-71DFE94246E5E76A1601B8938019923C d8093385e2149-wk-Fact-71DFE94246E5E76A1601B8938019923C" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e1057-wk-Fact-794A1869F8798C775B81B893800A6DA6 d8093385e1226-wk-Fact-794A1869F8798C775B81B893800A6DA6" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1344-wk-Fact-7DA9A9CAD969006FD132B8937FD32083" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1505-wk-Fact-7ED3D5A06DA641811A58B8938000C408" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1782-wk-Fact-7EE40EC09D85242D719AB893800A84E0" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2601-wk-Fact-7FE56C026237BA76D498B8938015293D" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e698-wk-Fact-82B43048FBEE6F3672F2B89380094FF5" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2733-wk-Fact-8ABA793256C1005F3F19B8938017A9B2" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1061-wk-Fact-8DCA9BC49239FD042533B893800A53CF" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e625-wk-Fact-A1E074F942AAC9033D6DB8938016D0B6" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2269-wk-Fact-A79FC62A46F8E76F5CA7B893800694A3" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1424-wk-Fact-A9B844D9D79DFD44E64DB8937FCCC2B6" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1827-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE d8093385e2912-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e701-wk-Fact-AE09011276505A34815AB893800FEC64" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1142-wk-Fact-B07D7B9BE56744C316DDB893801A9D41" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1022-wk-Fact-B6924E34411A34ED10EAB8B337F36C45 d8093385e1888-wk-Fact-B6924E34411A34ED10EAB8B337F36C45" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1703-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA d8093385e2411-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2289-wk-Fact-C1DDD03AE10FF9404F6AB8938012E3F3" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1182-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D d8093385e2018-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e1097-wk-Fact-C8FEBDCA5C3EB990D3E0B893800044E6" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1907-wk-Fact-CAA3495CF8BB8E12C464B89380044039" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8088448e2846-wk-Fact-CBF686121BE1AC6B2904B893800EF2DD" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e895-wk-Fact-D3827E83F30C694EF76CB8937FFE759C d8093385e1028-wk-Fact-D3827E83F30C694EF76CB8937FFE759C" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1625-wk-Fact-D679BA327FBD2B556510B8938006766F" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e819-wk-Fact-D9F27C1A04B3019CC1E5B893801B938F" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1464-wk-Fact-E6AE70E1C94B7E71386EB8937FF4DA69" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e1184-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F d8093385e1359-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F d8108495e798-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8090304e1586-wk-Fact-F3F6715DB4D17F67A78FB8B4C6517497" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8086815e741-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E d8088448e2958-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e817-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B d8093385e904-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d8084779e1143-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E d8086815e584-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E d8088448e3071-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E d8090304e625-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E d8093385e1292-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E d8093385e1700-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E d8108495e662-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E" toRefs="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"></ix:relationship></ix:resources></ix:header></div><div><a id="s1F8902830C5D55D29ACAAF5EC054403C"></a></div><div style="line-height:120%;"><hr></hr></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:13pt;"><span style="font-family:inherit;font-size:13pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:13pt;"><span style="font-family:inherit;font-size:13pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Washington, DC 20549</span></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:45px;"></td><td style="width:33px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">FORM</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d8081947e473-wk-Fact-C83DB02E237D05F56895B896476AB32D" name="dei:DocumentType" contextRef="FD2020Q1YTD">10-Q</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(Mark One)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span><ix:nonNumeric id="d8081947e479-wk-Fact-A66F4159C8AD608E126FB897D2C673FF" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9746;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d8081947e489-wk-Fact-BD869D4276D587CBAC0CB8968AB5BDD3" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q1YTD" format="ixt:datemonthdayyearen">March 31, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">OR</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span><ix:nonNumeric id="d8081947e497-wk-Fact-1D529DB8C777BCBB5BB9B897EAF7403C" name="dei:DocumentTransitionReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the transition period from _ to _ </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d8081947e510-wk-Fact-A29E6E9465C0CA7C9B0CB8981E995CE5" name="dei:EntityFileNumber" contextRef="FD2020Q1YTD"><span style="font-size:8pt;font-weight:bold;">001-38753</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;"><img src="modernalogoa04.jpg" alt="modernalogoa04.jpg" style="height:48px;width:212px;"></img></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:20pt;"><span style="font-family:inherit;font-size:20pt;"><br/></span></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:20pt;"><span><ix:nonNumeric id="d8081947e522-wk-Fact-2C65740D15373F5CA078B89665D12F61" name="dei:EntityRegistrantName" contextRef="FD2020Q1YTD"><span style="font-size:20pt;font-weight:bold;">Moderna, Inc.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:20pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:348px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86px;"></td><td style="width:86px;"></td><td style="width:86px;"></td><td style="width:86px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d8081947e544-wk-Fact-80466AA04D7F29F105C2B89843F99026" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d8081947e559-wk-Fact-BDC848D908FA93066343B898527DB5C3" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q1YTD">81-3467528</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(State or Other Jurisdiction of Incorporation or Organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(IRS Employer Identification No.)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d8081947e607-wk-Fact-44AF40EDDE17C93F1717B898860D9F41" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q1YTD">200 Technology Square</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d8081947e628-wk-Fact-554F52C973909CCC7E70B8989130AAE9" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q1YTD">Cambridge,</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d8081947e633-wk-Fact-48D9EAB701CCEC87AFC3B8989CA22146" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d8081947e643-wk-Fact-281D9597368F65E84D9FB898AF0578CB" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q1YTD">02139</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Address of Principal Executive Offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d8081947e669-wk-Fact-B4B830344D58132E7F9EB898DE35D8B8" name="dei:CityAreaCode" contextRef="FD2020Q1YTD"><span style="font-size:8pt;font-weight:bold;">617</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d8081947e674-wk-Fact-7D39482D023F52BBE345B898EBB249C0" name="dei:LocalPhoneNumber" contextRef="FD2020Q1YTD"><span style="font-size:8pt;font-weight:bold;">714-6500</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:10px;text-indent:16px;"><hr></hr></div><div style="line-height:174%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Trading symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonNumeric id="d8081947e719-wk-Fact-142E03551FC21D7E8955B899A2086FBC" name="dei:Security12bTitle" contextRef="FD2020Q1YTD">Common stock, par value $0.0001 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonNumeric id="d8081947e724-wk-Fact-589E14731DCC51763A6BB899AB69AB33" name="dei:TradingSymbol" contextRef="FD2020Q1YTD">MRNA</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonNumeric id="d8081947e729-wk-Fact-85A13D3D37433DAD05ADB899B929D5C9" name="dei:SecurityExchangeName" contextRef="FD2020Q1YTD" format="ixt-sec:exchnameen">The NASDAQ Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:11pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span><ix:nonNumeric id="d8081947e736-wk-Fact-A94B41D9609FDA69EBF6B89A2204323E" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q1YTD"><span style="font-size:8pt;font-weight:bold;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">  </span><span style="font-family:Arial Unicode MS;font-size:11pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">No  </span><span style="font-family:Wingdings;font-size:8pt;">o</span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:11pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span><ix:nonNumeric id="d8081947e754-wk-Fact-D72B127D837FD4E1D447B89BC3188B02" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q1YTD"><span style="font-size:8pt;font-weight:bold;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">  </span><span style="font-family:Arial Unicode MS;font-size:11pt;">&#9746;</span><span style="font-family:Wingdings;font-size:8pt;"> </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">No  </span><span style="font-family:Wingdings;font-size:8pt;">o</span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.73789173789174%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:20%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d8081947e793-wk-Fact-DA0A59EF8BA68E157088B89AB25866CF" name="dei:EntityFilerCategory" contextRef="FD2020Q1YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accelerated filer </span><span style="font-family:Wingdings;font-size:9pt;">o</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-accelerated filer </span><span style="font-family:Wingdings;font-size:9pt;">o</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Smaller reporting company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;"><span><ix:nonNumeric id="d8081947e837-wk-Fact-1162D7176CCDE7E67ED7B89AC4174F3A" name="dei:EntitySmallBusiness" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span><ix:nonNumeric id="d8081947e883-wk-Fact-C4842980A64E6A758BD9B89ACFAD1D5A" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-family:Wingdings;font-size:8pt;">o</span></div><div style="line-height:120%;text-align:left;padding-left:26px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:26px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Yes </span><span><ix:nonNumeric id="d8081947e902-wk-Fact-4BECAF90979AC9D8C980B89B1BDBC8E7" name="dei:EntityShellCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> No  </span><span style="font-family:Wingdings;font-size:8pt;">x</span></div><div style="line-height:120%;text-align:left;padding-left:26px;font-size:8pt;"><span style="font-family:Wingdings;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;text-indent:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of April 30, 2020, there were </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8081947e916-wk-Fact-6938C49EF1D825795EDFB8937FED2585" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q2April30" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">371,223,865</ix:nonFraction></span></span><span style="font-family:inherit;font-size:8pt;"> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:10px;text-indent:16px;"><hr></hr></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s0BE5BB1BED9F5B2A9A8342D1769B5352"></a></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This Quarterly Report on Form 10-Q (&#8220;Form 10-Q&#8221;), including the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the initiation, timing, progress, results, safety and efficacy, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our activities with respect to mRNA-1273, our investigational vaccine against the novel coronavirus;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our anticipated next steps for our development candidates and investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop development candidates and investigational medicines, including by applying learnings from one program to our other programs and from one modality to our other modalities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability and the potential to successfully manufacture our drug substances, delivery vehicles, development candidates, and investigational medicines for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain and maintain regulatory approval of our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to commercialize our products, if approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the pricing and reimbursement of our investigational medicines, if approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the implementation of our business model, and strategic plans for our business, investigational medicines, and technology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our investigational medicines and technology; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory, and commercialization expertise;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">future agreements with third parties in connection with the commercialization of our investigational medicines, if approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the size and growth potential of the markets for our investigational medicines, and our ability to serve those markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our financial performance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the rate and degree of market acceptance of our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory developments in the United States and foreign countries; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></td></tr></table><div><br/></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to produce our products or investigational medicines with advantages in turnaround times or manufacturing cost;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of competing therapies that are or may become available;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to attract and retain key scientific or management personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of laws and regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments relating to our competitors and our industry; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">other risks and uncertainties, including those discussed in Part II, Item 1A - Risk Factors in this Form 10-Q.&#160;</span></div></td></tr></table><div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some cases, forward-looking statements can be identified by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a guarantee of future performance. </span></div><div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q.</span></div><div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE REGARDING COMPANY REFERENCES</span></div><div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless the context otherwise requires, the terms &#8220;Moderna,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this Form 10-Q refer to Moderna, Inc. and its consolidated subsidiaries. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s5E8F8895ABE35A32AA3ECB8C299E7B51"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13%;"></td><td style="width:80%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:left;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s28BE6DF31B485642BEAACF1EA460BB80"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Financial Statements (Unaudited)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s28BE6DF31B485642BEAACF1EA460BB80">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sA63FB7D8B1AB56EC98F40F8D93780EA4"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sA63FB7D8B1AB56EC98F40F8D93780EA4">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s962E02E35E3B5585998B23F88D0A94C9"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s962E02E35E3B5585998B23F88D0A94C9">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sE400B4D4744355D89560CFB3EA1227B0"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sE400B4D4744355D89560CFB3EA1227B0">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF0572A32D02A5D9CAA8454A01E5ABDF4"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF0572A32D02A5D9CAA8454A01E5ABDF4">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sC20B8DE92FD95D2EA7909A07CECB17E1"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sC20B8DE92FD95D2EA7909A07CECB17E1">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sC31DE075E38B57F98C0119AA51019D95"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sC31DE075E38B57F98C0119AA51019D95">10</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s0E811634733F5300BB21FC9B4F2A419F"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s0E811634733F5300BB21FC9B4F2A419F">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s43DF10C1C39352A28C57B57FF08739B5"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Quantitative and Qualitative Disclosures about Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s43DF10C1C39352A28C57B57FF08739B5">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sD39B5B09E3DB5117904C4000C51E1F78"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sD39B5B09E3DB5117904C4000C51E1F78">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sDB42DFA537295D9EB9747A49DACCC6D5"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sDB42DFA537295D9EB9747A49DACCC6D5">54</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1A.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sFF88EEE533AD56FAB3E8A8E2F80D62E7"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sFF88EEE533AD56FAB3E8A8E2F80D62E7">54</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sD45DACB494825EE69911BC838F92658B"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sD45DACB494825EE69911BC838F92658B">106</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 6.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s06824821254858818E144842C4A00BF6"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s06824821254858818E144842C4A00BF6">106</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s83BED75C6D585A07988068FF7620A914"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">SIGNATURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s28BE6DF31B485642BEAACF1EA460BB80"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Financial Statements</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><a id="sA63FB7D8B1AB56EC98F40F8D93780EA4"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MODERNA, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, in thousands, except share and per share data)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e646-wk-Fact-FCB7F5C18B757531C4FAB8937FEDC285" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">391,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e665-wk-Fact-8B040FA40D5116DAE407B8937FD70BDB" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">235,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e680-wk-Fact-CB8FB7481F8D40E1FD4FB8937FCF3074" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">825,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e699-wk-Fact-09191919A1EE71CC1295B8938018B4D2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">867,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e719-wk-Fact-FF0982CD2DBEEC430E62B8937FDD8256" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e738-wk-Fact-5FFD9149C9C4CF9E83DBB8937FD0925C" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from related party</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e758-wk-Fact-A3D099AD25A18BF3EA8FB8937FC9BFD7" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e777-wk-Fact-1E12334CF0A233D4B3BAB8937FDB69A9" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e797-wk-Fact-6FD95ED13B84ACA5E3F7B8937FCE0B09" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e816-wk-Fact-AC28DA640B65E64EC4ADB8937FEF6A5A" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e836-wk-Fact-1CA23EBD37B38E581ED0B8937FD19C30" name="us-gaap:RestrictedCashCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e855-wk-Fact-89AE55DCE41D1D045F90B8937FCAD484" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e875-wk-Fact-250FC90FC48AE33B8D3EB8937FD39D11" name="us-gaap:AssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,249,936</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e894-wk-Fact-AF92B0C8F1E40690BFD9B8937FDE9D2F" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,128,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e915-wk-Fact-F5C917AC0C7426BD8416B8937FE1DC1B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">502,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e934-wk-Fact-25FC241F37F02E1E4775B8937FD7CF3B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e954-wk-Fact-558DF1603A8CCDA85CBFB8937FCD7C33" name="mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">202,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e973-wk-Fact-113458AB596CD8D5C17BB8937FEF297D" name="mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">201,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e993-wk-Fact-0DB5077D9DF77DB99501B8937FE01490" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,533</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1012-wk-Fact-78B369C60BB728FB25A9B8937FDB8A1C" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1032-wk-Fact-4172F40CBA3CC26827FBB8937FDA7E59" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1051-wk-Fact-370A45EEDD9A5B733D46B8937FD64354" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other non-current assets </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1071-wk-Fact-886F357B5FB2FC7702EDB8937FD4F5DB" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1090-wk-Fact-0F6E2379BC8B77EAC8B6B8937FDD77A8" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1115-wk-Fact-E237E9FC106061B46BEAB8937FD24F9B" name="us-gaap:Assets" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,067,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1134-wk-Fact-9D75CB92DE75992CCC7FB8937FDA7E92" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,589,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and Stockholders&#8217; Equity</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1236-wk-Fact-3D9EDDF206DEC1D71580B8937FD7938E" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,034</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1255-wk-Fact-F4776F1EE958610804CEB8937FD11FF2" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1270-wk-Fact-A6E1BF00CB70C3CAC400B8937FDEDEFE" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1289-wk-Fact-3481DE0A2E9AF9687BA2B8937FCF40F1" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,652</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1309-wk-Fact-6971641721D05ECFB977B8937FE17E3A" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1328-wk-Fact-6A7D6F0A9B406A6795A2B8937FDFB55F" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1349-wk-Fact-1921AA05B102B73D2800B8937FEE50B7" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,686</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1368-wk-Fact-3427191026EAC44A9429B8937FEDEF3A" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1388-wk-Fact-8266AB54405587AE587DB8937FE3D2BA" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1407-wk-Fact-D8C496BD2A7C06B09050B8937FDD00A9" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">143,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1427-wk-Fact-C3DA8FD9BDA45651BA26B8937FDB2AC0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1446-wk-Fact-23A642ECC8840BC9F76BB8937FCC2577" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease obligation, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1466-wk-Fact-E301DD914DA458C31061B8937FCDE2FE" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1485-wk-Fact-2DEF7B7076BAB361269FB8937FD01D5D" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">93,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease liabilities, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1505-wk-Fact-33C005D3215430FF981AB8937FEE7C36" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1524-wk-Fact-DDD0C8D2570F3206B9EFB8937FDEDECE" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other non-current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1544-wk-Fact-0E7BDA5FD9CC998E55E4B8937FEA1C59" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1563-wk-Fact-D33D02D38405ED1CBC63B8937FE26496" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1583-wk-Fact-1A96877C320CB5B8131AB8937FCB67C7" name="us-gaap:Liabilities" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">426,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1602-wk-Fact-99E9324F3D4C49E06F69B8937FE752FB" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">414,612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments and contingencies (Note 8)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1622-wk-Fact-C970E3480C87B80705D2B8937FD26887" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2020Q1" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1641-wk-Fact-934EFDD69E44174107D5B8937FD906CC" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock, par value $0.0001; 162,000,000&#160;shares authorized as of March 31, 2020</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;and December 31, 2019; no shares issued or outstanding at March 31, 2020 and </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8083825e1708-wk-Fact-96BC5E39F5B7BBD62873B8937FC91258" name="us-gaap:PreferredStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8083825e1727-wk-Fact-9C5F2E94108419117539B8937FDD978E" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 370,102,805 and 336,536,985 shares issued and outstanding as of March&#160;31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1747-wk-Fact-12EF990A36C4926A4D0EB8938019C628" name="us-gaap:CommonStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1766-wk-Fact-73414EDC06E051D2CACBB8937FEC3F66" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1787-wk-Fact-373D4239AAA4A0ED7FD1B8937FDD80E7" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,267,648</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1806-wk-Fact-94B27294A5F1D739BEEDB8937FE040E7" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,669,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive (loss) income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8083825e1826-wk-Fact-F482221C0B86B188321FB8937FD98CDB" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1846-wk-Fact-8BCCE6F43177FC7369F8B8937FD733A6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8083825e1866-wk-Fact-53CA5DED75748D323855B8937FD6BE55" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,620,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8083825e1886-wk-Fact-1C8F11ACACBB261C182CB8937FDE0A67" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,496,454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1907-wk-Fact-27485B920BFF3F513BCAB8937FD29C6E" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,640,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1926-wk-Fact-8342C7ACB3A424B72851B8937FDA096D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,174,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1951-wk-Fact-15619A8B39E6525AD2A6B8937FE5D852" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,067,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8083825e1970-wk-Fact-19B8CBB32C0113D0AB7BB8937FE39BF6" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,589,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s962E02E35E3B5585998B23F88D0A94C9"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MODERNA, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, in thousands, except share and per share data)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e606-wk-Fact-EE50BD8883124B6AD4BCB89380013503" name="us-gaap:Revenues" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e625-wk-Fact-A1E074F942AAC9033D6DB8938016D0B6" name="us-gaap:Revenues" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration revenue from related party</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e640-wk-Fact-F57182121120FB7B77E7B89380099599" name="us-gaap:Revenues" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborativeArrangementWithRelatedPartyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,270</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e659-wk-Fact-66360CB5AE1A1B5E4ABEB8938010E740" name="us-gaap:Revenues" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborativeArrangementWithRelatedPartyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e679-wk-Fact-72303648FED47CE77ED3B8938006991E" name="us-gaap:Revenues" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,932</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e698-wk-Fact-82B43048FBEE6F3672F2B89380094FF5" name="us-gaap:Revenues" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:64px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e718-wk-Fact-C45DF02DCBA131BF519AB893800B42AA" name="us-gaap:Revenues" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e737-wk-Fact-6C01246797B7AC79E810B893800D7458" name="us-gaap:Revenues" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e798-wk-Fact-A4E18F31B1C34A1F5875B8937FFE4CE0" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e817-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">130,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e837-wk-Fact-BB71746277CD54A12106B893801198AA" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e856-wk-Fact-388AA200DC25E9066B99B893800C8ED9" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:64px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e876-wk-Fact-EF8B277407C16D662C4EB8938014DFC7" name="us-gaap:OperatingExpenses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">139,251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e895-wk-Fact-D3827E83F30C694EF76CB8937FFE759C" name="us-gaap:OperatingExpenses" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e916-wk-Fact-B7A7E2794454FB32E131B893800F4911" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">130,862</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e936-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,641</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e957-wk-Fact-0F88B23A54A852EC0AA8B8937FFEA8F2" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e976-wk-Fact-326EE1AA525F98E1FA63B8938009353C" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,972</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e996-wk-Fact-A3343067282FBFA98FD6B8938003E121" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e1016-wk-Fact-156AE2DD85FA9D77014AB893801275AF" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before income taxes</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e1037-wk-Fact-62EEA85EE3E81C08B8E5B8938000C183" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">124,164</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e1057-wk-Fact-794A1869F8798C775B81B893800A6DA6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,600</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e1078-wk-Fact-9D0AD297A7A373FFB0F8B8938006AEB5" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e1097-wk-Fact-C8FEBDCA5C3EB990D3E0B893800044E6" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e1123-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">124,230</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e1143-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,576</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e1164-wk-Fact-334C08CA9FF5FC0D8533B893800D7CE7" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8084779e1184-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in net loss per share, basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e1200-wk-Fact-0B70C03E5259115FF9BDB893800E79A7" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">353,105,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8084779e1219-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">328,809,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">________</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><ix:footnote id="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></ix:footnote></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE400B4D4744355D89560CFB3EA1227B0"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MODERNA, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, in thousands)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8086815e564-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">124,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8086815e584-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized (loss) gain on available-for-sale debt securities, net of tax of $0 and $540, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8086815e641-wk-Fact-C3285AB7C5D339DFF2F9B8937FE8206D" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8086815e661-wk-Fact-16C6E45D368ABF511BFCB8937FCB92FD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: amounts recognized for net realized (gain) loss included in net loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8086815e681-wk-Fact-05907F86AECE785B47A0B8937FEAFA8A" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8086815e701-wk-Fact-280EF1911DA26D907515B8937FE3FF22" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive (loss) income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8086815e721-wk-Fact-84AE9EE8897ADE337019B8937FEB216F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8086815e741-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8086815e766-wk-Fact-9697BE40B7E20EE530DDB8937FE48CAB" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8086815e786-wk-Fact-27C8D3886673A4C3D82AB8937FC91677" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">130,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF0572A32D02A5D9CAA8454A01E5ABDF4"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MODERNA, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, in thousands except share data)</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:52%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-In</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:10px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e873-wk-Fact-9EC44F777EC711DC0CE0B8937FD77187" name="us-gaap:SharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">336,536,985</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e892-wk-Fact-170C932C3C59BB44CAE6B8937FDA79F8" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e911-wk-Fact-B44F2DB3C63B99AEE483B8937FCAB67D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,669,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e931-wk-Fact-C8AC1221151F332E579EB8937FD93243" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e950-wk-Fact-BEEF5D1E0DFC59797737B8937FDC09A7" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,496,454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e970-wk-Fact-8342C7ACB3A424B72851B8937FDA096D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,174,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from public offering of common stock, net of issuance costs of $1,108</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e986-wk-Fact-541FE5086B61AF5934B9B8AD9B0C90CD" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,263,158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1000-wk-Fact-80F968143A2457A97E11B8AD0C3012F9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1019-wk-Fact-072C1F966D5498E0028CB8AD0C29B7A4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">549,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1077-wk-Fact-56DFF93EF46E5DBDAEEDB8AD0C243508" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">549,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Vesting of restricted common stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1098-wk-Fact-233446894A4499CE83BFB8937FE427BB" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">113,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1189-wk-Fact-DB5D9261639BCA940B01B8937FFA7ECD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of options to purchase common stock, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1210-wk-Fact-0C40959079EDD148631AB8937FEB8BA4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,188,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1243-wk-Fact-BF98239AD721736452D7B89380198257" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1301-wk-Fact-1548D74B442D084282BCB8937FD2076F" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1355-wk-Fact-4C59CDD693309DBFB2DCB89380067028" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1413-wk-Fact-5771C6E1C7566D098570B8937FD41670" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized loss on marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e1487-wk-Fact-71D6D1762547D3AC1756B8937FCBECCB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e1526-wk-Fact-84AE9EE8897ADE337019B8937FEB216F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e1620-wk-Fact-2FB550F1E657CCEC59E4B8937FD43FA6" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">124,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e1640-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">124,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:10px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1662-wk-Fact-62550BDBF77BC1730BFFB8937FD14636" name="us-gaap:SharesOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">370,102,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1681-wk-Fact-C16FE33C9C4C40ACD974B8938019B548" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1700-wk-Fact-91CD1AB1389912749E29B893800461B0" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,267,648</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e1720-wk-Fact-D14662EB9BEFADBFC7DEB893801721E8" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e1740-wk-Fact-4007BD686F3B8E139F2EB8937FE4FFA8" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,620,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e1760-wk-Fact-27485B920BFF3F513BCAB8937FD29C6E" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,640,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:52%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-In</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:10px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2191-wk-Fact-25F457293E4134E54285B8938013432D" name="us-gaap:SharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">328,798,904</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2210-wk-Fact-F737D35F278423CA1F92B893800E1009" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2229-wk-Fact-109385CB5960C4776022B89380137CAF" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,538,155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e2249-wk-Fact-A762F5149650D4FDE907B893800A6D85" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e2269-wk-Fact-A79FC62A46F8E76F5CA7B893800694A3" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,006,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2289-wk-Fact-C1DDD03AE10FF9404F6AB8938012E3F3" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,530,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Vesting of restricted common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2305-wk-Fact-57338587B14A2752C816B893800251C5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">48,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2396-wk-Fact-28368F1B02540394CB54B8938018EDC2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of options to purchase common stock, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2417-wk-Fact-2E2B4ED22F6AE315B324B893800569F2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2450-wk-Fact-56133C99FD5278B908F8B893801072AD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2508-wk-Fact-393E94D668BA5E8C9C9DB89380111236" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Transition adjustment from adoption of ASC 606</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2601-wk-Fact-7FE56C026237BA76D498B8938015293D" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2620-wk-Fact-171B54BA2BAC4D6F68F9B89380150DE5" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Transition adjustment from adoption of ASC 842</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e2713-wk-Fact-6E98F6850B8815FC9558B893800F1738" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e2733-wk-Fact-8ABA793256C1005F3F19B8938017A9B2" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2788-wk-Fact-F87DFCE02C705E29892EB893800EBA28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2846-wk-Fact-CBF686121BE1AC6B2904B893800EF2DD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized gain on marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2920-wk-Fact-44258AE8048385CF22A7B893800FE8A4" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e2958-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e3051-wk-Fact-0468755339101634CF3BB893800565B3" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e3071-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:10px;text-indent:-6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e3094-wk-Fact-B11A43282055E5B4E6A6B893801007C7" name="us-gaap:SharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">328,853,340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e3113-wk-Fact-EAC1BB1E9EC00568CC00B8938004CD7A" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e3132-wk-Fact-98A6A9C4271BBDE39287B893800B2394" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,556,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e3152-wk-Fact-368452BC5E1D5B2A5D3DB893801297B8" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d8088448e3171-wk-Fact-3C6E0C87B7DA52EDD9B4B8938007040F" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,115,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d8088448e3191-wk-Fact-63A2E5079CEFCAF5726EB89380070257" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,442,325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">_______</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC20B8DE92FD95D2EA7909A07CECB17E1"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MODERNA, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited, in thousands)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e605-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">124,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e625-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e682-wk-Fact-5EDC6D9E517EE3DE39F8B893800F56C2" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e701-wk-Fact-AE09011276505A34815AB893800FEC64" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e721-wk-Fact-85174683CB181380D4DCB89380192E4A" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e740-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization/accretion of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e760-wk-Fact-5D4C8932B56EBA0C7800B89380091ABA" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e779-wk-Fact-2E84575AAA5FF3FC9F78B8937FF58F76" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss on disposal of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e800-wk-Fact-0A7B828CFB4220AE5747B8937FED5569" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e819-wk-Fact-D9F27C1A04B3019CC1E5B893801B938F" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;text-indent:-35px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes in assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e880-wk-Fact-6B2E07C1A038FBFD8481B8937FFF377B" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e900-wk-Fact-13B91B25EEEA209A05DDB8937FF9A56A" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable from related party</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e921-wk-Fact-F6473B781FD2BFACACEBB893801B75DF" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e941-wk-Fact-3D792C328A7A9FAF77F0B8937FD8E780" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e962-wk-Fact-CD40BFF2C4E9359BB9A6B8938004E2E6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e982-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Right-of-use assets, operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1002-wk-Fact-C22CAEDDA0D592892F22B8B337840B0B" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1022-wk-Fact-B6924E34411A34ED10EAB8B337F36C45" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1042-wk-Fact-A7FD8E64AF05B747F6CBB8937FE6AB20" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1061-wk-Fact-8DCA9BC49239FD042533B893800A53CF" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1081-wk-Fact-7647462909F1D691247FB8938014ABA8" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1101-wk-Fact-5061953B1C2C59733B33B8937FE3BCE5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32,557</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1122-wk-Fact-1D8F5664CB0685F31048B89380025FFE" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">474</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1142-wk-Fact-B07D7B9BE56744C316DDB893801A9D41" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1163-wk-Fact-B6A452B7DFE5FFDE7C27B8937FDCC8DE" name="mrna:OperatingLeaseLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1182-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D" name="mrna:OperatingLeaseLiabilities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:58px;text-indent:-36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1203-wk-Fact-29BE93C6EE8C822EEFEEB8937FF064FA" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1222-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1242-wk-Fact-8FEF75CF8EE749390F75B8938005094A" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">106,191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1262-wk-Fact-71DFE94246E5E76A1601B8938019923C" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">144,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Investing activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1324-wk-Fact-DFA4683EEF0C353EBC36B8938003B3B9" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">621,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1344-wk-Fact-7DA9A9CAD969006FD132B8937FD32083" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">429,517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1366-wk-Fact-9FFEC757654CA3468AA3B8938018BB38" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">269,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1385-wk-Fact-57606C3B8D696B7B20FBB8938013667B" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">403,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from sales of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1405-wk-Fact-CF7C2E9ABF9B27D26FACB89380144B69" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1424-wk-Fact-A9B844D9D79DFD44E64DB8937FCCC2B6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1444-wk-Fact-D5ECAC8178585AE824EEB89380157DB9" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1464-wk-Fact-E6AE70E1C94B7E71386EB8937FF4DA69" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,595</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1485-wk-Fact-12DA7F1560B53B426BDBB8938008E54A" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">316,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1505-wk-Fact-7ED3D5A06DA641811A58B8938000C408" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Financing activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from public offering of common stock, net of issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1567-wk-Fact-FB4A0A6CE98DF45845B3B8B4C670A49F" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">549,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1586-wk-Fact-F3F6715DB4D17F67A78FB8B4C6517497" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from issuance of common stock through equity plans, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1606-wk-Fact-1D9F4151497D23B158EBB8937FFF248E" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1625-wk-Fact-D679BA327FBD2B556510B8938006766F" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Charges to financing lease obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1645-wk-Fact-546EFC4124A64FB0CB4AB893800BA4E5" name="mrna:ChargesToFinancingLeaseLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1664-wk-Fact-68DBC17D0B4E10977736B8938009AD08" name="mrna:ChargesToFinancingLeaseLiabilities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:34px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1684-wk-Fact-ADD5F7F35202B02BFB1EB8938011043F" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">578,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1703-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1723-wk-Fact-C0EBBE777701951C30FDB8937FF51091" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">155,844</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d8090304e1742-wk-Fact-06331F9217E917C083EEB89380103D9E" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">155,734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash, cash equivalents and restricted cash, beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1763-wk-Fact-004D40751B24DABA63E6B89380001396" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247,699</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1782-wk-Fact-7EE40EC09D85242D719AB893800A84E0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">670,491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1808-wk-Fact-39EDF63C1C98DD365DFDB8937FF0B319" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">403,543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1827-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">514,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-cash investing and financing activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchases of property and equipment included in accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1888-wk-Fact-53E547EB25231CC8D531B893801A194E" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d8090304e1907-wk-Fact-CAA3495CF8BB8E12C464B89380044039" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">______</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC31DE075E38B57F98C0119AA51019D95"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MODERNA, INC.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s3E05FB375B54554FAC5DEC84F59E3C6F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-ABFD867EF8413195B0EEB8938025603B-0-wk-Fact-2F8753EEEC868E97EF07B8937FE15519" continuedAt="TextSelection-ABFD867EF8413195B0EEB8938025603B-1" escape="true">Description of the Business</ix:nonNumeric></span></div><ix:continuation id="TextSelection-ABFD867EF8413195B0EEB8938025603B-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a clinical stage biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since inception, we have incurred significant net losses. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090433e469-wk-Fact-6F1DA785E20044EC2D0CB93906AB71D9" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q1" unitRef="usd" decimals="-7" scale="9" sign="-" format="ixt:numdotdecimal">1.62</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, we anticipate that our expenses will increase significantly in connection with our ongoing activities to support our platform research, drug discovery and clinical development, infrastructure and Research Engine and Early Development Engine, digital infrastructure, creation of a portfolio of intellectual property, expansion into global markets, and administrative support.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not expect to generate significant revenue from sales of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for any of our investigational medicines, we expect to incur significant commercialization expenses. Our investigational vaccine against the novel coronavirus (mRNA-1273), which is currently in clinical trials, has been developed rapidly to respond to the global pandemic. We are expending significant efforts to further the rapid development of this potential vaccine and expect to continue to do so over the next 12 months. These efforts will require the expenditure of significant additional funds and the establishment of significant additional worldwide infrastructure and partnerships. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from potential mRNA medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs. We believe that our cash, cash equivalents, and investments as of&#160;</span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of our financial statements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our medicines, including mRNA-1273, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s1269CFD0935B5D01BACA740FCC80D887"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-0-wk-Fact-BD382E01F158C2F77594B8937FF7C8CE" continuedAt="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-1" escape="true">Summary of Basis of Presentation and Recent Accounting Standards</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-1" continuedAt="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-9F9A7C8203E185308C70B8938026E44F-0-wk-Fact-EE51011F71DAC1EB94D3B8937FF7D14F" continuedAt="TextSelection-9F9A7C8203E185308C70B8938026E44F-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2019 Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-2" continuedAt="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-3"><ix:continuation id="TextSelection-9F9A7C8203E185308C70B8938026E44F-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.</span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Accounting Policies</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are consistent with those described in our 2019 Form 10-K, except as noted within the&#160;&#8220;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</span><span style="font-family:inherit;font-size:10pt;">&#8221;&#160;section below.&#160;&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective on December 31, 2019, we lost our emerging growth company (EGC) status which accelerated the requirement of ASC 842 (Lease Accounting) adoption. As a result, we adjusted our previously reported consolidated financial statements effective January 1, 2019 in our 2019 Form 10-K, and amendments to previously filed Forms 10-Q were not required. Accordingly, our prior period condensed consolidated financial statements and information, as presented herein, have been restated to conform to the new standard. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="TextSelection-F0D59D82F6034EE3D8A2B93E9553AD48-0-wk-Fact-113B2F20B2125B99EDA4B93EB7C6B964" continuedAt="TextSelection-F0D59D82F6034EE3D8A2B93E9553AD48-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the effects of adopting ASC 842 on our condensed consolidated financial statements for the three months ended March 31, 2019&#160;(in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 842</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Previously reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e864-wk-Fact-637A021AF25C90A6986CB940F446EC1D" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">130,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e883-wk-Fact-685398ED32340730119FB940F7141F3F" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e904-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">130,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e924-wk-Fact-FA135B3F96ADD939A865B940FBD82A28" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e943-wk-Fact-5C853DE143A994F1D350B940FEAA7444" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e963-wk-Fact-388AA200DC25E9066B99B893800C8ED9" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e989-wk-Fact-59CEEE167FCBD6547B49B9410449D8E3" name="us-gaap:OperatingExpenses" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1008-wk-Fact-6713A2E67AD75EBA30FDB94106F104E5" name="us-gaap:OperatingExpenses" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1028-wk-Fact-D3827E83F30C694EF76CB8937FFE759C" name="us-gaap:OperatingExpenses" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1054-wk-Fact-B7FB2174E157D62050B8B9410C3FBD45" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1074-wk-Fact-BD42FA44BBAF4F91E1DAB9410F177BAA" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1093-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1120-wk-Fact-4993FBF2956B6C9DA5EFB941E4ACC223" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1140-wk-Fact-BC71E57885826C4C5206B941E7BF7FFD" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1160-wk-Fact-156AE2DD85FA9D77014AB893801275AF" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1187-wk-Fact-CDA17B8297A98D1C31CDB941EDC68020" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1207-wk-Fact-7B903777CCA2927DA1E9B941F084122D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1226-wk-Fact-794A1869F8798C775B81B893800A6DA6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1253-wk-Fact-438B28F55BE78C10F5C1B944B71820AB" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1273-wk-Fact-66CBEE88366206935F01B944BD408416" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1292-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1320-wk-Fact-C2CF8B4E91552BDD8389B942500239AF" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1359-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-3" continuedAt="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-4"><ix:continuation id="TextSelection-F0D59D82F6034EE3D8A2B93E9553AD48-1" continuedAt="TextSelection-AB3A8C1BA37469BBC0CEB8938027B727-0"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Previously reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 842 Adjustment during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1660-wk-Fact-438B28F55BE78C10F5C1B944B71820AB" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1680-wk-Fact-66CBEE88366206935F01B944BD408416" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1700-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1721-wk-Fact-44532D4E88F23FAF2614B9452424F10D" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,328</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1740-wk-Fact-BF1302AF6D7FAC3CD674B9466EE86AAB" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1760-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1786-wk-Fact-3BCD33BD9E260D8D614BB94537A74935" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1805-wk-Fact-65AFB73CDFA8962E7DA7B94672D92CFA" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1824-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1869-wk-Fact-BFC011B6E00D0584ADAEB9455B5C8DF0" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1888-wk-Fact-B6924E34411A34ED10EAB8B337F36C45" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e1914-wk-Fact-CB4A3D7A5098877C3D0FB94A254ED55D" name="mrna:IncreaseDecreaseInDeferredRentCredit" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1933-wk-Fact-ADB083B8162059131092B94A277A7497" name="mrna:IncreaseDecreaseInDeferredRentCredit" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e1998-wk-Fact-05DE9855FD833447E079B94581E98E48" name="mrna:OperatingLeaseLiabilities" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e2018-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D" name="mrna:OperatingLeaseLiabilities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2045-wk-Fact-8F2C1C61E79F0B566F38B94598467915" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2064-wk-Fact-C481BE262DBAD65A9AF8B94598545369" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2083-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e2109-wk-Fact-6BB4147743C79AD043F6B945B8053F80" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">143,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e2129-wk-Fact-54401B4DBB3BB8843512B945B7D722C1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e2149-wk-Fact-71DFE94246E5E76A1601B8938019923C" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">144,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charges to financing lease obligation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2262-wk-Fact-A5D94CE8121B38AB8CABB945DC54B57F" name="mrna:ChargesToFinancingLeaseLiabilities" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2281-wk-Fact-68DBC17D0B4E10977736B8938009AD08" name="mrna:ChargesToFinancingLeaseLiabilities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments on financing lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e2307-wk-Fact-D690678D8FB8901370AEB94881C53C17" name="mrna:PaymentsForLeaseFinancingObligation" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2327-wk-Fact-D8FB5789D54BE5537CA9B9488204A8C7" name="mrna:PaymentsForLeaseFinancingObligation" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by financing activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e2372-wk-Fact-48D16BD4A46EA53F60CAB945FDE7153E" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2392-wk-Fact-A0F15D95B9C3074D9410B945FDFA84E3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2411-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="TextSelection-3BB83807F9DDCC02E564B89380258F3E-0-wk-Fact-13BC02910EEE68FBD328B89380186A2D" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss includes net loss and other comprehensive (loss) income for the period. Other comprehensive (loss) income consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-21321DEA2227ECFF5F6FB8938026D219-0-wk-Fact-6D037C22BE3BCD007201B89380105C8E" escape="true"><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized&#160;Gain on Available-for-Sale Debt Securities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income, balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2526-wk-Fact-C8AC1221151F332E579EB8937FD93243" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e2541-wk-Fact-A909D74D689741B3C39BB8937FD52DFE" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss, balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8093385e2567-wk-Fact-D14662EB9BEFADBFC7DEB893801721E8" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="TextSelection-90DF67549D8561957F16B93D5F29F960-0-wk-Fact-08871AA5A37747949BD1B93DDD7936E4" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;</span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="TextSelection-6B32B1E16A28E7767950B8938026ADA6-0-wk-Fact-FD09E7BFEDA94A0C7347B8937FEBA9D5" escape="true"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-F106D1B45C609C54AEB7B893802646FF-0-wk-Fact-BDA58F892E6ED2EFA0C3B89380137ABC" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2758-wk-Fact-FCB7F5C18B757531C4FAB8937FEDC285" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">391,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2777-wk-Fact-394CCC8D4C25A361E765B8937FD03929" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">502,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2797-wk-Fact-1CA23EBD37B38E581ED0B8937FD19C30" name="us-gaap:RestrictedCashCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2816-wk-Fact-CDF34FA761328EC14D21B8937FD34105" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, non-current </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2841-wk-Fact-4172F40CBA3CC26827FBB8937FDA7E59" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2860-wk-Fact-DFF17C5DB8C7471248C6B8937FD47800" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,823</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;statements of cash flows</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2893-wk-Fact-39EDF63C1C98DD365DFDB8937FF0B319" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">403,543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8093385e2912-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">514,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-F291FF24AC6B897990A4B8938026A35B-0-wk-Fact-DF4466CC6A8BC71CE0E2B8937FF4A326" continuedAt="TextSelection-F291FF24AC6B897990A4B8938026A35B-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F291FF24AC6B897990A4B8938026A35B-1"><ix:continuation id="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-4"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.</span><span style="font-family:inherit;font-size:10pt;">  This standard changes how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. The amendments in this standard should be applied on a modified retrospective basis to all periods presented.&#160;We adopted this standard in the first quarter of 2020. Based on the composition of our investment portfolio and investment policy, the adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Topic 350): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.</span><span style="font-family:inherit;font-size:10pt;">&#160;This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). We adopted this standard in the first quarter of 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. This standard removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. This standard will be effective for us on January 1, 2021, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and disclosures upon adoption.</span></div></ix:continuation></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sC42BE2F4DA4C5086B69C171EFC66D775"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="TextSelection-38C1CF2FA6113B09B040B89380261F41-0-wk-Fact-B21AAC0EBFBDEF6F7999B8937FDB2C46" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-1" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-1" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-2"><ix:continuation id="TextSelection-AB3A8C1BA37469BBC0CEB8938027B727-0"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Collaboration Revenue by Strategic Collaborator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e587-wk-Fact-646D392203E534A7D993B8937FEEC90A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_MerckMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e606-wk-Fact-0B3484A4BAFA64DB46F4B8937FEE7FDD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_MerckMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AstraZeneca</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e626-wk-Fact-17F6BE1275DD91B32178B8937FEA4DAC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_AstraZenecaMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,270</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e645-wk-Fact-74D8BFD4C496081A8206B8937FE92A40" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_AstraZenecaMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vertex</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e670-wk-Fact-A89D2F7AC7533CB03DADB8937FE97269" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_VertexMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e689-wk-Fact-4F27FDCCFA8E7004B2EDB8937FE92E8D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_VertexMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e714-wk-Fact-78951C05862A62D12312B9042F412202" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_us-gaap_OtherCustomerMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e733-wk-Fact-D6EDFFB704B7261E7FCFB90431DBA447" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_us-gaap_OtherCustomerMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total collaboration revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e763-wk-Fact-10F0573C700FD5975884B8937FECBCF1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e782-wk-Fact-1B459A0622B6A1258B53B8937FEF27AD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="TextSelection-8F6E3BD3000261275805B893802744F7-0-wk-Fact-7FE711520D1B14027B8BB8937FEA2FA2" continuedAt="TextSelection-8F6E3BD3000261275805B893802744F7-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1025-wk-Fact-48ADE55B44DEB2442486B8937FF376E3" name="us-gaap:ContractWithCustomerAssetNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,972</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1044-wk-Fact-27DA581A7B8CABC67384B8937FF18885" name="mrna:ContractWithCustomerAssetIncreaseDuringPeriod" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8095399e1064-wk-Fact-E8195B73C75A372BC6F6B8937FF13DA4" name="mrna:ContractWithCustomerAssetDecreaseDuringPeriod" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1084-wk-Fact-B828A4899FA01EBE8C7FB8937FF3093A" name="us-gaap:ContractWithCustomerAssetNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1196-wk-Fact-4C59C3B06DA5E210A32BB8937FF09974" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">199,528</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1215-wk-Fact-B05CDA23840C03740C9DB8937FF46BE7" name="mrna:ContractWithCustomerLiabilityIncreaseDuringPeriod" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8095399e1235-wk-Fact-62B10A9445F6FEC54315B8937FF38E9C" name="mrna:ContractWithCustomerLiabilityDecreaseDuringPeriod" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1255-wk-Fact-EFDA87A74015F6F4DF53B8937FF25399" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">200,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-2" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-3"><ix:continuation id="TextSelection-8F6E3BD3000261275805B893802744F7-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue recognized in the period from:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1334-wk-Fact-C257A3F8B921D3135F13B8937FEB98A1" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied (or partially satisfied) in previous reporting periods </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1356-wk-Fact-32EDD6D7169019316638B9062F59B291" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;"> We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period is first applied to the beginning contract liability.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span><span style="font-family:inherit;font-size:10pt;"> Related to changes in estimated costs for our future performance obligations and estimated variable considerations. </span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1394-wk-Fact-E32F0A224F784655402CB8937FE7AA6B" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">278.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AstraZeneca &#8211; Strategic Alliances in Cardiovascular and Oncology</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2013 Option Agreement and Services and Collaboration Agreement</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement, the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018. We refer to these agreements in the forms that existed prior to the 2018 amendment and restatement as the 2013 AZ Agreements. Under the 2013 AZ Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. Pursuant to the 2013 AZ Agreements, AstraZeneca was responsible for all research, development and commercialization activities, while we provided specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca&#8217;s activities pursuant to an agreed upon services plan. Under the 2013 AZ Agreements, AstraZeneca could have requested we provide additional services, at AstraZeneca&#8217;s expense. Subject to customary &#8220;back-up&#8221; supply rights granted to AstraZeneca, we exclusively manufactured (or had manufactured) mRNA for all research, development and commercialization purposes under the 2013 AZ Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2013 AZ Agreements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, AstraZeneca acquired </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1419-wk-Fact-DDBDF7208B30A363AEFEB8937FD5C469" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions" contextRef="FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="option" decimals="INF" scale="0" format="ixt-sec:numwordsen">forty</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates under the 2013 AZ Agreements, AstraZeneca could have elected to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca could have then exercised one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates). If AstraZeneca did not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca&#8217;s rights to exercise an option and other rights granted under the 2013 AZ Agreements with respect to such development candidate (and related back-up candidates) would terminate, all rights to exploit such development candidate (and related back-up candidates) would be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) would be either assigned or licensed to us. Upon the earlier of termination of the 2013 AZ Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, would automatically terminate. On a target-by-target basis, we and AstraZeneca agreed to certain defined exclusivity obligations under the 2013 AZ Agreements with respect to the research, development and commercialization of mRNA medicines for such target.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1428-wk-Fact-D18D008B312C52770F03B8937FE60F26" name="us-gaap:DeferredRevenueAdditions" contextRef="D2013Q1Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">240.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Under the 2013 AZ Agreements, we were entitled to receive payments that are not related to any specific program of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1432-wk-Fact-D8595CCE768830509F9EB8937FEC3DF8" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">180.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate for the achievement of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1436-wk-Fact-514ED0301FDA8ACFEF17B8937FD34D05" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones" contextRef="FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="milestone" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> technical milestones relating to toxicity, delivery, and competition criteria. We achieved the toxicity and competition milestones in the year ended December&#160;31, 2015. The delivery milestone has expired. Under the 2013 AZ </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-3" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agreements, AstraZeneca was obligated to pay us a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1443-wk-Fact-663AC28F1028B2457C22B8937FD034A0" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee" contextRef="D2013Q1Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> option exercise fee with respect to each development candidate (and related back-up candidates) for which it exercised an option. In addition, upon AstraZeneca&#8217;s exercise of each option, we were eligible to receive certain payments contingent upon the achievement of specified clinical, regulatory, and commercial events. For any product candidate optioned by AstraZeneca, we were eligible to receive, per product candidate, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1447-wk-Fact-855460463B89F33F8FA4B8937FDA767C" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_DevelopmentMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments for achievement of development milestones, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1451-wk-Fact-3A6FAEB780B506734E8DB8937FEB63B0" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> payments for achievement of regulatory milestones, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1455-wk-Fact-D1C898F2D9294CFB04D8B8937FE1A8BB" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_CommercialMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> payments for achievement of commercial milestones. Additionally, under the 2013 AZ Agreements, we were entitled to receive, on a product-by-product basis, earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1459-wk-Fact-0528470DA4291F523EEFB8937FD05917" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" contextRef="D2013Q1Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, subject to certain reductions, with an aggregate minimum floor.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We received from AstraZeneca under the 2013 AZ Agreements an option exercise payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1468-wk-Fact-8C6F39882D57140D1B1AB8937FE113DA" name="us-gaap:DeferredRevenueAdditions" contextRef="FD2016Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (the 2016 VEGF Exercise) in the year ended December&#160;31, 2016, and a clinical milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1472-wk-Fact-FCBD1BF1AC92AC5A006DB8937FCA9DCF" name="us-gaap:DeferredRevenueAdditions" contextRef="FD2018Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_VEGFAProductAZD8601Member_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> with respect to AstraZeneca&#8217;s VEGF-A product (AZD8601) during the year ended December&#160;31, 2018, that is currently being developed in a Phase&#160;2 clinical trial in certain fields. Unless earlier terminated, the 2013 AZ Agreements would have continued until the expiration of AstraZeneca&#8217;s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party had the right to terminate the 2013 AZ Agreements upon the other party&#8217;s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca had the right to terminate the 2013 AZ Agreements for our material breach, then AstraZeneca could have elected, in lieu of terminating the 2013 AZ Agreements, in their entirety or with respect to such candidates, to have the 2013 AZ Agreements remain in effect, subject to reductions in certain payments we were eligible to receive and certain adjustments to AstraZeneca&#8217;s obligations under the 2013 AZ Agreements. AstraZeneca had the right to terminate the 2013 AZ Agreements in full, without cause, upon </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8095399e1476-wk-Fact-E266903A4A370DB902D3B8937FE3C873" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" contextRef="D2013Q1Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" format="ixt-sec:durday">90</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">-days&#8217; prior notice to us.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Strategic Alliance with AstraZeneca</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> &#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> IL-12 </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, we entered into a new Strategic Drug Development Collaboration and License Agreement, which we refer to as the 2016 AZ Agreement, with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL-12 protein.</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">The 2016 AZ Agreement initially included research activities with respect to a second discovery program. During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. For the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement, during a defined election period that commenced as of the effective date of the 2016 AZ Agreement (for the IL-12 program) and otherwise will commence on initiation of any such new discovery program, AstraZeneca may elect to participate in the clinical development of a development candidate arising under the 2016 AZ Agreement from such program. If AstraZeneca so elects (as it has for the IL-12 program), AstraZeneca will lead clinical development activities worldwide and we will be responsible for certain activities, including being solely responsible for manufacturing activities, all in accordance with an agreed upon development plan. AstraZeneca will be responsible for funding all Phase&#160;1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan), and Phase&#160;2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan) up to a defined dollar threshold. We and AstraZeneca will equally share the costs of Phase&#160;2 clinical development activities in excess of such dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and commercialization activities and instead receive tiered royalties, as described below.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and AstraZeneca will co-commercialize products in the United States in accordance with an agreed upon commercialization plan and budget, and on a product-by-product basis will equally share the U.S. profits or losses arising from such commercialization. Notwithstanding, on a product-by-product basis, prior to a specified stage of development of a given product, we have the right to elect not to participate in the further development and commercialization activities for such product. If we make such election, instead of participating in the U.S. profits and losses share with respect to such product, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2016 AZ Agreement, ranging from percentages in the mid-single digits to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1509-wk-Fact-C33C9C748DA3ACA8CD9AB8937FE8690B" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent" contextRef="D2016Q1Jan31az_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on worldwide net sales of products, subject to certain reductions with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected to not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to tiered royalties at rates ranging from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1513-wk-Fact-F58398A9AB1BF625C735B8937FE1073D" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" contextRef="D2016Q1Jan31az_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1517-wk-Fact-ED6C21CC95E2BA3B6AA9B8937FCDD786" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" contextRef="D2016Q1Jan31az_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on ex-U.S. net sales of the products, subject to certain reductions with an aggregate </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-4" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-5"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">minimum floor. Subject to customary &#8220;back-up&#8221; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. We and AstraZeneca have agreed to certain defined exclusivity obligations with each other under the 2016 AZ Agreement with respect to the development and commercialization of mRNA medicines for IL-12. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, our strategic alliance under the 2016 AZ Agreement will continue on a product-by-product basis (i)&#160;until both parties cease developing and commercializing such product without the intention to resume, if we have not elected our right not to participate in further development and commercialization of such product or (ii)&#160;on a country-by-country basis, until the end of the applicable royalty term for such product in such country, if we have elected our right not to participate in further development and commercialization of such product.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Either party may terminate the 2016 AZ Agreement upon the other party&#8217;s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2016 AZ Agreement in the event the other party challenges such party&#8217;s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2016 AZ Agreement in full or with respect to any program for scientific, technical, regulatory or commercial reasons at any time upon </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8095399e1535-wk-Fact-404BB5F0A84143D04466B8937FD6422D" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" contextRef="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" format="ixt-sec:durday">90</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; prior written notice to us. On a product-by-product basis, we have the right to terminate the 2016 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of such product for a period of </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;"> consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca&#8217;s control. On a product-by-product basis, if the 2016 AZ Agreement is terminated with respect to a given product, AstraZeneca&#8217;s rights in such product will terminate and, to the extent we terminated for AstraZeneca&#8217;s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing such product in the oncology field.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we continue developing and commercializing a given product following termination of the 2016 AZ Agreement by AstraZeneca in its discretion with respect to such product, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of such product and a high-single digit percentage of the amounts received by us from a third party in consideration of a license to such third party to exploit such product, in each case, until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2016 AZ Agreement with respect to such product prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Strategic Alliance with AstraZeneca &#8211; Relaxin</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we entered a new Collaboration and License Agreement, which we refer to as the 2017 AZ Agreement, under which AstraZeneca may clinically develop and commercialize a development candidate, now known as AZD7970, which is comprised of an mRNA construct for the relaxin protein designed by us and encapsulated in one of our proprietary lipid nanoparticles (LNP). We discovered and performed preclinical development activities for AZD7970 prior to the initiation of the strategic alliance with AstraZeneca under the 2017 AZ Agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the 2017 AZ Agreement, we will fund and be responsible for conducting preclinical development activities for AZD7970 through completion of IND-enabling GLP toxicology studies and AstraZeneca will lead pharmacological studies, each in accordance with an agreed upon discovery program plan. During a defined election period that commences as of the effective date of the 2017 AZ Agreement, AstraZeneca may elect to participate in further development and commercialization of AZD7970. Upon such election, AstraZeneca will lead clinical development activities for AZD7970 worldwide and we will be responsible for manufacturing AZD7970, certain regulatory matters and any other development activities that we agree to perform and that are set forth in an agreed upon development plan. AstraZeneca will be responsible for funding Phase&#160;1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared), and Phase&#160;2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared) up to a defined dollar threshold. Thereafter, we and AstraZeneca will equally share the costs of Phase&#160;2 clinical development activities in excess of such defined dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and co-commercialization activities and instead receive tiered royalties as described below. If the development candidate is determined to be IND-ready, and AstraZeneca does not timely elect to participate in the clinical development of AZD7970, AstraZeneca is obligated to reimburse us for certain costs we incurred in the manufacture and development of AZD7970, since execution of the 2017 AZ Agreement.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and AstraZeneca will co-commercialize AZD7970 in the United States in accordance with an agreed upon commercialization plan and budget, and will equally share U.S. profits or losses arising from such commercialization. Notwithstanding, prior to a specified </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-5" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-6"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">stage of development of AZD7970, we have the right to elect not to participate in the further development and commercialization activities for AZD7970. If we make such election, instead of participating in the U.S. profits and losses share with respect to AZD7970, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2017 AZ Agreement, ranging from percentages in the mid-single digits to the low 20s on worldwide net sales by AstraZeneca of AZD7970, subject to certain reductions, with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to receive tiered royalties at rates ranging from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1572-wk-Fact-7D5E94E90CAF9EFC7F42B8937FCF27E9" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" contextRef="D2017Q4Oct31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1576-wk-Fact-31B27E1086D2A4251EB7B8937FE30197" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" contextRef="D2017Q4Oct31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on annual ex-U.S. net sales of AZD7970, subject to certain reductions with an aggregate minimum floor. Subject to customary &#8220;back-up&#8221; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. Additionally, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2017 AZ Agreement with respect to the development and commercialization of mRNA medicines for Relaxin.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, our strategic alliance under the 2017 AZ Agreement will continue (i)&#160;until the expiration of AstraZeneca&#8217;s election period, if it does not elect to participate in the clinical development of AZD7970, (ii)&#160;until both parties cease developing and commercializing AZD7970 without the intention to resume, if we have not elected our right not to participate in further development and commercialization of AZD7970, (iii)&#160;on a country-by-country basis, until the end of the applicable royalty term for AZD7970 in such country, if we have elected our right not to participate in further development and commercialization of AZD7970 or (iv)&#160;following completion of IND-enabling studies with respect to AZD7970, if we provide AstraZeneca with written notice that we do not reasonably believe that the product is IND-ready.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Either party may terminate the 2017 AZ Agreement upon the other party&#8217;s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2017 AZ Agreement in the event the other party challenges the validity or enforceability of such party&#8217;s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2017 AZ Agreement in full for scientific, technical, regulatory or commercial reasons at any time upon </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8095399e1591-wk-Fact-161C0C3FD52DD31BF4AAB8937FE5D8F3" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" contextRef="D2017Q4Oct31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" format="ixt-sec:durday">90</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; prior written notice to us. We have the right to terminate the 2017 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of AZD7970 for a period of </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;"> consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca&#8217;s control. If AstraZeneca does not timely elect to participate in clinical development of AZD7970, or the Agreement is terminated, AstraZeneca&#8217;s rights in AZD7970 will terminate and, to the extent we terminated for AstraZeneca&#8217;s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing AZD7970 in the cardiovascular and cardiometabolic fields.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we continue developing and commercializing AZD7970 following a termination of the 2017 AZ Agreement by AstraZeneca in its discretion, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of AZD7970 and a high-single digit percentage of the amounts received by us from a third party in consideration for a license to such third party to exploit AZD7970, in each case until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2017 AZ Agreement with respect to AZD7970 prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2013 Agreements with AstraZeneca, amended and restated in 2018 </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, we entered into an Amended and Restated Option Agreement and a related Amended and Restated Services and Collaboration Agreement with AstraZeneca, or the 2018 A&amp;R Agreements, which amended and restated the 2013 AZ Agreements. Under the 2018 A&amp;R Agreements, we granted AstraZeneca certain exclusive rights and licenses to research, develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&amp;R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the 2018 A&amp;R Agreements, AstraZeneca is responsible for all research, development and commercialization activities and associated costs, while we provide specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca&#8217;s activities conducted pursuant to an agreed upon services plan. During this research and evaluation period, these research services, and manufacturing services in excess of a specified threshold, are provided at AstraZeneca&#8217;s expense, and manufacturing services below the specified threshold are provided at no additional expense to AstraZeneca. AstraZeneca may request we provide additional research and manufacturing services, at AstraZeneca&#8217;s expense, following the end of the research and </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-6" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-7"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">evaluation period. Subject to customary &#8220;back-up&#8221; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) mRNA for all research, development and commercialization purposes under the 2018 A&amp;R Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2018 A&amp;R Agreements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, and as further reflected in the 2018 A&amp;R Agreements, AstraZeneca acquired </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1629-wk-Fact-58B4278961ACA99DD384B8937FED5135" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions" contextRef="FI2018Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember" unitRef="option" decimals="INF" scale="0" format="ixt-sec:numwordsen">forty</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates, AstraZeneca may elect to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca may then exercise one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates) in certain fields. If AstraZeneca does not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca&#8217;s rights to exercise an option and other rights granted under the 2018 A&amp;R Agreements with respect to such development candidate (and related back-up candidates) will terminate, all rights to exploit such development candidate (and related back-up candidates) will be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) will be either assigned or licensed to us. Upon the earlier of termination of the 2018 A&amp;R Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, will automatically terminate.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a target-by-target basis, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2018 A&amp;R Agreements with respect to the research, development and commercialization of mRNA medicines for such target in certain fields. In addition, we and AstraZeneca have agreed to certain defined exclusivity obligations with respect to the research, development and commercialization of mRNA medicines coding for the same polypeptide as any development candidate being developed under the 2018 A&amp;R Agreements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the 2018 A&amp;R Agreements will continue until the expiration of AstraZeneca&#8217;s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party may terminate the 2018 A&amp;R Agreements upon the other party&#8217;s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca has the right to terminate the 2018 A&amp;R Agreements for our material breach, then AstraZeneca may elect, in lieu of terminating the 2018 A&amp;R Agreements, in their entirety or with respect to such candidates, to have the 2018 A&amp;R Agreements remain in effect, subject to reductions in certain payments we are eligible to receive and certain adjustments to AstraZeneca&#8217;s obligations under the 2018 A&amp;R Agreements. AstraZeneca may terminate the 2018 A&amp;R Agreements in full, without cause, upon </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8095399e1645-wk-Fact-6A20D70245CD4EF99FF9B8937FDF0174" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" contextRef="D2018Q2Jun30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember" format="ixt-sec:durday">90</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; prior notice to us.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We applied the provisions of ASC 606 (Revenue from Contracts with Customers) in accounting for these arrangements, except for the 2017 AZ Agreement which was accounted for under ASC 808 (Collaborative Arrangements). In August 2016, AstraZeneca exercised a product option available pursuant to the 2013 AZ Agreements to obtain exclusive rights to clinically develop and commercialize the VEGF-A product (AZD8601). This option exercise is referred to as the 2016 VEGF Exercise. Pursuant to ASC 606, we determined that the 2016 VEGF Exercise and the 2017 AZ Agreement should be accounted for as separate transactions as the agreements are not interrelated or interdependent. Conversely, the 2013 Agreements, as amended by the 2018 A&amp;R Agreements, and the 2016 AZ Agreement, were combined for accounting purposes and treated as a single agreement, as these agreements were negotiated in contemplation of each other. We refer to this combined transaction as the Combined 2018 AZ Agreements. We determined that all aspects of Combined 2018 AZ Agreements and the 2016 VEGF Exercise represent a transaction with a customer and therefore is accounted for in accordance with ASC 606.</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Combined 2018 AZ Agreements</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We identified the following performance obligations in the Combined 2018 AZ Agreements: (i) a combined performance obligation that includes a research license, research and development pool services, and manufacturing obligations related to the 2013 AZ Agreements, as amended by the 2018 A&amp;R Agreements, collectively referred to as the Combined 2018 AZ Agreement Performance Obligation, (ii) preclinical development services for IL-12, (iii) preclinical development services for an oncology development target, (iv) a combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12, </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-7" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-8"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and (v) a material right to receive development and commercialization rights and manufacturing services for an oncology development target.</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We concluded that the research license is not distinct from the research and development pool services or the manufacturing obligations related to the 2018 A&amp;R Agreements, as AstraZeneca cannot fully exploit the value of the research license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Any supply requested by AstraZeneca in excess of the minimum quantities specified in the agreement are considered customer options and treated as separate contracts for accounting purposes. Further, we concluded that AstraZeneca cannot exploit the value of the development and commercialization license for IL-12 without receipt of supply as the development and commercialization license does not convey to AstraZeneca the right to manufacture and therefore combined the development and commercialization license and the manufacturing obligations for IL-12 into one performance obligation.</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total transaction price was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1687-wk-Fact-C8901E75D05FB4136470B8937FE6D478" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">399.1</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1691-wk-Fact-D06EC71F8C0D0BCCCEAEB8937FCC5414" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">240.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront payments pertaining to the 2013 AZ Agreements and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1695-wk-Fact-2732109D8D858E673146B8937FE78146" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.1</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million of variable consideration comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1699-wk-Fact-82D969DC55D8A0A8CEA3B8937FDA11EB" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_EstimatedReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.1</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million of estimated reimbursement for IL-12 manufacturing obligations, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1704-wk-Fact-7CEAD9B43FC0FAFAD93AB90B532A7BA6" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_SublicenseReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of sublicense reimbursement and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1708-wk-Fact-BBFF5CFA0E121EFAB2D7B8937FE1F84F" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of milestone payments (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1712-wk-Fact-73A1E84B040A8323711DB8937FD6DDB5" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_ToxicityMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> toxicity milestone and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1716-wk-Fact-3C1DCF20DE62930D548DB8937FDBB708" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_CompetitionMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> competition milestone). We utilize the most likely amount method to determine the amount of reimbursement for IL-12 manufacturing obligations to be received. We determined that any sales-based royalties related to IL-12 will be recognized when the related sales occur as they were determined to relate predominately to the license granted and therefore have been excluded from the transaction price. In addition, we are eligible to receive future milestones and royalties on future commercial sales for optioned product candidates under the 2018 A&amp;R Agreements and future royalties under the 2016 Agreement; however, these amounts are not considered variable consideration under the Combined 2018 Agreements as we are only eligible to receive such amounts if AstraZeneca exercises its options (including certain options that are deemed to be material rights). We have concluded that the exercise of an optioned product candidate represents a separate transaction under ASC 606. We re-evaluate the transaction price at the end of each reporting period. There was a $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1720-wk-Fact-7D991998C182578BB705B8937FDEDC0E" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million decrease to the transaction price during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, resulting from a change in estimate of variable consideration. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. We developed the estimated standalone selling price for the licenses included in the Combined 2018 AZ Agreement Performance Obligation and the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12 primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the performance obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The estimated standalone selling price of the material right to receive development and commercialization rights and manufacturing services for an oncology development target was developed by estimating the amount of discount that AstraZeneca would receive when exercising the option and adjusting such amount by the likelihood that the option will be exercised.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to each performance obligation is as follows: (i) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1743-wk-Fact-BA006375B8B55183A31EB8937FE23D5C" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_Combined2018AZAgreementPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">293.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Combined 2018 AZ Agreement Performance Obligation, (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1747-wk-Fact-E673D9E2DD23120EAF6AB8937FDBC43C" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_IL12PerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the preclinical development services for IL-12 performance obligation, (iii) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1751-wk-Fact-1A092AC54781E6958094B8937FEEBF3B" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_OncologyDevelopmentTargetPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the preclinical development services for an oncology development target performance obligation, (iv) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1755-wk-Fact-6EF0AD86F675D707CAFDB8937FE5A2C3" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12, and (v) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1760-wk-Fact-3440B26C1857FFCE9FA8B8937FCDE082" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the material right to receive development and commercialization rights and manufacturing services for an oncology development target. As part of the allocation of the transaction price to each of the performance obligations, we concluded that the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1764-wk-Fact-73A1E84B040A8323711DB8937FD6DDB5" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_ToxicityMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> toxicity milestone and the estimated reimbursement for IL-12 manufacturing costs can be allocated entirely to specific performance obligations because the variable payment relates specifically to our effort to satisfy the performance obligation and such allocation is consistent with the allocation objectives of ASC 606.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the Combined 2018 AZ Agreement Performance Obligation and the preclinical development services for IL-12 and the other oncology target performance obligations. We recognize revenue related to the amounts allocated to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12 based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-8" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-9"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue for the Combined 2018 AZ Agreement Performance Obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to this combined performance obligation. We also estimate the development plan, including expected demand from AstraZeneca, and the associated costs for this combined performance obligation, as we will satisfy this combined performance obligation as the manufacturing services are performed.&#160;Management has applied significant judgment in the process of developing our budget estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1792-wk-Fact-DF0639800F167A4D2B8CB8937FECCD17" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1796-wk-Fact-40E6A1B23FDA8D7CDC54B8937FD983CF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from the Combined 2018 AZ Agreements. The revenue recognized for the three months ended March&#160;31, 2020 includes the amortization of deferred revenue due to the satisfaction of our performance obligation during the period, offset by a cumulative catch-up adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1800-wk-Fact-715E6B3636E002D47A8EB91258C41124" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> due to changes in estimated costs for our future performance obligations. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1809-wk-Fact-782F8254F50C0A051928B8937FE95171" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1813-wk-Fact-B5AFE9DFFBE1B603CB68B8937FDF15C6" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is expected to be recognized as revenue through December&#160;31, 2029 and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1817-wk-Fact-1AED75941B2F6C6AD0E9B8937FE6383F" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2028-01-01" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is expected to be recognized as revenue at the earlier of expiration or modification of the Combined 2018 AZ Agreement. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1821-wk-Fact-B06F1AE95F822C67F853B8937FD7E690" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">72.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1825-wk-Fact-E7121FEE29888736E0A5B8937FD88DA5" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">73.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, from the Combined 2018 AZ Agreements, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2016 VEGF Exercise</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We concluded that the 2016 VEGF Exercise should be treated as a separate transaction for accounting purposes. We identified one performance obligation in this arrangement which is comprised of the exclusive license to develop and commercialize VEGF and the manufacturing of clinical supply. We concluded that the VEGF license is not distinct from the manufacturing obligations because AstraZeneca cannot fully exploit the value of the license without receipt of such supply. This is due to limitations inherent in the licenses conveyed wherein AstraZeneca does not have the contractual right to manufacture during the term of the agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, the total transaction price was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1854-wk-Fact-4CBCF2736547EE40B840B8937FE424AC" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1858-wk-Fact-F18C57600CF828D7F7C0B8937FD196FD" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_FixedPaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in fixed payments pertaining to a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1862-wk-Fact-2E7A325E462F395B70DAB8937FE9D1DA" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_OptionExerciseFeeMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> option exercise fee and a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1866-wk-Fact-8902D77BA883EA255A46B8937FE4F402" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone achieved prior to the adoption of ASC 606, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1870-wk-Fact-BEAA312ECCF998D27934B9108D012A15" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_SublicenseReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> sublicense reimbursement and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1875-wk-Fact-2F0D9B6FAB0871E7A3ABB8937FDCFDC8" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of variable consideration related to the estimated reimbursement for clinical supply. We are eligible to receive future milestones and royalties on future commercial sales under this arrangement. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received and the amount of estimated reimbursement for clinical supply. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or AstraZeneca&#8217;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it is recognized as revenue based on the relative completion of the underlying performance obligation. There was a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1883-wk-Fact-673D6B0FB6C8F01EC6F5B8937FE6DABA" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="FD2020Q1YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> increase to the transaction price during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, resulting from a change in estimate of variable consideration. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue related to the amount of the transaction price allocated to the VEGF Exercise performance obligation based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we made a cumulative catch-up adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1905-wk-Fact-4192B08047CD8DB1003DB912DA6D6249" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="FD2020Q1QTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as a reduction of revenue due to changes in estimated costs for our future performance obligation associated with the 2016 VEGF Exercise. We did not recognize any collaboration revenue from the 2016 VEGF Exercise for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1917-wk-Fact-918106269F43F6E7E30DB8937FDB59A8" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through December&#160;31, 2025. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1922-wk-Fact-7CE8F6CC8D0CF1848630B90E3B77988B" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e1926-wk-Fact-2527D24F249ABE4BE9F3B8937FE24DAE" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> respectively, from the 2016 VEGF Exercise, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the control of the supply is expected to be transferred.</span></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-9" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-10"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2017 AZ Agreement</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We concluded the 2017 AZ Agreement is under the scope of ASC 808 as we and AstraZeneca are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. Additionally, we determined the development, manufacturing and commercialization activities are not deliverables under ASC 606. As a result, the activities conducted pursuant to the development, manufacturing and commercialization activities are accounted for as a component of the related expense in the period incurred. We considered the guidance in ASC 606 by analogy in determining the appropriate treatment for the transactions between us and AstraZeneca and concluded that reimbursement for transactions in which we are considered to be principal because we control a promised good or service before transferring that good or service to the customer, are accounted for as gross revenue. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1953-wk-Fact-3E69DFDB4BACF95F01E7B8937FEAEFC2" name="us-gaap:Revenues" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">t recognize any revenue from the 2017 AZ Agreement for both three month periods ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck &#8211; Strategic Alliances in Infectious Diseases and Cancer Vaccines</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2015 Strategic Alliance with Merck&#160;&#8211; Infectious Disease</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2015, we entered into a Master Collaboration and License Agreement with Merck, which was amended in each of January 2016, June 2016, and May 2019, and which we refer to, as amended, as the 2015 Merck Agreement. Pursuant to the 2015 Merck Agreement, we and Merck have agreed to research, develop, and commercialize potential mRNA medicines for the prevention of infections by RSV. As a part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to conclude the collaboration as it relates to development of potential mRNA medicines for other viruses, including mRNA-1278 for the prevention of VZV infection. Pursuant to the 2015 Merck Agreement, Merck is primarily responsible for research, development, and commercialization activities and associated costs of such research and commercialization. We are responsible for designing and manufacturing all mRNA constructs for preclinical and Phase&#160;1 and Phase&#160;2 clinical development purposes, and Merck pays us for such manufacture, and we are responsible for certain costs associated with the conduct of a Phase 1 clinical trial for an RSV vaccine product candidate (mRNA-1172). Responsibility for manufacturing mRNA constructs for late stage clinical development and commercialization purposes is to be determined.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2015 Merck Agreement includes a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period, expected to end on January 12, 2022, during which Merck may continue to preclinically and clinically develop RSV vaccine product candidates using mRNA constructs that were initially developed during an initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period which terminated in January 2019. Merck may, prior to January 12, 2022, elect to exclusively develop and commercialize up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e1994-wk-Fact-41F73C1C9366250586CCB8937FE330A9" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates" contextRef="I2019Q2May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="candidate" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> RSV vaccine product candidates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and Merck have agreed to certain defined exclusivity obligations during the term of the 2015 Merck Agreement with respect to mRNA investigational medicines against RSV. As part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to certain expectations to the existing exclusivity obligations, pursuant to which we will no longer be restricted from researching, developing, and commercializing an mRNA investigational medicine for the prevention of a specific set of respiratory infections, including RSV, for the pediatric population.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the 2015 Merck Agreement, we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2009-wk-Fact-DE7E5C5FF2A0606B437FB8937FE4558A" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="D2019Q2May31Merck_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment. We are eligible to receive, on a product-by-product basis, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2013-wk-Fact-51260550C48A65FDBC05B8937FD8E3A0" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="I2019Q2May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate milestone payments upon the achievement of certain development, regulatory, and commercial milestone events. To date, we have received from Merck a clinical milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2017-wk-Fact-47DC2CE71EF1F9F72CEBB8937FE52DB5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2019Q2May31Merck_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> with respect to the initiation of a Phase&#160;1 clinical trial for a Merck RSV vaccine product candidate. In addition, under the terms of the 2015 Merck Agreement, we are eligible to receive an additional milestone payment unless Merck elects not to continue with further clinical development of mRNA-1172. On a product-by-product basis, we are also entitled to receive royalties on Merck&#8217;s net sales of products at rates ranging from the mid-single digits to low teens, subject to certain reductions, with an aggregate minimum floor. Additionally, concurrent with entering into the 2015 Merck Agreement in 2015, Merck made a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2021-wk-Fact-3E0EB87FE34BA8B8813DB8937FDA03AB" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="D2015Q1Jan31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> equity investment in us, and concurrent with amending the 2015 Merck Agreement in January 2016, we received an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2025-wk-Fact-120378EEDE8DA2FFA378B8937FCB9209" name="us-gaap:DeferredRevenueAdditions" contextRef="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from Merck.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the 2015 Merck Agreement will continue on a product-by-product and country-by-country basis for so long as royalties are payable by Merck on a given product in a given country. Either party may terminate the 2015 Merck Agreement upon the other party&#8217;s material breach, either in its entirety or with respect to a particular program, product candidate, product or country, subject to specified notice and cure provisions. Merck may terminate the 2015 Merck Agreement in full or with respect to a particular product candidate or product upon certain advance notice to us for any reason, or earlier if Merck determines the alliance or product is no longer commercially practicable. If Merck has the right to terminate the 2015 Merck Agreement, in its entirety or with respect to a program, product candidate or product, for our material breach, then Merck may elect, in lieu of terminating the 2015 Merck </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-10" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-11"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agreement, to have the 2015 Merck Agreement remain in effect, subject to reductions in certain payments we are eligible to receive with respect to the terminable rights. Upon a termination of the 2015 Merck Agreement with respect to a program, all licenses and other rights granted to Merck with respect to such program will terminate and the continued development and commercialization of product candidates and products will revert to us. If the 2015 Merck Agreement is terminated with respect to a given product candidate or product, all licenses and other rights granted to Merck with respect to such product candidate or product will terminate and, to the extent we terminated for Merck&#8217;s breach, Merck will grant us licenses under select Merck technology for our continued development and commercialization of such product candidate or product. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined that all aspects of amended 2015 Merck Agreement represent a transaction with a customer and therefore the amended 2015 Merck Agreement is accounted for in accordance with ASC 606. The </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period was complete as of December 31, 2018 and we recognized the total transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2051-wk-Fact-890A73ED9B6A86F90FA2EF959F15405E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2055-wk-Fact-C7AEB3E71E310F1145E8B922DCE3D4BB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;in aggregate upfront payments and a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2059-wk-Fact-D739219F0F687C37E489B92388B82CED" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentResearchAndDevelopmentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;payment pertaining to achievement of a development milestone) in full as we concluded there were no unsatisfied performance obligations pertaining to the amended 2015 Merck Agreement. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) research services during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period following the initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period during which Merck may continue to preclinically and clinically develop product candidates and (ii) clinical mRNA supply for Phase 1 and Phase 2 and/or non-cGMP mRNA supply beyond the initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period. Therefore, such options will be accounted for as a separate contract upon the customer&#8217;s election. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Merck&#8217;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After completion of the initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period, and as part of the May 2019 amendment of the 2015 Merck Agreement, Merck elected to establish a new RSV vaccine product candidate and elected to conduct a Phase 1 clinical trial. We are responsible for certain costs associated with the conduct of the Phase 1 clinical trial.&#160;We determined that our obligation under the May 2019 amendment to reimburse Merck for certain costs associated with the RSV vaccine Phase 1 clinical trial represents consideration payable to a customer and is accounted for as a reduction of the transaction price. The consideration amount is determined based on the most likely method and recorded as contra-revenue as costs are incurred. The one-time payment upon election by Merck to continue developing RSV is fully constrained as it is contingent upon completion of the RSV Phase 1 clinical trial and upon decisions to be made by Merck to continue development thereafter. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2093-wk-Fact-CB867DB9A0052B680F32B8937FE60D86" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> deduction to the transaction price related to reimbursements paid to Merck for RSV vaccine Phase I clinical trial costs.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had no deferred revenue as of March 31, 2020 or December 31, 2019 from the amended 2015 Merck Agreement as all performance obligations under the amended 2015 were completed as of December 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized contra-revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2108-wk-Fact-2A503B7C2CC4826B01B4B8937FDFBD94" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_SeparateAgreementsWithMerckMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2020, related to consideration payable to Merck under the May 2019 Amendment. We recognized collaboration revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2112-wk-Fact-1C872250E7E8E9BB0A2FB926F472CEA3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_SeparateAgreementsWithMerckMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2019, pursuant to separate agreements with Merck related to the exercise of customer options to purchase clinical mRNA supply to further develop a product candidate after the initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period. Clinical mRNA supply is recognized as collaboration revenue at a point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Cancer Vaccine Strategic Alliance&#8212;Personalized mRNA Cancer Vaccines</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck, which we refer to as the PCV Agreement, to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient&#8217;s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient&#8217;s immune system against her or his own cancer cells.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-11" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-12"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase&#160;1 and Phase&#160;2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna&#8217;s manufacture and supply activities. We received an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2135-wk-Fact-11084AB72BD9D3E9A9FDB8937FE88C0D" name="us-gaap:DeferredRevenueAdditions" contextRef="D2016Q2Jun30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from Merck. In November 2017, we and Merck announced the achievement of a key milestone for the first-in-human dosing of a PCV (mRNA-4157) as a part of the alliance. The Phase&#160;1 open-label, dose escalation, multicenter clinical trial in the United States (KEYNOTE-603) is designed to assess the safety, tolerability and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with KEYTRUDA, in subjects with unresectable solid tumors.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for PCVs under the PCV Agreement and delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of PCVs by making a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2144-wk-Fact-F5DF3A5439791F96A8CAB8937FEE6E20" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="FI2016Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> participation payment to us. If Merck exercises its election and pays the participation payment, then the parties will equally co-fund subsequent clinical development of PCVs, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. Each party may also conduct additional clinical trials for PCVs that are not included in the jointly agreed development plan and budget, in which case the non-conducting party will reimburse the conducting party for half of the total costs for such trials, plus interest, from its share of future profits resulting from sales of such PCVs, if any. Merck will lead worldwide commercialization of PCVs, subject to Moderna&#8217;s option to co-promote PCVs in the United States, and the parties will equally share the profits or losses arising from worldwide commercialization. Until a PCV becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of such PCV, if any. Subject to customary &#8220;back-up&#8221; supply rights granted to Merck, we will manufacture (or have manufactured) PCVs for preclinical and clinical purposes. Manufacture of PCVs for commercial purposes will be determined by the parties in accordance with the terms of the PCV Agreement. Under the PCV Agreement, we grant certain licenses to Merck to perform its collaboration activities.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If Merck does not exercise its right to participate in future development and commercialization of PCVs, then Moderna will retain the exclusive right to develop and commercialize PCVs developed during the strategic alliance, subject to Merck&#8217;s rights to receive a percentage in the high teens to the low 20s, subject to reductions of our net profits on sales of such PCVs. During a limited period following such non-exercise, Merck has the right to perform clinical studies of such PCVs in combination with KEYTRUDA, for which we agree to use reasonable efforts to supply such PCVs. During such limited period, we also have the right to perform clinical studies of PCVs in combination with KEYTRUDA, for which Merck agrees to use reasonable efforts to supply KEYTRUDA. In addition, following its non-exercise, Merck is also entitled to receive a percentage in the high teens to the low 20s, subject to reductions, of our net profits on sales of certain PCVs first developed by us following such non-exercise and reaching a specified development stage within a defined period of time.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and Merck have agreed to certain defined, limited exclusivity obligations with respect to the development and commercialization of PCVs.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Expansion of the Cancer Vaccine Strategic Alliance&#8212;Shared Neoepitope Cancer Vaccines </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671 or V941, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events. Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCV increased to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2174-wk-Fact-B7994025CF5C2D92B447B8937FD038E7" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="I2018Q2Apr30_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. If Merck exercises its participation </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-12" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-13"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">rights, then the parties will equally co-fund subsequent clinical development of mRNA-5671, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. If Merck declines to participate in future development and commercialization activities following the initial Phase 1 and Phase 2 clinical trials for mRNA-5671, then we will retain the rights to develop and commercialize mRNA-5671. If Merck elects to participate in future development and commercialization of mRNA-5671, Merck may also conduct additional clinical trials for mRNA-5671 that are not included in the jointly agreed development plan and budget, in which case we will reimburse Merck for half of the total development costs for such clinical trials, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. If Merck does conduct additional clinical trials for mRNA-5671, we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials. Merck will lead worldwide commercialization of mRNA-5671, subject to our option to co-promote mRNA-5671 in the United States, and the parties will equally share the operating profits or losses arising from worldwide commercialization. Until mRNA-5671 becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. Subject to &#8220;back-up&#8221; supply rights granted to Merck, we will manufacture (or have manufactured) mRNA-5671 and other SAVs for preclinical and clinical purposes. After Merck exercises its right to participate in future development and commercialization of mRNA-5671 and other SAVs, we will grant the applicable development and commercialization licenses and the parties are obligated to discuss responsibility for future manufacturing, giving consideration to applicable criteria.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the PCV/SAV Agreement, for a defined period of time, either party may propose that the parties conduct additional programs for the research and development of SAVs directed to different shared neoantigens. If the parties agree to conduct any such programs, then we will be responsible for conducting and funding preclinical discovery and research activities for such SAVs, and otherwise the programs would be conducted on substantially the same terms as mRNA-5671 program. If we or Merck propose a new SAV program and the other party does not agree to conduct such program, then the PCV/SAV Agreement includes provisions allowing the proposing party to proceed with such development, at the proposing party&#8217;s expense. If Merck is the proposing party, we will be responsible for manufacturing and supplying material for such program at Merck&#8217;s expense. In such case, the non-proposing party will have the right to opt-in to such SAV program any time before the proposing party commits to performing Good Laboratory Practice (GLP)-toxicity studies. Until the expiration of a defined period of time following our completion of Phase&#160;1 and Phase&#160;2 clinical trials for any SAV program mutually agreed by the parties under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of such SAV by making a participation payment to us.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the PCV/SAV Agreement will continue on a program-by-program basis until Merck terminates its participation in such program. Following any such termination, we will retain the exclusive right to develop and commercialize PCVs or SAVs developed as a part of such program, subject to restrictions and certain limited rights retained by Merck.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2197-wk-Fact-F1CF7116F44F58C1E720B8937FCA406D" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="D2018Q2Apr30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesHPreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2201-wk-Fact-56FFDE19FD752E2DFF07B8937FE7A7B4" name="us-gaap:RedemptionPremium" contextRef="D2018Q2Apr30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesHPreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is determined to be a premium and recorded to deferred revenue.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</span></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined that the PCV/SAV Agreement should be accounted for separately from the amended 2015 Merck Agreement, as the agreements were not negotiated in contemplation of one another and the elements within each of the agreements are not closely interrelated or interdependent on each other. We determined that all aspects of the PCV/SAV Agreement represent a transaction with a customer and therefore the PCV/SAV Agreement is accounted for in accordance with ASC 606. In addition, the equity investment in our Series H redeemable convertible preferred stock was considered together with the PCV/SAV Agreement as the transactions were executed contemporaneously in contemplation of one another. Further, the purchase price paid by Merck with respect to the investment in the Series H redeemable convertible preferred stock was not representative of fair value on the date of such purchase. As such, the incremental proceeds received in excess of the fair value of the underlying stock related to the equity investment were included in the transaction price related to the PCV/SAV Agreement and the shares of Series H redeemable convertible preferred stock purchased by Merck were recorded at their respective fair value on the date of issuance.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We identified the following performance obligations in the PCV/SAV Agreement: (i) a research license and research and development services, including manufacturing and supply of PCVs, during the proof of concept (POC) term for the PCV program, referred to as the PCV Performance Obligation, and (ii) research license and manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, referred to as the KRAS Performance Obligation. We concluded that the research license is not distinct from the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, as Merck cannot fully exploit the value of the license without receipt of such services and supply. Our services and </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-13" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-14"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the research license has been combined with the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, into a single performance obligation. Similarly, we concluded that the research license is not distinct from the manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, as Merck cannot fully exploit the value of the license without receipt of such supply which must be provided by us. This is due to limitations inherent in the licenses conveyed wherein Merck does not have the contractual right to manufacture during the POC term. Therefore, the research license has been combined with the manufacturing and supply of mRNA-5671, during the POC term for the KRAS program, into a single performance obligation. Conversely, we concluded that the PCV Performance Obligation and the KRAS Performance Obligation are distinct from each other because Merck can fully exploit the value of each program for its intended purpose without the promises associated with the other program. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Merck participation election license related to future joint development and commercialization on a program-by-program basis, (ii) manufacturing and supply in support of certain SAV programs and/or the PCV program upon Merck election to not participate in future development and commercialization of that program and (iii) research and development services associated with certain SAV programs. Therefore, such options will be accounted for as a separate contract upon the customer&#8217;s election.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total transaction price was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2233-wk-Fact-791E24C3A0A4CECF8D28B8937FEBEF5A" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">213.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2237-wk-Fact-C36EBE5BA0F0293C1ABAB8937FEA8F57" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment pertaining to the PCV Agreement, the premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2241-wk-Fact-5A5E76E7C4B52842BE2EB8937FE5EE3F" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and a variable consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2245-wk-Fact-A4C1078CA1F4BBB0802EB92AF362AA72" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ClinicalSupplyReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a reimbursement for clinical supply. We determined there are no other components of variable consideration that should be included in the transaction price as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, as additional consideration to which we could be entitled is subject to Merck&#8217;s election to exercise a customer option that was deemed to be a marketing offer. We re-evaluate the transaction price at the end of each reporting period. During the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2258-wk-Fact-DAE7FCA003F9B2DA3ED3B92D25A7040E" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="FD2020Q1YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ClinicalSupplyReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> increase to the transaction price from a reimbursement for clinical supply. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling price of each performance obligation. We developed the estimated standalone selling price for the license included in each of the PCV Performance Obligation and the KRAS Performance Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a development candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the PCV Performance Obligation and the KRAS Performance Obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated cost, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to each performance obligation is as follows: (i) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2276-wk-Fact-5AC64EBC33C3432E0C1EB8937FE154B3" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_PCVPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">206.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the PCV Performance Obligation and (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2280-wk-Fact-9AF5CE071E8A7F678581B8937FE6ACC7" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_KRASPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> allocated to the KRAS Performance Obligation. We will recognize revenue related to amounts allocated to the PCV Performance Obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of research and development efforts. We recognize revenue related to the amounts allocated to the KRAS Performance Obligation based on the point in time upon which control of supply is transferred to Merck for each delivery of the associated supply. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2297-wk-Fact-6DA4669489D8C51D0924B8937FEAFD46" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2301-wk-Fact-9BF9212ED6D2E0B67BDCB8937FD9A559" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statements of operations, from the Merck PCV/SAV Agreement. The revenue recognized during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> includes the amortization of deferred revenue due to the satisfaction of our performance during the period, offset by a cumulative catch-up adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2310-wk-Fact-0B35B33C2EE73FAA64C2B92DCBBFB24D" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> due to changes in estimated costs for our future performance obligations. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2318-wk-Fact-5675E1E6289359354BD3B8937FE2775D" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through December&#160;31, 2024. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2322-wk-Fact-17A42DA8A47E2BBB09F7B8937FDFE915" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2326-wk-Fact-C3462CD0DEDE329D4E7AB8937FCE4F22" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2019, respectively, from the Merck PCV/SAV Agreement, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-14" continuedAt="TextSelection-38C1CF2FA6113B09B040B89380261F41-15"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Vertex &#8211; 2016 Strategic Alliance in Cystic Fibrosis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2016, we entered into a Strategic Collaboration and License Agreement, with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex, which we refer to as the Vertex Agreement. The Vertex Agreement, which was amended in July 2019, which we refer to as the 2019 Vertex Amendment, is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional CFTR proteins.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period that was extended through March 2020, leveraging our Platform technology and mRNA delivery expertise along with Vertex&#8217;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. The parties established a joint steering committee to oversee and coordinate activities under the Vertex Agreement. We and Vertex have granted each other certain licenses under the Vertex Agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the Vertex Agreement, we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2356-wk-Fact-3FFBCC956A66095209D3B8937FE8F0C7" name="us-gaap:DeferredRevenueAdditions" contextRef="D2016Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment from Vertex. In July 2019, Vertex elected to extend the initial </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year research period by </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> pursuant to the 2019 Vertex Amendment. In March 2020, based on the promising preclinical data generated to date, Vertex extended the conduct of the initial Research Plan through the First Extended Research Term (an additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8095399e2368-wk-Fact-2709811FAB3D85E2B070B8937FD82581" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod" contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" format="ixt-sec:durmonth">18</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">-month term) by making an additional payment to us. Vertex has rights to further extend the research period for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8095399e2372-wk-Fact-BDCDB61C509E8BBD4844B8937FEEFA79" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods" contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="extension_period" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year periods by making an additional payment to us for each </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year extension. We are eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2385-wk-Fact-7548D5A448F8123AB5B3B8937FEFE66B" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_DevelopmentMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments for achievement of development milestones, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2389-wk-Fact-AA071A26EA48D3606DDBB8937FED7CED" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments for achievement of regulatory milestones and potentially could receive an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2393-wk-Fact-E813C2A0B11A39EFA2CAB8937FE1B112" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesSubsequentProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment for achievement of a regulatory milestone for a second and each subsequent product under the Vertex Agreement. Vertex will also pay us tiered royalties at rates ranging from the low- to high-teens on worldwide net sales of products arising from the strategic alliance, subject to certain reductions, with an aggregate minimum floor. In connection with the strategic alliance, Vertex also made a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2397-wk-Fact-E26EFF6FB8FBA02CB86FB8937FECB8CA" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> equity investment in us. During the term of the Vertex Agreement, we and Vertex have agreed to certain defined exclusivity obligations under the Vertex Agreement with respect to the development and commercialization of certain mRNA medicines.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the Vertex Agreement will continue until the expiration of all royalty terms. Vertex may terminate the Vertex Agreement for convenience upon </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8095399e2407-wk-Fact-69C38881F7A2556F0F22B8937FE6624E" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" format="ixt-sec:durday">90</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;days&#8217; prior written notice, except if termination relates to a product in a country where Vertex has received marketing approval, which, in such case, Vertex must provide </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8095399e2411-wk-Fact-8E4B5C3131936782F640B8937FE4611A" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod" contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" format="ixt-sec:durday">180</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; prior written notice. Either party may terminate the Vertex Agreement upon the other party&#8217;s material breach, subject to specified notice and cure provisions. Each party may also terminate the Vertex Agreement in the event that the other party challenges the validity or enforceability of such party&#8217;s patent rights, subject to certain exceptions, or if the other party becomes insolvent.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, all performance obligations under the 2019 Vertex Amendment were completed and the total transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2430-wk-Fact-39B08D1B2F781B7874D1B8937FD619F8" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2434-wk-Fact-0FD20852246F0EC91A4BB8937FDFC810" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2438-wk-Fact-70256660A3AAFCFF8467B8937FD5025D" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ResearchAndDevelopmentFundingMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development funding related to the research and development services and supply of non-cGMP mRNA, was fully recognized.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The First Extended Research Term represents a contract modification and is accounted for as a separate contract. Pursuant to the 2019 Vertex Amendment, we identified one performance obligation comprised of: (i) a research, development and commercialization license and (ii) research and development services, including manufacturing and supply of non-cGMP mRNA, during the 18-month First Extended Research Term. We concluded that the license is not distinct from the research and development services, including manufacturing and supply of non-cGMP mRNA. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Vertex&#8217;s rights to extend the extended initial research period and (ii) clinical mRNA supply and/or non-cGMP mRNA supply beyond the extended initial research period. Therefore, such options will be accounted for as a separate contract upon the customer&#8217;s election. The total transaction price was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2447-wk-Fact-A461051FEDE185F1587AC3C9718895CF" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2451-wk-Fact-D4F424880D96C724CCA8C3C9AEC496E2" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q4_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2455-wk-Fact-CEE17C40854A0D5B71B1C3C9D7BE1055" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q4_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ResearchAndDevelopmentFundingMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development funding related to the research and development services and supply of non-cGMP mRNA. We utilize the most likely amount method to determine the amount of research and development funding to be received. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were no milestones included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Vertex&#8217;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any sales-</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-38C1CF2FA6113B09B040B89380261F41-15"><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each of the Vertex Agreement, the 2019 Vertex Amendment and the First Extended Research Term, the total transaction price was allocated entirely to a single performance obligation. We recognize revenue related to amounts allocated to the single performance obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of the research and development efforts.   </span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2484-wk-Fact-086AC0D814D425C81D9BB8937FE36039" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2488-wk-Fact-70081FACA1A4BAD7AD25B8937FD563D7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statements of operations, from Vertex. The revenue recognized during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> includes the amortization of the deferred revenue due to the satisfaction of our performance during the period. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2505-wk-Fact-99C16C4F1716A0DB8F50B8937FE049EB" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through the third quarter of 2021. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2509-wk-Fact-21D1A152215278783A15B8937FE58D66" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8095399e2513-wk-Fact-56E7C2AA87474D498AD4B8937FE7795D" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of March 31, 2020 and December 31, 2019, respectively, from the First Extended Research Term and the 2019 Vertex Amendment, classified as current and non-current in the condensed consolidated balance sheets based on the term of the research period.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s48B7E8EAAF1652E18953DBE94E3172A8"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-BA059394534CF5292F1FB8938027A521-0-wk-Fact-55D9EF6A637DB40587CDB8937FCFDE39" continuedAt="TextSelection-BA059394534CF5292F1FB8938027A521-1" escape="true">Grants</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BA059394534CF5292F1FB8938027A521-1" continuedAt="TextSelection-BA059394534CF5292F1FB8938027A521-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Biomedical Advanced Research and Development Authority (BARDA)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2016, we received an award of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e460-wk-Fact-2D3BE63E535E7E138C2AB8937FF20551" name="mrna:RevenueFromGrantsMaximumAward" contextRef="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> under Agreement No. HHSO100201600029C from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response, or ASPR within the U.S. Department of Health and Human Services, or HHS, to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e464-wk-Fact-0FC504D995AA9ACE5568B8937FF04EED" name="mrna:RevenueFromGrantsMaximumAward" contextRef="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialBaseAwardMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> supported toxicology studies, a Phase&#160;1 clinical trial, and associated manufacturing activities. Contract options were available, for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e468-wk-Fact-39508AE86DB5D885DF00B8937FD11D7D" name="mrna:RevenueFromGrantsMaximumAward" contextRef="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">117.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to support an additional Phase&#160;1 study of an improved Zika vaccine candidate, Phase&#160;2 and Phase&#160;3 clinical studies, as well as large-scale manufacturing for the Zika vaccine.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8090629e481-wk-Fact-394086F70406D62BB1C2B8937FD2DD5E" name="mrna:RevenueFromGrantsNumberOfContractOptionsExercised" contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember" unitRef="contract_option" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8090629e485-wk-Fact-037E0A8B14A55B34BA9EB8937FD31243" name="mrna:RevenueFromGrantsNumberOfContractOptions" contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember" unitRef="contract_option" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> contract options had been exercised resulting in </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e489-wk-Fact-B957EF90BC39C9A4D6A4B8937FF01E98" name="mrna:RevenueFromGrantsCurrentFundingCapacity" contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">117.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of available funding with an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e493-wk-Fact-FD73D9D6E6DDD0162D71B8937FCC869D" name="mrna:RevenueFromGrantsRemainingFundingCapacity" contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> available if the final contract option is exercised. For the three months ended March&#160;31, 2020 and 2019, we recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e498-wk-Fact-A41528EC149D512CE73CB8937FCF7AD2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_us-gaap_GrantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e502-wk-Fact-9EB1CF828D2FD8C7791DB8937FD1B395" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_us-gaap_GrantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, relating to the BARDA agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 16, 2020, we entered into a new agreement with BARDA (see Note 13).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Bill&#160;&amp; Melinda Gates Foundation (Gates Foundation)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Gates Foundation has committed up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e522-wk-Fact-0408ACD949BC05662851B8937FEF2307" name="mrna:RevenueFromGrantsMaximumAward" contextRef="D2016Q1Jan31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialProjectMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase&#160;1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections. Follow-on projects which could bring total potential funding under the framework agreement up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e526-wk-Fact-F64FB11A3DEA6DD11E24B8937FD2EE2E" name="mrna:RevenueFromGrantsMaximumAward" contextRef="D2016Q1Jan31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Gates Foundation certain non-exclusive licenses. In March 2019, the Gates Foundation provided an additional funding commitment up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e530-wk-Fact-83DFF95E6663EA96E736B8937FF0C043" name="mrna:RevenueFromGrantsMaximumAward" contextRef="D2019Q1Mar31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_FollowOnProjectMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to support a follow-on project.  </span></div><div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e541-wk-Fact-FF921234A2AE5C242BD5B8937FD88945" name="mrna:RevenueFromGrantsCurrentFundingCapacity" contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialProjectMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">21.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> has been committed for funding with up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e545-wk-Fact-E6D7832947E94C0B6CFEB8937FEEF997" name="mrna:RevenueFromGrantsRemainingFundingCapacity" contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> available, if additional follow-on projects are approved. We recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e549-wk-Fact-D0CD20AB629D48C1F971B8937FF09BAB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_us-gaap_GrantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to the Gates Foundation agreement for both of the three months ended March&#160;31, 2020 and 2019. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e553-wk-Fact-0819662646B5CDDFF492B8937FEF0006" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e558-wk-Fact-BD51EDE10F77904850B4B8937FD6CE04" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the Gates Foundation agreement.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-BA059394534CF5292F1FB8938027A521-2" continuedAt="TextSelection-BA059394534CF5292F1FB8938027A521-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Defense Advanced Research Projects Agency (DARPA)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2013, DARPA awarded us up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e580-wk-Fact-CCEE8DE9E2C551DCEAB0B8937FD2D52F" name="mrna:RevenueFromGrantsMaximumAward" contextRef="D2013Q4Oct31_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> under Agreement No.&#160;W911NF-13-1-0417, which was subsequently adjusted to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e584-wk-Fact-27750F0903C6B3E62ABEB8937FD00755" name="mrna:RevenueFromGrantsMaximumAward" contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, to research and develop potential mRNA medicines as a part of DARPA&#8217;s Autonomous Diagnostics to Enable Prevention and Therapeutics, or ADEPT, program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against chikungunya infection.</span></div></ix:continuation><div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"><ix:continuation id="TextSelection-BA059394534CF5292F1FB8938027A521-3" continuedAt="TextSelection-BA059394534CF5292F1FB8938027A521-4"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8090629e599-wk-Fact-7A3FD2F5E9297FB1BC89B8937FD9BAFB" name="mrna:RevenueFromGrantsCurrentFundingCapacity" contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> has been committed by DARPA. There was no revenue recognized for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-BA059394534CF5292F1FB8938027A521-4"> or 2019, related to the DARPA agreement.</ix:continuation> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sC0E29CF661F85A7D91883F8BFB95F9CA"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="TextSelection-2CDFF80AD40914532441B8938027C02F-0-wk-Fact-E8C505CABE7302557796B8937FF4A085" continuedAt="TextSelection-2CDFF80AD40914532441B8938027C02F-1" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-2CDFF80AD40914532441B8938027C02F-1" continuedAt="TextSelection-2CDFF80AD40914532441B8938027C02F-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Investments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="TextSelection-FBDCAA8C618BB59945F2B8938027A7E9-0-wk-Fact-B2E3131A7C3AAB9A07A0B8937FF548EC" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize our cash and available-for-sale securities by significant investment category at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e855-wk-Fact-25F1CFA82A845B7E5C62B893800AB0E6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">281,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e874-wk-Fact-07DA7945DEB5DC0A7810B89380014F8E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e894-wk-Fact-E4ABC6F9FF805E6A5996B89380181ACF" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e913-wk-Fact-BDE4CEFE47F7B47383B8B8938007F9D3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">281,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e932-wk-Fact-AD239BEC59494AF2D6E9B89380106A5F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">281,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e952-wk-Fact-0CFEA39036496F355B0CB8937FFF95A8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e971-wk-Fact-4AF473BA66A44020B68BB8938002249F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1287-wk-Fact-F4F6F9DF2F88ED60804DB89380129CF9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1306-wk-Fact-83CB8A17AC8EAE94EBFAB8938019193B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e1325-wk-Fact-A0E300C17ACDA784473EB89380009C40" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1346-wk-Fact-7D518748B43DEC1C7352B8938012FB5F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1365-wk-Fact-BC619FC456A173512236B8937FFB8A69" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1385-wk-Fact-389136949C426AE16B81B8937FF824BE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1404-wk-Fact-0C92265DD0C102A8D4F6B8937FFAC3EA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1429-wk-Fact-FF050AF85A1FB7503A3AB8938001F6B3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">212,701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1448-wk-Fact-607EBD7100399A7ED63CB8938003A641" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1467-wk-Fact-857B7C8B97BC4D987E04B89380076D92" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1487-wk-Fact-2A62428E733829F1A6D3B8937FF746F3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">214,028</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1506-wk-Fact-E050E81BBB64B877FEF4B8937FF65B55" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1526-wk-Fact-C0DB43B7EC7C6CE16EBFB89380137E84" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">141,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1545-wk-Fact-2082C0A0061D8886825CB8937FF81C07" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,007</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1570-wk-Fact-BD168117B87DF21DA45EB8938014E954" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,162,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1589-wk-Fact-9676E3FA7ABBE9255876B8937FFBD480" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e1608-wk-Fact-D4B47FC07FA79D67E4AEB89380019FA1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1629-wk-Fact-40DE3322C48822F8D0CCB893800CC30B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,156,052</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1648-wk-Fact-F79D198872C2CDC39F13B89380189ACC" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1668-wk-Fact-53EE3D6F5B5A8FB43E3AB893801AFCAF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">637,634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1687-wk-Fact-D5199D6A2AD0434694D0B89380140F77" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">418,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1717-wk-Fact-1FE48B3094779A48C159B8938007B839" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,725,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1736-wk-Fact-48A18A1A93D2A4348D74B893800D53E3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e1756-wk-Fact-2271DCB9B4D270F1A3A5B8938002C129" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1776-wk-Fact-BA6E3981CF4EE938DA96B89380154EC5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,720,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1795-wk-Fact-736CAF844A07F2B285D0B8937FF96511" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">391,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1815-wk-Fact-56100BF906C7CF159ADCB89380160556" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">825,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e1834-wk-Fact-966D1189618411A4AA20B89380176F9C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">502,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2185-wk-Fact-02A70816E7B44B4BE0D6B893800D6954" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2204-wk-Fact-0060FF2A19F1C8F3D54CB8938016E6A7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2224-wk-Fact-5EB790D2E18A14CA2922B8937FFBEB78" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2243-wk-Fact-D3FC05B895217E351444B8938001FFD7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2262-wk-Fact-9A7BBF2F395A71E4884AB8937FFBC673" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2282-wk-Fact-1D8D3D8D55B1B3EBA8D8B8937FFD9B56" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2301-wk-Fact-BC2E47C345A3AE27D50AB8937FFAF58E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2617-wk-Fact-704597308BFDCB9EA629B8937FFAB60B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,028</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2636-wk-Fact-D90FB9128DE834685D61B89380022364" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e2655-wk-Fact-8D94057395BABAA49E84B8938005EFA9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2676-wk-Fact-E8C6B6F222B03DC28CBAB8938003F2F5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2695-wk-Fact-817ABF6A30A39A6CBAAEB8938017F686" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2715-wk-Fact-863C9F344CAE374C6199B89380186553" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2734-wk-Fact-79F3C33CFBFB3927F5C5B893800809E7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2759-wk-Fact-E768DFEB0859516F9384B8937FFE7E5B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">117,891</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2778-wk-Fact-303EF7022DC685175453B8937FF69E47" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e2797-wk-Fact-E67F2AFADA1C7894C01FB893800AE5EC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2818-wk-Fact-B92320ED99586AA96FFCB8938016BDFD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118,149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2837-wk-Fact-35F969CE8F72DD17FA83B893800C7D62" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2857-wk-Fact-B20024C471E0637F92B5B89380127554" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">110,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2876-wk-Fact-3B96106FD911F91D6427B8938005505F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2901-wk-Fact-0A56DEFE8112B9C59226B8938005B04D" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">834,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2920-wk-Fact-C3D9DE551542B69EC84BB89380159539" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e2939-wk-Fact-054C8B38511708B5FF8EB893800F05B9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2960-wk-Fact-7D53B9CE3DC3B8C5999DB8938007E628" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">836,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2979-wk-Fact-6037D31900C1E81EFD0EB89380156FE0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e2999-wk-Fact-33B687965F45627BEE90B893801886E7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">687,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3018-wk-Fact-4F2CB4B1857F6A2B9929B89380115F49" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">149,122</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3048-wk-Fact-B8B8216E8652AFD15DCBB89380170209" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,259,980</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3067-wk-Fact-6450C1E34CA9B89E4098B8938016E5E6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e3087-wk-Fact-E0B38E060F31302417A0B8938014482A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3107-wk-Fact-0EB4E88DC59882067A5FB8938008AC72" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,262,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3126-wk-Fact-BE547C6C4235260FA374B8937FF827A1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">235,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3146-wk-Fact-A048C65F0BC55151B1F3B89380135112" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">867,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3165-wk-Fact-6F9E873352429B098CA5B893801B0128" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-2CDFF80AD40914532441B8938027C02F-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-F37367DE059D620BF35EB8938027E0E1-0-wk-Fact-2D18BA357DF96C1DC66DB8937FF5685F" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amortized cost and estimated fair value of marketable securities by contractual maturity at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3318-wk-Fact-556FB9D7D35498C8BD49B8937FF1FA00" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">826,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3337-wk-Fact-EA71BF57AF82F2251A21B8937FF31033" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">825,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3357-wk-Fact-3CEA7CE0B7373C380BD8B8937FF3AF27" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">506,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3376-wk-Fact-DDBCDC929C459403CA41B8937FF20457" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">502,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3406-wk-Fact-7249B33C75C026353308B8937FF15232" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,333,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3425-wk-Fact-454800A865878A0E4C76B8937FF2114B" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,328,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive (loss) income, net of applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any credit losses related to available-for-sale securities for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="TextSelection-173A98360CC71B19B6B5B8F8D9CAD1EB-0-wk-Fact-21433F9E59B0D952F2F0B8F93460C180" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 months or more</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e3900-wk-Fact-9EE151A9BB9A9915524EC387AB146840" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3920-wk-Fact-587B79CB3EBCDE6403ACC387AB09E24D" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3940-wk-Fact-C0D382F8E8DA68D1DA9EC387AAEF2F71" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3959-wk-Fact-8C1EF733AD1A868F9F0FC387AB0E6847" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e3978-wk-Fact-AE67D71989B2B1D28014B8F844436586" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e3999-wk-Fact-1FF2277D78FD4CB7C3F4B8F88DDFF811" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4019-wk-Fact-E26BE19AD4B0E690DA7EC387AAF6EA79" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4039-wk-Fact-387029D251C6DB6DD938C387AAFB96E2" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">709,128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4099-wk-Fact-97282015C3FB0E8BC3F5B8F83F0B9FB7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4120-wk-Fact-E7D780478746858661CEB8F88DD54C16" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">709,128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4150-wk-Fact-FD782B32BCA3A8C5D7EFB8F723C046D3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4169-wk-Fact-BCB5ACA8948A67A020B5B8F76AB6C3B6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">724,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4188-wk-Fact-DB3F4C0BF1C07B56B333B8F7C0B391EC" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4206-wk-Fact-DAA0F47CDBE44478141EB8F80230D62E" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4224-wk-Fact-E5BFC0AD1212FF8BC7B3B8F83FC3021C" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4244-wk-Fact-8C295F53822677A5492AB8F8901975C7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">724,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4525-wk-Fact-E15E5DE103CE8860BE6AC38950C13553" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4545-wk-Fact-6DA569617E155B81EF66C38950B55FA2" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,822</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4565-wk-Fact-4103520537B15DB1EBA6C38950B00FC2" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4584-wk-Fact-C99F93182603505A8035C38950BBCD13" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4603-wk-Fact-EF5FEF4074FCBD734E3EB8F83E5450F4" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4624-wk-Fact-055E0CD75401D44D2844B8F88EAA35DF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,822</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4644-wk-Fact-D9DDF0600DC0A81C58A5C38973400B4E" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4664-wk-Fact-AC6CFC43DACA532A8BCEC389756C4638" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,979</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4683-wk-Fact-E64715EB6BF38CC1215BC38977773B98" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4703-wk-Fact-F1B441A384AFC4E93BEAC389799E43B2" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4722-wk-Fact-13700394875F1A3EBE28C3897BEDB6B4" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4743-wk-Fact-47AA4C5EAB4A98960AA5C3897F969FB5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,979</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4768-wk-Fact-860B1C6948B67A1C94E2C38950A7E786" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4788-wk-Fact-3AA877C677F83E12538FC38950ABE479" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4807-wk-Fact-568EA2E451D961E3DC2AC38950A28DB7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4827-wk-Fact-F51BB7F9FB03DD7917D7C389509DF2BE" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4846-wk-Fact-4C5257905D6F007C8984B8F83FE8B357" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4867-wk-Fact-9EFC9776309DC1629CB4B8F88DF07271" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4898-wk-Fact-1CDBBC04DB422972FBB3B8F72067C2CD" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4918-wk-Fact-BB8C55024CE72421C481B8F76A3F0E78" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4938-wk-Fact-266E67EDEAFECF920393B8F7C07638C7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4957-wk-Fact-9C1DCBC0AEE2205E37F6B8F800A97878" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101936e4976-wk-Fact-84922716CF798BCD5725B8F8406FD7A7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101936e4997-wk-Fact-90ACB519056D973A5431B8F88ECE7236" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we held&#160;237&#160;and 19 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sFBD42BB84B605E04BCD4EACE4DD32894"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="TextSelection-831BB5788AADF090B2FDB8938027CD45-0-wk-Fact-353640447FD9C0E53A1EB8937FE9E55C" continuedAt="TextSelection-831BB5788AADF090B2FDB8938027CD45-1" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="TextSelection-831BB5788AADF090B2FDB8938027CD45-1" continuedAt="TextSelection-831BB5788AADF090B2FDB8938027CD45-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prepaid Expenses and Other Current Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="TextSelection-3896B39CF048458F8E15B893802719E6-0-wk-Fact-BC8DA6B3DE1F25139BE4B8937FDC5CF4" continuedAt="TextSelection-3896B39CF048458F8E15B893802719E6-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-831BB5788AADF090B2FDB8938027CD45-2"><ix:continuation id="TextSelection-3896B39CF048458F8E15B893802719E6-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e598-wk-Fact-2C142E1790CE95B6E293B8937FF4A4D3" name="us-gaap:PrepaidExpenseCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,410</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e617-wk-Fact-5185EB8739E384B9E424B8937FDECF91" name="us-gaap:PrepaidExpenseCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,475</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tenant incentives receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e637-wk-Fact-1ED5970E1291A496D32CB8937FF0AC59" name="mrna:TenantIncentivesReceivablesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e656-wk-Fact-4BDE4D2408FB88F4089AB893801AFB77" name="mrna:TenantIncentivesReceivablesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,093</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest receivable on marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e681-wk-Fact-3AC4B223BB78A902B70CB8937FF39693" name="us-gaap:InterestReceivableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e700-wk-Fact-E6334E6FC0F9CAFB09B5B8937FCF0068" name="us-gaap:InterestReceivableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e730-wk-Fact-6FD95ED13B84ACA5E3F7B8937FCE0B09" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e749-wk-Fact-AC28DA640B65E64EC4ADB8937FEF6A5A" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-2D4E4B35B1326416AD88B8938028EC07-0-wk-Fact-C073BD1CFC46E3EB402FB8937FF29E54" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e908-wk-Fact-C8D9A72FA56FF8358E4AB8937FF6A04D" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">109,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e927-wk-Fact-B263B3BD7409F282816AB8937FDF13F5" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e947-wk-Fact-76728C93FA18FBE3C80AB8937FE7EDAB" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e966-wk-Fact-65A3F617F27D9B241B6DB8937FDC6644" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture, fixtures and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e991-wk-Fact-99540A21D0CACAD196DDB8937FFBE53F" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1010-wk-Fact-B766C4D12B13DDA1DCEDB893801925C9" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1035-wk-Fact-E9B1F36B11E9F231280FB8937FF5CD7D" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1054-wk-Fact-3533F45AB8A993C79093B8937FF18871" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,985</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internally developed software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1079-wk-Fact-79205022EECCA699377CB8937FF47C9C" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1098-wk-Fact-7760E00CA1474C489429B8937FFD7B42" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use asset, financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1123-wk-Fact-E145848E30B5FC6A3CD3B8D2908F3B4D" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrna_RightOfUseAssetFinancingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,853</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1142-wk-Fact-B5D63CE02D3480F5E3B8B8D2961ABF26" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrna_RightOfUseAssetFinancingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,853</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1167-wk-Fact-CB65B56CB1F9ED6377BBB8937FFA160A" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1186-wk-Fact-3F49480F702F9EE9C83DB8937FFAE6DA" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1211-wk-Fact-60425542BD12848B6096B8938001F5EC" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1230-wk-Fact-7A4D9DA337001B1F18BFB8937FF04C85" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">296,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101929e1255-wk-Fact-4308F8363A5B7B0C48B3B8937FF5E159" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">101,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8101929e1275-wk-Fact-565D44205FEE4434E6CEB8937FD77683" name="mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1307-wk-Fact-558DF1603A8CCDA85CBFB8937FCD7C33" name="mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">202,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1326-wk-Fact-113458AB596CD8D5C17BB8937FEF297D" name="mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">201,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8101929e1354-wk-Fact-FF61343277C017291DCDB8937FF0D2FE" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8101929e1358-wk-Fact-9A7BD31CBBD1AD9A3B49B8937FE5116E" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-A60E1CDA7E17FFFAFC18B8938028FE26-0-wk-Fact-0EAF40D2D4430E581195B8937FDBE793" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1510-wk-Fact-9E061167754591C57B83B8937FDE0609" name="mrna:AccruedPropertyAndEquipmentCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1529-wk-Fact-93B60A4ABF6C3D11B101B8937FF3940D" name="mrna:AccruedPropertyAndEquipmentCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,029</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1549-wk-Fact-C68AA4A58B47C2EDBAADB8937FE72CDE" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1568-wk-Fact-948BBAAFD976A242D5C1B8937FE81D99" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">External goods and services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1593-wk-Fact-8D42E0F8CDED26BFC428B8937FF535B3" name="mrna:AccruedExternalGoodsAndServicesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1612-wk-Fact-B9B41D019B68FB0C521EB8937FF2D260" name="mrna:AccruedExternalGoodsAndServicesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1642-wk-Fact-A6E1BF00CB70C3CAC400B8937FDEDEFE" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8101929e1661-wk-Fact-3481DE0A2E9AF9687BA2B8937FCF40F1" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,652</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s520956fb0d2e4477868bc6f54e110a84"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-0-wk-Fact-FA363F8E7BC0871AF4A7B8CE68048194" continuedAt="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-1" escape="true"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LesseeFinanceLeasesTextBlock" id="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-0-wk-Fact-1ADDBE8FB8CB978E2AC1B8CECD83B99D" continuedAt="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-1" continuedAt="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-2"><ix:continuation id="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-1" continuedAt="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e454-wk-Fact-C9A7F4DB5624B5721D81B9778C49783F" name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" contextRef="FI2019Q4" unitRef="campus" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, or MTC, located in Norwood.  </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cambridge facility</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We occupy a multi-building campus in Technology Square in Cambridge, MA with a mix of offices and research laboratory space totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e473-wk-Fact-BBFB57696F6D49F83FCDB978BBBF376A" name="us-gaap:AreaOfRealEstateProperty" contextRef="FI2019Q4_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-2" continuedAt="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-3"><ix:continuation id="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-2" continuedAt="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, MA. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e482-wk-Fact-47EFB0D17DBEAB01AB53B978DC2DFF16" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of additional space at 200 Technology Square including space previously occupied under a sublease which expired on December 31, 2019. We will also completely early-exit our leased space of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e486-wk-Fact-F7659F9B93998B537DC7B9790232E804" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">60,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet at 500 Technology Square by May 2020. In addition, our current 200 Technology Square lease has been extended for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8105074e490-wk-Fact-FF27812A42BCA5B4D562B9795E0BE9EC" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> to 2029. The amendment provides an additional aggregated tenant improvement allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105074e494-wk-Fact-87382C3907CDC69AD00AB979791313E3" name="mrna:AllowanceForTenantImprovements" contextRef="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the design and construction of improvements at 200 Technology Square.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May&#160;2016, we entered into a lease agreement for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e504-wk-Fact-472D3F6FD57F51A6481EB97BAB5996FF" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">124,760</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office and laboratory space at 200&#160;Technology Square in Cambridge, Massachusetts. The lease commenced on September&#160;1, 2016, with the base rent subject to increases over an&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8105074e508-wk-Fact-3C1B3F7F8454C4316410B97BF457BC32" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember" format="ixt-sec:duryear">11</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">-year term. We have occupied the premises in six phases from September 2016 to January&#160;2020. We have the option to extend the lease term for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e512-wk-Fact-1A7F0B0871B3B7D232FDB97BD395ADBA" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" contextRef="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember" unitRef="extension_period" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;extension periods of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8105074e516-wk-Fact-725D80ACF759CC50F6ADB97C118D2EBA" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;each, at market-based rates. In addition to rent payments, the lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. As the amount of square footage that we lease increases over the term of the lease, we have recognized each phase&#8217;s total rent payments on a straight-line basis over the respective lease term. The lease provides us with an initial tenant allowance of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105074e520-wk-Fact-912BBA42984F6C2682C6B97C35DFF56F" name="mrna:LesseeOperatingLeaseTenantAllowancePricePerUnit" contextRef="D2016Q2May_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember" unitRef="USD_PER_sqft" decimals="INF" scale="0" format="ixt:numdotdecimal">10.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per square foot against which costs incurred are capitalized as leasehold improvements. In December 2018, in relation to the expansion of space from the agreement entered in May 2016, we entered into sublease agreements for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e525-wk-Fact-5C24C5CA5E2B16C56329B97C9DB5F441" name="us-gaap:AreaOfRealEstateProperty" contextRef="FI2018Q4_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">34,268</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet to expand our office and laboratory space at 200 Technology Square.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2015, we entered into a facility lease agreement for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e534-wk-Fact-ADD5503EEABCD68FBF14B97687C4ACDE" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2015Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">61,618</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office and laboratory space at 500&#160;Technology Square. The lease commenced in April&#160;2016, with the base rent escalating over the&#160;six-year term of the lease. The lease provides a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105074e538-wk-Fact-8BD021D6A71B0DDA5D16B976C12196E5" name="mrna:AllowanceForTenantImprovements" contextRef="I2015Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;tenant improvement allowance against which costs incurred are capitalized as leasehold improvements. The lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Moderna Technology Center North (MTC North)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we entered into a new lease agreement for office and laboratory space of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e552-wk-Fact-64BF8FC4F855C7813B79B9755A1C3DE3" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet, MTC North, located Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e556-wk-Fact-F20EA3DC2DC1730E4E3BB9756F951510" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember" unitRef="extension_period" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional five-year terms. Contemporaneously, we entered into an agreement to sublease approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e560-wk-Fact-FE44C7D2CE7141565D0FB97540EE5F16" name="mrna:LesseeOperatingLeasePercentageSubleased" contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">64</ix:nonFraction> percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the leased space to a third party. We have no rent obligations to the landlord for the space occupied by the third party. All sublease payments from the third party are paid directly to the landlord. The sublease can expire between May 2020 and February 2021 at the third party's option.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April&#160;2017, we entered into a lease agreement for land adjacent to our MTC manufacturing facility (see MTC South below). We determined, for accounting purposes, this land lease should be accounted for separately from the lease entered in August 2016 relating to the building. The lease commenced in April 2017, with the base rent&#160;escalating over the&#160;thirty-five-year term of the lease.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded to operating expenses in our consolidated statements of operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finance Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Moderna Technology Center manufacturing facility (MTC South)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2016, we entered into a lease agreement for approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e590-wk-Fact-51A1751B8A2C9F810846B973CF3F15EE" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Massachusetts. The lease commencement date for accounting purposes was October&#160;1, 2016. In connection with this lease, the landlord provided a tenant improvement allowance of approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105074e594-wk-Fact-920944348409B6F8A45BB9740A156118" name="mrna:AllowanceForTenantImprovements" contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;for costs associated with the design, engineering, and construction of tenant improvements for the building. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e598-wk-Fact-6CBBA739402FEA7DCBD6B973B680FE3E" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember" unitRef="extension_period" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;extension periods of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8105074e602-wk-Fact-552F4CB43764C92D54B7B9739C3CDEA3" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to ASC 842, the MTC South lease is bifurcated into a building lease and a land lease using an estimated incremental borrowing rate as of the lease commencement date. The building lease is classified as a financing lease and the land lease is classified as an operating lease. For accounting purposes, the lease term is determined to be </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8105074e611-wk-Fact-3BD65248AE1DB8931EBCB9736B9EA1D3" name="us-gaap:LesseeFinanceLeaseTermOfContract1" contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember" format="ixt-sec:duryear">35</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">, which is the non-cancelable period of the lease and includes the optional extension periods as we are reasonably certain that we will exercise the options to extend the lease term. Upon the adoption of&#160;ASC 842 at January 1, 2019, we derecognized the assets and liabilities recorded as a result of historical build-to-suit accounting under ASC 840 and recorded financing lease liabilities and financing right-of-use asset associated with the building lease. The financing right-of-use asset is amortized on a straight-line basis to depreciation expense over the remaining lease term. We record interest expense related to the financing lease liabilities in the consolidated statements of operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-3" continuedAt="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-4"><ix:continuation id="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-3" continuedAt="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-4"><ix:nonNumeric contextRef="FD2020Q1YTD" name="mrna:AssetsAndLiabilitiesLesseeTableTextBlock" id="TextSelection-9F376897B666C66B19ADB97D14B92AB4-0-wk-Fact-C00FC30D1A4F19AD3DFBB97D1FE3C00A" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2019 and March 31, 2020 were as follows (in thousands):&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating, net </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e797-wk-Fact-0DB5077D9DF77DB99501B8937FE01490" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,533</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e816-wk-Fact-78B369C60BB728FB25A9B8937FDB8A1C" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, financing, net </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) (4)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e838-wk-Fact-F67A3056AB2D6B7F711BB970CECFCD79" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,488</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e857-wk-Fact-9EDE656BDC2C4A44C657B970D01AE253" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e887-wk-Fact-6C3B541DFC346B94E729B970D1219216" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">110,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e906-wk-Fact-DE27DEC2E74FE04DAC89B970D2D950C4" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">95,958</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1071-wk-Fact-23577BA4690EBEE0C7BDB970FE96051F" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1090-wk-Fact-E4E3AED3F9B22B824DCEB9710015F001" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1157-wk-Fact-E301DD914DA458C31061B8937FCDE2FE" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1176-wk-Fact-2DEF7B7076BAB361269FB8937FD01D5D" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">93,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease liabilities, non-current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1201-wk-Fact-33C005D3215430FF981AB8937FEE7C36" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1220-wk-Fact-DDD0C8D2570F3206B9EFB8937FDEDECE" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total non-current lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1245-wk-Fact-2BADF498B4A693BEE479B97104E43E9A" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">147,849</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1264-wk-Fact-DB4703C3AE43A49802A5B971065DF65A" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">132,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1294-wk-Fact-9BED5F4E91EABF4FCB0AB9710722945D" name="mrna:OperatingAndFinanceLeaseLiability" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">151,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1313-wk-Fact-315054A9EC715F1AD3FDB971083949D7" name="mrna:OperatingAndFinanceLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">135,948</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Net of accumulated depreciation.</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) </sup></span><span style="font-family:inherit;font-size:10pt;">These assets are&#160;real estate assets related to the MTC South lease.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4) </sup></span><span style="font-family:inherit;font-size:10pt;">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5) </sup></span><span style="font-family:inherit;font-size:10pt;">Included in other current liabilities in the condensed consolidated balance sheets.</span></div></ix:nonNumeric><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-ABD5A84D1F7FAE8E86DDB98866948A1E-0-wk-Fact-4C36442126346DEE4C6AB9887555775C" escape="true"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the lease costs for the three months ended March 31, 2020 and 2019 were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1480-wk-Fact-1F05428C29327FD25FEDB96FD37D13D3" name="us-gaap:OperatingLeaseCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1499-wk-Fact-F6DAF93F8FE9E7BF7B32B96FD585BDA8" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease costs:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1565-wk-Fact-5CF83FCB82613EF3D8B7B96FD865C09D" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1584-wk-Fact-8EFB5CC3AC419837052BB96FDA3C9E26" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1609-wk-Fact-FA1D0C5A18A88DF0DD34B96FDBA2C409" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1628-wk-Fact-B86E3C11C3568FC25079B96FDD4C449F" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total financing lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1653-wk-Fact-958F9AFF6A24F9EEAB1EB96FDEC5B5B9" name="mrna:FinanceLeaseCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1672-wk-Fact-34F90443EA785CD7638DB96FE0AC662B" name="mrna:FinanceLeaseCost" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1697-wk-Fact-DF1715001598ABD83317B97009684AE7" name="us-gaap:VariableLeaseCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e1716-wk-Fact-351A338C23342B4E2BE1B9700AED3C67" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">894</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information relating to our leases for the three months ended March 31, 2020 and 2019 was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating cash flows used in operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8105074e1905-wk-Fact-2AA8149FF9B65447599AB96F1D9B566D" name="us-gaap:OperatingLeasePayments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,888</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8105074e1925-wk-Fact-7BC81016D0AF910A2BE5B96F1F53A3BE" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating cash flows used in financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8105074e1946-wk-Fact-65220F1883D3354D8CBBB96F20ADF85A" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8105074e1966-wk-Fact-DC6A9CFAEFE5152332C3B96F228B25EF" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-cash items:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Right-of-use assets reduced through lease modifications and reassessments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2084-wk-Fact-9C1DE18E686E78026BA6B96F29D66061" name="mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2103-wk-Fact-749877E53B91F8218C55B96F2B4A8DC0" name="mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2128-wk-Fact-F47B320EE5811332251EB96F2BE187CB" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2147-wk-Fact-D8C7580A9CA2EFDBA557B96F2D3D5472" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease non-cash items:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charges to financing lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2265-wk-Fact-DDF96D70811E28F4720FB96F23332941" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2284-wk-Fact-1A0A974BCF4779B8856DB96F2645FDA6" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-0D3A440FB906E4259E69B96A7C3C013B-0-wk-Fact-BB77CC2D00B1FF8E8A8EB96A9F7E4EB1" escape="true"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="TextSelection-9F6B205D8E0DBA253A66B96BA115EA9E-0-wk-Fact-7C68B38FCA11C23AF00EB96BABBF4932" escape="true"><ix:continuation id="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-4"><ix:continuation id="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating lease agreements at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, are as follows (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:4%;"></td><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:3%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(remainder of the year)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2402-wk-Fact-A6A8AEF4C0E40D889D9DB97FE98F4E54" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2421-wk-Fact-F1747F1B3B140E80FCB3B980435EE8AF" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2446-wk-Fact-1047E352A91018E178ABB96DEC855FE1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2465-wk-Fact-4A2270F430C973AACA21B96DEDCB2F44" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,894</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2495-wk-Fact-74A5E239330E5F4DD1FFB96DEED5F730" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2514-wk-Fact-859C8F335A95791691C1B96DEFFC3797" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2544-wk-Fact-DC4A73AC258504ED0AA0B96DF0B02BFA" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,962</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2563-wk-Fact-E0518EE7B3B8613F9A3FB96DF1F3634E" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2593-wk-Fact-E305BE5AE96E9061F435B96DF2A64669" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2612-wk-Fact-4165B8740E890CA57B3DB96DF3FF5337" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2642-wk-Fact-6BADF0AFE102CD6ABE8CB96DF4C559C3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2661-wk-Fact-22E7C54F98A4F745851FB96DF60F1582" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">264,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2691-wk-Fact-BF61F5744848CC1C2478B96DF6ED6A7B" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">195,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2710-wk-Fact-A5D2D2C475875E8320CCB96DF81D1683" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">293,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less amounts representing interest or imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8105074e2740-wk-Fact-0ACDB25FE12CC20C4446B96DF8EBD7F4" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">83,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8105074e2760-wk-Fact-F6F9661793FF4CC9A392B96DFA67B76C" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">254,093</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2796-wk-Fact-63AA2E85F637A865EDF2B96DFB1D39B8" name="us-gaap:OperatingLeaseLiability" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,917</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2815-wk-Fact-006032B162BDA111BE0BB96DFC24D3C0" name="us-gaap:FinanceLeaseLiability" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Include the optional extensions in the MTC South lease term which represent a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105074e2834-wk-Fact-943CED315E6305A4AE7FB96D490F7AE0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2020Q1_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105074e2838-wk-Fact-61CE85A0E5FF0478A245B96D7CE54704" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2020Q1_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">208.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> un-discounted future lease payments in operating leases and financing leases, respectively.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Based on an imputed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105074e2847-wk-Fact-026F5DC67CDC446D6925B96D24CFFC5A" name="mrna:LeasesImputedInterestRate" contextRef="FD2020Q1YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">17.2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation></ix:continuation></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sC2BE3A18BBAD5AEA81933654315E723D"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-41F2848F6093850D9118B89380284DD8-0-wk-Fact-BE2F143E0811D170D278B8938003DC35" continuedAt="TextSelection-41F2848F6093850D9118B89380284DD8-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-41F2848F6093850D9118B89380284DD8-1" continuedAt="TextSelection-41F2848F6093850D9118B89380284DD8-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Strategic Collaborations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8104319e476-wk-Fact-14D2BAA7826984019397B89380015BF8" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" contextRef="FI2020Q1_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for both periods as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> (see Note 3).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are not currently a party to any material legal proceedings.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification Obligations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through the three months ended March&#160;31, 2020 and the year ended December 31, 2019, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-41F2848F6093850D9118B89380284DD8-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments and Purchase Orders</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8104319e529-wk-Fact-D920C36B3F6AA8E7E597B8937FEFA48C" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_us-gaap_PurchaseCommitmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of non-cancelable purchase commitments for clinical services which are expected to be paid from 2020 to 2023.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December&#160;31, 2019, we had cancelable open purchase orders of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8104319e543-wk-Fact-385C9DCC35D965568F78B8937FFF9E6C" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_mrna_ClinicalOperationsAndSupportCommitmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8104319e547-wk-Fact-E27AD696EE58CCD27649B8937FF6ECB9" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q4_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_mrna_ClinicalOperationsAndSupportCommitmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in total under such agreements for our significant clinical operations and support. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December&#160;31, 2019, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s860CC398B9A255B98FC2685236BE7EC4"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-FB955CFA6C889870787CB89380288921-0-wk-Fact-295C9A2799C193CB3DD7B893801A9368" continuedAt="TextSelection-FB955CFA6C889870787CB89380288921-1" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><ix:continuation id="TextSelection-FB955CFA6C889870787CB89380288921-1" continuedAt="TextSelection-FB955CFA6C889870787CB89380288921-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February&#160;28, 2018 and May&#160;7,&#160;2018, the Board of Directors approved an amendment to our Certificate of Incorporation resulting in a total of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105319e461-wk-Fact-BE8345C4B2B35C1AED84B893801B21E6" name="us-gaap:CommonStockSharesAuthorized" contextRef="I2018Q1Feb28" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">775,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock and a total of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105319e465-wk-Fact-8A816BE653BAEA3C492FB8937FF7EBF0" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="I2018Q2May7" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">509,352,795</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of redeemable convertible preferred stock being authorized, respectively. Upon completion of our IPO, our authorized capital stock consists of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105319e469-wk-Fact-D39E849CCAA9EC712948B8937FC84367" name="us-gaap:CommonStockSharesAuthorized" contextRef="I2018Q4Dec11" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,600,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock, par value&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e473-wk-Fact-F9AB9E83BE79E2B63228B8937FF9BA35" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="I2018Q4Dec11" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share, and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105319e477-wk-Fact-0434DCA0086B603E16B4B8937FFB3E56" name="us-gaap:PreferredStockSharesAuthorized" contextRef="I2018Q4Dec11" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">162,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock, par value&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e482-wk-Fact-DC85316C834D4D3474DDB8937FFB75F6" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="I2018Q4Dec11" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share, all of which shares of preferred stock are undesignated.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 11, 2018, we completed our IPO, whereby we sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105319e491-wk-Fact-7AA72E57FBBB38AB1CAFB8937FC85E63" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">26,275,993</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e495-wk-Fact-BF7AE07AD210547A1560B8937FF827B5" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">23.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The aggregate net proceeds received by us from the IPO were&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e499-wk-Fact-8F555B1D34BF18E3CAB5B8937FFE4A49" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">563.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e503-wk-Fact-2CCC2C1D3055194B2F3EB8937FF66413" name="mrna:PaymentsOfUnderwritingDiscounts" contextRef="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e507-wk-Fact-D25968751A91DC4191F4B8937FF5C7EC" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;payable by us. Upon the closing of the IPO, all outstanding shares of our redeemable convertible preferred stock were converted into&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105319e512-wk-Fact-7B2691FE13548D93EC8AB8938003C1FF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="I2018Q4Dec11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">236,012,913</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of the common stock. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-FB955CFA6C889870787CB89380288921-2" continuedAt="TextSelection-FB955CFA6C889870787CB89380288921-3"><span style="font-family:inherit;font-size:10pt;">On February 14, 2020, we sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105319e521-wk-Fact-667BEF7AA272AA53CC15B8937FF1744E" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">26,315,790</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e525-wk-Fact-97714489A7AD1CF776FEB8937FF9F43F" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">19.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share through a public equity offering. The aggregate net proceeds from the offering were&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e529-wk-Fact-130B4AB5F66A22E3BE89B893801C7CEB" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">477.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, net of underwriting discounts, commissions and estimated offering expenses. In addition, the underwriters exercised their option to purchase an additional&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8105319e533-wk-Fact-60B4A8C8DB95DC76A00EB8937FF4CC8E" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,947,368</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock at the public offering price less the underwriting discount, resulting in additional net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8105319e537-wk-Fact-27A05DC3B117A674138BB8937FF7A22D" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.8</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-FB955CFA6C889870787CB89380288921-3">.</ix:continuation>  </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s84ED5EF1C954546A9108C16DD5FCC294"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-CF725775EA77EF17D12BB8938028AE5D-0-wk-Fact-83A7AC51B984925D17C8B893800BD03A" continuedAt="TextSelection-CF725775EA77EF17D12BB8938028AE5D-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CF725775EA77EF17D12BB8938028AE5D-1" continuedAt="TextSelection-CF725775EA77EF17D12BB8938028AE5D-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Plans</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2013, we adopted the 2013 Equity Incentive Plan (the 2013 Incentive Plan) and the 2013 Unit Option and Grant Plan (the 2013 Option Plan), which provided for the grant of incentive units, non-qualified unit options, and restricted and unrestricted unit awards to our employees, officers, directors, advisors, and outside consultants. Historically, we also granted restricted stock to founders, officers, directors, and advisors outside any of the Plans.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2016, we adopted the 2016 Stock Option and Grant Plan (the 2016 Equity Plan), which replaced the 2013 Option Plan and the 2013 Incentive Plan. The 2016 Equity Plan and provided for the grant of incentive stock options, non-qualified stock options, restricted stock, unrestricted stock, and restricted stock units to our employees, officers, directors, consultants, and other key persons.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the IPO, we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Plan. The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. We have initially reserved </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e470-wk-Fact-AD59914E3E93B935117EB8937FFEAE29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="I2018Q4Nov30_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock for the issuance of awards under the 2018 Equity Plan. The 2018 Equity Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e474-wk-Fact-FDBA5ACAF3093EB402C5B8937FCFBBAF" name="mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" contextRef="D2018Q4Nov30_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding number of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-CF725775EA77EF17D12BB8938028AE5D-2" continuedAt="TextSelection-CF725775EA77EF17D12BB8938028AE5D-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year period, with the first </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e491-wk-Fact-8DD296109F87AD4B6239B89380102D8F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of such awards vesting following </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e495-wk-Fact-B71827764C7E8679CD91B8937FCA5E62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> of continued employment or service. The remaining awards vests in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e499-wk-Fact-68567C972375DC0D735AB8938003C462" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="installment" decimals="INF" scale="0" format="ixt-sec:numwordsen">twelve</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> quarterly installments over the following twelve quarters. Stock options granted under the 2016 Equity Plan expire </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e503-wk-Fact-47E5B5BF49416D0E400AB893800D4B51" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrna_StockOptionAndGrantPlan2016Member" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a total of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e516-wk-Fact-C8059FBDF3ACD8DBEC8EB8937FD639E7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares reserved for future issuance under our Equity Plans, of which </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e520-wk-Fact-57BC7CA6A3FA2CE3C803B8937FF8A590" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">47.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares were reserved for equity awards previously granted, and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e524-wk-Fact-A32FE3F45843A7055994B8937FCCDE3C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2020Q1_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">27.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="TextSelection-B7363939C0D799103224B8938029800F-0-wk-Fact-098338A70E5ED90D0EDFB893800D9697" continuedAt="TextSelection-B7363939C0D799103224B8938029800F-1" escape="true">The following table summarizes our option activity during </ix:nonNumeric></span><ix:continuation id="TextSelection-B7363939C0D799103224B8938029800F-1" continuedAt="TextSelection-B7363939C0D799103224B8938029800F-2"><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></ix:continuation></div><ix:continuation id="TextSelection-B7363939C0D799103224B8938029800F-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span><span style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(1)</sup></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e738-wk-Fact-809ED6E484387E2A3213B8938001FB6A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">45,536,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e757-wk-Fact-20369CA0EC9D0F628451B8937FF9D235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e776-wk-Fact-B52090BD6631BFCF1570B89380008808" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e791-wk-Fact-32E175CE9EA6C4B2F35CB89380029156" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">7.2</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e806-wk-Fact-CB6D20F4B94540BFD5CBB8937FF75254" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">286,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e826-wk-Fact-E5564841E0FF39A5311EB893801BF719" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2020Q1YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,585,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e840-wk-Fact-789D442BC744E7E175D4B8937FFFE0A6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e859-wk-Fact-2C76027D96B5A68E2AB4B8937FF28AFA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8107703e915-wk-Fact-81F6CA5A895853CFDF8EB8937FFB4720" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,188,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e930-wk-Fact-20510793C6D98844B927B8937FFF9490" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e949-wk-Fact-0A93D85C84021374AEA0B8937FF9FC03" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8107703e1005-wk-Fact-B30975C49F653C62D76CB8937FF16CF8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2020Q1YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">944,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1020-wk-Fact-303ED13EE78812783057B8938000703A" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1039-wk-Fact-E6C86D8FAD253F766BA1B8937FF2A049" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1095-wk-Fact-A778D9682CEE3690F53CB8937FFA9908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">44,988,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1109-wk-Fact-47CD71239F6A5B10E89DB8937FFD5BF1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2020Q1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1128-wk-Fact-501D9A8C3ED39C666F57B8937FCDBDD1" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="FI2020Q1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e1148-wk-Fact-9231BB98A06439230F47B8937FF527A4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">7.3</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1158-wk-Fact-1CA88863354F94F4BCDFB8937FFE2F36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">669,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1183-wk-Fact-29D50806C2CC34CFCC9CB8938002F23A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,078,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1197-wk-Fact-2576907F316BF2F16A29B8937FFEF8AA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2020Q1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.04</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1216-wk-Fact-EEB986CDBD9954A7E63DB8937FF87A1E" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" contextRef="FI2020Q1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e1236-wk-Fact-32013FE60E381A522791B8937FFA0065" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">6.0</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1246-wk-Fact-8D2054960E107525460BB8937FFEB97C" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">417,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1271-wk-Fact-4E5E6FABB70DF459E6AFB8938005EEB3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,910,448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1285-wk-Fact-86169F24BA816423D648B8937FFD38A6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2020Q1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1304-wk-Fact-BE968485B141CBD5D9B0B8937FF8AF46" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" contextRef="FI2020Q1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e1324-wk-Fact-5190B314EDB53E704F57B8937FF6F102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">8.6</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1334-wk-Fact-2F734174F069507FF6C7B8937FF37058" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">252,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1374-wk-Fact-5B56D8FBBBD9734D2BE6B95DB9FCB8D6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> stock options were exercised. The total intrinsic value of options exercised was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8107703e1378-wk-Fact-81C863868BA3823D906BB89380199135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> March 31, 2020. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8107703e1387-wk-Fact-6CCFAB695DF4BA50D867B8937FC8996A" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-CF725775EA77EF17D12BB8938028AE5D-3" continuedAt="TextSelection-CF725775EA77EF17D12BB8938028AE5D-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Common Stock Units</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have granted restricted stock unit awards generally through the 2018 Equity Plan and 2016 Equity Plan. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-70B5C8DFB78A2A2C546FB893802991C4-0-wk-Fact-C76E1BE6F379E59006AEB8937FFD3A43" continuedAt="TextSelection-70B5C8DFB78A2A2C546FB893802991C4-1" escape="true">The following table summarizes our restricted stock unit activity during </ix:nonNumeric></span><ix:continuation id="TextSelection-70B5C8DFB78A2A2C546FB893802991C4-1" continuedAt="TextSelection-70B5C8DFB78A2A2C546FB893802991C4-2"><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></ix:continuation></div><ix:continuation id="TextSelection-70B5C8DFB78A2A2C546FB893802991C4-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">per Unit</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1491-wk-Fact-B3F8355BCF94743EC0E2B893800A95BD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,177,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1510-wk-Fact-56E359CFD681337CBFDDB893800A0758" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1525-wk-Fact-A03032142BDA4C012816B89380069051" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,057,348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1539-wk-Fact-F3CD97EB85056A84D423B893801673BC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8107703e1559-wk-Fact-7EE7C8805660A320DE04B8938000B501" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">113,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1574-wk-Fact-F401E690771C74ACB13BB8938014C457" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">20.73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8107703e1594-wk-Fact-AA88DBF55BFB7FCBDDF9B89380097380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1609-wk-Fact-80A31DFD7B30B4495046B893800CD747" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">20.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1629-wk-Fact-31DB587A5948223F62A4B8938016F0DE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,062,092</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1643-wk-Fact-4BB56F7693B1958DFEADB89380150BF2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">22.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Employee Stock Purchase Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, we adopted our 2018 Employee Stock Purchase Plan (ESPP), which became effective on December 5, 2018. The ESPP initially reserves and authorizes the issuance of up to a total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1667-wk-Fact-751C1A66C9C6BD36E962B893800261DC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="I2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">810,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock to participating employees. We will make one or more offerings, consisting of one or more purchase periods, each year to our employees to purchase shares under the ESPP. Offerings will usually begin every six months and will continue for </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month periods, referred to as offering periods. The purchase price at which shares are sold under the ESPP will be equal to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1675-wk-Fact-2B71F7267A1E6CB2355DB89380044E12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the lower of the fair market value of the shares on the first business day of the offering period or the last business day of the purchase period. Employees are generally eligible to participate through payroll deductions of between&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1679-wk-Fact-1092D268B99D9FFA25F4B893801C30D3" name="mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" contextRef="I2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1683-wk-Fact-00727DD5CFEB42DEAFC1B8937FCE084A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="I2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of their compensation and may not purchase more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1688-wk-Fact-B5C5295E980022A1B3E7B8937FCB7B1B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" contextRef="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock during each purchase period or&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8107703e1692-wk-Fact-DF364AAC36F1621BA305B8938006D4AA" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" contextRef="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;worth of shares of common stock in any calendar year.&#160;We began our first ESPP offering on June 1, 2019. There were </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> shares sold under the ESPP during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation and Stock-Based Compensation Expense</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation for options granted under our Equity Plans is determined using the Black-Scholes option pricing model. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-1E69789E09F368145A94B8938029B76F-0-wk-Fact-DF58AAEEA64E6AC38299B8937FCF926E" continuedAt="TextSelection-1E69789E09F368145A94B8938029B76F-1" escape="true">The weighted-average assumptions used to estimate the fair value of options granted for </ix:nonNumeric></span><ix:continuation id="TextSelection-1E69789E09F368145A94B8938029B76F-1" continuedAt="TextSelection-1E69789E09F368145A94B8938029B76F-2"><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></ix:continuation></div><ix:continuation id="TextSelection-1E69789E09F368145A94B8938029B76F-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1943-wk-Fact-C52021C4BD08CA8978DBB8938006AE66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e1963-wk-Fact-B501C2629B10C7340BEFB8937FCA5B06" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e1989-wk-Fact-2BF014FD7DCBBD330D86B8937FC9D315" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.14</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e2008-wk-Fact-D99CE3D0B62F98AE9C04B8938018DAE6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.12</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2033-wk-Fact-70C5964AB6DA388A8625B8937FCD4361" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2053-wk-Fact-EEC7AC7BD0E324CD28A6B8937FF772E7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividends</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2079-wk-Fact-9C7A74E2F7A23D9EAD6FB893800574F8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2099-wk-Fact-F4CED1CDB669EF39BFA7B89380082455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2130-wk-Fact-360E5D45EBD56E60D379B893800C035D" name="us-gaap:SharePrice" contextRef="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2149-wk-Fact-0CF41115F17048D4A708B89380141B2B" name="us-gaap:SharePrice" contextRef="FI2019Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-CF725775EA77EF17D12BB8938028AE5D-4"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-B2FD07782CBB8BB173D6B89380290CC0-0-wk-Fact-B3FF17F0ABC56AF00BD8B8938003226B" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the components and classification of stock-based compensation expense for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2305-wk-Fact-93BE8F4A318233BC9B7DB89380177B2B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2324-wk-Fact-A7820E37F85F37535637B89380114DCD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,487</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2344-wk-Fact-9AD0957F0D675F5ED608B893801B3718" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2363-wk-Fact-BC11E50B1F146AF58400B893801AD118" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,010</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2388-wk-Fact-A00675D4DEE531B24BFCB8937FD2082E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">562</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2407-wk-Fact-B838BFD549BC1E03662DB8937FC9E100" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2437-wk-Fact-7FA20B91DB9EDD84D33BB8937FC823A4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2456-wk-Fact-1F6399C1392C687CF797B893801BDB03" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2481-wk-Fact-841FCAD1D87543711D51B89380128BBF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2500-wk-Fact-131021C9BAF0D97B0461B8938008759D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2520-wk-Fact-9B56CBD5BB77FA5F0BA9B8937FFDBA08" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2539-wk-Fact-A2612B8CE64A17DA9B3FB8938007F27F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2569-wk-Fact-7FA20B91DB9EDD84D33BB8937FC823A4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8107703e2588-wk-Fact-1F6399C1392C687CF797B893801BDB03" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d8107703e2607-wk-Fact-FF25048A13380DBC2238B8937FCB0921" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to unvested stock-based compensation with respect to options and restricted stock granted. That cost is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d8107703e2611-wk-Fact-B103065911FADD975DE4B89380040303" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">3.19</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sEADF1AF0DE3E5F5EB9BEBF8AF4401DDD"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">11. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-823698E4432C3C19D50AB8938029908A-0-wk-Fact-DE0B1E4056DD76C718E7B8937FD4FD62" continuedAt="TextSelection-823698E4432C3C19D50AB8938029908A-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-823698E4432C3C19D50AB8938029908A-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion.&#160;Realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. We continued to maintain a full valuation allowance against all of our deferred tax assets based on management&#8217;s evaluation of all available evidence.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no significant income tax provisions or benefits for the three months ended March 31, 2020 and 2019.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sAAE3EE0F9B4A5235840079CE37521631"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-C5CAB44A74EFB32599E2B893802969B5-0-wk-Fact-787EEE9BE55C2032E17AB893801843D0" continuedAt="TextSelection-C5CAB44A74EFB32599E2B893802969B5-1" escape="true">Net Loss per Share </ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-A684FDCD44502787E84AB8938029EF8C-0-wk-Fact-EABFBAE2EA455A847EBEB89380023297" escape="true"><ix:continuation id="TextSelection-C5CAB44A74EFB32599E2B893802969B5-1" continuedAt="TextSelection-C5CAB44A74EFB32599E2B893802969B5-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are calculated as follows (in thousands, except share and per share data):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8108495e642-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">124,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8108495e662-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e729-wk-Fact-0B70C03E5259115FF9BDB893800E79A7" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">353,105,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e748-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">328,809,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8108495e778-wk-Fact-334C08CA9FF5FC0D8533B893800D7CE7" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8108495e798-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-D7711603858B3B1FA378B893802900F9-0-wk-Fact-B2ED2DAA6F1282B6BEA6B893801494AF" escape="true"><ix:continuation id="TextSelection-C5CAB44A74EFB32599E2B893802969B5-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following common stock equivalents, presented based on amounts outstanding as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and 2019 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:77%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e903-wk-Fact-A4F8C53D55D6967BDC97B8937FC8A6AA" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">44,988,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e917-wk-Fact-6CF37FC785D8F77710FFB8937FD086F3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">53,271,281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e932-wk-Fact-67844DECA70B109EB914B8BC04A2A1FD" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e946-wk-Fact-E16E16E624FD2C60A0AFB8937FD5C033" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">150,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e961-wk-Fact-1BAD2E24BA8A5FD92652B8937FD3CBCC" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,062,092</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e975-wk-Fact-5E781E798DACF4813FFCB8937FD169C4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,011,483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e990-wk-Fact-CDECFA2D691AD5FC777EB8937FC91036" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">47,050,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8108495e1004-wk-Fact-E3EEAAEC01F4BA613BF1B8937FC95C11" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">54,433,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0964960c668540099c3eba737858427c"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">13. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SubsequentEventsTextBlock" id="TextSelection-33930D7D4668DFEFE073B893802A7A65-0-wk-Fact-D6DD1FA159F5FE2E634BB89380151796" continuedAt="TextSelection-33930D7D4668DFEFE073B893802A7A65-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="TextSelection-33930D7D4668DFEFE073B893802A7A65-1" continuedAt="TextSelection-33930D7D4668DFEFE073B893802A7A65-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#444444;">On April 16, 2020, we entered into an agreement for a commitment of up to&#160;</span><span style="font-family:inherit;font-size:10pt;color:#444444;"><span>$<ix:nonFraction id="d8107804e454-wk-Fact-17A00E6A638AC690DC19B8B9639E8C5D" name="us-gaap:GrantsReceivable" contextRef="I2020Q2April16_srt_CounterpartyNameAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">483</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;color:#444444;">&#160;from the&#160;Biomedical Advanced Research and Development Authority&#160;(BARDA), a division of the&#160;Office of the Assistant&#160;Secretary for Preparedness and Response (</span><span style="font-family:inherit;font-size:10pt;color:#555555;">ASPR</span><span style="font-family:inherit;font-size:10pt;color:#444444;">) within the&#160;U.S. Department of Health and Human Services&#160;(HHS), to accelerate development of our mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2). Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><ix:continuation id="TextSelection-33930D7D4668DFEFE073B893802A7A65-2" continuedAt="TextSelection-33930D7D4668DFEFE073B893802A7A65-3"><span style="font-family:inherit;font-size:10pt;color:#444444;">On May 1, 2020, we entered into a </span><span style="font-family:inherit;font-size:10pt;color:#444444;"><span><ix:nonNumeric id="d8107804e467-wk-Fact-EBBDEFB9AE254B2B244CEAD25D77A946" name="mrna:CollaborativeArrangementTermOfArrangement" contextRef="D2020Q2May1_srt_CounterpartyNameAxis_mrna_LonzaLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:duryear">10</ix:nonNumeric></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;color:#444444;"><ix:continuation id="TextSelection-33930D7D4668DFEFE073B893802A7A65-3"> year strategic collaboration agreement with&#160;Lonza Ltd. to enable larger scale manufacture of our mRNA vaccine candidate mRNA-1273 against the SARS-CoV-2 and additional&#160;Moderna&#160;products in the future. Under the terms of the agreement, we plan to establish manufacturing suites at Lonza&#8217;s facilities in&#160;the United States&#160;and&#160;Switzerland&#160;for the manufacture of mRNA-1273 at both sites.</ix:continuation> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0E811634733F5300BB21FC9B4F2A419F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited financial information and related notes included in this Form 10-Q and our consolidated financial statements and related notes and other financial information in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on February 27, 2020 (the &#8220;2019 Form 10-K&#8221;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part II, Item 1A - Risk Factors in this Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases, independently and with our strategic collaborators. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Within our platform, we develop technologies that enable the development of mRNA medicines for diverse applications. When we identify technologies that we believe could enable a new group of potential mRNA medicines with shared product features, we call that group a &#8220;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">modality.&#8221; </span><span style="font-family:inherit;font-size:10pt;">While the programs within a modality may target diverse diseases, they share similar mRNA technologies, delivery technologies, and manufacturing processes to achieve shared product features. The programs within a modality will also generally share similar pharmacology profiles, including the desired dose response, the expected dosing regimen, the target tissue for protein expression, safety and tolerability goals, as well as pharmaceutical properties. Programs within a modality often have correlated technology risk, but because they pursue diverse diseases they often have uncorrelated biology risk. We have created six modalities to date:  </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:35px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">prophylactic vaccines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:35px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cancer vaccines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:35px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intratumoral immuno-oncology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:35px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">localized regenerative therapeutics;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:35px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">systemic secreted and cell surface therapeutics; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:35px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">systemic intracellular therapeutics.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019, we believed that positive Phase 1 data from our infectious disease vaccine portfolio, including our cytomegalovirus, or CMV, vaccine, and chikungunya antibody program reduced the risk of our prophylactic vaccines and systemic secreted and cell surface therapeutics modalities, which we have now designated core modalities. In these core modalities,&#160;our strategy is to invest in additional development candidates using our accumulated innovations in technology, our process insights and our preclinical and clinical experience. As such, we have brought five new development candidates forward in early 2020: interleukin-2, or IL-2,&#160;programmed death-ligand 1,&#160;or PD-L1,&#160;a pediatric Respiratory Syncytial Virus, or RSV vaccine, an Epstein-Barr Virus, or EBV, vaccine and a SARS-CoV-2 vaccine, as part of our mission to use our technology to advance global public health. Our exploratory modalities continue to be a critical part of advancing our strategy to maximize the application of our potential mRNA medicines.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a diverse development pipeline, and the broad potential applications of mRNA medicines have led us to raise significant capital and adopt a long-term approach to capital allocation that balances near-term risks and long-term value creation. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents, and investments of approximately </span><span style="font-family:inherit;font-size:10pt;">$1.72 billion</span><span style="font-family:inherit;font-size:10pt;">. We use this capital to fund operations and investing activities for technology creation, drug discovery and clinical development programs, infrastructure and capabilities to enable our research engine and early development engine (which includes our Moderna Technology Center or MTC), our digital infrastructure, creation of our portfolio of intellectual property and administrative support.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have incurred significant operating losses. Our net loss was $514.0 million and $384.7 million for the years ended December&#160;31, 2019 and 2018, respectively. Our net loss was </span><span style="font-family:inherit;font-size:10pt;">$124.2 million</span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, our accumulated deficit was </span><span style="font-family:inherit;font-size:10pt;">$1.62 billion</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the foreseeable future, we expect to continue to incur significant expenses and operating losses in connection with our ongoing activities, including as we:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue our platform research and drug discovery and development efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conduct clinical trials for our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manufacture clinical trial materials and develop large-scale manufacturing capabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek regulatory approval for our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintain, expand, and protect our intellectual property;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">hire additional personnel to support our program development effort to obtain regulatory approval and secure additional facilities for operations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue to operate as a public company.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not expect to generate revenue from the sale of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for and commercialize any of our investigational medicines, we expect to incur significant commercialization expenses.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from sales of our medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution, and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of one or more of our programs.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our medicines, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In response to the global outbreak of coronavirus, we are pursuing the rapid manufacture of our vaccine candidate, mRNA-1273 for the treatment of SARS-CoV-2, the novel strain of coronavirus that causes coronavirus disease 19, or COVID-19, in collaboration with the Vaccine Research Center and Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, or the NIH. The Coalition for Epidemic Preparedness Innovations, or CEPI, has funded the Current Good Manufacturing Practices cGMP manufacture of the preliminary clinical batches of the vaccine, and NIAID is conducting a Phase 1 clinical trial in the United States. In addition, we have submitted an Investigational New Drug, or IND, application to the FDA to evaluate mRNA-1273 in Phase 2 and late stage studies if supported by safety data from the NIH-led Phase 1 study.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also committing&#160;financial resources and personnel to the development of mRNA-1273, which may cause delays in or otherwise negatively impact our other development programs.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ultimate impacts of COVID-19 on our business are currently unknown. In March 2020, we announced that, based on the special concerns for the safety and health of pediatric patients and their caregivers, and the risks of disruption to the integrity of trials from COVID-19, we decided to pause new enrollment of our Phase 1 rare disease clinical trials (mRNA-3704 for MMA, mRNA-3927 for PA) and our age de-escalation trial for our pediatric respiratory vaccine (mRNA-1653 for hMPV/PIV3). These decisions will be re-evaluated on an ongoing basis as the COVID-19 situation evolves. We will continue to actively monitor the situation and may take further precautionary and preemptive actions as may be required by federal, state or local authorities or that we determine are in the best interests of public health and safety and that of our patient community, employees, partners, suppliers and stockholders. We cannot predict the effects that such actions, or the impact of COVID-19 on global business operations and economic conditions, may have on our business or strategy, including the effects on our ongoing and planned clinical development activities and prospects, or on our financial and operating results. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Pipeline</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This section describes the pipeline that has emerged thus far from the combination of our strategy, our platform, our infrastructure, and the resources we have amassed. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline which currently consists of 23 development candidates across our 22 programs. Over 1,900 subjects have been enrolled in our clinical trials since December 2015. Our diverse pipeline comprises programs across six modalities and a broad range of therapeutic areas. A modality is a group of potential mRNA medicines with shared product features, and the associated combination of mRNA technologies, delivery technologies, and manufacturing processes. Aspects of our pipeline have been supported through strategic alliances, including with AstraZeneca plc, or AstraZeneca, Merck &amp; Co, Inc., or Merck, and Vertex Pharmaceuticals Inc., or Vertex, and government-sponsored organizations and private foundations focused on global health initiatives, the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Defense Advanced Research Projects Agency, or DARPA, the NIH, CEPI and the Bill&#160;&amp; Melinda Gates Foundation, or the Gates Foundation.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following chart shows our current pipeline of 23 development candidates across our 22 programs, grouped into modalities-first the two core modalities where we believe we have reduced the technology risk, followed by the four exploratory modalities in which we are continuing to investigate the clinical use of mRNA medicines.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="developmentpipeline.jpg" alt="developmentpipeline.jpg" style="height:540px;width:720px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Abbreviations: AZ, AstraZeneca; G6Pase, glucose 6-phosphatase; IL-12, interleukin 12; IL-23, interleukin 23; IL-36&#611;, interleukin 36 gamma; MUT, methylmalonyl-CoA mutase; PAH, phenylalanine hydroxylase; PCCA/PCCB, propionyl-CoA carboxylase subunit A/B; VEGF-A, vascular endothelial growth factor&#160;A. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The breadth of biology addressable using mRNA technology is reflected in our current development pipeline of 22 programs. These span 26 different proteins or protein complexes: 11 different antigens (including virus-like particles) for infectious disease vaccines; two different cancer vaccines, one personalized cancer vaccine addressing neoantigens and one for a shared cancer antigen; four different immuno-modulator targets (including membrane and systemically secreted proteins) for immuno-oncology programs; one secreted, local regenerative factor for a heart failure program; four secreted or cell surface proteins of diverse biology (an antibody, an engineered protein hormone, a secreted cytokine and a cell surface receptor); and four intracellular enzymes for rare disease programs. The diversity of proteins made from mRNA within our development pipeline is shown in the figure below. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="modernacellmap.jpg" alt="modernacellmap.jpg" style="height:374px;width:720px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have developed six modalities, which are summarized as follows: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Prophylactic vaccines:</span><span style="font-family:inherit;font-size:10pt;"> Our prophylactic vaccines modality currently includes eight programs, six of which have entered into clinical trials. In addition, to the eight programs being developed, the H10N8 vaccine (mRNA-1440) and Chikungunya vaccine (mRNA-1388) are two public health programs that are not being further developed without government or other funding. Of these programs, we have demonstrated desired pharmacology, in the form of immunogenicity, in the Phase&#160;1 clinical trials for the following: H10N8 vaccine (mRNA-1440), H7N9 vaccine (mRNA-1851), RSV vaccine (mRNA-1777), Chikungunya vaccine (mRNA-1388), human metapneumovirus (hMPV)/ parainfluenza virus type 3 (PIV3) vaccine (mRNA-1653), Zika vaccine (mRNA-1893) and CMV vaccine (mRNA-1647). We have an ongoing Phase 1 trial for the next generation Zika vaccine (mRNA-1893) and Merck is conducting a Phase 1 trial for an additional RSV vaccine (mRNA-1172). Our SARS-CoV-2 vaccine (mRNA-1273) is in a Phase 1 clinical trial being run by the NIH and we have received FDA clearance to begin Phase 2 studies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:21px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Systemic secreted therapeutics:</span><span style="font-family:inherit;font-size:10pt;"> We have four systemic secreted and cell surface therapeutics development candidates in our pipeline. Our secreted programs include our antibody against Chikungunya virus (mRNA-1944), Relaxin (AZD7970) for the treatment of heart failure, and IL-2 (mRNA-6231) for autoimmune disorders. Our antibody against Chikungunya virus (mRNA-1944) is currently being evaluated in an ongoing Phase 1 dose escalation study in healthy adults that is randomized and placebo-controlled. The remaining programs for Relaxin (AZD7970) and IL-2 (mRNA-6231) are currently in preclinical development. We have a cell surface therapeutic program in this modality. PDL-1 (mRNA-6981) for autoimmune hepatitis is currently in preclinical development.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cancer vaccines: </span><span style="font-family:inherit;font-size:10pt;">We are currently developing two programs within our cancer vaccines modality. Our personalized cancer vaccine program mRNA-4157 is being developed in collaboration with Merck and is in a multiple-arm Phase&#160;1 trial and a randomized Phase 2 trial. A second personalized cancer vaccine, NCI-4650 was being developed in collaboration with the National Cancer Institute, or NCI, and was in an investigator-initiated single-arm Phase&#160;1 trial which has been completed. The two vaccines mRNA-4157 and NCI-4650 differ in the neoantigen selection protocols used, but are otherwise substantially the same. Our second program within this modality, mRNA-5671, is a KRAS vaccine. Our strategic collaborator Merck has a Phase 1 clinical trial ongoing for mRNA-5671.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intratumoral immuno-oncology: </span><span style="font-family:inherit;font-size:10pt;">We have three programs in this modality. The first program in this modality, OX40L (mRNA-2416), was designed to overcome technological challenges in advancing this modality, including engineering the mRNA sequence to minimize off-target effects, utilizing our proprietary LNPs to enhance safety and tolerability, and to demonstrate expression of a membrane protein in patients. OX40L (mRNA-2416) is currently being evaluated in an ongoing Phase&#160;1/2 trial in the United States, and protein expression has been demonstrated in a number of patients. Data from the monotherapy arm of this ongoing study of mRNA-2416</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span><span style="font-family:inherit;font-size:10pt;">showed that mRNA-2416 was well-tolerated at all dose levels studied with the majority of adverse events reported as grade 1 and 2 and no grade 3 adverse events reported. This data supports the evaluation of intratumoral mRNA-2416 with the anti-PD-L1 inhibitor durvalumab in solid tumors, which is ongoing in Part B of this study with a focus on advanced ovarian carcinoma. Our second program, OX40L/IL-23/IL-36&#947; (Triplet) (mRNA-2752), has dosed patients in a Phase 1 study for the treatment of advanced or metastatic solid tumor malignancies or lymphoma. Our third program, IL-12 (MEDI1191), is being developed in collaboration with AstraZeneca.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Localized regenerative therapeutics: </span><span style="font-family:inherit;font-size:10pt;">Our localized VEGF-A program, AZD8601, which is being developed by AstraZeneca, has completed a Phase&#160;1a/b trial to describe its safety, tolerability, protein production, and activity in diabetic patients. The study has met its primary objectives of describing safety and tolerability and secondary objectives of demonstrating protein production and changes in blood flow post AZD8601 administration. In this trial, AZD8601 was administered by intradermal injection in the forearm skin of patients for single ascending doses. These data are consistent with studies previously conducted in preclinical models. We believe these data provide clinical proof of mechanism for our mRNA technology outside of the vaccine setting</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">AstraZeneca has initiated a Phase 2a study of AZD8601 for VEGF-A for ischemic heart disease in patients undergoing coronary artery bypass grafting (CABG) surgery with moderately impaired systolic function, and the trial is ongoing.&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Systemic intracellular therapeutics: </span><span style="font-family:inherit;font-size:10pt;">We have four systemic intracellular therapeutics development candidates in our pipeline. Our intracellular programs address methylmalonic acidemia, or MMA (mRNA-3704), propionic acidemia, or PA (mRNA-3927), phenylketonuria, or PKU (mRNA-3283), and glycogen storage disorder type 1a, or GSD1a (mRNA-3745). We have an open IND for mRNA-3704 for a planned Phase 1/2 trial, and the FDA has also designated the investigation of mRNA-3704 for the treatment of isolated MMA due to MUT deficiency as a Fast Track development program. We have an open IND for mRNA-3927 for a planned Phase 1/2 trial and this program has also been designated as a Fast Track development program. PKU (mRNA-3283) is currently in preclinical development. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following are recent key updates for our development candidates:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Delays based on pandemic: </span><span style="font-family:inherit;font-size:10pt;">We are</span><span style="font-family:inherit;font-size:10pt;color:#444444;"> using a risk-based framework to evaluate new participant enrollment and new site initiation on a case-by-case basis.&#160;We&#160;remain committed to our clinical development plans and are working closely with all stakeholders to try to mitigate the impact of the pandemic on our ongoing clinical trials.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;color:#444444;">Based on the special concerns for the safety and health of pediatric patients and their caregivers, and the risks of disruption to the integrity of trials from COVID-19, we have decided to pause new enrollment of our Phase 1 rare disease clinical trials (mRNA-3704 for MMA, mRNA-3927 for PA) and our age de-escalation trial for our pediatric respiratory vaccine (mRNA-1653 for hMPV/PIV3). These decisions will be re-evaluated on an ongoing basis as the COVID-19 situation evolves.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SARS-COV-2 (mRNA-1273): </span><span style="font-family:inherit;font-size:10pt;">A Phase 1 study of mRNA-1273 is being conducted by the National Institutes of Health (NIH). The Phase 1 open-label study, which began on March 16, 2020 has completed enrollment of the original study: 45 healthy adult volunteers ages 18 to 55 years in three dose cohorts (25 &#181;g, 100 &#181;g and 250 &#181;g). The NIH recently amended the Phase 1 protocol to include an additional six cohorts: three cohorts of older adults (ages 56-70) and three cohorts of elderly adults (age 71 and above). Enrollment for these cohorts is ongoing. On May 6, 2020, we received FDA clearance to evaluate mRNA-1273 in a Phase 2 study.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CMV vaccine (mRNA-1647):&#160;</span><span style="font-family:inherit;font-size:10pt;">We announced positive data from the second interim analysis of the Phase 1 clinical trial of mRNA-1647, which has completed enrollment and is evaluating the safety and immunogenicity of mRNA-1647 in 181 healthy adult volunteers. The clinical trial population includes those who are na&#239;ve to CMV infection (CMV-seronegative) and those who had previously been infected by CMV (CMV-seropositive). Participants were randomized to receive either placebo, or 30, 90, 180 or 300 &#181;g of mRNA-1647 on a dosing schedule of 0, 2 and 6 months. This second planned interim analysis assessed safety and immunogenicity of the first three dose levels (30, 90, and 180 &#181;g) at seven months (one month after the third vaccination), and the highest dose level (300 &#181;g) at three months (one month after the second vaccination). Neutralizing antibody titers (levels of circulating antibodies that block infection) were assessed in two assays utilizing epithelial cells and fibroblasts, which measure immune response to the pentamer and gB vaccine antigens, respectively. gB antigen-specific T cell responses after the second and third vaccinations were measured in a subset of CMV-seronegative participants in the 30, 90 and 180 &#181;g dose levels utilizing an ELISpot assay. Pentamer-specific T cell assays remain in development. Vaccine-induced neutralizing antibody responses in the CMV-seronegative group were compared to the baseline neutralizing antibody titers in the CMV-seropositive group, noting that prior maternal CMV infection is associated with an approximately 30-fold lower risk of congenital CMV infection compared to the risk in the setting of maternal primary CMV infection.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In CMV-seronegative participants at seven months (one month after the third vaccination) in the 30, 90 and 180 &#181;g dose levels:</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;padding-left:72px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-72px;"><span style="font-family:inherit;font-size:10pt;">A dose-related increase in neutralizing antibody titers was observed in both epithelial cell and fibroblast assays.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;padding-left:72px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-72px;"><span style="font-family:inherit;font-size:10pt;">After the third vaccination, neutralizing antibody titers against epithelial cell infection were greater than 10 times higher in the 90 and 180 &#181;g dose levels than CMV-seropositive baseline titers at the 90 and 180 &#181;g dose levels.&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;padding-left:72px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-72px;"><span style="font-family:inherit;font-size:10pt;">After the third vaccination, neutralizing antibody titers against fibroblast infection were 1.3 to 1.4 times higher than CMV-seropositive baseline titers at the 90 and 180 &#181;g dose levels.&#160;</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In CMV-seropositive participants at seven months (one month after the third vaccination) in the 30, 90 and 180 &#181;g dose levels:</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A dose-related increase in neutralizing antibody titers was observed in both epithelial cell and fibroblast assays.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The third vaccination boosted neutralizing antibody titers against epithelial cell infection to levels of 22-fold to 40-fold over baseline titers in all dose levels.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The third vaccination boosted neutralizing antibody titers against fibroblast infection to levels of approximately 4-fold to 6-fold over baseline titers in all dose levels.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:108px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Participants receiving 300 &#181;g of mRNA-1647 followed through three months (one month after the second vaccination) continued to show consistent dose dependent increases in neutralizing antibodies against epithelial cell infection and against fibroblast infection in both CMV-seronegative and CMV seropositive groups. Safety and tolerability in participants receiving 300 &#181;g of mRNA-1647 was comparable to that observed at the 180 &#181;g dose level. In a subset of CMV-seronegative participants in the 30, 90 and 180 &#181;g dose levels, gB antigen-specific T cell activation was observed at all dose levels after the second and third vaccinations.</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A safety analysis indicated that the vaccine was generally well-tolerated. There were no vaccine-related serious adverse events. The most common solicited local adverse reaction, or AR, was injection site pain. The most common solicited systemic ARs were headache, fatigue, myalgia and chills. Fever was reported in 0%-55% of CMV-seronegative treatment groups and in 8%-67% of CMV-seropositive treatment groups. In general, solicited systemic ARs occurred less frequently after the third vaccination compared to the second, and were more common in the CMV-seropositive cohorts compared to the CMV seronegative cohorts. Grade 3 solicited ARs were more common in CMV-seropositive participants, and were fatigue (0%-27% of a given dose cohort), chills (0%-27% of a given dose cohort) and fever (0%-33% of a given dose cohort). As reported in the previous interim analysis, there was a single Grade 4 AR of an isolated lab finding of elevated partial thromboplastin time, which was elevated at baseline (Grade 1) and self-resolved on the next lab test with no associated clinical findings. Safety and tolerability data at the 300 &#181;g dose level were generally similar to that observed at the 180 &#181;g dose level.</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the small sample size limits the conclusions that can be drawn from the data, the findings from this interim analysis build on an earlier interim analysis of safety and immunogenicity data through one month after the second vaccination in the 30, 90 and 180 &#181;g dose levels. A 12-month interim analysis of safety and immunogenicity, which will report safety and immunogenicity results through six months after the third vaccination, is pending.</span></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">hMPV/PIV3 vaccine (mRNA-1653):</span><span style="font-family:inherit;font-size:10pt;"> The first 10 subjects in the Phase 1b age de-escalation clinical trial of mRNA-1653 have been enrolled and certain of these subjects have been dosed. This trial is suspended due to the COVID-19 pandemic.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Zika virus vaccine (mRNA-1893):</span><span style="font-family:inherit;font-size:10pt;"> All four cohorts (10 &#181;g, 30 &#181;g, 100 &#181;g, 250 &#181;g) of the Phase 1 study of mRNA-1893 have been dosed. In April, we announced positive data from the interim analysis from the 10 &#181;g and 30 &#181;g cohorts. The clinical trial population includes those who had not been infected by the Zika virus (flavivirus seronegative) and those who had previously been infected by the Zika virus (flavivirus seropositive). Participants were randomized to receive either placebo, 10, 30, 100 or 250 &#181;g of mRNA-1893 on a dosing schedule of day 1 and day 29. This first planned interim analysis assessed safety and immunogenicity of the first two dose levels (10 and 30 &#181;g) at day 57, 28 days after the second vaccination. Neutralizing antibody titers (levels of circulating antibodies that block infection) were assessed using Plague Reduction Neutralizing Test (PRNT</span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">50</sub></span><span style="font-family:inherit;font-size:10pt;">) and microneutralization assays (MN), which provide equivalent guidance for interpreting the neutralizing immune response. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:108px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the flavivirus-seronegative group: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Seroconversion rates after the second vaccination reached 94.4% in the 10 &#181;g dose level and 100% in the 30 &#181;g dose level, based on the PRNT</span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">50</sub></span><span style="font-family:inherit;font-size:10pt;">. MN data were consistent with PRNT</span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">50&#160;</sub></span><span style="font-family:inherit;font-size:10pt;">data.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A single vaccination of the 30 &#181;g dose level was sufficient to seroconvert baseline flavivirus seronegative participants. However, there was a clear benefit of a two-dose series given 28 days apart. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the flavivirus-seropositive group:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><span style="font-family:inherit;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The percentage of participants achieving a 4-fold boost in pre-existing PRNT</span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">50</sub></span><span style="font-family:inherit;font-size:10pt;"> titers after the second vaccination reached 50% in the 10 &#181;g dose level and 75% in the 30 &#181;g dose level, based on the PRNT</span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">50</sub></span><span style="font-family:inherit;font-size:10pt;">. MN data were consistent with PRNT</span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">50</sub></span><span style="font-family:inherit;font-size:10pt;"> data.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A safety analysis indicated that the 10 and 30 &#181;g dose levels were both generally well tolerated. There were no vaccine-related serious adverse events. The most common solicited local adverse reaction was local pain at the injection site. The safety profile did not appear affected by the second vaccination or a flavivirus-positive baseline serostatus. One participant experienced a Grade 4 Prothrombin Test increase at day 29 with no clinical manifestations and was not considered related to mRNA-1893 administration. </span></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the 10 and 30 &#181;g cohorts, further analysis of safety and immunogenicity at month 7 and month 13 is pending. The 100 and 250 &#181;g dose cohort participants have received their second vaccination at day 29 without clinical trial disruptions due to COVID-19; interim analysis of safety and immunogenicity is pending. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Personalized cancer vaccine (PCV) (mRNA-4157):</span><span style="font-family:inherit;font-size:10pt;">&#160;Patients continue to be dosed in the randomized Phase 2 clinical trial investigating&#160;a 1 mg dose of mRNA-4157&#160;in combination with Merck&#8217;s pembrolizumab (KEYTRUDA), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma.&#160;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OX40L (mRNA-2416):</span><span style="font-family:inherit;font-size:10pt;"> Based on available data, we have decided to focus the&#160;development of mRNA-2416 for the treatment of patients with ovarian cancer in combination with&#160;durvalumab&#160;(IMFINZI), a PD-L1 inhibitor.&#160;The&#160;safety cohort of the&#160;combination arm (mRNA-2416 and&#160;durvalumab) of this Phase 1/2 clinical trial continues to enroll&#160;and will be followed by a Phase 2 expansion cohort in patients with advanced ovarian carcinoma. We will not move forward with the mRNA-2416 monotherapy ovarian cancer arm of this study.&#160;&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Antibody against Chikungunya virus (mRNA-1944): </span><span style="font-family:inherit;font-size:10pt;">We are conducting a Phase 1 dose-escalation study in healthy adults that is randomized and placebo-controlled. The objective is to evaluate the safety and tolerability of escalating doses (0.1, 0.3, 0.6, mg/kg dose levels, without dexamethasone included in the premedication regimen, a dose level cohort at 0.6 mg/kg dose level, with dexamethasone included in the premedication regimen, with 8 subjects per cohort) of mRNA-1944 administered via intravenous infusion. In addition, there is a dose level cohort in which subjects will be administered two IV infusions of 0.3 mg/kg, one infusion on Day 1 and another subsequent infusion on Day 8, without dexamethasone in the premedication regimen. No further dose escalation beyond 0.6&#160;mg/kg is planned.&#160;Dose level cohorts 0.1, 0.3, 0.6 mg/kg without dexamethasone in the premedication regimen and dose level cohort 0.6 mg/kg with dexamethasone in the premedication regimen have been completed.</span><span style="font-family:Arial;font-size:10pt;color:#444444;"> </span><span style="font-family:inherit;font-size:10pt;color:#444444;">Enrollment of further subjects in the Company&#8217;s chikungunya virus antibody trial (mRNA-1944) has been paused by the site due to the impact of COVID-19.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;color:#444444;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Methylmalonic Acidemia (MMA) (mRNA-3704):</span><span style="font-family:inherit;font-size:10pt;"> The FDA granted Fast Track designation for mRNA-3704. At this time, enrollment is paused for this study.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;color:#444444;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Propionic Acidemia (PA) (mRNA-3927):</span><span style="font-family:inherit;font-size:10pt;"> The FDA granted Fast Track designation for mRNA-3927. At this time, enrollment is paused for this study.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBDD183AE6DCB54EA90848EE31E40BE37"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Operations Overview</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, we have not generated any revenue from the sale of potential mRNA medicines. Our revenue has been primarily derived from strategic alliances with Merck, Vertex and AstraZeneca, and from government-sponsored and private organizations including BARDA, DARPA and the Gates Foundation to discover, develop, and commercialize potential mRNA medicines. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$8.4 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$16.0 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, and was primarily comprised of collaboration revenue from our strategic alliances as follows (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">976</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,687</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vertex</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,056</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,614</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AstraZeneca</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,270</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">814</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">155</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:64px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total collaboration revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,457</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,115</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash received from strategic alliances was </span><span style="font-family:inherit;font-size:10pt;">$9.4 million</span><span style="font-family:inherit;font-size:10pt;"> and $4.8 million for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The timing of revenue recognition is not directly correlated to the timing of cash receipts. Total deferred revenue related to our strategic alliances as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$201.8 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$202.3 million</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant revenue for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;">$3.9 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$1.9 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, and was generated primarily from contracts with BARDA and the Gates Foundation, to develop mRNA medicine.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to generate revenue from sales of mRNA medicines and become profitable depends upon our ability to successfully develop and commercialize mRNA medicines. For the foreseeable future, we do not expect to generate revenue from product sales; provided, however, that the rapid acceleration of our work on mRNA-1273 may result in revenue to us, either based on sales of the product directly or through collaborators. In addition, we expect to continue to receive funding from our new contract with BARDA, which may result in significant additional amounts of revenue to Moderna during 2020. To the extent that existing or potential future strategic alliances generate revenue, our revenue may vary due to many uncertainties in the development of our mRNA medicines under these strategic alliances and other factors. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development efforts. We expect our programs to mature and advance to later stage clinical development, and we expect expenses to increase as we seek regulatory approvals for our investigational medicines and begin to commercialize any approved mRNA medicines.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expenses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The nature of our business and primary focus of our activities generate a significant amount of research and development costs. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses represent costs incurred by us for the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cost to develop our platform;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">discovery efforts leading to development candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">preclinical, nonclinical, and clinical development costs for our programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cost to develop our manufacturing technology and infrastructure; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">digital infrastructure costs.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The costs above comprise the following categories:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">personnel-related expenses, including salaries, benefits, and stock-based compensation expense;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses incurred under agreements with third parties, such as consultants, investigative sites, contract research organizations, or CROs, that conduct our preclinical studies and clinical trials, and in-licensing arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">costs of acquiring, developing, and manufacturing materials for preclinical studies and clinical trials, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses incurred for the procurement of materials, laboratory supplies, and non-capital equipment used in the research and development process; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">facilities, depreciation, and amortization, and other direct and allocated expenses incurred as a result of research and development activities.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use our employee and infrastructure resources for the advancement of our platform, and for discovering and developing programs. Due to the number of ongoing programs and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development programs are not recorded or maintained on a program- or modality-specific basis.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects our research and development expenses, including direct program specific expenses summarized by modality and indirect or shared operating costs summarized under other research and development expenses during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Program expenses by modality:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prophylactic vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,740</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,262</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cancer vaccines</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,467</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,086</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intratumoral immuno-oncology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,033</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,418</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Localized regenerative therapeutics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Systemic secreted and cell surface therapeutics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">692</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,633</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Systemic intracellular therapeutics</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,195</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,743</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total program-specific expenses by modality</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,127</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46,150</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other research and development expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discovery programs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,498</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,915</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Platform research</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,586</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,497</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technical development and unallocated manufacturing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,138</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,185</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shared discovery and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,752</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,883</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,036</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,783</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total research and development expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">115,137</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">130,413</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">__________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Include a total of 24 and 21 development candidates at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Program-specific expenses include external costs and allocated manufacturing costs of mRNA supply and consumables, and are reflected as of the beginning of the period in which the program was internally advanced to development or removed if development was ceased.</span></div></td></tr></table><div style="line-height:120%;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> &#8220;modality&#8221;</span><span style="font-family:inherit;font-size:10pt;"> refers to a group of programs with common product features and the associated combination of enabling mRNA technologies, delivery technologies, and manufacturing processes. The program-specific expenses by modality summarized in the table above include expenses we directly attribute to our programs, which consist primarily of external costs, such as fees paid to outside consultants, central laboratories, investigative sites, and CROs in connection with our preclinical studies and clinical trials, and allocated manufacturing costs of mRNA supply and consumables. Costs to acquire and manufacture mRNA supply for preclinical studies and clinical trials are recognized and included in unallocated manufacturing expenses when incurred, and subsequently allocated to program-specific manufacturing costs after completion of the program-specific production. The timing of allocating manufacturing costs to the specific program varies depending on the program development and production schedule. We do not allocate personnel-related costs, including stock-based compensation, costs associated with our general platform research, technical </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">development, and other shared costs on a program-specific basis. These costs were therefore excluded from the summary of program-specific expenses by modality.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discovery program expenses are costs associated with research activities for our programs in the preclinical discovery stage, and primarily consist of external costs for CROs and lab services, and allocated manufacturing cost of preclinical mRNA supply and consumables.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Platform research expenses are mainly costs to develop technical advances in mRNA science, delivery science, and manufacturing process design. These costs include personnel-related costs, computer equipment, facilities, preclinical mRNA supply and consumables, and other administrative costs to support our platform research. Technology development and unallocated manufacturing expenses are primarily related to non-program-specific manufacturing process development and manufacturing costs. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shared discovery and development expenses are research and development costs such as personnel-related costs and other costs, which are not otherwise included in development programs, discovery programs, platform research, technical development and unallocated manufacturing expenses, stock-based compensation, and other expenses.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The largest component of our total operating expenses has historically been our investment in research and development activities, including development of our platform, mRNA technologies, and manufacturing technologies. We expense research and development costs as incurred and cannot reasonably estimate the nature, timing, and estimated costs required to complete the development of the development candidates and investigational medicines we are currently developing or may develop in the future. There are numerous risks and uncertainties associated with the research and development of such development candidates and investigational medicines, including, but not limited to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><span style="font-family:inherit;font-size:10pt;">scope, progress, and expense of developing ongoing and future development candidates and investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><span style="font-family:inherit;font-size:10pt;">entry in and completion of related preclinical studies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><span style="font-family:inherit;font-size:10pt;">enrollment in and completion of subsequent clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><span style="font-family:inherit;font-size:10pt;">safety and efficacy of investigational medicines resulting from these clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><span style="font-family:inherit;font-size:10pt;">changes in laws or regulations relevant to the investigational medicines in development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><span style="font-family:inherit;font-size:10pt;">receipt of the required regulatory approvals; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><span style="font-family:inherit;font-size:10pt;">commercialization, including establishing manufacturing and marketing capabilities.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A change in expectations or outcomes of any of the known or unknown risks and uncertainties may materially impact our expected research and development expenditures. Continued research and development is central to the ongoing activities of our business. Investigational medicines in later stages of clinical development, including mRNA-1273 and mRNA-1647, generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development costs to continue to increase in the future as our investigational medicines progress through the development phases and as we identify and develop additional programs. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our investigational medicines, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time due to the early stage of development of our investigational medicines. Moreover, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we continue to progress mRNA-1273 through the development process in order to be useful during the current pandemic, we expect to incur significant additional expenses, including those related to clinical trials, expanding our manufacturing capabilities, regulatory filings and the related costs, expansion of our operations into foreign jurisdictions and commercialization and distribution efforts. At this time, the magnitude of these potential expenditures and whether or not they will be funded by third party contributions in whole or in part is not known. In connection with the new BARDA agreement to accelerate development of mRNA-1273, our revenue and expenses are expected to increase significantly. BARDA's funding is expected to offset those increased expenses that are covered under the BARDA agreement, subject to our obtaining reimbursement from BARDA.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative expenses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for executives, finance, legal, human resources, business development and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property, or IP. These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate general and administrative expenses will increase as we continue to expand the number of programs in development and prepare for the potential earlier establishment of commercial activities both within and outside the United States. In addition, if we obtain regulatory approval for any of our investigational medicines, including the potential accelerated approval for mRNA-1273, and do not enter into one or more third-party commercialization collaboration and manufacturing arrangements, we will incur significant expenses related to building a regulatory, manufacturing, sales and marketing team to support medicine sales, marketing, and distribution activities.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a broad IP portfolio covering our development and commercialization of mRNA vaccine and therapeutic programs, including those related to mRNA design, formulation, and manufacturing platform technologies. We regularly file patent applications to protect innovations arising from our research and development. We also hold trademarks and trademark applications in the United States and foreign jurisdictions. Costs to secure and defend our IP are expensed as incurred and are classified as general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses, including IP-related expenses, were </span><span style="font-family:inherit;font-size:10pt;">$24.1 million</span><span style="font-family:inherit;font-size:10pt;"> and $27.3 million for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. IP-related expenses, including our internal personnel-related costs, were $2.5&#160;million and $2.8 million for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and 2019, respectively. We did not incur litigation expenses related to our IP during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest income</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income consists of interest generated from our investments in cash and cash equivalents, money market funds, and high-quality fixed income securities.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other expense, net</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net consists of interest expense, gains (losses) from the sale of investments in marketable securities, and other income and expense unrelated to our core operations. Interest expense is primarily derived from our finance lease related to our Moderna Technology Center manufacturing facility, or MTC South.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical accounting policies and significant judgments and estimates</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the condensed consolidated financial statements prospectively from the date of change in estimates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material changes in our critical accounting policies and estimates in the preparation of our condensed consolidated financial statements during&#160;the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">&#160;compared to those disclosed in our Annual Report on Form 10-K for the year ended&#160;December&#160;31, 2019, or 2019 Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently issued accounting pronouncements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our condensed consolidated financial statements, such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of operations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize our condensed consolidated statements of operations for each period presented (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change 2020 vs. 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,457</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,115</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(9,658</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(68)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,932</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,910</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">106%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,389</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,025</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(7,636</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(48)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating Expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">115,137</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">130,413</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(15,276</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,114</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,253</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3,139</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">139,251</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">157,666</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(18,415</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(130,862</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(141,641</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,779</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(8)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,852</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,972</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3,120</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(28)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,154</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,931</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">777</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(40)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(124,164</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(132,600</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,436</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(24</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(375)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(124,230</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(132,576</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,346</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6)%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$7.6 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">48%</span><span style="font-family:inherit;font-size:10pt;">, for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to the same period in 2019, due to a decrease in collaboration revenue, partially offset by an increase in grant revenue. Collaboration revenue decreased by </span><span style="font-family:inherit;font-size:10pt;">$9.7 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">68%</span><span style="font-family:inherit;font-size:10pt;">, for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to the same period in 2019, mainly attributable to cumulative catch-up adjustments in revenue due to changes in estimated costs for our future performance obligations under the collaboration agreements with Merck and AstraZeneca, and a decrease in revenue from Merck, primarily driven by the timing of amortization of deferred revenue due to the satisfaction of our performance obligation. Grant revenue increased by </span><span style="font-family:inherit;font-size:10pt;">$2.0 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">106%</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to the same period in 2019, mainly due to an increase in revenue from BARDA. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating expenses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$15.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;">, for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to the same period in 2019. The decrease was primarily attributable to a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in lab supplies and materials of </span><span style="font-family:inherit;font-size:10pt;">$15.2 million</span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in clinical trial and manufacturing costs of </span><span style="font-family:inherit;font-size:10pt;">$4.5 million</span><span style="font-family:inherit;font-size:10pt;">, and a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in consulting and outside services of </span><span style="font-family:inherit;font-size:10pt;">$1.0 million</span><span style="font-family:inherit;font-size:10pt;">. These decreases were partially offset by an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in personnel related costs of </span><span style="font-family:inherit;font-size:10pt;">$3.1 million</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in depreciation and amortization of </span><span style="font-family:inherit;font-size:10pt;">$1.4 million</span><span style="font-family:inherit;font-size:10pt;"> and an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in stock-based compensation of </span><span style="font-family:inherit;font-size:10pt;">$1.3 million</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expenses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$3.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;">, for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to the same period in 2019. The decrease was mainly due to a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in legal related costs of </span><span style="font-family:inherit;font-size:10pt;">$1.6 million</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in consulting and outside services of </span><span style="font-family:inherit;font-size:10pt;">$1.5 million</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest income</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income decreased by </span><span style="font-family:inherit;font-size:10pt;">$3.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">28%</span><span style="font-family:inherit;font-size:10pt;">, for the three months ended March 31, 2020 compared to the same period in 2019. The decreases in interest income from our investments in marketable securities for the three month period was mainly attributable to adverse market conditions as a result of the coronavirus pandemic and its impact on global financial markets.   </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other expense, net</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes other expense, net for each period presented (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.62962962962963%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change 2020 vs. 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">321</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">324</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(10800)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,666</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,533</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(133</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">191</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(395</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">586</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(148)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,154</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,931</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">777</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(40)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other expense, net remained relatively flat for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to the same periods in 2019. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and capital resources</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have historically funded our operations primarily from the sale of equity instruments and from proceeds from certain strategic alliance arrangements and grant agreements. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and investments of </span><span style="font-family:inherit;font-size:10pt;">$1.72 billion</span><span style="font-family:inherit;font-size:10pt;">. Cash, cash equivalents and investments are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting primarily of government and corporate debt securities, are stated at fair value. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had current and non-current investments of approximately </span><span style="font-family:inherit;font-size:10pt;">$826.0 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$502.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We began construction of our manufacturing facility in Massachusetts, MTC South, in the second half of 2016 and completed the construction during 2019. In the second quarter of 2019, we entered into an additional lease for office and laboratory space nearby, or MTC North. We started construction of MTC North in the fourth quarter of 2019. Our capital expenditures related to our MTC facilities were $6.2 million and $3.6 million for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Cash disbursements related to our MTC facilities were $2.1 million and $5.7 million for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash flow</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the primary sources and uses of cash for each period presented (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by (used in):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(106,191</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(144,268</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(316,018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(11,759</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">578,053</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">293</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">155,844</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(155,734</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating activities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We derive cash flows from operations primarily from cash collected from certain strategic alliances. Our cash flows from operating activities are significantly influenced by our use of cash for operating expenses and working capital to support the business. We have historically experienced and will continue to expect negative cash flows from operating activities due to our investments in mRNA technologies, digital infrastructure, manufacturing technology, and infrastructure.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$106.2 million</span><span style="font-family:inherit;font-size:10pt;"> and consisted of net loss of </span><span style="font-family:inherit;font-size:10pt;">$124.2 million</span><span style="font-family:inherit;font-size:10pt;"> and non-cash adjustments of </span><span style="font-family:inherit;font-size:10pt;">$28.5 million</span><span style="font-family:inherit;font-size:10pt;">, minus a net change in assets and liabilities of </span><span style="font-family:inherit;font-size:10pt;">$10.5 million</span><span style="font-family:inherit;font-size:10pt;">. Non-cash items primarily included stock-based compensation of </span><span style="font-family:inherit;font-size:10pt;">$20.4 million</span><span style="font-family:inherit;font-size:10pt;">, and depreciation and amortization of </span><span style="font-family:inherit;font-size:10pt;">$7.4 million</span><span style="font-family:inherit;font-size:10pt;">. The net change in assets and liabilities was primarily due to an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in right-of-use assets related to operating leases of </span><span style="font-family:inherit;font-size:10pt;">$14.1 million</span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in accrued liabilities of </span><span style="font-family:inherit;font-size:10pt;">$13.0 million</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in prepaid expenses and other assets of </span><span style="font-family:inherit;font-size:10pt;">$4.3 million</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in accounts receivable of </span><span style="font-family:inherit;font-size:10pt;">$1.9 million</span><span style="font-family:inherit;font-size:10pt;">, and a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in deferred revenue of </span><span style="font-family:inherit;font-size:10pt;">$0.5 million</span><span style="font-family:inherit;font-size:10pt;">, partially offset by an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;">$15.2 million</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in other liabilities of </span><span style="font-family:inherit;font-size:10pt;">$5.7 million</span><span style="font-family:inherit;font-size:10pt;"> and an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in accounts payable of </span><span style="font-family:inherit;font-size:10pt;">$2.3 million</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$144.3 million</span><span style="font-family:inherit;font-size:10pt;"> and consisted of net loss of </span><span style="font-family:inherit;font-size:10pt;">$132.6 million</span><span style="font-family:inherit;font-size:10pt;"> and non-cash adjustments of </span><span style="font-family:inherit;font-size:10pt;">$24.8 million</span><span style="font-family:inherit;font-size:10pt;">, minus a net change in assets and liabilities of </span><span style="font-family:inherit;font-size:10pt;">$36.5 million</span><span style="font-family:inherit;font-size:10pt;">. Non-cash items primarily included stock-based compensation of </span><span style="font-family:inherit;font-size:10pt;">$18.5 million</span><span style="font-family:inherit;font-size:10pt;">, depreciation and amortization of </span><span style="font-family:inherit;font-size:10pt;">$7.3 million</span><span style="font-family:inherit;font-size:10pt;"> and amortization of investment premium and discount of </span><span style="font-family:inherit;font-size:10pt;">$1.0 million</span><span style="font-family:inherit;font-size:10pt;">. The net change in assets and liabilities was primarily due to a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">accrued liabilities of </span><span style="font-family:inherit;font-size:10pt;">$32.6 million</span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in deferred revenue of </span><span style="font-family:inherit;font-size:10pt;">$15.6 million</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;">$1.8 million</span><span style="font-family:inherit;font-size:10pt;">, partially offset by a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in accounts receivable of </span><span style="font-family:inherit;font-size:10pt;">$6.0 million</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in prepaid expense and other assets of </span><span style="font-family:inherit;font-size:10pt;">$3.4 million</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in accounts payable of </span><span style="font-family:inherit;font-size:10pt;">$1.7 million</span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of right-of use assets, operating lease of </span><span style="font-family:inherit;font-size:10pt;">$1.6 million</span><span style="font-family:inherit;font-size:10pt;"> and an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in other liabilities of </span><span style="font-family:inherit;font-size:10pt;">$0.8 million</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investing activities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our primary investing activities consist of purchases, sales, and maturities of our investments and capital expenditures for manufacturing, laboratory, computer equipment and software.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$316.0 million</span><span style="font-family:inherit;font-size:10pt;">, which included purchases of marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$621.3 million</span><span style="font-family:inherit;font-size:10pt;"> and purchases of property and equipment of </span><span style="font-family:inherit;font-size:10pt;">$6.2 million</span><span style="font-family:inherit;font-size:10pt;">, partially offset by proceeds from maturities of marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$269.7 million</span><span style="font-family:inherit;font-size:10pt;"> and proceeds from sales of marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$41.7 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$11.8 million</span><span style="font-family:inherit;font-size:10pt;">, which included purchases of marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$429.5 million</span><span style="font-family:inherit;font-size:10pt;">, and purchases of property and equipment of </span><span style="font-family:inherit;font-size:10pt;">$7.6 million</span><span style="font-family:inherit;font-size:10pt;">, partially offset by proceeds from maturities of marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$403.9 million</span><span style="font-family:inherit;font-size:10pt;"> and proceeds from sales of marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$21.4 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financing activities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generated cash from financing activities of </span><span style="font-family:inherit;font-size:10pt;">$578.1 million</span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, primarily from net proceeds from an equity offering of </span><span style="font-family:inherit;font-size:10pt;">$549.5 million</span><span style="font-family:inherit;font-size:10pt;"> and net proceeds from the issuance of common stock through our equity plans of </span><span style="font-family:inherit;font-size:10pt;">$28.4 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had insignificant financing activities for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operation and funding requirements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have incurred significant losses and negative cash flows from operations due to our significant research and development expenses. We have an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$1.62 billion</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. We expect to continue to incur significant losses in the foreseeable future and expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. Our ongoing work on mRNA-1273 will require significant additional investment during 2020, some of which may not be reimbursed or otherwise paid for by our partners or collaborators. In addition, we expect to continue to incur additional costs associated with operating as a public company driven, in part, by the increased compliance requirements of being a publicly traded company that no longer qualifies as an emerging growth company as of December 31, 2019. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to all the risks related to the development and commercialization of novel medicines, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors including the expenses related to the ongoing coronavirus pandemic, which may adversely affect our business. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We believe that our cash, cash equivalents, and investments as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of our financial statements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Until we can generate a sufficient amount of revenue from our programs, we expect to finance future cash needs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, potential future strategic alliances from which we receive upfront fees, milestone payments, and other forms of consideration, and marketing, manufacturing, distribution and licensing arrangements. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development or commercialization of one or more of our investigational medicines, or slow down or cease work on one or more of our programs. If we raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders or increased fixed payment obligations, and any such securities may have rights senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise funds through strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or investigational </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">medicines or grant licenses on terms that may not be favorable to us. Any of these events could significantly harm our business, financial condition, and prospects.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, other than disclosed at Note 8 to our condensed consolidated financial statements, there have been no material changes to our contractual obligations and commitments from those described under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our 2019 Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off balance sheet arrangements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we did not have any off-balance sheet arrangements, as defined in Item&#160;303(a)(4)(ii) of Regulation S-K.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s43DF10C1C39352A28C57B57FF08739B5"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our primary exposure to market risk relates to changes in interest rates. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents, and investments in marketable securities of </span><span style="font-family:inherit;font-size:10pt;">$1.72 billion</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$1.26 billion</span><span style="font-family:inherit;font-size:10pt;">, respectively. Our investment portfolio is comprised of money market funds and marketable debt securities (including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities, and commercial paper). Our primary investment objectives are the preservation of capital and the maintenance of liquidity and our investment policy defines allowable investments based on quality of the institutions and financial instruments designed to minimize risk exposure. Our exposure to interest rate sensitivity is affected by changes in the general level of U.S. interest rates. Our available for sale securities are subject to interest rate risk and will fall in value if market interest rates increase.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generally hold investments in marketable debt securities to maturity to limit our exposure to interest rate risk. Due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. If market interest rates were to increase immediately and uniformly by 100 basis points, or one percentage point, from levels at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the net fair value of our interest sensitive marketable securities would not experience a material change in fair market value.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently do not have significant exposure to foreign currencies as we hold no foreign exchange contracts, option contracts, or other foreign hedging arrangements. Further, our operations and revenue generating activities are denominated in U.S. dollars. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inflation generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on our business, financial condition, or results of operations during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sD39B5B09E3DB5117904C4000C51E1F78"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Controls and Procedures</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of&#160;March&#160;31, 2020. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of&#160;March&#160;31, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, which have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inherent Limitations on Effectiveness of Controls</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s3989A5ECB036581E8F7F5ED2CFB84D2E"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></div><div><a id="sDB42DFA537295D9EB9747A49DACCC6D5"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Legal Proceedings</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business.&#160;We are not currently a party to any material legal proceedings.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sFF88EEE533AD56FAB3E8A8E2F80D62E7"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Our business involves significant risks, some of which are described below. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the condensed consolidated financial statements and the related notes. If any of the following risks actually occur, it could harm our business, prospects, operating results and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Those risk factors below denoted with an &#8220;*&#8221; are newly added or have been materially updated from our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on February 27, 2020.</span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our business and creating a new class of medicines</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*Our business may continue to be adversely affected by the ongoing coronavirus pandemic. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The outbreak of SARS-CoV-2, the novel strain of coronavirus that causes COVID-19, has evolved into a global pandemic. The extent to which COVID-19 impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain COVID-19 or treat its impact, among others. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The spread of COVID-19 has resulted in the delay and interruption of certain of our business operations. Many of our clinical trials have been affected by the pandemic. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed (or continue to be paused or delayed) </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">due to changes in hospital or university policies, federal, state or local regulations or restrictions, prioritization of hospital resources toward pandemic efforts, travel restrictions, concerns for patient safety in a pandemic environment, or other reasons related to the pandemic. As previously disclosed, certain of our clinical trials have already been adversely affected, including the suspension of enrollment for our hMPV/PIV3 trial (mRNA-1653) and the pausing of enrollment and new site initiation for our rare disease clinical trials with open Investigational New Drug (IND) applications, methylmalonic acidemia (mRNA-3704) and propionic acidemia (mRNA-3927). As COVID-19 continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) have been implemented in many countries, and may impede participant movement, affect sponsor access to study sites, or interrupt </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">healthcare services, and we may be unable to conduct our clinical trials. Further, if the spread of the COVID-19 pandemic continues and our operations are adversely impacted, including due to the Governor of the Commonwealth of Massachusetts&#8217; order for the closure of non-essential businesses in Massachusetts, or the Non-Essential Business Closure, or from an outbreak in a facility, we risk a delay, default and/or nonperformance under existing agreements. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Infections and deaths related to the pandemic have disrupted and may continue to disrupt the United States&#8217; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay U.S. Food and Drug Administration, or FDA, review and/or approval with respect to, our clinical trials. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our development candidates. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently utilize third parties to, among other things, manufacture raw materials, components, parts, and consumables, and to perform quality testing. For example, we are dependent on&#160;Lonza Ltd. to enable larger scale manufacture of our mRNA vaccine candidate (mRNA-1273) against the SARS-CoV-2 virus. We also manufacture our products and perform various services at our manufacturing facility. Certain of our third party manufacturers and suppliers may pause their operations in response to the COVID-19 outbreak or otherwise encounter delays in providing their services. If either we or any third-party manufacturers or third parties in the supply chain for materials used in the production of our development candidates are adversely impacted by restrictions resulting from the COVID-19 outbreak, including, but not limited to, the Non-Essential Business Closure, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and research and development operations. In addition, delays and disruptions experienced by our strategic collaborators due to the COVID-19 outbreak could adversely impact the ability of such parties to fulfill their obligations, which could affect the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In response to the pandemic and in light of the Non-Essential Business Closure, we have closed our offices with our administrative employees continuing their work outside of our offices, restricted on-site staff to only those essential employees required to execute their job responsibilities. Due to this shelter-in-place order and other mandated local travel restrictions, certain of our employees conducting non-essential research and development or manufacturing activities are not able to access our laboratory or manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business, prospectus, operating results and financial condition, and the value of our common stock. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*Our pursuit of mRNA-1273, a potential vaccine for the SARS-CoV-2, is at an early stage.&#160; We may be unable to produce a vaccine that successfully treats the virus in a timely manner, if at all.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In response to the global outbreak of coronavirus, we are pursuing the rapid manufacture and clinical testing of mRNA-1273 in collaboration with the Vaccine Research Center and Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases or NIAID, part of the National Institutes of Health, or NIH. The Coalition for Epidemic Preparedness Innovations, or CEPI, has funded the current Good Manufacturing Practices, or cGMP, manufacture of the preliminary clinical batches of the vaccine, and NIAID is conducting Investigational New Drug-enabling, or IND-enabling, studies and is using such clinical batches to run the Phase 1 open-label clinical trial in the United States. &#160;Our development of the vaccine is in early stages, and we may be unable to produce a vaccine that successfully treats the virus in a timely manner, if at all. Additionally, our ability to develop an effective vaccine depends on the success of our scaled up manufacturing capability both at our own location and that of our manufacturing partner, which we have not previously tested and which will need to be funded by third parties in order to enable us to have sufficient capacity to respond to a global health challenge. &#160;We are also committing&#160;financial resources and personnel to the development of mRNA-1273, including to support a scale-up of manufacturing to enable a potential pandemic response, which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties surrounding the longevity and extent of coronavirus as a global health concern. &#160;Our business could be negatively impacted by our allocation of significant resources, including managerial and financial, to a global </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">health threat that is unpredictable and could rapidly dissipate or against which our vaccine, if developed, may not be partially or fully effective, and may ultimately prove unsuccessful or unprofitable.&#160;Furthermore, there are no assurances that our vaccine will be approved for inclusion in government stockpile programs, which may be material to the commercial success of the product candidate, either in the United States or abroad.</span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we have a dedicated manufacturing facility, we do not have sufficient manufacturing infrastructure to support a global roll-out of mRNA-1273 on our own. For example, </span><span style="font-family:inherit;font-size:10pt;color:#444444;">we are dependent on&#160;Lonza Ltd. to enable larger scale manufacture of mRNA-1273</span><span style="font-family:inherit;font-size:10pt;">. As a result, we have formed a strategic collaboration with Lonza Ltd. and will need to form additional collaborations with third parties, including contract manufacturing organizations, government and non-government organizations, and other funding and manufacturing sources to do so. We have not previously ramped our organization for a commercial launch of any product, and doing so in a pandemic environment with an urgent, critical global need creates additional challenges such as distribution channels, intellectual property disputes or challenges, and the need to establish teams of people with the relevant skills worldwide. We may also face challenges with sourcing a sufficient amount of raw materials to support the demand for a vaccine. We may be unable to effectively create a supply chain for mRNA-1273 that will adequately support demand. Furthermore, we will encounter significant additional capital requirements as we move through clinical studies of mRNA-1273 and toward a potential commercial launch. While our collaboration with BARDA will help us meet these capital requirements, additional investment, whether from our own capital resources or through collaborations with others, will be necessary. We cannot guarantee that any of these new challenges and requirements will be met in a timely manner or at all.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, another party may be successful in producing&#160;a more efficacious vaccine or other treatment for COVID-19 which may also lead to the diversion of governmental and quasi-governmental funding away from us and toward other companies. In particular, given the widespread media attention on the current COVID-19 pandemic, there are efforts by public and private entities to develop a COVID-19 vaccine as fast as possible, including by Johnson &amp; Johnson, GlaxoSmithKline, AstraZeneca, Sanofi and Pfizer. Those other entities may develop COVID-19 vaccines that are more effective than any we may develop, may develop a COVID-19 vaccine that becomes the standard of care, may develop a COVID-19 vaccine at a lower cost or earlier than we are able to develop any COVID-19 vaccine, or may be more successful at commercializing a COVID-19 vaccine. Many of these other organizations are much larger than we are and have access to larger pools of capital and broader manufacturing infrastructure. The success or failure of other entities, or perceived success or failure, may adversely impact our ability to obtain any future funding for our COVID-19 vaccine development efforts or to ultimately commercialize our vaccine, if approved. In addition, we may not be able to compete effectively if our product candidates do not satisfy government procurement requirements with respect to biodefense products.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*We are devoting significant resources to the scale-up and development of mRNA-1273, including for use by the U.S. government and other global governmental and commercial partners.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are working toward the large scale technical development, manufacturing scale-up and larger scale deployment of this potential vaccine through a variety of U.S. government mechanisms such as an Expanded Access Program or an Emergency Use Authorization program. For instance, we received a commitment from the Biomedical Advanced Research and Development Authority, or BARDA, to fund up to $483 million for our late-stage clinical development programs (assuming the success of the NIAID&#8217;s Phase 1 clinical trial of mRNA-1273) and our initiation of a Phase 2 clinical trial of mRNA-1273 under our own IND in the second quarter of 2020, as well as the scale-up of mRNA-1273 manufacture in 2020 to enable potential pandemic response. To support the scale-up, we may need to divert significant resources to this program, including in connection with our hiring skilled manufacturing staff to expand manufacturing capacity, engineers to manage process scale-up, and clinical and regulatory staff to support clinical development, which would require diversion of resources from our other programs. To the extent our funding collaborators have discretion over the distribution from time to time of funding commitments, we may not ultimately receive the full amount of committed funds and could be exposed to urgent needs for additional funding to support our manufacturing activities. Our funding collaborators may also impose restrictions on or mandate input as to our conduct of clinical trials, manufacturing activities or distribution activities, which may cause delays in the event of disagreement. In addition, since the path to licensure of any vaccine against COVID-19 is unclear, we may have a widely used vaccine in circulation in the United States or another country prior to our receipt of marketing approval. Unexpected safety issues in these circumstances could lead to significant reputational damage for Moderna and our technology platform going forward and other issues, including delays in our other programs, the need for re-design of our clinical trials and the need for significant additional financial resources.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*The regulatory pathway for mRNA-1273 is continually evolving, and may result in unexpected or unforeseen challenges.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, mRNA-1273 has moved rapidly through the FDA regulatory process. However, the speed at which all parties are moving to create, test and approve a vaccine for COVID-19 is highly unusual, and evolving or changing plans or priorities at the FDA, including based on new knowledge of COVID-19 and how the disease affects the human body, may significantly affect the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory pathway for mRNA-1273. Results from clinical testing may raise new questions and require us to redesign proposed clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects. In addition, the FDA&#8217;s analysis of clinical data may differ from our interpretation and the FDA may require that we conduct additional analyses.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has the authority to grant an Emergency Use Authorization to allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when there are no adequate, approved, and available alternatives. If we are granted an Emergency Use Authorization for mRNA-1273, we would be able to commercialize mRNA-1273 prior to FDA approval. Furthermore, the FDA may revoke an Emergency Use Authorization where it is determined that the underlying health emergency no longer exists or warrants such authorization, and we cannot predict how long, if ever, an Emergency Use Authorization would remain in place. Such revocation could adversely impact our business in a variety of ways, including if mRNA-1273 is not yet approved by the FDA and if we and our manufacturing partners have invested in the supply chain to provide mRNA-1273 under an Emergency Use Authorization.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*We will need to seek and secure significant funding through financings or from other sources. Clinical data or trial execution that creates delays, setbacks, or failures in one or more of our programs or modalities or the entire pipeline could result in an impaired ability or inability to finance or fund the Company in the future.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently advancing our pipeline of 23 development candidates across our 22 programs. Discovering development candidates and developing investigational medicines is expensive, and we expect to continue to spend substantial amounts to (i)&#160;perform basic research, perform preclinical studies, and conduct clinical trials of our current and future programs, (ii)&#160;continue to develop and expand our platform and infrastructure and supply preclinical studies and clinical trials with appropriate grade materials (including cGMP materials), (iii) seek regulatory approvals for our investigational medicines, and (iv)&#160;launch and commercialize any products for which we receive regulatory approval, including building our own commercial sales, marketing, and distribution organization. Furthermore, our ongoing work on mRNA-1273 will require significant additional investment during 2020 and beyond, some of which may not be reimbursed or otherwise paid for by our collaborators.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had approximately </span><span style="font-family:inherit;font-size:10pt;">$1.72 billion</span><span style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents, and investments. We expect that our existing cash, cash equivalents, and investments will be sufficient to fund our current operations through at least the next twelve months. However, our operating plan may change as a result of many factors currently unknown to us, including with respect to our development, manufacturing and commercialization of mRNA-1273, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, structured financings, government or other third-party funding, sales of assets, marketing and distribution arrangements, other collaborations and licensing arrangements, or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, our investigational medicines. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with discovery of development candidates and development of our investigational medicines are highly uncertain, we are unable to estimate the actual funds we will require for development, marketing, and commercialization activities. Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:60px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-60px;"><span style="font-family:inherit;font-size:10pt;">the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our development candidates and investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the results of research and our other platform activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the clinical development plans we establish for our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the terms of any agreements with our current or future strategic collaborators;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number and characteristics of development candidates and investigational medicines that we develop or may in-license;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome, timing, and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or the EMA, and other comparable foreign regulatory authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of filing, prosecuting, defending, and enforcing our patent claims and other intellectual property, or IP, rights, including patent infringement actions brought by third parties against us regarding our investigational medicines or actions by us challenging the patent or IP rights of others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effect of competing technological and market developments, including other products that may compete with one or more of our development candidates or investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs, whether in-house or outsourced; and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of establishing sales, marketing, and distribution capabilities for any investigational medicines for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our medicines on our own.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, we have financed our operations primarily through the sale of equity securities and revenue from strategic alliances and we cannot be certain that additional funding will be available to us on favorable terms, or at all. Until we can generate sufficient product or royalty revenue to finance our operations, which we may never do, we expect to finance our future cash needs through a combination of public or private equity or debt offerings, structured financings, debt financings, collaborations, strategic alliances, sales of assets, licensing arrangements, and other marketing or distribution arrangements. Any fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational medicines. In addition, we cannot guarantee that future financing will be available in sufficient amounts, at the right time, on favorable terms, or at all. Negative clinical trial data or setbacks, or perceived setbacks, in our programs or with respect to our technology could impair our ability to raise additional financing on favorable terms, or at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that may adversely affect our stockholders&#8217; rights.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. If we raise additional capital through debt financings, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional capital through marketing and distribution arrangements, sales of assets or other collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our development candidates and investigational medicines, technologies, future revenue streams, or research programs. We also could be required to seek strategic collaborators for one or more of our current or future investigational medicines at an earlier stage than otherwise would be desirable or relinquish our rights to development candidates, investigational medicines, or IP that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts, at the right time, on favorable terms, or at all, we may have to significantly delay, scale back, or discontinue the development or commercialization of one or more of our products or investigational medicines, or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition, and results of operations, cause the price of our common stock to decline, and negatively impact our ability to fund operations.</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We attempt to distribute our technology, biology, execution, and financing risks across a wide variety of therapeutic areas, disease states, programs, and technologies. However, our assessment of, and approach to, risk may not be comprehensive or effectively avoid delays or failures in one or more of our programs or modalities. Failures in one or more of our programs or modalities could adversely impact other programs or modalities in our pipeline and have a material adverse impact on our business, results of operations, and ability to fund our business.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are creating a new class of medicines based on mRNA, to improve the lives of patients. From the beginning, we designed our strategy and operations to realize the full potential value and impact of mRNA over a long time horizon across a broad array of human diseases. We have made investments in our platform, infrastructure, and clinical capabilities that have enabled us to establish a large pipeline of development candidates, of which many are in clinical trials or have an open IND. As our development candidates and investigational medicines progress, we or others may determine that: certain of our risk allocation decisions were incorrect or insufficient; we made platform level technology mistakes; individual programs or our mRNA science in general has technology or biology risks that were unknown or under-appreciated; our choices on how to develop our infrastructure to support our scale will result in an inability to manufacture our investigational medicines for clinical trials or otherwise impair our manufacturing; or we have allocated resources in such a way that large investments are not recovered and capital allocation is not subject to rapid re-direction. All of these risks may relate to our current and future programs sharing similar science (including mRNA science) and infrastructure, and in the event material decisions in any of these areas turn out to have been incorrect or under-optimized, we may experience a material adverse impact on our business and ability to fund our operations and we may never realize what we believe is the potential of mRNA.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*No mRNA drug has been approved in this new potential class of medicines, and may never be approved as a result of efforts by others or us. mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new class of medicines.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a potential new class of medicines, no mRNA medicines have been approved to date by the FDA or other regulatory agency. Successful discovery and development of mRNA medicines by either us or our strategic collaborators is highly uncertain and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">depends on numerous factors, many of which are beyond our or their control. We have made and will continue to make a series of business decisions and take calculated risks to advance our development efforts and pipeline, including those related to mRNA technology, delivery technology, and manufacturing processes, which may be shown to be incorrect based on further work by us, our strategic collaborators, or others. To date, there has never been a Phase 3 trial or a commercialized product in which mRNA is the primary active ingredient. However, we expect that we will enter into a Phase 3 trial for each of mRNA-1273 (SARS-CoV-2) and mRNA-1647 (CMV) in the near term. Our mRNA investigational medicines that appear promising in the early phases of development may fail to advance, experience delays in the clinic, experience clinical holds, or fail to reach the market for many reasons, including:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">discovery efforts at identifying potential mRNA medicines may not be successful;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">nonclinical or preclinical study results may show potential mRNA medicines to be less effective than desired or to have harmful or problematic side effects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">clinical trial results may show potential mRNA medicines to be less effective than expected (e.g., a clinical trial could fail to meet one or more endpoint(s)) or to have unacceptable side effects or toxicities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">adverse effects in any one of our clinical programs or adverse effects relating to our mRNA, or our lipid nanoparticles, or LNPs, may lead to delays in or termination of one or more of our programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">the insufficient ability of our translational models to reduce risk or predict outcomes in humans, particularly given that each component of our investigational medicines and development candidates may have a dependent or independent effect on safety, tolerability, and efficacy, which may, among other things, be species-dependent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">manufacturing failures or insufficient supply of cGMP materials for clinical trials, or higher than expected cost could delay or set back clinical trials, or make mRNA-based medicines commercially unattractive;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">our improvements in the manufacturing processes for this new class of potential medicines may not be sufficient to satisfy the clinical or commercial demand of our investigational medicines or regulatory requirements for clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">changes that we make to optimize our manufacturing, testing or formulating of cGMP materials could impact the safety, tolerability, and efficacy of our investigational medicines and development candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">pricing or reimbursement issues or other factors that delay clinical trials or make any mRNA medicine uneconomical or noncompetitive with other therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">failure to timely advance our programs or receive the necessary regulatory approvals or a delay in receiving such approvals, due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, Biologics License Application, or BLA, or the equivalent application, discussions with the FDA or EMA, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">the proprietary rights of others and their competing products and technologies that may prevent our mRNA medicines from being commercialized.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currently, mRNA is considered a gene therapy product by the FDA. Unlike certain gene therapies that irreversibly alter cell DNA and could act as a source of side effects, mRNA-based medicines are designed to not irreversibly change cell DNA; however, side effects observed in gene therapy could negatively impact the perception of mRNA medicines despite the differences in mechanism. In addition, because no product in which mRNA is the primary active ingredient has been approved, the regulatory pathway for approval is uncertain. The number and design of the clinical trials and preclinical studies required for the approval of these types of medicines have not been established, may be different from those required for gene therapy products, or may require safety testing like gene therapy products. Moreover, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one pharmaceutical product to the next, and may be difficult to predict.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred net losses in each year since our inception in 2009, including net losses of $514.0 million, $384.7 million and $255.9 million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$1.62 billion</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have devoted most of our financial resources to research and development, including our clinical and preclinical development activities and the development of our platform. To date, we have financed our operations primarily through the sale of equity securities and proceeds from strategic alliances and through grants from governmental and private organizations. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, sales of assets, strategic alliances, or additional grants. We have not commenced or completed pivotal clinical trials for any of our programs in clinical trials, or investigational medicines, and it may be several years, if ever, before we or our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">strategic collaborators have an investigational medicine ready for commercialization. Even if we obtain regulatory approval to market an investigational medicine, our future revenues will depend upon the size of any markets in which our investigational medicines have received approval, and our ability to achieve sufficient market acceptance, reimbursement from third-party payors, and adequate market share in those markets. We may never achieve profitability.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue or expand our research or development of our programs in preclinical development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue or expand the scope of our mRNA clinical trials for our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">initiate additional preclinical, clinical, or other studies for our development candidates and investigational medicines, including under our strategic alliance agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue to invest in our platform to conduct research to identify novel mRNA technology improvements, including identifying novel methods of mRNA delivery, such as lipid nanoparticles, or LNPs, that improve distribution and uptake of mRNA to specific tissues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">change or add to internal manufacturing capacity or capability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">change or add additional manufacturers or suppliers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">add additional infrastructure to our quality control and quality assurance groups to support our operations as we progress our investigational medicines toward commercialization;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">attract and retain skilled personnel, particularly in Cambridge and Norwood, Massachusetts and other global regions where we may establish operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts, including new sites in the United States and abroad;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek marketing approvals and reimbursement for our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek to identify and validate additional development candidates and investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acquire or in-license other development candidates, investigational medicines, and technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">make milestone or other payments under any in-license agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintain, protect, and expand our IP portfolio; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">experience any delays or encounter issues with any of the above.</span></div></td></tr></table><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*Our quarterly and annual operating results may fluctuate. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline and negatively impact our financing or funding ability as well as negatively impact our ability to exist as a standalone company.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our financial condition and operating results have varied in the past and will continue to fluctuate from quarter-to-quarter and year-to-year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Quarterly Report on Form 10-Q:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays or failures in advancement of existing or future development candidates into the clinic or investigational medicines in clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the feasibility of developing, manufacturing, and commercializing our programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to manage our growth;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcomes of research programs, clinical trials, or other product development or approval processes conducted by us and our strategic collaborators;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to develop or successfully commercialize mRNA medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of our strategic collaborators to develop and successfully commercialize mRNA medicines or other products developed from our IP;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our relationships, and any associated exclusivity terms, with strategic collaborators;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our contractual or other obligations to provide resources to fund our development candidates and investigational medicines, and to provide resources to our strategic collaborators or to the strategic alliances themselves;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our operation in a net loss position for the foreseeable future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risks associated with the international aspects of our business including the conduct of clinical trials in multiple locations and potential commercialization in such locations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to consistently manufacture our development candidates and investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to accurately report our financial results in a timely manner;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our dependence on, and the need to attract and retain, key management and other personnel;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain, protect, and enforce our IP rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to prevent the theft or misappropriation of our IP, know-how, or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">advantages that our competitors and potential competitors may have in securing funding, obtaining the rights to critical IP or developing competing technologies or products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain additional capital that may be necessary to expand our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our strategic collaborators&#8217; ability to obtain additional capital that may be necessary to develop and commercialize products under our strategic alliance agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">business interruptions such as power outages, strikes, acts of terrorism, or natural disasters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to use our net operating loss carryforwards to offset future taxable income.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to the various factors mentioned herein, and others, the results of any of our prior quarterly or annual periods should not be relied upon as indications of our future operating performance.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. We do not control the timing of disclosure of any such milestones related to any of our programs that are managed by our strategic collaborators. Any disclosure by our strategic collaborators or competitors of data or other events that are perceived as negative, whether or not such data are related to other data that we or others release, may have a material adverse impact on our stock price or overall valuation. Our stock price may decline as a result of unexpected clinical trial results in one or more of our programs, including adverse safety events reported for any of our programs.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business is highly dependent on the clinical advancement of our programs and modalities. Delay or failure to advance programs or modalities could adversely impact our business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Using our platform, we are developing product features for medicines based on mRNA. Over time, our platform work led to commonalities, where a specific combination of mRNA technologies, delivery technologies, and manufacturing processes generated a set of product features shared by multiple programs. This is what we call a &#8220;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">modality</span><span style="font-family:inherit;font-size:10pt;">.&#8221; We have historically utilized, and expect to continue to utilize, earlier programs in a modality to understand the technology risks within the modality, including manufacturing and pharmaceutical properties. Even if our earlier programs in a modality are successful in any phase of development any of such earlier programs may fail at a later phase of development, and other programs within the same modality may still fail at any phase of development including at phases where earlier programs in that modality were successful. This may be a result of technical challenges unique to that program or due to biology risk, which is unique to every program. As we progress our programs through clinical development, there may be new technical challenges that arise that cause an entire modality to fail.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we aim to segregate risk using modalities, there may be foreseen and unforeseen risks across modalities in whole or in part. These include, but are not limited to, mRNA, chemical modifications, and LNPs and their components. In addition, if any one or more of our clinical programs encounter safety, tolerability, or efficacy problems, developmental delays, regulatory issues, or other problems, our platform approach and business could be significantly harmed. We may believe that a particular modality has been de-risked but later determine that new and different risks exist with respect to such modality.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the biology risk across the majority of our pipeline represents targets and pathways not clinically validated by one or more approved drugs. While we believe we have made progress in seeking to reduce biology risk in certain settings, such as for vaccine targets for which we and others have shown the utility of neutralizing antibodies, the risk that the targets or pathways that we have selected may not be effective will continue to apply across the majority of our current and future programs.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">While we attempt to diversify our risks by developing one or more programs in each modality, there are&#160;risks&#160;that are unique to each modality and risks that are applicable across modalities. These risks may impair our ability to advance one or more of our programs in clinical development, obtain regulatory approval, or ultimately commercialize our programs, or cause us to experience significant delays in doing so, any of which may materially harm our business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain features in our development candidates and investigational medicines, including those related to mRNA, chemical modifications, surface chemistries, LNPs, and their components, may result in foreseen and unforeseen risks that are active across some or all of our modalities. Any such portfolio spanning risks, whether known or unknown, if realized in any one of our programs would have a material and adverse effect on our other programs and on our business as a whole.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are specific additional risks to certain of our modalities and our programs as a whole. For example, prophylactic vaccines typically require clinical testing in thousands to tens of thousands of healthy volunteers to define an approvable benefit-risk profile. The need to show a high degree of safety and tolerability when dosing healthy individuals could result in rare and even spurious </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">safety findings, negatively impacting a program prior to or after commercial launch. While we believe that certain safety, tolerability, and levels of immunogenicity we have observed in the early-stage clinical trials in our prophylactic vaccine programs are sufficient to initiate additional trials, there can be no assurance that we will observe acceptable safety or efficacy profiles in later-stage trials required for approval of these programs. For neoantigen cancer vaccines, to date, no molecular (non-cell-based) therapeutic protein vaccine has been shown to be effective against cancer and there are many clinical and manufacturing challenges to personalized medicines, including cell-based therapies and vaccines. These risks include: a rapid production turn-around time that is measured in weeks in order to supply patients in our clinical trials before further progression and mutation of their tumors, the significant costs incurred in making individualized vaccines, and potential lack of immune responses potentially due to the biology of the tumor or immune status of the patient. These and other risks apply to our PCV and other neoepitope investigational medicine programs. Additionally, there may be challenges in delivering an adequate quantity of active pharmaceutical ingredient, or API, required to drive efficacy due to the limitation in volume of API that can be delivered to a specific location, like a tumor or injured tissue. Our therapies for local injections often require specialized skills for conducting a clinical trial that could delay trials or slow or impair commercialization of an approved investigational medicine due to the poor adoption of injected local therapeutics or intratumoral therapies. In addition, the uncertain translatability of target selection from preclinical animal models, including mouse and non-human primate models, to successful clinical trial results may be impossible, particularly for immuno-oncology and systemic therapies, and cancer vaccines. In general, several biological steps are required for delivery of mRNA to translate into therapeutically active medicines. These processing steps may differ between individuals or tissues, and this could lead to variable levels of therapeutic protein, variable activity, immunogenicity, or variable distribution to tissues for a therapeutic effect. Gene therapies and mRNA-based medicines may activate one or more immune responses against any and all components of the drug product (e.g., the mRNA or the delivery vehicle, such as an LNP) as well as against the encoded protein, giving rise to potential immune reaction related adverse events. Eliciting an immune response against the encoded protein may impede our ability to achieve a pharmacologic effect upon repeat administration or a side effect. These risks apply to all of our programs, including our systemic secreted therapeutics and systemic intracellular therapeutics modalities.</span></div><div style="line-height:174%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to the research, development, regulatory review, and approval of our existing and future pipeline</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preclinical development is lengthy and uncertain, especially for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to the clinic, any of which may affect our ability to obtain funding and may have a material adverse impact on our platform or our business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Much of our pipeline is in preclinical development, and these programs could be delayed or not advance into the clinic. Before we can initiate clinical trials for a development candidate, we must complete extensive preclinical studies, including IND-enabling good laboratory practice, or GLP, toxicology testing, that support our planned INDs in the United States, or similar applications in other jurisdictions. We must also complete extensive work on Chemistry, Manufacturing, and Controls, or CMC, activities (including yield, purity and stability data) to be included in the IND submission. CMC activities for a new class of medicines such as mRNA require extensive manufacturing processes and analytical development, which is uncertain and lengthy. For instance, batch failures as we scale up our manufacturing have occurred and may continue to occur. In addition, we have in the past and may in the future have difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our preclinical or clinical development candidates. If we are required to produce new batches of our development candidates due to insufficient shelf life, it may delay the commencement or completion of preclinical studies or clinical trials of such development candidates. For example, we cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or other regulatory authorities will accept the results of our preclinical testing or our proposed clinical programs or if the outcome of our preclinical testing, studies, and CMC activities will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical development is lengthy and uncertain, especially with a new class of medicines such as mRNA medicines. Clinical trials of our investigational medicines may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which could affect our ability to obtain and maintain sufficient funding and would have a material adverse impact on our platform or our business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical testing is expensive and complex and can take many years to complete, and its outcome is inherently uncertain. We may not be able to initiate, may experience delays in, or may have to discontinue clinical trials for our investigational medicines. We and our strategic collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that we or our strategic collaborators conduct that could delay or prevent us or our strategic collaborators from successfully developing our investigational medicines, including:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA, other regulators, Institutional Review Boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site for any number of reasons, including concerns regarding safety and aspects of the clinical trial design;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we have in the past and intend to continue to optimize our manufacturing processes, including through changes to the scale and site of manufacturing, which may lead to potentially significant changes in our clinical trial designs, requiring additional cost and time, and, as a consequence, lead to a delay in plans for progressing one or more investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome of our preclinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">in an effort to optimize product features, we have in the past and may continue to make changes to our investigational medicines after we commence clinical trials of an investigational medicine, which may require us to repeat earlier stages of clinical testing or delay later stage testing of the investigational medicine;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical trials of any investigational medicines may fail to show safety or efficacy, or produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">preclinical and clinical data are often susceptible to varying interpretations and analyses, and many investigational medicines believed to have performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our investigational medicines may have undesirable side effects, such as the immunogenicity of the LNPs or their components, the immunogenicity of the protein made by the mRNA, or degradation products, any of which could lead to serious adverse events, or other effects. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us or our IRBs or ethics committees to suspend or terminate the trial of that investigational medicine or any other of our investigational medicines for which a clinical trial may be ongoing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of trial participants required for clinical trials of any investigational medicines may be larger than we anticipate, identification of trial participants for such trials may be limited, enrollment in these clinical trials may be slower than we anticipate due to perceived adverse effects, competitive trials, size of the patient population, or other reasons, or participants may withdraw from clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or withdraw from the trial, which may require that we add new clinical trial sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulators may elect to impose a clinical hold, or we or our investigators, IRBs, or ethics committees may elect to suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable benefit risk ratio;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of preclinical or nonclinical testing and studies and clinical trials of any investigational medicines may be greater than we anticipate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the supply or quality of our investigational medicines or other materials necessary to conduct clinical trials may be insufficient or inadequate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">safety and efficacy concerns regarding one or more of our investigational medicines will be considered by us and by the FDA and other global regulations as we pursue clinical trials of new investigational medicines, develop effective informed consent documentation and work with IRBs and scientific review committees, or SRCs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">safety or efficacy concerns regarding our investigational medicines may result from any safety or efficacy concerns arising from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies, such as gene therapy, that are perceived as similar to ours; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the FDA or other regulatory authorities, ethics committees, or the IRBs of the institutions in which such trials are being conducted, or if such trial is recommended for suspension or termination by the data safety monitoring board for such trial. We have in the past, and may in the future, be delayed in gaining clearance from the FDA or other regulators to initiate clinical trials through the imposition of a clinical hold in order to address comments from such regulators on our clinical trial design or other elements of our clinical trials. The clinical trials of other </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">companies working on mRNA medicines have been put on clinical hold by the FDA. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues, or adverse side effects, including those experienced by other investigational medicines in the same class as our investigational medicines, failure to demonstrate a benefit, or adequate benefit risk ratio, from using an investigational medicine, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our investigational medicines. We must also complete extensive CMC activities that require extensive manufacturing processes and analytical development, which is uncertain and lengthy. For instance, batch failures as we scale up our manufacturing have occurred and may continue to occur. In addition, we have in the past and may in the future have difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our clinical development candidates or investigational medicines. If we are required to produce new batches of our development candidates or investigational medicines due to insufficient shelf life, it may delay the commencement or completion of clinical trials of such development candidates or investigational medicines.</span></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, the FDA has indicated that prior to commencing later-stage clinical trials for our programs we will need to develop assays to measure and predict the potency of a given dose of our investigational medicines. Any delay in developing assays that are acceptable to the FDA or other regulators could delay the start of future clinical trials. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data for our clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Significant preclinical or nonclinical testing and studies or clinical trial delays for our investigational medicines also could allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our investigational medicines and harming our business and results of operations. Any delays in the development of our investigational medicines may harm our business, financial condition, and prospects significantly.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may experience delays in identifying and enrolling participants in our clinical trials which would delay the progress of our investigational medicines and result in increased expenses.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend on enrollment of participants in our clinical trials for our investigational medicines. We may find it difficult to enroll trial participants in our clinical trials, which could delay or prevent clinical trials of our investigational medicines. Identifying and qualifying trial participants to participate in clinical trials of our investigational medicines is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit trial participants to participate in testing our investigational medicines. Delays in enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our investigational medicines. If trial participants are unwilling to participate in our trials because of negative publicity from adverse events in our trials or other trials of similar products, or those related to specific therapeutic area, or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting trial participants, conducting studies, and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our product, or termination of the clinical trials altogether.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be able to identify, recruit, and enroll a sufficient number of trial participants, or those with required or desired characteristics to achieve diversity in a trial to complete our clinical trials in a timely manner. Patient and subject enrollment is affected by factors including:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">severity of the disease under investigation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complexity and design of the study protocol; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">size of the patient population; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">eligibility criteria for the study in question, including age-based eligibility criteria limiting subject enrollment to adolescent or pediatric populations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">proximity and availability of clinical study sites for prospective trial participants; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">availability of competing therapies and clinical trials, including between our own clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">efforts to facilitate timely enrollment in clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patient referral practices of physicians; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ability to monitor trial participants adequately during and after treatment; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinicians&#8217; and trial participants&#8217; perceptions as to the potential advantages and side effects of the investigational medicine being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the need, in the case of our personalized cancer vaccine, to wait for the manufacture of the personalized drug product; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain and maintain participant informed consent. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our clinical trials will compete with other clinical trials for investigational medicines that are in the same therapeutic areas as our investigational medicines, and this competition will reduce the number and types of trial participants available to us, because some trial participants who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a third party. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of trial participants who are available for our clinical trials at such clinical trial sites. Moreover, because in some cases our investigational medicines represent a departure from more traditional methods for disease treatment and prevention, potential trial participants and their doctors may be inclined to use conventional therapies or other new therapies rather than enroll trial participants in any future clinical trial involving mRNA investigational medicines. Additionally, if new investigational medicines, such as gene editing therapies, show encouraging results, potential trial participants and their doctors may be inclined to enroll trial participants in clinical trials using those investigational medicines. If such new investigational medicines show discouraging results or other adverse safety indications, potential trial participants and their doctors may be less inclined to enroll trial participants in our clinical trials. We also have entered into strategic alliances under which our strategic collaborators control the development of certain of our investigational medicines, which may provide us limited or no ability to influence the enrollment rate of our clinical trials.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we are able to enroll trial participants, there is no guarantee that they will ultimately be dosed as part of, or complete, a clinical trial. For example, although we have announced that the first patient has been enrolled in the Phase 1/2 study of mRNA-3704 in patients with isolated methylmalonic acidemia, or MMA, due to MUT deficiency, there is no guarantee that this patient will ultimately be dosed as part of, or complete, the Phase 1/2 study.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">mRNA medicines are a novel approach, and negative perception of the efficacy, safety, or tolerability of any investigational medicines that we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a potential new class of medicines, no mRNA medicines have been approved to date by the FDA or other regulators. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of mRNA medicine, or other products that are perceived to be similar to mRNA medicines, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our large pipeline of development candidates and investigational medicines could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, or SUSARs, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because we are developing some of our development candidates or investigational medicines for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. For instance, for MMA or PA, few clinical trials have been attempted. In addition, there has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these diseases. There have been some historical trials with other agents to address organic acidemias which may have utilized clinical endpoints that are less applicable to our efforts with our MMA and PA programs that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Some of our investigational medicines are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that our investigational medicines will be reviewed within its Center for Biologics Evaluation and Research, or CBER. Even though our mRNA investigational medicines are designed to have a different mechanism of action from gene therapies, the association of our investigational medicines with gene therapies could result in increased regulatory burdens, impair the reputation of our investigational medicines, or negatively impact our platform or our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been few approvals of gene therapy products in the United States or foreign jurisdictions, and there have been well-reported significant adverse events associated with their testing and use. Gene therapy products have the effect of introducing new DNA and potentially irreversibly changing the DNA in a cell. In contrast, mRNA is highly unlikely to localize to the nucleus, integrate into the DNA, or otherwise make any permanent changes to cell DNA. Consequently, we expect that our investigational medicines will have a different potential side effect profile from gene therapies.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future, and the implications for mRNA-based therapies is unknown. For example, the FDA has established the Office of Tissues and Advanced Therapies within CBER to consolidate the review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In the European Union, mRNA has been characterized as a Gene Therapy Medicinal Product. In certain countries, mRNA therapies have not yet been classified or any such classification is not known to us, specifically, in Japan, the Pharmaceuticals and Medical Devices Agency has not taken a position on the regulatory classification. Notwithstanding the differences between our mRNA investigational medicines and gene therapies, the classification of some of our mRNA investigational medicines as gene therapies in the United States, the European Union, and potentially other countries could adversely impact our ability to develop our investigational medicines, and could negatively impact our platform and our business. For instance, a clinical hold on gene therapy products across the field due to risks associated with altering cell DNA irreversibly may apply to our mRNA investigational medicines irrespective of the mechanistic differences between gene therapies and mRNA.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adverse events reported with respect to gene therapies or genome editing therapies could adversely impact one or more of our programs. Although our mRNA development candidates and investigational medicines are designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapies products caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our mRNA investigational therapies, and as a result may delay one or more of our trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory review agencies may have a negative effect on our business by lengthening the regulatory review process, requiring us to perform additional or larger studies, or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our investigational medicines, or lead to significant post-approval studies, limitations, or restrictions. As we advance our investigational medicines, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our investigational medicines.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may seek a breakthrough therapy designation for one or more of our investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval&#160;in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have received Fast Track Designation for some of our investigational medicines and may seek Fast Track Designation for others. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address significant unmet medical needs for this condition, the drug sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, and even if we believe a particular investigational medicine is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review, or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may fail to obtain and maintain orphan drug designations from the FDA for our future investigational medicines, as applicable.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our strategy includes filing for orphan drug designation where available for our investigational medicines, and we have received orphan drug designation from both the FDA and the European Commission for MMA (mRNA-3704) and PA (mRNA-3927). Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities for grant funding toward clinical trial costs, tax advantages, and user-fee waivers. However, orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA, or BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the original manufacturer is unable to assure sufficient product quantity.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care. In addition, while we may seek additional orphan drug designation for our investigational medicines, we may never receive such further designations.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our investigational medicines may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 , or collectively, the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that any of our investigational medicines approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any clinical trials of our oncology-related products that we conduct with a seamless trial design may not be acceptable to regulatory authorities in the form submitted, or at all, which may delay our clinical development and limit or change the type of information we may gather from our clinical trials.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may pursue a development program for our oncology-related products that relies upon a seamless trial design, which presents additional risks compared to traditional three-phase development programs. A seamless trial design can be achieved through a first-in-human, or FIH, multiple expansion cohort trial, which has a single protocol with an initial dose-escalation phase and also contains three or more additional patient cohorts with cohort-specific objectives. FIH multiple expansion cohort trials are intended to expedite development by seamlessly proceeding from initial determination of a potential effective dose to individual cohorts that have trial objectives typical of Phase 2 trials. Challenges and risks associated with such seamless trial designs include challenges in the timely dissemination of new safety information to investigators, IRBs, and regulators, exposing a large number of patients across cohorts to potentially suboptimal or toxic doses of an investigational drug, exposing more patients than is needed to achieve the cohort&#8217;s objectives, and missed interpretations of preliminary trial results and unplanned analyses which can lead to delays in clinical development. Regulatory authorities may find our seamless trial designs unacceptable based on these and other risks of utilizing such designs.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, investigational medicines we may develop, and our ability to generate revenue will be materially impaired.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain, and may prevent us from obtaining approvals for the commercialization of any development candidates and investigational medicines we may develop. Any mRNA medicine we may develop and the activities associated with its development and commercialization, including design, testing, manufacture, record-keeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and by comparable global health authorities. To obtain the requisite regulatory approvals to commercialize any of our investigational medicines, we and our strategic collaborators must demonstrate through extensive preclinical studies and clinical trials that our products are safe, pure, and potent or effective in humans, including the target population. Successful completion of clinical trials is a prerequisite to submitting a BLA to the FDA, a Marketing Authorization Application, or MAA, to the EMA, and similar marketing applications to comparable global regulatory authorities, for each investigational medicine and, consequently, the ultimate approval and commercial marketing of any investigational medicines.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to obtain marketing approval for an investigational medicine will prevent us from commercializing the investigational medicine in a given jurisdiction. We have not received approval to market any investigational medicines from regulatory authorities in any jurisdiction, and it is possible that none of our investigational medicines or any investigational medicines we may seek to develop in the future will ever obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and may need to rely on third-party CROs or regulatory consultants to assist us in this process. To our knowledge, there is no current precedent for an mRNA-based medicine such as the types we are developing being approved for sale by the FDA or any other global regulatory agency. Although we expect to submit BLAs for our mRNA-based investigational medicines in the United States, other jurisdictions may consider our mRNA-based investigational medicines to be new drugs, not biologics, and require different marketing applications. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the investigational medicine&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any investigational medicines we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities, or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the investigational medicines involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of an investigational medicine. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Additional delays or non-approval may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials, and the review process.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory agencies also may approve an mRNA medicine for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our investigational medicines.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA and other regulatory agencies review the CMC section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization. In addition, the regulatory agencies conduct pre-approval inspections at the time of a BLA. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the potential mRNA investigational medicine.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we experience delays in obtaining approval or if we fail to obtain approval of any investigational medicines we may develop, the commercial prospects for those investigational medicines will be harmed, and our ability to generate revenues will be materially impaired.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may never obtain EMA or other foreign regulatory body approval for any of our investigational medicines, and even if we do, we may never be able to commercialize any of our investigational medicines in any other jurisdiction, which would limit our ability to realize their full market potential.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In order to eventually market any of our investigational medicines in any particular foreign jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding safety and efficacy. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country-to-country and could delay or prevent the introduction of our products in those countries. The foreign regulatory approval process involves all of the risks associated with FDA approval. We do not have any investigational medicines approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our planned clinical trials or those of our strategic collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could delay or terminate clinical trials, or delay or prevent regulatory approval or market acceptance of any of our investigational medicines.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is typically an extremely high rate of attrition for product candidates across categories of medicines proceeding through clinical trials. These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. Most investigational medicines that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our investigational medicines.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of our investigational medicines are developed or intended to be co-administered with other developmental therapies or approved medicines. For example, our PCV investigational medicine (mRNA-4157) and our KRAS investigational medicine (mRNA-5671) in collaboration with Merck may be co-administered with Merck&#8217;s anti-PD-1 therapy, pembrolizumab. Our IL-12 investigational medicine (MEDI1191) in collaboration with AstraZeneca is being developed to be co-administered with checkpoint inhibitors (e.g., anti-PD-L1, anti-CTLA4). These combinations may have additional side effects. The uncertainty resulting from the use of our investigational medicines in combination with other therapies may make it difficult to accurately predict side effects in future clinical trials.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of our development candidates and investigational medicines are developed or intended for adolescent and/or pediatric patients under the age of eighteen. For example, we have&#160;clinical trial sites open for and have enrolled a patient in our MMA development candidate (mRNA-3704) for a first-in-human Phase 1/2 trial&#160;in patients between one and eighteen years of age. If successfully dosed, these will be the first of our investigational medicines given to subjects eighteen years of age or younger and mRNA-3704 will be the first of our investigational medicines from our systemic intracellular therapeutics modality dosed in humans. The uncertainty resulting from the first dosing of young, human subjects with an investigational medicine from our systemic intracellular therapeutics modality makes it difficult to accurately predict if significant adverse events or other side effects will be observed.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most of our investigational medicines are formulated and administered in an LNP which, when administered, may lead to systemic side effects related to the components of the LNP, some of which may not have been previously tested in humans. While we have continued to optimize our LNPs, there can be no assurance that our LNPs will not have undesired effects. Our LNPs could contribute, in whole or in part, to one or more of the following: immune reactions, infusion reactions, complement reactions, opsonization reactions, antibody reactions, or reactions to PEG. Certain aspects of our investigational medicines may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within liver pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our clinical trials. Many of these types of side effects have been seen for previously developed LNPs. There may be resulting uncertainty as to the underlying cause of any such adverse event, which would make it difficult to accurately predict side effects in future clinical trials and would result in significant delays in our programs.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting trial participants to any of our clinical trials, trial participants may withdraw from trials, or we may be required to abandon the trials or our development efforts of one or more development candidates or investigational medicines altogether. We, the FDA or other applicable regulatory authorities, or an IRB, may impose a clinical hold or suspend or terminate clinical trials of an investigational medicine at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, unfavorable benefit risk ratio may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition, and prospects.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for an investigational medicine, our products will remain subject to regulatory scrutiny.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we obtain regulatory approval in a jurisdiction, the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to comply with applicable regulatory requirements following approval of any of our investigational medicines, a regulatory agency may:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:60px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-60px;"><span style="font-family:inherit;font-size:10pt;">issue a warning letter asserting that we are in violation of the law; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek an injunction or impose civil or criminal penalties or monetary fines; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspend or withdraw regulatory approval or revoke a license; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspend any ongoing clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refuse to approve a pending BLA or supplements to a BLA submitted by us; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seize product; or </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refuse to allow us to enter into supply contracts, including government contracts. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any approved products and generate revenues.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of our investigational medicines cause undesirable side effects, it could delay or prevent their regulatory approval, limit the commercial potential, or result in significant negative consequences following any potential marketing approval. Investigational medicines we may develop may be associated with an adverse immune response or other serious adverse events, undesirable side effects, or unexpected characteristics. In addition to serious adverse events or side effects caused by any of our investigational medicines, the administration process or related procedures also can cause undesirable side effects. If any such events occur, the clinical trials of any of our investigational medicines could be suspended or terminated.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If in the future we are unable to demonstrate that such adverse events were caused by factors other than our investigational medicine, the FDA, the EMA, or other regulatory authorities could order us to cease further development of, or deny approval of, any of our investigational medicines for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we elect, or are required, to delay, suspend, or terminate any clinical trial of any of our investigational medicines, the commercial prospects of such investigational medicines may be harmed and our ability to generate product revenues from any of these investigational medicines may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop investigational medicines, and may harm our business, financial condition, result of operations, and prospects significantly.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, if we successfully obtain regulatory approval for an investigational medicine, the FDA or other regulatory authority could require us to adopt a Risk Evaluation and Mitigation Strategy to ensure that the benefits of treatment with such investigational medicine outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. Furthermore, if we or others later identify undesirable side effects caused by any product that we develop, several potentially significant negative consequences could result, including:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory authorities may suspend or withdraw approvals or revoke licenses of such product; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory authorities may require additional warnings on the label; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be required to change the way a product is administered or conduct additional clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we could be sued and held liable for harm caused to patients and their children; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our reputation may suffer. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these events could prevent us from achieving or maintaining market acceptance of any products we may identify and develop and could have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are successful in gaining approval for any of our investigational medicines, we will continue to face significant regulatory oversight of the manufacturing and distribution of our products. Product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP and adherence to commitments made in the BLA. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to generate product revenue is dependent on the success of one or more of our development candidates or investigational medicines, each of which is at an early-stage of development and will require significant additional development and clinical testing before we can seek marketing approval and begin commercial sales.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to generate product revenue is highly dependent on our or our strategic collaborators&#8217; ability to develop, obtain regulatory approval of, and successfully commercialize one or more of our development candidates or investigational medicines. Our development candidates and investigational medicines are in the early stages of development and will require additional clinical and nonclinical development, regulatory review, and approval in each jurisdiction in which we intend to market the products. In addition, substantial investment, access to sufficient commercial manufacturing capacity, and significant marketing efforts will be required before we can generate any revenue from product sales. Before obtaining marketing approval from regulatory authorities for the sale of our investigational medicines, we must conduct extensive clinical trials to demonstrate the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">safety and efficacy of the investigational medicines in humans. We cannot be certain that any of our investigational medicines will be successful in clinical trials and they may not receive regulatory approval even if they are successful in clinical trials. Even if approved, our investigational medicines also need to demonstrate health economic benefit in order to establish pricing and reimbursement. We may also need to conduct additional evaluation of safety and health outcomes in a post-approval setting.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to the manufacturing of our development candidates, investigational medicines and our future pipeline</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our mRNA development candidates and investigational medicines are based on novel technologies and any development candidates and investigational medicines we develop may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping. If we or any of our third-party manufacturers encounter such difficulties, our ability to supply material for clinical trials or any approved product could be delayed or stopped.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The manufacturing processes for our development candidates and investigational medicines are novel and complex. There are no mRNA medicines commercialized to date or manufactured at such scale. Due to the novel nature of this technology and limited experience at larger scale production, we may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping. These difficulties could be due to any number of reasons including, but not limited to, complexities of producing batches at larger scale, equipment failure, choice and quality of raw materials and excipients, analytical testing technology, and product instability. In an effort to optimize product features, we have in the past and may in the future make changes to our development candidates or investigational medicines in their manufacturing and stability formulation and conditions. This has in the past resulted in and may in the future result in our having to resupply batches for preclinical or clinical activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our development candidates and investigational medicines could materially delay our or our strategic collaborators&#8217; ability to continue the clinical trial for that development candidate or investigational medicine or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical or clinical supply.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our rate of innovation is high, which has resulted in and will continue to cause a high degree of technology change that can negatively impact product comparability during and after clinical development. Furthermore, technology changes may drive the need for changes in, modification to, or the sourcing of new manufacturing infrastructure or may adversely affect third-party relationships.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The process to generate mRNA investigational medicines encapsulated in LNPs is complex and, if not developed and manufactured under well-controlled conditions, can adversely impact pharmacological activity. Furthermore, we have not manufactured mRNA medicines at commercial scale. We may encounter difficulties in scaling up our manufacturing process, thereby potentially impacting clinical and commercial supply.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are scaling up our batch size to accommodate the clinical supply requirements of some of our programs. However, in many cases, we may have to utilize multiple batches of drug substance and drug product to meet the clinical supply requirement of a single clinical trial. Failure in our ability to scale up batch size or failure in any batch may lead to a substantial delay in our clinical trials.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we continue developing new manufacturing processes for our drug substance and drug product, the changes we implement to manufacturing process may in turn impact specification and stability of the drug product. Changes in our manufacturing processes may lead to failure of batches and this could lead to a substantial delay in our clinical trials. Our mRNA investigational medicines may prove to have a stability profile that leads to a lower than desired shelf life of the final approved mRNA medicine. This poses risk in supply requirements, wasted stock, and higher cost of goods.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our investigational medicines. If such equipment malfunctions or we encounter unexpected performance issues, we could encounter delays or interruptions to clinical and commercial supply. Due to the number of different programs, we may have cross contamination of products inside of our factories, CROs, suppliers, or in the clinic that affect the integrity of our products.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we scale the manufacturing output for particular programs, we plan to continuously improve yield, purity, and the pharmaceutical properties of our development candidates from IND-enabling studies through commercial launch, including shelf life stability, and solubility properties of drug product and drug substance. Because of continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after the change in process, more time is required for pharmaceutical property testing, such as 6 or 12 month stability testing. That may require resupplying clinical material or making additional cGMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are utilizing a number of raw materials and excipients that have a single source of supply, are new to the pharmaceutical industry, and are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our investigational medicines.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have established a number of analytical assays, and may have to establish several more, to assess the quality of our mRNA investigational medicines. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy, or stability. This may lead to an inability to release mRNA investigational medicines until the manufacturing or testing process is rectified.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product and product intermediates are extremely temperature sensitive, and we may learn that any or all of our products are less stable than desired. We may also find that transportation conditions negatively impact product quality. This may require changes to the formulation or manufacturing process for one or more of our investigational medicines and result in delays or interruptions to clinical or commercial supply. In addition, the cost associated with such transportation services and the limited pool of vendors may also add additional risks of supply disruptions.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As our drug development pipeline increases and matures, the increased demand for clinical and commercial supplies from our facilities and third parties may impact our ability to operate. We will require increased capacity across our entire supply chain. Furthermore, we rely on many service providers, including those that provide manufacturing or testing services, all of whom have inherent risks in their operations that may adversely impact our operations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently utilize, and expect to continue to utilize, third parties to, among other things, manufacture raw materials, components, parts, and consumables, and to perform quality testing. If the field of mRNA and other nucleic acid medicines continues to expand, we may encounter increasing competition for these materials and services. Demand for third-party manufacturing or testing facilities may grow at a faster rate than their existing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of such raw materials, components, parts, and consumables required to manufacture our mRNA investigational medicines. The use of service providers and suppliers could expose us to risks, including, but not limited to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">termination or non-renewal of supply and service agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disruptions to the operations of these suppliers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the supplier or service provider; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inspections of third-party facilities by regulatory authorities that could have a negative outcome and result in delays to or termination of their ability to supply our requirements.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to regulatory and operational risks associated with the physical and digital infrastructure at both our internal manufacturing facilities and at those of our external service providers.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, we completed construction of a new manufacturing facility, Moderna Technology Center, or MTC, in Norwood, Massachusetts that, among other things, is intended for cGMP manufacture of drug substance and drug product. While the design of the facility is based on current standards for biotechnology facilities, it has not been reviewed or pre-approved by any regulatory agency, nor has the facility been inspected by any regulatory agency such as the FDA. We have only recently begun producing drug substance and drug product at the MTC for our preclinical and clinical use. We could incur delays in implementing the full operational state of the facility, causing delays to clinical supply or extended use of third-party service providers, resulting in unplanned expenses. In constructing the MTC facility, we have incurred substantial expenditures, and expect to incur significant additional expenditures in validating and operating the facility in the future.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have designed the MTC to incorporate a significant level of automation of equipment with integration of several digital systems to improve efficiency of operations. We have attempted to achieve a high level of digitization for a clinical manufacturing facility relative to industry standards. While this is meant to improve operational efficiency, this may pose additional risk of process equipment malfunction and even overall manufacturing system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility, or potential cybersecurity breaches. This may lead to delay in supply or shutdown of our facility. Any disruption in our manufacturing capabilities at the MTC could cause delays in our production capacity for our drug substances or drug products, impose additional costs, or may require us to identify, qualify, and establish an alternative manufacturing site, the occurrence of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we expand our development and commercial capacity, we may establish additional manufacturing capabilities inside the MTC footprint or expand to other locations or geographies, which may lead to regulatory delays or prove costly. If we fail to select the correct location, complete the construction in an efficient manner, recruit the required personnel, and generally manage our growth effectively, the development and production of our investigational medicines could be delayed or curtailed. Additional investments may be needed if changes in our manufacturing process lead to required changes in the MTC&#8217;s infrastructure.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There are risks inherent in pharmaceutical manufacturing operations that could affect our ability and the ability of our third-party manufacturers or contract manufacturing organizations to meet our delivery requirements or provide adequate amounts of material.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The convergence of process and analytical technology, raw materials, consumables, equipment, physical infrastructure, including a clean room environment, and air handling and other utilities, results in complex procedures and systems that have to work effectively to manufacture our investigational medicines. Failure or process defects in any of the interrelated systems at either our manufacturing facilities or those of our third-party providers, could adversely impact our ability to manufacture and supply our investigational medicines.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our investigational medicines are inherently sensitive to shipping and storage conditions, which, in some cases, requires cold-chain logistics and could subject our investigational medicines to risk of loss or damage.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our investigational medicines are sensitive to temperature, storage, and handling conditions. Loss in investigational medicines could occur if the product or product intermediates are not stored or handled properly. Shelf life for our investigational medicines may vary by product and is not fully quantified and is expected to be variable, and it is possible that our investigational medicines could be lost due to expiration prior to use. Cold-chain logistics are required for certain of our investigational medicines. If we do not effectively maintain our cold-chain supply logistics, then we may experience an unusual number of returned or out of date products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to effectively maintain our cold-chain supply logistics, by us or third parties, has in the past and could in the future lead to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or otherwise.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*We are subject to significant regulatory oversight with respect to manufacturing our mRNA investigational medicines. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet cGMP requirements set forth in regulations promulgated by the FDA, EMA, and other global health authorities could result in significant delays in and costs of our products.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The manufacturing of vaccines and therapeutics for clinical trials or commercial sale is subject to extensive regulation. Components of a finished product approved for commercial use or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in clinical trials. Poor control of the cGMP production processes can lead to product quality failures that can impact our ability to supply product, resulting in cost overruns and delays to clinical timelines, which could be extensive. Such production process issues include but are not limited to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">critical deviations in the manufacturing process;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">facility and equipment failures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">contamination of the product due to an ineffective quality control strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">facility contamination as assessed by the facility and utility environmental monitoring program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ineffective process, equipment, or analytical change management, resulting in failed lot release criteria;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ineffective product stability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failed lot release or facility and utility quality control testing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failed or defective components or consumables.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We must supply all necessary documentation in support of a BLA or other marketing authorization application on a timely basis and must adhere to the FDA&#8217;s, EMA&#8217;s, and other countries&#8217; cGMP requirements which are enforced, in the case of the FDA, in part through its facilities inspection program.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with cGMP and manufacturing controls as described in the filing. If either we or one of our third-party manufacturing sites fails to provide sufficient quality assurance or control, the product approval to commercialize may not be granted. Inspections by regulatory authorities may occur at any time during the development or commercialization phase of products. The inspections may be product specific or facility specific for broader cGMP inspections or as a follow up to market or development issues that the regulatory agency may identify. Deficient inspection outcomes may influence the ability of our third-party manufacturers or suppliers to fulfill their supply obligations, impacting or delaying supply or delaying programs.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The manufacturing process for any products that we may develop is subject to the FDA and foreign regulatory authority approval process, and we may need to contract with manufacturers who we believe can meet applicable FDA and foreign regulatory authority requirements on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce investigational medicines to specifications acceptable to the FDA or other regulatory authorities, we or our strategic collaborators may not obtain or maintain the approvals we or they need to commercialize such products. Even if we or our strategic collaborators obtain regulatory approval for any of our mRNA medicines, there is no assurance that either we or our contract manufacturing organizations will be able to manufacture the approved medicine to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our investigational medicines, impair commercialization efforts, or increase our cost of goods. The occurrence of any of the foregoing could have an adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we may not have direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance, and qualified personnel. Furthermore, all of our contract manufacturers are engaged with other companies to supply or manufacture materials or products for such companies, which exposes our contract manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of our contract manufacturers&#8217; facility. In addition, to the extent that we rely on foreign contract manufacturers, including for mRNA-1273, we are or will be subject to additional risks, including the need to comply with import and export regulations. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of investigational medicines or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and investigational medicines (including those of our strategic collaborators) and our overall business operations. Our potential future dependence upon others for the manufacture of our investigational medicines and raw materials may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA, the EMA, and other foreign regulatory authorities may require us to submit product samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA, or other foreign regulatory authorities may require that we do not distribute a lot or lots until the relevant agency authorizes such release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Our third-party contract manufacturers have, in the past, experienced lot failures and some may have experienced product recalls. Lot failures have in the past caused, and lot failures or product recalls in the future with respect to product produced by either our own facilities or those of our third-party manufacturers could cause, us and our strategic collaborators to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations, and prospects.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also may encounter problems hiring and retaining the experienced scientific, quality-control, and manufacturing personnel needed to operate our manufacturing processes and operations, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. While we will train and qualify all personnel around the appropriate handling of our products and materials, we may not be able to control for or ultimately detect intentional sabotage or negligence by any employee or contractor.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks specific to certain investigational medicines</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our PCV investigational medicine is uniquely manufactured for each patient using a novel, complex manufacturing process and we may encounter difficulties in production.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We custom design and manufacture PCVs that are unique and tailored specifically for each patient. Manufacturing unique lots of PCVs is susceptible to product loss or failure due to issues with:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">logistics associated with the collection of a patient&#8217;s tumor, blood, or other tissue sample;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">shipping such samples to a facility for genetic sequencing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">next generation sequencing of the tumor mRNA;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">identification of appropriate tumor-specific mutations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the use of a software program, including proprietary and open source components, which is hosted in the cloud and a part of our investigational medicine, to assist with the design of the patient-specific mRNA, which software must be maintained and secured;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">effective design of the patient-specific mRNA that encodes for the required neoantigens;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">batch specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch that may not have been foreseen;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">quality control testing failures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unexpected failures of batches placed on stability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">shortages or quality control issues with single-use assemblies, consumables, or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significant costs associated with individualized manufacturing that may adversely affect our ability to continue development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">successful and timely manufacture and release of the patient-specific batch;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">shipment issues encountered during transport of the batch to the patient site of care; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to define a consistent safety profile at a given dose when each participant receives a unique vaccine.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have built and installed custom manufacturing equipment for PCV that has been incorporated into a personalized vaccine unit in the MTC. This unit is currently operational and we are producing batches of PCV from our location and a third-party supplier&#8217;s. This equipment may not function as designed which may lead to deviations in the drug product being produced. This can lead to increased batch failure and the inability to supply patients enrolled in the clinical trial. If our clinical development plans are expanded, due to the custom nature of the equipment and single-use assemblies, we may not be able to supply this expanded need reliably without significant investments. In addition, there will be considerable time to scale up our facilities or build new facilities before we can begin to meet any commercial demand if our PCV product is approved. This expansion or addition of new facilities could also lead to product comparability issues which can further delay introduction of new capacity.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because our PCVs are manufactured for each individual patient, we will be required to maintain a chain of identity with respect to each patient&#8217;s tissue sample, sequence data derived from such tissue sample, results of analysis of such patient&#8217;s genomic analysis, and the custom manufactured product for each patient. Maintaining such a chain of identity is difficult and complex, and failure to do so has in the past and may in the future result in product mix up, adverse patient outcomes, loss of product, or regulatory action including withdrawal of any approved products from the market. Further, as our PCV investigational medicine is developed through early-stage clinical trials to later-stage clinical trials towards approval and commercialization, we expect that multiple aspects of the complicated collection, analysis, manufacture, and delivery process will be modified in an effort to optimize processes and results. These changes may not achieve the intended objectives, and any of these changes could cause our PCVs to perform differently than we expect, potentially affecting the results of clinical trials.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our reliance on third parties</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have in the past entered into, and in the future may enter into, strategic alliances with third parties to develop investigational medicines. If these strategic alliances are not successful, our business could be adversely affected.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have limited resources to conduct clinical operations and have not yet established infrastructure for sales, marketing, or distribution. Accordingly, we have entered into strategic alliances under which our strategic collaborators have provided, and may in the future provide, funding and other resources for developing and potentially commercializing our investigational medicines. We expect to enter into additional strategic alliances to access additional funding, capabilities, and expertise in the future. Our existing strategic alliances, and any future strategic alliances we enter into, may pose a number of risks, including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">strategic collaborators may not perform their obligations as expected;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the clinical trials conducted as part of such strategic alliance may not be successful;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">strategic collaborators may not pursue development and commercialization of any investigational medicines that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the strategic collaborators&#8217; focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">strategic collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, abandon an investigational medicine, repeat or conduct new clinical trials, or require a new formulation of an investigational medicine for clinical testing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">strategic collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our investigational medicines if the strategic collaborators believe that competitive products are more </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:60px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">investigational medicines developed in strategic alliances with us may be viewed by our strategic collaborators as competitive with their own investigational medicines or products, which may cause strategic collaborators to cease to devote resources to the development or commercialization of our investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a strategic collaborator with marketing and distribution rights to one or more of our investigational medicines that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disagreements with strategic collaborators, including disagreements over proprietary rights, contract interpretation, or the preferred course of development of any investigational medicines, may cause delays or termination of the research, development, or commercialization of such investigational medicines, may lead to additional responsibilities for us with respect to such investigational medicines, or may result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">strategic collaborators may not properly maintain or defend our IP rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our IP or proprietary information or expose us to potential litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disputes may arise with respect to the ownership of IP developed pursuant to our strategic alliances;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">strategic collaborators may infringe the IP rights of third parties, which may expose us to litigation and potential liability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">strategic alliances may be terminated for the convenience of the strategic collaborator and, if terminated, the development of our investigational medicines may be delayed, and we could be required to raise additional capital to pursue further development or commercialization of the applicable investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we could face significant competition in seeking appropriate strategic collaborators and the negotiation process is time-consuming and complex; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our international operations through any future collaborations, acquisitions, or joint ventures may expose us to certain operating, legal, and other risks not encountered in the United States.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our strategic alliances do not result in the successful development and commercialization of programs, or if one of our strategic collaborators terminates its agreement with us, we may not receive any future research funding or milestone, earn-out, royalty, or other contingent payments under the strategic alliances. If we do not receive the funding we expect under these agreements, our development of investigational medicines could be delayed and we may need additional resources to develop our investigational medicines. In addition, in general our strategic collaborators have the right to terminate their agreements with us for convenience. A strategic collaborator has in the past terminated its agreement with us. If one of our strategic collaborators terminates its agreement with us, we may find it more difficult to attract new strategic collaborators and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval, and commercialization described in this Quarterly Report on Form 10-Q apply to the activities of our strategic collaborators.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our strategic collaborators control aspects of our clinical trials, regulatory activities, and other aspects of our strategic alliances, which could result in delays and other obstacles in the development and commercialization of our proposed products and materially harm our results of operations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For some programs, we depend on strategic collaborators to design and conduct clinical trials for our investigational medicines. As a result, we may not control the manner or time schedule in which these clinical trials are conducted, which may negatively impact our business operations. In addition, if any of our strategic collaborators withdraws support for one or more of our programs or proposed products or otherwise impairs their development, our business could be negatively affected.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may seek to establish additional strategic alliances and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. Certain of our strategic alliance agreements may restrict our ability to develop certain products.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our development programs and the potential commercialization of our development candidates and investigational medicines will require substantial additional cash to fund expenses. For some of our investigational medicines, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those investigational medicines.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We face significant competition in seeking appropriate strategic collaborators. Whether we reach a definitive agreement for any additional strategic alliances will depend, among other things, upon our assessment of the strategic collaborator&#8217;s resources and expertise, the terms and conditions of the proposed strategic alliance, and the proposed strategic collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">similar regulatory authorities outside the United&#160;States, the potential market for the subject investigational medicine, the costs and complexities of manufacturing and delivering such investigational medicine to trial participants, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The strategic collaborator may also consider alternative investigational medicines or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our investigational medicine. The terms of any additional strategic alliances or other arrangements that we may establish may not be favorable to us.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also restricted under our existing strategic alliance agreements from entering into certain future agreements on certain terms with potential strategic collaborators to pursue other targets on our own. These restrictions on working with targets, polypeptides, routes of administration, and fields could limit our ability to enter into strategic collaborations with future strategic collaborators or to pursue certain potentially valuable development candidates or investigational medicines.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be able to negotiate additional strategic alliances on a timely basis, on favorable terms, or at all. Strategic alliances are complex and time-consuming to negotiate and document. If we are unable to negotiate and enter into new strategic alliances, we may have to curtail the development of the investigational medicine for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on favorable terms or at all. If we do not have sufficient funds, we may not be able to further develop our investigational medicines or bring them to market and generate product revenue.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our development candidates and investigational medicines.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop, our development candidates and investigational medicines. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we have to switch to a replacement supplier, the manufacture and delivery of our development candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational medicines.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as part of the FDA&#8217;s approval of our investigational medicines, we will also require FDA review of the individual components of our process, which include the manufacturing processes and facilities of our single-source suppliers.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays to the development timelines for our development candidates or investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a lack of long-term supply arrangements for key components with our suppliers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">damage to our reputation caused by defective components produced by our suppliers; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on and expect to continue to rely on third parties to conduct aspects of our research, preclinical studies, protocol development, and clinical trials for our development candidates or investigational medicines. If these third parties do not perform satisfactorily, comply with regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our investigational medicines and our business could be substantially harmed.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our clinical trials. We currently rely and expect to continue to rely on third parties to conduct certain research and preclinical testing activities. In some cases, these third parties may terminate their engagements with us. If we need to enter into alternative arrangements, it would delay our discovery or product development activities.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory or contractual responsibilities. We will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements, and scientific standards. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and our CROs will be required to comply with regulations, including GCPs, for conducting, monitoring, recording, and reporting the results of preclinical studies and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial participants are adequately informed, among other things, of the potential risks of participating in clinical trials. We also are responsible for ensuring that the rights of our clinical trial participants are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, and comparable foreign regulatory authorities for any investigational medicines in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators, and trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with investigational medicines produced in accordance with the requirements in cGMP regulations. Our failure or the failure of our CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we intend to design the clinical trials for certain of our investigational medicines, our strategic collaborators will design the clinical trials that they are managing (in some cases, with our input) and in the case of clinical trials controlled by us, we expect that CROs will conduct all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also potentially lead to mistakes as well as difficulties in coordinating activities. Outside parties may:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">have staffing difficulties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fail to comply with contractual obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">experience regulatory compliance issues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">undergo changes in priorities or become financially distressed;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">form relationships with other entities, some of which may be our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">have human errors; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be subject to cyber-attacks.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs do not perform preclinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval, and commercialization of our investigational medicines may be delayed, we may not be able to obtain regulatory approval and commercialize our investigational medicines, or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also expect to rely on other third parties to transport, store, and distribute the required materials for our clinical trials. In the past certain of our third-party vendors have mishandled our materials, resulting in loss of full or partial lots of material. Any further performance failure on the part of these third parties could result in damaged products and could delay clinical development or marketing approval of any investigational medicines we may develop or commercialization of our medicines, if approved, producing additional losses and depriving us of potential product revenue, causing us to default on our contractual commitments, result in losses that are not covered by insurance, and damage our reputation and overall perception of our products in the marketplace.</span></div><div style="line-height:174%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our intellectual property</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our products.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">mRNA medicines are a relatively new scientific field, the continued development and potential use of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain IP protection in the field. We have obtained grants and issuances of patents on mRNA medicines and our delivery technology. The issued patents and pending patent applications in the United States and in key markets around the world that we own, claim many different methods, compositions, and processes relating to the discovery, development, manufacture, and commercialization of mRNA medicines and our delivery technology, including LNPs.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As the field of mRNA therapeutics and vaccines is maturing, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. It is likely that there will be significant litigation and other proceedings, such as interference, reexamination, and opposition proceedings, as well as</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> inter partes</span><span style="font-family:inherit;font-size:10pt;"> and post-grant review proceedings introduced by provisions of the America Invents Act, which became available to third-party challengers on September&#160;16, 2012, in various patent offices relating to patent rights in the mRNA field. We expect that oppositions will be filed in the European Patent Office, or EPO, and elsewhere relating to patents and patent applications in our portfolio. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. For example, a third party request for reexamination has been granted against one of our U.S. patents, which relates to our infectious disease vaccine program. We cannot be certain that such patent will survive or that the claims will remain in the current form. In addition, third parties may attempt to invalidate our IP rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our IP rights. Our defense against any attempt by third parties to circumvent or invalidate our IP rights could be costly to us, could require significant time and attention of our management, and could have a material adverse impact on our business and our ability to successfully compete in the field of mRNA therapeutics.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are many issued and pending third-party patents that claim aspects of oligonucleotide delivery technologies that we may need for our mRNA therapeutic and vaccine candidates. There are also many issued third-party patents that claim targeting genes or portions of genes that may be relevant for mRNA medicines we wish to develop. For example, we are aware of a third-party patent directed to methods of using mRNA to treat Fabry disease. In addition, there may be issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for our mRNA therapeutic candidates. Thus, it is possible that one or more organizations will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. If those organizations refuse to grant us a license to such patent rights on reasonable terms or a court rules that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms, we may be unable to perform research and development or other activities or market products covered by such patents.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages, or be required to stop our product development and commercialization efforts.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other IP rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> ex parte</span><span style="font-family:inherit;font-size:10pt;"> reexaminations, post-grant review, and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> inter partes</span><span style="font-family:inherit;font-size:10pt;"> review proceedings before the U.S. Patent and Trademark Office, or the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. In certain instances, we have instituted and may in the future institute</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> inter partes</span><span style="font-family:inherit;font-size:10pt;"> review proceedings against issued U.S. patents and opposition proceedings against European patents owned by third parties in the field of mRNA medicines. We have a number of these proceedings ongoing against third-party patents related to RNA vaccinations and mRNA delivery. If we are unsuccessful in invalidating certain of the third-party patents that we are currently challenging, those third parties may attempt to assert those patents against us should certain of our investigational medicines obtain regulatory approval. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our development candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our investigational medicines. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our investigational medicines may infringe. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our investigational medicines, any molecules formed during the manufacturing process, or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to commercialize such investigational medicine unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable investigational medicine unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to our IP may be offset by amounts paid by our collaborators to third parties who have competing or superior IP positions in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, in connection with certain license and strategic alliance agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to IP rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to IP rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could delay our research and development efforts and limit our ability to continue our operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary IP rights to product components and manufacturing processes for our development pipeline.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Presently we have rights to certain IP, through licenses from third parties and under patents that we own, to develop our development candidates and investigational medicines. Because our pipeline may involve additional development candidates that could require the use of proprietary rights held by third parties, the growth of our business could depend in part on our ability to acquire, in-license, or use these proprietary rights. In addition, our development candidates and investigational medicines may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party IP rights from third parties that we identify. The licensing and acquisition of third-party IP rights is a competitive area, and a number of more established companies are also </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">pursuing strategies to license or acquire third-party IP rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for IP, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the IP rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party IP rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party IP rights, our business, financial condition, and prospects for growth could suffer.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not able to obtain and enforce patent protection for our discoveries, our ability to effectively compete using our development candidates will be harmed.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends, in part, on our ability to protect proprietary methods and technologies that we develop under the patent and other IP laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold proprietary rights to some patents required for us to develop, manufacture, and commercialize our proposed products.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because certain U.S. patent applications are confidential until the patents issue, such as applications filed prior to November&#160;29, 2000, or applications filed after such date which will not be filed in foreign countries, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. For this and other reasons, we may be unable to secure desired patent rights, thereby losing exclusivity. Further, we may be required to obtain licenses under third-party patents to market our proposed products or conduct our research and development or other activities. If licenses are not available to us on favorable terms, we may not be able to market the affected products or conduct the desired activities.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our strategy depends on our ability to rapidly identify and seek patent protection for our discoveries. In addition, we may rely on third-party strategic collaborators to file patent applications relating to proprietary technology that we develop jointly as a part of certain strategic alliances. The process of obtaining patent protection is expensive and time-consuming. If our present or future strategic collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business may be adversely affected. Despite our efforts and the efforts of our strategic collaborators to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. While issued patents are presumed valid, this does not guarantee that the patent will survive a validity challenge or be held enforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable, or circumvented by parties attempting to design around our IP. Moreover, third parties or the USPTO may commence interference proceedings involving our patents or patent applications. Any challenge to, finding of unenforceability or invalidation, or circumvention of, our patents or patent applications, would be costly, would require significant time and attention of our management, could reduce or eliminate royalty payments to us from third-party licensors, and could have a material adverse impact on our business.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our pending patent applications may not result in issued patents. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts, and lawmakers. Moreover, there are periodic discussions in the U.S. Congress and in international jurisdictions about modifying various aspects of patent law. For example, the America Invents Act, which took effect in March 2013, included a number of changes to the patent laws of the United States. If any of the enacted changes prevent us from adequately protecting our discoveries, including our ability to pursue infringers of our patents to obtain injunctive relieve or for substantial damages, our business could be adversely affected. One major provision of the America Invents Act changed U.S. patent practice from a first-to-invent to a first-to-file system. If we fail to file an invention before a competitor files on the same invention, we no longer have the ability to provide proof that we were in possession of the invention prior to the competitor&#8217;s filing date, and thus would not be able to obtain patent protection for our invention. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how, or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We license patent rights from third-party owners. If such owners do not properly or successfully obtain, maintain, or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to licenses that give us rights to third-party IP that is necessary or useful for our business. In particular, we have obtained licenses from Cellscript, LLC and its affiliates to patent rights covering modified mRNA chemistries and from certain other parties for IP useful in our formulation efforts. We may enter into additional licenses to third-party IP in the future.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success will depend in part on the ability of our licensors to obtain, maintain, and enforce patent protection for our licensed IP. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the IP we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our strategic collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our strategic alliance agreements or result in termination of an agreement by one or more of our strategic collaborators.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license IP rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing of IP is important to our business and involves complex legal, business, and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. We are a party to certain IP license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some cases, patent prosecution of our licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary IP we license from them, we could lose our rights to the IP and our competitors could market competing products using the IP. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our strategic collaborators. Disputes may arise regarding IP subject to a licensing agreement, including:</span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which our technology and processes that are not subject to the licensing agreement infringe on IP of the licensor; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the sublicensing of patent and other rights under our collaborative development relationships; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ownership of inventions and know-how resulting from the joint creation or use of IP by our licensors and us and our strategic collaborators; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the priority of invention of patented technology. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If disputes over IP that we have licensed prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop and commercialize the affected development candidates or investigational medicines. We are generally also subject to all of the same risks with respect to protection of IP that we license, as we are for IP that we own, which are described below. If we or our licensors fail to adequately protect this IP, our ability to commercialize products could suffer.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to patent protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants, and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain former employees have obtained employment with companies or academic institutions that could be considered competitive with us and are operating their business in areas that are similar to ours, including in their business model, product discovery efforts, mRNA-based product development, or formulation technology such as our LNPs. This competition may be limited by contractual provisions which may or may not be enforceable by us in the Commonwealth of Massachusetts or other jurisdictions. In addition, we may not be aware of such competitive employment arrangements until after our trade secrets have been disclosed to potentially competitive companies.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, from time to time we are subject to claims that we, or our employees, consultants, or independent contractors, have inadvertently or otherwise used or disclosed IP, including trade secrets or other proprietary information, of any of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable IP rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other IP.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other IP. Ownership disputes may arise, for example, from conflicting obligations of consultants or others who are involved in developing our development candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable IP rights, such as exclusive ownership of, or right to use, valuable IP. Such an outcome could have a material adverse impact on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United&#160;States in several stages over the lifetime of the patents or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance could have a material adverse impact on our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issued patents covering our development candidates and investigational medicines could be found invalid or unenforceable if challenged in court.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we or one of our strategic collaborators initiated legal proceedings against a third party to enforce a patent covering one of our development candidates or investigational medicines, the defendant could counterclaim that the patent covering our development candidate or investigational medicine is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include reexamination, post-grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our development candidates or investigational medicines. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, there may be invalidating prior art that we and the patent examiner were unaware of during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part of the patent protection for our development candidates and investigational medicines. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As is the case with other biotechnology companies, our success is heavily dependent on IP, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect our IP rights throughout the world.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filing, prosecuting, and defending patents on development candidates and investigational medicines in all countries throughout the world would be prohibitively expensive, and our IP rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect IP rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United&#160;States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other IP rights may not be effective or sufficient to prevent them from competing.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many companies have encountered significant problems in protecting and defending IP rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other IP protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our IP rights around the world may be inadequate to obtain a significant commercial advantage from the IP that we develop or license.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*Our reliance on government funding and collaboration from government and quasi-governmental entities for certain of our programs adds uncertainty to our research and development efforts with respect to those programs and may impose requirements that increase the costs of development, commercialization and production of any programs developed under those government-funded programs.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The development of each of our Zika vaccine (mRNA-1893), our antibody against Chikungunya virus (mRNA-1944), and our Chikungunya vaccine (mRNA-1388), are currently being funded through subcontracts with funding from either the Biomedical </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advanced Research and Development Authority, or BARDA, or Defense Advanced Research Projects Agency, or DARPA. Our SARS-CoV-2 vaccine (mRNA-1273) is being developed in collaboration with NIAID, and NIAID plans to conduct IND-enabling studies and the NIH is conducting a Phase 1 open-label clinical trial of mRNA-1273 in the United States. CEPI has agreed to fund the manufacture of the preliminary clinical batches of mRNA-1273 and, if the Phase 1 clinical trial is successful, BARDA has agreed to fund the advancement of mRNA-1273 to FDA licensure. Contracts and grants funded by the U.S. government and its agencies, including our agreements funded by BARDA and DARPA and our collaboration with NIAID, include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">terminate agreements, in whole or in part, for any reason or no reason; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">claim rights, including IP rights, in products and data developed under such agreements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">audit contract-related costs and fees, including allocated indirect costs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspend or debar the contractor or grantee from doing future business with the government; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">control and potentially prohibit the export of products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">pursue criminal or civil remedies under the False Claims Act, False Statements Act, and similar remedy provisions specific to government agreements; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limit the government&#8217;s financial liability to amounts appropriated by the U.S. Congress on a fiscal-year basis, thereby leaving some uncertainty about the future availability of funding for a program even after it has been funded for an initial period. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not have the right to prohibit the U.S. government from using certain technologies developed by us, and we may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally takes the position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, government contracts and grants, and subcontracts and subawards awarded in the performance of those contracts and grants, normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">specialized accounting systems unique to government contracts and grants; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">public disclosures of certain contract and grant information, which may enable competitors to gain insights into our research program; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination, and affirmative action programs, and environmental compliance requirements. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:60px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, under these agreements we are subject to the obligations to and the rights of the U.S. government set forth in the Bayh-Dole Act of 1980, or the Bayh-Dole Act. As a result, the U.S. government may have rights in certain inventions developed under these government-funded programs, including a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations, also referred to as &#8220;march-in rights.&#8221; While the U.S. government has sparingly used, and to our knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the U.S. government requires that any products embodying any invention generated through the use of U.S. government funding be manufactured substantially in the United States. The manufacturing preference requirement can be waived </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. manufacturers for products covered by such intellectual property.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As an organization, we are relatively new to government contracting and new to the regulatory compliance obligations that such contracting entails. If we fail to maintain compliance with those obligations, we may be subject to potential liability and to termination of our contracts.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a U.S. government contractor, we are subject to financial audits and other reviews by the U.S. government of our costs and performance on their contracts, as well as our accounting and general business practices related to these contracts. Based on the results of its audits, the government may adjust our contract-related costs and fees, including allocated indirect costs. Although adjustments arising from government audits and reviews have not had a material adverse impact on our financial condition or results of operations in the past, we cannot assure you that future audits and reviews will not have those effects.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CEPI is a global organization that has publicly stated its intent to work with multiple global organizations on potential vaccines and therapies targeting the novel coronavirus, including other companies working on mRNA based approaches. There is a possibility that our confidential information may become exposed to others during this process, including the details and timing of our vaccine efforts.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to commercialization of our pipeline</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have no sales, distribution, or marketing experience, and may invest significant financial and management resources to establish these capabilities. If we are unable to establish such capabilities or enter into agreements with third parties to market and sell our future products, if approved, we may be unable to generate any revenues.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Given our stage of development, we have no sales, distribution, or marketing experience. To successfully commercialize any products that may result from our development programs, we will need to develop sales and marketing capabilities in the United States, Europe, or other regions, either on our own or with others. We may enter into strategic alliances with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our future strategic collaborators do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we may be unable to generate sufficient product revenue to sustain our business. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without a significant internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing products, new treatment methods, and new technologies, we may be unable to commercialize successfully any products that we develop.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and other public and private research organizations are pursuing the development of novel products for the same diseases that we are targeting or expect to target. Many of our competitors have:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">greater financial, technical, and human resources than we have at every stage of the discovery, development, manufacture, and commercialization of products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">more extensive experience in preclinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing, and selling products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">investigational medicines that are based on previously tested or accepted technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">products that have been approved or are in late stages of development; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborative arrangements in our target markets with leading companies and research institutions.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will face intense competition from products that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop products. We also expect to face competition from new products that enter the market. There are a number of products currently under development, which may become commercially available in the future, for the treatment of conditions for which we are trying, or may in the future try, to develop products. These products may be more effective, safer, less expensive, or marketed and sold more effectively, than any products we develop.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate competing with the largest pharmaceutical companies in the world, many of which are all currently conducting research in the fields of infectious diseases, immuno-oncology, rare genetic diseases, and cancer vaccines. Some of these companies have greater financial and human resources than we currently have. In addition to these large pharmaceutical companies, we may directly compete with fully-integrated biopharmaceutical companies and other immunotherapy-focused oncology companies, as well as a number of companies focused on mRNA medicines or shared tumor antigen and neoantigen therapeutics, some of which have entered into collaboration and funding agreements with larger pharmaceutical or biotechnology companies.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we successfully develop investigational medicines, and obtain approval for them, we will face competition based on many different factors, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the safety and effectiveness of our products relative to alternative therapies, if any;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and scope of regulatory approvals for these products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the availability and cost of manufacturing, marketing, and sales capabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the price of any approved mRNA medicine;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reimbursement coverage; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patent position.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our competitors may develop or commercialize products with significant advantages over any products we develop based on any of the factors listed above or on other factors. In addition, our competitors may develop strategic alliances with or receive funding from larger pharmaceutical or biotechnology companies, providing them with an advantage over us. Our competitors may therefore be more successful in commercializing their products than we are, which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our products, if approved.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The commercial success of any current or future investigational medicine, if approved, will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ethical, social, and legal concerns about genetic research could result in additional regulations restricting or prohibiting the products and processes we may use. Even with the requisite approvals, the commercial success of our products will depend in part on the medical community, patients, and third-party or governmental payors accepting mRNA medicines in general, and our products in particular, as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, trial participants, third-party payors, and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our investigational medicines, if approved for commercial sale, will depend on a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential efficacy and potential advantages over alternative treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to offer our products, if approved, at competitive prices;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prevalence and severity of any side effects resulting from checkpoint inhibitors or other products or therapies with which our products are co-administered;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">relative convenience and ease of administration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any restrictions on the use of our products, if approved, together with other medications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">publicity concerning our products or competing products and treatments; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sufficient third-party insurance coverage or reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the products may require significant resources and may never be successful. Our efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors due to the complexity and uniqueness of our programs.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we are successful in obtaining marketing approval for any product, commercial success of any approved products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs, and entry into managed care organizations, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors do not provide adequate coverage and reimbursement levels for any of our products once approved, whether due to healthcare reform legislation or otherwise, market acceptance and commercial success would be reduced.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, if any of our products are approved for marketing, we or a strategic collaborator will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports for such product, and will need to continue to comply (or ensure that our third-party providers comply) with cGMP and current GCPs for any clinical trials that we or a strategic collaborator conduct post-approval. In addition, there is always the risk that we or a strategic collaborator or regulatory authority might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any such failure to comply or other issues with our investigational medicines identified post-approval could have a material adverse impact on our business, financial condition, and results of operations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may market our products outside of the United States, and we will be subject to the risks of doing business outside of the United States.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because we plan to market our products, if approved, outside of the United States, our business is subject to risks associated with doing business outside of the United States including, an increase in our expenses, diversion of our management&#8217;s attention from the acquisition or development of investigational medicines, or forgoing profitable licensing opportunities in these geographies. Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">efforts to develop an international sales, marketing, and distribution organization;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unexpected changes in foreign laws and regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">difficulty of effective enforcement of contractual provisions in local jurisdictions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inadequate IP protection in foreign countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">trade-protection measures, import or export licensing requirements such as Export Administration Regulations promulgated by the U.S. Department of Commerce and fines, penalties, or suspension or revocation of export privileges;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effects of applicable foreign tax structures and potentially adverse tax consequences; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significant adverse changes in foreign currency exchange rates.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to FDA and related regulatory requirements in the United States and abroad, we are subject to extensive additional federal, state and foreign anti-bribery regulations, which include the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and similar laws in other countries outside of the United States. We are developing and implementing a corporate compliance program based on what we believe are current best practices in the pharmaceutical industry for companies similar to ours, but we cannot guarantee that we, our employees, our consultants, or our third-party contractors are or will be in compliance with all federal, state, and foreign regulations regarding bribery and corruption. Moreover, our strategic collaborators and third-party contractors located outside the United States may have inadequate compliance programs or may fail to respect the laws and guidance of the territories in which they operate. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition, and results of operations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The insurance coverage and reimbursement status of newly-approved products, particularly in a new class of medicines, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments such as the medicines that we hope to develop and sell. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. In addition, because our personalized cancer vaccine and intratumoral immuno-oncology investigational medicines represent new approaches to the treatment of cancer, we cannot accurately estimate how these products would be priced, whether reimbursement could be obtained, or any potential revenue. Sales of our investigational medicines will depend substantially, both domestically and abroad, on the extent to which the costs of our investigational medicines will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government health administration </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">authorities, private health coverage insurers, and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our investigational medicines. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment in any of our products.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products, including genetic medicines and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European countries.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical products, or medicinal products, as they are commonly referred to in the European Union, with limited participation from the marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our strategic collaborators. If the regulatory authorities in these foreign jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our strategic collaborators, our revenues from sales by us or our strategic collaborators, and the potential profitability of our drug products, in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run healthcare systems. These international price control efforts have impacted all regions of the world, but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our investigational medicines. For example, the U.S. government recently released a &#8220;Blueprint&#8221;, or plan, to reduce the cost of drugs. This Blueprint contains certain measures that the HHS is already working to implement. For example, in May 2019, CMS issued a final rule that amends the Medicare Advantage and Medicare Part D prescription drug benefit regulations to reduce out of pocket costs for plan enrollees and allow Medicare plans to negotiate lower rates for certain drugs. Among other things, the final rule now allows Medicare Advantage plans the option to use step therapy, a type of pre-authorization, for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, or restrictions on certain product access, and marketing cost disclosure and transparency measures, which, in some cases, are designed to encourage importation from other countries and bulk purchasing.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to experience pricing pressures in connection with the sale of any of our investigational medicines, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may face competition in the United States for our development candidates, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act contains provisions that may change U.S. importation laws and expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. These changes to U.S. importation laws will not take effect unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 18, 2019, FDA issued a notice of proposed rulemaking that, if finalized, would allow for the importation of certain prescription drugs from Canada. The Secretary of HHS would make the above certification to Congress upon issuance of a final rule based on this proposal. FDA also issued a draft guidance document outlining a potential pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The regulatory and market implications of the notice of proposed rulemaking and draft guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our business.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part D coverage gap discount program. Considerable uncertainty remains regarding the implementation and impact of the ACA.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing legal and constitutional challenges in the Fifth Circuit Court and the United States Supreme Court, and the Trump Administration has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Additionally, Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what affect further changes to the ACA would have on our business.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, created measures for spending reductions by the U.S. Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year. These reductions will remain in effect through 2029 unless additional Congressional action is taken.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our development candidates, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our investigational medicines, restrict or regulate post-approval activities, and affect our ability to commercialize any products for which we obtain marketing approval.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that additional foreign, state, and federal healthcare reform measures or proposals will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our investigational medicines or additional pricing pressures. In the event that the pricing structures for healthcare products, such as the investigational medicines we are developing, change materially and limit payments for such </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">investigational medicines, our business will be adversely impacted as our products may no longer be commercially viable based on their expected net present value, we may have invested significant resources in products that cannot be commercially developed, or we may determine that assets that have reached an early phase of development cannot or will not be taken into further development, notwithstanding their clinical viability. In addition, development assets or clinical programs that are part of our strategic alliances may no longer be deemed commercially viable to pursue based on our strategic collaborators&#8217; assessments of the impact of any proposed, announced, or legislated pricing reforms.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state, and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from investigational medicines that we may successfully develop and for which we may obtain regulatory approval, and may affect our overall financial condition and ability to develop investigational medicines.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Due to the novel nature of our technology, we face uncertainty related to pricing and reimbursement for these investigational medicines.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Target patient populations for certain of our investigational medicines, such as those for rare genetic diseases, may be relatively small, and certain of our investigational medicines, like PCV, require customization on an individual scale. As a result, the pricing and reimbursement of our investigational medicines, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our investigational medicines will be adversely affected. The manner and level at which reimbursement is provided for services related to our investigational medicines (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our products.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the market opportunities for our development candidates or investigational medicines are smaller than we believe they are, our revenue may be adversely affected and our business may suffer. Because the target patient populations for some of our programs are small, we must be able to successfully identify clinical trial participants and achieve a significant market share to maintain profitability and growth.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An important area of focus of our research and product development activities is the development of treatments for severe rare genetic diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our programs, are based on estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of clinical trial participants in the United States, Europe, and elsewhere may turn out to be lower than expected, potential clinical trial participants may not be otherwise amenable to treatment with our products, or new clinical trial participants may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market opportunities of some of our programs may be limited to those patients who are ineligible for or have failed prior treatments and for which the market opportunities may be small.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA often approves new therapies initially only for use by patients with relapsed or refractory advanced disease. We expect to initially seek approval of our PCV and intratumoral immuno-oncology investigational medicines in this context. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment and potentially as a first line therapy but there is no guarantee that our investigational medicines, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our projections of both the number of people who have the cancers we may be targeting, as well as the subset of people with these cancers in a position to receive second or third line therapy, and who have the potential to benefit from treatment with our investigational medicines, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of trial participants may turn out to be lower than expected. Additionally, the potentially addressable patient population for our investigational medicines may be limited or may not be amenable to treatment with our investigational medicines. Even if we obtain significant market share for our products, if approved, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our business and operations</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, we had approximately 850 full-time employees and, in connection with the growth and advancement of our pipeline and operating as a public company, we expect to increase the number of employees and the scope of our operations. To manage our anticipated development and expansion, including expansion outside of the United States, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a growing biotechnology company, we are actively pursuing development candidates and investigational medicines in many therapeutic areas and across a wide range of diseases. Successfully developing products for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources, and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources and early stage of growth, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our investigational medicines. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our investigational medicines, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to retain key employees, consultants, and advisors and to attract, retain, and motivate qualified personnel. We may not be able to retain employees or executives who have vested stock options.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent upon members of our management and scientific teams. Each of our executive officers and all of our employees, including key scientists and clinicians, are employed &#8220;at will,&#8221; meaning we or each officer or employee may terminate the employment relationship at any time. The loss of any of these persons&#8217; services may adversely impact the achievement of our research, development, financing, and commercialization objectives. We currently do not have &#8220;key person&#8221; insurance on any of our employees. Many of our key employees, including members of our executive team, have been with us for a long period of time, and have valuable, fully vested stock options or other long-term equity incentives. We may not be able to retain these employees due to the competitive environment in the biotechnology industry, particularly in Cambridge, Massachusetts.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we rely on consultants, contractors, and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory approval, and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current employees or advisors might impede the achievement of our research, development, regulatory approval, and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part time workers. We may not be able to retain the services of such personnel which might result in delays in the operation of our business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, also will be critical to our success. Competition for skilled personnel, including in mRNA and LNP research, clinical operations, regulatory affairs, therapeutic area management, and manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on favorable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, adverse publicity, failure to succeed in preclinical or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants, or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have never generated any revenue from product sales and may never be profitable.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize our investigational medicines. We do not anticipate generating revenues from product sales for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">completing research, preclinical, and clinical development of our development candidates and investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seeking and obtaining U.S. and foreign marketing approvals for investigational medicines for which we complete clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developing a sustainable, stable, consistent, and transferable manufacturing process or processes for our development candidates and investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developing a sustainable, scalable, consistent, time sensitive, and transferable manufacturing process for our personalized cancer vaccine investigational medicine;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">furthering the development of our own manufacturing capabilities and manufacturing relationships with third parties in order to provide adequate (in amount and quality) products and services to support clinical development and the market demand for our investigational medicines, if approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining market acceptance of our investigational medicines as a treatment option;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">launching and commercializing investigational medicines for which we obtain marketing approval and reimbursement, either by collaborating with a strategic collaborator or, if launched independently, by establishing a sales force, marketing, and distribution infrastructure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">addressing any competing technological and market developments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">implementing additional internal systems and infrastructure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintaining, defending, protecting, and expanding our portfolio of IP rights, including patents, trade secrets and know-how; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">attracting, hiring, and retaining qualified personnel.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if one or more of the investigational medicines that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved investigational medicine. Our expenses could increase beyond expectations if we are required by the FDA, the EMA, or other regulatory agencies to perform clinical and other studies or make changes to our manufacturing or quality systems in addition to those that we currently anticipate. Even if we are able to generate </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our internal computer systems, or those of our strategic collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs and our manufacturing operations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our internal computer systems and those of our current and any future strategic collaborators, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, cybersecurity threats, war, and telecommunication and electrical failures. While we have not experienced any such material system failure, accident, or security breach to date that we are aware of, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from one or more ongoing or completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition because of our approach to running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss, or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, either under the General Data Protection Regulation, or GDPR, and relevant member state law in the European Union, other foreign laws, and the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and other relevant state and federal privacy laws in the United States. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our investigational medicines could be delayed.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may use our financial and human resources to pursue a particular research program or investigational medicine and fail to capitalize on programs or investigational medicines that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because we have limited resources, we must choose to pursue and fund the development of selected research programs or investigational medicines and may forego or delay pursuit of opportunities with other programs or investigational medicines that could later prove to have greater commercial potential. Our resource allocation decisions, or our contractual commitments to provide resources to our strategic collaborators under strategic alliance agreements, may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for investigational medicines may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular investigational medicine, we may relinquish valuable rights to that investigational medicine through a strategic alliance, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such investigational medicine, or we may allocate internal resources to an investigational medicine in a therapeutic area in which it would have been more advantageous to enter into a strategic alliance.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not successful in discovering, developing, and commercializing additional products beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although a substantial amount of our efforts will focus on the clinical trials and potential approval of our existing investigational medicines, a key element of our strategy is to discover, develop, and potentially commercialize additional products beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own drug discovery efforts, exploring potential strategic alliances for the development of new products, and in-licensing technologies. Identifying new investigational medicines requires substantial technical, financial, and human resources, whether or not any investigational medicines are ultimately identified. Even if we identify investigational medicines that initially show promise, we may fail to successfully develop and commercialize such products for many reasons, including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the research methodology used may not be successful in identifying potential investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">competitors may develop alternatives that render our investigational medicines obsolete;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">investigational medicines we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an investigational medicine may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an investigational medicine may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unsuccessful in identifying and developing additional products, our potential for growth may be impaired.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any investigational medicine that we may develop.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We face an inherent risk of product liability exposure related to the testing of any of our current or future investigational medicines in clinical trials, and we may face an even greater risk if we commercialize any investigational medicine that we may develop. If we cannot successfully defend ourselves against claims that our investigational medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">decreased demand for any investigational medicine that we may develop;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">loss of revenue;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">substantial monetary awards to patients, healthy volunteers, or their children;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significant time and costs to defend the related litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the inability to commercialize any investigational medicine(s) that we may develop; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">injury to our reputation and significant negative media attention.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We carry product liability insurance which we believe to be sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for investigational medicines, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we obtain FDA approval for any of our investigational medicines and begin commercializing those products in the United States, our operations will be directly, or indirectly through our prescribers, customers, and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act, and Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed sales, marketing, and educational programs. In addition, we may be subject to patient privacy laws enacted by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the for the purchase, order or recommendation or arranging of, any good, leasing, or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. The government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or federal civil money penalties statute. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, and formulary managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, they are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. The ACA amends the intent requirement of the federal Anti-Kickback Statute to provide that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other government payors that are false or fraudulent. In addition, the government may assert that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">96</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:60px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">statute. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Companies that submit claims directly to payors may also be liable under the False Claims Act for the direct submission of such claims. The False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. The ACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act. </span></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The anti-inducement law prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:60px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA and its implementing regulations, which create new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private), or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses, and health care providers as well as their respective &#8220;business associates,&#8221; those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal transparency laws, including the federal Physician Payment Sunshine Act, which require disclosure of payments and other transfers of value provided by manufacturers of drugs, devices, biologicals and medical supplies to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and state laws governing the privacy and security of health information in certain circumstances are also applicable to us and many of them differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:60px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of EU Member States, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">97</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">professional organization, or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The collection and use of personal health data in the European Union had previously been governed by the provisions of the Data Protection Directive, which has been replaced by the GDPR which became effective on May&#160;25, 2018. While the Data Protection Directive did not apply to organizations based outside the European Union, the GDPR has expanded its reach to include any business, regardless of its location, that provides goods or services to residents in the EU. This expansion would incorporate our clinical trial activities in European Union member states. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information&#8221; which includes health and genetic information of data subjects residing in the EU. GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the European Union to the United States or other regions that have not been deemed to offer &#8220;adequate&#8221; privacy protections. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States, which may deviate slightly from the GDPR, may result in significant fines. As a result of the implementation of the GDPR, we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR. For example, it is not clear if the authorities will conduct random audits of companies doing business in the EU, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance may be onerous and adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition, or results of operations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our results of operations could be adversely affected by general conditions in the global economy and financial markets, including by the current coronavirus pandemic, or any other health epidemic. The most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the most recent global financial crisis, could result in a variety of risks to our business, including weakened demand for our investigational medicines and our ability to raise additional capital when needed on favorable terms, if at all. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*We or the third parties upon whom we depend may be adversely affected by natural disasters, health epidemics or other business interruptions such as cybersecurity attacks and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural disasters or health epidemics could severely disrupt our operations, and have a material adverse impact on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, cybersecurity attack, health epidemic or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our manufacturing facilities or those of our third-party contract manufacturers, limited our ability to access or use our digital information systems or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. Cybersecurity liability insurance is difficult to obtain and may not cover any damages we would sustain based on any breach of our computer security protocols or other cybersecurity attack. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse impact on our business.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our products become subject to a product recall it could harm our reputation, business, and financial results.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA and similar foreign governmental authorities have the authority to require the recall of certain commercialized products. In the case of the FDA, the authority to require a recall of a biologic product must be based on an FDA finding that a batch, lot of other quantity of the biologic product presents an imminent or substantial hazard to the public health. In addition, foreign governmental bodies have the authority to require the recall of any investigational medicine in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our investigational medicines would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall announcement could harm our reputation with customers and negatively affect our sales, if any.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*The investment of our cash, cash equivalents, and investments is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, we had approximately $1.72 billion in cash, cash equivalents, and investments. These investments are subject to general credit, liquidity, market, and interest rate risks. We may realize losses in the fair value of these investments, which would have a negative effect on our consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity, and financial condition.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our projections and accruals.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues, and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The amount of and our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2019, we had federal and state net operating loss carryforwards of $981.8 million and $978.8 million, respectively, a portion of which will begin to expire in 2030. As of December&#160;31, 2019, we also had federal and state research and development tax credit carryforwards of $45.6 million and $23.9 million, respectively, which begin to expire in 2030 and 2029, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">respectively. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. While federal net operating losses generated after December&#160;31, 2018 will not be subject to expiration, the deduction for such net operating loss in any taxable year will be limited to 80% of our taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself. In general, under Sections 382 and 383 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses, or NOLs or tax credits, or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. As of December&#160;31, 2019, none of our NOLs or credits will expire due to Sections 382 and 383, however, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code and limit our ability to utilize our NOLs and credits. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. In addition, the rules regarding timing of revenue and expense recognition for tax purposes in connection with various transactions we have are complex and uncertain in various respects and could be subject to challenge by taxing authorities. In the event any such challenge is sustained, the net operating losses could be materially reduced and/or we could be determined to be a material cash taxpayer for one or more years. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOL or credit carryforwards.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we engage in future acquisitions, joint ventures, or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may evaluate various acquisitions and collaborations, including licensing or acquiring complementary products, IP rights, technologies, or businesses. Any potential acquisition, joint venture, or collaboration may entail numerous risks, including: </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased operating expenses and cash requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the assumption of additional indebtedness or contingent liabilities; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">assimilation of operations, IP, and products of an acquired company, including difficulties associated with integrating new personnel; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or investigational medicines and regulatory approvals; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, if we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses, and acquire intangible assets that could result in significant future amortization expense.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, we may not be able to locate suitable acquisition or strategic collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to ownership of our common stock</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*The price of our common stock has been volatile and fluctuates substantially, which could result in substantial losses for stockholders.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our stock price has been and in the future, may be subject to substantial volatility. For example, our stock traded within a range of a high price of $56.38 and a low price of $11.54 per share for the period of December&#160;7, 2018, our first day of trading on the Nasdaq Global Select Market, through April 30, 2020. As a result of this volatility, our stockholders could incur substantial losses.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The stock market in general, and the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above your initial purchase price. The market price for our common stock may be influenced by many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">results of clinical trials of our investigational medicines or those of our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of competitive products or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">commencement or termination of strategic alliances;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory or legal developments in the United States and other countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the recruitment or departure of key personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the level of expenses related to any of our investigational medicines or clinical development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the results of our efforts to discover, develop, acquire, or in-license additional investigational medicines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in the structure of healthcare payment systems;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general economic, industry, and market conditions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the numerous programs in our pipeline, the development of which could each generate news or significant adverse events that could impact financial results or recommendations by securities analysts; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">public announcements by us or our strategic collaborators regarding the progress of our development candidates or investigational medicines or similar public announcements by our competitors.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our quarterly or annual results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our results may, in turn, cause the price of our stock to fluctuate substantially. We believe that period-to-period comparisons of our results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, public statements by us, government agencies, the media or others relating to the coronavirus outbreak (including regarding efforts to develop a coronavirus vaccine) have in the past resulted, and may in the future result, in significant fluctuations in our stock price. Given the global focus on the coronavirus outbreak, any information in the public arena on this topic, whether or not accurate, could have an outsized impact (either positive or negative) on our stock price.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations, and prospects.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management will have broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our investigational medicines. Pending their use, we may invest our cash, cash equivalents, and investments, in a manner that does not produce income or that loses value.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. In addition, the federal securities laws, including the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the Securities and Exchange Commission, or SEC, and Nasdaq have imposed various requirements on public companies, including requirements to file annual, quarterly, and event driven reports with respect to our business and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time consuming and costly. For example, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. We may not be able to produce reliable financial statements or file these financial statements as part of a periodic report in a timely manner with the SEC or comply with the Nasdaq listing requirements. In addition, we could make errors in our financial statements that could require us to restate our financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we were an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, our auditors were not required to formally attest to the effectiveness of our internal control over financial reporting. As of the end of our fiscal year ended December 31, 2019, we qualified as a &#8220;large accelerated filer&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act and, as a result, ceased to qualify as an emerging growth company. Accordingly, commencing with our Annual Report on Form 10-K for the year ended December 31, 2019, we were required to have our auditors formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. Our compliance with Section 404 necessitates that we incur substantial accounting expense and expend significant management efforts. We will continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act. or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are in the early stages of developing our policies and practices regarding pre-approval access and any policy we develop and implement may result in a negative perception of our Company and have a material adverse impact on our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we advance our pipeline, patients and their physicians have sought access to our investigational medicines outside of sponsored clinical trials and prior to regulatory approval. While we will continue to review and respond to these early access requests, at this stage in our development of a new class of medicines, we are not providing access to our investigational medicines outside of the clinical trial setting. As our development programs progress further, we will continue our dialogue with patients and their families, advocacy leaders, physicians, and others on this and other topics. We will post our pre-approval access policies in accordance with regulatory guidelines.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As a general matter, we do not currently plan on providing forward-looking guidance regarding the expected timing of milestones in our business. We plan to report on the status of our programs, including the achievement of milestones and related data, on a retrospective basis, or as otherwise required by U.S. federal securities laws applicable to us, which may lead to speculation about our prospects that could have a material adverse effect on our business. If we do provide forward-looking guidance on the expected timing of milestones, we may not meet those timelines which may have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe the early stage nature of most of our portfolio is not suitable to providing forward-looking guidance on the expected timing of individual program milestones, particularly data readout timing. While as a general matter we intend to periodically report on the status of our development programs, including articulating anticipated next steps in the form of development plans or potential data readouts, for the majority of our programs, we do not currently plan to provide forward-looking guidance on the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">102</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">timing of those next steps. We have provided forward looking guidance as to the expected timing of certain milestones and clinical steps in our CMV program, our most advanced clinical program. If we are unable to meet the timelines established in this guidance our business may be materially and adversely impacted, particularly due to delays in the CMV program. In addition, we do not control the timing of disclosure of any such milestones related to any of our programs that are managed by our strategic collaborators. Any disclosure by our strategic collaborators of data that is perceived as negative, whether or not such data are related to other data that we or others release, may have a material adverse impact on our stock price or overall valuation. Not providing forward-looking guidance on the expected timing of program milestones may lead to speculation by investors, shareholders, analysts, and other market participants and in the media as to the progress of our individual development candidates, investigational medicines, or our programs as a whole, which may have a material adverse impact on our stock price or valuation. In the event that we do choose to provide forward looking guidance on the expected timing of milestones in our business, we may be required to later update any movement in the timing of such milestones, including delays, which may have the effect of investors speculating in our stock or otherwise have a material adverse impact on our business. The ability to predict with accuracy the timing of clinical readouts or progress in clinical trials is difficult and subject to change based on many factors, most of which are out of our control, including other risks and uncertainties included in this prospectus supplement.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to certain restrictions described below. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The holders of up to 61.6 million shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, the number of shares of our common stock reserved for issuance under our 2018 Stock Option and Incentive Plan automatically increased on January&#160;1, 2020 and will automatically increase each January&#160;1 thereafter by 4% of the number of shares of common stock outstanding on the immediately preceding December&#160;31 or such lesser number of shares determined by our compensation committee. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, certain of our employees, executive officers, and directors have entered or may enter into Rule 10b5-1 trading plans providing for sales of shares of our common stock from time to time. Under a Rule&#160;10b5-1 trading plan, a broker executes trades pursuant to parameters established by the employee, director, or officer when entering into the plan, without further direction from the employee, officer, or director. A Rule&#160;10b5-1 trading plan&#160;may be amended or terminated in some circumstances. Our employees, executive officers, and directors also may buy or sell additional shares outside of a Rule&#160;10b5-1 trading plan&#160;when they are not in possession of material, nonpublic information.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or development candidates or investigational medicines.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license IP rights, and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through collaborations and alliances and licensing arrangements with third parties or through asset sales, we may have to relinquish valuable rights to our technologies or development candidates or investigational medicines, or grant licenses on terms unfavorable to us.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">103</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">research about our business, our stock price may decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our executive officers, directors, five percent stockholders, and their affiliates beneficially owned approximately 40.8% of our outstanding common stock. Therefore, these stockholders will have the ability to influence us through their ownership positions. For example, these stockholders, acting together, may be able to exert significant influence over matters such as elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Provisions in our amended and restated certificate of incorporation and by-laws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation, by-laws, and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and amended and restated by-laws include provisions that:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend, and other rights superior to our common stock;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">create a classified board of directors whose members serve staggered three-year terms;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, our chief executive officer, or our president;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">prohibit stockholder action by written consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provide that our directors may be removed only for cause;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">specify that no stockholder is permitted to cumulate votes at any election of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expressly authorize our board of directors to modify, alter, or repeal our amended and restated by-laws; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any provision of our amended and restated certificate of incorporation or amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">An active trading market for our common stock may not be sustained.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our shares of common stock began trading on the Nasdaq Global Select Market on December 7, 2018. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not currently intend to declare or pay cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">*Our amended and restated by-laws designate the Court of Chancery of the State of Delaware or the United States District Court for the District of Massachusetts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to our amended and restated by-laws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders, (3)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees, or stockholders arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated by-laws, or (4)&#160;any action asserting a claim governed by the internal affairs doctrine (the &#8220;Delaware Forum Provision&#8221;). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act, or the Exchange Act. Our amended and restated by-laws further provide that the United States District Court for the District of Massachusetts is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the &#8220;Federal Forum Provision&#8221;). We have chosen the United States District Court for the District of Massachusetts as the exclusive forum for such causes of action because our principal executive offices are located in Cambridge, Massachusetts. In addition, our amended and restated by-laws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;19, 2018, in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sciabacucchi v. Salzberg</span><span style="font-family:inherit;font-size:10pt;">, C.A. No. 2017-0931-JTL (Del. Ch.), the Court of Chancery of the State of Delaware issued a decision declaring that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are ineffective and invalid under Delaware law. However, that decision was appealed to the Delaware Supreme Court and on March 18, 2020, the Delaware Supreme Court reversed the Court of Chancery and ruled that such federal forum selection provisions are &#8220;facially valid&#8221; under Delaware law. In light of the Delaware Supreme Court&#8217;s ruling, we intend to enforce our Federal Forum Provision designating the District of Massachusetts as the exclusive forum for Securities Act claims.We recognize that the Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection clauses in our amended and restated by-laws may limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees, which may discourage the filing of lawsuits against us and our directors, officers, and employees, even though an action, if successful, might benefit our stockholders. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid.</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD45DACB494825EE69911BC838F92658B"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Sales of Unregistered Securities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None. </span></div><div style="line-height:174%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Proceeds from Public Offering of Common Stock</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act. We are holding the balance of the net proceeds in cash, cash equivalents, and investments. We invested the funds received in short-term, interest-bearing investment-grade securities and government securities.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s06824821254858818E144842C4A00BF6"></a></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. Exhibits</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Exhibits listed below are filed or incorporated by reference as part of this Form 10-Q.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit Index</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit3113312020.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit3123312020.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit3213312020.htm"><span style="font-family:inherit;font-size:10pt;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.INS*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Instance Document</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.SCH*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.CAL*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Document</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.DEF*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.LAB*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.PRE*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Link Document</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:26px;"></td><td style="width:693px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:46px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:46px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:26px;"></td><td style="width:693px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filed herewith</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:26px;"></td><td style="width:693px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">+</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:26px;"></td><td style="width:693px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">106</span></div></div><hr style="page-break-after:always"></hr><div><a id="s83BED75C6D585A07988068FF7620A914"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;" href="#s5E8F8895ABE35A32AA3ECB8C299E7B51"><span style="font-family:Arial;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:384px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:17%;"></td><td style="width:43%;"></td><td style="width:4%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MODERNA, INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ St&#233;phane Bancel</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;7, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">St&#233;phane Bancel</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principal Executive Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Lorence Kim, M.D.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;7, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lorence Kim, M.D.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principal Financial Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">107</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit3113312020.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCE80B7E0F6045206893ECB071B4BEB83"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, St&#233;phane Bancel, certify that:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form&#160;10-Q of Moderna,&#160;Inc.;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:42px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:24%;"></td><td style="width:25%;"></td><td style="width:5%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 7, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;/s/ St&#233;phane Bancel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">St&#233;phane Bancel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit3123312020.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s89B7E78355D951138C76E97F1026B096"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Lorence Kim, M.D., certify that:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form&#160;10-Q of Moderna,&#160;Inc.;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:5%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 7, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;/s/ Lorence Kim</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lorence Kim M.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit3213312020.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s611BDAFDF8D5587A868253D11066282C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION&#160;1350</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Moderna, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, St&#233;phane Bancel, Chief Executive Officer of the Company, and Lorence Kim, M.D., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></td></tr></table><div style="line-height:174%;padding-bottom:21px;text-align:left;padding-left:84px;text-indent:-19px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:24%;"></td><td style="width:25%;"></td><td style="width:5%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 7, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;/s/ St&#233;phane Bancel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">St&#233;phane Bancel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 7, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;/s/ Lorence Kim </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lorence Kim, M.D. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:174%;padding-bottom:12px;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mrna-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.modernatx.com/20200331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrna="http://www.modernatx.com/20200331" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.modernatx.com/role/BalanceSheetComponents">
        <link:definition>2106100 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>2406404 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>2406402 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsPropertyAndEquipmentNetDetails" roleURI="http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails">
        <link:definition>2406403 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.modernatx.com/role/BalanceSheetComponentsTables">
        <link:definition>2306301 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.modernatx.com/role/CollaborationAgreements">
        <link:definition>2103100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails">
        <link:definition>2403405 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails">
        <link:definition>2403403 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails">
        <link:definition>2403406 - Disclosure - Collaboration Agreements - Merck &#8211; Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRemainingPerformanceObligationDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails">
        <link:definition>2403404 - Disclosure - Collaboration Agreements - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails">
        <link:definition>2403402 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.modernatx.com/role/CollaborationAgreementsTables">
        <link:definition>2303301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTimingOfSatisfactionDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails">
        <link:definition>2403408 - Disclosure - Collaboration Agreements - Timing of Satisfaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails">
        <link:definition>2403407 - Disclosure - Collaboration Agreements - Vertex &#8211; 2016 Strategic Alliance in Cystic Fibrosis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.modernatx.com/role/CommitmentsAndContingencies">
        <link:definition>2108100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" roleURI="http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails">
        <link:definition>2408402 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesStrategicCollaborationsDetails" roleURI="http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails">
        <link:definition>2408401 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical">
        <link:definition>1003001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.modernatx.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://www.modernatx.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAdditionalInformationDetails" roleURI="http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>2401401 - Disclosure - Description of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.modernatx.com/role/FinancialInstruments">
        <link:definition>2105100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails">
        <link:definition>2405403 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails">
        <link:definition>2405402 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables">
        <link:definition>2305301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsUnrealizedLossPositionDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails">
        <link:definition>2405404 - Disclosure - Financial Instruments - Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Grants" roleURI="http://www.modernatx.com/role/Grants">
        <link:definition>2104100 - Disclosure - Grants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantsDetails" roleURI="http://www.modernatx.com/role/GrantsDetails">
        <link:definition>2404401 - Disclosure - Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.modernatx.com/role/IncomeTaxes">
        <link:definition>2134100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.modernatx.com/role/Leases">
        <link:definition>2107100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetInformationDetails" roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails">
        <link:definition>2407403 - Disclosure - Leases - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.modernatx.com/role/LeasesDetails">
        <link:definition>2407402 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails">
        <link:definition>2407404 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails">
        <link:definition>2407405 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.modernatx.com/role/LeasesTables">
        <link:definition>2307301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.modernatx.com/role/NetLossPerShare">
        <link:definition>2137100 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>2437402 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>2437403 - Disclosure - Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.modernatx.com/role/NetLossPerShareTables">
        <link:definition>2337301 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.modernatx.com/role/ShareholdersEquity">
        <link:definition>2108100 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.modernatx.com/role/ShareholdersEquityDetails">
        <link:definition>2408401 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.modernatx.com/role/StockBasedCompensation">
        <link:definition>2128100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2428402 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails">
        <link:definition>2428403 - Disclosure - Stock-Based Compensation - Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails">
        <link:definition>2428404 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2428406 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.modernatx.com/role/StockBasedCompensationTables">
        <link:definition>2328301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails">
        <link:definition>2428405 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.modernatx.com/role/SubsequentEvents">
        <link:definition>2138100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.modernatx.com/role/SubsequentEventsDetails">
        <link:definition>2438401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfBasisOfPresentationAndRecentAccountingStandards" roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards">
        <link:definition>2102100 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2402404 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails">
        <link:definition>2402403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies">
        <link:definition>2202201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2402405 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables">
        <link:definition>2302302 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" name="A2013OptionAgreementAndServicesAndCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" name="A2016StrategicAllianceWithAstraZenecaIL12Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" name="A2017StrategicAllianceWithAstraZenecaRelaxinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_AccruedExternalGoodsAndServicesCurrent" name="AccruedExternalGoodsAndServicesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mrna_AccruedPropertyAndEquipmentCurrent" name="AccruedPropertyAndEquipmentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mrna_AllowanceForTenantImprovements" name="AllowanceForTenantImprovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember" name="AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_AssetsAndLiabilitiesLesseeTableTextBlock" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_AstraZenecaMember" name="AstraZenecaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_CambridgeMassachusettsMember" name="CambridgeMassachusettsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ChangeInContractwithCustomerAssetRollForward" name="ChangeInContractwithCustomerAssetRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ChangeInContractwithCustomerLiabilityRollForward" name="ChangeInContractwithCustomerLiabilityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ChargesToFinancingLeaseLiabilities" name="ChargesToFinancingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ClinicalOperationsAndSupportCommitmentMember" name="ClinicalOperationsAndSupportCommitmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ClinicalSupplyReimbursementMember" name="ClinicalSupplyReimbursementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" name="CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_CollaborationArrangementMember" name="CollaborationArrangementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_CollaborativeArrangementTermOfArrangement" name="CollaborativeArrangementTermOfArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_CollaborativeArrangementWithRelatedPartyMember" name="CollaborativeArrangementWithRelatedPartyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_Combined2018AZAgreementPerformanceObligationMember" name="Combined2018AZAgreementPerformanceObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_Combined2018AZAgreementsMember" name="Combined2018AZAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_CommercialMilestonesMember" name="CommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_CompetitionMilestonesMember" name="CompetitionMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ContractOptionsMember" name="ContractOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ContractWithCustomerAssetDecreaseDuringPeriod" name="ContractWithCustomerAssetDecreaseDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mrna_ContractWithCustomerAssetIncreaseDuringPeriod" name="ContractWithCustomerAssetIncreaseDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod" name="ContractWithCustomerLiabilityDecreaseDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod" name="ContractWithCustomerLiabilityIncreaseDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_CurrentMarketableSecuritiesMember" name="CurrentMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_DefenseAdvancedResearchProjectsAgencyMember" name="DefenseAdvancedResearchProjectsAgencyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member" name="DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember" name="DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_EmployeeStockPurchasePlan2018Member" name="EmployeeStockPurchasePlan2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_EstimatedReimbursementMember" name="EstimatedReimbursementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_FinanceLeaseCost" name="FinanceLeaseCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_FiveHundredTechnologySquareMember" name="FiveHundredTechnologySquareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_FixedPaymentsMember" name="FixedPaymentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_FollowOnProjectMember" name="FollowOnProjectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_IL12PerformanceObligationMember" name="IL12PerformanceObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_IncreaseDecreaseInDeferredRentCredit" name="IncreaseDecreaseInDeferredRentCredit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" name="IncreaseDecreaseInRightOfUseAssetOperatingLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_InitialBaseAwardMember" name="InitialBaseAwardMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_InitialProjectMember" name="InitialProjectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_KRASPerformanceObligationMember" name="KRASPerformanceObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_LandAdjacentToNorwoodMember" name="LandAdjacentToNorwoodMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_LeasesImputedInterestRate" name="LeasesImputedInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" name="LesseeOperatingLeaseNumberOfExtensionPeriods" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_LesseeOperatingLeasePercentageSubleased" name="LesseeOperatingLeasePercentageSubleased" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit" name="LesseeOperatingLeaseTenantAllowancePricePerUnit" nillable="true" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_LonzaLtdMember" name="LonzaLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_MerckAgreement2015Member" name="MerckAgreement2015Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_MerckMember" name="MerckMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_MilestonePaymentsMember" name="MilestonePaymentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_NoncurrentMarketableSecuritiesMember" name="NoncurrentMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_NorwoodMassachusettsMember" name="NorwoodMassachusettsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_OfficeLaboratoryAndLightManufacturingSpaceMember" name="OfficeLaboratoryAndLightManufacturingSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_OncologyDevelopmentTargetPerformanceObligationMember" name="OncologyDevelopmentTargetPerformanceObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_OperatingAndFinanceLeaseLiability" name="OperatingAndFinanceLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mrna_OperatingAndFinanceLeaseRightOfUseAsset" name="OperatingAndFinanceLeaseRightOfUseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mrna_OperatingLeaseLiabilities" name="OperatingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_OptionExerciseFeeMember" name="OptionExerciseFeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_PCVPerformanceObligationMember" name="PCVPerformanceObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_PCVSAVAgreementMember" name="PCVSAVAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_PaymentsForLeaseFinancingObligation" name="PaymentsForLeaseFinancingObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mrna_PaymentsOfUnderwritingDiscounts" name="PaymentsOfUnderwritingDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_PerformanceObligationAxis" name="PerformanceObligationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_PerformanceObligationDomain" name="PerformanceObligationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" name="PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_PersonalizedMRNACancerVaccinesProductsMember" name="PersonalizedMRNACancerVaccinesProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" name="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization" name="PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" name="PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mrna_PublicEquityOfferingMember" name="PublicEquityOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_RegulatoryMilestonesSubsequentProductsMember" name="RegulatoryMilestonesSubsequentProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" name="ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee" name="ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod" name="ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod" name="ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod" name="ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod" name="ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected" name="ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" name="ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent" name="ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" name="ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" name="ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ResearchAndDevelopmentFundingMember" name="ResearchAndDevelopmentFundingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" name="RestrictedStockAndRestrictedStockUnitsRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_RevenueFromGrantsCurrentFundingCapacity" name="RevenueFromGrantsCurrentFundingCapacity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mrna_RevenueFromGrantsMaximumAward" name="RevenueFromGrantsMaximumAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mrna_RevenueFromGrantsNumberOfContractOptions" name="RevenueFromGrantsNumberOfContractOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_RevenueFromGrantsNumberOfContractOptionsExercised" name="RevenueFromGrantsNumberOfContractOptionsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_RevenueFromGrantsRemainingFundingCapacity" name="RevenueFromGrantsRemainingFundingCapacity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mrna_RightOfUseAssetFinancingMember" name="RightOfUseAssetFinancingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" name="RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_SeparateAgreementsWithMerckMember" name="SeparateAgreementsWithMerckMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ServiceBasedAwardsMember" name="ServiceBasedAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_StockOptionAndGrantPlan2016Member" name="StockOptionAndGrantPlan2016Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_StockOptionAndIncentivePlan2018Member" name="StockOptionAndIncentivePlan2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" name="StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_SublicenseReimbursementMember" name="SublicenseReimbursementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mrna_TenantIncentivesReceivablesCurrent" name="TenantIncentivesReceivablesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mrna_TheBillAndMelindaGatesFoundationMember" name="TheBillAndMelindaGatesFoundationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_ToxicityMilestonesMember" name="ToxicityMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_TwoHundredTechnologySquareMember" name="TwoHundredTechnologySquareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_TwoHundredTechnologySquareSubleaseAgreementsMember" name="TwoHundredTechnologySquareSubleaseAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" name="USGovernmentAgenciesAndCorporateDebtSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_UpfrontPaymentMember" name="UpfrontPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember" name="UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_UpfrontPaymentResearchAndDevelopmentMember" name="UpfrontPaymentResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_VEGFAProductAZD8601Member" name="VEGFAProductAZD8601Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_VEGFExercise2016Member" name="VEGFExercise2016Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_VariableConsiderationMember" name="VariableConsiderationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mrna_VertexMember" name="VertexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>mrna-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponents" xlink:href="mrna-20200331.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsTables" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreements" xlink:href="mrna-20200331.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsTables" xlink:href="mrna-20200331.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsTimingOfSatisfactionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingencies" xlink:href="mrna-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:href="mrna-20200331.xsd#CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:href="mrna-20200331.xsd#CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="mrna-20200331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:href="mrna-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionOfBusiness" xlink:href="mrna-20200331.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails" xlink:href="mrna-20200331.xsd#DescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstruments" xlink:href="mrna-20200331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:href="mrna-20200331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/Grants" xlink:href="mrna-20200331.xsd#Grants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantsDetails" xlink:href="mrna-20200331.xsd#GrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:href="mrna-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:href="mrna-20200331.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:href="mrna-20200331.xsd#LeasesBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesDetails" xlink:href="mrna-20200331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:href="mrna-20200331.xsd#LeasesLeaseCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:href="mrna-20200331.xsd#LeasesMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:href="mrna-20200331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShare" xlink:href="mrna-20200331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="mrna-20200331.xsd#NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="mrna-20200331.xsd#NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareTables" xlink:href="mrna-20200331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/ShareholdersEquity" xlink:href="mrna-20200331.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/ShareholdersEquityDetails" xlink:href="mrna-20200331.xsd#ShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensation" xlink:href="mrna-20200331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationOptionsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:href="mrna-20200331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEvents" xlink:href="mrna-20200331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:href="mrna-20200331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AccruedPropertyAndEquipmentCurrent" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent_a34f8675-fe5d-b8ae-8c53-b893ac046b12" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_mrna_AccruedPropertyAndEquipmentCurrent_a34f8675-fe5d-b8ae-8c53-b893ac046b12" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AccruedExternalGoodsAndServicesCurrent" xlink:label="loc_mrna_AccruedExternalGoodsAndServicesCurrent_347be40b-191b-1c13-6c5b-b893ab9c9a6c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_mrna_AccruedExternalGoodsAndServicesCurrent_347be40b-191b-1c13-6c5b-b893ab9c9a6c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_f68f267d-78ad-b62f-6b0e-44daadd4feda" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_f68f267d-78ad-b62f-6b0e-44daadd4feda" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_3cbfb247-62e8-5cba-3a7c-69ab8708e7e6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:to="loc_us-gaap_InterestReceivableCurrent_3cbfb247-62e8-5cba-3a7c-69ab8708e7e6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TenantIncentivesReceivablesCurrent" xlink:label="loc_mrna_TenantIncentivesReceivablesCurrent_3224bf2b-961d-e841-4fc8-b893ac5aa247" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:to="loc_mrna_TenantIncentivesReceivablesCurrent_3224bf2b-961d-e841-4fc8-b893ac5aa247" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_194b9646-6f92-f665-41a8-b893ab8ce310" xlink:type="locator" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" xlink:label="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_afa2220a-84d4-2d0f-e328-b893ad1e7bfc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_194b9646-6f92-f665-41a8-b893ab8ce310" xlink:to="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_afa2220a-84d4-2d0f-e328-b893ad1e7bfc" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization" xlink:label="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_d07231f1-0391-de45-c52c-b893abec22a9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_194b9646-6f92-f665-41a8-b893ab8ce310" xlink:to="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_d07231f1-0391-de45-c52c-b893abec22a9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_96b88c28-1e98-9d45-1451-c49d58f81cb0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_96b88c28-1e98-9d45-1451-c49d58f81cb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_194b9646-6f92-f665-41a8-b893ab8ce310" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_194b9646-6f92-f665-41a8-b893ab8ce310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_362d72d3-5e94-ebab-8f86-75d06c8c7ee4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_362d72d3-5e94-ebab-8f86-75d06c8c7ee4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b130e83a-7e35-8950-f084-78ccb28f2eab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b130e83a-7e35-8950-f084-78ccb28f2eab" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChargesToFinancingLeaseLiabilities" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_ed0af127-429f-6050-6be9-b893acd7367d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_ed0af127-429f-6050-6be9-b893acd7367d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e3f9215c-1f64-e636-ccb3-9c51d05b0a6d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e3f9215c-1f64-e636-ccb3-9c51d05b0a6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d1d20cfe-f038-824a-0236-247c2a122ebc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d1d20cfe-f038-824a-0236-247c2a122ebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c8905fa8-9b6b-867f-c840-12e5f98e855d" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c8905fa8-9b6b-867f-c840-12e5f98e855d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae064a9e-7563-5fa2-95b8-bfe0f620685d" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae064a9e-7563-5fa2-95b8-bfe0f620685d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9c560dfb-d3ee-5129-5a3f-0e84995641c7" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9c560dfb-d3ee-5129-5a3f-0e84995641c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_da15d1b8-e3a2-b00e-0b9b-b893ab743161" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_da15d1b8-e3a2-b00e-0b9b-b893ab743161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingLeaseLiabilities" xlink:label="loc_mrna_OperatingLeaseLiabilities_6707c3e5-350d-4770-a46c-b893ab21de7e" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_mrna_OperatingLeaseLiabilities_6707c3e5-350d-4770-a46c-b893ab21de7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dea146b3-6d50-c215-7c85-641051f14bf2" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dea146b3-6d50-c215-7c85-641051f14bf2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c0d234a1-03bb-5202-e965-8bbc035fc049" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c0d234a1-03bb-5202-e965-8bbc035fc049" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c0d234a1-03bb-5202-e965-8bbc035fc049" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7d2f9305-3a51-279b-17e9-0a8bec7eba1b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7d2f9305-3a51-279b-17e9-0a8bec7eba1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fe6fe2fb-1c28-638d-7c2f-bc065610ad60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fe6fe2fb-1c28-638d-7c2f-bc065610ad60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/Grants" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/GrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseLiability" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_b0925668-20d8-402e-d65e-b8e71b99d3c6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_b0925668-20d8-402e-d65e-b8e71b99d3c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_78c5511c-7f4e-ac05-d333-b8e71a9eb27f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_b0925668-20d8-402e-d65e-b8e71b99d3c6" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_78c5511c-7f4e-ac05-d333-b8e71a9eb27f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_78c5511c-7f4e-ac05-d333-b8e71a9eb27f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_362d72d3-5e94-ebab-8f86-75d06c8c7ee4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_78c5511c-7f4e-ac05-d333-b8e71a9eb27f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_362d72d3-5e94-ebab-8f86-75d06c8c7ee4" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_cf4b4f24-8104-b514-3876-b8e71b3eeacd" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_cf4b4f24-8104-b514-3876-b8e71b3eeacd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_69276cd8-bc14-59c0-d638-5bf78fc9d77e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_cf4b4f24-8104-b514-3876-b8e71b3eeacd" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_69276cd8-bc14-59c0-d638-5bf78fc9d77e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FinanceLeaseCost" xlink:label="loc_mrna_FinanceLeaseCost_8366ec81-a120-753e-40c9-b8e71a982158" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6bc46d1-fec7-6b3b-527e-4ad756896790" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_FinanceLeaseCost_8366ec81-a120-753e-40c9-b8e71a982158" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6bc46d1-fec7-6b3b-527e-4ad756896790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_a4a8e3bb-2ee6-a2f3-d86b-f05bd98679a7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_FinanceLeaseCost_8366ec81-a120-753e-40c9-b8e71a982158" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_a4a8e3bb-2ee6-a2f3-d86b-f05bd98679a7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_585156c8-71c1-ada7-fa32-ec99a518c7a0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_56214e92-975b-87e2-d6f8-a5f1e857c6ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_585156c8-71c1-ada7-fa32-ec99a518c7a0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_56214e92-975b-87e2-d6f8-a5f1e857c6ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9048fd47-13cc-d6eb-d7dd-e8d53f87b993" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_585156c8-71c1-ada7-fa32-ec99a518c7a0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9048fd47-13cc-d6eb-d7dd-e8d53f87b993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c4c9d759-d9f6-eec5-3320-115ed3ebdd52" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_585156c8-71c1-ada7-fa32-ec99a518c7a0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c4c9d759-d9f6-eec5-3320-115ed3ebdd52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_48ac7df5-3392-98b1-a73f-b2f41673ff75" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_585156c8-71c1-ada7-fa32-ec99a518c7a0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_48ac7df5-3392-98b1-a73f-b2f41673ff75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c21c69f2-c329-91b2-f24a-9debaed02565" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_585156c8-71c1-ada7-fa32-ec99a518c7a0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c21c69f2-c329-91b2-f24a-9debaed02565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_80ad803a-a5b3-2c23-a7a0-aed644e501db" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_585156c8-71c1-ada7-fa32-ec99a518c7a0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_80ad803a-a5b3-2c23-a7a0-aed644e501db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/ShareholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/ShareholdersEquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>mrna-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponents" xlink:href="mrna-20200331.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsTables" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreements" xlink:href="mrna-20200331.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsTables" xlink:href="mrna-20200331.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsTimingOfSatisfactionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingencies" xlink:href="mrna-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:href="mrna-20200331.xsd#CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:href="mrna-20200331.xsd#CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="mrna-20200331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:href="mrna-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionOfBusiness" xlink:href="mrna-20200331.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails" xlink:href="mrna-20200331.xsd#DescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstruments" xlink:href="mrna-20200331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:href="mrna-20200331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/Grants" xlink:href="mrna-20200331.xsd#Grants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantsDetails" xlink:href="mrna-20200331.xsd#GrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:href="mrna-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:href="mrna-20200331.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:href="mrna-20200331.xsd#LeasesBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesDetails" xlink:href="mrna-20200331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:href="mrna-20200331.xsd#LeasesLeaseCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:href="mrna-20200331.xsd#LeasesMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:href="mrna-20200331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShare" xlink:href="mrna-20200331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="mrna-20200331.xsd#NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="mrna-20200331.xsd#NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareTables" xlink:href="mrna-20200331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/ShareholdersEquity" xlink:href="mrna-20200331.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/ShareholdersEquityDetails" xlink:href="mrna-20200331.xsd#ShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensation" xlink:href="mrna-20200331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationOptionsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:href="mrna-20200331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEvents" xlink:href="mrna-20200331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:href="mrna-20200331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RightOfUseAssetFinancingMember" xlink:label="loc_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" xlink:label="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization" xlink:label="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_760C125C40AC19992FC0B8EC0D7825F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_760C125C40AC19992FC0B8EC0D7825F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_D74D1274643594315CE7B8EC0D782664_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_760C125C40AC19992FC0B8EC0D7825F5" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_D74D1274643594315CE7B8EC0D782664_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_D74D1274643594315CE7B8EC0D782664" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_760C125C40AC19992FC0B8EC0D7825F5" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_D74D1274643594315CE7B8EC0D782664" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VariableConsiderationMember" xlink:label="loc_mrna_VariableConsiderationMember_00B604227A1994739674B8EC0D79B695" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_D74D1274643594315CE7B8EC0D782664" xlink:to="loc_mrna_VariableConsiderationMember_00B604227A1994739674B8EC0D79B695" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationAxis" xlink:label="loc_mrna_PerformanceObligationAxis_710DB90A91DFD02D8C8DB8EC0D79C469" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_mrna_PerformanceObligationAxis_710DB90A91DFD02D8C8DB8EC0D79C469" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationDomain" xlink:label="loc_mrna_PerformanceObligationDomain_B32C3D52F57254669CAAB8EC0D7AD06F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mrna_PerformanceObligationAxis_710DB90A91DFD02D8C8DB8EC0D79C469" xlink:to="loc_mrna_PerformanceObligationDomain_B32C3D52F57254669CAAB8EC0D7AD06F_default" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationDomain" xlink:label="loc_mrna_PerformanceObligationDomain_B32C3D52F57254669CAAB8EC0D7AD06F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mrna_PerformanceObligationAxis_710DB90A91DFD02D8C8DB8EC0D79C469" xlink:to="loc_mrna_PerformanceObligationDomain_B32C3D52F57254669CAAB8EC0D7AD06F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IL12PerformanceObligationMember" xlink:label="loc_mrna_IL12PerformanceObligationMember_CEA839887181CEA82172B8EC0D7AAE11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_PerformanceObligationDomain_B32C3D52F57254669CAAB8EC0D7AD06F" xlink:to="loc_mrna_IL12PerformanceObligationMember_CEA839887181CEA82172B8EC0D7AAE11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0FC5A142D4C058484B5FB8EC0D7A40E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0FC5A142D4C058484B5FB8EC0D7A40E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0FC5A142D4C058484B5FB8EC0D7A40E1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0FC5A142D4C058484B5FB8EC0D7A40E1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:label="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_568DD69F141F7E53FBDFB8EC0D7B6DD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_568DD69F141F7E53FBDFB8EC0D7B6DD5" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" xlink:label="loc_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" xlink:label="loc_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember" xlink:label="loc_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementsMember" xlink:label="loc_mrna_Combined2018AZAgreementsMember_E95185B5489E577DD1A7B8EC0D7C50BC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_Combined2018AZAgreementsMember_E95185B5489E577DD1A7B8EC0D7C50BC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFExercise2016Member" xlink:label="loc_mrna_VEGFExercise2016Member_FE0BE716431DE63F23F9B8EC0D7C9DE4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_VEGFExercise2016Member_FE0BE716431DE63F23F9B8EC0D7C9DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_162A429E0F3557EA1911B8EC0D7C5CDA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_srt_RangeAxis_162A429E0F3557EA1911B8EC0D7C5CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_162A429E0F3557EA1911B8EC0D7C5CDA" xlink:to="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_162A429E0F3557EA1911B8EC0D7C5CDA" xlink:to="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9FF704B313201E9EE49BB8EC0D7D9353" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558" xlink:to="loc_srt_MaximumMember_9FF704B313201E9EE49BB8EC0D7D9353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558" xlink:to="loc_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_CDA4D068E13C2E724C3CB8EC0D7D8911" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_CDA4D068E13C2E724C3CB8EC0D7D8911" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_CDA4D068E13C2E724C3CB8EC0D7D8911" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034_default" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_CDA4D068E13C2E724C3CB8EC0D7D8911" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentMilestonesMember" xlink:label="loc_mrna_DevelopmentMilestonesMember_4884D545638DBA08F5F1B8EC0D7E5335" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_DevelopmentMilestonesMember_4884D545638DBA08F5F1B8EC0D7E5335" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RegulatoryMilestonesMember" xlink:label="loc_mrna_RegulatoryMilestonesMember_657207A1D2C439FF8FAEB8EC0D7E3ADC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_RegulatoryMilestonesMember_657207A1D2C439FF8FAEB8EC0D7E3ADC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CommercialMilestonesMember" xlink:label="loc_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ToxicityMilestonesMember" xlink:label="loc_mrna_ToxicityMilestonesMember_30A730F1AC8122883E1DB8EC0D7E7FCF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_ToxicityMilestonesMember_30A730F1AC8122883E1DB8EC0D7E7FCF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CompetitionMilestonesMember" xlink:label="loc_mrna_CompetitionMilestonesMember_DC2403528053AE1112D9B8EC0D8456CB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_CompetitionMilestonesMember_DC2403528053AE1112D9B8EC0D8456CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D0B275916055BFB36C19B8EC0D846258" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D0B275916055BFB36C19B8EC0D846258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_3986DE57BAD0DB843A2DB8EC0D8495FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D0B275916055BFB36C19B8EC0D846258" xlink:to="loc_us-gaap_ProjectMember_3986DE57BAD0DB843A2DB8EC0D8495FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_3986DE57BAD0DB843A2DB8EC0D8495FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D0B275916055BFB36C19B8EC0D846258" xlink:to="loc_us-gaap_ProjectMember_3986DE57BAD0DB843A2DB8EC0D8495FF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFAProductAZD8601Member" xlink:label="loc_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_3986DE57BAD0DB843A2DB8EC0D8495FF" xlink:to="loc_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BA3E248508B3D327CC8FB8EC0D85372B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_srt_ProductOrServiceAxis_BA3E248508B3D327CC8FB8EC0D85372B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D81AEE71E2051EB0273EB8EC0D85A8FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_BA3E248508B3D327CC8FB8EC0D85372B" xlink:to="loc_srt_ProductsAndServicesDomain_D81AEE71E2051EB0273EB8EC0D85A8FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D81AEE71E2051EB0273EB8EC0D85A8FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_BA3E248508B3D327CC8FB8EC0D85372B" xlink:to="loc_srt_ProductsAndServicesDomain_D81AEE71E2051EB0273EB8EC0D85A8FE" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_8BE83270D44CF78351E8B8EC0D853B02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D81AEE71E2051EB0273EB8EC0D85A8FE" xlink:to="loc_mrna_CollaborationArrangementMember_8BE83270D44CF78351E8B8EC0D853B02" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_A1243C6286C60755E840B8EC0D863B44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_DeferredRevenueAdditions_A1243C6286C60755E840B8EC0D863B44" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_7483B294CBA5FC40908FB8EC0D874449" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_7483B294CBA5FC40908FB8EC0D874449" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_885D428574D1C93BDB0FB8EC0D87D9EA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_885D428574D1C93BDB0FB8EC0D87D9EA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7BD6CCE9D6138AC49EBDB8EC0D881754" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7BD6CCE9D6138AC49EBDB8EC0D881754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_A7B80BFA7D77B2F30A27B8EC0D89B09D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_A7B80BFA7D77B2F30A27B8EC0D89B09D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94B919FDEC32D0E1AC8FB8EC0D894785" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94B919FDEC32D0E1AC8FB8EC0D894785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6AF9B4407ED70D44CC32B8EC0D89E000" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6AF9B4407ED70D44CC32B8EC0D89E000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_DF6B8C4EAC89D3460D03EF95F6F6C327" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_DF6B8C4EAC89D3460D03EF95F6F6C327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_DF6B8C4EAC89D3460D03EF95F6F6C327" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_DF6B8C4EAC89D3460D03EF95F6F6C327" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MerckAgreement2015Member" xlink:label="loc_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:to="loc_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_SeparateAgreementsWithMerckMember" xlink:label="loc_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:to="loc_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVSAVAgreementMember" xlink:label="loc_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:to="loc_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C741EBDF13B707FE1A16EF95F6F75806" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_srt_ProductOrServiceAxis_C741EBDF13B707FE1A16EF95F6F75806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3B69CD4612E8F52A8300EF95F6F8B2B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_C741EBDF13B707FE1A16EF95F6F75806" xlink:to="loc_srt_ProductsAndServicesDomain_3B69CD4612E8F52A8300EF95F6F8B2B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3B69CD4612E8F52A8300EF95F6F8B2B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_C741EBDF13B707FE1A16EF95F6F75806" xlink:to="loc_srt_ProductsAndServicesDomain_3B69CD4612E8F52A8300EF95F6F8B2B5" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_81BC3F3912C693904CC5EF95F6F88374" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3B69CD4612E8F52A8300EF95F6F8B2B5" xlink:to="loc_mrna_CollaborationArrangementMember_81BC3F3912C693904CC5EF95F6F88374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_A88EE8CAD192E63E9048EF95F6F8FD46" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_A88EE8CAD192E63E9048EF95F6F8FD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_7796F7611B62B2DD0602EF95F6F88597_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_A88EE8CAD192E63E9048EF95F6F8FD46" xlink:to="loc_us-gaap_ProjectMember_7796F7611B62B2DD0602EF95F6F88597_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_7796F7611B62B2DD0602EF95F6F88597" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_A88EE8CAD192E63E9048EF95F6F8FD46" xlink:to="loc_us-gaap_ProjectMember_7796F7611B62B2DD0602EF95F6F88597" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_7796F7611B62B2DD0602EF95F6F88597" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:to="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:to="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_8C1000571A4CA8063069EF95F6FA140C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_8C1000571A4CA8063069EF95F6FA140C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_8C1000571A4CA8063069EF95F6FA140C" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_8C1000571A4CA8063069EF95F6FA140C" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MilestonePaymentsMember" xlink:label="loc_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:to="loc_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentMember" xlink:label="loc_mrna_UpfrontPaymentMember_582F923B87117FD97ACBEF95F6FBEC70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:to="loc_mrna_UpfrontPaymentMember_582F923B87117FD97ACBEF95F6FBEC70" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentResearchAndDevelopmentMember" xlink:label="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:to="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ClinicalSupplyReimbursementMember" xlink:label="loc_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:to="loc_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_26A8D98CD4F0AC96570AEF95F6FC51FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_26A8D98CD4F0AC96570AEF95F6FC51FC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_7BE0EA6BC62120901400EF95F6FD2A5A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_7BE0EA6BC62120901400EF95F6FD2A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5187D7F881D56670C636EF95F6FDC670" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5187D7F881D56670C636EF95F6FDC670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_747BC77F82D6A90A138CEF95F6FDD533" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_DeferredRevenueAdditions_747BC77F82D6A90A138CEF95F6FDD533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5670C1115B4C31CAFD88EF95F6FE5F6A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5670C1115B4C31CAFD88EF95F6FE5F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_009CCF087DED6ACE466DEF95F6FE9DF1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_009CCF087DED6ACE466DEF95F6FE9DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedemptionPremium" xlink:label="loc_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9BE19B78078088FB3A7AC3813AE89856" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9BE19B78078088FB3A7AC3813AE89856" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_477C9C147F4F526079AEC3813ADCC662" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_477C9C147F4F526079AEC3813ADCC662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_477C9C147F4F526079AEC3813ADCC662" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_477C9C147F4F526079AEC3813ADCC662" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVSAVAgreementMember" xlink:label="loc_mrna_PCVSAVAgreementMember_4E96DC11A6583AFE24EDC3813ADC9AA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_PCVSAVAgreementMember_4E96DC11A6583AFE24EDC3813ADC9AA8" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MerckAgreement2015Member" xlink:label="loc_mrna_MerckAgreement2015Member_E0B8E6F8EAF9B02A0F5DC3813ADD903C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_MerckAgreement2015Member_E0B8E6F8EAF9B02A0F5DC3813ADD903C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFExercise2016Member" xlink:label="loc_mrna_VEGFExercise2016Member_9AA97EB70C07D061738DC3813ADD74DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_VEGFExercise2016Member_9AA97EB70C07D061738DC3813ADD74DE" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:label="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementsMember" xlink:label="loc_mrna_Combined2018AZAgreementsMember_AB6072EDF3C7980EAF4BC3813ADDD97D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_Combined2018AZAgreementsMember_AB6072EDF3C7980EAF4BC3813ADDD97D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" xlink:label="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_3F2CDFF0D1CF27C99A89C3813ADD9689" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_3F2CDFF0D1CF27C99A89C3813ADD9689" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationAxis" xlink:label="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationDomain" xlink:label="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:to="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79_default" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationDomain" xlink:label="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:to="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementPerformanceObligationMember" xlink:label="loc_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IL12PerformanceObligationMember" xlink:label="loc_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OncologyDevelopmentTargetPerformanceObligationMember" xlink:label="loc_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member" xlink:label="loc_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember" xlink:label="loc_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVPerformanceObligationMember" xlink:label="loc_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_KRASPerformanceObligationMember" xlink:label="loc_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_78E35BD438924F3C7A16C3813AE40408" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_78E35BD438924F3C7A16C3813AE40408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_78E35BD438924F3C7A16C3813AE40408" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_78E35BD438924F3C7A16C3813AE40408" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FixedPaymentsMember" xlink:label="loc_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OptionExerciseFeeMember" xlink:label="loc_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VariableConsiderationMember" xlink:label="loc_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_EstimatedReimbursementMember" xlink:label="loc_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_SublicenseReimbursementMember" xlink:label="loc_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MilestonePaymentsMember" xlink:label="loc_mrna_MilestonePaymentsMember_C64FE79E1C6012A1CF2CC3813AE66079" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_MilestonePaymentsMember_C64FE79E1C6012A1CF2CC3813AE66079" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentMember" xlink:label="loc_mrna_UpfrontPaymentMember_A91CE1F07AF8B943AC67C3813AE6CFE6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_UpfrontPaymentMember_A91CE1F07AF8B943AC67C3813AE6CFE6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember" xlink:label="loc_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_UpfrontPaymentMember_A91CE1F07AF8B943AC67C3813AE6CFE6" xlink:to="loc_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentResearchAndDevelopmentMember" xlink:label="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_B23907BAC8C9A281FADAC3813AE6D99C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_UpfrontPaymentMember_A91CE1F07AF8B943AC67C3813AE6CFE6" xlink:to="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_B23907BAC8C9A281FADAC3813AE6D99C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentFundingMember" xlink:label="loc_mrna_ResearchAndDevelopmentFundingMember_147E0C1A368DB3D877E5C3813AE60D9B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_ResearchAndDevelopmentFundingMember_147E0C1A368DB3D877E5C3813AE60D9B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ClinicalSupplyReimbursementMember" xlink:label="loc_mrna_ClinicalSupplyReimbursementMember_630A1EDABA5512B40414C3813AE7C906" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_ClinicalSupplyReimbursementMember_630A1EDABA5512B40414C3813AE7C906" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_E81417464115D98EC3F4C3813AE7B31C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_E81417464115D98EC3F4C3813AE7B31C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_E81417464115D98EC3F4C3813AE7B31C" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749_default" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_E81417464115D98EC3F4C3813AE7B31C" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ToxicityMilestonesMember" xlink:label="loc_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749" xlink:to="loc_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CompetitionMilestonesMember" xlink:label="loc_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749" xlink:to="loc_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_26E5740EBFE4B379D2BAC3813AE8D799" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9BE19B78078088FB3A7AC3813AE89856" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_26E5740EBFE4B379D2BAC3813AE8D799" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1599CB22352EDC4653C9B8EC0DF22EE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:to="loc_srt_ProductOrServiceAxis_1599CB22352EDC4653C9B8EC0DF22EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0BDB94A3D50E230FD22EB8EC0DF286DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1599CB22352EDC4653C9B8EC0DF22EE4" xlink:to="loc_srt_ProductsAndServicesDomain_0BDB94A3D50E230FD22EB8EC0DF286DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0BDB94A3D50E230FD22EB8EC0DF286DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1599CB22352EDC4653C9B8EC0DF22EE4" xlink:to="loc_srt_ProductsAndServicesDomain_0BDB94A3D50E230FD22EB8EC0DF286DC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0BDB94A3D50E230FD22EB8EC0DF286DC" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_B7F701E97183327F3E20B8EC0DF40A3B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:to="loc_srt_MajorCustomersAxis_B7F701E97183327F3E20B8EC0DF40A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_B7F701E97183327F3E20B8EC0DF40A3B" xlink:to="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_B7F701E97183327F3E20B8EC0DF40A3B" xlink:to="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MerckMember" xlink:label="loc_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:to="loc_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AstraZenecaMember" xlink:label="loc_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:to="loc_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VertexMember" xlink:label="loc_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:to="loc_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCustomerMember" xlink:label="loc_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:to="loc_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1EC0AF7407A952D355E3B8EC0DFAF6CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1EC0AF7407A952D355E3B8EC0DFAF6CE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3F17E9311D2787ABA5E2CBD94A7CB5AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3F17E9311D2787ABA5E2CBD94A7CB5AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3F17E9311D2787ABA5E2CBD94A7CB5AC" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3F17E9311D2787ABA5E2CBD94A7CB5AC" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementsMember" xlink:label="loc_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:to="loc_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFExercise2016Member" xlink:label="loc_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:to="loc_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVSAVAgreementMember" xlink:label="loc_mrna_PCVSAVAgreementMember_09B089F7FBE86F3ADC76CBD94A7D1899" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:to="loc_mrna_PCVSAVAgreementMember_09B089F7FBE86F3ADC76CBD94A7D1899" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" xlink:label="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_2B3AD40E517E25D45B5DCBD94A7EC14E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:to="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_2B3AD40E517E25D45B5DCBD94A7EC14E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" xlink:label="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:to="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896_default" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentMilestonesMember" xlink:label="loc_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:to="loc_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RegulatoryMilestonesMember" xlink:label="loc_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:to="loc_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RegulatoryMilestonesSubsequentProductsMember" xlink:label="loc_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:to="loc_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_133B2397BC9E1D41EC79C3813A5E2470" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_srt_ProductOrServiceAxis_133B2397BC9E1D41EC79C3813A5E2470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CDAA5B539D3C8D92CA03C3813A5EAD3B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_133B2397BC9E1D41EC79C3813A5E2470" xlink:to="loc_srt_ProductsAndServicesDomain_CDAA5B539D3C8D92CA03C3813A5EAD3B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CDAA5B539D3C8D92CA03C3813A5EAD3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_133B2397BC9E1D41EC79C3813A5E2470" xlink:to="loc_srt_ProductsAndServicesDomain_CDAA5B539D3C8D92CA03C3813A5EAD3B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CDAA5B539D3C8D92CA03C3813A5EAD3B" xlink:to="loc_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentMember" xlink:label="loc_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:to="loc_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentFundingMember" xlink:label="loc_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:to="loc_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_E8C897039C01B8BE645BC3813A6212CC" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ContractWithCustomerLiability_E8C897039C01B8BE645BC3813A6212CC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="loc_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:to="loc_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0593B7D9B047F07EFE4BB89403A3CC28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0593B7D9B047F07EFE4BB89403A3CC28" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_011004F9A95DD390FCF3B89403A178BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_011004F9A95DD390FCF3B89403A178BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1FA0C9A7F33AB023D91FB89403A258CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_011004F9A95DD390FCF3B89403A178BF" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1FA0C9A7F33AB023D91FB89403A258CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1FA0C9A7F33AB023D91FB89403A258CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_011004F9A95DD390FCF3B89403A178BF" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1FA0C9A7F33AB023D91FB89403A258CD" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_477E19192F01241616E9B89403A24841" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1FA0C9A7F33AB023D91FB89403A258CD" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_477E19192F01241616E9B89403A24841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_EA3630974BDCABC9CD6AB89403A26AFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_EA3630974BDCABC9CD6AB89403A26AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_AA2621C6944A216A6E38B89403A262AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_EA3630974BDCABC9CD6AB89403A26AFB" xlink:to="loc_us-gaap_ProjectMember_AA2621C6944A216A6E38B89403A262AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_AA2621C6944A216A6E38B89403A262AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_EA3630974BDCABC9CD6AB89403A26AFB" xlink:to="loc_us-gaap_ProjectMember_AA2621C6944A216A6E38B89403A262AA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_AFF3A09CA9AC0DA2C2D5B89403A30C25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_AA2621C6944A216A6E38B89403A262AA" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_AFF3A09CA9AC0DA2C2D5B89403A30C25" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0593B7D9B047F07EFE4BB89403A3CC28" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4A900FEA9BCD5D48490CB8A04C1F9314" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:to="loc_srt_ProductOrServiceAxis_4A900FEA9BCD5D48490CB8A04C1F9314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4A900FEA9BCD5D48490CB8A04C1F9314" xlink:to="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4A900FEA9BCD5D48490CB8A04C1F9314" xlink:to="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_077F666AF928DA2589BFB8A04C1F05EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:to="loc_mrna_CollaborationArrangementMember_077F666AF928DA2589BFB8A04C1F05EA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborativeArrangementWithRelatedPartyMember" xlink:label="loc_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:to="loc_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_54F40A8816CB22B98A5BB8A04C20E913" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:to="loc_us-gaap_GrantMember_54F40A8816CB22B98A5BB8A04C20E913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:to="loc_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:to="loc_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7FE6A5FE944D229D5D9CB8A04BF20BDD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7FE6A5FE944D229D5D9CB8A04BF20BDD" xlink:to="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AFF841DBEB9C9DEA193FB8A04BF07F5E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_AFF841DBEB9C9DEA193FB8A04BF07F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AFF841DBEB9C9DEA193FB8A04BF07F5E" xlink:to="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AFF841DBEB9C9DEA193FB8A04BF07F5E" xlink:to="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E33424E8BF7D62373598B8A04BF053B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:to="loc_us-gaap_CommonStockMember_E33424E8BF7D62373598B8A04BF053B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:to="loc_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7FE6A5FE944D229D5D9CB8A04BF20BDD" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_871104879BDAF35DDD3AB8A04BF44D3D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_NetIncomeLoss_871104879BDAF35DDD3AB8A04BF44D3D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:to="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="loc_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CurrentMarketableSecuritiesMember" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_NoncurrentMarketableSecuritiesMember" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6F5E8B60B62F781500ACC3813A29CC1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6F5E8B60B62F781500ACC3813A29CC1F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78ABFB1B81B24DFBB77EC3813A29EB7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6F5E8B60B62F781500ACC3813A29CC1F" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78ABFB1B81B24DFBB77EC3813A29EB7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78ABFB1B81B24DFBB77EC3813A29EB7B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78ABFB1B81B24DFBB77EC3813A29EB7B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_B24B604522DB58C95187C3813A2AF653" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:to="loc_us-gaap_CertificatesOfDepositMember_B24B604522DB58C95187C3813A2AF653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_76E67DC73CDCF4A36091C3813A2A4F10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_76E67DC73CDCF4A36091C3813A2A4F10" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_4F3C9F6DE5286CE4A3FAC3813A2AE7E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:to="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_4F3C9F6DE5286CE4A3FAC3813A2AE7E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/Grants" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/GrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:to="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:to="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:to="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TheBillAndMelindaGatesFoundationMember" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:to="loc_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:to="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:to="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:to="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:to="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:to="loc_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:to="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:to="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_InitialBaseAwardMember" xlink:label="loc_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="loc_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractOptionsMember" xlink:label="loc_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="loc_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_InitialProjectMember" xlink:label="loc_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="loc_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FollowOnProjectMember" xlink:label="loc_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="loc_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsMaximumAward" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsNumberOfContractOptions" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TwoHundredTechnologySquareMember" xlink:label="loc_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TwoHundredTechnologySquareSubleaseAgreementsMember" xlink:label="loc_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FiveHundredTechnologySquareMember" xlink:label="loc_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LandAdjacentToNorwoodMember" xlink:label="loc_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OfficeLaboratoryAndLightManufacturingSpaceMember" xlink:label="loc_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:to="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:to="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:to="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CambridgeMassachusettsMember" xlink:label="loc_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:to="loc_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_NorwoodMassachusettsMember" xlink:label="loc_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:to="loc_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit" xlink:label="loc_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AllowanceForTenantImprovements" xlink:label="loc_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeasePercentageSubleased" xlink:label="loc_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LeasesImputedInterestRate" xlink:label="loc_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:to="loc_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:to="loc_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/ShareholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:to="loc_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PublicEquityOfferingMember" xlink:label="loc_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:to="loc_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:to="loc_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E843F74AD0954148F92AB94C012F9711" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E843F74AD0954148F92AB94C012F9711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D8482081A37605293F4FB94C0130FF6D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E843F74AD0954148F92AB94C012F9711" xlink:to="loc_us-gaap_ClassOfStockDomain_D8482081A37605293F4FB94C0130FF6D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D8482081A37605293F4FB94C0130FF6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E843F74AD0954148F92AB94C012F9711" xlink:to="loc_us-gaap_ClassOfStockDomain_D8482081A37605293F4FB94C0130FF6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D8482081A37605293F4FB94C0130FF6D" xlink:to="loc_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02273BBFFB6E1B8946E0B94C01327A31" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02273BBFFB6E1B8946E0B94C01327A31" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PaymentsOfUnderwritingDiscounts" xlink:label="loc_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6AC0D3626DE7DB50DB1AB94C0132AFAD" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6AC0D3626DE7DB50DB1AB94C0132AFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6C7A6614CFE2B756555EB94C0133D4CE" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6C7A6614CFE2B756555EB94C0133D4CE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:to="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:to="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:to="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3AC0B2CF89C8302354D3B94C0114B6BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:to="loc_us-gaap_AwardTypeAxis_3AC0B2CF89C8302354D3B94C0114B6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3AC0B2CF89C8302354D3B94C0114B6BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3AC0B2CF89C8302354D3B94C0114B6BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ServiceBasedAwardsMember" xlink:label="loc_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:to="loc_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:to="loc_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:to="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:to="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:to="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StockOptionAndIncentivePlan2018Member" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StockOptionAndGrantPlan2016Member" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:to="loc_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_EmployeeStockPurchasePlan2018Member" xlink:label="loc_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:to="loc_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32EF08B24D6086241A03B8B0B83D5536" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A70BD9878745E100BF8CB8B0B83C7BA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32EF08B24D6086241A03B8B0B83D5536" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A70BD9878745E100BF8CB8B0B83C7BA9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_40007E6195F1336906B8B8B0B83CF6E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A70BD9878745E100BF8CB8B0B83C7BA9" xlink:to="loc_us-gaap_AwardTypeAxis_40007E6195F1336906B8B8B0B83CF6E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3D40E19726A9515DAD5BB8B0B83DDED4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_40007E6195F1336906B8B8B0B83CF6E4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3D40E19726A9515DAD5BB8B0B83DDED4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3D40E19726A9515DAD5BB8B0B83DDED4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_40007E6195F1336906B8B8B0B83CF6E4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3D40E19726A9515DAD5BB8B0B83DDED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3D40E19726A9515DAD5BB8B0B83DDED4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32EF08B24D6086241A03B8B0B83D5536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32EF08B24D6086241A03B8B0B83D5536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B1973579BC0F79F85CB0B8A04A78ADBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:to="loc_us-gaap_AwardTypeAxis_B1973579BC0F79F85CB0B8A04A78ADBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B1973579BC0F79F85CB0B8A04A78ADBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B1973579BC0F79F85CB0B8A04A78ADBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C78D6EB198323CF13DA2B8A04A79F639" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C78D6EB198323CF13DA2B8A04A79F639" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:to="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:to="loc_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:to="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:to="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:to="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:to="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:to="loc_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:to="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DCC08A4B061065953F3AEACE3AE8B3D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:to="loc_srt_RangeAxis_DCC08A4B061065953F3AEACE3AE8B3D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2397ABACC02A8507E0FAEACE3AE8DD45_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_DCC08A4B061065953F3AEACE3AE8B3D7" xlink:to="loc_srt_RangeMember_2397ABACC02A8507E0FAEACE3AE8DD45_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2397ABACC02A8507E0FAEACE3AE8DD45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_DCC08A4B061065953F3AEACE3AE8B3D7" xlink:to="loc_srt_RangeMember_2397ABACC02A8507E0FAEACE3AE8DD45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2397ABACC02A8507E0FAEACE3AE8DD45" xlink:to="loc_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:to="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_916014675173360C7492EACE3AEAA882" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_916014675173360C7492EACE3AEAA882" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LonzaLtdMember" xlink:label="loc_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:to="loc_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:to="loc_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:to="loc_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborativeArrangementTermOfArrangement" xlink:label="loc_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:to="loc_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:to="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:to="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:to="loc_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:to="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:to="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:to="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:to="loc_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9B780ED64025DE5E5FE9B8EC0E3D54B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9B780ED64025DE5E5FE9B8EC0E3D54B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_274B1D46AC5E8594EC8FB8EC0E3D6F52_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9B780ED64025DE5E5FE9B8EC0E3D54B1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_274B1D46AC5E8594EC8FB8EC0E3D6F52_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_274B1D46AC5E8594EC8FB8EC0E3D6F52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9B780ED64025DE5E5FE9B8EC0E3D54B1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_274B1D46AC5E8594EC8FB8EC0E3D6F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_1FE5516C4651E0A3BCF9B943759BE57A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_274B1D46AC5E8594EC8FB8EC0E3D6F52" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_1FE5516C4651E0A3BCF9B943759BE57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0F969434A9ECF401BF30B940F422F436" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0F969434A9ECF401BF30B940F422F436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_E9833D8F6AE98D4D1EACB940FB9E0406" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_E9833D8F6AE98D4D1EACB940FB9E0406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8730D2FFF4019F6E5E58B9410415082E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_OperatingExpenses_8730D2FFF4019F6E5E58B9410415082E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_95790B26214A9388C70AB941E4729F24" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_95790B26214A9388C70AB941E4729F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2594923F52E9893D0CC2B94248F69ECA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_NetIncomeLoss_2594923F52E9893D0CC2B94248F69ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_84A2E97F94390A4CDDB2B9424FDE5EED" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_84A2E97F94390A4CDDB2B9424FDE5EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4CAF48A771FF881B9620B94523F647AE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4CAF48A771FF881B9620B94523F647AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6A6E9143448CE953E31FB945377F3DEE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6A6E9143448CE953E31FB945377F3DEE" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_2CB52C42196D6A4BEDF4B9455B014F79" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_2CB52C42196D6A4BEDF4B9455B014F79" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IncreaseDecreaseInDeferredRentCredit" xlink:label="loc_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingLeaseLiabilities" xlink:label="loc_mrna_OperatingLeaseLiabilities_46E64577E78600AE357DB9458199FEB4" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_OperatingLeaseLiabilities_46E64577E78600AE357DB9458199FEB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_BB89C8E0015ADB9D59B8B945981364B1" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_BB89C8E0015ADB9D59B8B945981364B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChargesToFinancingLeaseLiabilities" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_32A3895A838D5934D262B945DC1ECA3E" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_32A3895A838D5934D262B945DC1ECA3E" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PaymentsForLeaseFinancingObligation" xlink:label="loc_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>mrna-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9F532DB9184217DF6ABDB8B0B833B3FA_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9F532DB9184217DF6ABDB8B0B833B3FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9F532DB9184217DF6ABDB8B0B833B3FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9F532DB9184217DF6ABDB8B0B833B3FA" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9F532DB9184217DF6ABDB8B0B833B3FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:to="lab_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:to="lab_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175_label_en-US" xlink:label="lab_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:to="lab_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4_terseLabel_en-US" xlink:label="lab_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4_label_en-US" xlink:label="lab_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:to="lab_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:type="arc" />
    <link:label id="lab_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595_label_en-US" xlink:label="lab_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:to="lab_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC_label_en-US" xlink:label="lab_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:to="lab_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Common Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_B8784042A4C26C27E80BC37F5BA007EE_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_B8784042A4C26C27E80BC37F5BA007EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_B8784042A4C26C27E80BC37F5BA007EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_B8784042A4C26C27E80BC37F5BA007EE" xlink:to="lab_us-gaap_LeasesAbstract_B8784042A4C26C27E80BC37F5BA007EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:type="arc" />
    <link:label id="lab_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418_terseLabel_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">200 Technology Square</link:label>
    <link:label id="lab_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418_label_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Hundred Technology Square [Member]</link:label>
    <link:label id="lab_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418_documentation_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Hundred Technology Square</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TwoHundredTechnologySquareMember" xlink:label="loc_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:to="lab_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:type="arc" />
    <link:label id="lab_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9_terseLabel_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">200 Technology Square, Sublease Agreements</link:label>
    <link:label id="lab_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9_label_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Hundred Technology Square, Sublease Agreements [Member]</link:label>
    <link:label id="lab_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9_documentation_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Hundred Technology Square, Sublease Agreements [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TwoHundredTechnologySquareSubleaseAgreementsMember" xlink:label="loc_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:to="lab_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:type="arc" />
    <link:label id="lab_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A_terseLabel_en-US" xlink:label="lab_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">500 Technology Square</link:label>
    <link:label id="lab_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A_label_en-US" xlink:label="lab_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five Hundred Technology Square [Member]</link:label>
    <link:label id="lab_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A_documentation_en-US" xlink:label="lab_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five Hundred Technology Square [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FiveHundredTechnologySquareMember" xlink:label="loc_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:to="lab_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:type="arc" />
    <link:label id="lab_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4_terseLabel_en-US" xlink:label="lab_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land adjacent to Norwood</link:label>
    <link:label id="lab_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4_label_en-US" xlink:label="lab_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Adjacent To Norwood [Member]</link:label>
    <link:label id="lab_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4_documentation_en-US" xlink:label="lab_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Land Adjacent To Norwood [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LandAdjacentToNorwoodMember" xlink:label="loc_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:to="lab_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:type="arc" />
    <link:label id="lab_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479_terseLabel_en-US" xlink:label="lab_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office, laboratory, and light manufacturing space</link:label>
    <link:label id="lab_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479_label_en-US" xlink:label="lab_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office, Laboratory, And Light Manufacturing Space [Member]</link:label>
    <link:label id="lab_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479_documentation_en-US" xlink:label="lab_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office, Laboratory, And Light Manufacturing Space [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OfficeLaboratoryAndLightManufacturingSpaceMember" xlink:label="loc_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:to="lab_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:to="lab_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:to="lab_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:type="arc" />
    <link:label id="lab_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618_terseLabel_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cambridge Leases</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618_label_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618_documentation_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CambridgeMassachusettsMember" xlink:label="loc_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:to="lab_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:type="arc" />
    <link:label id="lab_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5_terseLabel_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Norwood Leases</link:label>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5_label_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Norwood, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5_documentation_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Norwood, Massachusetts</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_NorwoodMassachusettsMember" xlink:label="loc_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:to="lab_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of campuses</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease, Number of Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of office space (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:type="arc" />
    <link:label id="lab_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant allowance (in usd per sqft)</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Tenant Allowance, Price Per Unit</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Tenant Allowance, Price Per Unit</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit" xlink:label="loc_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:to="lab_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, term of lease</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:type="arc" />
    <link:label id="lab_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA_terseLabel_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA_label_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA_documentation_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AllowanceForTenantImprovements" xlink:label="loc_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:to="lab_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:type="arc" />
    <link:label id="lab_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage subleased</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Percentage Subleased</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Percentage Subleased</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeasePercentageSubleased" xlink:label="loc_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:to="lab_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:type="arc" />
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of extension periods</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Periods</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Periods</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:to="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amounts representing interest or imputed interest, operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts representing interest or imputed interest, finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:type="arc" />
    <link:label id="lab_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7_terseLabel_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Imputed interest rate</link:label>
    <link:label id="lab_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7_label_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Imputed Interest Rate</link:label>
    <link:label id="lab_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7_documentation_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases, Imputed Interest Rate</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LeasesImputedInterestRate" xlink:label="loc_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:to="lab_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09A92D014300B527F21BB89403FF2769_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09A92D014300B527F21BB89403FF2769" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09A92D014300B527F21BB89403FF2769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09A92D014300B527F21BB89403FF2769" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09A92D014300B527F21BB89403FF2769" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543283D658BEEA50A009B894040172DF_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543283D658BEEA50A009B894040172DF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543283D658BEEA50A009B894040172DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543283D658BEEA50A009B894040172DF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543283D658BEEA50A009B894040172DF" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:to="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11_periodStartLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_7ABC618154D698A9276FB89404027D01_periodEndLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_7ABC618154D698A9276FB89404027D01" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_7ABC618154D698A9276FB89404027D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_7ABC618154D698A9276FB89404027D01" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_7ABC618154D698A9276FB89404027D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding and Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price per Share, Exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price per Share (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E573A069037436145828B8940321157F_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E573A069037436145828B8940321157F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E573A069037436145828B8940321157F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E573A069037436145828B8940321157F" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E573A069037436145828B8940321157F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:to="lab_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:to="lab_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:type="arc" />
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92_terseLabel_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92_label_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92_documentation_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:to="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:type="arc" />
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747_terseLabel_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Bill &amp; Melinda Gates Foundation</link:label>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747_label_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747_documentation_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TheBillAndMelindaGatesFoundationMember" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:to="lab_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:type="arc" />
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A_terseLabel_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DARPA</link:label>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A_label_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defense Advanced Research Projects Agency [Member]</link:label>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A_documentation_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defense Advanced Research Projects Agency [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:to="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:to="lab_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:to="lab_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3_label_en-US" xlink:label="lab_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:to="lab_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF_label_en-US" xlink:label="lab_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="lab_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:type="arc" />
    <link:label id="lab_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C_terseLabel_en-US" xlink:label="lab_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial base award</link:label>
    <link:label id="lab_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C_label_en-US" xlink:label="lab_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Base Award [Member]</link:label>
    <link:label id="lab_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C_documentation_en-US" xlink:label="lab_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Base Award</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_InitialBaseAwardMember" xlink:label="loc_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:to="lab_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:type="arc" />
    <link:label id="lab_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8_terseLabel_en-US" xlink:label="lab_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract options</link:label>
    <link:label id="lab_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8_label_en-US" xlink:label="lab_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Options [Member]</link:label>
    <link:label id="lab_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8_documentation_en-US" xlink:label="lab_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Options</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractOptionsMember" xlink:label="loc_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:to="lab_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:type="arc" />
    <link:label id="lab_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703_terseLabel_en-US" xlink:label="lab_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial project</link:label>
    <link:label id="lab_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703_label_en-US" xlink:label="lab_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Project [Member]</link:label>
    <link:label id="lab_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703_documentation_en-US" xlink:label="lab_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Project [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_InitialProjectMember" xlink:label="loc_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:to="lab_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:type="arc" />
    <link:label id="lab_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B_terseLabel_en-US" xlink:label="lab_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Follow-on project</link:label>
    <link:label id="lab_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B_label_en-US" xlink:label="lab_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Follow-On Project [Member]</link:label>
    <link:label id="lab_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B_documentation_en-US" xlink:label="lab_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Follow-On Project [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FollowOnProjectMember" xlink:label="loc_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:to="lab_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:type="arc" />
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award amount</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsMaximumAward" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:to="lab_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:type="arc" />
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of contract options exercised</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Number Of Contract Options Exercised</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Number Of Contract Options Exercised</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:to="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:type="arc" />
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of contract options</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Number Of Contract Options</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Number Of Contract Options</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsNumberOfContractOptions" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:to="lab_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:type="arc" />
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount committed for funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:to="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:type="arc" />
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Remaining Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Grants, Remaining Funding Capacity</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:to="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:to="lab_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837_label_en-US" xlink:label="lab_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:to="lab_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56_label_en-US" xlink:label="lab_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:to="lab_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:type="arc" />
    <link:label id="lab_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92_terseLabel_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-Based Awards [Member]</link:label>
    <link:label id="lab_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92_label_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service-Based Awards [Member]</link:label>
    <link:label id="lab_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92_documentation_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service-Based Awards [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ServiceBasedAwardsMember" xlink:label="loc_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:to="lab_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F" xlink:to="lab_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:to="lab_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:to="lab_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:to="lab_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:type="arc" />
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816_terseLabel_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option And Incentive Plan 2018</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816_label_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816_documentation_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StockOptionAndIncentivePlan2018Member" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:to="lab_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:type="arc" />
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6_terseLabel_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option and Grant Plan 2016</link:label>
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6_label_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option And Grant Plan 2016 [Member]</link:label>
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6_documentation_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option And Grant Plan 2016 [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StockOptionAndGrantPlan2016Member" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:to="lab_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:type="arc" />
    <link:label id="lab_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9_terseLabel_en-US" xlink:label="lab_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9_label_en-US" xlink:label="lab_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:label id="lab_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9_documentation_en-US" xlink:label="lab_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_EmployeeStockPurchasePlan2018Member" xlink:label="loc_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:to="lab_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage of additional shares authorized</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:to="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of installments</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration recorded as a result of stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:to="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price at which shares are sold, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum percentage of compensation through payroll deductions</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:to="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of compensation through payroll deductions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum shares to be purchased during purchase period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:type="arc" />
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum value of shares to be purchased during purchase period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation cost related to non-vested stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period of cost expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2FE0C099942038A9DBCEB8940451099A_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_2FE0C099942038A9DBCEB8940451099A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2FE0C099942038A9DBCEB8940451099A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FE0C099942038A9DBCEB8940451099A" xlink:to="lab_us-gaap_EarningsPerShareAbstract_2FE0C099942038A9DBCEB8940451099A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8" xlink:to="lab_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted common stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:to="lab_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted common stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_790A520B466D9F1D5002B8B1AEFEB498_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_790A520B466D9F1D5002B8B1AEFEB498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_790A520B466D9F1D5002B8B1AEFEB498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_790A520B466D9F1D5002B8B1AEFEB498" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_790A520B466D9F1D5002B8B1AEFEB498" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C260E05ACE792964831B93ADA9A613C_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C260E05ACE792964831B93ADA9A613C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C260E05ACE792964831B93ADA9A613C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C260E05ACE792964831B93ADA9A613C" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C260E05ACE792964831B93ADA9A613C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards and Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:to="lab_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:to="lab_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Internally developed software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:type="arc" />
    <link:label id="lab_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B_terseLabel_en-US" xlink:label="lab_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset, financing</link:label>
    <link:label id="lab_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B_label_en-US" xlink:label="lab_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right Of Use Asset, Financing [Member]</link:label>
    <link:label id="lab_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B_documentation_en-US" xlink:label="lab_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right Of Use Asset, Financing [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RightOfUseAssetFinancingMember" xlink:label="loc_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:to="lab_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:to="lab_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:type="arc" />
    <link:label id="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824_terseLabel_en-US" xlink:label="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824_label_en-US" xlink:label="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824_documentation_en-US" xlink:label="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" xlink:label="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:to="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:type="arc" />
    <link:label id="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63_negatedLabel_en-US" xlink:label="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63_label_en-US" xlink:label="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63_documentation_en-US" xlink:label="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization" xlink:label="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:to="lab_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:type="arc" />
    <link:label id="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A_totalLabel_en-US" xlink:label="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A_label_en-US" xlink:label="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</link:label>
    <link:label id="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A_documentation_en-US" xlink:label="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:to="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD_netLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_BE7F553AC95C3E626FE3C3813A5BD384_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_BE7F553AC95C3E626FE3C3813A5BD384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_BE7F553AC95C3E626FE3C3813A5BD384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_BE7F553AC95C3E626FE3C3813A5BD384" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_BE7F553AC95C3E626FE3C3813A5BD384" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:type="arc" />
    <link:label id="lab_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387_terseLabel_en-US" xlink:label="lab_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Vertex Agreement</link:label>
    <link:label id="lab_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387_label_en-US" xlink:label="lab_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Collaboration And License Agreement, With Vertex Pharmaceuticals Incorporated, And Vertex Pharmaceuticals (Europe) Limited [Member]</link:label>
    <link:label id="lab_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387_documentation_en-US" xlink:label="lab_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic Collaboration And License Agreement, With Vertex Pharmaceuticals Incorporated, And Vertex Pharmaceuticals (Europe) Limited [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" xlink:label="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:to="lab_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Milestone [Axis]</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Milestone [Axis]</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Milestone [Axis]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Milestone [Domain]</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Milestone [Domain]</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Research And Development Arrangement, Contract To Perform For Others, Milestone [Axis]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:type="arc" />
    <link:label id="lab_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA_terseLabel_en-US" xlink:label="lab_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA_label_en-US" xlink:label="lab_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA_documentation_en-US" xlink:label="lab_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentMilestonesMember" xlink:label="loc_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:to="lab_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:type="arc" />
    <link:label id="lab_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D_terseLabel_en-US" xlink:label="lab_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D_label_en-US" xlink:label="lab_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D_documentation_en-US" xlink:label="lab_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RegulatoryMilestonesMember" xlink:label="loc_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:to="lab_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:type="arc" />
    <link:label id="lab_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741_terseLabel_en-US" xlink:label="lab_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestones, Subsequent Products</link:label>
    <link:label id="lab_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741_label_en-US" xlink:label="lab_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestones, Subsequent Products [Member]</link:label>
    <link:label id="lab_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741_documentation_en-US" xlink:label="lab_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestones, Subsequent Products [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RegulatoryMilestonesSubsequentProductsMember" xlink:label="loc_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:to="lab_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:type="arc" />
    <link:label id="lab_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D_terseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D_label_en-US" xlink:label="lab_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:to="lab_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Basis of Pricing [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Basis of Pricing [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Basis of Pricing [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Basis of Pricing [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:type="arc" />
    <link:label id="lab_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924_terseLabel_en-US" xlink:label="lab_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924_label_en-US" xlink:label="lab_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment [Member]</link:label>
    <link:label id="lab_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924_documentation_en-US" xlink:label="lab_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentMember" xlink:label="loc_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:to="lab_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Funding</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Funding [Member]</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Funding [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentFundingMember" xlink:label="loc_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:to="lab_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront cash payments</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:to="lab_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Research Period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Research Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research extension period elected</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Research Extension Period Elected</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Research Extension Period Elected</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research extension period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Research Extension Period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Research Extension Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total collaboration revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment received, research extension period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Payment Received, Research Extension Period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Payment Received, Research Extension Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of extension periods</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Extension Periods</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Extension Periods</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated arrangement consideration</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from equity investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Termination Period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Termination Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written notice period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Marketing Approval, Termination Period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Marketing Approval, Termination Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to the transaction price</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred revenue due to the satisfaction of our performance obligation during the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_2D75342F451B69C9AD69EACE3AC03E9D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_2D75342F451B69C9AD69EACE3AC03E9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2D75342F451B69C9AD69EACE3AC03E9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2D75342F451B69C9AD69EACE3AC03E9D" xlink:to="lab_us-gaap_SubsequentEventsAbstract_2D75342F451B69C9AD69EACE3AC03E9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3255AF910F4470D4D7B3B89404AD033B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3255AF910F4470D4D7B3B89404AD033B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3255AF910F4470D4D7B3B89404AD033B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3255AF910F4470D4D7B3B89404AD033B" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3255AF910F4470D4D7B3B89404AD033B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="loc_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:to="lab_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:type="arc" />
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919_terseLabel_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Operations And Support Commitment</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919_label_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919_documentation_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:to="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelable open purchase orders</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:type="arc" />
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets:</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1_label_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Contract with Customer Asset [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1_documentation_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Contract with Customer Asset [Roll Forward]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChangeInContractwithCustomerAssetRollForward" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:to="lab_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E" xlink:type="arc" />
    <link:label id="lab_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3_terseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3_label_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Asset Increase During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer Asset Increase During Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractWithCustomerAssetIncreaseDuringPeriod" xlink:label="loc_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3" xlink:to="lab_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3" xlink:type="arc" />
    <link:label id="lab_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B_label_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Asset Decrease During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer Asset Decrease During Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractWithCustomerAssetDecreaseDuringPeriod" xlink:label="loc_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B" xlink:to="lab_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_890E047A861E2DF24F30B8EC0DD983CF_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_890E047A861E2DF24F30B8EC0DD983CF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_890E047A861E2DF24F30B8EC0DD983CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_890E047A861E2DF24F30B8EC0DD983CF" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet_890E047A861E2DF24F30B8EC0DD983CF" xlink:type="arc" />
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities:</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF_label_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Contract with Customer Liability [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF_documentation_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Contract with Customer Liability [Roll Forward]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:to="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_0A7C74C6061BE2D2D26EB8EC0DD92617_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_0A7C74C6061BE2D2D26EB8EC0DD92617" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0A7C74C6061BE2D2D26EB8EC0DD92617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_0A7C74C6061BE2D2D26EB8EC0DD92617" xlink:to="lab_us-gaap_ContractWithCustomerLiability_0A7C74C6061BE2D2D26EB8EC0DD92617" xlink:type="arc" />
    <link:label id="lab_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7_terseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability Increase During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability Increase During Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod" xlink:label="loc_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7" xlink:to="lab_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7" xlink:type="arc" />
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability Decrease During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability Decrease During Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod" xlink:label="loc_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45" xlink:to="lab_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_AD7221496341E4A0AF9BB8EC0DDADA4D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_AD7221496341E4A0AF9BB8EC0DDADA4D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_AD7221496341E4A0AF9BB8EC0DDADA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_AD7221496341E4A0AF9BB8EC0DDADA4D" xlink:to="lab_us-gaap_ContractWithCustomerLiability_AD7221496341E4A0AF9BB8EC0DDADA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8B6BA7E717E984E4A017B8EC0DDA6D7C_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8B6BA7E717E984E4A017B8EC0DDA6D7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amounts included in contract liabilities at the beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8B6BA7E717E984E4A017B8EC0DDA6D7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8B6BA7E717E984E4A017B8EC0DDA6D7C" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8B6BA7E717E984E4A017B8EC0DDA6D7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Common Stock Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares/Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F3C410DBD6EFB5ECE2EDB8B0B83F7C81_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F3C410DBD6EFB5ECE2EDB8B0B83F7C81" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, non-vested at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F3C410DBD6EFB5ECE2EDB8B0B83F7C81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F3C410DBD6EFB5ECE2EDB8B0B83F7C81" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F3C410DBD6EFB5ECE2EDB8B0B83F7C81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Fair Value per Share/Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, non-vested at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled, forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C91E0D4607F0833A175FB8B0B840EA39_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C91E0D4607F0833A175FB8B0B840EA39" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, non-vested at end of period (usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C91E0D4607F0833A175FB8B0B840EA39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C91E0D4607F0833A175FB8B0B840EA39" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C91E0D4607F0833A175FB8B0B840EA39" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:to="lab_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219_label_en-US" xlink:label="lab_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:to="lab_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:to="lab_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:type="arc" />
    <link:label id="lab_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99_terseLabel_en-US" xlink:label="lab_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lonza Ltd</link:label>
    <link:label id="lab_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99_label_en-US" xlink:label="lab_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lonza Ltd [Member]</link:label>
    <link:label id="lab_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99_documentation_en-US" xlink:label="lab_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lonza Ltd [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LonzaLtdMember" xlink:label="loc_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:to="lab_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:to="lab_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:to="lab_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant commitment</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:to="lab_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:type="arc" />
    <link:label id="lab_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E_terseLabel_en-US" xlink:label="lab_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E_label_en-US" xlink:label="lab_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Of Arrangement</link:label>
    <link:label id="lab_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E_documentation_en-US" xlink:label="lab_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Of Arrangement</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborativeArrangementTermOfArrangement" xlink:label="loc_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:to="lab_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_9672A921D50E780BD961B8940437CD54_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_9672A921D50E780BD961B8940437CD54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9672A921D50E780BD961B8940437CD54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_9672A921D50E780BD961B8940437CD54" xlink:to="lab_us-gaap_EquityAbstract_9672A921D50E780BD961B8940437CD54" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0282A9D592AAFA017687B894048952D9_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0282A9D592AAFA017687B894048952D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0282A9D592AAFA017687B894048952D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0282A9D592AAFA017687B894048952D9" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0282A9D592AAFA017687B894048952D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available-for-sale debt securities, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C" xlink:to="lab_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698" xlink:to="lab_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_013490B0811E460D54C3B8B0B99307A4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_013490B0811E460D54C3B8B0B99307A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_013490B0811E460D54C3B8B0B99307A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_013490B0811E460D54C3B8B0B99307A4" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_013490B0811E460D54C3B8B0B99307A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization/accretion of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B" xlink:type="arc" />
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E_negatedTerseLabel_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E_label_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Right Of Use Asset, Operating Leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E_documentation_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Right Of Use Asset, Operating Leases</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E" xlink:to="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1" xlink:type="arc" />
    <link:label id="lab_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083_terseLabel_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083_label_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:label id="lab_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083_documentation_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingLeaseLiabilities" xlink:label="loc_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083" xlink:to="lab_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock through equity plans, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F" xlink:to="lab_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F" xlink:type="arc" />
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB_terseLabel_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges to financing lease obligation</link:label>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB_label_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charges To Financing Lease Liabilities</link:label>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB_documentation_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charges To Financing Lease Liabilities</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChargesToFinancingLeaseLiabilities" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB" xlink:to="lab_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CD5227F51AB06F4619E5B8B0B9999F41_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CD5227F51AB06F4619E5B8B0B9999F41" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CD5227F51AB06F4619E5B8B0B9999F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CD5227F51AB06F4619E5B8B0B9999F41" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CD5227F51AB06F4619E5B8B0B9999F41" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E" xlink:type="arc" />
    <link:label id="lab_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72_terseLabel_en-US" xlink:label="lab_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Merck Agreement</link:label>
    <link:label id="lab_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72_label_en-US" xlink:label="lab_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck Agreement 2015 [Member]</link:label>
    <link:label id="lab_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72_documentation_en-US" xlink:label="lab_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck Agreement 2015 [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MerckAgreement2015Member" xlink:label="loc_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:to="lab_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:type="arc" />
    <link:label id="lab_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87_terseLabel_en-US" xlink:label="lab_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate Agreements With Merck</link:label>
    <link:label id="lab_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87_label_en-US" xlink:label="lab_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Agreements With Merck [Member]</link:label>
    <link:label id="lab_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87_documentation_en-US" xlink:label="lab_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Separate Agreements With Merck [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_SeparateAgreementsWithMerckMember" xlink:label="loc_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:to="lab_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:type="arc" />
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PCV Agreement</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp And Dohme Corp [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp And Dohme Corp [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:type="arc" />
    <link:label id="lab_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7_terseLabel_en-US" xlink:label="lab_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PCV/SAV Agreement</link:label>
    <link:label id="lab_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7_label_en-US" xlink:label="lab_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PCVSAV Agreement [Member]</link:label>
    <link:label id="lab_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7_documentation_en-US" xlink:label="lab_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PCVSAV Agreement [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVSAVAgreementMember" xlink:label="loc_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:to="lab_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:type="arc" />
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PCV products</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personalized MRNA Cancer Vaccines Products [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personalized MRNA Cancer Vaccines Products [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:to="lab_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:to="lab_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series H Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E_label_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series H Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:to="lab_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:type="arc" />
    <link:label id="lab_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E_terseLabel_en-US" xlink:label="lab_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E_label_en-US" xlink:label="lab_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments [Member]</link:label>
    <link:label id="lab_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E_documentation_en-US" xlink:label="lab_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MilestonePaymentsMember" xlink:label="loc_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:to="lab_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:type="arc" />
    <link:label id="lab_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C_terseLabel_en-US" xlink:label="lab_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment, Research And Development</link:label>
    <link:label id="lab_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C_label_en-US" xlink:label="lab_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment, Research And Development [Member]</link:label>
    <link:label id="lab_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C_documentation_en-US" xlink:label="lab_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment, Research And Development [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentResearchAndDevelopmentMember" xlink:label="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:to="lab_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:type="arc" />
    <link:label id="lab_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211_terseLabel_en-US" xlink:label="lab_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Supply Reimbursement</link:label>
    <link:label id="lab_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211_label_en-US" xlink:label="lab_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Supply Reimbursement [Member]</link:label>
    <link:label id="lab_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211_documentation_en-US" xlink:label="lab_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Supply Reimbursement [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ClinicalSupplyReimbursementMember" xlink:label="loc_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:to="lab_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Performance Period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Performance Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Product Candidates</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Product Candidates</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total collaboration revenue (contra-revenue)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease to the transaction price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate net proceeds from the offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769_terseLabel_en-US" xlink:label="lab_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium recorded to deferred revenue</link:label>
    <link:label id="lab_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769_label_en-US" xlink:label="lab_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedemptionPremium" xlink:label="loc_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:to="lab_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:type="arc" />
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC_terseLabel_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC_label_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Property And Equipment, Current</link:label>
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC_documentation_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Property And Equipment, Current</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AccruedPropertyAndEquipmentCurrent" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC" xlink:to="lab_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation-related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A" xlink:type="arc" />
    <link:label id="lab_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A_terseLabel_en-US" xlink:label="lab_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External goods and services</link:label>
    <link:label id="lab_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A_label_en-US" xlink:label="lab_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued External Goods And Services, Current</link:label>
    <link:label id="lab_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A_documentation_en-US" xlink:label="lab_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued External Goods And Services, Current</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AccruedExternalGoodsAndServicesCurrent" xlink:label="loc_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A" xlink:to="lab_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881_verboseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Budgeted amount</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:type="arc" />
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE_terseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Revenue by Strategic Collaborator</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE_label_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:to="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:type="arc" />
    <link:label id="lab_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221_terseLabel_en-US" xlink:label="lab_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221_label_en-US" xlink:label="lab_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221_documentation_en-US" xlink:label="lab_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MerckMember" xlink:label="loc_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:to="lab_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:type="arc" />
    <link:label id="lab_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A_terseLabel_en-US" xlink:label="lab_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A_label_en-US" xlink:label="lab_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A_documentation_en-US" xlink:label="lab_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AstraZenecaMember" xlink:label="loc_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:to="lab_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:type="arc" />
    <link:label id="lab_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7_terseLabel_en-US" xlink:label="lab_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vertex</link:label>
    <link:label id="lab_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7_label_en-US" xlink:label="lab_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vertex [Member]</link:label>
    <link:label id="lab_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7_documentation_en-US" xlink:label="lab_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vertex [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VertexMember" xlink:label="loc_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:to="lab_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCustomerMember" xlink:label="loc_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:to="lab_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Total Consolidated Net Revenues from Strategic Collaborators</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Balances of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5097368C313CA6798269B968A1D103FA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5097368C313CA6798269B968A1D103FA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less amounts representing interest or imputed interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5097368C313CA6798269B968A1D103FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5097368C313CA6798269B968A1D103FA" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5097368C313CA6798269B968A1D103FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89" xlink:to="lab_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83815CC6CC3922DFCE25B968A1D8AEB1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83815CC6CC3922DFCE25B968A1D8AEB1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less amounts representing interest or imputed interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83815CC6CC3922DFCE25B968A1D8AEB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83815CC6CC3922DFCE25B968A1D8AEB1" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83815CC6CC3922DFCE25B968A1D8AEB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E" xlink:to="lab_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_43441758B7502120C52AB89404CC2940_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_43441758B7502120C52AB89404CC2940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43441758B7502120C52AB89404CC2940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43441758B7502120C52AB89404CC2940" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_43441758B7502120C52AB89404CC2940" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92" xlink:type="arc" />
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF_terseLabel_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF_label_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF_documentation_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF" xlink:to="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_B580FBED48D9DE4D4A49B8A04C1E8814_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_B580FBED48D9DE4D4A49B8A04C1E8814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B580FBED48D9DE4D4A49B8A04C1E8814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_B580FBED48D9DE4D4A49B8A04C1E8814" xlink:to="lab_us-gaap_IncomeStatementAbstract_B580FBED48D9DE4D4A49B8A04C1E8814" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97_label_en-US" xlink:label="lab_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:to="lab_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:type="arc" />
    <link:label id="lab_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368_terseLabel_en-US" xlink:label="lab_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue from related party</link:label>
    <link:label id="lab_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368_label_en-US" xlink:label="lab_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With Related Party [Member]</link:label>
    <link:label id="lab_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368_documentation_en-US" xlink:label="lab_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With Related Party [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborativeArrangementWithRelatedPartyMember" xlink:label="loc_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:to="lab_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="lab_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:to="lab_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC_label_en-US" xlink:label="lab_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:to="lab_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:to="lab_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:to="lab_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:to="lab_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:to="lab_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E" xlink:to="lab_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares used in net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:type="arc" />
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC_terseLabel_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted common stock units</link:label>
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC_label_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock And Restricted Stock Units (RSU) [Member]</link:label>
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC_documentation_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock And Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:to="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B" xlink:to="lab_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash and Available-for-Sale Securities by Significant Investment Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrealized Loss on Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF" xlink:type="arc" />
    <link:label id="lab_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02_terseLabel_en-US" xlink:label="lab_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant incentives receivables</link:label>
    <link:label id="lab_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02_label_en-US" xlink:label="lab_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Incentives Receivables, Current</link:label>
    <link:label id="lab_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02_documentation_en-US" xlink:label="lab_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tenant Incentives Receivables, Current</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TenantIncentivesReceivablesCurrent" xlink:label="loc_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02" xlink:to="lab_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable on marketable securities</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46" xlink:to="lab_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, operating, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, financing, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996" xlink:type="arc" />
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660" xlink:to="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financing lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1" xlink:type="arc" />
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750" xlink:type="arc" />
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseLiability" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_A58D8C63C49E22FB33AAB94C0249ED3B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_A58D8C63C49E22FB33AAB94C0249ED3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of Adoption of 842 on Condensed Financial Statements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_A58D8C63C49E22FB33AAB94C0249ED3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_A58D8C63C49E22FB33AAB94C0249ED3B" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_A58D8C63C49E22FB33AAB94C0249ED3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:to="lab_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:to="lab_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:type="arc" />
    <link:label id="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063_terseLabel_en-US" xlink:label="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities of U.S. government agencies and corporate entities</link:label>
    <link:label id="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063_label_en-US" xlink:label="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies And Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063_documentation_en-US" xlink:label="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US Government Agencies And Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:to="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8" xlink:type="arc" />
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F_terseLabel_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Marketable Securities</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F_label_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F_documentation_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CurrentMarketableSecuritiesMember" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:to="lab_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:type="arc" />
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2_terseLabel_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- Current Marketable Securities</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2_label_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2_documentation_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_NoncurrentMarketableSecuritiesMember" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:to="lab_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6" xlink:to="lab_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets, financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense for financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD" xlink:type="arc" />
    <link:label id="lab_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD_totalLabel_en-US" xlink:label="lab_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financing lease costs</link:label>
    <link:label id="lab_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD_label_en-US" xlink:label="lab_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD_documentation_en-US" xlink:label="lab_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FinanceLeaseCost" xlink:label="loc_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD" xlink:to="lab_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC" xlink:to="lab_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E" xlink:to="lab_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows used in financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023" xlink:type="arc" />
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143_terseLabel_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets reduced through lease modifications and reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143_label_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143_documentation_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:label="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143" xlink:to="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing cash flows provided by financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on available-for-sale debt securities, net of tax of $0 and $540, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: amounts recognized for net realized (gain) loss included in net loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:type="arc" />
    <link:label id="lab_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45_terseLabel_en-US" xlink:label="lab_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Combined 2018 AZ Agreements</link:label>
    <link:label id="lab_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45_label_en-US" xlink:label="lab_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Combined 2018 AZ Agreements [Member]</link:label>
    <link:label id="lab_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45_documentation_en-US" xlink:label="lab_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Combined 2018 AZ Agreements [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementsMember" xlink:label="loc_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:to="lab_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:type="arc" />
    <link:label id="lab_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981_terseLabel_en-US" xlink:label="lab_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 VEGF Exercise</link:label>
    <link:label id="lab_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981_label_en-US" xlink:label="lab_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VEGF Exercise 2016 [Member]</link:label>
    <link:label id="lab_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981_documentation_en-US" xlink:label="lab_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VEGF Exercise 2016 [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFExercise2016Member" xlink:label="loc_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:to="lab_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_88B43E945FBE371AA17AB8A04C6237C3_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_88B43E945FBE371AA17AB8A04C6237C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_88B43E945FBE371AA17AB8A04C6237C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_88B43E945FBE371AA17AB8A04C6237C3" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_88B43E945FBE371AA17AB8A04C6237C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:to="lab_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900B88DC5B499CA822A2B8A04C63D040_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900B88DC5B499CA822A2B8A04C63D040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900B88DC5B499CA822A2B8A04C63D040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900B88DC5B499CA822A2B8A04C63D040" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900B88DC5B499CA822A2B8A04C63D040" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B" xlink:to="lab_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA" xlink:to="lab_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4" xlink:type="arc" />
    <link:label id="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_83222DC9A44B7CEE58BDB8A04C642AB7_verboseLabel_en-US" xlink:label="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_83222DC9A44B7CEE58BDB8A04C642AB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_83222DC9A44B7CEE58BDB8A04C642AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_83222DC9A44B7CEE58BDB8A04C642AB7" xlink:to="lab_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_83222DC9A44B7CEE58BDB8A04C642AB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_21CDF5C7FD25D0BD1295B8A04C64DFE0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_21CDF5C7FD25D0BD1295B8A04C64DFE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21CDF5C7FD25D0BD1295B8A04C64DFE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_21CDF5C7FD25D0BD1295B8A04C64DFE0" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_21CDF5C7FD25D0BD1295B8A04C64DFE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD_label_en-US" xlink:label="lab_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD" xlink:to="lab_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D" xlink:to="lab_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_EA7945D047EB9386A5B5B8A04C6BA5AB_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_EA7945D047EB9386A5B5B8A04C6BA5AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_EA7945D047EB9386A5B5B8A04C6BA5AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_EA7945D047EB9386A5B5B8A04C6BA5AB" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_EA7945D047EB9386A5B5B8A04C6BA5AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386" xlink:to="lab_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_51C97D9597F1793A8BC0B8A448A1DC45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_51C97D9597F1793A8BC0B8A448A1DC45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease obligation, non-current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51C97D9597F1793A8BC0B8A448A1DC45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51C97D9597F1793A8BC0B8A448A1DC45" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_51C97D9597F1793A8BC0B8A448A1DC45" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_D39B5BF4275DA7B3DEDDB8A04C6C9247_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_D39B5BF4275DA7B3DEDDB8A04C6C9247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease liabilities, non-current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_D39B5BF4275DA7B3DEDDB8A04C6C9247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_D39B5BF4275DA7B3DEDDB8A04C6C9247" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_D39B5BF4275DA7B3DEDDB8A04C6C9247" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063_label_en-US" xlink:label="lab_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063" xlink:to="lab_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED" xlink:to="lab_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.0001; 162,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares issued or outstanding at March 31, 2020 and December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4" xlink:to="lab_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 370,102,805 and 336,536,985 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589" xlink:to="lab_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E" xlink:to="lab_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5EC1DFBFD09F0AD13D0CB8A04C6EDCE2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5EC1DFBFD09F0AD13D0CB8A04C6EDCE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5EC1DFBFD09F0AD13D0CB8A04C6EDCE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5EC1DFBFD09F0AD13D0CB8A04C6EDCE2" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5EC1DFBFD09F0AD13D0CB8A04C6EDCE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67" xlink:to="lab_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:to="lab_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:type="arc" />
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2" xlink:to="lab_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_BE5F06100CAEFD0DB65FB89404F6C6CD_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BE5F06100CAEFD0DB65FB89404F6C6CD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BE5F06100CAEFD0DB65FB89404F6C6CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_BE5F06100CAEFD0DB65FB89404F6C6CD" xlink:to="lab_us-gaap_StockholdersEquity_BE5F06100CAEFD0DB65FB89404F6C6CD" xlink:type="arc" />
    <link:label id="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835_terseLabel_en-US" xlink:label="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 AZ Agreements</link:label>
    <link:label id="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835_label_en-US" xlink:label="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2013 Option Agreement And Services And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835_documentation_en-US" xlink:label="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2013 Option Agreement And Services And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:label="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:to="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:type="arc" />
    <link:label id="lab_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F_terseLabel_en-US" xlink:label="lab_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Obligation [Axis]</link:label>
    <link:label id="lab_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F_label_en-US" xlink:label="lab_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Obligation [Axis]</link:label>
    <link:label id="lab_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F_documentation_en-US" xlink:label="lab_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Obligation [Axis]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationAxis" xlink:label="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:to="lab_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:type="arc" />
    <link:label id="lab_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79_terseLabel_en-US" xlink:label="lab_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Obligation [Domain]</link:label>
    <link:label id="lab_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79_label_en-US" xlink:label="lab_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Obligation [Domain]</link:label>
    <link:label id="lab_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79_documentation_en-US" xlink:label="lab_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Performance Obligation [Axis]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationDomain" xlink:label="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="lab_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:type="arc" />
    <link:label id="lab_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D_terseLabel_en-US" xlink:label="lab_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Combined 2018 AZ Agreement Performance Obligation</link:label>
    <link:label id="lab_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D_label_en-US" xlink:label="lab_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Combined 2018 AZ Agreement Performance Obligation [Member]</link:label>
    <link:label id="lab_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D_documentation_en-US" xlink:label="lab_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Combined 2018 AZ Agreement Performance Obligation [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementPerformanceObligationMember" xlink:label="loc_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:to="lab_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:type="arc" />
    <link:label id="lab_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C_terseLabel_en-US" xlink:label="lab_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IL12 Performance Obligation</link:label>
    <link:label id="lab_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C_label_en-US" xlink:label="lab_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IL12 Performance Obligation [Member]</link:label>
    <link:label id="lab_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C_documentation_en-US" xlink:label="lab_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IL12 Performance Obligation [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IL12PerformanceObligationMember" xlink:label="loc_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:to="lab_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:type="arc" />
    <link:label id="lab_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10_terseLabel_en-US" xlink:label="lab_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oncology Development Target Performance Obligation</link:label>
    <link:label id="lab_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10_label_en-US" xlink:label="lab_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology Development Target Performance Obligation [Member]</link:label>
    <link:label id="lab_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10_documentation_en-US" xlink:label="lab_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oncology Development Target Performance Obligation [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OncologyDevelopmentTargetPerformanceObligationMember" xlink:label="loc_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:to="lab_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:type="arc" />
    <link:label id="lab_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887_terseLabel_en-US" xlink:label="lab_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development And Commercialization License And Manufacturing Obligations For IL12</link:label>
    <link:label id="lab_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887_label_en-US" xlink:label="lab_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Commercialization License And Manufacturing Obligations For IL12 [Member]</link:label>
    <link:label id="lab_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887_documentation_en-US" xlink:label="lab_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Commercialization License And Manufacturing Obligations For IL12 [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member" xlink:label="loc_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:to="lab_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:type="arc" />
    <link:label id="lab_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF_terseLabel_en-US" xlink:label="lab_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target</link:label>
    <link:label id="lab_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF_label_en-US" xlink:label="lab_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target [Member]</link:label>
    <link:label id="lab_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF_documentation_en-US" xlink:label="lab_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember" xlink:label="loc_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:to="lab_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:type="arc" />
    <link:label id="lab_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D_terseLabel_en-US" xlink:label="lab_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PCV Performance Obligation</link:label>
    <link:label id="lab_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D_label_en-US" xlink:label="lab_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PCV Performance Obligation [Member]</link:label>
    <link:label id="lab_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D_documentation_en-US" xlink:label="lab_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PCV Performance Obligation [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVPerformanceObligationMember" xlink:label="loc_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:to="lab_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:type="arc" />
    <link:label id="lab_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484_terseLabel_en-US" xlink:label="lab_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KRAS Performance Obligation</link:label>
    <link:label id="lab_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484_label_en-US" xlink:label="lab_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KRAS Performance Obligation [Member]</link:label>
    <link:label id="lab_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484_documentation_en-US" xlink:label="lab_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KRAS Performance Obligation [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_KRASPerformanceObligationMember" xlink:label="loc_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:to="lab_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:type="arc" />
    <link:label id="lab_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D_terseLabel_en-US" xlink:label="lab_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Payments</link:label>
    <link:label id="lab_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D_label_en-US" xlink:label="lab_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Payments [Member]</link:label>
    <link:label id="lab_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D_documentation_en-US" xlink:label="lab_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Payments [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FixedPaymentsMember" xlink:label="loc_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:to="lab_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:type="arc" />
    <link:label id="lab_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9_terseLabel_en-US" xlink:label="lab_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Exercise Fee</link:label>
    <link:label id="lab_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9_label_en-US" xlink:label="lab_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercise Fee [Member]</link:label>
    <link:label id="lab_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9_documentation_en-US" xlink:label="lab_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Exercise Fee [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OptionExerciseFeeMember" xlink:label="loc_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:to="lab_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:type="arc" />
    <link:label id="lab_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB_terseLabel_en-US" xlink:label="lab_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Consideration</link:label>
    <link:label id="lab_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB_label_en-US" xlink:label="lab_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Consideration [Member]</link:label>
    <link:label id="lab_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB_documentation_en-US" xlink:label="lab_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Consideration [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VariableConsiderationMember" xlink:label="loc_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:to="lab_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:type="arc" />
    <link:label id="lab_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB_terseLabel_en-US" xlink:label="lab_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Reimbursement</link:label>
    <link:label id="lab_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB_label_en-US" xlink:label="lab_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Reimbursement [Member]</link:label>
    <link:label id="lab_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB_documentation_en-US" xlink:label="lab_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Reimbursement [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_EstimatedReimbursementMember" xlink:label="loc_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:to="lab_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:type="arc" />
    <link:label id="lab_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA_terseLabel_en-US" xlink:label="lab_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublicense Reimbursement</link:label>
    <link:label id="lab_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA_label_en-US" xlink:label="lab_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublicense Reimbursement [Member]</link:label>
    <link:label id="lab_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA_documentation_en-US" xlink:label="lab_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublicense Reimbursement [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_SublicenseReimbursementMember" xlink:label="loc_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:to="lab_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:type="arc" />
    <link:label id="lab_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6_terseLabel_en-US" xlink:label="lab_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock</link:label>
    <link:label id="lab_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6_label_en-US" xlink:label="lab_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock [Member]</link:label>
    <link:label id="lab_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6_documentation_en-US" xlink:label="lab_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember" xlink:label="loc_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:to="lab_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:type="arc" />
    <link:label id="lab_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0_terseLabel_en-US" xlink:label="lab_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toxicity Milestone</link:label>
    <link:label id="lab_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0_label_en-US" xlink:label="lab_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toxicity Milestones [Member]</link:label>
    <link:label id="lab_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0_documentation_en-US" xlink:label="lab_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toxicity Milestones [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ToxicityMilestonesMember" xlink:label="loc_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:to="lab_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:type="arc" />
    <link:label id="lab_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178_terseLabel_en-US" xlink:label="lab_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Competition Milestone</link:label>
    <link:label id="lab_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178_label_en-US" xlink:label="lab_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Competition Milestones [Member]</link:label>
    <link:label id="lab_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178_documentation_en-US" xlink:label="lab_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Competition Milestones [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CompetitionMilestonesMember" xlink:label="loc_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:to="lab_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF_label_en-US" xlink:label="lab_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:to="lab_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:type="arc" />
    <link:label id="lab_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62_terseLabel_en-US" xlink:label="lab_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Equity Offering</link:label>
    <link:label id="lab_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62_label_en-US" xlink:label="lab_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Equity Offering [Member]</link:label>
    <link:label id="lab_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62_documentation_en-US" xlink:label="lab_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Equity Offering [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PublicEquityOfferingMember" xlink:label="loc_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:to="lab_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:to="lab_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:to="lab_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:type="arc" />
    <link:label id="lab_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6_terseLabel_en-US" xlink:label="lab_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting discounts</link:label>
    <link:label id="lab_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6_label_en-US" xlink:label="lab_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Of Underwriting Discounts</link:label>
    <link:label id="lab_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6_documentation_en-US" xlink:label="lab_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Of Underwriting Discounts</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PaymentsOfUnderwritingDiscounts" xlink:label="loc_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:to="lab_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock converted into common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses, Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value, Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses, 12 months or more</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value, 12 months or more</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses, Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value, Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Basis of Presentation and Recent Accounting Standards</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7" xlink:type="arc" />
    <link:label id="lab_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678_terseLabel_en-US" xlink:label="lab_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 AZ Agreement</link:label>
    <link:label id="lab_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678_label_en-US" xlink:label="lab_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Strategic Alliance With AstraZeneca &#8211; IL12 [Member]</link:label>
    <link:label id="lab_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678_documentation_en-US" xlink:label="lab_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Strategic Alliance With AstraZeneca &#8211; IL12 [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" xlink:label="loc_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:to="lab_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:type="arc" />
    <link:label id="lab_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835_terseLabel_en-US" xlink:label="lab_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 AZ Agreement</link:label>
    <link:label id="lab_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835_label_en-US" xlink:label="lab_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Strategic Alliance With AstraZeneca &#8211; Relaxin [Member]</link:label>
    <link:label id="lab_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835_documentation_en-US" xlink:label="lab_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Strategic Alliance With AstraZeneca &#8211; Relaxin [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" xlink:label="loc_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:to="lab_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:type="arc" />
    <link:label id="lab_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33_terseLabel_en-US" xlink:label="lab_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 A&amp;R Agreements</link:label>
    <link:label id="lab_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33_label_en-US" xlink:label="lab_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended And Restated Option Agreement Related Amended And Restated Services And Collaboration Agreement With AstraZeneca [Member]</link:label>
    <link:label id="lab_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33_documentation_en-US" xlink:label="lab_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended And Restated Option Agreement Related Amended And Restated Services And Collaboration Agreement With AstraZeneca [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember" xlink:label="loc_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:to="lab_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B_label_en-US" xlink:label="lab_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:to="lab_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:type="arc" />
    <link:label id="lab_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F_terseLabel_en-US" xlink:label="lab_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestones</link:label>
    <link:label id="lab_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F_label_en-US" xlink:label="lab_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F_documentation_en-US" xlink:label="lab_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CommercialMilestonesMember" xlink:label="loc_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:to="lab_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:type="arc" />
    <link:label id="lab_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A_terseLabel_en-US" xlink:label="lab_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VEGF-A product (AZD8601)</link:label>
    <link:label id="lab_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A_label_en-US" xlink:label="lab_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VEGF-A Product (AZD8601) [Member]</link:label>
    <link:label id="lab_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A_documentation_en-US" xlink:label="lab_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VEGF-A Product (AZD8601) [Member]</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFAProductAZD8601Member" xlink:label="loc_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:to="lab_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Options</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Options</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earn-out payments</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tiered royalties at default rate</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tiered royalties</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:type="arc" />
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Suspension period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65" xlink:to="lab_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:to="lab_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:to="lab_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:to="lab_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31" xlink:to="lab_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs of $1,108 (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs of $1,108</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options to purchase common stock, net (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options to purchase common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition adjustment from adoption of ASU</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_C9215667C7081FE40572B8A04BF44C54_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_C9215667C7081FE40572B8A04BF44C54" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_C9215667C7081FE40572B8A04BF44C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_C9215667C7081FE40572B8A04BF44C54" xlink:to="lab_us-gaap_SharesOutstanding_C9215667C7081FE40572B8A04BF44C54" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326_label_en-US" xlink:label="lab_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:to="lab_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:type="arc" />
    <link:label id="lab_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9_label_en-US" xlink:label="lab_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:to="lab_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:type="arc" />
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:to="lab_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:to="lab_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E" xlink:to="lab_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6" xlink:type="arc" />
    <link:label id="lab_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C_terseLabel_en-US" xlink:label="lab_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred lease obligation</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C_label_en-US" xlink:label="lab_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Deferred Rent Credit</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C_documentation_en-US" xlink:label="lab_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Deferred Rent Credit</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IncreaseDecreaseInDeferredRentCredit" xlink:label="loc_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:to="lab_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC" xlink:type="arc" />
    <link:label id="lab_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809_negatedTerseLabel_en-US" xlink:label="lab_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on financing lease obligation</link:label>
    <link:label id="lab_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809_label_en-US" xlink:label="lab_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Lease Financing Obligation</link:label>
    <link:label id="lab_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809_documentation_en-US" xlink:label="lab_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Lease Financing Obligation</link:label>
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PaymentsForLeaseFinancingObligation" xlink:label="loc_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:to="lab_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_DA04326C619CB2F63F1FB894047A24C6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_DA04326C619CB2F63F1FB894047A24C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_DA04326C619CB2F63F1FB894047A24C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_DA04326C619CB2F63F1FB894047A24C6" xlink:to="lab_us-gaap_RestrictedCashCurrent_DA04326C619CB2F63F1FB894047A24C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865E140DF5AC3165E94EB894047BE662_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865E140DF5AC3165E94EB894047BE662" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865E140DF5AC3165E94EB894047BE662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865E140DF5AC3165E94EB894047BE662" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865E140DF5AC3165E94EB894047BE662" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_E2A06BB3FC4CA195C5D4B89403DB9D39_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_E2A06BB3FC4CA195C5D4B89403DB9D39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_E2A06BB3FC4CA195C5D4B89403DB9D39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_E2A06BB3FC4CA195C5D4B89403DB9D39" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_E2A06BB3FC4CA195C5D4B89403DB9D39" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD" xlink:to="lab_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3" xlink:to="lab_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769_label_en-US" xlink:label="lab_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="lab_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807_terseLabel_en-US" xlink:label="lab_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807_label_en-US" xlink:label="lab_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807" xlink:to="lab_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB" xlink:to="lab_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4" xlink:to="lab_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421" xlink:to="lab_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB_label_en-US" xlink:label="lab_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB" xlink:to="lab_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F_label_en-US" xlink:label="lab_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F" xlink:to="lab_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F" xlink:to="lab_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74" xlink:to="lab_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F" xlink:to="lab_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06" xlink:to="lab_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F" xlink:to="lab_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E" xlink:to="lab_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE_label_en-US" xlink:label="lab_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE" xlink:to="lab_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02" xlink:to="lab_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D_label_en-US" xlink:label="lab_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D" xlink:to="lab_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B_label_en-US" xlink:label="lab_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B" xlink:to="lab_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059_label_en-US" xlink:label="lab_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059" xlink:to="lab_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E" xlink:to="lab_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99" xlink:to="lab_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8_label_en-US" xlink:label="lab_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8" xlink:to="lab_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3" xlink:to="lab_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758" xlink:to="lab_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C_label_en-US" xlink:label="lab_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C" xlink:to="lab_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555_label_en-US" xlink:label="lab_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555" xlink:to="lab_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28" xlink:to="lab_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC" xlink:to="lab_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF" xlink:to="lab_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF" xlink:to="lab_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>mrna-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponents" xlink:href="mrna-20200331.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/BalanceSheetComponentsTables" xlink:href="mrna-20200331.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreements" xlink:href="mrna-20200331.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsTables" xlink:href="mrna-20200331.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsTimingOfSatisfactionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:href="mrna-20200331.xsd#CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingencies" xlink:href="mrna-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:href="mrna-20200331.xsd#CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:href="mrna-20200331.xsd#CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="mrna-20200331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="mrna-20200331.xsd#CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:href="mrna-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionOfBusiness" xlink:href="mrna-20200331.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails" xlink:href="mrna-20200331.xsd#DescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstruments" xlink:href="mrna-20200331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:href="mrna-20200331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails" xlink:href="mrna-20200331.xsd#FinancialInstrumentsUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/Grants" xlink:href="mrna-20200331.xsd#Grants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantsDetails" xlink:href="mrna-20200331.xsd#GrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:href="mrna-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:href="mrna-20200331.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:href="mrna-20200331.xsd#LeasesBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesDetails" xlink:href="mrna-20200331.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:href="mrna-20200331.xsd#LeasesLeaseCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:href="mrna-20200331.xsd#LeasesMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:href="mrna-20200331.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShare" xlink:href="mrna-20200331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="mrna-20200331.xsd#NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="mrna-20200331.xsd#NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/NetLossPerShareTables" xlink:href="mrna-20200331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/ShareholdersEquity" xlink:href="mrna-20200331.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/ShareholdersEquityDetails" xlink:href="mrna-20200331.xsd#ShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensation" xlink:href="mrna-20200331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationOptionsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:href="mrna-20200331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:href="mrna-20200331.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEvents" xlink:href="mrna-20200331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:href="mrna-20200331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:href="mrna-20200331.xsd#SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0163DB59B4342644FA1DB89403D0E112" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0163DB59B4342644FA1DB89403D0E112" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3A99ACD9EBAE8D38828DB89403D031B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61802CDE92F7C9BCA3B4B8D1EFFF4F13" xlink:type="locator" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AccruedPropertyAndEquipmentCurrent" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61802CDE92F7C9BCA3B4B8D1EFFF4F13" xlink:to="loc_mrna_AccruedPropertyAndEquipmentCurrent_5D7946AA1E6B8B43D1DBB8D1F0007DEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61802CDE92F7C9BCA3B4B8D1EFFF4F13" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C8E9EDF1A9A19EA75DECB8D1F000C01A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AccruedExternalGoodsAndServicesCurrent" xlink:label="loc_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61802CDE92F7C9BCA3B4B8D1EFFF4F13" xlink:to="loc_mrna_AccruedExternalGoodsAndServicesCurrent_F49320D9E22311A5B86DB8D1F001C81A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61802CDE92F7C9BCA3B4B8D1EFFF4F13" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6CE49F73E94C5356AB3BB8D1F00179CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0CAC66AF56FFA1A4B267B89405264FF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0CAC66AF56FFA1A4B267B89405264FF8" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1C2ADDBC65F5C3985C6AB89405262ACF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TenantIncentivesReceivablesCurrent" xlink:label="loc_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0CAC66AF56FFA1A4B267B89405264FF8" xlink:to="loc_mrna_TenantIncentivesReceivablesCurrent_51EA8A62F4387C8A11F6B89405261B02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0CAC66AF56FFA1A4B267B89405264FF8" xlink:to="loc_us-gaap_InterestReceivableCurrent_3928387028C7E4C0F175B8940526FD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0CAC66AF56FFA1A4B267B89405264FF8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_BF4D8EB2803AAB3D9B45B8940527A01D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8B4E8001E8F587CCB0D8B8D1EFF1FE3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8B4E8001E8F587CCB0D8B8D1EFF1FE3F" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BB58205945ABF6B83A1BB8D1EFF39BDB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_EquipmentMember_D63F45AD1F6ABC9917B2B8D1EFF40779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_A0F15B5A321C93965FF2B8D1EFF4D6B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_D6A759189F39CA80C6A7B8D1EFF452DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_ComputerEquipmentMember_8FA1D7968EAA4144C084B8D1EFF46FA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_AA670C806FEA24FFA913B8D1EFF4ED8C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RightOfUseAssetFinancingMember" xlink:label="loc_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_mrna_RightOfUseAssetFinancingMember_01C8BCE3277CB309E5C3B8D315FE181B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C7B6CF0F84869C8BB34DB8D1EFF3F5AE" xlink:to="loc_us-gaap_ConstructionInProgressMember_5F717FA2B80DB6ADA7F5B8D1EFF506F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E392A53BE1385CAF0067B8D1EFF22D5E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization" xlink:label="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization_A5393ECEE44C57CF03F9B8D1EFF54824" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization" xlink:label="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization_565BFD208A06B0F7ED35B8D1EFF59F63" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0E829DB6BB99CC72BD86B8D1EFF6D70A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_B0C402D3D45FB81DEE95B8D1EFF50AF9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2F8A703C0C06EE30CF1EB8D1EFF6E4BD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FCADC1B4082C8DA47F46B89404078136" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FCADC1B4082C8DA47F46B89404078136" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_17FA94B42D3A4F0D7611B8940407989C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FCADC1B4082C8DA47F46B89404078136" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9E827FE7B45E29EC8C97B894040856B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FCADC1B4082C8DA47F46B89404078136" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0C1EB6C5EE4BD22407BBB8940408F367" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_BAC63ADA6496D13704B4B894047DA4B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_BAC63ADA6496D13704B4B894047DA4B2" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_E64446E45724B29E2558B894047EC7CF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_152E470CC432F2D5C738B8EC0D77D7A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_152E470CC432F2D5C738B8EC0D77D7A5" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_760C125C40AC19992FC0B8EC0D7825F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_760C125C40AC19992FC0B8EC0D7825F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_D74D1274643594315CE7B8EC0D782664" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_760C125C40AC19992FC0B8EC0D7825F5" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_D74D1274643594315CE7B8EC0D782664" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VariableConsiderationMember" xlink:label="loc_mrna_VariableConsiderationMember_00B604227A1994739674B8EC0D79B695" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_D74D1274643594315CE7B8EC0D782664" xlink:to="loc_mrna_VariableConsiderationMember_00B604227A1994739674B8EC0D79B695" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationAxis" xlink:label="loc_mrna_PerformanceObligationAxis_710DB90A91DFD02D8C8DB8EC0D79C469" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_mrna_PerformanceObligationAxis_710DB90A91DFD02D8C8DB8EC0D79C469" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationDomain" xlink:label="loc_mrna_PerformanceObligationDomain_B32C3D52F57254669CAAB8EC0D7AD06F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationAxis_710DB90A91DFD02D8C8DB8EC0D79C469" xlink:to="loc_mrna_PerformanceObligationDomain_B32C3D52F57254669CAAB8EC0D7AD06F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IL12PerformanceObligationMember" xlink:label="loc_mrna_IL12PerformanceObligationMember_CEA839887181CEA82172B8EC0D7AAE11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationDomain_B32C3D52F57254669CAAB8EC0D7AD06F" xlink:to="loc_mrna_IL12PerformanceObligationMember_CEA839887181CEA82172B8EC0D7AAE11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0FC5A142D4C058484B5FB8EC0D7A40E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0FC5A142D4C058484B5FB8EC0D7A40E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0FC5A142D4C058484B5FB8EC0D7A40E1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:label="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_568DD69F141F7E53FBDFB8EC0D7B6DD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_568DD69F141F7E53FBDFB8EC0D7B6DD5" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2016StrategicAllianceWithAstraZenecaIL12Member" xlink:label="loc_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member_EC46119BE19065A69935B8EC0D7B7678" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember" xlink:label="loc_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember_B449D943FE78756CEB9DB8EC0D7BD835" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember" xlink:label="loc_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember_FC77D7A747D08DADD73DB8EC0D7CCF33" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementsMember" xlink:label="loc_mrna_Combined2018AZAgreementsMember_E95185B5489E577DD1A7B8EC0D7C50BC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_Combined2018AZAgreementsMember_E95185B5489E577DD1A7B8EC0D7C50BC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFExercise2016Member" xlink:label="loc_mrna_VEGFExercise2016Member_FE0BE716431DE63F23F9B8EC0D7C9DE4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_C5F7478949D86FC1236AB8EC0D7A15B9" xlink:to="loc_mrna_VEGFExercise2016Member_FE0BE716431DE63F23F9B8EC0D7C9DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_162A429E0F3557EA1911B8EC0D7C5CDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_srt_RangeAxis_162A429E0F3557EA1911B8EC0D7C5CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_162A429E0F3557EA1911B8EC0D7C5CDA" xlink:to="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9FF704B313201E9EE49BB8EC0D7D9353" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558" xlink:to="loc_srt_MaximumMember_9FF704B313201E9EE49BB8EC0D7D9353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B83DB0B0BA9D0FF241B1B8EC0D7C7558" xlink:to="loc_srt_MinimumMember_B1DB472A1148620E0F38B8EC0D7D916B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_CDA4D068E13C2E724C3CB8EC0D7D8911" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_CDA4D068E13C2E724C3CB8EC0D7D8911" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_CDA4D068E13C2E724C3CB8EC0D7D8911" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentMilestonesMember" xlink:label="loc_mrna_DevelopmentMilestonesMember_4884D545638DBA08F5F1B8EC0D7E5335" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_DevelopmentMilestonesMember_4884D545638DBA08F5F1B8EC0D7E5335" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RegulatoryMilestonesMember" xlink:label="loc_mrna_RegulatoryMilestonesMember_657207A1D2C439FF8FAEB8EC0D7E3ADC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_RegulatoryMilestonesMember_657207A1D2C439FF8FAEB8EC0D7E3ADC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CommercialMilestonesMember" xlink:label="loc_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_CommercialMilestonesMember_002B9C3F16745B1E4914B8EC0D7E920F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ToxicityMilestonesMember" xlink:label="loc_mrna_ToxicityMilestonesMember_30A730F1AC8122883E1DB8EC0D7E7FCF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_ToxicityMilestonesMember_30A730F1AC8122883E1DB8EC0D7E7FCF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CompetitionMilestonesMember" xlink:label="loc_mrna_CompetitionMilestonesMember_DC2403528053AE1112D9B8EC0D8456CB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_C4AC1F5C69BB31CB22A2B8EC0D7DC034" xlink:to="loc_mrna_CompetitionMilestonesMember_DC2403528053AE1112D9B8EC0D8456CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D0B275916055BFB36C19B8EC0D846258" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D0B275916055BFB36C19B8EC0D846258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_3986DE57BAD0DB843A2DB8EC0D8495FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D0B275916055BFB36C19B8EC0D846258" xlink:to="loc_us-gaap_ProjectMember_3986DE57BAD0DB843A2DB8EC0D8495FF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFAProductAZD8601Member" xlink:label="loc_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_3986DE57BAD0DB843A2DB8EC0D8495FF" xlink:to="loc_mrna_VEGFAProductAZD8601Member_B27E12B10890BC0339C6B8EC0D854F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BA3E248508B3D327CC8FB8EC0D85372B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_srt_ProductOrServiceAxis_BA3E248508B3D327CC8FB8EC0D85372B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D81AEE71E2051EB0273EB8EC0D85A8FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_BA3E248508B3D327CC8FB8EC0D85372B" xlink:to="loc_srt_ProductsAndServicesDomain_D81AEE71E2051EB0273EB8EC0D85A8FE" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_8BE83270D44CF78351E8B8EC0D853B02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D81AEE71E2051EB0273EB8EC0D85A8FE" xlink:to="loc_mrna_CollaborationArrangementMember_8BE83270D44CF78351E8B8EC0D853B02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_CD97A8090611056B10E3B8EC0D780F5E" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions_52470741E4FBD7E49CEFB8EC0D866B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_A1243C6286C60755E840B8EC0D863B44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_DeferredRevenueAdditions_A1243C6286C60755E840B8EC0D863B44" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_7483B294CBA5FC40908FB8EC0D874449" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_7483B294CBA5FC40908FB8EC0D874449" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones_AAFC329CC5D8FF96C884B8EC0D87161D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee_EEB8060122769E450A65B8EC0D87B8E9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_6A45DD77E48CD3CF5AE9B8EC0D87C2C7" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_885D428574D1C93BDB0FB8EC0D87D9EA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_885D428574D1C93BDB0FB8EC0D87D9EA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent_98BC412F90E7ADABA0E6B8EC0D88AC35" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent_A75AEA483AA109B02E06B8EC0D88AEDA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod_0260A1B05B2B02733710B8EC0D88465E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7BD6CCE9D6138AC49EBDB8EC0D881754" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7BD6CCE9D6138AC49EBDB8EC0D881754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_A7B80BFA7D77B2F30A27B8EC0D89B09D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_A7B80BFA7D77B2F30A27B8EC0D89B09D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94B919FDEC32D0E1AC8FB8EC0D894785" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94B919FDEC32D0E1AC8FB8EC0D894785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6AF9B4407ED70D44CC32B8EC0D89E000" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6AF9B4407ED70D44CC32B8EC0D89E000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8E786D222F793DCA2783B8EC0D86BA6A" xlink:to="loc_us-gaap_Revenues_83305747B27DF7617D01B8EC0D894B65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_CF099195F7881143EB58B8EC0DD27B74" xlink:type="locator" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChangeInContractwithCustomerAssetRollForward" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_CF099195F7881143EB58B8EC0DD27B74" xlink:to="loc_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_86268EEE81F895DEDD51B8EC0DD3477E" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractWithCustomerAssetIncreaseDuringPeriod" xlink:label="loc_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:to="loc_mrna_ContractWithCustomerAssetIncreaseDuringPeriod_649571A786BD12EDE007B8EC0DD3DAA3" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractWithCustomerAssetDecreaseDuringPeriod" xlink:label="loc_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:to="loc_mrna_ContractWithCustomerAssetDecreaseDuringPeriod_093E0D883F20587BFE93B8EC0DD3B90B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_890E047A861E2DF24F30B8EC0DD983CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_525466362C9DC970DDFCB8EC0DD241B1" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_890E047A861E2DF24F30B8EC0DD983CF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_CF099195F7881143EB58B8EC0DD27B74" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0A7C74C6061BE2D2D26EB8EC0DD92617" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0A7C74C6061BE2D2D26EB8EC0DD92617" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod" xlink:label="loc_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:to="loc_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod_F8214CAD7438DEF2B7ADB8EC0DDA9CE7" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod" xlink:label="loc_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:to="loc_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod_7B272BE0E2878B9010DBB8EC0DDABB45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_AD7221496341E4A0AF9BB8EC0DDADA4D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_A3C5E0853C46EC674644B8EC0DD9ACCF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_AD7221496341E4A0AF9BB8EC0DDADA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8B6BA7E717E984E4A017B8EC0DDA6D7C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_CF099195F7881143EB58B8EC0DD27B74" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8B6BA7E717E984E4A017B8EC0DDA6D7C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_5261B550BCE94807E100EF95F6F5A1BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_5261B550BCE94807E100EF95F6F5A1BB" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_DF6B8C4EAC89D3460D03EF95F6F6C327" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_DF6B8C4EAC89D3460D03EF95F6F6C327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_DF6B8C4EAC89D3460D03EF95F6F6C327" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MerckAgreement2015Member" xlink:label="loc_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:to="loc_mrna_MerckAgreement2015Member_3314878B1E98965C88F6EF95F6F7CD72" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_SeparateAgreementsWithMerckMember" xlink:label="loc_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:to="loc_mrna_SeparateAgreementsWithMerckMember_5350715B45E507696B94EF95F6F70B87" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_0FC698218153D89A0916EF95F6F7EC1A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVSAVAgreementMember" xlink:label="loc_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_AF700CC35C5EC11A543DEF95F6F6010B" xlink:to="loc_mrna_PCVSAVAgreementMember_35D8143B83518DCA0FBAEF95F6F7F3F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C741EBDF13B707FE1A16EF95F6F75806" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_srt_ProductOrServiceAxis_C741EBDF13B707FE1A16EF95F6F75806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3B69CD4612E8F52A8300EF95F6F8B2B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_C741EBDF13B707FE1A16EF95F6F75806" xlink:to="loc_srt_ProductsAndServicesDomain_3B69CD4612E8F52A8300EF95F6F8B2B5" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_81BC3F3912C693904CC5EF95F6F88374" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3B69CD4612E8F52A8300EF95F6F8B2B5" xlink:to="loc_mrna_CollaborationArrangementMember_81BC3F3912C693904CC5EF95F6F88374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_A88EE8CAD192E63E9048EF95F6F8FD46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_A88EE8CAD192E63E9048EF95F6F8FD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_7796F7611B62B2DD0602EF95F6F88597" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_A88EE8CAD192E63E9048EF95F6F8FD46" xlink:to="loc_us-gaap_ProjectMember_7796F7611B62B2DD0602EF95F6F88597" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_7796F7611B62B2DD0602EF95F6F88597" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5E843C1A7C51E785A074EF95F6F92CB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19A76D29455B908E7EE8EF95F6F98810" xlink:to="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B77F630C4D1BE01BA688EF95F6F9D3BA" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_1814D763180DD3BB7CE8EF95F6F9176E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_8C1000571A4CA8063069EF95F6FA140C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_8C1000571A4CA8063069EF95F6FA140C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_8C1000571A4CA8063069EF95F6FA140C" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MilestonePaymentsMember" xlink:label="loc_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:to="loc_mrna_MilestonePaymentsMember_CB2A15A0BB8232CC632BEF95F6FA108E" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentMember" xlink:label="loc_mrna_UpfrontPaymentMember_582F923B87117FD97ACBEF95F6FBEC70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:to="loc_mrna_UpfrontPaymentMember_582F923B87117FD97ACBEF95F6FBEC70" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentResearchAndDevelopmentMember" xlink:label="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:to="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_003D2E500ADFFFC9337BEF95F6FB7C8C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ClinicalSupplyReimbursementMember" xlink:label="loc_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_66CB2E701DD00699A37AEF95F6FA14B4" xlink:to="loc_mrna_ClinicalSupplyReimbursementMember_E2091523A96B3A68D670EF95F6FB8211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_22C630815B2A94CFD81BEF95F6F66B5C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod_8B894BF57E77F6BAD22EEF95F6FB8D69" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_26A8D98CD4F0AC96570AEF95F6FC51FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_26A8D98CD4F0AC96570AEF95F6FC51FC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates_346A2FF48A158D76568DEF95F6FCFCFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_EBBC03FD1EE2024FD655EF95F6FD8E3C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_7BE0EA6BC62120901400EF95F6FD2A5A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_7BE0EA6BC62120901400EF95F6FD2A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_BFD50CB69172FC9E2204EF95F6FD7877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5187D7F881D56670C636EF95F6FDC670" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5187D7F881D56670C636EF95F6FDC670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_747BC77F82D6A90A138CEF95F6FDD533" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_DeferredRevenueAdditions_747BC77F82D6A90A138CEF95F6FDD533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_BD6E55017A92B3B00A97EF95F6FEB9EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5670C1115B4C31CAFD88EF95F6FE5F6A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5670C1115B4C31CAFD88EF95F6FE5F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_009CCF087DED6ACE466DEF95F6FE9DF1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_009CCF087DED6ACE466DEF95F6FE9DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5D60EC4629B6BDD28AD8EF95F6FE8C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedemptionPremium" xlink:label="loc_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_FB72B28DC6180950CF81EF95F6FBBA6F" xlink:to="loc_us-gaap_RedemptionPremium_B58D7D4B7AFAF093F7E5EF95F6FE0769" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_7F1A1E0E2BD6B9303A6FC3813ADB21E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7F1A1E0E2BD6B9303A6FC3813ADB21E7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_477C9C147F4F526079AEC3813ADCC662" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_477C9C147F4F526079AEC3813ADCC662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_477C9C147F4F526079AEC3813ADCC662" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVSAVAgreementMember" xlink:label="loc_mrna_PCVSAVAgreementMember_4E96DC11A6583AFE24EDC3813ADC9AA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_PCVSAVAgreementMember_4E96DC11A6583AFE24EDC3813ADC9AA8" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MerckAgreement2015Member" xlink:label="loc_mrna_MerckAgreement2015Member_E0B8E6F8EAF9B02A0F5DC3813ADD903C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_MerckAgreement2015Member_E0B8E6F8EAF9B02A0F5DC3813ADD903C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFExercise2016Member" xlink:label="loc_mrna_VEGFExercise2016Member_9AA97EB70C07D061738DC3813ADD74DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_VEGFExercise2016Member_9AA97EB70C07D061738DC3813ADD74DE" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:label="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_EECA2FE71EA61AD97586C3813ADD3835" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementsMember" xlink:label="loc_mrna_Combined2018AZAgreementsMember_AB6072EDF3C7980EAF4BC3813ADDD97D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_Combined2018AZAgreementsMember_AB6072EDF3C7980EAF4BC3813ADDD97D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" xlink:label="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_3F2CDFF0D1CF27C99A89C3813ADD9689" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2990F1A900DCBAEC7CA8C3813ADC4508" xlink:to="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_3F2CDFF0D1CF27C99A89C3813ADD9689" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationAxis" xlink:label="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PerformanceObligationDomain" xlink:label="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationAxis_FB3864163D378E7D8552C3813ADDA94F" xlink:to="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementPerformanceObligationMember" xlink:label="loc_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_Combined2018AZAgreementPerformanceObligationMember_CAA69D40E4C089817A85C3813ADE429D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IL12PerformanceObligationMember" xlink:label="loc_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_IL12PerformanceObligationMember_B10411A5A433E2933ACDC3813ADE4F8C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OncologyDevelopmentTargetPerformanceObligationMember" xlink:label="loc_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_OncologyDevelopmentTargetPerformanceObligationMember_167753E750F7A50D6BD8C3813AE39D10" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member" xlink:label="loc_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_42144E0AAF1DD2E57ECEC3813AE30887" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember" xlink:label="loc_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_D45177066A02765425F8C3813AE4D5FF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVPerformanceObligationMember" xlink:label="loc_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_PCVPerformanceObligationMember_1F642AFFD1BE41D88B63C3813AE4432D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_KRASPerformanceObligationMember" xlink:label="loc_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_PerformanceObligationDomain_4104F13D2F88F5006487C3813ADEEB79" xlink:to="loc_mrna_KRASPerformanceObligationMember_0DADD9AF5352CFCB5B87C3813AE49484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_78E35BD438924F3C7A16C3813AE40408" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_78E35BD438924F3C7A16C3813AE40408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_78E35BD438924F3C7A16C3813AE40408" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FixedPaymentsMember" xlink:label="loc_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_FixedPaymentsMember_6A2FBC69F7EDEB4D6670C3813AE53B0D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OptionExerciseFeeMember" xlink:label="loc_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_OptionExerciseFeeMember_994EFBFA992861C472A2C3813AE563A9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VariableConsiderationMember" xlink:label="loc_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_VariableConsiderationMember_28E8F692E64466359F29C3813AE5E5BB" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_EstimatedReimbursementMember" xlink:label="loc_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_EstimatedReimbursementMember_0A1CF26A2037FB2D3E9BC3813AE5BCCB" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_SublicenseReimbursementMember" xlink:label="loc_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_SublicenseReimbursementMember_D4EC22C2E62AB7B0A75BC3813AE5C2CA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MilestonePaymentsMember" xlink:label="loc_mrna_MilestonePaymentsMember_C64FE79E1C6012A1CF2CC3813AE66079" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_MilestonePaymentsMember_C64FE79E1C6012A1CF2CC3813AE66079" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentMember" xlink:label="loc_mrna_UpfrontPaymentMember_A91CE1F07AF8B943AC67C3813AE6CFE6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_UpfrontPaymentMember_A91CE1F07AF8B943AC67C3813AE6CFE6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember" xlink:label="loc_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_UpfrontPaymentMember_A91CE1F07AF8B943AC67C3813AE6CFE6" xlink:to="loc_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_7491CE7082C2C0888E03C3813AE69DA6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentResearchAndDevelopmentMember" xlink:label="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_B23907BAC8C9A281FADAC3813AE6D99C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_UpfrontPaymentMember_A91CE1F07AF8B943AC67C3813AE6CFE6" xlink:to="loc_mrna_UpfrontPaymentResearchAndDevelopmentMember_B23907BAC8C9A281FADAC3813AE6D99C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentFundingMember" xlink:label="loc_mrna_ResearchAndDevelopmentFundingMember_147E0C1A368DB3D877E5C3813AE60D9B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_ResearchAndDevelopmentFundingMember_147E0C1A368DB3D877E5C3813AE60D9B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ClinicalSupplyReimbursementMember" xlink:label="loc_mrna_ClinicalSupplyReimbursementMember_630A1EDABA5512B40414C3813AE7C906" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_0AA138ADCC6B1694B056C3813AE46953" xlink:to="loc_mrna_ClinicalSupplyReimbursementMember_630A1EDABA5512B40414C3813AE7C906" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_E81417464115D98EC3F4C3813AE7B31C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_E81417464115D98EC3F4C3813AE7B31C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_E81417464115D98EC3F4C3813AE7B31C" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ToxicityMilestonesMember" xlink:label="loc_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749" xlink:to="loc_mrna_ToxicityMilestonesMember_E01758D926F64A5D6BAFC3813AE78DA0" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CompetitionMilestonesMember" xlink:label="loc_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_D8E82FBB124EBA09BD02C3813AE71749" xlink:to="loc_mrna_CompetitionMilestonesMember_58413FED45813629F8A7C3813AE77178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9BE19B78078088FB3A7AC3813AE89856" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2A1A3AC1E091FFDDB663C3813ADB4EF9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9BE19B78078088FB3A7AC3813AE89856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_26E5740EBFE4B379D2BAC3813AE8D799" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_9BE19B78078088FB3A7AC3813AE89856" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_26E5740EBFE4B379D2BAC3813AE8D799" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_E98C5C4FB941919D69A5B8EC0DF15329" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_E98C5C4FB941919D69A5B8EC0DF15329" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1599CB22352EDC4653C9B8EC0DF22EE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:to="loc_srt_ProductOrServiceAxis_1599CB22352EDC4653C9B8EC0DF22EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0BDB94A3D50E230FD22EB8EC0DF286DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1599CB22352EDC4653C9B8EC0DF22EE4" xlink:to="loc_srt_ProductsAndServicesDomain_0BDB94A3D50E230FD22EB8EC0DF286DC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0BDB94A3D50E230FD22EB8EC0DF286DC" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember_B0BD523DFEBB5D4318B7B8EC0DF3EFAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_B7F701E97183327F3E20B8EC0DF40A3B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:to="loc_srt_MajorCustomersAxis_B7F701E97183327F3E20B8EC0DF40A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_B7F701E97183327F3E20B8EC0DF40A3B" xlink:to="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_MerckMember" xlink:label="loc_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:to="loc_mrna_MerckMember_37278E2676D5A919C813B8EC0DF47221" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AstraZenecaMember" xlink:label="loc_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:to="loc_mrna_AstraZenecaMember_001511F872B37B91EFC7B8EC0DF8B72A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VertexMember" xlink:label="loc_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:to="loc_mrna_VertexMember_8ED3E1072204F5658781B8EC0DF837D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCustomerMember" xlink:label="loc_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9622AE7F505301F5DC91B8EC0DF4608D" xlink:to="loc_us-gaap_OtherCustomerMember_54448E0221433FB4D5B9B9046F88EC9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_00C44B7F98A26985E439B8EC0DF1C8B4" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1EC0AF7407A952D355E3B8EC0DFAF6CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9E18A3C32FD576CBDF87B8EC0DFAC586" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1EC0AF7407A952D355E3B8EC0DFAF6CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_19E94AC2966683AD8ED7B894031913C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_19E94AC2966683AD8ED7B894031913C8" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6EF9366CD7A402658141B8940319D9C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_19E94AC2966683AD8ED7B894031913C8" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_D12AE11B691153AB4151B894031AE813" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_7EBC6CD61F9AC3C00C81CBD94A7CF3B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7EBC6CD61F9AC3C00C81CBD94A7CF3B3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3F17E9311D2787ABA5E2CBD94A7CB5AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3F17E9311D2787ABA5E2CBD94A7CB5AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3F17E9311D2787ABA5E2CBD94A7CB5AC" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_Combined2018AZAgreementsMember" xlink:label="loc_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:to="loc_mrna_Combined2018AZAgreementsMember_302FE125DDDDEFD90084CBD94A7DBF45" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_VEGFExercise2016Member" xlink:label="loc_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:to="loc_mrna_VEGFExercise2016Member_A18E067C5F931133029DCBD94A7D0981" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PCVSAVAgreementMember" xlink:label="loc_mrna_PCVSAVAgreementMember_09B089F7FBE86F3ADC76CBD94A7D1899" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:to="loc_mrna_PCVSAVAgreementMember_09B089F7FBE86F3ADC76CBD94A7D1899" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" xlink:label="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_2B3AD40E517E25D45B5DCBD94A7EC14E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CC26A950A22AE626665CCBD94A7C0F8B" xlink:to="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_2B3AD40E517E25D45B5DCBD94A7EC14E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_35321356C2B34A162317CBD94A7EC8FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_787979CB0EC5801ECE3ECBD94A7C0FD6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_47F10D3FFBD2236793DDCBE4E04DFBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6C20BEBE84D3306CFEA6CBD94A7E4357" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_835DDC0A11687C7FF1F8CBD94A7E482B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_BE7F553AC95C3E626FE3C3813A5BD384" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_BE7F553AC95C3E626FE3C3813A5BD384" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B866DD15732B208D189DC3813A5C7DEE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember" xlink:label="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3086C68D7F78984F8BCAC3813A5C20C2" xlink:to="loc_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_C56841305C041624BC93C3813A5CD387" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_94ECF5438880330CA047C3813A5DB58C" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DevelopmentMilestonesMember" xlink:label="loc_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:to="loc_mrna_DevelopmentMilestonesMember_549890DEA08551DE6B77C3813A5D4EEA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RegulatoryMilestonesMember" xlink:label="loc_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:to="loc_mrna_RegulatoryMilestonesMember_C1CF774284D4277DDB7FC3813A5D587D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RegulatoryMilestonesSubsequentProductsMember" xlink:label="loc_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain_0F51DAA10C7423F70C5DC3813A5D1896" xlink:to="loc_mrna_RegulatoryMilestonesSubsequentProductsMember_D9572610700AB12CF01FC3813A5D7741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_133B2397BC9E1D41EC79C3813A5E2470" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_srt_ProductOrServiceAxis_133B2397BC9E1D41EC79C3813A5E2470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CDAA5B539D3C8D92CA03C3813A5EAD3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_133B2397BC9E1D41EC79C3813A5E2470" xlink:to="loc_srt_ProductsAndServicesDomain_CDAA5B539D3C8D92CA03C3813A5EAD3B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CDAA5B539D3C8D92CA03C3813A5EAD3B" xlink:to="loc_mrna_CollaborationArrangementMember_1C08D9608893930060D2C3813A5E0B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_0F7B384C771A2D2B309CC3813A5E2AE2" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_UpfrontPaymentMember" xlink:label="loc_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:to="loc_mrna_UpfrontPaymentMember_2E6B7BB9634A23297E2BC3813A5F2924" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentFundingMember" xlink:label="loc_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_71FDFFC3ED87F65772A9C3813A5E46FD" xlink:to="loc_mrna_ResearchAndDevelopmentFundingMember_80CD3C7E4427AEE34239C3813A5F9EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_80E7F5D629CD25CB239FC3813A5B93A4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_DeferredRevenueAdditions_4D728D8CCBA51074E74CC3813A5F1B39" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_0200FF7DE0F8B38CFB40C3813A6027CB" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected_40228DDCE24D68AFA93BC3813A6029FA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod_81E69676AECC4D6779C0C3813A60EF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CCF523D41D4F7296E2DDC3813A60C1F6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod_C055E67DE101BCE77AE1C3813A6000CA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods_D1EEC29D1509F0AD7DACC3813A60F600" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_A8F10944131E559D51E8C3813A613EA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_C4F5D853D5E04708C6D1C3813A61D1E1" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod_8F988DB94A6E6B8CFA18C3813A619AFD" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod_53896EB1D9DCF3BA3C54C3813A6104F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_EA9A8263B50B1422D8D8C3813A61D602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_830BBD74492D8CA004FCC3813A61B88F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_E8C897039C01B8BE645BC3813A6212CC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_B82E0C1D46190949D506C3813A5FB02E" xlink:to="loc_us-gaap_ContractWithCustomerLiability_E8C897039C01B8BE645BC3813A6212CC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5244AE9D0523F4A22F55B8CB2D64710F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5244AE9D0523F4A22F55B8CB2D64710F" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4A8C2092A4941175E365B8CB2D679FFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3255AF910F4470D4D7B3B89404AD033B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3255AF910F4470D4D7B3B89404AD033B" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3A873D0298A75101F516B89404AD1A68" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="loc_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:to="loc_us-gaap_PurchaseCommitmentMember_F9A02EBE86783C6C74E4B89404AE175F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_06F4599E7DF644C32BE3B89404AD6D60" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_0CA1319D8F4E01BF70E6B89404AE1919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_98C9F6BF1A15E0542EC9B89404AD398D" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_F7B76141441C6F86E827B89404AE8DE5" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_E01EEACC520B2F1C3AB5B89404AF648D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6C2093B009882415A0F3B89403A18DDB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6C2093B009882415A0F3B89403A18DDB" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_011004F9A95DD390FCF3B89403A178BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_011004F9A95DD390FCF3B89403A178BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1FA0C9A7F33AB023D91FB89403A258CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_011004F9A95DD390FCF3B89403A178BF" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1FA0C9A7F33AB023D91FB89403A258CD" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_477E19192F01241616E9B89403A24841" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1FA0C9A7F33AB023D91FB89403A258CD" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_477E19192F01241616E9B89403A24841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_EA3630974BDCABC9CD6AB89403A26AFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_EA3630974BDCABC9CD6AB89403A26AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_AA2621C6944A216A6E38B89403A262AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_EA3630974BDCABC9CD6AB89403A26AFB" xlink:to="loc_us-gaap_ProjectMember_AA2621C6944A216A6E38B89403A262AA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_AFF3A09CA9AC0DA2C2D5B89403A30C25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_AA2621C6944A216A6E38B89403A262AA" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_AFF3A09CA9AC0DA2C2D5B89403A30C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0593B7D9B047F07EFE4BB89403A3CC28" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_BB3FB1313765952B9E4DB89403A11B97" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0593B7D9B047F07EFE4BB89403A3CC28" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0593B7D9B047F07EFE4BB89403A3CC28" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_25272303485C05515F29B89403A39881" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_88B43E945FBE371AA17AB8A04C6237C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_88B43E945FBE371AA17AB8A04C6237C3" xlink:to="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0912415B3B3F461F53ABB8A04C632B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8AB845353284D78B1265B8A04C634641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_CBC9A148263BF89BE632B8A04C6365AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_68A714997F86CA121EC2B8A04C63E953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900B88DC5B499CA822A2B8A04C63D040" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900B88DC5B499CA822A2B8A04C63D040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:to="loc_us-gaap_RestrictedCashCurrent_017AB29B035A440F7A91B8A04C63108B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9004C8150A3D37DA331AB8A04C620102" xlink:to="loc_us-gaap_AssetsCurrent_C9C325C5EAA65BEC5239B8A04C644DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_CF9A24EEED7235B91AF0B8A04C64C8F4" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_83222DC9A44B7CEE58BDB8A04C642AB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:to="loc_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_83222DC9A44B7CEE58BDB8A04C642AB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21CDF5C7FD25D0BD1295B8A04C64DFE0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_21CDF5C7FD25D0BD1295B8A04C64DFE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_054E3131DF07CECFF847B8A04C645258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0582A12CDCBD4E3C54C1B8A04C6551E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5A255376D27A0CC8DB13B8A04C62B79D" xlink:to="loc_us-gaap_Assets_2E553DC5B8460CCF1864B8A04C6AD1FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_88B43E945FBE371AA17AB8A04C6237C3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:to="loc_us-gaap_AccountsPayableCurrent_DF8330DA6B95F41FCC4FB8A04C6AE00D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_EA7945D047EB9386A5B5B8A04C6BA5AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_EA7945D047EB9386A5B5B8A04C6BA5AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_856EBC980BACFB73D13CB8A04C6B4452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4232B039991A1B4646A5B8A04C6B2503" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A8B447B85A7ED30D9CD3B8A04C6AD7A1" xlink:to="loc_us-gaap_LiabilitiesCurrent_16544747C48C51014D2BB8A04C6BE386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1C26EF71226C3A7281C8B8A04C6B647F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51C97D9597F1793A8BC0B8A448A1DC45" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51C97D9597F1793A8BC0B8A448A1DC45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_D39B5BF4275DA7B3DEDDB8A04C6C9247" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_D39B5BF4275DA7B3DEDDB8A04C6C9247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_F1EBB3A1901AA037D534B8A04C6C297A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_Liabilities_A4818A1FFBD9FB9A1527B8A04C6CF063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_CommitmentsAndContingencies_A7540E323AA59B870E03B8A04C6CC2ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:to="loc_us-gaap_PreferredStockValue_298114D70F6BA6D08A11B8A04C6D26D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:to="loc_us-gaap_CommonStockValue_5E429C913C1147200D21B8A04C6DC589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_DDA2F6D9FD83A078ED8AB8A04C6D2C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE8A8081B52FC7178B3B8A04C6E1D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5EC1DFBFD09F0AD13D0CB8A04C6EDCE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5EC1DFBFD09F0AD13D0CB8A04C6EDCE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1CB883FBBE76731B80A3B8A04C6C29A6" xlink:to="loc_us-gaap_StockholdersEquity_26679854A89E7F055D40B8A04C6E6A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5B2C07FB80ADF8CFF06AB8A04C6A1054" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1992CF6D2EF8D19F6C2BB8A04C6E5379" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1FC724CFD1C0D95C0F8EB89403DBAAC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1FC724CFD1C0D95C0F8EB89403DBAAC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_E2A06BB3FC4CA195C5D4B89403DB9D39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_E2A06BB3FC4CA195C5D4B89403DB9D39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:to="loc_us-gaap_PreferredStockSharesIssued_B8A1D15D985B2DA66358B89403DB4DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3A094A9C748CB7781846B89403DB511D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4CFE68E291F505A7130DB89403DC8CC2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4CFE68E291F505A7130DB89403DC8CC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_55FFAEC322C79B1BA9FAB89403DCD84E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_55FFAEC322C79B1BA9FAB89403DCD84E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:to="loc_us-gaap_CommonStockSharesIssued_E9191159E97882CFED7FB89403DC83C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FFDE39498A80A7854C0CB89403DA1188" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2E69F635B2F8F4B65BC8B89403DC9002" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:to="loc_us-gaap_NetIncomeLoss_51A9CE323828E5CD1E53B8B0B992B96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:to="loc_us-gaap_ShareBasedCompensation_AA7503994CFD19CF3738B8B0B992B698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_013490B0811E460D54C3B8B0B99307A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_013490B0811E460D54C3B8B0B99307A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_A4ECC907C45D3F4140E0B8B0B9934407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_761B282D5D7F82E3BC28B8B0B9932675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_103E9118BCADB0F60BEAB8B0B992C291" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_DACF9C77D7997925EB5FB8B0B99493B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9689E3C34E28FC70F9AEB8B0B99445B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B66F937824645F7DBA4FB8B0B994C60B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_BD514CA1D07608B7514DB8B0B994D43E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7D02AC856B8586F1BC59B8B0B994F95B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_851A9C287093A20EA5F2B8B0B9942354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_D1E504CBF4751C6B1017B8B0B9952EF1" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingLeaseLiabilities" xlink:label="loc_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_mrna_OperatingLeaseLiabilities_FF4653B1EDA824F8E9A4B8B0B995C083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_385BD2642CF43F9093D2B8B0B9931E2F" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C036F5BE1CBC553B8230B8B0B99583DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_B10AC8F3F6A6CD3FBE0AB8B0B9917E10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_AE3BD8CA5922C456D119B8B0B9959017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1FEEA2603D839E94B67FB8B0B9963E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_78543ADCEC889012536EB8B0B99673A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_629AA89BEB873A052E94B8B0B99603B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ED3B20764445B3D29DBB8B0B996AF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70297B7CE3CFE30B2C85B8B0B9968219" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_586FAC683582F4B5A523B8B0B9979E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A320F0D919B72340E68DB8B4C6193C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:to="loc_us-gaap_ProceedsFromStockPlans_B90749F5A45171365DBAB8B0B9976D8F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChargesToFinancingLeaseLiabilities" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_F06C47BE6B253149BDE6B8B0B99817FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8FF919757A1391C4DD6AB8B0B997AD16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_39098B0543B3F94C8260B8B0B998BD54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4AB634FFA1159DA88D7BB8B0B998B046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15C50796DAD25520E336B8B0B9983B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CD5227F51AB06F4619E5B8B0B9999F41" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CD5227F51AB06F4619E5B8B0B9999F41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CE6173738DB9D0F6A15B8B0B99126DA" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8992C7D0C8271F0D76DB8B0B999C706" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CF9BD7938D1FDBFBB1DEB8B0B999577E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3A967B8314B281DE591BB8A04BFD6937" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0705AA38BC68D084436DB8A04BFD68EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3A967B8314B281DE591BB8A04BFD6937" xlink:to="loc_us-gaap_NetIncomeLoss_0705AA38BC68D084436DB8A04BFD68EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3A967B8314B281DE591BB8A04BFD6937" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_FA28F9C51C74F27BA2BDB8A04BFE7CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4264822162788A61AFFBB8A04BFEFF04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_335D41254B84C3588F18B8A04BFD74E7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7BE77FDE441B3FFC418DB8A04BFFA59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3A967B8314B281DE591BB8A04BFD6937" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8BC1F3217D06B83A815FB8A04BFF4CB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0282A9D592AAFA017687B894048952D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0282A9D592AAFA017687B894048952D9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_D8A9A22F229CD69AE57AB894048A2066" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B580FBED48D9DE4D4A49B8A04C1E8814" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B580FBED48D9DE4D4A49B8A04C1E8814" xlink:to="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4A900FEA9BCD5D48490CB8A04C1F9314" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:to="loc_srt_ProductOrServiceAxis_4A900FEA9BCD5D48490CB8A04C1F9314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4A900FEA9BCD5D48490CB8A04C1F9314" xlink:to="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborationArrangementMember" xlink:label="loc_mrna_CollaborationArrangementMember_077F666AF928DA2589BFB8A04C1F05EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:to="loc_mrna_CollaborationArrangementMember_077F666AF928DA2589BFB8A04C1F05EA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborativeArrangementWithRelatedPartyMember" xlink:label="loc_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:to="loc_mrna_CollaborativeArrangementWithRelatedPartyMember_C621556DED617C4FA760B8A04C20A368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_54F40A8816CB22B98A5BB8A04C20E913" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E0DD3724B8BA2475374EB8A04C1FBCF3" xlink:to="loc_us-gaap_GrantMember_54F40A8816CB22B98A5BB8A04C20E913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3D1B72B5214CB3DE3766B8A04C1E3A97" xlink:to="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_913F778F04D219ACEBE4B8A04C202DE9" xlink:to="loc_us-gaap_Revenues_1142267699E13C212504B8A04C2036FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_506F4C4BA61AA7A8E8A3B8A04C21A8EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6534B9E5D18384795D20B8A04C214324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_EDED3561ABDE4FB66BF2B8A04C217210" xlink:to="loc_us-gaap_OperatingExpenses_C7B3406DC66F4EB4C0F5B8A04C211D1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ACCF0E6841C1B59A7BDB8A04C22D655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_42021CEB504F7113417EB8A04C22290D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_F1363E28F7A02A24D195B8A04C226009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_C829DA9D3F3DB3E426B7B8A04C22D13D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_10BF24529BB8C59D05CAB8A04C22C027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_NetIncomeLoss_4EE33DDA4A7B76EBE71BB8A04C22453E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_775E363C5AC8FCE29994B8A04C23EDB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5F083A5E12D62D122A35B8A04C20CAD6" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97EF2D7BFA78A8531F00B8A04C23F2AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6D4031A3920441D6D7BEB8A04BEE9460" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6D4031A3920441D6D7BEB8A04BEE9460" xlink:to="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67C0AEA17DEF461CC692B8A04BEFD565" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_A6903ACA93FCD8A37C45B8A04BEFFE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F47C883E15D4B41ADE6AB8A04BEFE0E7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0D4B21B1F7C5C3B04F00B8A04BEF1C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_AFF841DBEB9C9DEA193FB8A04BF07F5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_AFF841DBEB9C9DEA193FB8A04BF07F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_AFF841DBEB9C9DEA193FB8A04BF07F5E" xlink:to="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E33424E8BF7D62373598B8A04BF053B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:to="loc_us-gaap_CommonStockMember_E33424E8BF7D62373598B8A04BF053B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_CD66FE22EB989220F580B8A04BF01820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0317B18C27E714FFCDB7B8A04BF150ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CE820D049F78C76FF77EB8A04BF0F10C" xlink:to="loc_us-gaap_RetainedEarningsMember_86BF1F588F26DEBE71C0B8A04BF1E1C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7FE6A5FE944D229D5D9CB8A04BF20BDD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AF58922C0D3331C24C6FB8A04BEEDB63" xlink:to="loc_us-gaap_StatementLineItems_7FE6A5FE944D229D5D9CB8A04BF20BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7FE6A5FE944D229D5D9CB8A04BF20BDD" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_SharesOutstanding_D3CFEDFE0ED103F83114B8A04BF25ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockholdersEquity_CB0556BD97D7D92C3195B8A04BF23A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3DEF68AC6F89759630D9B8AD9AF8A0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F6D5E842D9B9614F7AA0B8AD0C02C101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_B790FC7EA03CB65C26E0B8A04BF3B456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92FFCF42E0A39BCE0056B8A04BF3FA9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AF988B176F4689E68D46B8A04BF3F2CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E9085E217D0A28AC5088B8A04BF3E633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F6F4F43F0AD04985A5D6B8A04BF32A2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F803AB2C2409FFDBE99AB8A04BF3A829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_CE472DA58C0B44A2372BB8A04BF44C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_871104879BDAF35DDD3AB8A04BF44D3D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_NetIncomeLoss_871104879BDAF35DDD3AB8A04BF44D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_C9215667C7081FE40572B8A04BF44C54" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_SharesOutstanding_C9215667C7081FE40572B8A04BF44C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E2512DC62B87FD151E98B8A04BF4DD3D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84E13C1A4AD934C496FAB8A04BF27D5C" xlink:to="loc_us-gaap_StockholdersEquity_E2512DC62B87FD151E98B8A04BF4DD3D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_790A520B466D9F1D5002B8B1AEFEB498" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_790A520B466D9F1D5002B8B1AEFEB498" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_040C495CD3DA9CE164EBB8B1AF0B040F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_DocumentType_6FA19FC0EA7F4F8F061EB8A02CE4F807" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_DocumentQuarterlyReport_39BE07D11CE3155E3333B8A02CE4DFCB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_DocumentPeriodEndDate_5EB129E41514AA62FF27B8A02CE406E4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_DocumentTransitionReport_2131C1ADE65B5233F0C3B8A02CE53421" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityFileNumber_1E018912573A8DF6C559B8A02CE5D2DB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityRegistrantName_60E3BB2C9A48BED1E55EB8A02CEA189F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityIncorporationStateCountryCode_742FCED53CEDC8F38ADEB8A02CEA611F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityTaxIdentificationNumber_C15F0FC2326B738D89CCB8A02CEB0E74" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityAddressAddressLine1_C620CC73B150966CA3D9B8A02CEBBC8F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityAddressCityOrTown_35916551F398266D6092B8A02CEBCD06" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityAddressStateOrProvince_ADE76832712EF1C3C5D4B8A02CEB630F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityAddressPostalZipCode_2D66F31B8321B603F038B8A02CEB039E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_CityAreaCode_679CFE3654C784F12270B8A02CEBD0DE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_LocalPhoneNumber_6E39320A9D76D05DA49EB8A02CECFD02" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_Security12bTitle_FDDCF6E4E756E5EC150FB8A02CECD46D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_TradingSymbol_FF4E7761699711372CD8B8A02CEC092B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_SecurityExchangeName_56D1B40FEE3877EEB7D3B8A02CECC059" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityCurrentReportingStatus_E7757C28E43C1F80FD14B8A02CECD33E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityInteractiveDataCurrent_1B7740B6E196B7BEC101B8A02CEDEA99" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityFilerCategory_A716523D44AF6EA26EABB8A02CED38B8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntitySmallBusiness_691DFA76290C3B50816FB8A02CED06E3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityEmergingGrowthCompany_AB1DDAB98D3B42212145B8A02CED6758" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityShellCompany_6A78B4764CAC2531798CB8A02CED2C0C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_D77E10462838A3BEFE74B8A02CEE493D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_AmendmentFlag_7C67014132BE4E7D63E9B8A02CEE8555" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_DocumentFiscalYearFocus_05007EA43AD3190CBB71B8A02CEEEE28" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_DocumentFiscalPeriodFocus_581807F6D41B6D6D29F3B8A02CEE49EC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_EntityCentralIndexKey_72CC3787BA57044170BBB8A02CEE15EF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43DF866C34CA439FC0C9B8A02CE4C769" xlink:to="loc_dei_CurrentFiscalYearEndDate_9ADF3799C16FBC62DCFDB8A02CEE12EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4AF555B0EEC1A5F82EF6B89403DEA1EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4AF555B0EEC1A5F82EF6B89403DEA1EA" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_986AE376F4285D2DB6CAB89403DE6322" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C260E05ACE792964831B93ADA9A613C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C260E05ACE792964831B93ADA9A613C" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FA00A36B379801B4A1E2B93ADA9E816D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_70BCA574677BB84C46DFB89404F0252B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_70BCA574677BB84C46DFB89404F0252B" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_60DB83DA27EAFE7C79B9B89404F09140" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_10203D15597B1C24F174B89403D36DB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_10203D15597B1C24F174B89403D36DB0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1C319ACEE0CDE6FE731CB89403D414D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_52950F715CB72B88646DB89403D4ED33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5E1B602FAA99D6CEEEEB89403D55776" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_3DD5603786C0B3798924B89403D4B0B0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5E1B602FAA99D6CEEEEB89403D55776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_10203D15597B1C24F174B89403D36DB0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_140966A0449547AF71D7B89403D55E9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_BA0FD9A74C894B6AEABEB89403D5A32C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0D94EE2DFBF1D9F57EDEB89403D53B07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8E5D5C5D850D8DBE6083B89403D55213" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C6443D1925787D65999EB8A04B19C31E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C6443D1925787D65999EB8A04B19C31E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:to="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_BAD25BBBCF7B29395C3AB8A04B1A39F5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_99F5296BBCB8844A3FB9B8A04B1AC7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="loc_us-gaap_CertificatesOfDepositMember_699512525C3B97324DCFB8A04B1BA3DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8D4A958C6086C87E4649B8A04B1BA099" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0A3999FA2921AE772816B8A04B1AAC54" xlink:to="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_CC8CB9E67256C29AEBB6B8A04B1B6063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F09D568B0E197C72909EB8A04B1BD578" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2154A74AC57D425985FCB8A04B1B25BA" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E667756C7B10DF2BFF10B8A04B1C15D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_623690686C2A5BB03164B8A04B1C8708" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_030B9595D6B73D4086ABB8A04B1CD0D8" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CurrentMarketableSecuritiesMember" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_87CAB3EA555B58AFFCA8B8A04B1DB20F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_NoncurrentMarketableSecuritiesMember" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21DEB2C232F88195FE69B8A04B1C901A" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_772C2155C80260F97B70B8A04B1D24B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5C6C736620B350602C9DB8A04B1ACB0D" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A56FA3EBCDB553E3076B8A04B1D96F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F8CD04DC2711DE1C1596B8A04B1E5DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_711C53E8AA03C183489BB8A04B1EDD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_46604A30958D1B97DC52B8A04B1DFB91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3B80118CEABDEC462F32B8A04B1E28CD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_F483748439B92693DB88B8EC0CC708A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_96F22177B6F6A16AF14CB8EC0CC782C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9DE48ABDD676A9BAFD6EB8EC0CC7E212" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_97153DCB15210D3A8F86B8F9345347D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12A1E47214FDE07E4A52C3813A29FC67" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6F5E8B60B62F781500ACC3813A29CC1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12A1E47214FDE07E4A52C3813A29FC67" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6F5E8B60B62F781500ACC3813A29CC1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78ABFB1B81B24DFBB77EC3813A29EB7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6F5E8B60B62F781500ACC3813A29CC1F" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78ABFB1B81B24DFBB77EC3813A29EB7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78ABFB1B81B24DFBB77EC3813A29EB7B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_B24B604522DB58C95187C3813A2AF653" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:to="loc_us-gaap_CertificatesOfDepositMember_B24B604522DB58C95187C3813A2AF653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_76E67DC73CDCF4A36091C3813A2A4F10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_76E67DC73CDCF4A36091C3813A2A4F10" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_4F3C9F6DE5286CE4A3FAC3813A2AE7E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3479967940F29A673B95C3813A2909BE" xlink:to="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_4F3C9F6DE5286CE4A3FAC3813A2AE7E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6F5E8B60B62F781500ACC3813A29CC1F" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_A3DDA058615E86EE6994C3813A2B96C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_965F35FA2D23C6DDCAD0C3813A2B1142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_F039A7798261F5B802CFC3813A2BFE69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_91139FF1B1F72C5643EBC3813A2BA5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A250A5404FEC1E85C6C5C3813A2BDA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C624E6F35023433AD958C3813A2A9A2E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_DD57C6384C5F7FDB48B4C3813A2C42B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Grants" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_653AD9875D17DD23F1FFB8940439C2D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_653AD9875D17DD23F1FFB8940439C2D5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1F433C7F76B522A849A1B894043A0FD1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E573A069037436145828B8940321157F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E573A069037436145828B8940321157F" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:to="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6B61879E65086E6977A8B89403217575" xlink:to="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_19F0D7459D74AE32CDE4B8940322DC92" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TheBillAndMelindaGatesFoundationMember" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:to="loc_mrna_TheBillAndMelindaGatesFoundationMember_422304BAFF453C82BBFDB8940322B747" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ECB63A1548D8CD22F31B8940321FCC1" xlink:to="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_E09F9124B3953EC4B9F2B8940322FF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:to="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_F6D75B0AB4405209C019B894032278B6" xlink:to="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78A472F406D6F1F7F385B894032254F9" xlink:to="loc_us-gaap_GrantMember_3BB93050CCEFB7C7DE01B894032329A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9ABA07326E99FB10663EB8940323331A" xlink:to="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_InitialBaseAwardMember" xlink:label="loc_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="loc_mrna_InitialBaseAwardMember_C32A2CB1551DFAB444A0B8940323D15C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ContractOptionsMember" xlink:label="loc_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="loc_mrna_ContractOptionsMember_266DE6373FBC276B5D6BB89403240FC8" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_InitialProjectMember" xlink:label="loc_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="loc_mrna_InitialProjectMember_D8BCCBE51539347B50FAB89403246703" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FollowOnProjectMember" xlink:label="loc_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_BE2F4112AEC21A7AFD60B8940323C9AF" xlink:to="loc_mrna_FollowOnProjectMember_3C38CC45220A3DAF4751B8940324687B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CEA5FF470511085FCEC7B894032122F2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsMaximumAward" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_79F46599F9745A415F9AB89403246765" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_DFDE33625FEE70FAB352B89403257E0B" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsNumberOfContractOptions" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptions_28FA8B376D8ACAFFDDDFB8940325089F" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_FCE767CE1AE5723709E9B894032500D2" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_261397FFDE2978107437B89403257820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B1739D060A0FE0AE19C8B89403270BBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86CB0DD4092E6950E78FB894032463DD" xlink:to="loc_us-gaap_ContractWithCustomerLiability_E19686265AC14BB44099B8940327EE62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43441758B7502120C52AB89404CC2940" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43441758B7502120C52AB89404CC2940" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4122B3D831E39CFCABECB89404CD6D92" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_B1FD220D80D63D046050B968A22FC447" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B1FD220D80D63D046050B968A22FC447" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4D55056088E47AABD9B4B968A22F515C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B1FD220D80D63D046050B968A22FC447" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_5C2672394DAC135B5879B968A22F905A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_DB81A27EA561946A7611B968A25F541D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_B558E9F8462A6A6403B6B968A25F0996" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:to="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_6A4C49E6A33DA9D3715BB968A25FC660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_10C72EE0DC38A7B167DEB968A25FA79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_EC24B024C70E960BBD46B968A260F137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_E95C07DC42DC034364DBB968A2609AC1" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_FFB3EA6B9C59D5C5B385B968A260F750" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingAndFinanceLeaseLiability" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_BCC3631D98346928E55FB968A25ED3B6" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiability_B0BE30AB570538BF5A4AB968A26026DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_B8784042A4C26C27E80BC37F5BA007EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B8784042A4C26C27E80BC37F5BA007EE" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_B0FE6C4A14114AB20AA6C37F5BA776ED" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TwoHundredTechnologySquareMember" xlink:label="loc_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_TwoHundredTechnologySquareMember_51A7642B329655AE40A8C37F5BA82418" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_TwoHundredTechnologySquareSubleaseAgreementsMember" xlink:label="loc_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember_6EB84B5D7B2A6EA58623C37F5BA825C9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FiveHundredTechnologySquareMember" xlink:label="loc_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_FiveHundredTechnologySquareMember_476F3D33D7C63D574848C37F5BA8139A" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LandAdjacentToNorwoodMember" xlink:label="loc_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_LandAdjacentToNorwoodMember_B04903946DE20970A9EAC37F5BA813E4" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OfficeLaboratoryAndLightManufacturingSpaceMember" xlink:label="loc_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_83B6ABF7D7DB286D5933C37F5BA8F63A" xlink:to="loc_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember_F8C3939A601709CB22B2C37F5BA98479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:to="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_B554ACB66C4C800D4EE3C37F5BA90B76" xlink:to="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CambridgeMassachusettsMember" xlink:label="loc_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:to="loc_mrna_CambridgeMassachusettsMember_94623211972F4B758134C37F5BA93618" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_NorwoodMassachusettsMember" xlink:label="loc_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AFF9E419DBD4060157D1C37F5BA96EDF" xlink:to="loc_mrna_NorwoodMassachusettsMember_F54B86D2F6A4CB533AF8C37F5BAA5EC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_99C224DA1EEA986D0128C37F5BA0BA82" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_DF083E49FCE4634A3C33C37F5BAA05E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_EEA5073EE30A22248591C37F5BAA6BB5" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit" xlink:label="loc_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit_39659D436C1EE2783582C37F5BAAD13D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_E0C271650574200DEC8CC37F5BABFE89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_63DBBE060AEF9A88365DC37F5BAB7CC1" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AllowanceForTenantImprovements" xlink:label="loc_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_AllowanceForTenantImprovements_18966EAA81289527E935C3811EAD23BA" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeasePercentageSubleased" xlink:label="loc_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_LesseeOperatingLeasePercentageSubleased_6B15204E284DF8754F21C37F5BAB5405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0D9A50E6CCD8084B7D6EC37F5BAB5A31" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2B368F1E5E32CF79A3BAC37F5BAB6B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D39F053115A0E0C374E3C37F5BAC4F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3F0938279F4E9C661C36C37F5BAC89F2" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LeasesImputedInterestRate" xlink:label="loc_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_F45A8CF924D8CC32DEDBC37F5BAA174A" xlink:to="loc_mrna_LeasesImputedInterestRate_583F0AA1D9A2B5F1CD8BC37F5BAC25B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_us-gaap_OperatingLeaseCost_4195904BE5DD63554DB2CBD94A0FFFA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9BC26F8C09D815313188CBD94A0F00AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_648693F71E0F79E4B833CBD94A1019DD" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_FinanceLeaseCost" xlink:label="loc_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_mrna_FinanceLeaseCost_1F42855283209A900829CBD94A109CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_us-gaap_VariableLeaseCost_839C5A03AE66D993FC5ECBD94A105BBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_us-gaap_OperatingLeasePayments_4F8CA91124DBF4503A88CBD94A10899E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_37156E43496E426871EDCBD94A10D023" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:label="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_5508FC542BE5C1C58193CBD94A115143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C5AAB5FEFEDB94A613D3CBD94A11D04A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_971F85A2E2E7AD96FD2DCBD94A0FEE09" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_F31D1F6F44054A7BB1B9CBD94A1103DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_7AE234766845B07DE205B968A1CF98DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7AE234766845B07DE205B968A1CF98DD" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4E0D0D9BDEC18DFB442CB98082E4F871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1E858ED6B658BFC29385B968A1D01E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9EC93D9059AF6DC87E23B968A1D0B426" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_CC3DB15C13507FACC1D1B968A1D1313C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44F56807A193389620F2B968A1D130A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1855425C9B692D270600B968A1D1B170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8D970BC48496F5ADCD53B968A1D1C79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5097368C313CA6798269B968A1D103FA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5097368C313CA6798269B968A1D103FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_D79B4724CE05EDFA452DB968A1D02C60" xlink:to="loc_us-gaap_OperatingLeaseLiability_06F548E611DB822A694BB968A1D10E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7AE234766845B07DE205B968A1CF98DD" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4C397262886FF5BAD31FB9808312F07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_463DD60748B368608594B968A1D2E03B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1B1F4CF2F87E8E0DCCC7B968A1D264D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1DA53DCA83311ADDA844B968A1D39C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_73A2BF5B8DE16AE867A2B968A1D30478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_E6A55F0EF0BADF78E943B968A1D37FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0EC5A77C9826BA94675DB968A1D8CB7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83815CC6CC3922DFCE25B968A1D8AEB1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83815CC6CC3922DFCE25B968A1D8AEB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_64116CA32FB58B5DFE56B968A1D20C7B" xlink:to="loc_us-gaap_FinanceLeaseLiability_4E093FB9BB2A0272AA7BB968A1D9707E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1BC1ADA693679214001AB968A225587F" xlink:type="locator" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1BC1ADA693679214001AB968A225587F" xlink:to="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_0E4E0594630F06B18FAFB968A225A9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1BC1ADA693679214001AB968A225587F" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_9B2860BB6A9D975E76EAB968A226FB10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1BC1ADA693679214001AB968A225587F" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_339A2C6C5611D1666A4DB968A22621BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1BC1ADA693679214001AB968A225587F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_11490C90BC1099AEAD40B968A226A5C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_FF8187A058E047D8A564B894047016BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FF8187A058E047D8A564B894047016BA" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0FE61E8A9617DD2A85C8B894047091C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_431287036947CADCF280B8B0B815A485" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_431287036947CADCF280B8B0B815A485" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_89AE2E778108E5A60E0EB8B0B8162133" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_DFB8AD6244AE3EC6A3A2B8B0B81602BD" xlink:to="loc_us-gaap_NetIncomeLoss_89AE2E778108E5A60E0EB8B0B8162133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_431287036947CADCF280B8B0B815A485" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_F3C92FC7268244BF6E60B8B0B81642E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9F3B01FB7B72C73AB777B8B0B8161FF0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_F3C92FC7268244BF6E60B8B0B81642E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_5CC9A265A3AA5167F0FEB8B0B8171043" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_431287036947CADCF280B8B0B815A485" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_5CC9A265A3AA5167F0FEB8B0B8171043" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2FE0C099942038A9DBCEB8940451099A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FE0C099942038A9DBCEB8940451099A" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_086E80847D50A8EC6793B8940451EA3C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:to="loc_us-gaap_EmployeeStockOptionMember_558AD81D59C57EBC54BAB8940452C2B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:to="loc_us-gaap_RestrictedStockMember_0621659080683ED2432CB89404528409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_575B5EB2B96ABCB654ABB8940452AECE" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_BC7E0B440E11949F15BBB8940453A6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1B0C46F136F4EB478BEDB89404514F14" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91A41AFF0C364CD98B14B8940453932A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1B4211544CD6DB1EE8CEB8940453EBFB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E0BB93E83654A3846588B894040AB5EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E0BB93E83654A3846588B894040AB5EE" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CC686DA90FF8F76FE733B894040A0909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E0BB93E83654A3846588B894040AB5EE" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_BD20E7970E6E84B5EF4CB894040A288C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9672A921D50E780BD961B8940437CD54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9672A921D50E780BD961B8940437CD54" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_026816F09B6A6F6EDB0EB89404370DF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0E862611D8A6118B1419B94C012EFB29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0E862611D8A6118B1419B94C012EFB29" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_C1AFA26508D3D680A791B94C012EC7A3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:to="loc_us-gaap_IPOMember_F436A12268A6305021DAB94C012FAFCF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PublicEquityOfferingMember" xlink:label="loc_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:to="loc_mrna_PublicEquityOfferingMember_DD95C2D09AAF4781A886B94C012F6E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_736380C2529781C9FC24B94C012F7EFF" xlink:to="loc_us-gaap_OverAllotmentOptionMember_BB3E164FC5FC21DAEDCCB94C012F6209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E843F74AD0954148F92AB94C012F9711" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E843F74AD0954148F92AB94C012F9711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D8482081A37605293F4FB94C0130FF6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E843F74AD0954148F92AB94C012F9711" xlink:to="loc_us-gaap_ClassOfStockDomain_D8482081A37605293F4FB94C0130FF6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D8482081A37605293F4FB94C0130FF6D" xlink:to="loc_us-gaap_CommonStockMember_9915D3103DC84CE49E08B94C013041CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_958957CB048361B2C922B94C012E9DC8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A53A214BE12D8C58897FB94C01304BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_A91AA371910E17B6FACEB94C0131AB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4A4E35DBD649F1BECABFB94C01318132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9DB82F617ADFCD6C1D70B94C0131BC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6F36E57FD6BF828DE15FB94C0131E167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_302BA1CB753B7D2D4472B94C01311D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4DEE38F966459A3C4133B94C0132926F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02273BBFFB6E1B8946E0B94C01327A31" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_02273BBFFB6E1B8946E0B94C01327A31" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PaymentsOfUnderwritingDiscounts" xlink:label="loc_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_mrna_PaymentsOfUnderwritingDiscounts_0A9FFA72018B1AF1ABE1B94C013204A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6AC0D3626DE7DB50DB1AB94C0132AFAD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6AC0D3626DE7DB50DB1AB94C0132AFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_550E929435579FD97A0AB94C01323895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6C7A6614CFE2B756555EB94C0133D4CE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_09A8BCD693C590FEB730B94C01304548" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6C7A6614CFE2B756555EB94C0133D4CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19A5EC4B3B75A780BB71B894051845D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19A5EC4B3B75A780BB71B894051845D2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_251DAA19FE8595CCFF12B89405187EBC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0C0BE4E29040C1547312B94C0113693C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0C0BE4E29040C1547312B94C0113693C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:to="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_79A4342DCDEF1D3B44EFB94C01137837" xlink:to="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70754DD1959C2BAA0B37B94C01143DE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_BB76B6430DE183C703E5B94C01130E56" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_BDFAA68ED95C9B303425B94C0114AC5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3AC0B2CF89C8302354D3B94C0114B6BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:to="loc_us-gaap_AwardTypeAxis_3AC0B2CF89C8302354D3B94C0114B6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3AC0B2CF89C8302354D3B94C0114B6BB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ServiceBasedAwardsMember" xlink:label="loc_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:to="loc_mrna_ServiceBasedAwardsMember_89515C1F2DC27B04B631B94C01150F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C86BEA247F9F92200E85B94C0115F42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC39F6C1729F8F8F1E7AB94C01142D5D" xlink:to="loc_us-gaap_EmployeeStockMember_6A1BAF82D0218E768BE4B94C0115BEB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:to="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_95CA76D35FDB620D5B2CB94C011667F8" xlink:to="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StockOptionAndIncentivePlan2018Member" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_3B2C15B33AF0ED587FB4B94C01166816" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_StockOptionAndGrantPlan2016Member" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:to="loc_mrna_StockOptionAndGrantPlan2016Member_7E15E190D5AD29FD7B5AB94C011657B6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_EmployeeStockPurchasePlan2018Member" xlink:label="loc_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9D164FC9C6377DBDCCDCB94C0116E5A5" xlink:to="loc_mrna_EmployeeStockPurchasePlan2018Member_92CAEFFD38EDE6337338B94C011613B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268224D10C2F939AD393B94C0113C7A8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8A8A15B7BDC78131F33FB94C0117A914" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_ED8986A3BE7FD9DE0B9DB94C01176344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3B25E750F09F6C7619A9B94C01175F29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_B5E9A9239402DD2735B2B94C011755E9" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_E1288CEBC30C968BEB4DB94C01184F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9F789D685EB525EDE337B94C0118ACE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5529C6E6A5E46273E693B94C0118946C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_EDFCDEFE8D72BFBB6677B94C0118E8ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_E8F56925B47FA8436BCEB94C0118AC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2FE73447D89E69952237B94C01187E29" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod_5677849EA164385C7738B94C01199E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_C6AD8368056BFD927871B94C0119A079" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_47BD19D1D6F4D8E00A26B94C0119A7E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4D79ECFF51F79C4013CAB94C011970C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_14CB7DBDEBDB7E91C68CB94C0119F45C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_AEFB726B5EB7453ABC91B94C0119FB0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_545B73F1B952A0221466B94C011AFF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2C72CE4DCF2A190D427FB94C0117FE55" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_84BC77D249EEB5AD03D0B94C011A0321" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B2A9760111F54225324B89403FE8670" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B2A9760111F54225324B89403FE8670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7995B13442EE49762A91B89403FE3F23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7FBE4925F6457CF29E73B89403FFDC9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D9C03013B0F4D31F0C4CB89403FF1081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_93EBC743A1B3B1505BD2B89403FF6133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09A92D014300B527F21BB89403FF2769" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956E7395B6D403F825F5B89403FE8D6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09A92D014300B527F21BB89403FF2769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B2A9760111F54225324B89403FE8670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1711D8AA19A14DCB95FCB8940400311D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7275109ED81075D76343B89404004F1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C87B2D3EB460A7AA20B5B8940400923C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23C360488CA0DC9604C9B8940400C0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543283D658BEEA50A009B894040172DF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0A9929AD89FB79EB148EB89404003EE8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543283D658BEEA50A009B894040172DF" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B2A9760111F54225324B89403FE8670" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1880C077AF58BF8BE751B89404011D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31942C8380936A8AEE83B8940401A45E" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_F44FED2EBC9DC2A48457B89404011F05" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_B8A2EA2AA6F90CA15D5CB89404021C51" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_7ABC618154D698A9276FB89404027D01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_61270C4AD24E54E09CA2B89404015EB6" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_7ABC618154D698A9276FB89404027D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B2A9760111F54225324B89403FE8670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_292D9CE1376F2637E637B8940402D434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C3A08A628AE0FFADB003B89404023686" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_249F24F65A037C3C72E9B89404033627" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2299DC430AE2C3807B9AB8940403491D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_634865D4F1C32B19A96FB894040321D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4E45AE8FE1781F8EEDD4B8940403C89E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EB75A6A4C527637B070AB8940402C058" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3E69F29BAC02CA02E6CCB89404030985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B2A9760111F54225324B89403FE8670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8A7CCFB24965A16273ABB89404040C8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_DAF35519C32138C31C28B8940404DF31" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_B5C598C0673CB1F6B113B89404040AB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4CFCA13BF1DB6B4A105EB89404040B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_8B180D8D7C86E9CE805EB89404048BE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A6AB434B45AEE5A3F68BB89404055E8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_650EDAFB3119FF5A9D40B8B0B83C556E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A70BD9878745E100BF8CB8B0B83C7BA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_650EDAFB3119FF5A9D40B8B0B83C556E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A70BD9878745E100BF8CB8B0B83C7BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_40007E6195F1336906B8B8B0B83CF6E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A70BD9878745E100BF8CB8B0B83C7BA9" xlink:to="loc_us-gaap_AwardTypeAxis_40007E6195F1336906B8B8B0B83CF6E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3D40E19726A9515DAD5BB8B0B83DDED4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_40007E6195F1336906B8B8B0B83CF6E4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3D40E19726A9515DAD5BB8B0B83DDED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3D40E19726A9515DAD5BB8B0B83DDED4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6BF6A754B93F4302494AB8B0B83D6210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32EF08B24D6086241A03B8B0B83D5536" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A70BD9878745E100BF8CB8B0B83C7BA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32EF08B24D6086241A03B8B0B83D5536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32EF08B24D6086241A03B8B0B83D5536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94D5677DCFEE72F41447B8B0B83E3318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E0BC40C46579ED910824B8B0B83EEE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4ABE4BB2C5502D8BB77FB8B0B83E1B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB93EC1C3CAC5FC3F4D1B8B0B83E8410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F3C410DBD6EFB5ECE2EDB8B0B83F7C81" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0A594A5E9E689F682D5AB8B0B83EE567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F3C410DBD6EFB5ECE2EDB8B0B83F7C81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32EF08B24D6086241A03B8B0B83D5536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0FE3B791E549A82B3AF2B8B0B83F5570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CA90B51B3632993A2FE5B8B0B83F4F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AD250DBE3283EEDDE609B8B0B83F0E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DAAC7B5A4987406C501EB8B0B84080CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C91E0D4607F0833A175FB8B0B840EA39" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_BFEEA989197D266AE91FB8B0B83FEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C91E0D4607F0833A175FB8B0B840EA39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4403ADF2DEE622788F0FB8A04A774F1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4403ADF2DEE622788F0FB8A04A774F1C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B1973579BC0F79F85CB0B8A04A78ADBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:to="loc_us-gaap_AwardTypeAxis_B1973579BC0F79F85CB0B8A04A78ADBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B1973579BC0F79F85CB0B8A04A78ADBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C78D6EB198323CF13DA2B8A04A79F639" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C78D6EB198323CF13DA2B8A04A79F639" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:to="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_DBCB22FD1504CD0B08CFB8A04A79D2AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61CF73C6A852CFAA6600B8A04A78EBF4" xlink:to="loc_us-gaap_EmployeeStockMember_0C168F042BA26004BADBB8A04A798A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4A68A8BB7C006B0E0D94B8A04A79DBD4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0B09D17C569723974848B8A04A7A77E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D92F3AA94347CAE1AA39B8A04A796582" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_84E4E326CE101C809010B8A04A7A045E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D5C417755CFB672FC1AEB8A04A783A2F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25C4ACD6B0FCBF1D1718B8A04A7A669B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_F3324E6A6D7F9FB32F4AB8A04A7A73CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB0E902D3A98373551A3B8C3A6317DF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB0E902D3A98373551A3B8C3A6317DF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_80F851BFA14F3E325BECB8C3A632494F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB0E902D3A98373551A3B8C3A6317DF4" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70EC005839460C92E830B8C3A632CDE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB0E902D3A98373551A3B8C3A6317DF4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9CBC58A8C9FBB3FCAC2DB8C3A632989A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB0E902D3A98373551A3B8C3A6317DF4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F62CDD8C42ED444186D6B8C3A63340BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9F532DB9184217DF6ABDB8B0B833B3FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9F532DB9184217DF6ABDB8B0B833B3FA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:to="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_04205E62BCBA73807CEDB8B0B833980A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE96719991984DA93786B8B0B834E80E" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8D51212F87B23A411F2DB8B0B83457CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:to="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_DEEC6C7E669E5A38A52EB8B0B8354175" xlink:to="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6748B7ED3EFDA547D809B8B0B8358EE4" xlink:to="loc_srt_WeightedAverageMember_A931E876B9EE70F5E2EAB8B0B835D595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2222557798ADBE5FE42AB8B0B833EE08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_28CB14767EF4FE9A7F76B8B0B836C830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_893CBD5FFBD432EE30A9B8B0B836234A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_84D6641C3D2121151987B8B0B836449E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ACB961186078B4F1A830B8B0B836ACA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9CC60BA62574E615EC29B8B0B8369B3E" xlink:to="loc_us-gaap_SharePrice_43CD5BCFC2C1B526BB5BB8B0B836D1FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2D75342F451B69C9AD69EACE3AC03E9D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2D75342F451B69C9AD69EACE3AC03E9D" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_B0139A322166EEB0F50FEACE3AC37E0B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_27E87425F635925188B5EACE3AE7D06A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_27E87425F635925188B5EACE3AE7D06A" xlink:to="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DCC08A4B061065953F3AEACE3AE8B3D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:to="loc_srt_RangeAxis_DCC08A4B061065953F3AEACE3AE8B3D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2397ABACC02A8507E0FAEACE3AE8DD45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_DCC08A4B061065953F3AEACE3AE8B3D7" xlink:to="loc_srt_RangeMember_2397ABACC02A8507E0FAEACE3AE8DD45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2397ABACC02A8507E0FAEACE3AE8DD45" xlink:to="loc_srt_MaximumMember_F47A0AF2D87E0C29488DEACE3AE95219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:to="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_D8C469A88C8F7F96FE81EACE3AE92868" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_916014675173360C7492EACE3AEAA882" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_916014675173360C7492EACE3AEAA882" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_LonzaLtdMember" xlink:label="loc_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_F3B71C6B42A06E045371EACE3AE97DD8" xlink:to="loc_mrna_LonzaLtdMember_5C742E9D4264F59447F2EAD2E9363D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ED63BA350BDB0B258E6EACE3AEA69D7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0CEA2F76772AA0A0948FEACE3AEABF3A" xlink:to="loc_us-gaap_SubsequentEventMember_83D1644FE1BAAE275BA7EACE3AEB5A75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_D815F776F8132EEFC9DCEACE3AE89311" xlink:to="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:to="loc_us-gaap_GrantsReceivable_3379FD27FF89A774E0B2EACE3AEB9D0E" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_CollaborativeArrangementTermOfArrangement" xlink:label="loc_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B7D1F3593A5520C92EDEACE3AEB22A3" xlink:to="loc_mrna_CollaborativeArrangementTermOfArrangement_483EB25E235D2D74CFF4EAD25D63F82E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0348DE4543FCBD429D60B89404D807FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0348DE4543FCBD429D60B89404D807FB" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5AA4C281BED1648DEC00B89404D946E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_85C3AEA2513542A70889B89404F43E4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85C3AEA2513542A70889B89404F43E4D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_772885FAFB2E2EF3F5AEB89404F4FAFC" xlink:to="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FA237746772C07A71D2FB89404F56CD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC6CC6E0AC0FC9CB1EB0B89404F5FB34" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_CECBE488F093F0AEFB38B89404F50271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_F486887D88A0D9A0B4C1B89404F4A44D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DBD0C57D16DC419DDACDB89404F5A432" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:to="loc_us-gaap_StockholdersEquity_C379176F71A5B113B87EB89404F6C8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B84404DC8925DA46A7B6B89404F69794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BE5F06100CAEFD0DB65FB89404F6C6CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_36F2F230F668B8B5971DB89404F6EF5E" xlink:to="loc_us-gaap_StockholdersEquity_BE5F06100CAEFD0DB65FB89404F6C6CD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_548BDD72D20C3BC9475CB8EC0E35FB03" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_548BDD72D20C3BC9475CB8EC0E35FB03" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:to="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_2098AF27EC8CF155ADF3B942AB016326" xlink:to="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_430FFDD82204ACE3CF78B942D44A0C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3A8CED7AE8CC7F86C6FEB942AB021CE9" xlink:to="loc_srt_RestatementAdjustmentMember_C6C39E6A8E77A0FB4B6DB942FBC0F20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9B780ED64025DE5E5FE9B8EC0E3D54B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9B780ED64025DE5E5FE9B8EC0E3D54B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_274B1D46AC5E8594EC8FB8EC0E3D6F52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9B780ED64025DE5E5FE9B8EC0E3D54B1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_274B1D46AC5E8594EC8FB8EC0E3D6F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_1FE5516C4651E0A3BCF9B943759BE57A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_274B1D46AC5E8594EC8FB8EC0E3D6F52" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_1FE5516C4651E0A3BCF9B943759BE57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_030241B08FD38BCA1676B93FF61EA9D6" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0F969434A9ECF401BF30B940F422F436" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0F969434A9ECF401BF30B940F422F436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_E9833D8F6AE98D4D1EACB940FB9E0406" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_E9833D8F6AE98D4D1EACB940FB9E0406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8730D2FFF4019F6E5E58B9410415082E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_OperatingExpenses_8730D2FFF4019F6E5E58B9410415082E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_OperatingIncomeLoss_F1A6B4F6AFFEC5CAF927B9410C0E051E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_95790B26214A9388C70AB941E4729F24" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_95790B26214A9388C70AB941E4729F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_233ABA0FA9FC1C4FFFC9B941ED8EC9E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2594923F52E9893D0CC2B94248F69ECA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_NetIncomeLoss_2594923F52E9893D0CC2B94248F69ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_84A2E97F94390A4CDDB2B9424FDE5EED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_84A2E97F94390A4CDDB2B9424FDE5EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4CAF48A771FF881B9620B94523F647AE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4CAF48A771FF881B9620B94523F647AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6A6E9143448CE953E31FB945377F3DEE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6A6E9143448CE953E31FB945377F3DEE" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_2CB52C42196D6A4BEDF4B9455B014F79" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_2CB52C42196D6A4BEDF4B9455B014F79" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_IncreaseDecreaseInDeferredRentCredit" xlink:label="loc_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_IncreaseDecreaseInDeferredRentCredit_6666468E61CE9FB81EAAB94A25242B7C" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_OperatingLeaseLiabilities" xlink:label="loc_mrna_OperatingLeaseLiabilities_46E64577E78600AE357DB9458199FEB4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_OperatingLeaseLiabilities_46E64577E78600AE357DB9458199FEB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_BB89C8E0015ADB9D59B8B945981364B1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_BB89C8E0015ADB9D59B8B945981364B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60019F4737627E10457DB945B74FCCCC" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_ChargesToFinancingLeaseLiabilities" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_32A3895A838D5934D262B945DC1ECA3E" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_32A3895A838D5934D262B945DC1ECA3E" xlink:type="arc" />
    <link:loc xlink:href="mrna-20200331.xsd#mrna_PaymentsForLeaseFinancingObligation" xlink:label="loc_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_mrna_PaymentsForLeaseFinancingObligation_0A193BA87A04DE59D585B94881760809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8303C5A6A5FEB4498B24B93FF625CDD1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FFAD5517487F5A2824C1B945FDB7893B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0A6C3CA57F0D519FF938C3813B707659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3B62684E98F473318C51C3813B7153A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_FC4F0C51A0D9D18AB7AAC3813B723135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8FED0169A0D802AFC4B3C3813B7083DB" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4CA61B0CF8B430CC013C3813B72F929" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7C369A6295F7849D5987B894047A40BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27F02BCA3A46D29CB844B894047AC108" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7C369A6295F7849D5987B894047A40BE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27F02BCA3A46D29CB844B894047AC108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_DA04326C619CB2F63F1FB894047A24C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7C369A6295F7849D5987B894047A40BE" xlink:to="loc_us-gaap_RestrictedCashCurrent_DA04326C619CB2F63F1FB894047A24C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_C76A374A081D20D4A00FB894047BB790" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7C369A6295F7849D5987B894047A40BE" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_C76A374A081D20D4A00FB894047BB790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865E140DF5AC3165E94EB894047BE662" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7C369A6295F7849D5987B894047A40BE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865E140DF5AC3165E94EB894047BE662" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_449B4694E4CD31297E2FB94C02493D82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_A58D8C63C49E22FB33AAB94C0249ED3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_449B4694E4CD31297E2FB94C02493D82" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_A58D8C63C49E22FB33AAB94C0249ED3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_449B4694E4CD31297E2FB94C02493D82" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A54B6B7446CFCFC6EE9CB94C024910AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_449B4694E4CD31297E2FB94C02493D82" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_42DEEB2CA6C8C7C055A5B94C024AE75F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_449B4694E4CD31297E2FB94C02493D82" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_C4B158C9E1F6DBBBB747B94C024AA77E" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>developmentpipeline.jpg
<DESCRIPTION>PIPELINE
<TEXT>
begin 644 developmentpipeline.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0 \ # 2(  A$! Q$!_\0
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MD5-;_&35)/ WCK0]7:\US4/%4]A-/J][?/)*GV9W8!MP)DW;P.6&-HZ]N_\
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MIE_J'@R34/$&F:1?:':WT6K^1%]EN#*5WP^2VYXS,P#!@&!.1G! !\^4444
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MAJQFO/LTSFY5YHK>8Q.ID:!85E# KY;.K.4;8&&"? : "BBB@ HHHH ****
M"BBB@ HHHH **** .G^'?Q U'X9^)/[;TN&UGNOLMQ:;+M&9-DT+1.<*RG(5
MR1SUQUZ5Z)JG[7/CO6-*2QN?[/81^'X?#J3B.42K%'*DHF!\S'G%HTRV,$*/
MESS7 +\*_%;*"-&FP1GET!_]"I?^%4^*_P#H#R_]_$_^*H [FY_:K\6"_.HZ
M9INB:!JMQJL&M:E?Z;;2+)J=U%G8TX>1EVY9R4C5%)=B1DU>T_\ :Y\0:+:V
MUCI7A3PMI6E0O?.VGV<%VD<OVN,1S@M]H\Q> "I1U*] 0H"UYQ_PJGQ7_P!
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MZPVEVNE3W1+SQVDUS,LDA)+2,]Q-+(68GG+X]JP:ZW_A5/BO_H#R_P#?Q/\
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M*EE5BIX) /44 >5T5UO_  JGQ7_T!Y?^_B?_ !5'_"J?%?\ T!Y?^_B?_%4
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MERG,EDDRB%SD')02[3T';M0!ZQ\/_AWX?\0Z+H$^J/J7VK5]7DTQ?LDT:)$
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M '\M?_CU '*T5U7_  I[XD?]$^UK_OY:_P#QZC_A3WQ(_P"B?:U_W\M?_CU
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M1_T3[6O^_EK_ /'J/^%/?$C_ *)]K7_?RU_^/4 <K175?\*>^)'_ $3[6O\
MOY:__'J/^%/?$C_HGVM?]_+7_P"/4 <K175?\*>^)'_1/M:_[^6O_P >H_X4
M]\2/^B?:U_W\M?\ X]0!RM%=5_PI[XD?]$^UK_OY:_\ QZJVI?"_X@:3I]U?
M7?@+68;2UB:>:0O;$(B@LQXF[ &@#GJ*ZK_A3WQ(_P"B?:U_W\M?_CU'_"GO
MB1_T3[6O^_EK_P#'J .5HKJO^%/?$C_HGVM?]_+7_P"/4?\ "GOB1_T3[6O^
M_EK_ /'J .5HKJO^%/?$C_HGVM?]_+7_ ./4?\*>^)'_ $3[6O\ OY:__'J
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M1_T3[6O^_EK_ /'J .5HKJO^%/?$C_HGVM?]_+7_ ./4?\*>^)'_ $3[6O\
MOY:__'J .5HKJO\ A3WQ(_Z)]K7_ '\M?_CU'_"GOB1_T3[6O^_EK_\ 'J .
M5HKJO^%/?$C_ *)]K7_?RU_^/4?\*>^)'_1/M:_[^6O_ ,>H Y6BNAL_A?\
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M]_+7_P"/55U3X/\ Q'72[PMX UI%$+Y8O:X VGGB:@#GZ*** "BBB@ HHHH
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M=/7?>:=!>1O<6R\<R1AMR#D=0.HJC;_%3P7=^';KQ!!XOT&;0;2407&J1ZG
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M_M@4445^I'X*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH YC_A8VA_W[[_P677_QNC_A8VA_W[[_ ,%EU_\ &ZZ>B@#F/^%C:'_?OO\
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MC_A8VA_W[[_P677_ ,;KIZ* .8_X6-H?]^^_\%EU_P#&Z/\ A8VA_P!^^_\
M!9=?_&ZZ>B@#F/\ A8VA_P!^^_\ !9=?_&Z/^%C:'_?OO_!9=?\ QNNGHH Y
MC_A8VA_W[[_P677_ ,;H_P"%C:'_ '[[_P %EU_\;KIZ* .8_P"%C:'_ '[[
M_P %EU_\;H_X6-H?]^^_\%EU_P#&ZZ>B@#F/^%C:'_?OO_!9=?\ QNJ>M?$3
M1)-'OT5[[<UO(!G3;D?PGOY==G5#7O\ D!ZC_P!>TG_H)H _-NBBB@ HHHH
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M1?[>&@VWV/\ X6$?%)ETW^W_ .T/M?V,7 O(O/\ (\WY=I4S9^R?N/+'S?\
M+.JCZ-X]T7P'.FGW7BAKF_T+1;K49KY[Z^FBF,SB_P#)3S4E63RN6AMWC<8&
MP*V,_2?]J67_ #]P?]_5_P :/[4LO^?N#_OZO^- '%? ^'5+?P! FJWVHZ@_
MVF?R)M5L;BSG,/F'8#'<S33XZ[3,^\KC(%=_57^U++_G[@_[^K_C1_:EE_S]
MP?\ ?U?\: +5%5?[4LO^?N#_ +^K_C1_:EE_S]P?]_5_QH M455_M2R_Y^X/
M^_J_XT?VI9?\_<'_ ']7_&@"U157^U++_G[@_P"_J_XT?VI9?\_<'_?U?\:
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MN#_OZO\ C7\^XJO]:KSK<JCS.]ELC^P,!A7@<+3PSFY\B2N]V6J*J_VI9?\
M/W!_W]7_ !H_M2R_Y^X/^_J_XURG>6J*J_VI9?\ /W!_W]7_ !H_M2R_Y^X/
M^_J_XT 6J*J_VI9?\_<'_?U?\:/[4LO^?N#_ +^K_C0!:KF+?_DI=_\ ]@BW
M_P#1T];O]J67_/W!_P!_5_QKFK?4K3_A9-\WVJ';_9-N-WF#&?.F]Z .OHJK
M_:EE_P _<'_?U?\ &C^U++_G[@_[^K_C0!:HJK_:EE_S]P?]_5_QH_M2R_Y^
MX/\ OZO^- %JBJO]J67_ #]P?]_5_P :/[4LO^?N#_OZO^- %JBJO]J67_/W
M!_W]7_&C^U++_G[@_P"_J_XT 6J*J_VI9?\ /W!_W]7_ !H_M2R_Y^X/^_J_
MXT 8?@K_ (^/$O\ V%Y?_1<=>>0_%SP?<:J=('@>].B/XI.E#5_LEBUB^K"7
M?Y@03&8MYHSYOE<,,DC!([?PEJ4"MXG\NYMQ*=4F,?F2@*3Y<>,^V:\$^'_P
M!U[PVWAB[N=/\#:=XBTB_N-6O/$^G:G))?ZM-)YS&WD8VD;)"[2X8L\A"J %
M)P0 >M7'CCP O[0,'A8:)#/X]GTMY7UB/3XB8H!@_9WN/OY*D-L&1@@G&1G
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M^ ]*T:[O=.>]A5Y;IK$A(#-)(TLGE@G(3>[8SVQ75?VI9?\ /W!_W]7_ !H
MM455_M2R_P"?N#_OZO\ C1_:EE_S]P?]_5_QH M455_M2R_Y^X/^_J_XT?VI
M9?\ /W!_W]7_ !H M455_M2R_P"?N#_OZO\ C1_:EE_S]P?]_5_QH M455_M
M2R_Y^X/^_J_XT?VI9?\ /W!_W]7_ !H M455_M2R_P"?N#_OZO\ C1_:EE_S
M]P?]_5_QH M50U[_ ) >H_\ 7M)_Z":E_M2R_P"?N#_OZO\ C5'7=3LVT34
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MEMF%M_O+<(ZC':1.E>M?LTWWB;X2^)=;\+>(]!UI]2\0:</$\%K=36?GWVH
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M#FYC9#N4@+$, ;B: /7/^$#\-?\ 0NZ3_P" ,7_Q-'_"!^&O^A=TG_P!B_\
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M#\-?]"[I/_@#%_\ $UNT4 87_"!^&O\ H7=)_P# &+_XFC_A _#7_0NZ3_X
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M.5!)"@L2<# R2<9)K%_X5SH?]R^_\&=U_P#'*/\ A7.A_P!R^_\ !G=?_'*
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MK'_@?+_\54=QX\\374$D,WB+5IH9%*/')?2LK*1@@@MR"*.;$?R1_P# G_\
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M_A7.A_W+[_P9W7_QR@#IZ*YC_A7.A_W+[_P9W7_QRC_A7.A_W+[_ ,&=U_\
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MQCHO@?P]JC^.=+:+?>[KS3[RUW:DJ3(L9BENK*&VO"@W[HH6MFD S&YKK_\
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M-NK0ZG*9+D80 &1BJDD@ \J.O04 <?J6@Z%X7^%/C'Q#%H&GW5YI<NJSPK/
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MW^ OAOQ)K%_/<>)-5T2\\0)=6,R6DUJK7<<UO"DL">;"[ ;+17^0AN&))7@
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MYYHZ;\+O!/A719=";Q%*J:?9Z193_:KZ 2PQVUPTEH9/E&#([%<D?-C"X/-
M&+IFJ>&_$'Q'T;1-/\#I#H5XFH#^UKRT01W;6S(F8"LA(4,7!\Q%W  IE>:]
M-_X5GX4_Z %C_P!^A7G?A#_A6MOXAE\2Z5\4;75--T8W!33EUJREL-,^UR O
MRB[P&=?E$DC!>53 XKUVXUW3;6TM;J;4+6&UNWCCMYI)E5)FD($:HQ.&+$C
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M.IW7?SU>GWV[BP''&99?CN>K6=:CLT^W=.RU7317ZI=/OV3X>>&O^%@PV_\
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M73T4 <Q_PK/PI_T +'_OT*/^%9^%/^@!8_\ ?H5T]% ',?\ "L_"G_0 L?\
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M\*?] "Q_[]"NGHH YC_A6?A3_H 6/_?H4?\ "L_"G_0 L?\ OT*Z>B@#F/\
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M51_P@-K_ -!77?\ P;7'_P 50!T]%<Q_P@-K_P!!77?_  ;7'_Q5'_" VO\
MT%==_P#!M<?_ !5 '&>*+ZZTOX%_$*[L;BXM+V ZU)#/:OLEC<3SD,C=F!Z&
MO.]=DU^30[NUT9O'$'AJZUB%(;R_BU>>\@(M&:4F.-DO6@:5448EBC#L3N,8
MV-V6I:#I^C_"GQCJMV=3U:WLI=5D?3I=5FCBN52>;Y'^\/F Y)4YR20:@T_Q
M+;Z3?:GIOC$ZOI&J6:VTD5MH&N7^L_:4G$NP1HD*3,X\B4LHB("C=NQG: 8'
MAF#QK>>"Y]>U:/Q;+KFG>";%K>P2ZN;0RWYCNEN,Q899)\"/(=)"#L(4MM-<
MS9GXBP^"]<M+&X\677DZK=-87GV+5+>:2!M&<H56[EEGVBYZ"1S^\Q@+E5'H
MOC#X@>$/#6F64]GK7B#6+F]6TEA@AU"^"+%<3K"C2RA66 DE]JR;2QC90,@X
MOV_BOP@MU;6=YXAU]+RXNVM%^QW>I7$$3?:GMH_.F$86$O(A4>9M!8$*S@;B
M 8OB/X>WU]HNLZ __"3WFEVWBO2+FQ>35+]YQ"?LIG*W'F>:T:L9F^\0C D;
M2@VX-C=>+?##:OI46F>)U;4-2MWT_P"RVERT*+_;ET]T[2*I6+-N\;'>5\Q"
M,;ATZKP[X_\ ">O0VRR7_B^RO[N\O;2VLG;5&>1;>X$+2G$?RQ_-&6<C:A8@
MME6Q?T;Q9X-U2XT:R;Q)KPO]2BMV#6UYJ,MG')-&)(XFNBBQH[*05238[!D^
M0;@" >=M;_$?^UO'LSZIXD&K?8=6"V=MI-\L"C=_H1@N'NFMF?9Y946L(?[P
MDPV<]+XIM+GPIH/B;1YH?&M_9MK4"Z1<6UUK5W+;A[.,R2/+:N;F2!'\T^7O
MVER%RO!7N]>7PWX9UO2](O\ 7/$@U+4@S6UO;W5]<%E5D5W8QA@B*9$R[X4!
MLD@9-8T?B[P--8WMVOB3Q28K4Q?*3J8>Y$K[(FMDV;KE';A6A#J<C!YH \[\
M93>)K'7O"$?AB?QO<6&G1Z2T$M]::O-)?QM>;;IKCF)(W6-27%VLK,K#RTBP
M6;U?QS;>)!XZT_3M,;4FT?Q (DNKRWE<)IGV9_,D(('[OSXSY><CE0>IK(OO
M&W@'3=/L;R?Q-XH$5Y'<31I&=3DE1('$<[2Q*A>$1N0'\P+MYSC!J1?$GA./
MQ&^B3>(-=DOWN3!;1:?>ZA=EU$<#M)(43;&H^TQY;<4"L"7'S!0#CX] \::E
M9_$&^FG\6#4;+3;PZ) E]=0(\S7>HA2B!E61O*^S[0V0!Y17'RFJWCK5_%7B
MO3/$&H:=_P )9I>F_P!LPO9)+IFK1>?$NGH-CQVK17L,;3EOFC1P&7+HP-='
MJWQ(\&VNE/>:?J?B_5#'>6-LT49U1&:.ZF\N.>,&/,L1"R%7C#*Y0*&RPK7D
M\7> H9]8BD\5^((AI4%Q<7,TES?I"8[=@MP8I2-DWEL0KB(L5/!P: +:ZU-#
M\*?"U]K^E^)+'57MEB^W65@-6U/39#"R^<RBW9B[#*EOL_!DPZ*,XI:?I][I
M/@WX2V%Y8_V;86NH0075J<XC1+:=;02!R2#YHMN"21(5%6;77O!EWI^HWG_"
M1^);6/3XXI;B.^FU"VF5)79(F$4BJ[AV1E4JIW$<9IWBC_A"K'6H_#.M:QX@
MGGNO)5XGEOKBU3S9"D(FE4-%$7=<*)&7<<8SQ0!YOJ/@CQ!I_ACQ"MK;>(+@
MZQ8>)TN=/D>XEM]YO-UKY<!^2-F5GVE%!<,2=W!#-?\ !7B*ZM_$[_V)>>?:
M^&=4\.V&RT9Q+#%]G-L5"@9+F23"@\[#CH:]+NM>\$6.CPZI/XMUJ.RE6[<.
MVH7FY1:[OM!9/O)Y90AMP&#@=2 8$\3>"I-%FU3^W_%BQ0WHT]K1_P"TUO6N
M"@D$:VA3SW8QL)/E0_)EON@F@"IK?PU\0::E[XVOM0MM>\7V,EG=V\>CZ4UH
MK06WFB2!(WEF=I)8KBX3._!+1X VY-?3_#FK:Y;Z+<W^E7$5UXAU6;Q%JBS0
M,#;0PQ$65L_ VR+_ *)\K?Q12G%0:Y\3O 6G_#75O&5AXEU_5;.QD>T%JE]?
M1SO=A-XMS&1YB-C!.4^49)X4U<NO&W@[28;R;5->\26T<$A&RWFU2>:*)8(9
MGDN(A%N@5!.FYF&Q<KN8,2J@'+:5\*_$\O@?P'J>OSPZC=V-OH]A!I-CHTEM
M);0&[M))_M.^:4NR"!<D", !R5Y^7J/!OA?5I/$]CX8U/3+E_#G@CSY+.>>'
M$6H>8"MDL;, K^3;O)&_/W]A-;-C-H\EYK45[J>N6,5AK$.CQS?VQ<R">26*
M%XR<'Y,M.$YXR!SSBJ&M^*/!_A^_\N[\2ZTMHIFADD34+^27SXYX8/+2-$8/
M^\G5"0V=V  WS%0#'A:UO+?Q[JD>EZQ:Z')X<6U>'6-+?3GLFA$OE65LGEQA
MT3S'(=-_S, )6&T+Z+XGAU\_#6"[A-PWB33X(+]K>U<J;J:(*\D'R]1)ADQ@
M_>'H*P%_X0O7+>!9];UUHVOHK40ZA<7L31W0A6[1724 HRH%?+ ;2,'##%3^
M#;KPMX^^TC1M>\32-;QQS,MY/?VC-%)N\N5!,$+QML;$BY4[3@\4 >3_ !AD
M\>2^"=-GL3XJM=7U"QU'68TT^+4;@PW3%&M[)H[5HS&RHP4&9_)!1\Q2,PV]
MNLVI7'Q(>?55\:+K#75L^D1Z8MRNE?8S;1^8+@?\>HQ*;C>)OW_"^7SY8JJ^
ML:MK-[HD'ABPN-135K2ZU&VFU/QA=VB-:120HDGR03<R><&"]EQDY) R8/B(
MVM3>';;1+2\N-0U728=573M2\:26=S<A]Y:*Q4JRW3H(G+$M$@!C.[#$J 1Z
M+_;PT&V^Q_\ "PCXI,NF_P!O_P!H?:_L8N!>1>?Y'F_+M*F;/V3]QY8^;_EG
M51]&\>Z+X#G33[KQ0US?Z%HMUJ,U\]]?313&9Q?^2GFI*LGE<M#;O&XP-@5L
M9[J;5K#3=+\:7.J2Z[8W7AIB6LQKTSO<QM&'@=3D8,A)0#G#JP!;&:U]&T])
MKJ[LM9EUS2K^VLH;]HH=<N;E6C=3O"D;2Q21'4@+R-A_CV@ N_ ^'5+?P! F
MJWVHZ@_VF?R)M5L;BSG,/F'8#'<S33XZ[3,^\KC(%=_7EUYJG@ZQL4O'\4:]
M)#)90ZA']GOKV9Y(9G"0E$3+,SL=JH 78YP#@U0N_%G@>ST&QU=_$7BJ2VO&
MG6*"W_M.:['D,4G+VR(9HQ&PVN70!20#@D9 /8**\EG\1^"8M9M]+3Q3KT]S
M<",1W$-Y?268:2/S(HWND!A1W4JRHSAF#I@'<N:GAGQAX,\27FF:?'XCU_\
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M_P#05UW_ ,&UQ_\ %4 =/17,?\(#:_\ 05UW_P &UQ_\51_P@-K_ -!77?\
MP;7'_P 50!T]%<Q_P@-K_P!!77?_  ;7'_Q5'_" VO\ T%==_P#!M<?_ !5
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MU2VTW38=3\=7&A:-,FH3Z?XC:RMC>:WY4J);11(T)B9G#.VV.+?*H0Q@ DT
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MN7MK80VS$QW,9WS3<%23^\ )XV@ ],_X1G7/^AOOO_ .U_\ C='_  C.N?\
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M5\_45G_JOE'_ #Y_\FE_\D;?Z]\1?]!/_DD/_D3Z!_X:^US_ )XWW_@5:_\
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M)*Z:.8_X1G7/^AOOO_ .U_\ C='_  C.N?\ 0WWW_@':_P#QNNGHK$ZCF/\
MA&=<_P"AOOO_  #M?_C='_",ZY_T-]]_X!VO_P ;KIZ* .8_X1G7/^AOOO\
MP#M?_C='_",ZY_T-]]_X!VO_ ,;KIZ* .8_X1G7/^AOOO_ .U_\ C=<]!X>U
MG_A85['_ ,)3>"4:7 QF^RV^2#+-A<>7C P3TSS7I%<Q;_\ )2[_ /[!%O\
M^CIZ #_A&=<_Z&^^_P# .U_^-T?\(SKG_0WWW_@':_\ QNNGHH YC_A&=<_Z
M&^^_\ [7_P"-T?\ ",ZY_P!#???^ =K_ /&ZZ>B@#F/^$9US_H;[[_P#M?\
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MFYA\V.: +UGX^TS4-:UBPM_B9YT.CV?VR_U*/^SVM+91(Z,DD@7Y'4H2P;&
M1S74:+:W?B32[?4](\?R:KIUP-T-Y916<T,H!(RKK&01D$<'M7D]Q\ _%VL:
M:\%Y%X>TU[#2]+TZQ_LG4+N WGV*Y\Y3))''');*XP (S(8B207Z5ZW\*?!]
MSX)\*&RO((+:\FNIKN6*WU&ZU *SN3S<7),DK8QEB%!.<** +7_",ZY_T-]]
M_P" =K_\;H_X1G7/^AOOO_ .U_\ C==/10!S'_",ZY_T-]]_X!VO_P ;H_X1
MG7/^AOOO_ .U_P#C==/10!S'_",ZY_T-]]_X!VO_ ,;H_P"$9US_ *&^^_\
M .U_^-UT]% ',?\ ",ZY_P!#???^ =K_ /&Z/^$9US_H;[[_ , [7_XW73T4
M <Q_PC.N?]#???\ @':__&Z/^$9US_H;[[_P#M?_ (W73T4 <Q_PC.N?]#??
M?^ =K_\ &Z/^$9US_H;[[_P#M?\ XW73T4 <Q_PC.N?]#???^ =K_P#&Z/\
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M_(U'_%9_]0+_ ,C4 =/17,?\5G_U O\ R-1_Q6?_ % O_(U '3T5S'_%9_\
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M--T;P?JOAW0VT72=$\(Z7H[!P=/L[1X;<AOOCRU 7G)SQSF@#G+/XI>(M/\
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M>SR)-VWSLXVG.* /S_HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?JTEU]OMM%DAMK>$V<\?[R![QGER[@?)(A&X'H#0!T"_&CPA)>:7;QZG-/\
MVE';RP3P6%S) BSL4A$LRQF.%G8%565E)/&,UE:3\?\ PW>: =4OHM4T]?MM
MY:BW_LF\FEV6\K1O.R+#N6( *6D(V(6V%MPKF;S]FF2;4/#5W;>(K>VNM)6$
M2:HFF&+4MRN[RB"YAFC*1RF1]T,RSQ\\+ZM\2?LR_P#"1+ T^HZ#?3VUSJ1M
MO[:\-1ZA%%;WD_GD".27'GQO]V7A2"0T1H ['5/CIX4\/7FH0:I?E?LLCX.G
MVEU>XA2*&22:3RX2(T47$>7R4 927!)"Z?Q5^( ^&O@N;7A%8SA;BVMP=2O_
M +%:IYTR1>9)/L?8B[]Q.T\"N8F^ \;:EXCN8M9$46K:=>:>D(LE @$]O:0A
MOE8 [?LF=H"@[\#&WG0\2?!U=0TV0Z1K5Y8ZRT]G<K<:E=7FH62O;S1RC;9M
M<K&@)C _=E" 3S0!4\)_'K2=8\,W6JZE]E(AU#^S8W\+SRZ[!>R>4LO^C-!"
M))=J,=_[H;2C]0NZM:Z^./@NSC21]5F> Z6FM-/!I]S+%%9LCNLTCI&5C4K&
M^-Y!)&,9(%<OKWP'U+Q-8SOJ>O:1>ZG?:HNH:E%/H;OI5XBVWV=(FLS<_-M"
MI(&DD?$B [<!0LWA[X '0O .H^&CKPG^U^&K7PZ+H66S8(5G FV>8<Y\_P"[
MD8V]>> #O]/\<:1J46D2)+<P?VM))%9I>V,]L\K(K,PVRHK+\J,PW ;@,KD<
MUS=Q\=/"UI>1K)>M-;W4<#60LK*[N;FY:3[00%AC@)(*VTC*5+9"DX VEMGX
MC>"9/'?A.32K?4Y=%OE>.6VU*!"TEO(I'S* R]5W*>1PYK&_X5#!#X^TCQ#:
MWPMK738K:&+3UM\C9#!=PJ-^[CB[!Z<>7C^+@ V+CXI>%[6Q^V3:H([?R[R7
M>T$H^6T?R[CC;G*L<8ZM_#FGZ;\2M U;PWJVNQ7-Q!8:2)#?"_LI[.:VV1B1
MO,AF1)%^1E8949# C(-<+_PH;4)M0O/M'BBWFTGR=6AL[)M'20QB_G6:3S_,
MD>.<*R[0/+4%6(//S58\)_ J3P[\.?%OA6;68FM]<2>.&WTVVFM['31)&5Q;
MP2SS&-=S%RJN$R>%7G(!!-\=;Z'X@:?X5N+'POI%[<6]G<-;ZUXH^RWC_:'D
M CMX!;-YSJ(QD!@-S!0<?,:6@?M&3>(?%\N@6NG^&[J]>]OM/M]/L_$PEU))
M+?SL/<VIMU\F)O(Y8.Y7S$^5L\=)I_A/QDWB@^);35-*T,ZC:6=OJ6DZAI3W
MLBM TN3%/'=QJ PE;!*-CY21U6H-!^$FLV.L:>-2\0Z??:!INL7>M65G;Z0\
M%TLTS3D+)<&X=65?M#_=C0MA<G&X, :EK\5$U31?!=UIVGBXO?$DRQ"RDN0C
M6JJC-<ER%.3%L92,#+[5R,YK7TSQY93:';7VI#^S)GO1I<T!W2"*[\WRO+W!
M?NE\;6(4$,IXW8K+\,?"V/PWX\UCQ#_:#7-M<"06&G>5M6P,[B6[*MN.[S95
M5SD#&,<@U%IO@"?5/ >OZ=J+/IVH:_<7-\[*0[V4DC9AP5."\06+E3C<A(/>
M@"UK_P 9/"7AF&2:^U"X,<4L\4IM=/N;GRO(($[N(HVVQQE@&E.$4G!;-6KS
MXI>&M/\ %47AZ:_E&I221P;DLYWMHY77='%)<JAACD9<%8W<,=R8!W+GSKXA
M?LUR>.O!^D: =>LS!:Z9<V5RVJZ4;Y);B;:6OHHS,JQ7(?S")"'($K@8R2>M
ML/AOKFCZ]<2Z?XHAM=#U":&ZU&R.F![F65((X66*<R;8XW6*/<IC=AE]KKD%
M0!5^.7A6^##3K_S76:W4->6MU;13Q2SK");>0PD7";F #Q[D)9,NH8-5C2?C
M=X.UK2[[4+34;IK6SB@G;S-,NHGFCG++ T"-$&G$C*RH8@^XC R>*P;7X-Z]
M_P ([8^'K[QA#<:'I;62Z=;PZ2(I!';SQR+]H<RMYLFV)4W((E&YB4;*A:FL
M?LZ6VM>%X-'N=4M[D6^CZ9IL?VS35GMWDLI6E226%GQ)&Y(#19'&<."00 >G
M>&?$VG>+M)34=,EEDMV=HRMQ;R6\L;JQ5DDBD571@1RK*#[5JUROPT\#1_#S
MPK'I*#3%;SI)W71]+CTVU#.Q.(X$)V@# ^9F8XR6-=50 4444 %%%% !1110
M 4444 <S\3O^2=>)O^P=/_Z+-?FK7Z5?$[_DG7B;_L'3_P#HLU^:M?J? _\
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MB@ KF+?_ )*7?_\ 8(M__1T]=/7,6_\ R4N__P"P1;_^CIZ .GHHHH ****
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M ) >H_\ 7M)_Z":OU0U[_D!ZC_U[2?\ H)H _-NBBB@ HHHH **** "BBB@
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M?_CE+)_R4J#_ +!$G_HY*Z:@#F/^$FUS_H4+[_P,M?\ XY1_PDVN?]"A??\
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MA0OO_ RU_P#CE=/10!YGX9\5:GIR^);B7PW<K FHS332/>6R+"!&A;<6D X
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MG_0H7W_@9:__ !RC_A)M<_Z%"^_\#+7_ ..5T]% ',?\)-KG_0H7W_@9:_\
MQRC_ (2;7/\ H4+[_P #+7_XY73T4 <Q_P )-KG_ $*%]_X&6O\ \<H_X2;7
M/^A0OO\ P,M?_CE=/10!S'_"3:Y_T*%]_P"!EK_\<H_X2;7/^A0OO_ RU_\
MCE=/10!S'_"3:Y_T*%]_X&6O_P <H_X2;7/^A0OO_ RU_P#CE=/10!S'_"3:
MY_T*%]_X&6O_ ,<H_P"$FUS_ *%"^_\  RU_^.5T]% ',?\ "3:Y_P!"A??^
M!EK_ /'*IZUXDUMM'OU;PE?(IMY 6-W;''RGG_65V=4->_Y >H_]>TG_ *":
M /S;HK&_X2RQ_P">&I_^"JZ_^-T?\)98_P#/#4__  577_QN@#9HK&_X2RQ_
MYX:G_P""JZ_^-T?\)98_\\-3_P#!5=?_ !N@#9HK&_X2RQ_YX:G_ ."JZ_\
MC='_  EEC_SPU/\ \%5U_P#&Z -FBL;_ (2RQ_YX:G_X*KK_ .-T?\)98_\
M/#4__!5=?_&Z -FBL;_A++'_ )X:G_X*KK_XW1_PEEC_ ,\-3_\ !5=?_&Z
M-FBL;_A++'_GAJ?_ (*KK_XW1_PEEC_SPU/_ ,%5U_\ &Z -FBL;_A++'_GA
MJ?\ X*KK_P"-T?\ "66/_/#4_P#P577_ ,;H V:*QO\ A++'_GAJ?_@JNO\
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MM'^4,V%*#YN<3Z?\$=7L_BD-;G:VOM,DOX=4>XEUS45>&5+58?+6Q1A;R'*
MB9SD*Q4H< UUO_"\/#O_ $#?&'_A%:S_ /(E'_"\/#O_ $#?&'_A%:S_ /(E
M 'H%%>?_ /"\/#O_ $#?&'_A%:S_ /(E'_"\/#O_ $#?&'_A%:S_ /(E 'H%
M%>?_ /"\/#O_ $#?&'_A%:S_ /(E'_"\/#O_ $#?&'_A%:S_ /(E &U\3O\
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MN_\ ^P1;_P#HZ>L;_A>'AW_H&^,/_"*UG_Y$KG8/C1X?'Q"O9_[/\6;&TN!
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M6L__ ")0!Z!17G__  O#P[_T#?&'_A%:S_\ (E'_  O#P[_T#?&'_A%:S_\
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M[I=X5D5R2KH&??TKZ3^#NA:OX7^%7A/2->\D:O8Z9;VUPD";51EC"[/ON"5
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M(1,)<K+(@WK#P>>V:Z9_B)X(M_BS'\,8]*636[J-M<E\FRC^RI,K+(&D;/\
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MHK&\*^+-/\9:=-?Z7(9[*.ZFM5GX*2M$Y1V0@G*[E8 ]\5LT %%%% !1110
M4444 %%%% !1110 4444 ?F91110 4444 %%%% !1176_"_[&OBV*34--FU*
MRC@F:3RK3[5]G^0@3M$>'5&(8@\8'X4 <E17N,WPGL/%&NW33R06LR-:7\CZ
M1%]GM7TR1#NG6)QF.0;<D?=!;A:RM+^%.@:[X)GU2QN;\ZDT%U=06MQ*D3F.
M-SMVH\:B9=HRSI(-I_A/2@#R.BO<;KX=>%=::QG$<VC65EX9@U2Y47&6G+L0
M"62!V!')9PC9&T;5QFLJ;X:^$[!=:NY;C6+VRM+BQAACC_T63%PI)W&6$$XP
M"&V ,,<#.0 >1T5[[IOP=\/)J.NK8SWX?1[NXL96N_(G2?%K+(&5&APA#)CG
M<>X*G&.!\;>!]+\,:?)#;PZQ<:C;0VD\U]L1[%Q/'OQP 8^3A22V[:>E ' 4
M444 %?<O@'XN>!;7P+X<AF\:>'H9H]-MD>.358%96$2@@@OP0:^&J_0/X>:!
MIDG@#PRS:=:,S:9:DDP*23Y2^U !_P +D\ _]#QX;_\ !M;_ /Q='_"Y/ /_
M $/'AO\ \&UO_P#%UT'_  CVE?\ 0,L__ =/\*/^$>TK_H&6?_@.G^% '/\
M_"Y/ /\ T/'AO_P;6_\ \71_PN3P#_T/'AO_ ,&UO_\ %UT'_"/:5_T#+/\
M\!T_PH_X1[2O^@99_P#@.G^% '/_ /"Y/ /_ $/'AO\ \&UO_P#%T?\ "Y/
M/_0\>&__  ;6_P#\770?\(]I7_0,L_\ P'3_  H_X1[2O^@99_\ @.G^% '/
M_P#"Y/ /_0\>&_\ P;6__P 71_PN3P#_ -#QX;_\&UO_ /%UT'_"/:5_T#+/
M_P !T_PH_P"$>TK_ *!EG_X#I_A0!Y[X%^+G@6WTJ^67QIX>B9M5OW ?58 2
MK74I4_?Z$$$>QKHO^%R> ?\ H>/#?_@VM_\ XNN-UQ(/#OP8\=ZOI]M;6VH6
M+ZQ/;W"VD<C1ND\Q4A65@V,# ((XZ&N*T?XC6_AB/Q3>)_;'CC3+%;"SB37O
M#HL+N+4IY&7R/+ALHY2A1X')$#L V5WD[0 >S_\ "Y/ /_0\>&__  ;6_P#\
M71_PN3P#_P!#QX;_ /!M;_\ Q=>377Q=DMUTO4[GPA#IAET^]#Z+?VTEL)[E
M+NTAA9&FM4N&4B9MJK!YC[L+$[;0;"_';38/".BZ[>>"+*!=6O;C18+?SA%)
M_:J3O#';E9X(F6.38S>8ZJR8PT8- 'J/_"Y/ /\ T/'AO_P;6_\ \71_PN3P
M#_T/'AO_ ,&UO_\ %UYEKGQ.N/#^M>)+&U\%Z;J\^E)=7URMS?QP1Q0V]M9R
M2) 5M"7)-S\HDQDAB74$*OM-OHNCW5O%-'IMF8Y%#KFW3H1D=J ,/_A<G@'_
M *'CPW_X-K?_ .+H_P"%R> ?^AX\-_\ @VM__BZZ#_A'M*_Z!EG_ . Z?X4?
M\(]I7_0,L_\ P'3_  H Y_\ X7)X!_Z'CPW_ .#:W_\ BZ/^%R> ?^AX\-_^
M#:W_ /BZZ#_A'M*_Z!EG_P" Z?X4?\(]I7_0,L__  '3_"@#G_\ A<G@'_H>
M/#?_ (-K?_XNC_A<G@'_ *'CPW_X-K?_ .+KH/\ A'M*_P"@99_^ Z?X4?\
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M:W_^+H_X7)X!_P"AX\-_^#:W_P#BZZ#_ (1[2O\ H&6?_@.G^%'_  CVE?\
M0,L__ =/\* .?_X7)X!_Z'CPW_X-K?\ ^+H_X7)X!_Z'CPW_ .#:W_\ BZZ#
M_A'M*_Z!EG_X#I_A1_PCVE?] RS_ / =/\* .?\ ^%R> ?\ H>/#?_@VM_\
MXNC_ (7)X!_Z'CPW_P"#:W_^+KH/^$>TK_H&6?\ X#I_A1_PCVE?] RS_P#
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M^@AX;_\ "GTW_P"2*_2[_A'M*_Z!EG_X#I_A1_PCVE?] RS_ / =/\*#Y?\
MUZS+_GW#[I?_ "1^:/\ PK75?^@AX;_\*?3?_DBH;SP!J-A9SW4VH>'O*AC:
M1_+\1Z>[;0,G"K.2QP.@!)[5^FG_  CVE?\ 0,L__ =/\*YKXFZ#ID?PV\6,
MNG6BLNDW9#"!00?)?VH#_7K,O^?</NE_\D?GM_PK75?^@AX;_P#"GTW_ .2*
M/^%:ZK_T$/#?_A3Z;_\ )%?I=_PCVE?] RS_ / =/\*/^$>TK_H&6?\ X#I_
MA0'^O69?\^X?=+_Y(_-'_A6NJ_\ 00\-_P#A3Z;_ /)%'_"M=5_Z"'AO_P *
M?3?_ )(K]+O^$>TK_H&6?_@.G^%'_"/:5_T#+/\ \!T_PH#_ %ZS+_GW#[I?
M_)'YH_\ "M=5_P"@AX;_ /"GTW_Y(H_X5KJO_00\-_\ A3Z;_P#)%?I=_P (
M]I7_ $#+/_P'3_"C_A'M*_Z!EG_X#I_A0'^O69?\^X?=+_Y(_-'_ (5KJO\
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MSJ=U)))<^4<;D#%]N#M )*DXZ$5F6_B?6+/29=+@U:^@TR7/F6<=RZPOGKE
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M?6=K=L)'%RDA4O,SRR;5!^=PO3 ' S],>$;A+KPGHLT3;HI+*%U;&,@QJ0:
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MD_\ \<H_X4)X$_Z 7_DY/_\ '*] J*YN8;.WEN+B5(((E+R2R,%5% R6)/
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M ..5Z!10!Y__ ,*$\"?] +_R<G_^.4?\*$\"?] +_P G)_\ XY7H%% 'G_\
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M-/%O_8(N_P#T2] &-_PH3P)_T O_ "<G_P#CE'_"A/ G_0"_\G)__CE>@44
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M@UP@NXD*R E%#1A5.0Q8AMPR" =I_P *$\"?] +_ ,G)_P#XY1_PH3P)_P!
M+_R<G_\ CE>23_&#QGHU[-KDUSIFM7&JZ!I,VFZ;I986UN]Y>-&C,DUPJ2LN
M\#S/,A$NW'[OK7M7PI\3:WXJ\*&Y\164%CJ\%U-:SQV[PD$HY&2D4\ZQMC@Q
M^:Y4@Y- %#_A0G@3_H!?^3D__P <H_X4)X$_Z 7_ ).3_P#QRO0** //_P#A
M0G@3_H!?^3D__P <H_X4)X$_Z 7_ ).3_P#QRO0** //_P#A0G@3_H!?^3D_
M_P <H_X4)X$_Z 7_ ).3_P#QRO0** //_P#A0G@3_H!?^3D__P <H_X4)X$_
MZ 7_ ).3_P#QRO0** //_P#A0G@3_H!?^3D__P <H_X4)X$_Z 7_ ).3_P#Q
MRO0** //_P#A0G@3_H!?^3D__P <H_X4)X$_Z 7_ ).3_P#QRO0** //_P#A
M0G@3_H!?^3D__P <H_X4)X$_Z 7_ ).3_P#QRO0** //_P#A0G@3_H!?^3D_
M_P <H_X4)X$_Z 7_ ).3_P#QRO0** /S,KF;Z^/A'XE>&-?!V6]TS:3=MT^5
M^8\_1QG\*Z:L3QIX>/BCPY=Z?&ZQ3N \,C9 212"IR.1R/UH-Z%9T*L:L=XM
M,^AM%\0!%7YJ^:_VUOA3XQ^,'B3P[>>&=+&I6]GH6JVLS?:(XRLDB)Y:89AD
MM@@=N.2*LVOB#XG6J*H;PNY48W,+G)]^*N+XT^*2C 'A3_OFZ_QH/M\7F&68
MJ+BY-7\CW;P3>7/A_P"'7AC2KT"*\L=+M;6>,,&"R)"JL 1P<$'FO-/CYXOE
ML_ ]Y:6K9OM4==.MUSU:4X/_ ([NKD)?%WQ0FZCPJ/H+G_&LEM+\4^)/$6E7
MWB672?LNG,\L<.G>;\\C# +;_3J.:!5LVP4,+.%!OF:LM/D='I.G1:/I=I8P
M_P"JMXEB7W &,UZG\%5CN+KQ3;_V3!JUT^B7)MX9%D9V8 ?(@1@3N!YQ\W'!
M'.?-Z*#X(^@O&6BZ-XBLFCU"R2WN=/\ #.F72:FLDGF("Z(RE=VPJ%8_PY]Z
MC\3?#?PGIVMZ-80Z'?0P3:U:V<5Y(3'#?6[D;R&-PS29!!WQ(@&<'!(KP&B@
M#WSP+\/?#OBSQ%JZR>';=--M-572U2WFNI)$3=)^]<>:-A.%'F%M@*X$9)IE
MK\+M$31]+%QH)^QS65^]_KK7,JFTDB>41,1OV+DJJX93N[<@UX-5_4->OM4L
M=.L[J?S;;3XVBMDV*/+5F+$9 R>23SF@#WBQ^&?@F.#0UGTJ\N[&Y2Q;^VL^
M5!-)*ZAT,IN0&_B78D0=<9)P":LZ#X!L_"_A^[#>%UFUR\L=818+KSS+(L3H
M(D5 XZJQY4;B,$'U^;Z* /?K[P+I]Y'%<PZ'-XJU-;72T.FS7\P:*"2 EY0V
M_* ,%4$Y1 >5Q5#1/AKX>U;X:WM__9K6^H0P7<AO;BX>2(-&YV@7$3&)<* -
MDD8+DY4@8->(44 %?H-X.T>PUSX9^&+74K*WU"V_LZRE\FZB65-Z(C(VU@1E
M6 8'L0"*_/FOM;P'\,=0N/ _AV4?$+Q9 )-.MV$<<MF%3,2G S;$X'UH ]%N
M/!N@71N#/H>FS&XNH[Z;S+2-O-N(PHCF;(YD78F&/(VC!X%(W@OP\T,,)T'3
M#%#>-J,<9LX]J71+$SJ-O$A+,2X^;YCSS7,?\*KU'_HH_C#_ +^V?_R-1_PJ
MO4?^BC^,/^_MG_\ (U &W-\,_"%S;P6\WA31)8+>U^Q0Q/IT)6.WW!_)4%<!
M-RJVT<94''%:\V@Z;<ZM::I-IUK+J=I&\5O>O IFA1\;U1R-RAL#(!YP,UQO
M_"J]1_Z*/XP_[^V?_P C4?\ "J]1_P"BC^,/^_MG_P#(U '4ZIX0T+7-6T_5
M-2T33M0U/3F+V5[=6D<LUJQZF-V!*'@?=(Z5%:>!O#=A?ZK?6WA_2K>]U8;=
M0N8;*)9+P<\3,%S(.3][/6N;_P"%5ZC_ -%'\8?]_;/_ .1J/^%5ZC_T4?QA
M_P!_;/\ ^1J .AT_X?\ A?2/#EQX>L?#>D66@7(<3Z5;V,4=K*&&'W1!=K9'
M7(YK<AACMX4BB18XD4*B(,*H'  '85P7_"J]1_Z*/XP_[^V?_P C4?\ "J]1
M_P"BC^,/^_MG_P#(U $^AZK-HG@O7+VVLIM1NH]3U'R+2!"S2R&\E"+P#@%B
M,L>%&2< $UY);Z/XZ\#V7BC^U-(^SWVL6]@]YJ?A::[U!Y&-ZXO)QMMHY%D$
M4_R1QAV58EP<+FM?_A%]0\)_#GQ1X@'CCQ9,-,N-4N/LL=S9QB7R[B4\L;5L
M%L9)QU)X[5O^"?"FH^,M";4?^$]\86>+RZM/+^TV;_ZFXDAW9^R#[WE[L8XS
MCG&: .%\467BCQ-X@NO$,5AXHMK^%-6O=!@(ND%K)'';VT7[H'R=S*ES*J3<
M/YH&#DBMK0&UN/4H?[%3QE_PBDNIVLBR:X;UKQQ!#/-<L5N#YT<4CK;Q"-PJ
MLVX*NUAN?XYT;QAX/OUGC\0^*+OPW%):Q7&H2ZS917#O-,(MMO;BQ?S2I9.'
M>,L6PNXUW?\ PJO4?^BC^,/^_MG_ /(U 'DEQX,\:7>AW,KZIXRAUBXT6RE<
MQZA=B)-3N[DXV*K#:EH/O*N%*,/-#;1C3U'0?$NI7MQK%Y/XR"31:UJ$]C8W
MMW OV>%A%9VD<<979)*-LP*8DRK ,%8@^D?\*KU'_HH_C#_O[9__ "-1_P *
MKU'_ **/XP_[^V?_ ,C4 >=Z=>>,[%QH%_\ \)->:G%<:3;S:C#;7 @-I;6Z
M7%Q,)<",O/(L\)"%G.Y P&16+JVD_$33-&MKJSU#Q-#?7.BV\^MS3)=ZA'"]
MS=JSI;VR.C;X(UG0K 5E"2+R6"5Z]_PJO4?^BC^,/^_MG_\ (U'_  JO4?\
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M +^V?_R-0!Z!17G_ /PJO4?^BC^,/^_MG_\ (U'_  JO4?\ HH_C#_O[9_\
MR-0!Z!17G_\ PJO4?^BC^,/^_MG_ /(U'_"J]1_Z*/XP_P"_MG_\C4 >@45Y
M_P#\*KU'_HH_C#_O[9__ "-1_P *KU'_ **/XP_[^V?_ ,C4 >@45Y__ ,*K
MU'_HH_C#_O[9_P#R-1_PJO4?^BC^,/\ O[9__(U 'H%%>?\ _"J]1_Z*/XP_
M[^V?_P C4?\ "J]1_P"BC^,/^_MG_P#(U 'H%%>?_P#"J]1_Z*/XP_[^V?\
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M>H_]%'\8?]_;/_Y&H ZEO!^@MXB;7VT33CKS0?9CJAM(_M1A_P">?FXW;?\
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M6:_+VOU"^)W_ "3KQ-_V#I__ $6:_+V@_7. ?^8K_MS_ -N"BBB@_7 HHHH
M*^D/V9?VD9O"5Q:>$_$LSSZ)*XBL[MLLUHQ. A[F,G_OGZ=/G&.-YI%CC1GD
M8A551DDGH *^U_V:?V:4\&1V_BCQ1;J^OL ]I92#(L@>C,/^>G_H/UZ!\CQ/
M7P%+ 2CCE>_PI;W[KM;J_P [V?T?1110?SJ%<Q\4/^2:>+?^P1=_^B7KIZYC
MXH?\DT\6_P#8(N__ $2] '3T444 %%%% !1110 4444 <S)_R4J#_L$2?^CD
MKIJYF3_DI4'_ &")/_1R5TU !1110 4444 %%%% !7,6_P#R4N__ .P1;_\
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M_A-X+.".WC:31KHL510H)Q> 9P/2O,J* /6O^&MOBGZ^#_\ P377_P FT?\
M#6WQ3]?!_P#X)KK_ .3:\EHH ]:_X:V^*?KX/_\ !-=?_)M'_#6WQ3]?!_\
MX)KK_P"3:\EHH ]:_P"&MOBGZ^#_ /P377_R;1_PUM\4_7P?_P"":Z_^3:\E
MHH ]:_X:V^*?KX/_ /!-=?\ R;1_PUM\4_7P?_X)KK_Y-KR6B@#TO1_VGOB;
MHEO-#!)X3=);F:Z8R:/=$[I9&D8#%X.,L<>V.M7_ /AK;XI^O@__ ,$UU_\
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M_AK;XI^O@_\ \$UU_P#)M'_#6WQ3]?!__@FNO_DVO):* /6O^&MOBGZ^#_\
MP377_P FT?\ #6WQ3]?!_P#X)KK_ .3:\EHH ]:_X:V^*?KX/_\ !-=?_)M'
M_#6WQ3]?!_\ X)KK_P"3:\EHH ]:_P"&MOBGZ^#_ /P377_R;1_PUM\4_7P?
M_P"":Z_^3:\EHH ]:_X:V^*?KX/_ /!-=?\ R;1_PUM\4_7P?_X)KK_Y-KR6
MB@#TO2_VGOB;I+WS0R>$V-Y<M=2;]'NCAB%! Q>=/E%7_P#AK;XI^O@__P $
MUU_\FUY+10!ZU_PUM\4_7P?_ .":Z_\ DVC_ (:V^*?KX/\ _!-=?_)M>2T4
M >M?\-;?%/U\'_\ @FNO_DVC_AK;XI^O@_\ \$UU_P#)M>2T4 >M?\-;?%/U
M\'_^":Z_^3:/^&MOBGZ^#_\ P377_P FUY+10!ZU_P -;?%/U\'_ /@FNO\
MY-H_X:V^*?KX/_\ !-=?_)M>2T4 >M?\-;?%/U\'_P#@FNO_ )-H_P"&MOBG
MZ^#_ /P377_R;7DM% 'K7_#6WQ3]?!__ ()KK_Y-H_X:V^*?KX/_ /!-=?\
MR;7DM% 'K7_#6WQ3]?!__@FNO_DVC_AK;XI^O@__ ,$UU_\ )M>2T4 >M?\
M#6WQ3]?!_P#X)KK_ .3:/^&MOBGZ^#__  377_R;7DM% 'K7_#6WQ3]?!_\
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MF>C_ (8W\=?]#%X=_P"_,]?4FM^,(].U#2+&SBCU"ZU%)+E0)@BK;1JIDFR
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M&D:E%XMU#PYHEOH/AR:[MX[.TLKBWGMU*6Z"78UL[P_?+$B-R,L2V'+ >X4
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MK23Y\DIN3;(22-APN&(KTG_A)M<_Z%"^_P# RU_^.4?\)-KG_0H7W_@9:_\
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MCW;.B-YKOB.95#;<*!D-Z)_PDVN?]"A??^!EK_\ '*/^$FUS_H4+[_P,M?\
MXY0!R5G\"8M/TN6QAUJ1D>UTJW\R:W!<FSN7N"YPP&9"Y&  %Z\]*YF;]E^:
M[\1:YJL_B*Q:;4K'5-/-TNC'[;)'=NK(;BX:<M.80@1!A%"84!<5ZG_PDVN?
M]"A??^!EK_\ '*/^$FUS_H4+[_P,M?\ XY0!QEG\(?$^CZYIESI_BK2'TVPN
M+JZBL=2T*6<QRW%Q++)(CI=Q@/Y<IB#%6P-Q &]A61:?LO:;:ZIXAE2YTFWM
M]26\,-U:>'[>/58Y;B3S-TUZ23,L;;MJA$R,!R^*]*_X2;7/^A0OO_ RU_\
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M_CE'_"3:Y_T*%]_X&6O_ ,<H Z>BN8_X2;7/^A0OO_ RU_\ CE'_  DVN?\
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MO_Y94?VCAN[_ / 9?Y!_9^([+_P*/^9\TT5]+?\ #*/@G_HM?A[_ ,"=+_\
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MQ0ASDH1D<,K,C @JQ!!IVN^-O#OA>VNKG6=?TO2+>T,:W$U]>1PI"7^X'+,
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M;_A++'_GAJ?_ (*KK_XW1_PEEC_SPU/_ ,%5U_\ &ZV:* ,;_A++'_GAJ?\
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M10!Y_P#\+P\._P#0-\8?^$5K/_R)1_PO#P[_ - WQA_X16L__(E>@44 >?\
M_"\/#O\ T#?&'_A%:S_\B4?\+P\._P#0-\8?^$5K/_R)7H%% 'G_ /PO#P[_
M - WQA_X16L__(E'_"\/#O\ T#?&'_A%:S_\B5Z!10!Y_P#\+P\._P#0-\8?
M^$5K/_R)1_PO#P[_ - WQA_X16L__(E>@44 >?\ _"\/#O\ T#?&'_A%:S_\
MB4?\+P\._P#0-\8?^$5K/_R)7H%% 'CWQ$^-'A^\\!^(8(]/\6*\EA,BF7P=
MJ\:@E#U9K4!1[D@5^<O_  QGXP_Y_?\ RUO$?_RKK]5?B=_R3KQ-_P!@Z?\
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M&I/"G_0/UC_OS%_\=H_UTI?\_P"/W!]1RS^;\3\YO^&,_&'_ #^_^6MXC_\
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MZ!^L?]^8O_CM'_#4GA3_ *!^L?\ ?F+_ ..T?ZZ4O^?\?N#ZCEG\WXGYS?\
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MP1;_ /HZ>@#&_P"%X>'?^@;XP_\ "*UG_P"1*/\ A>'AW_H&^,/_  BM9_\
MD2O0** //_\ A>'AW_H&^,/_  BM9_\ D2C_ (7AX=_Z!OC#_P (K6?_ )$K
MT"B@#S__ (7AX=_Z!OC#_P (K6?_ )$H_P"%X>'?^@;XP_\ "*UG_P"1*] H
MH \__P"%X>'?^@;XP_\ "*UG_P"1*/\ A>'AW_H&^,/_  BM9_\ D2O0** /
M/_\ A>'AW_H&^,/_  BM9_\ D2C_ (7AX=_Z!OC#_P (K6?_ )$KT"B@#Q[P
MC\:/#]O-X@+:?XL/F:I(XV>#M7? *1]<6IP>.AP:YIK?X<-</*;#Q[\VO?\
M"0;/^$/U?;YW7RO^/+_4[LOMZ[B><'%>P>"O^/CQ+_V%Y?\ T7'734 ?/&OQ
M^!/$&L:OJ#M\1;5]6BNX+R*W\&ZGLDCN(8(F7YM/8C;]FB92"#NSDD';6OKG
MB#P1X@T7QGIEQ:^/$@\51&&]:+P;JP:-3;K!^Z)LB =J@_,&YSVXKW"B@#Y:
MNO 7PHN-9UW5!9?$*"[UF73)KEHO!^J##6+H\>W-@<;RB[^N<<;:Z3PM<^#?
M!WB"6^TV\^)T.EM=W%]'X>'A35ET^*>?)E<*MB)&!+,PC>1D5F)"@@$?0-%
M'S/!H/@'3=$\.6&DWGQ0T2XT.PFTJ'4]/\)ZHEU+:3,&DB=CIY4995(=%5U*
M@JRFIK[0_AG>^*KWQ,MG\0+;Q%/>V5]%JT?@_56NK9K:)852.1[%F*.@*R*Y
M?=O;H<8^DJ* //\ _A>'AW_H&^,/_"*UG_Y$H_X7AX=_Z!OC#_PBM9_^1*]
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M]D7QK\/IDOO#FL:+:W\OA"71IHWFF$46I2>3&]U'B+D&*%,G ):-<CDD>A^
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M567X;W\)E1KRQ^T*7,4&]]\\:$;I$^3&T YPQ#<'CBI_>QBG[%-VMT>WZ_\
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M -'3T =/1110 4444 %%%% !1110 4444 <AX;O1IMMXONS#+<"WU*XE\F
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MNE\\_:+AY,R;0N_D_>V@#/7  I@>Y:3\(?#.B^*- >6&YU&">[O+&>SN+I)
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M2W3< Z>8DZ@A V:[6U\*WUCJ.J:A;> /!MO?ZJI34+J*^99;Q3U$S"RS(/\
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M/17,?VAXR_Z .A?^#N;_ .1*/[0\9?\ 0!T+_P '<W_R)0!T]%<Q_:'C+_H
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M;Q(W@:[TN71M*N;2&PN[ZT,E]<7$D'"-'*ZK @ARS.5<Y&(R1@]5X/O(M/\
M#.L74\\-M##J>I.TUPX2- +N7EB>@'<UYKH?CWQ3X1NF3Q#?ZQJOB&>-(/\
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MIJ "BBB@ HHHH **** "N8M_^2EW_P#V"+?_ -'3UT]<Q;_\E+O_ /L$6_\
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M?\)G=?\ 0JZ[_P!\0?\ QZNGHH YC_A,[K_H5==_[X@_^/4?\)G=?]"KKO\
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MW_F=Y_P@GA__ *&:3_OU9?\ R;1_P@GA_P#Z&:3_ +]67_R;7!T4?7,'_P!
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MMD&__6H=W^MQCMUKH?\ A,[K_H5==_[X@_\ CU+)_P E*@_[!$G_ *.2NFH
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M*.O:M)\3_#>I>(%U>-]%U62&ULVMI8K$(S!%FA\J&[M'5, B83))O!65<88
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ME4ZK):7$<I-P18JRDA'PV9""Y]S7KW_"^_ G_0=_\DY__C='_"^_ G_0=_\
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MS_\ QNC_ (7WX$_Z#O\ Y)S_ /QN@#T"BO/_ /A??@3_ *#O_DG/_P#&Z/\
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M9SM%=%_PBVG_ /0VZ/\ ]^KW_P"1Z/\ A%M/_P"AMT?_ +]7O_R/1_8V8?\
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M1_POOP)_T'?_ "3G_P#C= 'H%%>?_P#"^_ G_0=_\DY__C='_"^_ G_0=_\
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MFV1%O+1F*KEE4,0H!)  KEO^%]^!/^@[_P"2<_\ \;H_X7WX$_Z#O_DG/_\
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MZN?]/O\ R7_@A_JA_P!/_P#R7_[8_2NBOS4HH_U<_P"GW_DO_!#_ %0_Z?\
M_DO_ -L?I77,?%#_ ))IXM_[!%W_ .B7K\^Z*/\ 5S_I]_Y+_P $/]4/^G__
M )+_ /;'Z5T5^:E%'^KG_3[_ ,E_X(?ZH?\ 3_\ \E_^V/TKHK\U**/]7/\
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MU8$$=B"*FH **** "BBJVH:E::3:M<WUU#9VRLJF:XD$:!F8*HR3C)8@#U)
MH LT444 %%%95QXJT6UDNTGUBPA>T5WN%DND4PJBHSEP3\H59(R2>@=2>HH
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M,896,JD1'8\I$J[R%1030!]$*VY01W]1BEKY<\7_  )UN^CBLX- NAX=DO\
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M?#.L6]O"ADDFEL)51% R68E<  #.31[>E_.OO0?6:'\Z^]'/45TO_"L?&/\
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MJ-ZJ?:(;X"P58U8 #RF;;&HQ(OW@X Q]&:/X?TOP[#<1:5IMGID5Q.]U,EG
MD2R3.<O(P4#+L>K'D]ZT* /DG7--\?MJ&I7+-X@T^PN+Q(M0OX]/U"ZG^S+=
MZJ8@B6DT-RR M;?ZE\A&0D&,D5HZC_PGNFZ]X$NS/XLUF=+73XY+)K2_L1*/
M,<R2.\$MQ;*^THLD=\F2H)696Y'U+10!\J-H>KZ#H<VG6\/CRWA2YU_[,NFO
MJ1D.JM=AK)F<'+0-&2P9R;8DN9"6.:[>#1_%\?C,:R\VO-?C7EM/(-U<?V?]
MD.E L?(W>24^TY/F;<AQC=VKW2B@#Y,\-V'C^;P7XA_M'7?%T=])#9'4-N@Z
MH/L]R)R9Q%NOS-*N RM_9^Q-K*8P?NUZ;X-U;Q3'^SKJ=S<:7K/]OVMK>"V@
M:YN'O+C:7*-$US!]H&>B":)I<*N?,/S-[-10!\P?#S1O%FN>7H>J7OBV70?^
M$F8B]QJ^ERR69TLL/GN)WNDC%R,?-+]_C"A@M4O$5CXEU?P[H=MXBMO&EWJ9
ML-%_L^*R@NWMWE2Y4W;7BH#'YF%5F-QC@ Q_-NKZLHH \]\9:'J>M_$C0/)N
M-6ATRUTN\N=MG=SV]L]VLML8!,8V4/QYF$8D,-^01FO*?#R^*[;PCJVJVUWX
MLM+C2=*LM3OQXBGN8UGU6!WDNX8_M! \F2,%#Y?^CC<A3E21],5GZYX?TOQ-
MI[6&L:;9ZM8LZR&VOH$FC+*P96VL",@@$'L0#0!\R_%J7QY<^";"\L)O%,6J
M:I9ZCK< TV+4+CR9V\LVMD8[1H_*98RH!FD,.Y),Q2LV5;XD\-Z\GC[Q9X@@
MTWQ-;ZI>:9J:Z?/I\=ZD9N#8Z<4^6/Y 25F"EQR\8 )9% ^K** /EW3;/XAS
M>(/&37>L>*(=0DM=31[>ST:\:&)"^+1X)I;T6KN(RC*MJB2'#ARKY)]&_9RN
M-<;P[K5MK$.J&*#4"+2]U)M0'VF,HO,<6H+]JB48R5D>4!F;9(5PJ^N44 %%
M%% 'YF5G^ =6/@_XT2PD[+3Q'99'H;B#_P"P)_$U6_X1.Q_Y[ZG_ .#6Z_\
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M*/\ #O\ T$O&'_A:ZS_\ET?\*/\ #O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\
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M*/\ #O\ T$O&'_A:ZS_\ET?\*/\ #O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\
M#O\ T$O&'_A:ZS_\ET?\*/\ #O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\ #O\
MT$O&'_A:ZS_\ET?\*/\ #O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\ #O\ T$O&
M'_A:ZS_\ET?\*/\ #O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\ #O\ T$O&'_A:
MZS_\ET?\*/\ #O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\ #O\ T$O&'_A:ZS_\
MET?\*/\ #O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\ #O\ T$O&'_A:ZS_\ET?\
M*/\ #O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\ #O\ T$O&'_A:ZS_\ET?\*/\
M#O\ T$O&'_A:ZS_\ET >@45Y_P#\*/\ #O\ T$O&'_A:ZS_\ET?\*/\ #O\
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M'_T$?^2S_P#D0_U:S7_GS_Y-'_,^MZ*^2/\ A,?#O_0+\8?^'$UG_P"/4?\
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M'_"C_#O_ $$O&'_A:ZS_ /)= 'H%<Q;_ /)2[_\ [!%O_P"CIZQO^%'^'?\
MH)>,/_"UUG_Y+KG8/@OX?/Q"O8/[0\6;%TN!P?\ A,=7WY,LPY;[5N(XZ9P.
M?4T >Q45Y_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET
M>@45Y_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45
MY_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45Y_\
M\*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45Y_\ \*/\
M._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET ;7@K_CX\2_\ 87E_
M]%QUTU>/>$?@OX?N)O$ ;4/%@\O5)$&SQCJZ9 2/KBZ&3SU.370_\*/\._\
M02\8?^%KK/\ \ET >@45Y_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8
M?^%KK/\ \ET >@45Y_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%K
MK/\ \ET >@45Y_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\
M\ET >@45Y_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET
M>@45Y_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45
MY_\ \*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45Y_\
M\*/\._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45Y_\ \*/\
M._\ 02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45Y_\ \*/\._\
M02\8?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45Y_\ \*/\._\ 02\8
M?^%KK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET >@45Y_\ \*/\._\ 02\8?^%K
MK/\ \ET?\*/\._\ 02\8?^%KK/\ \ET ?!E%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5]J>*?'.J_#O]G_ ,.:QHL-G/J/DZ1:1I?JYA_?R00D
MG:0>!(2,'KC@]*^*Z_0;P=H]AKGPS\,6NI65OJ%M_9UE+Y-U$LJ;T1&1MK C
M*L P/8@$4 >-3?'/X@:!J^IIJO\ PCE[I^B^++'PW=_8]/GADNUNA"1+&6N7
M$103KE6#AL'E:XGP;XJ\07'Q*TR--0\365U<^+==BEU+5-9EETJ]LH&G'V."
MW,[JDR_NRH\J,XC8JQ -?6%QX-T"Z-P9]#TV8W%U'?3>9:1MYMQ&%$<S9',B
M[$PQY&T8/ I&\%^'FAAA.@Z88H;QM1CC-G'M2Z)8F=1MXD)9B7'S?,>>: /B
M[X _';Q+HFIZ%'XYUK4;NUT?P=J6ORW%S=O(FH6TCV\D#ON/SRH1/"-V3\HP
M?FKT7]F/XKZ]8W_B;2/'-UX@U"_N;*/Q3 MYI5^)HED.VYM+>&2+S)(X7\L+
MY2LN)..E?0$WPS\(7-O!;S>%-$E@M[7[%#$^G0E8[?<'\E05P$W*K;1QE0<<
M5KS:#IMSJUIJDVG6LNIVD;Q6]Z\"F:%'QO5'(W*&P,@'G S0!X-\8/%5M+=:
M%XQT;Q=K>GO8ZAID5]HAN9;.6"UENO+W-ILB1M(\S'9F?HBEXP2N&Y3QY>:S
MH=]\:/%'A/6-?AM/".EM806\^M7MW#+J$L:S3S^7-*Z*((Y$"*@ !+''"U]-
M:CX-T#6-<L=:O]#TV]UBP&+34+BTCDN+?_KG(1N3J>A%6+3P_I=@NH+:Z;9V
MRZA*T]X(8$47,C*%9Y,#YV*@ ELD@ 4 ?)?BKXF^*?!OA+XG^&_#MYX@OK>V
MO1;Z?X@,=WK#Z7"=-BN)F>90\F2[81G;"F7.0J8KZ,^!^N2^)/@[X+U*>:[N
M+BXTBV:::^21)I)!&H=V\P!CE@3N/W@=P)!!/0:5X-T#0M!DT33=#TW3]%D#
MJ^FVMI'%;L'SO!C4!2&R<\<YYK1L;&VTNR@L[.WBM+2WC6*&W@0)'&BC"JJC
M@    #I0!Q>D^';;Q=X#\2:)>/+%::A?:I:RO 0'57NIE)4D$ X/<&L%?!/P
MYDT'6=?;7[:7P]JIOX;N^_M*(6C&[>&*91,, $/ J+ALABPZXQKV^HWND?#7
MQ;>Z;:RWNHP7.KR6MM!&9'EE%Q/L4*.22V!7BVD_#/Q+I>DZ?X-M=,NSHN@Z
M^GV1GMF6.Z<JMP96<C'E*BRQ[\!2\X"D,@% 'NNC_#RR\,Z7KTNJ>(-2UFXU
M"U$%YK&KR0)*EO&CA5'E11QJJ!Y&SLR2Q+$\8Z+P['I]AIL6D6%VETNDQQV4
MB^8KR1E8T*K)CHQ1D;&!PP.,$5\OZ3X<\6^(_"NJ+XEU/Q1JMEJ1L+35['^Q
M]5L665[J(W!CW74K$)&)%)M8T@(?.2!QUNG^#M<@FN+^WNO$&C3:HFNW5U+-
M=W$<-O$H$%H'#-M\TJ(I1(P\W]V?FV@B@#W^YU"ULYK6*XN88);J3R;=)) K
M32;6?8@/WFVHS8'.%)Z U8KYSDO/&'B*QL/%QT[4I;RXTO4-;TZQ5)'2TE,$
M=M8PX PKNDTTSC[P+'J$&)3X)\4:/K&VPU3QC?&TUS3[>V>[U*YDCN%AMQ/=
MSON8*8Y@#;X8>4' *J&8D@'T!?7UMI=C<7EY<16EG;QM+-<3N$CC11EF9CP
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M02CD9*13SK&V.#'YKE2#DU;L_ACX.T^'58K7PGH=M%JRLNHI#IL*+>!B2PF
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M:^$*^X-5^(4GPQ^!7AS78=+_ +9E6VTNT2S%P(-[3M#"#O*D#!DSR.<8R.M
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M?6BRZEHH%AI'V>1?LL]M+MC^TH8G#/NE<9(Y3[I /<_^$9US_H;[[_P#M?\
MXW1_PC.N?]#???\ @':__&Z^>[/XL>)M0^$/C3Q+;^,M>O=-TW5%LO#>M066
MGV\^NR.L<(0K):M'Y1N7(5T13M!R3M-?2/@O3]9TOPGI-IXAU0:UKL5LBWNH
M"%(A/-CYV"( JC.< #IB@#SNTDU#PGX#\1Z_/XDU,VFF76IW,L%I:6K22".X
ME+;=Z@;FP3@D#)["LY?B1JD;3V5W+XNL?$2RPQ6_A^6QTN2ZN_-61D:-XW:
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M_P# .U_^-T?\(SKG_0WWW_@':_\ QNNGHH YC_A&=<_Z&^^_\ [7_P"-T?\
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MMB/Y:?\ X*I?_(!_9U'^:?\ X,J?_)&K]JT3_H'7W_@<G_QFC[5HG_0.OO\
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MFH1NOP)EF6-G%QE7FT_[S_S.8_X1G7/^AOOO_ .U_P#C='_",ZY_T-]]_P"
M=K_\;KIZ*]<\XYC_ (1G7/\ H;[[_P  [7_XW1_PC.N?]#???^ =K_\ &ZZ>
MB@#S>3P]K/\ PL&&/_A*KSS?[+D;SOLMMG'FI\N/+QCOTSQ70_\ ",ZY_P!#
M???^ =K_ /&Z63_DI4'_ &")/_1R5TU ',?\(SKG_0WWW_@':_\ QNC_ (1G
M7/\ H;[[_P  [7_XW73T4 <Q_P (SKG_ $-]]_X!VO\ \;H_X1G7/^AOOO\
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MA@@M&AZ\<4 ._P"$9US_ *&^^_\  .U_^-T?\(SKG_0WWW_@':__ !NNGHH
MYC_A&=<_Z&^^_P# .U_^-T?\(SKG_0WWW_@':_\ QNNGHH YC_A&=<_Z&^^_
M\ [7_P"-T?\ ",ZY_P!#???^ =K_ /&ZZ>B@#F/^$9US_H;[[_P#M?\ XW1_
MPC.N?]#???\ @':__&ZZ>B@#F/\ A&=<_P"AOOO_  #M?_C='_",ZY_T-]]_
MX!VO_P ;KIZ* .8_X1G7/^AOOO\ P#M?_C='_",ZY_T-]]_X!VO_ ,;KIZ*
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MSH5<1S;&)9?,5MIY&*SY/@#X#E;7F;0V/]MQ7$%XOVVXV^7.P:=8E\S$ D8
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MD27F#D>:VW,F#S\V:OKH&OK?&^&F^%Q>F;[0;@02>9YIC$1DW8SN\L!,]=H
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M_P 5G_U O_(U'_%9_P#4"_\ (U '3T5S'_%9_P#4"_\ (U'_ !6?_4"_\C4
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MD+83-=WX9\3:=XNTE-1TR662W9VC*W%O);RQNK%622*15=&!'*LH/M7D=_\
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M4A9"1*#QRIQP<'J#3;;XH:#\2%EBLK&SU]=&GBO9TL->L9?LDD;%D>01S_*
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M^+HI8J51U8K1M[K_ (!L_P#"3:Y_T*%]_P"!EK_\<H_X2;7/^A0OO_ RU_\
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M<I9/^2E0?]@B3_T<E=-0!S'_  DVN?\ 0H7W_@9:_P#QRC_A)M<_Z%"^_P#
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M 9%%:_\ P@_C'_H1_%'_ ()I_P#XFC_A!_&/_0C^*/\ P33_ /Q- &116O\
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M[*_T32]:N;RPB^)=A8W!,K:/;:%<):B<Q"+SA_H_F$[5!V%S'N&[9GF@#O\
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MZ!17G_\ PN?3O^A<\8?^$U>?_&Z/^%SZ=_T+GC#_ ,)J\_\ C= 'H%<Q;_\
M)2[_ /[!%O\ ^CIZQO\ A<^G?]"YXP_\)J\_^-U@P_%>T7QU>7Q\->+_ +.^
MFP0AO^$;O,[A+*2,>7Z,* /7J*\__P"%SZ=_T+GC#_PFKS_XW1_PN?3O^A<\
M8?\ A-7G_P ;H ] HKS_ /X7/IW_ $+GC#_PFKS_ .-T?\+GT[_H7/&'_A-7
MG_QN@#T"BO/_ /A<^G?]"YXP_P#":O/_ (W1_P +GT[_ *%SQA_X35Y_\;H
M] HKS_\ X7/IW_0N>,/_  FKS_XW1_PN?3O^A<\8?^$U>?\ QN@#T"BO/_\
MA<^G?]"YXP_\)J\_^-T?\+GT[_H7/&'_ (35Y_\ &Z -GP7_ *_Q+_V%Y?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>modernacellmap.jpg
<DESCRIPTION>CELL MAP
<TEXT>
begin 644 modernacellmap.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'S \ # 2(  A$! Q$!_\0
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MIU7CUJO:(GV;/5[2\CO(V>/<-K%65U*LI'8@_A^=35D^%H[)=&@DL;Q=0AE
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ML>I:-J%^+FQTZ!(K>8,Y2/SF#/YJXX1#&JJ/NG!->2_\*#\>?] +_P G(/\
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M/_/IJ/\ WZC_ /BZR/C[_P P+_MO_P"TZ\RET.]AT:#57AQ83S-!'-O7YG4
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M_P DKC_XW2YEW/2_L7,_^@6I_P" 2_R/1J*\Y_X:(^'W_0P?^25Q_P#&Z/\
MAHCX??\ 0P?^25Q_\;HYEW#^Q<S_ .@6I_X!+_(]&HKSG_AHCX??]#!_Y)7'
M_P ;H_X:(^'W_0P?^25Q_P#&Z.9=P_L7,_\ H%J?^ 2_R/1J*\Y_X:(^'W_0
MP?\ DE<?_&Z/^&B/A]_T,'_DE<?_ !NCF7</[%S/_H%J?^ 2_P CT:BO.?\
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MQ1\,="\33?:9K4V6I@?)J6GGR+E?^!#[P]F!%>@>3UXSV_\ K5 ]OQSS^F:
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MM=*\/^*(+&82?9M;NM*9;"?:2,I,"P&<'&\#ICKQ3T%J+X!^ NC_  _\6?\
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M*>23<\Z#.!M0C![$G'KCBHX?A'JMU<6<5O>Z?<+<BXQ-'))L1X!F1&RF<^F
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MF/\ O=3U/Q3//^1E7]0HHHKSCPPKYR_; _YE+_M[_P#:-?1M?.7[8'_,I?\
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M*?!^D:M( D]Q;JTZCCRY@-LJ_@X8?A7Q=I/AF3]HK]LJ^N-<A6]\.:? E_\
M99ANC:Q10+6)E/!$CR>:1W!85[?#XR)T74O#NDF93XLE:?19-AS;B8XOT;^X
M\#>;(0<<R =C72_!'PC86=_XL\7V482#Q!<PPV3#'_'C:Q+!#M_V699''JK*
M: /+/A+=2^ ?C1_8$\C;)3/X?F9S]\PYFLW/N8LC/K)5'QMI_C[XW?&F_P#"
M>HZ5J,'P=L;U/M,R(MO]M:*,9C+L0TD1F!SL!Z=N,;'[2GAN\\,>-M.\6:8!
M&;XP!)3]R+4;<[H-Q["5!L_[9X[BO;_"_B[3_'?AFRUS3&S:W2<QM]^&0</$
MX[,C94CU% 'G_P 8M-MM.\+^'Q:P1VUO8ZM9Q0PQ(%1(VW1;5 X VMC I/A:
MQ/@'1T/_ "QC: ?1'9!^BU9^-T@_X1W2H,_--K-F /97+G]$-<AX \6SZ7X;
MTBV?2YA;7#&1;UFQ$!),S9)QCC<.]:T]&95-CU"BJ]A>+?VB3J,*V<<Y!P2,
M@]P<9![C%6*Z#G"BBB@ HHHH **** "BBB@ HHILT@AA>1LE44L<=>* '45Y
MOX-^.ND^,+G2XFT?5]$35K"74M.FU)("EU#'MWE?)FD*D!U.'"G'2H+7]H#1
MY_#:^()]"\06&C/+9B.]N;6,0R0W+A([A7$A78"1N4D2*",IS2NAV9Z?17/V
M?C:QOO'.H^%8(KB2^T^RAO;F<*OD1B5F5(R=V=Y",V-N,=^U=!3$%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '@?QI\>1CQ<=*$37XTZ-'CM;9/,)F<'<7[ JNT#I@2$GJ,>-:HJ75]<:E=Z
M/<ZGY@CA-I Z[H65MY9E(*L,%>A^4XSG->D1_:[W4_$^HW,(BCU"Y=HFXRT0
M:1AQGH!LZ]2M>9^#O%FF:7>:]:ZNBQ23:B\L#2*@5N I*EA@GCG!!Z5^PY?1
MCAL+"G'LK^K5W_7D?S1G&)GCL?5KSVNTO))V7X?F/U#XQ:9:VZVFCV-T\^$7
M[-)$496)  /&,@D#/S$DYXJ#7-/UNRTR+7-3@L;*6:XBBCBAC\V5(W^4N\@(
MX)XVGN/:K'Q0TO1IM&M]0MI(X;^"[@<2?-RC-M)4E<X&1QDC'>M_QPQ_X06!
MGN([=%N[=7>YY4(L[EL]\9"8_ 5WWE$\FT);?Y[$/A7Q3?>$A:7%KIPTS6;3
M<8^5\J=/NOG^]&Q SC!!53U -?7.@ZS!X@T>TU&V)\JX0/M((*GHRGT(((/N
M*^/_  OXLM_%5YJ&A73QR0 MY,\#J=L+9V,I_O#=SGU(^GTM\&?.C\"PV\[;
MY+>ZN8LX(R/.8@_B"#^..M?'\2T:<J<,0E[U[>JZ?=;\3]*X%Q5:%:K@I/W+
M<R79II/[[_@=S1117Y^?L9B:QXZ\-^';P6FK>(-*TR[(1A!>7L4,A#DJAVLP
M/)! ]2#4EUXRT"QUZWT.YUS3;?6K@!H=-ENXUN90<X*QD[B.#T'8UYK\2O@W
MJOC37O&M]:S:>B:UX6&AVOVAG#1SB21]SX0X3YEY&3D=*R)/V?\ 4V\>7M_,
M;/4M(O\ 4;+4I)+G5[^)K=H$0%%M8F6*8YB4I([ IGE7"@&;LJR/88?%^@W.
MORZ%%K6G2ZW&F^33$NXS<JO')BSN Y'..]9FB^,O ]CHLR:3KGA^WTG3'6VE
M6RNX%@M'9L+&P4[4)8X"G&2:\WA^"/B*.XTW3OM&CQZ5IFM7NNV^K_/)?323
MB;;')$4"8!FPS>8=RQJ-H[<I:_LV^,[C2]3AU&]T<SWMEI-JP%_/-$6M+KS'
M(4P*L:,F=L:*%4\>K$N^P67<].7QK\*/AQ#;:GIMQX9TV/6K\6'VO2/LR":;
M/S>8Z$ A<Y8D_+D9ZBMC1/$W@CPS8W5W&VB>%(+S4YX)&:XM(!=W2N5=B8W*
MM(Q'0G?V8 \5R&K_  >UYM4U?4;"33))9?%MIXBMK>:>2)7BBMXXF1V$;;&)
M5B,*PZ>O'$>(/!?B'X8Z_:ZFND?\)#]M_MV)UMK2YNH(([NX69"?)ADD$F!M
MVF,(WS RKQE7:'9,]\A^(WA.XOK&SB\4:-+>7\0FM+=-0A,EQ&02'C7=EU.#
MR,C@U)I'CWPSX@DFCTOQ%I.I20P_:94L[Z*4I$?^6C!6.%_VCQ7S;\*?V8?$
M&D^']*BU6&UFM[S[!?W,=]J]_%)9211H#%]EA9896!C7:[L-F3E7"@'M?#W[
M/FJZ=H/AK3KR31YEL/"^H:'=J?->.66X>-E.%",R85LG<C<\>H=WV"R[GLWA
M_P 5:+XMM7NM#UBPUFVC?RWFT^Y2=%;^Z2A(!]JU*\E^!OPM\0_#R^URXUF]
M@D@O4MXX+5+Q[]XO+5@?])EACE*8("1MOV '#'->M52(9Y'\??\ F!?]M_\
MVG7D=?5NH:/8:MY?VZQM[SR\[/M$2R;<XSC(XS@?E5/_ (0_0?\ H":=_P"
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M916S;YC<">0.) Y7&3M<!\=0'# 'FO<?^$/T'_H":=_X"1_X4?\ "'Z#_P!
M33O_  $C_P *TI\+XVE+FAB$G\RHX*M%WC,^>+SQ5<W7ANVT-8(+>RBG-T_E
M!R\TI4+O<LQYP,84 >U8M?4/_"'Z#_T!-._\!(_\*/\ A#]!_P"@)IW_ ("1
M_P"%93X1Q-1IRK+MLR'E]26\CYU\'_\ (VZ)_P!?T'_HQ:^H:RX?"NBV\R2Q
M:/812QL&1TM4#*0<@@@<&M2OK,CRJ>54YPG)2YG?0]#"X=X=--WN>6_M$_\
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M5T6ZO]/3Q#HUAINJ'4-0CT^UM[5(Q<PHF8<QC:LHW\+N/S]"3FO%]'\.^+]
MU2UU&PT35(+VUD$L,GV!VVL.AP5(/XBH;SPCXIO[N>YGT'5))YG:21OL,@RQ
M.2<!?4U@L+9V==>O7KY_UY'-'!I-IXI6MO?6^OG;K?\ RW/7IO#.E7RZS:1^
M'WC\0/X;:06UQIT%O-),)1MECMHW?RG*GD84\9QS6EJUB-/7XA:-I>F6815T
MB0V=O91/\A1?.? 4\ 9;=_"26!!)->$_\(-XD_Z%_5/_  "D_P#B:/\ A!O$
MG_0OZI_X!2?_ !-:?58-ZUD_^'3[^7XFWU6DWKB$UIVW3B_YO[MK>9[7XD\,
MQV=[JX\)^&=,U?41K\MO>6<UE')';VXC7RUP<>3&26)D4KR/O#%4_#GAK3M6
M^%\R_P!C66G7<=K>/+J4UM#=VDI5B1_I*.9(9%X"AFP>N'S7D'_"#>)/^A?U
M3_P"D_\ B:/^$&\2?]"_JG_@%)_\35?5XJ"C[9:-._73YV_R*6&IJ"A]95TT
M[]=/^WK>FFGXGMO[.O\ R)-[_P!A!_\ T7%7J5><? ?2KW1_"%Y#?V=Q93-?
M.XCN(FC8KY<8S@@<9!_*O1Z^0S!J6*J-=S\JSJ2EF-:47=7"BBBO//$"OG+]
ML#_F4O\ M[_]HU]&UY/\>/A/J_Q0_L/^RKFRM_L/G^9]L=USO\O&W:C?W#UQ
MVJ9:H^HX9Q-'!YM1KUY<L5S7;\XR7YGQ[17M7_#)OB[_ *".B_\ ?^;_ .-4
M?\,F^+O^@CHO_?\ F_\ C5<_++L?O'^LF4?]!,3LOAMX]AAT#X9R7'B>UB@T
MNUU6&[@N]2C4Q2E)/LVZ)WR1L^56P0,A<\XIUAXVT+4)M/O+O5X;CQ//X-@B
MBU!=4AM;A;L3/YB&[D#+#,8\#<XSCC(S7%_\,F^+O^@CHO\ W_F_^-4?\,F^
M+O\ H(Z+_P!_YO\ XU1RR['R\ZV12G*?UM*]_P 92E;TO*SVT1T7B+XC6^GZ
M3\3;K1M5L]&UNY32(UDTK51+)<2(S":2.54BWM@C>T:XR6.2#70S:]HDGPWO
MM*7Q!I^JPM8:8]C]HU:,S23K*C2A+12!"R9(^YO?DEFY->>?\,F^+O\ H(Z+
M_P!_YO\ XU2Q_LH^,8I%=-3T9'4Y5EN)@01T(/E4<LNP2K9'9*.+2LT__ 5%
M)7W^SWZOR:]9\;^*-%TOQQKMOXYU.PU+3/\ A)+*33;!I$G:SC5"9G:($F-.
M5# @;CDX;/.79^/-&M_&6A)JFH:>;G&J11ZG/XAAU"01R1,(TDDCB2..,MC8
MK.2N2"%!K@M2_9A\=:Q?37NH:YI=]>3'=)<7-W/)(YZ99C$23]:K?\,F^+O^
M@CHO_?\ F_\ C5'++L<U.61JFHSQBORVTNE\/+=+SW=[W?8[6P\60:/]FTFR
M\4V%M>GX?G3U>VU:)(5OUF8JAF#A%< M@ENYP<'E-<\764]KJD?ACQ%IVG^+
M6TW1E@U#^TH8 8HXL3Q+.S!58-MW)N!8#&#C%<7_ ,,F^+O^@CHO_?\ F_\
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M=1U9J]*HHJMB0HHHH **** "BBB@ HHHH *KZE--;:==36\7G7$<3O''_?8
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M I5^\OU'\Z2E7[R_4?SH &^\?K7/^(_#'_"1,RR2M&AC"(Z,0T9R2W&,,&&
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M@CH2>*^DJ$P:.1\:?$:/P?K6C:1'H>J:]J6JQW$L%OIGV<$+"$+EC--&.CC
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MNXF6WC\TX1"W\1]< 'COTR*WZY#XIZ#K/B3PM]BT,6OVS[1%,3=.4P$8.-K
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M\2+GQ5J-Y>WLSO)9,UK"%C6.$!@N_:O+$DHK$EC][&!BO>PN5U)24JL?=?\
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MA=1U[6M+FVH^Y8K-93$R_/PQV+N)R#G@#(KF]-_:.\56/A.QU_5]/TB]BO\
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MI] T"U\-:<MC9R7DL"L6#7U]/>2<]O,F=VQ[9P.U9'Q-U*#3? ^K>=))&US
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M^=)2K]Y?J/YT #?>/UI*5OO'ZTE !1110 4444 %1K"%G>3NPQ4E% !1110
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MOWE^H_G24J_>7ZC^=  WWC]:2E;[Q^M)0 4444 %%%% !1110 4444 %%%%
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M;\.J^:/P+A1T<-CJ-7$0YE>WSZ/Y,_1&BL%O&5D\FRW2:[/_ $QC)_0XI_\
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MQV?]?B4I/$%W99-_H][;+V81[E_/@5D^*/B7I&A^';V]DNFCD2,B-$&)"Y'
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MR$'7 9.6XY&!GJ/HFN>\!>#;7P#X9MM&M)IKB.)GD:6X(W,SL6;H !R>@_\
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M;>/D1Q+\TLS?W47N?T'<BN2\5_&,?VDV@>#++_A)O$+?*WE'_1K;MND?IQZ
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MF%%%-5=HQ0 ZN$\=I_9OB[PEK &%6Y:SE;VD&!^7S&N[KDOBE8M=^#KF1/\
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MLY>#"[$J-K C!VYX8@'FC4-#+\+_ !:\5:M^S;X=U0:HDGC;Q#J)TJRO7@B
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M9&/^$D\8*WWK'2OR:8_X?S'O75UVU?W5*-'J]7^B^[\SRZ"]OB)XA[+W8_\
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M\E_5V7;/3[?3X]D$83U/<_4TV^U2UTY<W$RH?[O5C^%9DZ7]PNZ\O(]/B/\
MRSB/S?G_ (5#:K86SYL[.2^GS_K7&?QR>GY4U34G>3OZ?YLEUG%<M.*BO/\
M2*U_(F;5]0U+C3K/RXS_ ,O%SP/J!WJ&308%87&L7K73]0LC;8Q]%JW-_:$T
M9:XN(=.A[X.6_.LQK[0[*7):34[G_9!D)_I6JDHZ1T]-7]_^1DZ<JFLUS?XM
M%_X"OU-!-:4J(=*LFG5> 579&/\ /X4'2M0U'_C^O##&?^6-MQ^9_P#UU7_M
M36KU0MEIB6<?027;8Q_P$<_SIK>%[O4 6U75YI$ZF&WQ&G_U_P JRYU'X=/Q
M9T>Q<U[[;\ME_F32:AH/AA2#+#'*.H7YY/TR:J'Q3J>J<:1H\A0]+B\.Q/KC
MO^!I\?\ PC/AWE!;^:O\2_O7S]><5*?%%S=\:=I%S<9Z238C3\ZAWD[M7]3:
M*4%RQT79%7_A%=5UCG6=8D\H];6R&Q/H3W_$5IV>@Z+X:B\R."WM=O6>4C=_
MWTU4VL?$6I?Z^^ATZ,_P6R;F_,_T-.M_ ^FJ_G7C3:A+W>ZD)_S^-)OHW]Q2
M75+[Q+GQYIT<GDV:SZE/V2UC+?K_ (9JN;OQ5K'$%K;Z-"?^6D[>9)^ _P 1
M6VMWINEQ^7$884'\$*C^0IG]LO-_Q[6<TW^TPVK^=<SQ%*.BW^_\!^K^XQX_
MA[!=R++K%_=:M(.=LCE8Q]%!X_.NBL=,L])AV6EM%;)W\M0N?KZU4VZM==6A
MM%]AN;_"FMH<3#=>W<LX_P!M]J_E6<J]2>T7\]%_7R!)+X46;G6[*U^_<*3_
M '4^8_I57^VKJZXL]/D8=I)OD'_U_P Z/M6D:;_JS$&'3RQN/YTX:S--_P >
MMA-*.S2?(*YG4;T<[>FK_7\@YO/[AG]GZI>?\?%ZMLG]RW'/YU+;^';"W.]X
M_/?J7F.[_P"M3?+U>Z^])#:+_L#<U)_PCL<QS=W,]T?1GPOY5*@F[J#;[R_I
M_D%O*_J3S:UI]BNTSQC'1(^?Y56_MRZNO^/+3I7':2;Y%_\ K_G4N_2=+Z&"
M-AZ?,W^-,_X2))N+6UN+H^JKA?SIRF]I32\EJ_Z^07[L9]AU:]_X^+U;5#_!
M;KS^=2V_AFPA;?)&US)W>9MV?PZ4S?K5W]U(+)?5CO;_  I/^$=:XYO;Z>Y_
MV0=J_E4\B;NH.3[R_P"#_D*WE?U+,^L:?IJ[&FC0+_RSCY/Y"JG_  D$]UQ8
M:=-,.TDGR+_]>K]KH]E9X,5NBL/XB,G\S5MF"C).!ZFNCEK2WDDO+_-_Y%VD
M^MC$^P:OJ'-S>K9I_P \[8<_G4UKX7T^W;>\1N9.I><[B?PZ5/<:]86N=]U&
M3Z(=Q_2J?_"0S77%CIT\_H\GR+^=8-8>+]Y\S^]_<3[BWU_$VE58U"JH51T
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M23T%<SK'Q*\.Z*2DNHQSS9P(;7]ZQ/I\O /U-9H^%_\ :;!]?UN^U@]3#O\
M*B_[Y!_D172:/X6TC05 L-.M[9A_RT5,O^+'D_G3U*Y,%2^*;F_)<J^]Z_\
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M<JG<ME"3%:H?8#&?KQ[YKT1$6-%1%"JHP%48 'I2T6[A_:+HKEP<%3\]Y?\
M@73_ +=2*]AI]KI=JEM9V\5K;QC"Q0H%4?@*L44C,%ZU1Y+DY.[>HM%(K!NE
M+0(**1L[>.35;4-4M='LWNK^YBL[=/O2S.%4?B:!QBY-1BKLM55OM3M=+M9;
MF[GCMK>(9>65@JJ/<FO/KKXL7OB.>2S\$Z-+K$BG:VHW(,5K&?7)P6^G'MFB
MT^$=SKUU'?>--8EUN=3N6PA)CM(SZ!1C=]>,]\U-^Q[*RY4%S8Z?)_=WF_\
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M6UE&^;1=P_V;A:&UO5EY_L)__ A?\*"?J]3NO_ E_F;M%8"^(-1V\Z%.#[2
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MW2.L:^K$ 50N/$VD6N?-U2SC/HTZY_+-8T?PO\/*VZ2UDG/K)._]"*O0>!=
MM\;-*MS_ -=%W_SS1J/EP<=Y2?R2_5D-Q\1?#EOG?JL1_P"N:L_\@:HGXJ:-
M(V+6*^OSTQ;VY/\ ,BNDM]#TZUQY.GVL./\ GG"J_P A5Q5"J !@#H!1J'/@
MX[4Y/UDE^4?U.-_X3O5+C'V/PGJ,N>AN#Y([=R#2?VMXWNO]3HEA9 ]#<W&_
M_P!!-=I118?UJE'X*$?GS/\ 6WX'%_V+XTON+C7[.P4]5L[;?^K ']:0_#62
M\_Y"7B35KP=T2;RT_+FNUI%7;WHL/^T*\?X=H^D4OQM?\3D[7X5^&K1M_P#9
MWVB3.2UQ(SY_ G'Z5OZ?I=CI:[;2R@M1_P!,8E3^0J]2%0>:+'-5Q5>M_%FW
MZMBT56N=2L[//VBZ@@_ZZ2!?YFLFZ\?>'+3/F:S9G_KG*'_]!S01"A5J?!!O
MT3-^FLV*XVX^+_AF%ML5W-=O_=AMWR?S J%OB7->-_Q+O"^LW8[.\/EH?QYH
MNCL66XO=TVO73\['=4B@CJ:X;_A(/'-]S;>&K.P4]&O+H/\ HI!_2C^R?'VH
M?Z_7--TQ6ZBSMS(1_P!]C^M*X_J#C_$JPC_V]?\ ])YCNJH:CKFF:6#]NO[6
MTQ_SVF5#^IKD_P#A5\U__P A?Q/J]^.\<<OE1G_@/-7;#X3^%=/P1I27#]VN
M7:3/X$X_2C4?L<%#XZKE_AC^LFOR(;[XO>%[%O+BO7OINT5G"SD_0X /YU4/
MQ \1:MQHO@Z\*-]V;4G$ QZ[3U_ UVMCI=EI:[;.SM[1>FV")4'Z"K5&H_K&
M#I_PZ/-_BD_RCR_FSS]M(^(6M?\ 'UK6G:%$W5+& RN!]6_H:6'X-Z9=2K-K
MFH:CX@G'/^F7#!!] .1],UW](V=IQUIV#^T\1%6HVA_A23^_?\3.TGPWI6@I
MMT[3K:S[;H8@K'ZGJ?QK2I%SMYZTC2!6Q3/-G.51\TW=^8ZFM&&.2*=100%%
M%% !1110 4444 %%%% "  =!B@L%&3TI/,&[;WIQ&1@T (K!AD=*6D4!1@<"
MEH **** "BBB@ HHHH AN'96 !P.M6=-8M<0$]?,7^=1LH;J,U/8C%W !P/,
M7^=(%N5Y(_,7&<41IY:XSFG44Q!1110,***KW#'?C/% BQ13(26C!-/H&%>)
MZ?\ #?Q1IMYI-Y<76H:KIR:UJ%S)H#/:)':^=+/Y%TCJJNX59"6C>1C^]R!F
M,*?:FD53@TZD.Y\V^ _A+XCT?5[%KCPO]AU9+BSE3Q)]IMV^S6\>G10RV_RN
M9/FD1QM52ASN)X&>8\4_LY:[K?AT7VE>%(]$U[3;&TMY8&FM9!K-RCL;B=E)
M>.57RIS/M9^0Z@ 9^N:*7*A\S/D7P/97WQ#\"V.G3^%[/5M0TFUU#36T:W:.
MU.DWDDB&&[,,LF(@N)1N@),><1H!E%]"G^"C:OXJ:^U?0;357FU9FN;JY\N3
MS[0:8L0#!CDH;A0?+(^\ Q' -=%\4/A->WVK)XR\$W"Z3XTM!SSB'4$'6*4=
M"2!@$^P/0%=#X6?&C3?B%YFEWD3:'XML\I>Z+=?+(K#JR9^\O?U'?L2O)COU
M1YUX#^$?B72_'7A_4]9LM2DN[6.U(U&.XT_R+:%+-8WMWD,;79/F!_W:-Y3>
M9NW Y%>@RZ#\86D<Q^.O Z1Y.U6\%WC$#L"?[6&3[X%>E4C-M4DU5B;GR_XF
M\&_$Z'Q;J%E?>+/!DWVX"]CD;PA=A78*$<*/[4RI&!GDYKC]9^"OC>ZRS>)_
M"2,?XH?"]XI_].9KZM\8>&4\6:?&D<OV/4K9_-L[H#/EO[CNIZ$=P:\]M[QV
MNY--U&W^P:O$,R6K'AQ_STB/\:'U'(Z'%?2X*=.K!0E\2\V<T[IW/G:/P'\5
MO"4R3V'CC1]1B1@7L9-'N85=<\A2;U@#CO\ SKUKPKXMM_$@-J+FXL-7C'[S
M3K[#'ZH>-P^E;^J:;G.!7#^(O#<&H*/-0B1#F.:,[70^JMVKU8P4/A,;W.PN
M(7VGS% ;_9/%8MY%R:YZS\5:[HH\B]\O6K9>%E<^7< >YZ-^AJ>'Q5=^)-2@
MTK0](FGU6X.U%F8;(QW=L?PCK5.2BKL#TOX%Z6TWB#6M3*_NX(DLT;U8DNW\
MU'X5[/6+X/\ #$'A#P_;:; =Y0;IICUED/+.?J?R&!VK:KXW$U?;57-;'9%<
MJL(V0IP,FA22N32T5S%!52Y1HVW1_4KZU;J-XRS9%2XJ0T[$=K,)AE?Q]JL5
M4FA: ^=$,L/O+_>JQ#,L\8=#D&HC/7EEN7*.G-'8\Y^(WCB^\*ZY!:V4%L4>
MW68M(K%LEF'9AQ\HKG%^-6N*N/LU@WN8W_\ BZ7XU_\ (U6O_7DG_HR2K>E^
M#=/OOAO_ &I8:=#K5ZD<WVW9=/'<6C _(ZIG:R!1D@KDYX/I^!YGF.<3S?%X
M?!XAQC"[MY*VR2;;U[;79^P8#!9;'+</6Q-%2<[*_F[[MM)%3_A=6N'K::?_
M -^W_P#BZ@E^+VKR_P#+GIZGU6.0?^ST^X^%PA\J3^UXUMKF>TALYY8MJS><
MNXL?F.T( ?7)':M:T^%%AI?C?3M)U2YO98;A9R4:S,)8QJ2"&#E2I SE6)XP
M0N<CS8XGB>JU&59I72NY1M=NR^]]NFJT.]X?(::;C36S>B>R5W_7?3<R(OC)
MKD/ BLV'HR.?_9JE_P"%UZY_SZ:?_P!^Y/\ XNELOA'=:EHZ7UM/<O\ :+>6
M[MO]"/E&-"<+)(&(21@"0OS#ISS3[CX6V-I#.TVNR![?3H=3E5;'($;X&U3Y
MG+ GIP#GJ.TQQ?%"BI>UDDU?64>U^K[:C>%R!RM[--[;2[VZ+N1#XTZV/^73
M3_\ OW)_\73)/C%J\GWK'33_ -LG_P#BZNM\)Y=M[96\\%U<?:[.&"XDB=&*
M3(6SP^U0!U!5CQP1WY#Q%I&F:4VRPU9M0D25XI8I;5H60J<;ARP*GG'(/J!6
M&*S/B/"PYZ]=I>L>C::7?5=+Z:[&M# 9)7ERTJ*;]'VO\OG;L;I^+6K?PVEB
MA]523_XNG+\8M=3HEI^*.?\ V:M.X^%UI,S2R:BEA$D=@NVWM'?<UP.#AI3R
M#UYQUP!TJ+_A7&FQZ2MO)>3#5F\0?V09UA!C &!TWCC!W9ZY&W&/FK?VW$D6
M_P!\UO\ :CK9V_-.U[7,O99')+]TGMT?57_(KK\:M<4<VU@WUC?_ .+I?^%U
MZY_SZZ?_ -^Y/_BZ;IWPULM4UK4+&VU6\D2RF%O+/_9ZJH<N5)RTH4+QW8,<
M\*<5!=?#F#18[B76M7_L^!;^2PADCM3,'9!DNP# JO(Z;CUXXJ?[0XG4/:.N
M^777FC;31W=[+7N/ZED+ER>R5^W+*^OE:Y9_X77KG_/KI_\ W[D_^+H_X75K
MG_/KI_\ W[D_^+I-.^$=[J.AQ7L<\KRSVTEU!Y5HS6Y1,_*TV1L=L$A=OIDC
M-='<?#+1[^V6WM8?L5S,^FQI<;GD\LS1DR':6P<D9_EBNJCB.**T>;V[5U=7
M:UT;TWZ+K;=&%3#Y!3ER^Q3MO9/35+^K7V9SO_"Z]<_Y]=/_ ._<G_Q=(?C5
MK;?\NFG_ /?N3_XNK?A_X;V:75O)?2_;H)UU&,0[6CVM;J0K9#<Y.#CV[UG7
M'PQ>+PC/K2WLF^&"*X:":V\H,KD#Y"7WG&>I0*>Q-8O'<3^SYU7D[)MJZNDD
MI7^YK:[-5A,AY^3V2Z+9ZMMJWWKJ3_\ "Z]<_P"?33_^_<G_ ,77KVAWTFI:
M+I]Y*%66XMXY6"# !903CVYKP3QQX9L_".L2Z7#J$U_=0$"9FMA$@RH8;3O8
MGKSD#\:]K\(7]N_AG2$$R;ULX05S@\(*^UX/S+,*V.Q&&S&KS."V;3L[Z[:'
MRG$V!P5+"4:^!IV4GNDUI;3<W:B>T@D^_#&W^\H-2*VX4M?KQ^;IM;%.31[&
M3[UG#^" 5 _AG3).MHH_W6(_D:TZ*1JJU2.TG]YBMX0TQCD1.ASGY9#3?^$1
MME_U=U>1?[DO_P!:MRB@T^LUOYF87_"-3+_J]7O5&.A?-)_8.I)C9KDPQ_>B
M#?UK>H/-%@^LU>Z^Y?Y&!_9>NH!LUE&Y_C@6D^R^)%^[>V<G/\2$?R%=!10/
MZQ+K&/W(Y_\ XJ9&_P"8=(/^!XIOVOQ,J\V5DY_V7(_F:Z*B@?UA=81^[_@G
M._VEXB5AG1X7'?;<*/YFFC7M<7._P^S$?W;E?\*Z2B@/;PZTH_\ DW^9S8\3
M:KM);P[<#_=E!_I2?\)9?!26\/WP_P!T9_I72T4#]M1_Y]+[W_F<S_PF4RJ2
M^@ZFOTA)%-'CH9&=&U,#_KA_]>NHHH'[6A_SZ_%G,-X\A126TG5@/7[,/_BJ
M8OQ#LV8 Z=J2CU, _P#BJZJB@/:X?K2_\F_X!S'_  L"Q_Y\M0_\!_\ Z])_
MPL*Q_P"?+4?_  '_ /KUT[9VTU.M&H>TP_\ S[?_ (%_P#F?^%AV/_/EJ/\
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MXC;'8@=,XP:L>&_#EMJ7A$SW6F6UY]LTRZNOM%K8PQI'*"VU=^"WF#'"H44
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M=GZ=N7\M/30]%9?A4TU!:?YW_/7U-/Q)X@N/%&M76J7211W%P5++""$&%"\
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M **0YQQUH&>]  .*6BB@ HHHH **** "DV\YH)H% "T$9HHH  ,44G.?:EH
M*:K9I6&X4BI@YH =0.*0MMZTM ",<#-(K;J=10 4444 %%%% !2-GC%+10 C
M+N&*14V^].HH *B6,[O:I:* "BBB@ HHHH 9)&6.13E7:N*6B@ HHHH ****
M &R*67BB-2JX-.HH **1L[3CK0N=HW=: %HHHH **8K,6((XI] !1110 444
M4 %%%% !1110 4444 %36?\ Q^0?]=%_G4-36?\ Q^0?]=%_G2!;D-%%%, H
MHHH *A:)%;).!GI4U(RA^",T"%HHHH&%%%% !1110!#.3D#M34C+X/\ #4RL
M)!TX]Z\K^(7C*?2?'"V%SXQ_X0ZVCM+>?3X?LD4_]KSM*ZR0['0R3;0L0\N
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M8T#6QU]K>:W\+? ?AO2;7PCJWC.[MK9;:8>'Y[)%@V* "3=W%OE3T&W)^4Y
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M$HJ7X=Y7;2K4OZQ_^1&N-<POK3A]TO\ Y(^<=-\$:UJ^[[):+*5^\OGQJP_
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M<N=HSUH ,<DTM1LS!N.E24 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6WCEDN91/>7$AGN)%!"LYP,*.R@!5 ]%&<G)JW103M&3TH$%%-616.!UIU,
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M[NG%<.+PWUF,;2Y7%II^GZ-:,ZL/7]A)W5TU9K^NVX22+#&SNP1%&2S'  K
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M'_71?YT@6Y#1113 B6?=)C'%2TFQ=V<#-+0 4444 ,F<QID"DAD,BY(J2B@
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MN;F* ?\ 31PM %FBL&3QIIJ\0F>[/_3"%B/S.!5:3QI(?]3I4Q'_ $VE1/\
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MFFK'L;(/'I3J #I1110 4444 %%%% !1110 4444 %%%% !364YR#SZ4ZB@
MHHHH ;)'YB^AI(XRF2>M/HH **** "BBB@!LC;5S21OO7FGT@4+P!@4 +112
M%@" 3S0 M%%% !1110 45$)LR;<<=*EH$%0S%PPVYQ[5-10,1<[1GKWI:**
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MTV^ET:YNY%L!=R3L"LPE"D+@#8<] #GIZT^ZU35-0!\VY6QA[QVOWOQ<_P!
M*;OLAOFVB:T<FE>$8762X)N)3N;<=\TI[<#G],5EWWC"^N,K9VZV<?\ SUN/
MF?\ !!P/Q-8]OLDF>/3;9[R<GYVB^;G_ &I#Q^9K5@\'W=PIEU*\6RA')CMS
MEL>[GI^ I62W(Y8QUD[G'^*/$&GZ3:M?^(=7BBMT(S/J,ZQQ*2<# .%'-/\
M#*R>.].BO] DM;W2Y"52^2=6A;!P=NTG.""/PJM\6FTNS\*P1^'X-1FO(=3L
MIY+W1;,WES$J3HS.N8Y-Q &<;&'M7*^*+CQ1XLTNVDAUOQ4D%MHVH313)%<:
M;=37:-'Y(E1(X-S<L%7RP& /#=:7,^B+NW\*L>G7/A/1=!$#^(M<2-IG$<<(
MD$(D?!.U1G<QP#P/0U?M=8L-,79H6B*@_P"?B9?*'UYRQKP;5+&\G\<6$\EI
MK\^MQZO'/#(8YWT];7[*0&)(,0(D)SG$FX_W,5E_VEK5IX;>26X\500N-+CU
M)KJ2Y6<WC7(%RMOO.[:5.,0_NSD!.<TO4.2_Q,^@+[7KR[NEMKK5E@FD1I%M
M+4B-F0$!B.=Q +*"?<>M5%MH(6+K&I?O(WS,?Q/->#ZHNNI:PW-K!X@:R\N[
MM[>YFCNWO(;9[RVVF3 ^T-A1(=N5E*+PRGYAF7TGBX>$-)=YO$+7-K/?(D2V
M^HQ/<K]H_=$O&\DL;"/E/M"31D'#'.35<UNA=DMD?1S2>]5HK^"XDF2&:.5X
M7\N548$QM@':V.AP0<'L17D5YHVM:QXBDN+F7Q!:17&I-%)!;W]Q'%';_8%?
M"^6P4#SQC>N#NR >2#BV$NNRV=L?$[>*ETQDRYTT78N1<?9+39D0_O-N[[3_
M +&_.[G%5S#/=IKE85!8]3@ #))] .YK0L_#>LZB RVR6<9Z-=-\W_?(Y_/%
M97@_5%TN>SO+VTO+EA:JG[P1M/'(<;BX4[=QZ$KQG..*ZZ3XA1_\L=+NW_ZZ
M%$_K2DWT,Y.6T41P_#V1L&YU20^JV\2I^IS5M/A[I@_UDMY-_OSD?RQ67/\
M$+4#GRM,AB'_ $UG+?R6J,WC[6F^ZMC%]$9OZU-IF=JC.I7P'H:];+?[O*Y_
MK5NQ\*Z1IUPL]O80QS+]U\9(^F>E<"WCG7?^?JW7_=MQ_4U%_P )QKP_Y?H_
M_ =:7+(7LY]ST[4-+M-6A\F\MX[B/J%D7./<>E8K?#W0V/%M(GLL[C^M<7_P
MGVO+_P O5NWUMQ_C3A\1M=7JUFWUA8?^S4<LD"IS6S.M;X;Z,W072_[MPW^-
M02?#'36'[NZOHS_UU##]17.#XG:TO6&Q;_@+C^M#?%+6/^?:Q_)_\:=I#Y:G
M<O:A\,+N-"UEJ*SD?\L[F/;G_@2_X5Q,WF032PS1M%-$Q22-NJL.U;MS\2M>
MF4A9+6W]XX23_P"/&N9FN'FEDEED:6:1B[R.<EB>]7&_4UCS?:)&DIC25"TE
M132E8V*\D#(JC0ED5)/O(K?45/9ZM?::0;.^N;;V24[?R/%>@Z/\,]#U+2K>
MX6]NKDRH&\Z.8 $]\#''TJKJ'P=;!-AJC9[)=1@C_OI<?RJ.9&7M(O1F3I_Q
M4UJQP+A8-0C'7<OEO^8X_2NOT?XH:-JS+#=%M.F;C;<XV'V##C\\5YQJW@?7
MM'RTM@T\0_Y:VI\P?EU'Y5SK2 LR'[PX*L,'\0:.6+V%R0EL>\:IX#T'7!YC
M6:12-R)K4^6Q]^.#^-<7K'P@O8-SZ9>I=+VBN1L;Z!AP?Q KG?!OCJ[\*WD4
M32--I;N%D@8Y\O)QN3T^G0U[AJ&I6NE6,EY=S+!;1C<TC= *A\T3)\]-V/GC
M5M+OM%<QZC9S6IZ9D7*'Z,.#4N@^*]2\-R!["Z819R;>0[HF_#M]17KL?Q.\
M*ZCF&34(PK<%;B)E4_F,4_\ X03PGKG^DPV-K*K<[[60A3_WR<57-W1I[3I-
M&IX3\1)XHT.WU!(FA,F5:,G.&!P<'N,UK-D*2!DXX%<=X\T#4/\ A$4L_#H:
MU$# FWMCL9XQG*J?7//O7DND^._$.@SE([^9]AP]O>9<#V(/(J%'FU1DH<VJ
M+FH_$?Q3_:DZR7SV4L;E3:K$H"8/3!&3]:Z#0?C-?V[*FK6J7<?>:W&QQ_P'
MH?PQ5BW\=>&_&2+;^)--CM+@\"YQE/P<?,OXU!K7PDE2+[5H5VM_;L-RPRL-
MQ'^RXX/XU>FS1K[NTE8]+T+Q/IOB2'S+"Z64C[T9X=/JIY%:E?-JQW.FWW(F
ML;Z$^Z2)_G\J]#\,_%2:WV0:TGFQ]!>1+R/]]1_,?E4N'8B5)[Q/3Z*AL[R"
M_MTGMI4GA<962,Y!J:LS *:D@?.!BG44 %%%% !1110!'(S*PP,BI*** "BB
MB@ HHHH **0-EB.XI: "BBB@!D<GF9XQBGT44 (2!U.*6FR1B0 &E;(4[>N.
M* %IK1AF#'J*$W;?FZTI8+C)QF@!:*** "BBB@"-H T@<<$5)38Y/,!.,4Z@
M I-P! )YI::T89@QZB@!U,CC\M<9S3Z* "BBHIY3'C ZT 2T=.G%-C8L@)&#
M2[ANQGGTH 6IK/\ X_(/^NB_SJ&IK/\ X_(/^NB_SI MR&BD9@BY)P*4$, 1
MR*8!1110!Q/B^WU;2?&&D>(]-T2Y\10Q6=QI\]E9301SQ^8\4BRKYTD:$9BV
ML-X/S*0#@UQ&LZ7<:]X^TK1S'9:?<:]813>)=%M+P3&UAMY \;'"KE9=S0,Q
M W#&-P4U[;12L.Y\XWGP?OH=,DLD\ Q7EN)=9BMX(Y+2)(;J>X5[74!^\&T+
M&-N\#SDVX5"#6I_PK7Q+9_&*#7+72VEDD;;=:S=?99(PGV58]T4R-'=(V0<P
M2)-$2P8%2 1[U12L/F9\_P#A3X7ZW865NL/A@:"T3:.E]']I@)U&YM[L27%[
M\CD-E,G?)B5^C*,#/T!113V$W<**8\RH<'D^U.5@PR.E,0M%%% !1110 P2@
MR%,<T^BD9@N,G&: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &
MLQ49 S2NPC5F8X51DFJM_JUMINP3/^\?A(D!9W^BCDU5M=>M[ZZ^QR07%O(X
M("W$>W=@<CJ><=C19CL]S"L]2&H7XU.]A\^-03:6['Y8AV<CNQ'?M2->W_B*
MX/V2/[0 <&9SM@3Z'^(_3\ZU8_!=BN%>6XFMU^[;R2?(!Z<#)'U-3>(IIM/T
MD"S'D+O5&>-,^4G=@/R^F:UYET.CVBVB<[JVG_V9$$.IS7&JO@QV\*J$'NRX
M.%]R:>[K&I=V"J.K,< 5'I]I)=%ETV S%CF2[F)"D^I8\L?85LKH%AID7VO5
M;A;EDYW38$:G_93I_,U7-R[E<RCHW=F/:_:M4.+"V,J?\_$V4B'T/5OP%7Y/
M#]CI\(N-<OA,O_/-CY<6?0*.6_'-/DU^_P!6;RM)M_(AZ?:IUY_X"O;\?RJB
MVGV5A,9KR5]2ON[.V['^'X4M6+WI;Z%O_A))[B,0:)IPB@7@3W"[$'T0<G\<
M5G7=I'(X?5[V34)1R(<XC7_@(X_.F7VMNRA2P@0\+''U/L,<G\*?8^&]2U/#
M,HT^ _Q3#,A^B]OQ_*G91W*M&&I!<:PMO%B,1VD(X!X%>>?$[7=4M5\/_8;C
M6K*"]OVAENM+T[[5,ZB"5PJ(8921E 250X /(KVW3?".G::RR&(W5P/^6UP=
M[?AV'X"K>H:38WUS87EW&&ET^5KBWD9RHC<QM&6X.#\KL.<CGUJ'/L0ZW9'S
M/9_$#Q'IWAG198K2?Q-<ZDMU>6DWV"Z,MQ8QRA8Y&2UMGVNX=,!HXU(Y8H?E
MJ#5?'^HZ9J&K?\)%IZOI]CJG[FWB92^Q+#[4H>.2(88,JL/G!#MC=A/F],\6
M>%?".K0RVMCILLA:>XG>ZAOKF%%,YS.BE)%+1N1N:(?NV;D@FL63X?Z%-=7%
MQ/9&XDN9/-F6:5VB=S"82?*W;!F-BI 4 C&>@HCSO<TBY/5E2U\8:S#?:=::
MSH4%A+?7)@CDM;_[1%M\B27.3&C;@8RI4J!\P(9N0,3PW\2KK7O%&F0"W!M-
M7M+62&$2*1 SQW4C-NVY?(A4=O7Z[/\ PJ[PZMMY7V>\=_-6874FI7+7*LJL
MJ@3F3S H5W&T-MP[<?,<DGPR\.-;VT*6,D"VR11P/;W<T4D2QAU0*ZN&&!+(
M#@\AB#D5I[Q9B?\ "U;Z:.QGMM#@N+>>VL9W+:CL96NI'CC51Y3;@&4%CQ\I
MR,D8/9>%O%":[HD=X^GK:W/FRPRQ"8RHKQR-&VURJEAE3@E0<'H*S;?P+H.G
MVT4,-B(H84MHT7S7PJV[EX1][^%B3[]\UHZ7I]M80&UTZ%V0R22^7"&D.YW+
ML<\]68G\:$GU8&E)J4K=-J#_ &159[J1NKL:T(/#>L7?^KTR91_>F*QC]3FK
MJ^ =4*[IYK*T7_;<L?Y 471//%=3G&D/J:C:2ND?PKIUO_Q]^)K9#W6)5S^I
M-1_V=X3A_P!9K5Y<GTB4_P!$HYD'.CG&DIC.?>NBW>"X<YCU*X[Y)<?U%']I
M>#HS@:)=RG./G8]?Q>CF\@YO(YEI*C:2NH&N>$@-P\-R,,;LG!X_[ZI3KWA,
M9SX98?\ ?/\ C1S>0N9]CDVDIC2&NO\ [<\',V'\.R+SCY0O]&H&H>!)NNEW
M4)_V0W]&HYO(.;R.,:2HVDKMQ9^ KCI<WEIGU:0?S!I1X0\*WI_T3Q*8R>@D
M=#_,"CF0<Z['"-)4;25W\GPGEF7-CK-K=#MN3'ZJ365>?#+Q!:Y*VT-RH[PR
MC/Y'%/F0^>/<PM'\1:CX>F,FGW30!CEHB-T;?53_ #%=YH_QGB.U-6L7B/>:
MU^=?Q4\C]:X*^T/4=.S]JL+F ?WGB./S'%9W#="#0TI"<8R/H72?%FD:X!]B
MU"&9O^>>[:__ 'R>:?JWAG2M<'^G6$%R?[S)\WYCFOG1H0V"5Y'0]ZV=+\7Z
M[HNT6NHS>6O2*8^8OY&L^3L9>R_E9ZY:?#'PY9W27"6&YT.Y5DD9E!'0X)Q3
MOB-X=N?$WA>:TM"/M".LR(3@.5_A_'^>*Y'2_C+<QX74=.64=Y+5MI_[Y/\
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M^/R#_KHO\ZAJ:S_X_(/^NB_SI MR!E#K@C(H "@ =*6BF 445'%(S[MR[<4
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M76YH62VOW\P,<1W!XY_NM[^_>NDJ&K&33CN%%%%(04444 %,DC+,&#8(I]%
M!1110 44V0,RX4X-*N=HSR: %HIHD#2%>XIU !2,5^Z<<]C2TUHPS!CU% #J
M*** "BBB@ HHHH **0YW#'3O3)9A%CC)H$1S+(T@VYQVQ5CM38Y!(N13J $4
M[E!QCZT*ZL< Y-,N%D:,B/K44,;;P2,8ZT#+-%%% !TIJ.)%R*=2*H48 P*
M%HHIJR*W0YH =4UG_P ?D'_71?YU#4UG_P ?D'_71?YT@6Y-]GC_ +OZFC[/
M'_=_4T45)0?9X_[OZFC[/'_=_4T44 'V>/\ N_J:/L\?]W]3110 ?9X_[OZF
MC[/'_=_4T44 'V>/^[^IH^SQ_P!W]3110 ?9X_[OZFC[/'_=_4T44 )]GC_N
M_J:7[/'_ '?U-%% !]GC_N_J:/L\?]W]3110 ?9X_P"[^IH^SQ_W?U-%% !]
MGC_N_J:/L\?]W]3110 ?9X_[OZFC[/'_ '?U-%% !]GC_N_J:/L\?]W]3110
M ?9X_P"[^IH^SQ_W?U-%% !]GC_N_J:/L\?]W]3110 ?9X_[OZFC[/'_ '?U
M-%% !]GC_N_J::]NBHQ YQZFBB@#F-)C7^S3/C,TI+.^>2<U#?0I]F(QPS*I
MY/0L ?THHK<ZS>UR,6.B7+P#RFCCPA4_=[<5@PVL44**JX&,]3^=%%3'8SI[
M&CX8M8I$O)V3,WFF/?DYVCH*Q+>);]I)[D>=+O90SG. #T Z#\***:W81^)G
M2^&K>/\ L6W^7H6 Y/\ >-)XF=K'1YI8&,<@P P-%%9]3/[1S,>GV\D:L\0D
M=QEFD)8G\374^'(5DT.S+98[,9)/J:**N6Q=38XBX8WE_=2SDR.DK(I8_=4'
MH/2F>2GI^M%%6:%>[C"1C;QE@.M=3K5K%X?\.B73T%M*X7=(O+'([DT45,MT
M1+=''+&)I"\F9'9P"SDL3D9ZFD\E-HX/*G/)]:**HT-K1M+M9HS))$'<<C<2
M1D>U:GDHHVA0%! P.F#UHHK-[B&&->>/[WZ4TPKZ=@>IHHI 1M"G/'ZGN:I:
MA^Y&4XY(_(<4458'/27D[]96'R*?E..2>>E1M&)&.XLWS'JQ]***H9$UK%D#
M;QD+U/3&:KM&NW..=A?\<XS110 ]K>/>1MXW@?ACI2?9XSQ@^G4T44 1O"F"
M=O.&;KW'2H3"FXC:, J/P/4444P!84;&1_?[GL>*>UO'G[O;/4]J**0#'@0*
M?E[+^IYH^SQ[ON_Q,/R'%%% "I A3./X5/4T_P"SQ\G'OU/>BB@!IMH]P&WC
M=M_ #-,\I-I..=F[\<]:**8$OV>/=]WHWJ?2C[/&NTA<$' .3FBBD!W?P[OK
MC5&GM;N5KF!1@)+\WZFLGQ]HMEI.K0K:6ZP+(,LJDXS],\?A114?:,_M'.-;
MQ[3\O;U->UZ%"C:+8$@DF!.Y_NBBBB8JFQ=%O'_=_4TDEG#-&R/&'1A@JW((
MHHK(Q/(M5L(+36+Z"*/9%'+A%R>!Z56^SQ_W?UHHKH.I;'7_  Z=FN+RU+,;
M>-%=(R3A23SBM;QE8P+:P7(C G654#Y.=IZCZ445F_B,G\9B_98I%*,F5/!&
M36S:V\>H>#]]R/-=$9E9B<@KG!SZ\444Y%R,Z"WCN+2,2+O#H-V>_%=%X;'V
MC1;9Y27?!&XDYX) HHHEL34V-/[/'_=_4T?9X_[OZFBBLC$/L\?]W]31]GC_
M +OZFBB@ ^SQ_P!W]31]GC_N_J:** #[/'_=_4T?9X_[OZFBB@ ^SQ_W?U-'
MV>/^[^IHHH 3[-'G.WGZFE^SQ_W?U-%% !]GC_N_J:/L\?\ =_4T44 'V>/^
M[^IH^SQ_W?U-%% !]GC_ +OZFC[/'_=_4T44 'V>/^[^IH^SQ_W?U-%% !]G
MC_N_J:@N+6(L/E[>IHHIH!UO;1A<;>_J:E^SQ_W?U-%% !]GC_N_J:/L\?\
M=_4T44@#[/'_ '?U-'V>/^[^IHHH /L\?]W]31]GC_N_J:** $:WCVGY>WJ:
D@M[6+=G;V]3113$6/L\?]W]34MK;QBZA.W^->Y]:**12W/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>modernalogoa04.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 modernalogoa04.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2764&AO=&]S:&]P(#,N,  X0DE-! 0
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M 0 !.$))300F       .             #^    X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-! H
M      $  #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              #E   #XP
M       !                          $              ^,   #E
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #E
M %)G:'1L;VYG   #XP    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    Y0    !29VAT;&]N9P   ^,
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!$       $! #A"24T$%       !     4X
M0DE-! P     &ND    !    H    "4   '@  !%8   &LT &  !_]C_X@Q8
M24-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D
M!@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0
M  #3+4A0("
M             !%C<')T   !4    #-D97-C   !A    &QW='!T   !\
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M0S8Q.38V+3(N,0
M                    6%E:(        /-1  $    !%LQ865H@
M             %A96B        !OH@  ./4   .06%E:(        &*9  "W
MA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:
M  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M     $P)5@!0    5Q_G;65A<P         !
M H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X
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M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "4
MH ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&
M!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'
M!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&
M!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /3OMN$6VN&1
M5MQR6WNWMBLCEMNOZ/\ MH>)U7IF<]S,/+IR'LU<VI[7$#][:T_17)]%Z/5U
M7K?6&YLOP,;.LL^S<-LN<YXWVQ[GMIK9_-_\(K/UNZ3@]+P:^M],HKP\O MK
M<UU+0QKFEPK=78RK8US7;_\ ,_1J'W)UQ4.$?:Z!Y/ ,T>7]R1RY.'A(B/;C
M/)'BA"?^-_@/29G5.FX):,W*JQW.U:VQ[6DCQ#7%'INIOJ;=18VVIXEEC"'-
M(_DN;[5C=,^K?3S0,OJ=%>=U#+ MR;KVBSW.$^G4VS<VJJK^:KV?F*GT"EG2
MOK/U+H^-+<)]3,NJHDD,<=M=@9_6W_\ 0K3A.5Q)  EI_6#$<&&4,@QSE+)A
MCQRL#V\D1+@G[?Z7Z7^&]-9974QUEK@QC1+GN(  \7.*IT=<Z+D6BBC.Q[;2
M8:QMK"2?Y #O?_96#9CGZT]?RL?*>[]C])>*_L[26BZ_\]UNW_1;=O\ U'\Y
M:M7+^J7U=RL8X[L&FH$0VRE@KL!_>%C!N_STN*<K,0*'?])1PX,?#'-.?N2
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M3X:@8G6.E9MGIXF91?9^Y78USM/Y#3N7'XN=T/K?4\CJ77\NH8]-AJZ=@6O
M:UC?^U%E7YSKOY?_ %'H^G=ZC5]0<VG;3DXF%D-UHR<<MJ<QX^@_]%LW[?Y:
M7NDZ@QKM(^HI/(Q@1#(,W'0XI8\?'BQF7Z/^LX?TWK;+*ZJW66N#*V N>]Q
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M)')$C#D$(@0UGA]@<&$QXOGX8?/^^OU'J6#TS&=DYMK::FCN=2?W:V_2>_\
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M_1;;)GTY+]FV=GTG?NJRC&)'%?4VMSY1D]NK]&..,W^]'B>:^J5;;:^N5/\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T *@    @
M# $   ,    !#Z    $!  ,    ! X8   $"  ,    #    G@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HS," P-SHT,#HU,0     $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   /CH , !     $
M  #E          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
M2     $   !(     3A"24T#_0      "      !    _^$!@$U- "H    (
M  P!   #     0^@   ! 0 #     0.&   ! @ #     P   )X!!@ #
M 0 "   !$@ #     0     !%0 #     0 #   !&@ %     0   *0!&P %
M     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*'
M:0 $     0   .@   $@  @ "  (   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,S @,#<Z-# Z-3$
M!)    <    $,#(R,: !  ,    !__\  * "  0    !   #XZ #  0    !
M    Y0         & 0,  P    $ !@   1H !0    $   %N 1L !0    $
M  %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M5R"-+M9\=/8&ZG0B%;+DQ@Q%0$PLSS&LJ,%TB8"]T46;EY8P3 !ZAZJ^"@%
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M'^LGB)HXQS\^(P/LU0B_XY?$?=O&Y%O#'XV+O[EQ]#;. ]A1>>?+ NT;MMT
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M?7)"O0,>F8X&.DDTBR*)%$"G76, J&GM;9."@0++#/;DX]Z6:S.A)X]2$K/
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M>53ZCT9H OQ'Q^(U:G$Q4=!149"0[)O'1$-'LXJ+CVB946K".CVR;1BR;(D
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M2N/9<32^BL7DY.9+5;'>:LD<41J5I8BSB4KI_']\,;0O\DVY'^3F,/\ :O\
MV]WOU/\ [_\ &?\ @.1_XM3_ *5]FL\_\S@ZS?[K^F/]D]U?]D-']\,;0O\
M)/N1_DYC'_:MH^__ !G_ (#D?^+5_P"E?Q^/PT?YG!UF_P!U_3'^R>ZO^R&N
M;9BXY&QW->++_B:WX=W&.ZYD&J3-7DB*U?%RO8)*,U$$'Z!396$"O(QV*$BQ
M6#D=!XU063,4Z93!\=_>F(OT[-*6AD2EF%XB>RJ>UB/<D'\D_C1N%D0_)E!&
MI-LSP%]>=C[LV[N_#;UZ:0Y/;F7I96JR9;=:=[5)EDDKN1M#UAM0B2M80\K)
M!-(C JQ&LC^CUY1?PFXC+^(C/%?4%]Q>%M19G,8$QL-#L$:T:+IH@8R::RD+
M:Y@K@Q?:4*W0*8Y@1)KD["LM'EIZQ/"VJ3LR^O!EK2QM&1S]4<T_QX/J/J&G
M']T=VG7O=-]E[S$"?2.W]U'#23J!W?1NX,=:FEC9^ S(E[$4C&#Z(99" "[:
MV/Z11^ W;S]*]A^J"VNQU"_6,7_5K/\ [D7U:2OW-C]OO4?\T,=_CF/6\>#[
M1(ZB\/K!(LVJ:#VY-;3?)M8H !WTC8+9,@U<K" <S'3@6<*P()N8@@R1*(^S
MKN[.@2' 5"H]Z>2S/(>/QG-B2,$\^OI''&O//[GT].-5^\9NX+.?\1G4#SY6
MD@PLV*V_10DE:];&XBEYL2 D]JMD)KU@@< R3NW'+'3--2C56]3Y^D0_)MP;
M]."GU"M.EYU"_E3%_OV3^#MK1C[FW_-.W[^8:_Y08G6GN";BB'QUL,H%E:-$
MDYW+L];K]8GG;*#AR9*P/ZG!MS+<NX9LU@ZXR401,/0DN\>J)@!G"AC]39%1
M:^#CF XDN3SS.2 &XCD:O&O/KRH6'O7UXY=B/CI4^.?=UW<OB"W'C)I7:ALZ
MAAMO8V#N/EQ*V.KY>]($Y[1)-?R<ZR.!W.D,*L>(U"MNU+]4]U^?+1S27BY*
M)?HD<,92/>1SUNH4ITUVCUNHV<HJ$, E.15%4Y#%, E,4P@(" Z_$B++&\;C
ME)$9&!]05<%6!'V@D:]]6S-3M5KE=VCGJ3PV8)%)5DF@D66-U8$%65U5@000
M1R#SJ1_T?M^XA=W6<JB4YP:.L+S*JR74/(SJMY$J#-J<P<^0F32EGI0$0$0[
MIN0AU#S473]R,K(G)_"8N4GU^)2>F03]H[VXY^'<>/0^FQ/W12O'>Z.;!S)4
M&:+>])$< >D63VUF9IE'IZ!WJ0-Z$#W!Z'TX>EQ:,J2V(]@^=YJ =JL9NS1<
M)CMB[04,DLBA?+#&5Z=%)0@@=-0U9=S9$CD$IB*&(8I@$.>IUN^TU; W.P]K
M6#%5!Y /9/(JS <D?C0"4?8#S\M4'\'^TJF\?$)T_HY"))Z.+MWMRV(I%#H\
MFWL=:R5 ,I]UE^E(:)=6Y!0,"#SQK GH^N X*OX1R1N+?,DEK?D*X/*!"OE4
MR&5CJ33T(UV[19*B7N(A-V=\Y&4*4W0X"NQ F+S;@(\'8%%!7N9)AS+)-['$
MS <K#$D<DA0_^5E<*_J1^ 0?(ZL-]T7ZA7\COS;/36"=DPVV\+#N&[75F"6<
M[FGLQ0R3KSVN:.*@B%4D=T?TE<X)$O H9TQ-9PZ-&C60=^F"(+<9M+S9C>89
M(N7QJ3,VBH.CI$4<15WJ+%Q/U=\T4,45$#*2+(D:^,@)%5XB0D60F[3I0IN)
MN.BF0PUZ%EYDC@DLUSP.5L5T:2/@GGM\S@PN1Z^5(X^>G)X?M_W^FG5_8VYZ
M4[Q0+G:.+S,0=ECMX',6(L?EJ\R@A9 M6=K,"ORB7*U:?CNB4A$OHX_ZY-V?
M\!X;_G^2=0?I[_+N5///-6D>?^%M<?Q^OG\FK_\ W2_]B^D'[_WI_!]LZJ8T
MT]9.:D$W5E*?CXT I@ 0^S_M--Y^[F6#Q:8/+]XP (:3^4_;Q'Z?#+X;_P#K
M_LX^7UZV7Z2$C[GKN,@\?][SJ\/T&]NH$?I!(U7WIP:QHT:-&I(_2(PY[@=O
MX?CP_*!_YUE-*;J#^R%/]X/_ (:7^/\ \M;#?<VOYG?47\\J?^(ZVJNZBD1"
MJ5A%,.E-&O0J1"A\Q$XUL0H?F* !IIU@!7K@#@"&( ?4!&O UD5F&9\ME'8\
ML^1NLQ^MFLRDG]).OH=>[7.U/9Z1'\G; _TTO/J-/Z7G4'^5<;S\/:)_\$OR
M_CQ^76CGW-K^:3U _,>'_'V/TR'A@_("VM_1FU_I:5U(MJ?M?QO]2D_A$VJR
M>*G^>'ZL?G3-_!*FIV][KPNV;C65S+MM3.UJ+[(^$<IB_4Y]!JBYBZ_6;(_(
M/+D)8Y["6-+I#SZF/+YP'2ZS;?1F[WM2J?*6]C[Y('), 6NTC ?$]K13(/\
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M ?X[B9EUU!_*910QA_?$=2#:@XV_COZ6P?Z]N<ZK3XJG9_$/U89CR1NB5/\
MU8Z=.-1^A5 'Y-;TU(M5]U_#>X?R#^C7@_ _D.C4@_ D^7OFX/F^PYD;\GX4
ML>Z3FP?V9'_HJ?\ PM'])/Y?EQK9;Q^_SO6P_P ]-L^O_P"D]Q:=CQEJ-(WC
MA\9G]5(*NG=1=TB\'01*)SFCH"X0_KI<0#S[;"%=R$BN;W$0:*''R+SU.MYP
M&; V& Y->:M/]?NK*L;GT_H4D9C]0!)^&J+^"?/5L#XC=C^UR+%#F8L[@1(Y
M"J+.1PMT44Y/[JQ>BK5HP/5I)E4<\\:S?P!,J0=HVE6O%R;MN6SXMR?-N7T:
M!P\5\';NU9S$+*G3$>H47,JVLD>4X!R \8)3  F*)N;L&TDF-M5.1YM>V9>W
MY^39C0H_V\RQSK]@4<@<@:9OW0_:=_$]8L3NIHI#B]V;5H1U[)7\%])8*6:C
M>J*W''?%4DQE@J3R1;Y'H#P]C4\U031HT:X3N?R5#8>VZYLR9/ND6D=4,9V^
M3*9<P%*YDAAG36$C$^?WSF7FG$?%,T_>JZ>(I!YG#7,S-E*>)R-B0\".I,%^
M7=)(ACAC'Q]Z25TC7T_&8:GW2O;%[>?4G8VU\?%)-9S.Z,-4XC')BK>W0RWK
M3<?"*G1CL6YG_<0P2.?1=3N^CC_KEW9_P'AO^?Y)TONG@ N94#Y5*(_NEKU_
MK:TE^Z7_ +%](/W_ +T_@^V=5,::FLG-2"[J?^'SH/T_;3_Z"Q=I/Y3]O*'_
M ,[8;C_]A_'ZOAK9;I+_ *'KN+_\/>KO\/W3JOK3@UC3HT:-22>D1_*!V_?1
M!*?7:3TINH7ID*?[P;^W-(/X\?WN=;#?<VOYG?47\\J?^(ZVJOJO^MFN_P !
M1']'M]-.O_*\']1B_P#<761&5_93)?O^Y_")-?NZ]VO@U/9Z1'\G; _TTO/J
M-/Z7?4+^5<;^^)_\$NM'/N;7\TGJ!^8\/^/L?ID/#!^0%M;^C-K_ $M*ZD>U
M/VOXW^I2?PB;59/%3_/#]6/SIF_@E367N,-L%EMVN)XG)6+(L)#.&'FKX\;#
MH$*#R_49V?Q<Q4FQA,3KFHUT49RL)G,8BZYIB(22%U-MUF_,WA@7R==+M1.^
M[31E:-1R]FL>6,:\>K2Q,6DA7GWN^5 "[H0U?!?XAJ?1W=]S;.[+1K[#WI+7
M6W=<GR=O9Z$>32S,J@-Q1LPGV#*LH!CC%.X[^50DCDQ#PU.,-5Z)4H3;5O)>
MR=0D:$F6J4_*LJPE'")(N*$D>RJ62&::#B7B9>!!,8UK83-3LU&#9%M8"1KQ
M@M*2O%VUNZ*K!'CLL61(!Y=>WVN_9&O"K!90!I%\H\HDH4@( DH7L\QWMXG_
M  7Y;/YB]U0Z)5ZN:J;A8Y?,[2IV*L<AMVP;$^8VS,TD=.[2R)?VJ7'+*)TL
M2/+CS:AL)5J4$1&Y';Q/Q03D)G?#DK#BGW?6;#)E,<L2I\N?4HY2FC))<@^^
M!0Q1+[C  ZGR9;%R)YB9*BT8]2XMP=H_ICYGN_IXUG7<Z9=1\?;-"]L#>E2Z
M&[/9;&U\W%8+<\<+$]$.WV=H(/RYTO#>/QBML>W:L3$9BVVU[/&8%FJB$#7*
M3)IS-.B7RR9@1DK==(PR\(1@Q/\ &+PT*_?SSM0J;,Z$6BN>4:1_+[QQU&)T
MHRQW[A7B,1$O5C9AZ/-.ON.%YY,4+M(QX4F(-YBV0Z*^"WJIU*RM.UNO#Y+I
M_LQ)5DR&4SM1J69MP(P+U<-@[8CO/8G7W8[MVO7Q\*EIQ):>-:DRR.$IL[RE
MN4W O^(-N21DW<.ULTG<:0XGVO86R1DEXJIVK0R9KIAT4ZDF4,K"KM$T6*D\
MTB640J9G7Y%L$7VGAK&2O_3E_O:&.9ITDD'!NW"Q;S . #% Y[^]?<,R1QQ^
M['(JVF\876G:?3#IU6\.?3!ZL-R7%U<-GDQ\WFIMG;,"KW8F>9&/=F\[VA;R
M3,\ZX^:Y/<43Y&M+JJ_38UDCJ4WBZ[*\G;?\ZM]_FV]"6:0SNQ1MRO;BMHF4
M?XSR4Q<)*#<U&S=,QO@I;%DDG,LZ636:-+"M)HRZA&4ZP0!3[LPEC'7CFJ(D
M$$LRV)'B![J5P,',IX![8I7'FB1N56=G20@/$IUO\''7':G438$OAVZG/3EN
M18RUA=OQY-PE?=&V+$;K]!I+(P7Z7PZ.T=*)&2:;')5>FK3X^Q(63[)^,=MT
MW$5>&@<R6FN8+S2V:HM9N+MD@2$HED>HHD*M,5&V2BA(EFV?J\U$ZY/R3699
M+*&8M3S:*)9)Q)L-O&A=BCCR$L5"Z %<R-V59F ]9(IF/9%W$'\#*X93RJO*
M!WFL77/P5]2NFV6O9#9>)R>_=CRS/+0N8>LU[/XR!W8I2S.'J*UR66LGNMDL
M?6EHSHHGE%%W-6-FTIG7",'$FGYG,6+8J#*D"XS$CD"ILHOLB'4"@/W$LFU$
MAB^93 J(&#W<]25LGCD3S'R%)$XY[VM0*O'U]QDX_MZJS4V%OJ_<&/H[,W9<
MOEB@I5=NY>>WW@\%?9XJ;2]P/H1V<@_'2.=^_&"K,S$O]MVQE:4ROEK(AE*6
MID.J1\@YBH$9<QHY=ACXI&Y7UNMSY-11O'2\6B,%$@N2382,H\2*BV@VX-WQ
M31OCL*9)YK/X%K<22>@<E#'34 22SOSVI*J]B]P,32/QV7R\/G@RRE*Y7ZF]
M?(ZNT-F[:"YP;<S%BM%;R(I@68Y]Q<R&##X:!E62S3MN,A<[#5GK587+RJ)X
M=6+;=A/BL84Q9?FS5G=*9;;5&65BT=D?I1\LIB>T/74>+Q'[G<K,3N_".5FQ
MUFIW**HM7#EOVEU8G@(9:^Y,=7G3RY8;DD4D?<#V.D,ZLI*DJ>U@1[K%?0<$
MCUU<GQ*[LP^^O"-OC=NWI)9L)G,1B+>+GFA:O)8I+N_$P16/(?B2)+"P^=%'
M*J3+$Z":.*7NC6Y'3RU@QJ1_B2[;<N</[=U$;[MNC1PA0;)<5+@Y=-&2CF)I
M%^FS.$[=4;0U:"GVZ;D CV048+'.U;J!,2E<24:N648L]46X\9;P&63,8\,M
M>2Q[1%(J@I6LOW&6O*%X_!3=TG8I[5>*5X 04[FV(\,74[9OB)Z.7/#]U+FC
M?<.,PJX:"*:<17,[MZ@L;X?,8J:;N[LWMPPUUL(HED7V*IDG2:*>VD#L-I/%
M6VJ;H*M%GD+Y6\/Y/\,@2PXUR+/L(!=&2$"D5^"U@EC1T1;HQ=7J.R/'+%F"
M-^DTI#QR@] S;%;KQ61C033Q4;? \RO9D$:EO@?(FD[(YE)_% (E X[XUY'-
M&>L/A)ZM]*<O;6OM[*;RVKYKMC=T;:QUC(QR5>2R?2V.IBS=PUJ-.U9UM1FF
MTG/LEVR@+#:-IW!X&H\6I-7#-.*JS%)IF5%_-Y JL:W,4H=0@B=U*I]\XA]X
MD@"BAQ$"D(8P@ ]B7*XR%"\N0I1J/FUJ$?H'O\D_8.2=(_$].NH&=M+1PNR-
MVY6VS!17H;=R]J0$GCWUBJ-Y:C]TS]JJ/5B .=3H\2WB[0F9*S([6MF1IZV?
M9 43J]RR5%1<NU=3S!^N#56CXWB100G9!6PJ"2.E9I5DB1Y&K.(J&9OB20R3
M=>;EW9'?A;&8KS7BG(CGLA'5IU/^EZ\1 E*RGA79D#2*3&D;*Y?6E/A?\'%[
M964K=6>MXQ^&7;BMEL+M>Y;I2Q4+%=/-3/;GN"23'UH\:H-FI16=VBM)';O3
M5S5]EE9_PEMF%LV?;=54,D/I(N2\IR32XVBJ*2;AS#T-LFS[$-66K KI:+3G
MD6ZR[NU2C%(AW<@Y2BCKO&D"Q<J2;:.%FQ%"1[19;5UDFD@[CVP(J\1HR@E3
M8(9FG<>O)2'EA"&:JOC ZW8CK1U+67;->J=K[3JS83$Y=:D45W<$AG\R[E9K
M!B2VV/DD2.'$5+#LL-:)K:QP39"Q$N*/2*/P&[>?I7L/U06UQNH7I!BS_P"6
MM?X.+3T^YL?M]ZC_ )H8[_',>FH<./Y"6U/Z%J;_ # -2C;/[ 8K]Z)_?;52
M_$O_ #?NKGY\YS^$G6U==W2.U/GZ1#\FW!GTX'^H=ITO.H7I4Q?[\E_@[_WM
M:,?<V_YIV_?S#7_*#$Z8[PQ/D";6OHP8_P!)2>I%M3]K^._I)_X5/JLWBG_G
MANK'YUV?X-5UN_4AT@-?P?</Y!_1KP?@?R'^]HU(/P)/E[YO^AS(W]:6/M)S
M8/[-?#_4J?U^O\+2_O?_ #^>MEO'[_.];#_/3;/^2>XM5NV:MPERK=@J-FCF
M\O7+3"RE=GHIV7K:R4--,EXZ38."?LD7;)RL@H'D/0H/(0'STX)H8[$,L$RA
MXIHWBE0_!HY%*NI_*I(UCQB\G>PN3QV8Q=F2GDL5>J9+'VX3VRU;M&>.S5L1
MM\GAGB213_1*-1G6>M;@>";O,&XUR+D+=A6TKOF$,\?&70KN4L:NW@.SU28E
M&R"C6)R'5P205!7PXKLY1HWF4(YW7)=1D]34D61V=F1(BM)"2RQ2/Z17ZA(+
M1.ZCA9U 4L O=%,BRA'@95?;/%9/IUXZ>B0PF3MUL-OO$1P6+L, 23);4W/#
M#Y(R]*I+(LMS;>7[I$*>9V359I*3V(<G32>"F7;GQ'MH>Y>O1\G3\O5:LV1P
M@@,ECW(4O&TVZQ+Y1,#JL@CIAVW;SI$#<R#)5IW,1:@@'2[ XBF5EX_<N'R$
M:E+D5>4@=U:VZ03*Q^0#L$E _HH6D7ZR#Z#+CJ7X:.LG2[)6*F;V;ELGC8Y)
M!5W'MRG:S>"N0(Q5)_:J4,DE R#AA5RD-*VO/K#V\,>U9&W5;:\20SF>R+G3
M%M6CVJ!W D>W2#6DW1"!S$D9",7CJ:EW!N7)-I%Q[QTJ;V4D3F\M?78S.)J(
M9)\C310">!/&\C ?'RXHR\LA_P![&C-]0U!MM=)>IV\+L6/VUL'=F6L2R+$&
MKX/(+5B9CP&M7YH(J-*(?NIK=B"%!ZNX&IH=\V]K)G$^GW>VO:)4[$.#:2VE
M,@Y#M\H@ZB2VF.IS1S*?"*TE$@EK5%AO"'=P,1*<YFQ6$T68\<E+HQ<6DM<_
MG;.XI#2QD$QHUE>U+R"K3+ KNUB?U"Q5XT!,4;GN>4IROG>5$NH?03H7M?PJ
MX^'JAUER^-&_<Y+5VYMK"5)(KC8FSFYHJGT;BB&'TIG[WG"'(7*G%'&XT6P+
M+TWMVWZ)Z./^N7=G_ >&_P"?Y)U]73W^7,K]M6B?[K:_CZ:COW2_]B^D'[_W
MI_!]LZJ8TT]9.:6UD'A?X.R/N_A]Z,S<LIM,EPMQQW=6M?C)6J)4E22QJTK[
M.%;+L750=SAF+Q*NM#29"3Z:ZAUG(M7#0#)%2B]C:M.SF!F7LVUG%FK:\E3!
MY/?4$/EKZPF3L8PJ7]_N]YNUE].+.;=\56_=L]&;O1"EA-IS;7O87<F#ER-J
MIEVSJUMSS9":[+'/%F8J G@;)3"J6Q[1JJ1>;',0Y=DNI1JL>C1HTN?>EPS<
M);Y;C3KME*X90K<I2JTXJ\6WH<I5F#%PQ<2CB6.N^3GZC8EU'0.'!R%,@X;H
M@B4I11$_,XQO-[8J9R>*>S8M0M%#Y(6 P]I4NS]Q\R&0]W+$<@\< <#GGFRO
M0_Q1[ZZ"87-8/:>&VKDZN=RD>5MR;@J9:Q/'/%4CIK' V/S&-C6$QQAB'CD?
MO)(<+PNF&Q[-..8,H]$QSHL6C9FD=42BH9-JB1 AE!*4A1.8I $XE*4HF$>1
M0#R"1(H1%0<\(JJ.>.>%  YX '/I\@!]FJX6)FLSSV'"AYYI)G"\A0TKL[!0
M22%!8\<DGCXD_'7MZ_6O3K&>]+9!C#?+2ZC1LI6.]5N*IMH5MD:XH;^!8/W$
M@K$NX<47JD_7K$@=H#9ZJ<"(-VZW> AA6$@"0W#S>"KYR.O'8FL0BO(TB& Q
M<L64*0WFQR#CT!''!^W3MZ']=]U]!<YF<_M/&X#)V\WBDQ%J+<%?(6*\==+D
M-T20+C\CC9%F\V!%+22R)V%AY?<0P[?@7#-;V]8>H&%:A(34K6<=01*_#2-C
M78N9QVS3<N'159)>-81;%5QUN3E$S:/:IB0I?B@'F(_=C:,>,I5Z,3R21UU9
M5>7M\Q@SM(>[L5%]"Y X4>@'/)Y)@?4'>V3ZC[TW%OC,UZ-3*;ER#9&[6QD<
M\5"&9HXXBE6.U8MV%C[8E($MB5N2?>XX Z[K[M0[2Y=V?"UVH;O))U;+A69*
MBY*=E^ZLCXU<L8&>EU"D B9[,P=QTG 610H%3(9_(Q1IL6Z:;9&801(0I(WE
MMK8K+.TSH]:TWXUBJ51I#]<T;*T<A^M^U9B/=\T  :LMT?\ %?U>Z-58L1A,
MK5SVV(3^"VSNB*?(XZFI/+KBYX;-7(XQ3RS"O5N+1\UFE>G([,653(^CC1YW
MYC1.[=XWBS*")$9'"J#Q^@D(CTD,Y;908MW2A2\N:@-&93#S$$B!Y:BS=.W[
MN5RZ=I^/=CV+ <_9>X+=OIS[O)Y/ Y]+;UONF%I:X%SH]!);"\,];?$D%>1^
M![PBEVK8EA4GGW3-.0.!WD^NM=[>^!+M-Q'+QUFR7+6S/T[&JD<(QEL385_'
MQETA R2SBFQ .'DD!3![;*<L\O$."^PYC52\^?6Q^QL;599+DTN0=2#Y;*(*
MQ(]>6A5I)']?BKSO&PX#(WS374?Q^=8-Y4[.*VO4Q'3O'VD,;VL.UC(;C$;>
MCI'F[ACAJ]P]!/0Q=*Y&?>BM(?@ZMBQ91;)I&QC-K'1T>V09,&#%NDT9,F;5
M(J+9HT:H$30;-FZ)")(((D(DDD0J:92E* !-55454151% 554!550. JJ.
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M$B:(?PW8>*S]>L3<[,&TBLIT(-D%N^5,W?Z ,F?B9O!5\Y%7BL33PBO*TJ&
MQ@EF0H0WF1R#C@^G''V\Z=?1#KKNKH+GLQN':>-P.2N9K$##68L_7OV*\=87
M:U[S(%Q^1QLBS>;61>7ED3L9AV=W##MN!L-US;WA^@86J$A-2M:QU I5Z&D;
M&LQ<3CMFDX<."*R2\:PBV*KCJ<'*)VT>U3$I2_% /,1^W'48\;2@HQ/))' K
M!7E[?,;OD>0ENQ47\9R!PH] /B?4P7J!O7)]1MY[BWQF:]&IE-RY!\E=K8U)
MXJ,4[QQQLM:.S8M3I'Q&"!+8E8$GWN. .N:^[4.T#Y^6@^OIHTMO:3PP,';.
M,O6K,^.+EE.?LMNK,W59&/NDI5'L(BQG9^&L3M=FA"5"!?)NTWL(U20,L_71
M*V47*HBHJ*:J<6PNTZ6$MFW7M6YG]G>L$G,!0([Q,6_!PQMW#R5 //'!/()X
MXLYUA\56_>M6S,1L?<V%VGCL7ALI0RU:Q@ZF7@OO/C\=>QD,<TE[,Y"!H6@O
MRO($KHYE2,JZJ&1F2:E.JQZY[E'%&-\UTN6QYE:F0-[IDV0I9"!L+%-XT,HG
MU=AXU./2XCY)F8PJL)2/6:R+!;DLS=(*@!P^:W3JWX&K6X([$+^I20<@$<\,
MI]&1UY/:Z%77Y$:D>U-W;FV/FZ>Y-HYO(;?SE%B:V1QMAH)@K<"2&4#F.S5F
M4=EBI926M8CYCGBD0E=(KRWZ//@JRRB\EAS-=\Q6U<*J+#7[- QV38EF!Q$2
MM8IT,K39QNU3 0*09:4GGGES4=*B/E!K?3^J[$TLA+64\DQV(%M@$\\!)%DK
M. OP!D,SGUY8D\ZOSL[[H]U Q=2.KO78^W]W2QJJ#(XR_9VM<FX #2VXA4S6
M/DF8\DBG3Q\/R6)!KYC'?HZN,8R60=Y3W'W2Y1"9RG5A:51H>A.%P((""2DU
M+SU]$$5.72J"$4@OT"().$C]*A?36Z>1JX-K*/)'^ZCK55@8^O/I++-87CZ^
M82?CZ^OIU=R?=*-UVZ<D.T^F>#PEQ@0E[.9Z[N&./GXNM&GC]O#O7XKYEN2/
MNX+QN.5+I<7;1,"X1P_9,)XBI#&@U2W5^5@+%(1')Q:IH9>)=0[B8F;%*D?R
M$U,(MGBQF:\J=XW9F$$6S5)H'AM3*OA<?3HST*D/D16(9(9I%]Z>3S(VC+O*
MX9G=0Q[._E%^"J%]W5'MU]8^H.^]YXS?6\L]8W#E\/D:F0QM>[S'B:(IW(KL
M=*CC*AKUJ-)Y84$T=1899@.^69YOPNN,;)>'3AS8B_R+(8JM>2;*KDMI66<V
M2_25:D$V:=56G%F!HP*_5JX9(ZYI]V#L71G93E2;]DJ(E4%3X\'MNK@I+,M>
MQ:G:S'%&WM!AX586D9>T111^I,AYY)^ U..NGB5WKU_K[:K[NQ&V,6FUYLI-
M1.WJN4KM,V62@DXM?2.6R898QCXC#Y0A(+R=Y?E>W?\ J1:KOHT:-&C1HT:-
M&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1H
MT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&
MC1HT:-&C1KA%UL^8XZQ/FE4JK%_!I V\$\49JNU' ':HJ+G.HG*M0*)71UD0
M3%$@E*D ^WS YIEB,=M6Q1BER>2F@N,9/-B65(U3B1A& K5I208PK%N\@DD>
MG' 7F>RV^*N2L0X?#5[./3R?(G>!YFE#1(TC,RW(@"LI= OEJ0%!//(8_&J7
M?<6'WE'CA]__ !0Y'_YWEKK+A]B'XYFP/_S,?_0M<%MP=41^+MVI_P CF/\
M>R0U^W4+=G9_9HEG9:;',X!PX,22>$8+M%&S<$%3=XBYYEP4#E4*GR(+=3NB
M;M 4HG Y/CRF+V;#C[,N/RT\MU$!KQ--'*)'[T':46K&>"I;U\Q>WCN)(]T]
M#!YOJ)9RU.#+8&K!C9)66W.E>2%XHO+D(D61\A*H(<)[OE.7![!P3W#ZO*UA
MRG!GA0QQ6F<ZDX*]&56<ME'AVRB8MP:)$12D8\R952G<',J/>*82 3XH2_&<
MS;=';ESVHYZ_+39#$*R1R+$'#"3S&+M!.&*D( H[" Q/O?N>QO+)[PQ_L/WK
M8J#(B43FV\L3SF)E,0A0(EJL5#JTK%SW@E ON'COXP?(.Z8!]G'D6(#\_J1U
MY>[W_JC#^W^F6C!]..?7.V>/K]KB_1_I#4!?<_6(<]NUJ3'TX'T=8]?K]?I;
MY:]<V1-UP&#IQQ$'\^8%-!NR@;S^]$WPG*!.H.0"<1 "\Q'R /+]G!=-N#_G
M_:'H?47(CQ]O'T>2>/J'J?AKU'=/6CD=NTZ#<\>AH3K^@L<R /R\@?/GTYUH
MS)$Q?8>DKR5#@6LS;0/'%+&. %RBBFLLF604*BF[8F>&;D$Q2%3=$'D/B.2A
M$C)'@> JX6UEHX,U=EJ8PB<FQ'Q&[,B,85+&*<1>80.2T;#]QR"P8-/=5[<E
M' 2VMMXV&_F@U4+4F[I8T621!98(LU9IS$I("K-&>#YGO!"C9;-DO> '/IQE
M#<OF'X/O1'ZU>7[_ )#IC#;_ $M^>XKGR_T["/RCUQFD\V[>NG)"[0QO'U_1
MEG_GSO&O4/D[>4 CTXOA1_%^IU[_ /K U[!M[I3\]QW/^70^O_\ %_\ /KY7
MWAU['';LW&GZ_P#.NS_U[K7.-)2Z3-(A9+($,V@;<X(\]:1;4HIH(BD_=(LE
M 2,Z?&0,Z8IMG*B)G2QDCK&*(D$.V18[@K8FIE[=?"6Y+N+C:+V:S(>YW[H8
MVE!81PAQ',TD:N(U#*@(YY[B\-HW-P7]O8^WNC'Q8S.2K8]MI0 K''V6IHZ[
M*C3V3&9JRPS-&T\A1I"I(X[1CI]E3>J1TY(WQ+!%1*X7*D!8%ZY J15# F4%
MR6XI5P O( 6*4"J@'64  W+35AVWTD:*(ONBZ7:-"Y-N*/W^T%N4.+)C]>?<
M8DK\.3QI#6-Z>(19YQ#L;%^6LL@C7Z-LR@1AR%'FKGU$O"\?A% 5OQ@H! 'Y
MILL[X_V.(H+^33\0^N0#^G]&O<-L]'_7G=%T?5_)\'_57K_'ZM?(=[>(STXV
M/BCR#S_G1:_1_KA''Y#Z^OV'7=L"73<+9Y:PM\RT6+J\2UCVBT*^9,%XU9Q(
M'<G(LT,DO.RXNDA;!WA433;@V.F!#G6%R0J4-WIB=CXZM1?:F9LY&S)-*EN&
M:9+")"J I*&2E5\MO,]SL9I#("2 @0EF3TUW!U1S%[*P[^VW2P]&"M!)C[5:
MM+4DEM-*RR0-'+D[YF0Q?A.]4A$)0*S2><H3X#+N2-W,%?YV*QKC"$F:4U]7
MA"2[B(=2B\@16,:+O5EET+1&D3.G)*/&H-Q9H&33;D$>[U@NIVML8#IE<PE.
MSG]Q7*F6D\\VZL=F*ND!6Q(D2(DF.L%@U=8I3()G#,Y [2"BQC?.[.N6-W1D
M:6T=G8W(;=A]E&.OS49[LUH/3KRV9))(<W35"EQ[$ B-:-D6)2?,#"1^7GS#
MOW#[W#E>-_%:1_3\-_S\M2 ;6Z,?/=5[U_\ .,'IZ?\ H?U]?XG40;??B7X;
MMV%B>[]S_G-<X/K]7WR_5]OK]GPU]SBO)^\R:R%6(K(6*(&)I+UXX2L<HC#.
MXQ>/9%8NE4W2+Q:V2"9%".R-RE1%BZ%T!A;%*D94'*/&W%M[I74PF0LX3<EV
MSEX8D:C6>U%82>4S1JT;Q)C(&*F(O[PFC$9 <E@I1Y%LW>'7V_NC#TMT;*Q5
M+;UB>1,K<BH6*<M6 5IF6>.>7/VT#+.L7X,U9VF!,*A&<2Q]*W'WC<?47=52
MP50(JW,GS>44L3U_'KRJK)T@JS+'M4VK>?@SMDU45'*IG!RO"KF*"91;"@(.
M.%L3$;$R<>1;>.:LXN:%ZPHQ03)766-UE,\C2/2N"1E98U" Q% >XB0/^#EG
M5?<75C!S89.FVV*.=@L0WGRL]NM+=>O/&]85(4AARF-:%9(WL.TC"<2E0H,!
MC/G9A-FCB'!YEPK6_F\O@A)C_P#?0_T:8/WJ=#^.?OLR'Y/I.O\ ]2_Q]?TI
M]NH'BF#@+T]PQ3MY)^@[O/=Z^G/WT?D^7SUXPS7Q% .3HP=6%_C"?%'JLDW*
MJ'4'-,RY[^4B '^\%8X@1(!ZS>11'1]Z?0[@\[OR">Z??&2KN4/KZ]@PI+\?
MC=H]6X[1ZG7X_5!\57 *].<)(_/I$V%N1+)P1PAE;=06,/\ BF1CVH#W'@*3
MK?\ E>:R'!8QLTUC6NL[%D-G%H+0-?><UV;E^HY:INBG(1[&&=@S:*.W2;=-
M\U.\.V(@F<#*@44OMRIA+F?Q]3/7I:.$EL.MR[%PDL<*QR-&03#8$7FRK%&S
MM#((ED+LO"DBSF]<ANG';0R^0VCBZ^4W3!3B?&XRSS)7ELO- DX=5LTFG%>!
MYYEB6S ]AHEB1PS@%= YQXD_S8*JH_Q.E?S?MBZ>/WH=!_\ =ADO[*5O^;!Z
MJLO4/Q:'NYZ>8(>I"_\ T<R'P^1_;?ZG^L/LUX#9SXEO['!55_/2Y4?G'E^V
M,'/R]_+]/O\ U]Z'0;_=ADO[+5?^H?R_VOT^'ZA^+8!>WI[@2>"2#MO(GU^0
M'&\!Q^DZWGMXM&9[9C8DOG*GQU.O83$JV)%1R2C%N[B$ 0&.?J,EI6;6CU5U
M3NFITE7RAE$VJ;XJ223I-,$YO;'[6QN<-;:.4GRN(]EKR&Q.RRO':?O$\*RK
M7J),J*L<@985"F0Q%F:,MJR73#+[]S6U?;>HF#J8/<2Y"["E6G&]:*Q0C$1J
MVFJRWLC)4DDD:>!HY+3F18%M*L<<Z(,#/,[<34KER"6 :BB0%U030+491Z5$
MO<,!4BO$LD F\*F'(@.4N2:X!W2>R8 TY(]G] RD?.\\HQ*+W,V2K1%SP.6\
MML!W1%CZE&Y*<]I]1SJM$G4;Q>>9/_WM=OP]LC=D*X"_9"#O;\&+*;Q[+ C'
M"B9 J2@>8O 8#7I'SSQ/ #F7 E3$?Q? >7_[_P )/F/Y/_;S]OWG] >>/OQR
M7!^?TM6/!]?3]@1Z?;^G7K7J/XO.TENF^!Y#$ #;F1'N\#@^N\#S\3\/J^ U
MJK:MD7=E=I>VM=QF,X2E0[&-CEZY)QD4ZA%G<FJZ73>,3MG=HL1GJ7A2E<=]
M)-H5H=,J:AW O$RHKKJ'A.G.*K8V39&>MY:S-/.MZ"Q8CMK% L:-%*'BQ]$1
M-YA9.QC*90W(">4>]S=&]T=:=P7,U%U3VGC<!2KU*LF+M4J-C'236WFD6>N\
M-C,Y9K">2%D\Q%@$#+VLTIG41<ESQF+?[6LJ6N$Q!A2LS^.&"D:2L3KNOOIM
MU+-U8E@X>NG+MK>8=,BA919^U!KZM:G;IMDRG[W,'*\CVAMCHY?V[C[>Y=U9
M"GG9A/[?3CNPU(ZSK9F2)(XY<1:)4UUAD\SSY YD)'9P46&=1-\>)7%[SS..
MV/L+"Y#:E9JHQ&2L8NUD9[L;T:DMB:6>#<V/166[):@$!IPO&L*\^9^NR<;4
MW <4P.71M\J/S?\ (:8'\O[9@>X/WO/W_O:DPV9X??GO3)GX_P"JU4?5Q_J!
M^7YZ@[=2/&#R0O3?;XXXX)VUD3S^-S_KR'U#ZOCKK6!LR\06RY8J4'F'"58K
M^-I!:13M$ZTKDA"NHENE$2#ADZ;O7-ZETA4-)HL6WAQC'1G!'!TB@@8P.4(Y
MO#;'1FAMW(V]L;KR%W.0K :%26[#:CL.UJ".6-XH\15;@5WFD[_/C"% Q[Q[
MC3/IQOCQ,97>6&Q^^]AX7&[4LO:7+9"MB+>.GIQI1LRUYH[$^Y\BG)N1UX3%
M[',TJRLJ^7^NIH+=I>]S-%KU2<[:<>0]^EY"8?(6D)6/7E_5,<BS34CS-XYK
M8JXL87SDRX*O/$.$VWA4T3H 9XFH6&=.<1L/+7<BF^\U:P]6&K$]#V:9*QLS
MM*5F#SR4;RCRD"%8O+1G\QG#D1%2R^M&X>K.WL5AY>D^V<?N+(6+L\>5%^K-
M?%.LD*M7,=2#+8B0^?(9.^QYTR1>2L9B[IT=<)&W#<5H/=MVIX_B_4),^?\
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9-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6807078944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) - Restricted Common Stock Units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares/Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at beginning of period (in shares) | shares</a></td>
<td class="nump">1,177,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares) | shares</a></td>
<td class="nump">1,057,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(113,991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled, forfeited (in shares) | shares</a></td>
<td class="num">(58,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at end of period (in shares) | shares</a></td>
<td class="nump">2,062,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Share/Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at beginning of period (usd per share) | $ / shares</a></td>
<td class="nump">$ 19.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued (usd per share) | $ / shares</a></td>
<td class="nump">25.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share) | $ / shares</a></td>
<td class="nump">20.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled, forfeited (usd per share) | $ / shares</a></td>
<td class="nump">20.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at end of period (usd per share) | $ / shares</a></td>
<td class="nump">$ 22.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6648543264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating, net</a></td>
<td class="nump">$ 100,533<span></span>
</td>
<td class="nump">$ 86,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets, financing, net</a></td>
<td class="nump">9,488<span></span>
</td>
<td class="nump">9,544<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset', window );">Total</a></td>
<td class="nump">110,021<span></span>
</td>
<td class="nump">95,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="nump">3,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">108,919<span></span>
</td>
<td class="nump">93,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">38,930<span></span>
</td>
<td class="nump">38,689<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Total non-current lease liabilities</a></td>
<td class="nump">147,849<span></span>
</td>
<td class="nump">132,364<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 151,836<span></span>
</td>
<td class="nump">$ 135,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6808522752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2020</div></th>
<th class="th"><div>Dec. 11, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 07, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509,352,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,108<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549,455<span></span>
</td>
<td colspan="2" class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,275,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from the offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PaymentsOfUnderwritingDiscounts', window );">Underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock converted into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,012,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrna_PublicEquityOfferingMember', window );">Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">26,315,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share)</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">$ 477,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriting option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">3,947,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">$ 71,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PaymentsOfUnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Underwriting Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PaymentsOfUnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrna_PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrna_PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6769315344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) - Collaboration Revenue by Strategic Collaborator - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">$ 4,457<span></span>
</td>
<td class="nump">$ 14,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember', window );">Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">10,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember', window );">Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">2,056<span></span>
</td>
<td class="nump">2,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6648629680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 1,620,684<span></span>
</td>
<td class="nump">$ 1,496,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831312208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Merck &#8211; Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1">53 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>candidate</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (474,000)<span></span>
</td>
<td class="num">$ (15,604,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,601,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 199,528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amortization of deferred revenue due to the satisfaction of our performance obligation during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member', window );">2015 Merck Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod', window );">Research period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates', window );">Number of product candidates | candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue (contra-revenue)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Decrease to the transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member', window );">2015 Merck Agreement | Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue (contra-revenue)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member', window );">2015 Merck Agreement | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue (contra-revenue)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member', window );">2015 Merck Agreement | Upfront Payment, Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue (contra-revenue)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_SeparateAgreementsWithMerckMember', window );">Separate Agreements With Merck | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue (contra-revenue)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,100,000)<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV Agreement | Series H Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from the offering</a></td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Premium recorded to deferred revenue</a></td>
<td class="nump">13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV Agreement | PCV products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">243,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 83,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | Clinical Supply Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Decrease to the transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | PCV products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="nump">$ 243,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue (contra-revenue)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Decrease to the transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Performance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Research Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_SeparateAgreementsWithMerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_SeparateAgreementsWithMerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ClinicalSupplyReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ClinicalSupplyReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6647118416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Collaboration Revenue by Strategic Collaborator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AstraZeneca</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,270</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vertex</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total collaboration revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,115</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,718</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,370</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199,528</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,304</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue recognized in the period from:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied (or partially satisfied) in previous reporting periods </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;"> We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period is first applied to the beginning contract liability.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span><span style="font-family:inherit;font-size:10pt;"> Related to changes in estimated costs for our future performance obligations and estimated variable considerations. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was </span><span style="font-family:inherit;font-size:10pt;"><span>$278.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AstraZeneca &#8211; Strategic Alliances in Cardiovascular and Oncology</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2013 Option Agreement and Services and Collaboration Agreement</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement, the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018. We refer to these agreements in the forms that existed prior to the 2018 amendment and restatement as the 2013 AZ Agreements. Under the 2013 AZ Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. Pursuant to the 2013 AZ Agreements, AstraZeneca was responsible for all research, development and commercialization activities, while we provided specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca&#8217;s activities pursuant to an agreed upon services plan. Under the 2013 AZ Agreements, AstraZeneca could have requested we provide additional services, at AstraZeneca&#8217;s expense. Subject to customary &#8220;back-up&#8221; supply rights granted to AstraZeneca, we exclusively manufactured (or had manufactured) mRNA for all research, development and commercialization purposes under the 2013 AZ Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2013 AZ Agreements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, AstraZeneca acquired </span><span style="font-family:inherit;font-size:10pt;"><span>forty</span></span><span style="font-family:inherit;font-size:10pt;"> options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates under the 2013 AZ Agreements, AstraZeneca could have elected to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca could have then exercised one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates). If AstraZeneca did not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca&#8217;s rights to exercise an option and other rights granted under the 2013 AZ Agreements with respect to such development candidate (and related back-up candidates) would terminate, all rights to exploit such development candidate (and related back-up candidates) would be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) would be either assigned or licensed to us. Upon the earlier of termination of the 2013 AZ Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, would automatically terminate. On a target-by-target basis, we and AstraZeneca agreed to certain defined exclusivity obligations under the 2013 AZ Agreements with respect to the research, development and commercialization of mRNA medicines for such target.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$240.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Under the 2013 AZ Agreements, we were entitled to receive payments that are not related to any specific program of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$180.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate for the achievement of </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> technical milestones relating to toxicity, delivery, and competition criteria. We achieved the toxicity and competition milestones in the year ended December&#160;31, 2015. The delivery milestone has expired. Under the 2013 AZ </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agreements, AstraZeneca was obligated to pay us a </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> option exercise fee with respect to each development candidate (and related back-up candidates) for which it exercised an option. In addition, upon AstraZeneca&#8217;s exercise of each option, we were eligible to receive certain payments contingent upon the achievement of specified clinical, regulatory, and commercial events. For any product candidate optioned by AstraZeneca, we were eligible to receive, per product candidate, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments for achievement of development milestones, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> payments for achievement of regulatory milestones, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> payments for achievement of commercial milestones. Additionally, under the 2013 AZ Agreements, we were entitled to receive, on a product-by-product basis, earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to </span><span style="font-family:inherit;font-size:10pt;"><span>12%</span></span><span style="font-family:inherit;font-size:10pt;">, subject to certain reductions, with an aggregate minimum floor.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We received from AstraZeneca under the 2013 AZ Agreements an option exercise payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the 2016 VEGF Exercise) in the year ended December&#160;31, 2016, and a clinical milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> with respect to AstraZeneca&#8217;s VEGF-A product (AZD8601) during the year ended December&#160;31, 2018, that is currently being developed in a Phase&#160;2 clinical trial in certain fields. Unless earlier terminated, the 2013 AZ Agreements would have continued until the expiration of AstraZeneca&#8217;s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party had the right to terminate the 2013 AZ Agreements upon the other party&#8217;s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca had the right to terminate the 2013 AZ Agreements for our material breach, then AstraZeneca could have elected, in lieu of terminating the 2013 AZ Agreements, in their entirety or with respect to such candidates, to have the 2013 AZ Agreements remain in effect, subject to reductions in certain payments we were eligible to receive and certain adjustments to AstraZeneca&#8217;s obligations under the 2013 AZ Agreements. AstraZeneca had the right to terminate the 2013 AZ Agreements in full, without cause, upon </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;">-days&#8217; prior notice to us.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Strategic Alliance with AstraZeneca</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> &#8211;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> IL-12 </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, we entered into a new Strategic Drug Development Collaboration and License Agreement, which we refer to as the 2016 AZ Agreement, with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL-12 protein.</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">The 2016 AZ Agreement initially included research activities with respect to a second discovery program. During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. For the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement, during a defined election period that commenced as of the effective date of the 2016 AZ Agreement (for the IL-12 program) and otherwise will commence on initiation of any such new discovery program, AstraZeneca may elect to participate in the clinical development of a development candidate arising under the 2016 AZ Agreement from such program. If AstraZeneca so elects (as it has for the IL-12 program), AstraZeneca will lead clinical development activities worldwide and we will be responsible for certain activities, including being solely responsible for manufacturing activities, all in accordance with an agreed upon development plan. AstraZeneca will be responsible for funding all Phase&#160;1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan), and Phase&#160;2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan) up to a defined dollar threshold. We and AstraZeneca will equally share the costs of Phase&#160;2 clinical development activities in excess of such dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and commercialization activities and instead receive tiered royalties, as described below.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and AstraZeneca will co-commercialize products in the United States in accordance with an agreed upon commercialization plan and budget, and on a product-by-product basis will equally share the U.S. profits or losses arising from such commercialization. Notwithstanding, on a product-by-product basis, prior to a specified stage of development of a given product, we have the right to elect not to participate in the further development and commercialization activities for such product. If we make such election, instead of participating in the U.S. profits and losses share with respect to such product, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2016 AZ Agreement, ranging from percentages in the mid-single digits to </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> on worldwide net sales of products, subject to certain reductions with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected to not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to tiered royalties at rates ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>30%</span></span><span style="font-family:inherit;font-size:10pt;"> on ex-U.S. net sales of the products, subject to certain reductions with an aggregate </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">minimum floor. Subject to customary &#8220;back-up&#8221; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. We and AstraZeneca have agreed to certain defined exclusivity obligations with each other under the 2016 AZ Agreement with respect to the development and commercialization of mRNA medicines for IL-12. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, our strategic alliance under the 2016 AZ Agreement will continue on a product-by-product basis (i)&#160;until both parties cease developing and commercializing such product without the intention to resume, if we have not elected our right not to participate in further development and commercialization of such product or (ii)&#160;on a country-by-country basis, until the end of the applicable royalty term for such product in such country, if we have elected our right not to participate in further development and commercialization of such product.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Either party may terminate the 2016 AZ Agreement upon the other party&#8217;s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2016 AZ Agreement in the event the other party challenges such party&#8217;s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2016 AZ Agreement in full or with respect to any program for scientific, technical, regulatory or commercial reasons at any time upon </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; prior written notice to us. On a product-by-product basis, we have the right to terminate the 2016 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of such product for a period of </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;"> consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca&#8217;s control. On a product-by-product basis, if the 2016 AZ Agreement is terminated with respect to a given product, AstraZeneca&#8217;s rights in such product will terminate and, to the extent we terminated for AstraZeneca&#8217;s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing such product in the oncology field.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we continue developing and commercializing a given product following termination of the 2016 AZ Agreement by AstraZeneca in its discretion with respect to such product, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of such product and a high-single digit percentage of the amounts received by us from a third party in consideration of a license to such third party to exploit such product, in each case, until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2016 AZ Agreement with respect to such product prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Strategic Alliance with AstraZeneca &#8211; Relaxin</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we entered a new Collaboration and License Agreement, which we refer to as the 2017 AZ Agreement, under which AstraZeneca may clinically develop and commercialize a development candidate, now known as AZD7970, which is comprised of an mRNA construct for the relaxin protein designed by us and encapsulated in one of our proprietary lipid nanoparticles (LNP). We discovered and performed preclinical development activities for AZD7970 prior to the initiation of the strategic alliance with AstraZeneca under the 2017 AZ Agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the 2017 AZ Agreement, we will fund and be responsible for conducting preclinical development activities for AZD7970 through completion of IND-enabling GLP toxicology studies and AstraZeneca will lead pharmacological studies, each in accordance with an agreed upon discovery program plan. During a defined election period that commences as of the effective date of the 2017 AZ Agreement, AstraZeneca may elect to participate in further development and commercialization of AZD7970. Upon such election, AstraZeneca will lead clinical development activities for AZD7970 worldwide and we will be responsible for manufacturing AZD7970, certain regulatory matters and any other development activities that we agree to perform and that are set forth in an agreed upon development plan. AstraZeneca will be responsible for funding Phase&#160;1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared), and Phase&#160;2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared) up to a defined dollar threshold. Thereafter, we and AstraZeneca will equally share the costs of Phase&#160;2 clinical development activities in excess of such defined dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and co-commercialization activities and instead receive tiered royalties as described below. If the development candidate is determined to be IND-ready, and AstraZeneca does not timely elect to participate in the clinical development of AZD7970, AstraZeneca is obligated to reimburse us for certain costs we incurred in the manufacture and development of AZD7970, since execution of the 2017 AZ Agreement.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and AstraZeneca will co-commercialize AZD7970 in the United States in accordance with an agreed upon commercialization plan and budget, and will equally share U.S. profits or losses arising from such commercialization. Notwithstanding, prior to a specified </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">stage of development of AZD7970, we have the right to elect not to participate in the further development and commercialization activities for AZD7970. If we make such election, instead of participating in the U.S. profits and losses share with respect to AZD7970, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2017 AZ Agreement, ranging from percentages in the mid-single digits to the low 20s on worldwide net sales by AstraZeneca of AZD7970, subject to certain reductions, with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to receive tiered royalties at rates ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>30%</span></span><span style="font-family:inherit;font-size:10pt;"> on annual ex-U.S. net sales of AZD7970, subject to certain reductions with an aggregate minimum floor. Subject to customary &#8220;back-up&#8221; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. Additionally, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2017 AZ Agreement with respect to the development and commercialization of mRNA medicines for Relaxin.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, our strategic alliance under the 2017 AZ Agreement will continue (i)&#160;until the expiration of AstraZeneca&#8217;s election period, if it does not elect to participate in the clinical development of AZD7970, (ii)&#160;until both parties cease developing and commercializing AZD7970 without the intention to resume, if we have not elected our right not to participate in further development and commercialization of AZD7970, (iii)&#160;on a country-by-country basis, until the end of the applicable royalty term for AZD7970 in such country, if we have elected our right not to participate in further development and commercialization of AZD7970 or (iv)&#160;following completion of IND-enabling studies with respect to AZD7970, if we provide AstraZeneca with written notice that we do not reasonably believe that the product is IND-ready.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Either party may terminate the 2017 AZ Agreement upon the other party&#8217;s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2017 AZ Agreement in the event the other party challenges the validity or enforceability of such party&#8217;s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2017 AZ Agreement in full for scientific, technical, regulatory or commercial reasons at any time upon </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; prior written notice to us. We have the right to terminate the 2017 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of AZD7970 for a period of </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;"> consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca&#8217;s control. If AstraZeneca does not timely elect to participate in clinical development of AZD7970, or the Agreement is terminated, AstraZeneca&#8217;s rights in AZD7970 will terminate and, to the extent we terminated for AstraZeneca&#8217;s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing AZD7970 in the cardiovascular and cardiometabolic fields.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we continue developing and commercializing AZD7970 following a termination of the 2017 AZ Agreement by AstraZeneca in its discretion, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of AZD7970 and a high-single digit percentage of the amounts received by us from a third party in consideration for a license to such third party to exploit AZD7970, in each case until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2017 AZ Agreement with respect to AZD7970 prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2013 Agreements with AstraZeneca, amended and restated in 2018 </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, we entered into an Amended and Restated Option Agreement and a related Amended and Restated Services and Collaboration Agreement with AstraZeneca, or the 2018 A&amp;R Agreements, which amended and restated the 2013 AZ Agreements. Under the 2018 A&amp;R Agreements, we granted AstraZeneca certain exclusive rights and licenses to research, develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&amp;R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the 2018 A&amp;R Agreements, AstraZeneca is responsible for all research, development and commercialization activities and associated costs, while we provide specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca&#8217;s activities conducted pursuant to an agreed upon services plan. During this research and evaluation period, these research services, and manufacturing services in excess of a specified threshold, are provided at AstraZeneca&#8217;s expense, and manufacturing services below the specified threshold are provided at no additional expense to AstraZeneca. AstraZeneca may request we provide additional research and manufacturing services, at AstraZeneca&#8217;s expense, following the end of the research and </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">evaluation period. Subject to customary &#8220;back-up&#8221; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) mRNA for all research, development and commercialization purposes under the 2018 A&amp;R Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2018 A&amp;R Agreements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, and as further reflected in the 2018 A&amp;R Agreements, AstraZeneca acquired </span><span style="font-family:inherit;font-size:10pt;"><span>forty</span></span><span style="font-family:inherit;font-size:10pt;"> options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates, AstraZeneca may elect to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca may then exercise one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates) in certain fields. If AstraZeneca does not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca&#8217;s rights to exercise an option and other rights granted under the 2018 A&amp;R Agreements with respect to such development candidate (and related back-up candidates) will terminate, all rights to exploit such development candidate (and related back-up candidates) will be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) will be either assigned or licensed to us. Upon the earlier of termination of the 2018 A&amp;R Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, will automatically terminate.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a target-by-target basis, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2018 A&amp;R Agreements with respect to the research, development and commercialization of mRNA medicines for such target in certain fields. In addition, we and AstraZeneca have agreed to certain defined exclusivity obligations with respect to the research, development and commercialization of mRNA medicines coding for the same polypeptide as any development candidate being developed under the 2018 A&amp;R Agreements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the 2018 A&amp;R Agreements will continue until the expiration of AstraZeneca&#8217;s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party may terminate the 2018 A&amp;R Agreements upon the other party&#8217;s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca has the right to terminate the 2018 A&amp;R Agreements for our material breach, then AstraZeneca may elect, in lieu of terminating the 2018 A&amp;R Agreements, in their entirety or with respect to such candidates, to have the 2018 A&amp;R Agreements remain in effect, subject to reductions in certain payments we are eligible to receive and certain adjustments to AstraZeneca&#8217;s obligations under the 2018 A&amp;R Agreements. AstraZeneca may terminate the 2018 A&amp;R Agreements in full, without cause, upon </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; prior notice to us.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We applied the provisions of ASC 606 (Revenue from Contracts with Customers) in accounting for these arrangements, except for the 2017 AZ Agreement which was accounted for under ASC 808 (Collaborative Arrangements). In August 2016, AstraZeneca exercised a product option available pursuant to the 2013 AZ Agreements to obtain exclusive rights to clinically develop and commercialize the VEGF-A product (AZD8601). This option exercise is referred to as the 2016 VEGF Exercise. Pursuant to ASC 606, we determined that the 2016 VEGF Exercise and the 2017 AZ Agreement should be accounted for as separate transactions as the agreements are not interrelated or interdependent. Conversely, the 2013 Agreements, as amended by the 2018 A&amp;R Agreements, and the 2016 AZ Agreement, were combined for accounting purposes and treated as a single agreement, as these agreements were negotiated in contemplation of each other. We refer to this combined transaction as the Combined 2018 AZ Agreements. We determined that all aspects of Combined 2018 AZ Agreements and the 2016 VEGF Exercise represent a transaction with a customer and therefore is accounted for in accordance with ASC 606.</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Combined 2018 AZ Agreements</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We identified the following performance obligations in the Combined 2018 AZ Agreements: (i) a combined performance obligation that includes a research license, research and development pool services, and manufacturing obligations related to the 2013 AZ Agreements, as amended by the 2018 A&amp;R Agreements, collectively referred to as the Combined 2018 AZ Agreement Performance Obligation, (ii) preclinical development services for IL-12, (iii) preclinical development services for an oncology development target, (iv) a combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12, </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and (v) a material right to receive development and commercialization rights and manufacturing services for an oncology development target.</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We concluded that the research license is not distinct from the research and development pool services or the manufacturing obligations related to the 2018 A&amp;R Agreements, as AstraZeneca cannot fully exploit the value of the research license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Any supply requested by AstraZeneca in excess of the minimum quantities specified in the agreement are considered customer options and treated as separate contracts for accounting purposes. Further, we concluded that AstraZeneca cannot exploit the value of the development and commercialization license for IL-12 without receipt of supply as the development and commercialization license does not convey to AstraZeneca the right to manufacture and therefore combined the development and commercialization license and the manufacturing obligations for IL-12 into one performance obligation.</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total transaction price was </span><span style="font-family:inherit;font-size:10pt;"><span>$399.1</span></span><span style="font-family:inherit;font-size:10pt;"> million comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$240.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront payments pertaining to the 2013 AZ Agreements and </span><span style="font-family:inherit;font-size:10pt;"><span>$159.1</span></span><span style="font-family:inherit;font-size:10pt;"> million of variable consideration comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$38.1</span></span><span style="font-family:inherit;font-size:10pt;"> million of estimated reimbursement for IL-12 manufacturing obligations, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of sublicense reimbursement and </span><span style="font-family:inherit;font-size:10pt;"><span>$120.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of milestone payments (</span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> toxicity milestone and </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> competition milestone). We utilize the most likely amount method to determine the amount of reimbursement for IL-12 manufacturing obligations to be received. We determined that any sales-based royalties related to IL-12 will be recognized when the related sales occur as they were determined to relate predominately to the license granted and therefore have been excluded from the transaction price. In addition, we are eligible to receive future milestones and royalties on future commercial sales for optioned product candidates under the 2018 A&amp;R Agreements and future royalties under the 2016 Agreement; however, these amounts are not considered variable consideration under the Combined 2018 Agreements as we are only eligible to receive such amounts if AstraZeneca exercises its options (including certain options that are deemed to be material rights). We have concluded that the exercise of an optioned product candidate represents a separate transaction under ASC 606. We re-evaluate the transaction price at the end of each reporting period. There was a $</span><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span><span style="font-family:inherit;font-size:10pt;"> million decrease to the transaction price during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, resulting from a change in estimate of variable consideration. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. We developed the estimated standalone selling price for the licenses included in the Combined 2018 AZ Agreement Performance Obligation and the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12 primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the performance obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The estimated standalone selling price of the material right to receive development and commercialization rights and manufacturing services for an oncology development target was developed by estimating the amount of discount that AstraZeneca would receive when exercising the option and adjusting such amount by the likelihood that the option will be exercised.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to each performance obligation is as follows: (i) </span><span style="font-family:inherit;font-size:10pt;"><span>$293.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Combined 2018 AZ Agreement Performance Obligation, (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the preclinical development services for IL-12 performance obligation, (iii) </span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the preclinical development services for an oncology development target performance obligation, (iv) </span><span style="font-family:inherit;font-size:10pt;"><span>$88.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12, and (v) </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the material right to receive development and commercialization rights and manufacturing services for an oncology development target. As part of the allocation of the transaction price to each of the performance obligations, we concluded that the </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> toxicity milestone and the estimated reimbursement for IL-12 manufacturing costs can be allocated entirely to specific performance obligations because the variable payment relates specifically to our effort to satisfy the performance obligation and such allocation is consistent with the allocation objectives of ASC 606.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the Combined 2018 AZ Agreement Performance Obligation and the preclinical development services for IL-12 and the other oncology target performance obligations. We recognize revenue related to the amounts allocated to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12 based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue for the Combined 2018 AZ Agreement Performance Obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to this combined performance obligation. We also estimate the development plan, including expected demand from AstraZeneca, and the associated costs for this combined performance obligation, as we will satisfy this combined performance obligation as the manufacturing services are performed.&#160;Management has applied significant judgment in the process of developing our budget estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from the Combined 2018 AZ Agreements. The revenue recognized for the three months ended March&#160;31, 2020 includes the amortization of deferred revenue due to the satisfaction of our performance obligation during the period, offset by a cumulative catch-up adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> due to changes in estimated costs for our future performance obligations. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is </span><span style="font-family:inherit;font-size:10pt;"><span>$106.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;"><span>$96.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> is expected to be recognized as revenue through December&#160;31, 2029 and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> is expected to be recognized as revenue at the earlier of expiration or modification of the Combined 2018 AZ Agreement. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$72.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$73.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, from the Combined 2018 AZ Agreements, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2016 VEGF Exercise</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We concluded that the 2016 VEGF Exercise should be treated as a separate transaction for accounting purposes. We identified one performance obligation in this arrangement which is comprised of the exclusive license to develop and commercialize VEGF and the manufacturing of clinical supply. We concluded that the VEGF license is not distinct from the manufacturing obligations because AstraZeneca cannot fully exploit the value of the license without receipt of such supply. This is due to limitations inherent in the licenses conveyed wherein AstraZeneca does not have the contractual right to manufacture during the term of the agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, the total transaction price was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$60.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fixed payments pertaining to a </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> option exercise fee and a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone achieved prior to the adoption of ASC 606, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> sublicense reimbursement and </span><span style="font-family:inherit;font-size:10pt;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of variable consideration related to the estimated reimbursement for clinical supply. We are eligible to receive future milestones and royalties on future commercial sales under this arrangement. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received and the amount of estimated reimbursement for clinical supply. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or AstraZeneca&#8217;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it is recognized as revenue based on the relative completion of the underlying performance obligation. There was a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> increase to the transaction price during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, resulting from a change in estimate of variable consideration. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue related to the amount of the transaction price allocated to the VEGF Exercise performance obligation based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we made a cumulative catch-up adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> as a reduction of revenue due to changes in estimated costs for our future performance obligation associated with the 2016 VEGF Exercise. We did not recognize any collaboration revenue from the 2016 VEGF Exercise for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is </span><span style="font-family:inherit;font-size:10pt;"><span>$56.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through December&#160;31, 2025. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$43.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$41.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> respectively, from the 2016 VEGF Exercise, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the control of the supply is expected to be transferred.</span></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2017 AZ Agreement</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We concluded the 2017 AZ Agreement is under the scope of ASC 808 as we and AstraZeneca are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. Additionally, we determined the development, manufacturing and commercialization activities are not deliverables under ASC 606. As a result, the activities conducted pursuant to the development, manufacturing and commercialization activities are accounted for as a component of the related expense in the period incurred. We considered the guidance in ASC 606 by analogy in determining the appropriate treatment for the transactions between us and AstraZeneca and concluded that reimbursement for transactions in which we are considered to be principal because we control a promised good or service before transferring that good or service to the customer, are accounted for as gross revenue. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t recognize any revenue from the 2017 AZ Agreement for both three month periods ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck &#8211; Strategic Alliances in Infectious Diseases and Cancer Vaccines</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2015 Strategic Alliance with Merck&#160;&#8211; Infectious Disease</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2015, we entered into a Master Collaboration and License Agreement with Merck, which was amended in each of January 2016, June 2016, and May 2019, and which we refer to, as amended, as the 2015 Merck Agreement. Pursuant to the 2015 Merck Agreement, we and Merck have agreed to research, develop, and commercialize potential mRNA medicines for the prevention of infections by RSV. As a part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to conclude the collaboration as it relates to development of potential mRNA medicines for other viruses, including mRNA-1278 for the prevention of VZV infection. Pursuant to the 2015 Merck Agreement, Merck is primarily responsible for research, development, and commercialization activities and associated costs of such research and commercialization. We are responsible for designing and manufacturing all mRNA constructs for preclinical and Phase&#160;1 and Phase&#160;2 clinical development purposes, and Merck pays us for such manufacture, and we are responsible for certain costs associated with the conduct of a Phase 1 clinical trial for an RSV vaccine product candidate (mRNA-1172). Responsibility for manufacturing mRNA constructs for late stage clinical development and commercialization purposes is to be determined.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2015 Merck Agreement includes a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period, expected to end on January 12, 2022, during which Merck may continue to preclinically and clinically develop RSV vaccine product candidates using mRNA constructs that were initially developed during an initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period which terminated in January 2019. Merck may, prior to January 12, 2022, elect to exclusively develop and commercialize up to </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> RSV vaccine product candidates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and Merck have agreed to certain defined exclusivity obligations during the term of the 2015 Merck Agreement with respect to mRNA investigational medicines against RSV. As part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to certain expectations to the existing exclusivity obligations, pursuant to which we will no longer be restricted from researching, developing, and commercializing an mRNA investigational medicine for the prevention of a specific set of respiratory infections, including RSV, for the pediatric population.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the 2015 Merck Agreement, we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment. We are eligible to receive, on a product-by-product basis, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate milestone payments upon the achievement of certain development, regulatory, and commercial milestone events. To date, we have received from Merck a clinical milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> with respect to the initiation of a Phase&#160;1 clinical trial for a Merck RSV vaccine product candidate. In addition, under the terms of the 2015 Merck Agreement, we are eligible to receive an additional milestone payment unless Merck elects not to continue with further clinical development of mRNA-1172. On a product-by-product basis, we are also entitled to receive royalties on Merck&#8217;s net sales of products at rates ranging from the mid-single digits to low teens, subject to certain reductions, with an aggregate minimum floor. Additionally, concurrent with entering into the 2015 Merck Agreement in 2015, Merck made a </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> equity investment in us, and concurrent with amending the 2015 Merck Agreement in January 2016, we received an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> from Merck.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the 2015 Merck Agreement will continue on a product-by-product and country-by-country basis for so long as royalties are payable by Merck on a given product in a given country. Either party may terminate the 2015 Merck Agreement upon the other party&#8217;s material breach, either in its entirety or with respect to a particular program, product candidate, product or country, subject to specified notice and cure provisions. Merck may terminate the 2015 Merck Agreement in full or with respect to a particular product candidate or product upon certain advance notice to us for any reason, or earlier if Merck determines the alliance or product is no longer commercially practicable. If Merck has the right to terminate the 2015 Merck Agreement, in its entirety or with respect to a program, product candidate or product, for our material breach, then Merck may elect, in lieu of terminating the 2015 Merck </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agreement, to have the 2015 Merck Agreement remain in effect, subject to reductions in certain payments we are eligible to receive with respect to the terminable rights. Upon a termination of the 2015 Merck Agreement with respect to a program, all licenses and other rights granted to Merck with respect to such program will terminate and the continued development and commercialization of product candidates and products will revert to us. If the 2015 Merck Agreement is terminated with respect to a given product candidate or product, all licenses and other rights granted to Merck with respect to such product candidate or product will terminate and, to the extent we terminated for Merck&#8217;s breach, Merck will grant us licenses under select Merck technology for our continued development and commercialization of such product candidate or product. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined that all aspects of amended 2015 Merck Agreement represent a transaction with a customer and therefore the amended 2015 Merck Agreement is accounted for in accordance with ASC 606. The </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period was complete as of December 31, 2018 and we recognized the total transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;in aggregate upfront payments and a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;payment pertaining to achievement of a development milestone) in full as we concluded there were no unsatisfied performance obligations pertaining to the amended 2015 Merck Agreement. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) research services during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period following the initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period during which Merck may continue to preclinically and clinically develop product candidates and (ii) clinical mRNA supply for Phase 1 and Phase 2 and/or non-cGMP mRNA supply beyond the initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period. Therefore, such options will be accounted for as a separate contract upon the customer&#8217;s election. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Merck&#8217;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After completion of the initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period, and as part of the May 2019 amendment of the 2015 Merck Agreement, Merck elected to establish a new RSV vaccine product candidate and elected to conduct a Phase 1 clinical trial. We are responsible for certain costs associated with the conduct of the Phase 1 clinical trial.&#160;We determined that our obligation under the May 2019 amendment to reimburse Merck for certain costs associated with the RSV vaccine Phase 1 clinical trial represents consideration payable to a customer and is accounted for as a reduction of the transaction price. The consideration amount is determined based on the most likely method and recorded as contra-revenue as costs are incurred. The one-time payment upon election by Merck to continue developing RSV is fully constrained as it is contingent upon completion of the RSV Phase 1 clinical trial and upon decisions to be made by Merck to continue development thereafter. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> deduction to the transaction price related to reimbursements paid to Merck for RSV vaccine Phase I clinical trial costs.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had no deferred revenue as of March 31, 2020 or December 31, 2019 from the amended 2015 Merck Agreement as all performance obligations under the amended 2015 were completed as of December 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized contra-revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2020, related to consideration payable to Merck under the May 2019 Amendment. We recognized collaboration revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2019, pursuant to separate agreements with Merck related to the exercise of customer options to purchase clinical mRNA supply to further develop a product candidate after the initial </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year research period. Clinical mRNA supply is recognized as collaboration revenue at a point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Cancer Vaccine Strategic Alliance&#8212;Personalized mRNA Cancer Vaccines</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck, which we refer to as the PCV Agreement, to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient&#8217;s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient&#8217;s immune system against her or his own cancer cells.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase&#160;1 and Phase&#160;2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna&#8217;s manufacture and supply activities. We received an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> from Merck. In November 2017, we and Merck announced the achievement of a key milestone for the first-in-human dosing of a PCV (mRNA-4157) as a part of the alliance. The Phase&#160;1 open-label, dose escalation, multicenter clinical trial in the United States (KEYNOTE-603) is designed to assess the safety, tolerability and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with KEYTRUDA, in subjects with unresectable solid tumors.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for PCVs under the PCV Agreement and delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of PCVs by making a </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> participation payment to us. If Merck exercises its election and pays the participation payment, then the parties will equally co-fund subsequent clinical development of PCVs, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. Each party may also conduct additional clinical trials for PCVs that are not included in the jointly agreed development plan and budget, in which case the non-conducting party will reimburse the conducting party for half of the total costs for such trials, plus interest, from its share of future profits resulting from sales of such PCVs, if any. Merck will lead worldwide commercialization of PCVs, subject to Moderna&#8217;s option to co-promote PCVs in the United States, and the parties will equally share the profits or losses arising from worldwide commercialization. Until a PCV becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of such PCV, if any. Subject to customary &#8220;back-up&#8221; supply rights granted to Merck, we will manufacture (or have manufactured) PCVs for preclinical and clinical purposes. Manufacture of PCVs for commercial purposes will be determined by the parties in accordance with the terms of the PCV Agreement. Under the PCV Agreement, we grant certain licenses to Merck to perform its collaboration activities.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If Merck does not exercise its right to participate in future development and commercialization of PCVs, then Moderna will retain the exclusive right to develop and commercialize PCVs developed during the strategic alliance, subject to Merck&#8217;s rights to receive a percentage in the high teens to the low 20s, subject to reductions of our net profits on sales of such PCVs. During a limited period following such non-exercise, Merck has the right to perform clinical studies of such PCVs in combination with KEYTRUDA, for which we agree to use reasonable efforts to supply such PCVs. During such limited period, we also have the right to perform clinical studies of PCVs in combination with KEYTRUDA, for which Merck agrees to use reasonable efforts to supply KEYTRUDA. In addition, following its non-exercise, Merck is also entitled to receive a percentage in the high teens to the low 20s, subject to reductions, of our net profits on sales of certain PCVs first developed by us following such non-exercise and reaching a specified development stage within a defined period of time.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and Merck have agreed to certain defined, limited exclusivity obligations with respect to the development and commercialization of PCVs.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Expansion of the Cancer Vaccine Strategic Alliance&#8212;Shared Neoepitope Cancer Vaccines </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671 or V941, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events. Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCV increased to </span><span style="font-family:inherit;font-size:10pt;"><span>$243.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. If Merck exercises its participation </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">rights, then the parties will equally co-fund subsequent clinical development of mRNA-5671, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. If Merck declines to participate in future development and commercialization activities following the initial Phase 1 and Phase 2 clinical trials for mRNA-5671, then we will retain the rights to develop and commercialize mRNA-5671. If Merck elects to participate in future development and commercialization of mRNA-5671, Merck may also conduct additional clinical trials for mRNA-5671 that are not included in the jointly agreed development plan and budget, in which case we will reimburse Merck for half of the total development costs for such clinical trials, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. If Merck does conduct additional clinical trials for mRNA-5671, we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials. Merck will lead worldwide commercialization of mRNA-5671, subject to our option to co-promote mRNA-5671 in the United States, and the parties will equally share the operating profits or losses arising from worldwide commercialization. Until mRNA-5671 becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. Subject to &#8220;back-up&#8221; supply rights granted to Merck, we will manufacture (or have manufactured) mRNA-5671 and other SAVs for preclinical and clinical purposes. After Merck exercises its right to participate in future development and commercialization of mRNA-5671 and other SAVs, we will grant the applicable development and commercialization licenses and the parties are obligated to discuss responsibility for future manufacturing, giving consideration to applicable criteria.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the PCV/SAV Agreement, for a defined period of time, either party may propose that the parties conduct additional programs for the research and development of SAVs directed to different shared neoantigens. If the parties agree to conduct any such programs, then we will be responsible for conducting and funding preclinical discovery and research activities for such SAVs, and otherwise the programs would be conducted on substantially the same terms as mRNA-5671 program. If we or Merck propose a new SAV program and the other party does not agree to conduct such program, then the PCV/SAV Agreement includes provisions allowing the proposing party to proceed with such development, at the proposing party&#8217;s expense. If Merck is the proposing party, we will be responsible for manufacturing and supplying material for such program at Merck&#8217;s expense. In such case, the non-proposing party will have the right to opt-in to such SAV program any time before the proposing party commits to performing Good Laboratory Practice (GLP)-toxicity studies. Until the expiration of a defined period of time following our completion of Phase&#160;1 and Phase&#160;2 clinical trials for any SAV program mutually agreed by the parties under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of such SAV by making a participation payment to us.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the PCV/SAV Agreement will continue on a program-by-program basis until Merck terminates its participation in such program. Following any such termination, we will retain the exclusive right to develop and commercialize PCVs or SAVs developed as a part of such program, subject to restrictions and certain limited rights retained by Merck.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> is determined to be a premium and recorded to deferred revenue.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</span></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined that the PCV/SAV Agreement should be accounted for separately from the amended 2015 Merck Agreement, as the agreements were not negotiated in contemplation of one another and the elements within each of the agreements are not closely interrelated or interdependent on each other. We determined that all aspects of the PCV/SAV Agreement represent a transaction with a customer and therefore the PCV/SAV Agreement is accounted for in accordance with ASC 606. In addition, the equity investment in our Series H redeemable convertible preferred stock was considered together with the PCV/SAV Agreement as the transactions were executed contemporaneously in contemplation of one another. Further, the purchase price paid by Merck with respect to the investment in the Series H redeemable convertible preferred stock was not representative of fair value on the date of such purchase. As such, the incremental proceeds received in excess of the fair value of the underlying stock related to the equity investment were included in the transaction price related to the PCV/SAV Agreement and the shares of Series H redeemable convertible preferred stock purchased by Merck were recorded at their respective fair value on the date of issuance.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We identified the following performance obligations in the PCV/SAV Agreement: (i) a research license and research and development services, including manufacturing and supply of PCVs, during the proof of concept (POC) term for the PCV program, referred to as the PCV Performance Obligation, and (ii) research license and manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, referred to as the KRAS Performance Obligation. We concluded that the research license is not distinct from the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, as Merck cannot fully exploit the value of the license without receipt of such services and supply. Our services and </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the research license has been combined with the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, into a single performance obligation. Similarly, we concluded that the research license is not distinct from the manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, as Merck cannot fully exploit the value of the license without receipt of such supply which must be provided by us. This is due to limitations inherent in the licenses conveyed wherein Merck does not have the contractual right to manufacture during the POC term. Therefore, the research license has been combined with the manufacturing and supply of mRNA-5671, during the POC term for the KRAS program, into a single performance obligation. Conversely, we concluded that the PCV Performance Obligation and the KRAS Performance Obligation are distinct from each other because Merck can fully exploit the value of each program for its intended purpose without the promises associated with the other program. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Merck participation election license related to future joint development and commercialization on a program-by-program basis, (ii) manufacturing and supply in support of certain SAV programs and/or the PCV program upon Merck election to not participate in future development and commercialization of that program and (iii) research and development services associated with certain SAV programs. Therefore, such options will be accounted for as a separate contract upon the customer&#8217;s election.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total transaction price was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$213.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment pertaining to the PCV Agreement, the premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and a variable consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a reimbursement for clinical supply. We determined there are no other components of variable consideration that should be included in the transaction price as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, as additional consideration to which we could be entitled is subject to Merck&#8217;s election to exercise a customer option that was deemed to be a marketing offer. We re-evaluate the transaction price at the end of each reporting period. During the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> increase to the transaction price from a reimbursement for clinical supply. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling price of each performance obligation. We developed the estimated standalone selling price for the license included in each of the PCV Performance Obligation and the KRAS Performance Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a development candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the PCV Performance Obligation and the KRAS Performance Obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated cost, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to each performance obligation is as follows: (i) </span><span style="font-family:inherit;font-size:10pt;"><span>$206.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the PCV Performance Obligation and (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> allocated to the KRAS Performance Obligation. We will recognize revenue related to amounts allocated to the PCV Performance Obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of research and development efforts. We recognize revenue related to the amounts allocated to the KRAS Performance Obligation based on the point in time upon which control of supply is transferred to Merck for each delivery of the associated supply. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statements of operations, from the Merck PCV/SAV Agreement. The revenue recognized during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> includes the amortization of deferred revenue due to the satisfaction of our performance during the period, offset by a cumulative catch-up adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> due to changes in estimated costs for our future performance obligations. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is </span><span style="font-family:inherit;font-size:10pt;"><span>$81.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through December&#160;31, 2024. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$81.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$83.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2019, respectively, from the Merck PCV/SAV Agreement, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Vertex &#8211; 2016 Strategic Alliance in Cystic Fibrosis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2016, we entered into a Strategic Collaboration and License Agreement, with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex, which we refer to as the Vertex Agreement. The Vertex Agreement, which was amended in July 2019, which we refer to as the 2019 Vertex Amendment, is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional CFTR proteins.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period that was extended through March 2020, leveraging our Platform technology and mRNA delivery expertise along with Vertex&#8217;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. The parties established a joint steering committee to oversee and coordinate activities under the Vertex Agreement. We and Vertex have granted each other certain licenses under the Vertex Agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the Vertex Agreement, we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment from Vertex. In July 2019, Vertex elected to extend the initial </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year research period by </span><span style="font-family:inherit;font-size:10pt;">six months</span><span style="font-family:inherit;font-size:10pt;"> pursuant to the 2019 Vertex Amendment. In March 2020, based on the promising preclinical data generated to date, Vertex extended the conduct of the initial Research Plan through the First Extended Research Term (an additional </span><span style="font-family:inherit;font-size:10pt;"><span>18</span></span><span style="font-family:inherit;font-size:10pt;">-month term) by making an additional payment to us. Vertex has rights to further extend the research period for </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> additional </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year periods by making an additional payment to us for each </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year extension. We are eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$55.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments for achievement of development milestones, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$220.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments for achievement of regulatory milestones and potentially could receive an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment for achievement of a regulatory milestone for a second and each subsequent product under the Vertex Agreement. Vertex will also pay us tiered royalties at rates ranging from the low- to high-teens on worldwide net sales of products arising from the strategic alliance, subject to certain reductions, with an aggregate minimum floor. In connection with the strategic alliance, Vertex also made a </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> equity investment in us. During the term of the Vertex Agreement, we and Vertex have agreed to certain defined exclusivity obligations under the Vertex Agreement with respect to the development and commercialization of certain mRNA medicines.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the Vertex Agreement will continue until the expiration of all royalty terms. Vertex may terminate the Vertex Agreement for convenience upon </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;">&#160;days&#8217; prior written notice, except if termination relates to a product in a country where Vertex has received marketing approval, which, in such case, Vertex must provide </span><span style="font-family:inherit;font-size:10pt;"><span>180</span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; prior written notice. Either party may terminate the Vertex Agreement upon the other party&#8217;s material breach, subject to specified notice and cure provisions. Each party may also terminate the Vertex Agreement in the event that the other party challenges the validity or enforceability of such party&#8217;s patent rights, subject to certain exceptions, or if the other party becomes insolvent.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, all performance obligations under the 2019 Vertex Amendment were completed and the total transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development funding related to the research and development services and supply of non-cGMP mRNA, was fully recognized.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The First Extended Research Term represents a contract modification and is accounted for as a separate contract. Pursuant to the 2019 Vertex Amendment, we identified one performance obligation comprised of: (i) a research, development and commercialization license and (ii) research and development services, including manufacturing and supply of non-cGMP mRNA, during the 18-month First Extended Research Term. We concluded that the license is not distinct from the research and development services, including manufacturing and supply of non-cGMP mRNA. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Vertex&#8217;s rights to extend the extended initial research period and (ii) clinical mRNA supply and/or non-cGMP mRNA supply beyond the extended initial research period. Therefore, such options will be accounted for as a separate contract upon the customer&#8217;s election. The total transaction price was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$35.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$31.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development funding related to the research and development services and supply of non-cGMP mRNA. We utilize the most likely amount method to determine the amount of research and development funding to be received. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were no milestones included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Vertex&#8217;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any sales-</span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each of the Vertex Agreement, the 2019 Vertex Amendment and the First Extended Research Term, the total transaction price was allocated entirely to a single performance obligation. We recognize revenue related to amounts allocated to the single performance obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of the research and development efforts.   </span></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statements of operations, from Vertex. The revenue recognized during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> includes the amortization of the deferred revenue due to the satisfaction of our performance during the period. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is </span><span style="font-family:inherit;font-size:10pt;"><span>$35.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through the third quarter of 2021. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of March 31, 2020 and December 31, 2019, respectively, from the First Extended Research Term and the 2019 Vertex Amendment, classified as current and non-current in the condensed consolidated balance sheets based on the term of the research period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816156448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, or MTC, located in Norwood.  </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cambridge facility</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We occupy a multi-building campus in Technology Square in Cambridge, MA with a mix of offices and research laboratory space totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, MA. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately </span><span style="font-family:inherit;font-size:10pt;"><span>50,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of additional space at 200 Technology Square including space previously occupied under a sublease which expired on December 31, 2019. We will also completely early-exit our leased space of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>60,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet at 500 Technology Square by May 2020. In addition, our current 200 Technology Square lease has been extended for </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> to 2029. The amendment provides an additional aggregated tenant improvement allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the design and construction of improvements at 200 Technology Square.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May&#160;2016, we entered into a lease agreement for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>124,760</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office and laboratory space at 200&#160;Technology Square in Cambridge, Massachusetts. The lease commenced on September&#160;1, 2016, with the base rent subject to increases over an&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>11</span></span><span style="font-family:inherit;font-size:10pt;">-year term. We have occupied the premises in six phases from September 2016 to January&#160;2020. We have the option to extend the lease term for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;">&#160;extension periods of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">&#160;each, at market-based rates. In addition to rent payments, the lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. As the amount of square footage that we lease increases over the term of the lease, we have recognized each phase&#8217;s total rent payments on a straight-line basis over the respective lease term. The lease provides us with an initial tenant allowance of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$10.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per square foot against which costs incurred are capitalized as leasehold improvements. In December 2018, in relation to the expansion of space from the agreement entered in May 2016, we entered into sublease agreements for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>34,268</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet to expand our office and laboratory space at 200 Technology Square.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2015, we entered into a facility lease agreement for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>61,618</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office and laboratory space at 500&#160;Technology Square. The lease commenced in April&#160;2016, with the base rent escalating over the&#160;six-year term of the lease. The lease provides a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;tenant improvement allowance against which costs incurred are capitalized as leasehold improvements. The lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Moderna Technology Center North (MTC North)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we entered into a new lease agreement for office and laboratory space of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet, MTC North, located Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> additional five-year terms. Contemporaneously, we entered into an agreement to sublease approximately </span><span style="font-family:inherit;font-size:10pt;"><span>64 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the leased space to a third party. We have no rent obligations to the landlord for the space occupied by the third party. All sublease payments from the third party are paid directly to the landlord. The sublease can expire between May 2020 and February 2021 at the third party's option.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April&#160;2017, we entered into a lease agreement for land adjacent to our MTC manufacturing facility (see MTC South below). We determined, for accounting purposes, this land lease should be accounted for separately from the lease entered in August 2016 relating to the building. The lease commenced in April 2017, with the base rent&#160;escalating over the&#160;thirty-five-year term of the lease.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded to operating expenses in our consolidated statements of operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finance Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Moderna Technology Center manufacturing facility (MTC South)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2016, we entered into a lease agreement for approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Massachusetts. The lease commencement date for accounting purposes was October&#160;1, 2016. In connection with this lease, the landlord provided a tenant improvement allowance of approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;for costs associated with the design, engineering, and construction of tenant improvements for the building. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;">&#160;extension periods of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to ASC 842, the MTC South lease is bifurcated into a building lease and a land lease using an estimated incremental borrowing rate as of the lease commencement date. The building lease is classified as a financing lease and the land lease is classified as an operating lease. For accounting purposes, the lease term is determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>35 years</span></span><span style="font-family:inherit;font-size:10pt;">, which is the non-cancelable period of the lease and includes the optional extension periods as we are reasonably certain that we will exercise the options to extend the lease term. Upon the adoption of&#160;ASC 842 at January 1, 2019, we derecognized the assets and liabilities recorded as a result of historical build-to-suit accounting under ASC 840 and recorded financing lease liabilities and financing right-of-use asset associated with the building lease. The financing right-of-use asset is amortized on a straight-line basis to depreciation expense over the remaining lease term. We record interest expense related to the financing lease liabilities in the consolidated statements of operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2019 and March 31, 2020 were as follows (in thousands):&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating, net </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, financing, net </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) (4)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,958</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease liabilities, non-current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total non-current lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,849</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,364</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Net of accumulated depreciation.</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) </sup></span><span style="font-family:inherit;font-size:10pt;">These assets are&#160;real estate assets related to the MTC South lease.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4) </sup></span><span style="font-family:inherit;font-size:10pt;">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5) </sup></span><span style="font-family:inherit;font-size:10pt;">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the lease costs for the three months ended March 31, 2020 and 2019 were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease costs:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total financing lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information relating to our leases for the three months ended March 31, 2020 and 2019 was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating cash flows used in operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,888</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,725</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating cash flows used in financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-cash items:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Right-of-use assets reduced through lease modifications and reassessments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,416</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease non-cash items:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charges to financing lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating lease agreements at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, are as follows (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:4%;"/><td style="width:60%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:3%;"/></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(remainder of the year)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less amounts representing interest or imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(254,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Include the optional extensions in the MTC South lease term which represent a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$208.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> un-discounted future lease payments in operating leases and financing leases, respectively.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Based on an imputed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>17.2%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, or MTC, located in Norwood.  </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cambridge facility</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We occupy a multi-building campus in Technology Square in Cambridge, MA with a mix of offices and research laboratory space totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, MA. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately </span><span style="font-family:inherit;font-size:10pt;"><span>50,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of additional space at 200 Technology Square including space previously occupied under a sublease which expired on December 31, 2019. We will also completely early-exit our leased space of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>60,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet at 500 Technology Square by May 2020. In addition, our current 200 Technology Square lease has been extended for </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> to 2029. The amendment provides an additional aggregated tenant improvement allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the design and construction of improvements at 200 Technology Square.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May&#160;2016, we entered into a lease agreement for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>124,760</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office and laboratory space at 200&#160;Technology Square in Cambridge, Massachusetts. The lease commenced on September&#160;1, 2016, with the base rent subject to increases over an&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>11</span></span><span style="font-family:inherit;font-size:10pt;">-year term. We have occupied the premises in six phases from September 2016 to January&#160;2020. We have the option to extend the lease term for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;">&#160;extension periods of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">&#160;each, at market-based rates. In addition to rent payments, the lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. As the amount of square footage that we lease increases over the term of the lease, we have recognized each phase&#8217;s total rent payments on a straight-line basis over the respective lease term. The lease provides us with an initial tenant allowance of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$10.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per square foot against which costs incurred are capitalized as leasehold improvements. In December 2018, in relation to the expansion of space from the agreement entered in May 2016, we entered into sublease agreements for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>34,268</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet to expand our office and laboratory space at 200 Technology Square.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2015, we entered into a facility lease agreement for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>61,618</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office and laboratory space at 500&#160;Technology Square. The lease commenced in April&#160;2016, with the base rent escalating over the&#160;six-year term of the lease. The lease provides a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;tenant improvement allowance against which costs incurred are capitalized as leasehold improvements. The lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Moderna Technology Center North (MTC North)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we entered into a new lease agreement for office and laboratory space of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet, MTC North, located Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> additional five-year terms. Contemporaneously, we entered into an agreement to sublease approximately </span><span style="font-family:inherit;font-size:10pt;"><span>64 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the leased space to a third party. We have no rent obligations to the landlord for the space occupied by the third party. All sublease payments from the third party are paid directly to the landlord. The sublease can expire between May 2020 and February 2021 at the third party's option.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April&#160;2017, we entered into a lease agreement for land adjacent to our MTC manufacturing facility (see MTC South below). We determined, for accounting purposes, this land lease should be accounted for separately from the lease entered in August 2016 relating to the building. The lease commenced in April 2017, with the base rent&#160;escalating over the&#160;thirty-five-year term of the lease.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded to operating expenses in our consolidated statements of operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finance Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Moderna Technology Center manufacturing facility (MTC South)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2016, we entered into a lease agreement for approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Massachusetts. The lease commencement date for accounting purposes was October&#160;1, 2016. In connection with this lease, the landlord provided a tenant improvement allowance of approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;for costs associated with the design, engineering, and construction of tenant improvements for the building. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;">&#160;extension periods of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to ASC 842, the MTC South lease is bifurcated into a building lease and a land lease using an estimated incremental borrowing rate as of the lease commencement date. The building lease is classified as a financing lease and the land lease is classified as an operating lease. For accounting purposes, the lease term is determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>35 years</span></span><span style="font-family:inherit;font-size:10pt;">, which is the non-cancelable period of the lease and includes the optional extension periods as we are reasonably certain that we will exercise the options to extend the lease term. Upon the adoption of&#160;ASC 842 at January 1, 2019, we derecognized the assets and liabilities recorded as a result of historical build-to-suit accounting under ASC 840 and recorded financing lease liabilities and financing right-of-use asset associated with the building lease. The financing right-of-use asset is amortized on a straight-line basis to depreciation expense over the remaining lease term. We record interest expense related to the financing lease liabilities in the consolidated statements of operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2019 and March 31, 2020 were as follows (in thousands):&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating, net </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, financing, net </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) (4)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,958</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease liabilities, non-current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total non-current lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,849</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,364</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Net of accumulated depreciation.</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) </sup></span><span style="font-family:inherit;font-size:10pt;">These assets are&#160;real estate assets related to the MTC South lease.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4) </sup></span><span style="font-family:inherit;font-size:10pt;">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5) </sup></span><span style="font-family:inherit;font-size:10pt;">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the lease costs for the three months ended March 31, 2020 and 2019 were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease costs:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total financing lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information relating to our leases for the three months ended March 31, 2020 and 2019 was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating cash flows used in operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,888</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,725</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating cash flows used in financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-cash items:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Right-of-use assets reduced through lease modifications and reassessments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,416</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease non-cash items:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charges to financing lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating lease agreements at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, are as follows (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:4%;"/><td style="width:60%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:3%;"/></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(remainder of the year)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less amounts representing interest or imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(254,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Include the optional extensions in the MTC South lease term which represent a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$208.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> un-discounted future lease payments in operating leases and financing leases, respectively.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Based on an imputed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>17.2%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6819158656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">162,000,000<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">370,102,805<span></span>
</td>
<td class="nump">336,536,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">370,102,805<span></span>
</td>
<td class="nump">336,536,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6829804256">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th" colspan="2"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">328,798,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,530,241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 2,538,155<span></span>
</td>
<td class="num">$ (1,320)<span></span>
</td>
<td class="num">$ (1,006,627)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">48,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(132,576)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,576)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">328,853,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,442,325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">2,556,709<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="num">(1,115,008)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">336,536,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,174,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">2,669,426<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
<td class="num">(1,496,454)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from public offering of common stock, net of issuance costs of $1,108 (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,263,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from public offering of common stock, net of issuance costs of $1,108</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">549,455<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">549,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">113,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,188,671<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,188,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 28,357<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,931)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(124,230)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124,230)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">370,102,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,640,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 3,267,648<span></span>
</td>
<td class="num">$ (6,127)<span></span>
</td>
<td class="num">$ (1,620,684)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6624061008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Assets And Liabilities, Lessee</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2019 and March 31, 2020 were as follows (in thousands):&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating, net </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, financing, net </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) (4)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,958</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease liabilities, non-current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total non-current lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,849</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,364</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Net of accumulated depreciation.</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3) </sup></span><span style="font-family:inherit;font-size:10pt;">These assets are&#160;real estate assets related to the MTC South lease.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4) </sup></span><span style="font-family:inherit;font-size:10pt;">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5) </sup></span><span style="font-family:inherit;font-size:10pt;">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the lease costs for the three months ended March 31, 2020 and 2019 were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing lease costs:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total financing lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information relating to our leases for the three months ended March 31, 2020 and 2019 was as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating cash flows used in operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,888</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,725</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating cash flows used in financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-cash items:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Right-of-use assets reduced through lease modifications and reassessments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,416</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease non-cash items:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charges to financing lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease Maturity</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating lease agreements at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, are as follows (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:4%;"/><td style="width:60%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:3%;"/></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(remainder of the year)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less amounts representing interest or imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(254,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Include the optional extensions in the MTC South lease term which represent a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$208.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> un-discounted future lease payments in operating leases and financing leases, respectively.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Based on an imputed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>17.2%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturity</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating lease agreements at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, are as follows (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:4%;"/><td style="width:60%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:3%;"/></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing Leases </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(remainder of the year)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,962</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less amounts representing interest or imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(254,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">Include the optional extensions in the MTC South lease term which represent a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$208.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> un-discounted future lease payments in operating leases and financing leases, respectively.</span></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></span><span style="font-family:inherit;font-size:10pt;">Based on an imputed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>17.2%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6623940784">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="2">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td colspan="2" class="nump">$ 3,789,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td colspan="2" class="num">(3,789,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td colspan="2" class="num">(27,984,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td colspan="2" class="nump">$ 27,984,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816191168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion.&#160;Realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. We continued to maintain a full valuation allowance against all of our deferred tax assets based on management&#8217;s evaluation of all available evidence.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no significant income tax provisions or benefits for the three months ended March 31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6627580592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Effect of Adoption of 842 on Condensed Financial Statements</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the effects of adopting ASC 842 on our condensed consolidated financial statements for the three months ended March 31, 2019&#160;(in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 842</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Previously reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,253</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(141,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(141,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,820</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,931</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,657</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,576</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Previously reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 842 Adjustment during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,657</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,576</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(550</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(143,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(144,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charges to financing lease obligation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments on financing lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by financing activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Collaboration Revenue by Strategic Collaborator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AstraZeneca</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,270</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vertex</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total collaboration revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,115</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized&#160;Gain on Available-for-Sale Debt Securities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income, balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,804</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss, balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash and Cash Equivalents</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,720</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, non-current </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,823</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;statements of cash flows</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403,543</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>514,757</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,720</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, non-current </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,823</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;statements of cash flows</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403,543</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>514,757</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6714289792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">47,050,690<span></span>
</td>
<td class="nump">54,433,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">44,988,598<span></span>
</td>
<td class="nump">53,271,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2,062,092<span></span>
</td>
<td class="nump">1,011,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>moderna10-q3312020_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrna="http://www.modernatx.com/20200331"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrna-20200331.xsd" xlink:type="simple"/>
    <context id="FD2020Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2020Q2April30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborativeArrangementWithRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborativeArrangementWithRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborativeArrangementWithRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborativeArrangementWithRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_MerckMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_MajorCustomersAxis_us-gaap_OtherCustomerMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_MajorCustomersAxis_us-gaap_OtherCustomerMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_AstraZenecaMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_AstraZenecaMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_VertexMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_VertexMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_MerckMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ClinicalSupplyReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:ClinicalSupplyReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="D2018Q2Jun30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_SeparateAgreementsWithMerckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:SeparateAgreementsWithMerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2028-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ClinicalSupplyReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:ClinicalSupplyReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:VariableConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_KRASPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:KRASPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2013Q1Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_FixedPaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:FixedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesSubsequentProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:RegulatoryMilestonesSubsequentProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="D2013Q1Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_DevelopmentMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ResearchAndDevelopmentFundingMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:ResearchAndDevelopmentFundingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-31</instant>
        </period>
    </context>
    <context id="D2018Q2Apr30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="FI2016Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_EstimatedReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:EstimatedReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_SeparateAgreementsWithMerckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:SeparateAgreementsWithMerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:VariableConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan31az_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2016StrategicAllianceWithAstraZenecaIL12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_CommercialMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-31</instant>
        </period>
    </context>
    <context id="D2016Q1Jan31az_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2016StrategicAllianceWithAstraZenecaIL12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2016StrategicAllianceWithAstraZenecaIL12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_OncologyDevelopmentTargetPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:OncologyDevelopmentTargetPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="I2018Q2Apr30_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ResearchAndDevelopmentFundingMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:ResearchAndDevelopmentFundingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_SublicenseReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:SublicenseReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2017Q4Oct31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Oct31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_ToxicityMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:ToxicityMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2019Q2May31Merck_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2019Q2May31Merck_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="D2015Q1Jan31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_Combined2018AZAgreementPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:Combined2018AZAgreementPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_CompetitionMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:CompetitionMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2017Q4Oct31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_OptionExerciseFeeMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:OptionExerciseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:VEGFExercise2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_VEGFAProductAZD8601Member_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:VEGFAProductAZD8601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:VariableConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_PCVPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PCVSAVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:PCVPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="I2019Q2May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_mrna_PerformanceObligationAxis_mrna_IL12PerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:PerformanceObligationAxis">mrna:IL12PerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2016Q2Jun30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_DevelopmentMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis">mrna:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentResearchAndDevelopmentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:UpfrontPaymentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2016Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_SublicenseReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">mrna:SublicenseReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:Combined2018AZAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2015Q4Dec31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MerckAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2013Q4Oct31_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-10-01</startDate>
            <endDate>2013-10-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialProjectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialProjectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialBaseAwardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialBaseAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2019Q1Mar31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_FollowOnProjectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:FollowOnProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrna_RightOfUseAssetFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:RightOfUseAssetFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrna_RightOfUseAssetFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:RightOfUseAssetFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2015Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:FiveHundredTechnologySquareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:OfficeLaboratoryAndLightManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-31</instant>
        </period>
    </context>
    <context id="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:TwoHundredTechnologySquareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:TwoHundredTechnologySquareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:TwoHundredTechnologySquareSubleaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:OfficeLaboratoryAndLightManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:FiveHundredTechnologySquareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="D2016Q2May_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:TwoHundredTechnologySquareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="I2017Q2Apr30_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_LandAdjacentToNorwoodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mrna:LandAdjacentToNorwoodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-30</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_mrna_ClinicalOperationsAndSupportCommitmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_us-gaap_PurchaseCommitmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_mrna_ClinicalOperationsAndSupportCommitmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-11</startDate>
            <endDate>2018-12-11</endDate>
        </period>
    </context>
    <context id="I2018Q4Dec11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2018-12-11</instant>
        </period>
    </context>
    <context id="I2018Q1Feb28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-14</startDate>
            <endDate>2020-02-14</endDate>
        </period>
    </context>
    <context id="I2018Q4Dec11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-11</instant>
        </period>
    </context>
    <context id="I2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-14</instant>
        </period>
    </context>
    <context id="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-14</startDate>
            <endDate>2020-02-14</endDate>
        </period>
    </context>
    <context id="I2018Q2May7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="I2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-11</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-05</startDate>
            <endDate>2018-12-05</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrna_StockOptionAndGrantPlan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndGrantPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Nov30_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="D2018Q4Nov30_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-30</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="I2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-05</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2020Q2May1_srt_CounterpartyNameAxis_mrna_LonzaLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:LonzaLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="I2020Q2April16_srt_CounterpartyNameAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-16</instant>
        </period>
    </context>
    <unit id="milestone">
        <measure>mrna:milestone</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="candidate">
        <measure>mrna:candidate</measure>
    </unit>
    <unit id="option">
        <measure>mrna:option</measure>
    </unit>
    <unit id="campus">
        <measure>mrna:campus</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="extension_period">
        <measure>mrna:extension_period</measure>
    </unit>
    <unit id="USD_PER_sqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utreg:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>mrna:installment</measure>
    </unit>
    <unit id="contract_option">
        <measure>mrna:contract_option</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2020Q1YTD"
      id="Fact-31B3957CB3FD149B37B8B8937FDA62EE-wk-Fact-31B3957CB3FD149B37B8B8937FDA62EE">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q1YTD"
      id="Fact-67A1CA98180DB9A6F703B8937FD3FDBA-wk-Fact-67A1CA98180DB9A6F703B8937FD3FDBA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q1YTD"
      id="Fact-CEF44D7B60C5D837F80EB8937FCD1224-wk-Fact-CEF44D7B60C5D837F80EB8937FCD1224">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q1YTD"
      id="Fact-BB833D2DCB33AFDE1757B8937FD81D3D-wk-Fact-BB833D2DCB33AFDE1757B8937FD81D3D">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q1YTD"
      id="Fact-C4F85CF7AC1855137752B8937FCAE50A-wk-Fact-C4F85CF7AC1855137752B8937FCAE50A">0001682852</dei:EntityCentralIndexKey>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="FI2019Q4_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"
      decimals="-5"
      id="Fact-AE164D7AF8FFECDE0D04B8937FF7BF3C-wk-Fact-AE164D7AF8FFECDE0D04B8937FF7BF3C"
      unitRef="usd">243000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod
      contextRef="D2015Q4Dec31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      id="Fact-2ADE5F30DEC8C5F1D44BB91A4211B80A-wk-Fact-2ADE5F30DEC8C5F1D44BB91A4211B80A">P3Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod
      contextRef="D2019Q2May31Merck_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      id="Fact-2BE76D7A2ACDD82162B7B91B8BB2D293-wk-Fact-2BE76D7A2ACDD82162B7B91B8BB2D293">P3Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod
      contextRef="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member"
      id="Fact-67515B79C5E8A44864C3B90888E1263E-wk-Fact-67515B79C5E8A44864C3B90888E1263E">P12M</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod
      contextRef="D2017Q4Oct31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember"
      id="Fact-F29864B0880F6E7BB2B5B908F98C1D67-wk-Fact-F29864B0880F6E7BB2B5B908F98C1D67">P12M</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod
      contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      id="Fact-F2FDC441B2B6A540FE90B930B047EC74-wk-Fact-F2FDC441B2B6A540FE90B930B047EC74">P1Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected
      contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      id="Fact-30FF93B66A96CECA1260B932A982A4C0-wk-Fact-30FF93B66A96CECA1260B932A982A4C0">P6M</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod
      contextRef="D2015Q4Dec31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      id="Fact-E51931C93B14F13A3FE0B91A8DF6C335-wk-Fact-E51931C93B14F13A3FE0B91A8DF6C335">P4Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod
      contextRef="D2016Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      id="Fact-759A6C7946BAA1890DCDB931C72019BB-wk-Fact-759A6C7946BAA1890DCDB931C72019BB">P3Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod
      contextRef="D2019Q2May31Merck_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      id="Fact-DD51807AA4B2A919C094B91C6AB15AE2-wk-Fact-DD51807AA4B2A919C094B91C6AB15AE2">P4Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod
      contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      id="Fact-48933DE20FC152D7B9E8B9302DC1089A-wk-Fact-48933DE20FC152D7B9E8B9302DC1089A">P3Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="FI2019Q4_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember"
      decimals="-5"
      id="Fact-9D5B6F2A48C784ECEF42B8937FF44315-wk-Fact-9D5B6F2A48C784ECEF42B8937FF44315"
      unitRef="usd">19700000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod
      contextRef="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member"
      id="Fact-331C3B2E83BCB4F6E7B0B959EE0A4E3E-wk-Fact-331C3B2E83BCB4F6E7B0B959EE0A4E3E">P6M</mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-66C6D930F2A12B1C0F70B8938009493D-wk-Fact-66C6D930F2A12B1C0F70B8938009493D"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-04175EA856DC4BF88E90B893800E749D-wk-Fact-04175EA856DC4BF88E90B893800E749D"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-D77088086B1ABDD53A64B893800922C2-wk-Fact-D77088086B1ABDD53A64B893800922C2"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-BA919DF4BDFFD4C56636B893800DEE39-wk-Fact-BA919DF4BDFFD4C56636B893800DEE39"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-CE94331CFA137CD5A9B3B89380123AFE-wk-Fact-CE94331CFA137CD5A9B3B89380123AFE"
      unitRef="shares">336536985</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-762C3359AAB42FD26C6AB8938008D420-wk-Fact-762C3359AAB42FD26C6AB8938008D420"
      unitRef="shares">370102805</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-1F64D099C01CD649037AB89380108271-wk-Fact-1F64D099C01CD649037AB89380108271"
      unitRef="shares">336536985</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-61C93BD998EFEBF06F40B893800C3972-wk-Fact-61C93BD998EFEBF06F40B893800C3972"
      unitRef="shares">370102805</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="INF"
      id="Fact-71995AEA8D55E9171452B8937FF128D9-wk-Fact-71995AEA8D55E9171452B8937FF128D9"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember"
      id="Fact-20F64D1B7CBAEBE77C96B983BB638A00-wk-Fact-20F64D1B7CBAEBE77C96B983BB638A00">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="I2015Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember"
      id="Fact-3BD6DCAD174C4D0A0B7EB982AA5C515A-wk-Fact-3BD6DCAD174C4D0A0B7EB982AA5C515A">P6Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="I2017Q2Apr30_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_LandAdjacentToNorwoodMember"
      id="Fact-3637C2CFFD9424D4B480B9837E07CDE2-wk-Fact-3637C2CFFD9424D4B480B9837E07CDE2">P35Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="Fact-66752301688B0DE17B93B8937FD96B17-wk-Fact-66752301688B0DE17B93B8937FD96B17"
      unitRef="usd">540000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="Fact-1CE20C57408CDFCA47CAB8937FD99274-wk-Fact-1CE20C57408CDFCA47CAB8937FD99274"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="Fact-3CF32CA797658B19E0D5B8AFD4E65652-wk-Fact-3CF32CA797658B19E0D5B8AFD4E65652"
      unitRef="usd">1108000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-C93697D4C8EA59183EDFB893800F07DB-wk-Fact-C93697D4C8EA59183EDFB893800F07DB"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-ED4FC7F2EB2F1268DE99B893800E9EE5-wk-Fact-ED4FC7F2EB2F1268DE99B893800E9EE5"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-57EE37F22F9BE97E99A2B893800F4C99-wk-Fact-57EE37F22F9BE97E99A2B893800F4C99"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-17927E649323BF4555BBB893800DE19F-wk-Fact-17927E649323BF4555BBB893800DE19F"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0D0F7B4CB610979C09FCB893800C1EB9-wk-Fact-0D0F7B4CB610979C09FCB893800C1EB9"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-B203F3741A79C8A3736EB8938011A20E-wk-Fact-B203F3741A79C8A3736EB8938011A20E"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-2E1B62FE052983734293B893800A6784-wk-Fact-2E1B62FE052983734293B893800A6784"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-E6EA1290E67EDE6CD90CB8938008B8CC-wk-Fact-E6EA1290E67EDE6CD90CB8938008B8CC"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      id="Fact-C9B4B7CDE5A93FC60529CBE482A9CACA-wk-Fact-C9B4B7CDE5A93FC60529CBE482A9CACA">P8Y9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2028-01-01"
      id="Fact-65B7E827A4605E09C871CBE4A8BA8558-wk-Fact-65B7E827A4605E09C871CBE4A8BA8558">P9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      id="Fact-41E277A6D1789753DA03CBE70B32F551-wk-Fact-41E277A6D1789753DA03CBE70B32F551">P3Y9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      id="Fact-6D3EF974EBB69D3E7835CBE7F0126CF8-wk-Fact-6D3EF974EBB69D3E7835CBE7F0126CF8">P1Y6M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      id="Fact-94D33FF9A3F2E9C07077CBE62F52B109-wk-Fact-94D33FF9A3F2E9C07077CBE62F52B109">P4Y9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:Revenues
      contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember"
      decimals="INF"
      id="Fact-EF9CF300F2C43F439459B8937FF0012E-wk-Fact-EF9CF300F2C43F439459B8937FF0012E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember"
      id="Fact-1DC140A9B67101BC0130B95A3DD482B0-wk-Fact-1DC140A9B67101BC0130B95A3DD482B0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="FD2020Q1YTD"
      id="d8081947e473-wk-Fact-C83DB02E237D05F56895B896476AB32D">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q1YTD"
      id="d8081947e479-wk-Fact-A66F4159C8AD608E126FB897D2C673FF">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q1YTD"
      id="d8081947e489-wk-Fact-BD869D4276D587CBAC0CB8968AB5BDD3">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q1YTD"
      id="d8081947e497-wk-Fact-1D529DB8C777BCBB5BB9B897EAF7403C">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q1YTD"
      id="d8081947e510-wk-Fact-A29E6E9465C0CA7C9B0CB8981E995CE5">001-38753</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q1YTD"
      id="d8081947e522-wk-Fact-2C65740D15373F5CA078B89665D12F61">Moderna, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q1YTD"
      id="d8081947e544-wk-Fact-80466AA04D7F29F105C2B89843F99026">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q1YTD"
      id="d8081947e559-wk-Fact-BDC848D908FA93066343B898527DB5C3">81-3467528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q1YTD"
      id="d8081947e607-wk-Fact-44AF40EDDE17C93F1717B898860D9F41">200 Technology Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q1YTD"
      id="d8081947e628-wk-Fact-554F52C973909CCC7E70B8989130AAE9">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q1YTD"
      id="d8081947e633-wk-Fact-48D9EAB701CCEC87AFC3B8989CA22146">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q1YTD"
      id="d8081947e643-wk-Fact-281D9597368F65E84D9FB898AF0578CB">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q1YTD"
      id="d8081947e669-wk-Fact-B4B830344D58132E7F9EB898DE35D8B8">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q1YTD"
      id="d8081947e674-wk-Fact-7D39482D023F52BBE345B898EBB249C0">714-6500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q1YTD"
      id="d8081947e719-wk-Fact-142E03551FC21D7E8955B899A2086FBC">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q1YTD"
      id="d8081947e724-wk-Fact-589E14731DCC51763A6BB899AB69AB33">MRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q1YTD"
      id="d8081947e729-wk-Fact-85A13D3D37433DAD05ADB899B929D5C9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q1YTD"
      id="d8081947e736-wk-Fact-A94B41D9609FDA69EBF6B89A2204323E">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q1YTD"
      id="d8081947e754-wk-Fact-D72B127D837FD4E1D447B89BC3188B02">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q1YTD"
      id="d8081947e793-wk-Fact-DA0A59EF8BA68E157088B89AB25866CF">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q1YTD"
      id="d8081947e837-wk-Fact-1162D7176CCDE7E67ED7B89AC4174F3A">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q1YTD"
      id="d8081947e883-wk-Fact-C4842980A64E6A758BD9B89ACFAD1D5A">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q1YTD"
      id="d8081947e902-wk-Fact-4BECAF90979AC9D8C980B89B1BDBC8E7">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q2April30"
      decimals="INF"
      id="d8081947e916-wk-Fact-6938C49EF1D825795EDFB8937FED2585"
      unitRef="shares">371223865</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e646-wk-Fact-FCB7F5C18B757531C4FAB8937FEDC285"
      unitRef="usd">391720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e665-wk-Fact-8B040FA40D5116DAE407B8937FD70BDB"
      unitRef="usd">235876000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e680-wk-Fact-CB8FB7481F8D40E1FD4FB8937FCF3074"
      unitRef="usd">825981000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e699-wk-Fact-09191919A1EE71CC1295B8938018B4D2"
      unitRef="usd">867124000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e719-wk-Fact-FF0982CD2DBEEC430E62B8937FDD8256"
      unitRef="usd">5617000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e738-wk-Fact-5FFD9149C9C4CF9E83DBB8937FD0925C"
      unitRef="usd">5032000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e758-wk-Fact-A3D099AD25A18BF3EA8FB8937FC9BFD7"
      unitRef="usd">1683000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e777-wk-Fact-1E12334CF0A233D4B3BAB8937FDB69A9"
      unitRef="usd">337000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e797-wk-Fact-6FD95ED13B84ACA5E3F7B8937FCE0B09"
      unitRef="usd">23903000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e816-wk-Fact-AC28DA640B65E64EC4ADB8937FEF6A5A"
      unitRef="usd">19403000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e836-wk-Fact-1CA23EBD37B38E581ED0B8937FD19C30"
      unitRef="usd">1032000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e855-wk-Fact-89AE55DCE41D1D045F90B8937FCAD484"
      unitRef="usd">1032000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e875-wk-Fact-250FC90FC48AE33B8D3EB8937FD39D11"
      unitRef="usd">1249936000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e894-wk-Fact-AF92B0C8F1E40690BFD9B8937FDE9D2F"
      unitRef="usd">1128804000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e915-wk-Fact-F5C917AC0C7426BD8416B8937FE1DC1B"
      unitRef="usd">502479000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e934-wk-Fact-25FC241F37F02E1E4775B8937FD7CF3B"
      unitRef="usd">159987000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e954-wk-Fact-558DF1603A8CCDA85CBFB8937FCD7C33"
      unitRef="usd">202066000</mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e973-wk-Fact-113458AB596CD8D5C17BB8937FEF297D"
      unitRef="usd">201495000</mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e993-wk-Fact-0DB5077D9DF77DB99501B8937FE01490"
      unitRef="usd">100533000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1012-wk-Fact-78B369C60BB728FB25A9B8937FDB8A1C"
      unitRef="usd">86414000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1032-wk-Fact-4172F40CBA3CC26827FBB8937FDA7E59"
      unitRef="usd">10791000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1051-wk-Fact-370A45EEDD9A5B733D46B8937FD64354"
      unitRef="usd">10791000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1071-wk-Fact-886F357B5FB2FC7702EDB8937FD4F5DB"
      unitRef="usd">1736000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1090-wk-Fact-0F6E2379BC8B77EAC8B6B8937FDD77A8"
      unitRef="usd">1931000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1115-wk-Fact-E237E9FC106061B46BEAB8937FD24F9B"
      unitRef="usd">2067541000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1134-wk-Fact-9D75CB92DE75992CCC7FB8937FDA7E92"
      unitRef="usd">1589422000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1236-wk-Fact-3D9EDDF206DEC1D71580B8937FD7938E"
      unitRef="usd">11034000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1255-wk-Fact-F4776F1EE958610804CEB8937FD11FF2"
      unitRef="usd">7090000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1270-wk-Fact-A6E1BF00CB70C3CAC400B8937FDEDEFE"
      unitRef="usd">55020000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1289-wk-Fact-3481DE0A2E9AF9687BA2B8937FCF40F1"
      unitRef="usd">67652000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1309-wk-Fact-6971641721D05ECFB977B8937FE17E3A"
      unitRef="usd">58842000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1328-wk-Fact-6A7D6F0A9B406A6795A2B8937FDFB55F"
      unitRef="usd">63310000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1349-wk-Fact-1921AA05B102B73D2800B8937FEE50B7"
      unitRef="usd">9686000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1368-wk-Fact-3427191026EAC44A9429B8937FEDEF3A"
      unitRef="usd">5063000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1388-wk-Fact-8266AB54405587AE587DB8937FE3D2BA"
      unitRef="usd">134582000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1407-wk-Fact-D8C496BD2A7C06B09050B8937FDD00A9"
      unitRef="usd">143115000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1427-wk-Fact-C3DA8FD9BDA45651BA26B8937FDB2AC0"
      unitRef="usd">142989000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1446-wk-Fact-23A642ECC8840BC9F76BB8937FCC2577"
      unitRef="usd">138995000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1466-wk-Fact-E301DD914DA458C31061B8937FCDE2FE"
      unitRef="usd">108919000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1485-wk-Fact-2DEF7B7076BAB361269FB8937FD01D5D"
      unitRef="usd">93675000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1505-wk-Fact-33C005D3215430FF981AB8937FEE7C36"
      unitRef="usd">38930000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1524-wk-Fact-DDD0C8D2570F3206B9EFB8937FDEDECE"
      unitRef="usd">38689000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1544-wk-Fact-0E7BDA5FD9CC998E55E4B8937FEA1C59"
      unitRef="usd">1247000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1563-wk-Fact-D33D02D38405ED1CBC63B8937FE26496"
      unitRef="usd">138000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1583-wk-Fact-1A96877C320CB5B8131AB8937FCB67C7"
      unitRef="usd">426667000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1602-wk-Fact-99E9324F3D4C49E06F69B8937FE752FB"
      unitRef="usd">414612000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2020Q1"
      id="d8083825e1622-wk-Fact-C970E3480C87B80705D2B8937FD26887"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d8083825e1641-wk-Fact-934EFDD69E44174107D5B8937FD906CC"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1708-wk-Fact-96BC5E39F5B7BBD62873B8937FC91258"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1727-wk-Fact-9C5F2E94108419117539B8937FDD978E"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1747-wk-Fact-12EF990A36C4926A4D0EB8938019C628"
      unitRef="usd">37000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1766-wk-Fact-73414EDC06E051D2CACBB8937FEC3F66"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1787-wk-Fact-373D4239AAA4A0ED7FD1B8937FDD80E7"
      unitRef="usd">3267648000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1806-wk-Fact-94B27294A5F1D739BEEDB8937FE040E7"
      unitRef="usd">2669426000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1826-wk-Fact-F482221C0B86B188321FB8937FD98CDB"
      unitRef="usd">-6127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1846-wk-Fact-8BCCE6F43177FC7369F8B8937FD733A6"
      unitRef="usd">1804000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1866-wk-Fact-53CA5DED75748D323855B8937FD6BE55"
      unitRef="usd">-1620684000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1886-wk-Fact-1C8F11ACACBB261C182CB8937FDE0A67"
      unitRef="usd">-1496454000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1907-wk-Fact-27485B920BFF3F513BCAB8937FD29C6E"
      unitRef="usd">1640874000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1926-wk-Fact-8342C7ACB3A424B72851B8937FDA096D"
      unitRef="usd">1174810000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8083825e1951-wk-Fact-15619A8B39E6525AD2A6B8937FE5D852"
      unitRef="usd">2067541000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8083825e1970-wk-Fact-19B8CBB32C0113D0AB7BB8937FE39BF6"
      unitRef="usd">1589422000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember"
      decimals="-3"
      id="d8084779e606-wk-Fact-EE50BD8883124B6AD4BCB89380013503"
      unitRef="usd">3187000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember"
      decimals="-3"
      id="d8084779e625-wk-Fact-A1E074F942AAC9033D6DB8938016D0B6"
      unitRef="usd">13301000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborativeArrangementWithRelatedPartyMember"
      decimals="-3"
      id="d8084779e640-wk-Fact-F57182121120FB7B77E7B89380099599"
      unitRef="usd">1270000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborativeArrangementWithRelatedPartyMember"
      decimals="-3"
      id="d8084779e659-wk-Fact-66360CB5AE1A1B5E4ABEB8938010E740"
      unitRef="usd">814000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember"
      decimals="-3"
      id="d8084779e679-wk-Fact-72303648FED47CE77ED3B8938006991E"
      unitRef="usd">3932000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember"
      decimals="-3"
      id="d8084779e698-wk-Fact-82B43048FBEE6F3672F2B89380094FF5"
      unitRef="usd">1910000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e718-wk-Fact-C45DF02DCBA131BF519AB893800B42AA"
      unitRef="usd">8389000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e737-wk-Fact-6C01246797B7AC79E810B893800D7458"
      unitRef="usd">16025000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e798-wk-Fact-A4E18F31B1C34A1F5875B8937FFE4CE0"
      unitRef="usd">115137000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e817-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B"
      unitRef="usd">130413000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e837-wk-Fact-BB71746277CD54A12106B893801198AA"
      unitRef="usd">24114000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e856-wk-Fact-388AA200DC25E9066B99B893800C8ED9"
      unitRef="usd">27253000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e876-wk-Fact-EF8B277407C16D662C4EB8938014DFC7"
      unitRef="usd">139251000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e895-wk-Fact-D3827E83F30C694EF76CB8937FFE759C"
      unitRef="usd">157666000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e916-wk-Fact-B7A7E2794454FB32E131B893800F4911"
      unitRef="usd">-130862000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e936-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB"
      unitRef="usd">-141641000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e957-wk-Fact-0F88B23A54A852EC0AA8B8937FFEA8F2"
      unitRef="usd">7852000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e976-wk-Fact-326EE1AA525F98E1FA63B8938009353C"
      unitRef="usd">10972000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e996-wk-Fact-A3343067282FBFA98FD6B8938003E121"
      unitRef="usd">-1154000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e1016-wk-Fact-156AE2DD85FA9D77014AB893801275AF"
      unitRef="usd">-1931000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e1037-wk-Fact-62EEA85EE3E81C08B8E5B8938000C183"
      unitRef="usd">-124164000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e1057-wk-Fact-794A1869F8798C775B81B893800A6DA6"
      unitRef="usd">-132600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e1078-wk-Fact-9D0AD297A7A373FFB0F8B8938006AEB5"
      unitRef="usd">66000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e1097-wk-Fact-C8FEBDCA5C3EB990D3E0B893800044E6"
      unitRef="usd">-24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8084779e1123-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618"
      unitRef="usd">-124230000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8084779e1143-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
      unitRef="usd">-132576000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d8084779e1164-wk-Fact-334C08CA9FF5FC0D8533B893800D7CE7"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q1YTD"
      decimals="2"
      id="d8084779e1184-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d8084779e1200-wk-Fact-0B70C03E5259115FF9BDB893800E79A7"
      unitRef="shares">353105021</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q1YTD"
      decimals="0"
      id="d8084779e1219-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52"
      unitRef="shares">328809986</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8086815e564-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618"
      unitRef="usd">-124230000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8086815e584-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
      unitRef="usd">-132576000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8086815e641-wk-Fact-C3285AB7C5D339DFF2F9B8937FE8206D"
      unitRef="usd">-7610000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8086815e661-wk-Fact-16C6E45D368ABF511BFCB8937FCB92FD"
      unitRef="usd">1908000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8086815e681-wk-Fact-05907F86AECE785B47A0B8937FEAFA8A"
      unitRef="usd">321000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8086815e701-wk-Fact-280EF1911DA26D907515B8937FE3FF22"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8086815e721-wk-Fact-84AE9EE8897ADE337019B8937FEB216F"
      unitRef="usd">-7931000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8086815e741-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E"
      unitRef="usd">1911000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8086815e766-wk-Fact-9697BE40B7E20EE530DDB8937FE48CAB"
      unitRef="usd">-132161000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8086815e786-wk-Fact-27C8D3886673A4C3D82AB8937FC91677"
      unitRef="usd">-130665000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e873-wk-Fact-9EC44F777EC711DC0CE0B8937FD77187"
      unitRef="shares">336536985</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8088448e892-wk-Fact-170C932C3C59BB44CAE6B8937FDA79F8"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e911-wk-Fact-B44F2DB3C63B99AEE483B8937FCAB67D"
      unitRef="usd">2669426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8088448e931-wk-Fact-C8AC1221151F332E579EB8937FD93243"
      unitRef="usd">1804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8088448e950-wk-Fact-BEEF5D1E0DFC59797737B8937FDC09A7"
      unitRef="usd">-1496454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8088448e970-wk-Fact-8342C7ACB3A424B72851B8937FDA096D"
      unitRef="usd">1174810000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e986-wk-Fact-541FE5086B61AF5934B9B8AD9B0C90CD"
      unitRef="shares">30263158</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8088448e1000-wk-Fact-80F968143A2457A97E11B8AD0C3012F9"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e1019-wk-Fact-072C1F966D5498E0028CB8AD0C29B7A4"
      unitRef="usd">549452000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8088448e1077-wk-Fact-56DFF93EF46E5DBDAEEDB8AD0C243508"
      unitRef="usd">549455000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e1098-wk-Fact-233446894A4499CE83BFB8937FE427BB"
      unitRef="shares">113991</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8088448e1189-wk-Fact-DB5D9261639BCA940B01B8937FFA7ECD"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e1210-wk-Fact-0C40959079EDD148631AB8937FEB8BA4"
      unitRef="shares">3188671</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e1243-wk-Fact-BF98239AD721736452D7B89380198257"
      unitRef="usd">28357000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8088448e1301-wk-Fact-1548D74B442D084282BCB8937FD2076F"
      unitRef="usd">28357000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e1355-wk-Fact-4C59CDD693309DBFB2DCB89380067028"
      unitRef="usd">20413000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8088448e1413-wk-Fact-5771C6E1C7566D098570B8937FD41670"
      unitRef="usd">20413000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8088448e1487-wk-Fact-71D6D1762547D3AC1756B8937FCBECCB"
      unitRef="usd">-7931000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8088448e1526-wk-Fact-84AE9EE8897ADE337019B8937FEB216F"
      unitRef="usd">-7931000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8088448e1620-wk-Fact-2FB550F1E657CCEC59E4B8937FD43FA6"
      unitRef="usd">-124230000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8088448e1640-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618"
      unitRef="usd">-124230000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e1662-wk-Fact-62550BDBF77BC1730BFFB8937FD14636"
      unitRef="shares">370102805</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8088448e1681-wk-Fact-C16FE33C9C4C40ACD974B8938019B548"
      unitRef="usd">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e1700-wk-Fact-91CD1AB1389912749E29B893800461B0"
      unitRef="usd">3267648000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8088448e1720-wk-Fact-D14662EB9BEFADBFC7DEB893801721E8"
      unitRef="usd">-6127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8088448e1740-wk-Fact-4007BD686F3B8E139F2EB8937FE4FFA8"
      unitRef="usd">-1620684000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8088448e1760-wk-Fact-27485B920BFF3F513BCAB8937FD29C6E"
      unitRef="usd">1640874000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e2191-wk-Fact-25F457293E4134E54285B8938013432D"
      unitRef="shares">328798904</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8088448e2210-wk-Fact-F737D35F278423CA1F92B893800E1009"
      unitRef="usd">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e2229-wk-Fact-109385CB5960C4776022B89380137CAF"
      unitRef="usd">2538155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8088448e2249-wk-Fact-A762F5149650D4FDE907B893800A6D85"
      unitRef="usd">-1320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8088448e2269-wk-Fact-A79FC62A46F8E76F5CA7B893800694A3"
      unitRef="usd">-1006627000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d8088448e2289-wk-Fact-C1DDD03AE10FF9404F6AB8938012E3F3"
      unitRef="usd">1530241000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e2305-wk-Fact-57338587B14A2752C816B893800251C5"
      unitRef="shares">48911</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8088448e2396-wk-Fact-28368F1B02540394CB54B8938018EDC2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e2417-wk-Fact-2E2B4ED22F6AE315B324B893800569F2"
      unitRef="shares">5525</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e2450-wk-Fact-56133C99FD5278B908F8B893801072AD"
      unitRef="usd">57000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8088448e2508-wk-Fact-393E94D668BA5E8C9C9DB89380111236"
      unitRef="usd">57000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8088448e2601-wk-Fact-7FE56C026237BA76D498B8938015293D"
      unitRef="usd">27984000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d8088448e2620-wk-Fact-171B54BA2BAC4D6F68F9B89380150DE5"
      unitRef="usd">-27984000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8088448e2713-wk-Fact-6E98F6850B8815FC9558B893800F1738"
      unitRef="usd">-3789000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8088448e2733-wk-Fact-8ABA793256C1005F3F19B8938017A9B2"
      unitRef="usd">3789000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e2788-wk-Fact-F87DFCE02C705E29892EB893800EBA28"
      unitRef="usd">18497000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8088448e2846-wk-Fact-CBF686121BE1AC6B2904B893800EF2DD"
      unitRef="usd">18497000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8088448e2920-wk-Fact-44258AE8048385CF22A7B893800FE8A4"
      unitRef="usd">1911000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8088448e2958-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E"
      unitRef="usd">1911000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8088448e3051-wk-Fact-0468755339101634CF3BB893800565B3"
      unitRef="usd">-132576000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8088448e3071-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
      unitRef="usd">-132576000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8088448e3094-wk-Fact-B11A43282055E5B4E6A6B893801007C7"
      unitRef="shares">328853340</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8088448e3113-wk-Fact-EAC1BB1E9EC00568CC00B8938004CD7A"
      unitRef="usd">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8088448e3132-wk-Fact-98A6A9C4271BBDE39287B893800B2394"
      unitRef="usd">2556709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8088448e3152-wk-Fact-368452BC5E1D5B2A5D3DB893801297B8"
      unitRef="usd">591000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8088448e3171-wk-Fact-3C6E0C87B7DA52EDD9B4B8938007040F"
      unitRef="usd">-1115008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-3"
      id="d8088448e3191-wk-Fact-63A2E5079CEFCAF5726EB89380070257"
      unitRef="usd">1442325000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e605-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618"
      unitRef="usd">-124230000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e625-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
      unitRef="usd">-132576000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e682-wk-Fact-5EDC6D9E517EE3DE39F8B893800F56C2"
      unitRef="usd">20413000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e701-wk-Fact-AE09011276505A34815AB893800FEC64"
      unitRef="usd">18497000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e721-wk-Fact-85174683CB181380D4DCB89380192E4A"
      unitRef="usd">7449000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e740-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA"
      unitRef="usd">7316000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e760-wk-Fact-5D4C8932B56EBA0C7800B89380091ABA"
      unitRef="usd">-515000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e779-wk-Fact-2E84575AAA5FF3FC9F78B8937FF58F76"
      unitRef="usd">1005000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e800-wk-Fact-0A7B828CFB4220AE5747B8937FED5569"
      unitRef="usd">-137000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e819-wk-Fact-D9F27C1A04B3019CC1E5B893801B938F"
      unitRef="usd">-19000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e880-wk-Fact-6B2E07C1A038FBFD8481B8937FFF377B"
      unitRef="usd">585000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e900-wk-Fact-13B91B25EEEA209A05DDB8937FF9A56A"
      unitRef="usd">-6040000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e921-wk-Fact-F6473B781FD2BFACACEBB893801B75DF"
      unitRef="usd">1346000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e941-wk-Fact-3D792C328A7A9FAF77F0B8937FD8E780"
      unitRef="usd">66000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e962-wk-Fact-CD40BFF2C4E9359BB9A6B8938004E2E6"
      unitRef="usd">4305000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e982-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE"
      unitRef="usd">-3354000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1002-wk-Fact-C22CAEDDA0D592892F22B8B337840B0B"
      unitRef="usd">14119000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1022-wk-Fact-B6924E34411A34ED10EAB8B337F36C45"
      unitRef="usd">-1620000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1042-wk-Fact-A7FD8E64AF05B747F6CBB8937FE6AB20"
      unitRef="usd">2331000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1061-wk-Fact-8DCA9BC49239FD042533B893800A53CF"
      unitRef="usd">1731000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1081-wk-Fact-7647462909F1D691247FB8938014ABA8"
      unitRef="usd">-12953000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1101-wk-Fact-5061953B1C2C59733B33B8937FE3BCE5"
      unitRef="usd">-32557000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1122-wk-Fact-1D8F5664CB0685F31048B89380025FFE"
      unitRef="usd">-474000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1142-wk-Fact-B07D7B9BE56744C316DDB893801A9D41"
      unitRef="usd">-15604000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mrna:OperatingLeaseLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1163-wk-Fact-B6A452B7DFE5FFDE7C27B8937FDCC8DE"
      unitRef="usd">15244000</mrna:OperatingLeaseLiabilities>
    <mrna:OperatingLeaseLiabilities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1182-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D"
      unitRef="usd">-1848000</mrna:OperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1203-wk-Fact-29BE93C6EE8C822EEFEEB8937FF064FA"
      unitRef="usd">5732000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1222-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED"
      unitRef="usd">811000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1242-wk-Fact-8FEF75CF8EE749390F75B8938005094A"
      unitRef="usd">-106191000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1262-wk-Fact-71DFE94246E5E76A1601B8938019923C"
      unitRef="usd">-144268000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1324-wk-Fact-DFA4683EEF0C353EBC36B8938003B3B9"
      unitRef="usd">621257000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1344-wk-Fact-7DA9A9CAD969006FD132B8937FD32083"
      unitRef="usd">429517000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1366-wk-Fact-9FFEC757654CA3468AA3B8938018BB38"
      unitRef="usd">269733000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1385-wk-Fact-57606C3B8D696B7B20FBB8938013667B"
      unitRef="usd">403940000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1405-wk-Fact-CF7C2E9ABF9B27D26FACB89380144B69"
      unitRef="usd">41729000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1424-wk-Fact-A9B844D9D79DFD44E64DB8937FCCC2B6"
      unitRef="usd">21413000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1444-wk-Fact-D5ECAC8178585AE824EEB89380157DB9"
      unitRef="usd">6223000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1464-wk-Fact-E6AE70E1C94B7E71386EB8937FF4DA69"
      unitRef="usd">7595000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1485-wk-Fact-12DA7F1560B53B426BDBB8938008E54A"
      unitRef="usd">-316018000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1505-wk-Fact-7ED3D5A06DA641811A58B8938000C408"
      unitRef="usd">-11759000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1567-wk-Fact-FB4A0A6CE98DF45845B3B8B4C670A49F"
      unitRef="usd">549455000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1586-wk-Fact-F3F6715DB4D17F67A78FB8B4C6517497"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1606-wk-Fact-1D9F4151497D23B158EBB8937FFF248E"
      unitRef="usd">28357000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1625-wk-Fact-D679BA327FBD2B556510B8938006766F"
      unitRef="usd">57000</us-gaap:ProceedsFromStockPlans>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1645-wk-Fact-546EFC4124A64FB0CB4AB893800BA4E5"
      unitRef="usd">241000</mrna:ChargesToFinancingLeaseLiabilities>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1664-wk-Fact-68DBC17D0B4E10977736B8938009AD08"
      unitRef="usd">236000</mrna:ChargesToFinancingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1684-wk-Fact-ADD5F7F35202B02BFB1EB8938011043F"
      unitRef="usd">578053000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1703-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA"
      unitRef="usd">293000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1723-wk-Fact-C0EBBE777701951C30FDB8937FF51091"
      unitRef="usd">155844000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1742-wk-Fact-06331F9217E917C083EEB89380103D9E"
      unitRef="usd">-155734000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8090304e1763-wk-Fact-004D40751B24DABA63E6B89380001396"
      unitRef="usd">247699000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d8090304e1782-wk-Fact-7EE40EC09D85242D719AB893800A84E0"
      unitRef="usd">670491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8090304e1808-wk-Fact-39EDF63C1C98DD365DFDB8937FF0B319"
      unitRef="usd">403543000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q1"
      decimals="-3"
      id="d8090304e1827-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE"
      unitRef="usd">514757000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8090304e1888-wk-Fact-53E547EB25231CC8D531B893801A194E"
      unitRef="usd">6610000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8090304e1907-wk-Fact-CAA3495CF8BB8E12C464B89380044039"
      unitRef="usd">14127000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-ABFD867EF8413195B0EEB8938025603B-0-wk-Fact-2F8753EEEC868E97EF07B8937FE15519">Description of the Business&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are a clinical stage biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#x2019;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Since inception, we have incurred significant net losses. As of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had an accumulated deficit of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.62 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, we anticipate that our expenses will increase significantly in connection with our ongoing activities to support our platform research, drug discovery and clinical development, infrastructure and Research Engine and Early Development Engine, digital infrastructure, creation of a portfolio of intellectual property, expansion into global markets, and administrative support.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We do not expect to generate significant revenue from sales of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for any of our investigational medicines, we expect to incur significant commercialization expenses. Our investigational vaccine against the novel coronavirus (mRNA-1273), which is currently in clinical trials, has been developed rapidly to respond to the global pandemic. We are expending significant efforts to further the rapid development of this potential vaccine and expect to continue to do so over the next 12 months. These efforts will require the expenditure of significant additional funds and the establishment of significant additional worldwide infrastructure and partnerships. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from potential mRNA medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs. We believe that our cash, cash equivalents, and investments as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our medicines, including mRNA-1273, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q1"
      decimals="-7"
      id="d8090433e469-wk-Fact-6F1DA785E20044EC2D0CB93906AB71D9"
      unitRef="usd">-1620000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-4CC0CBD6CDDF11B7AED6B89380261A04-0-wk-Fact-BD382E01F158C2F77594B8937FF7C8CE">Summary of Basis of Presentation and Recent Accounting Standards&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are consistent with those described in our 2019 Form 10-K, except as noted within the&#160;&#x201c;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x201d;&#160;section below.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective on December 31, 2019, we lost our emerging growth company (EGC) status which accelerated the requirement of ASC 842 (Lease Accounting) adoption. As a result, we adjusted our previously reported consolidated financial statements effective January 1, 2019 in our 2019 Form 10-K, and amendments to previously filed Forms 10-Q were not required. Accordingly, our prior period condensed consolidated financial statements and information, as presented herein, have been restated to conform to the new standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables summarize the effects of adopting ASC 842 on our condensed consolidated financial statements for the three months ended March 31, 2019&#160;(in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 842&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Previously reported&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157,666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(141,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(141,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Previously reported&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 842 Adjustment during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Operating activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets, operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(143,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(144,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financing activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Charges to financing lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payments on financing lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net cash (used in) provided by financing activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss includes net loss and other comprehensive (loss) income for the period. Other comprehensive (loss) income consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of accumulated other comprehensive loss for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/span&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&#160;Gain on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated other comprehensive income, balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated other comprehensive loss, balance at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;391,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;502,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,823&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;403,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;514,757&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;  This standard changes how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. The amendments in this standard should be applied on a modified retrospective basis to all periods presented.&#160;We adopted this standard in the first quarter of 2020. Based on the composition of our investment portfolio and investment policy, the adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-15,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Topic 350): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). We adopted this standard in the first quarter of 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the FASB issued ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. This standard removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. This standard will be effective for us on January 1, 2021, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and disclosures upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-9F9A7C8203E185308C70B8938026E44F-0-wk-Fact-EE51011F71DAC1EB94D3B8937FF7D14F">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F0D59D82F6034EE3D8A2B93E9553AD48-0-wk-Fact-113B2F20B2125B99EDA4B93EB7C6B964">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables summarize the effects of adopting ASC 842 on our condensed consolidated financial statements for the three months ended March 31, 2019&#160;(in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 842&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Previously reported&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157,666&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(141,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(141,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Previously reported&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 842 Adjustment during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Operating activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets, operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(143,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(144,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financing activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Charges to financing lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payments on financing lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net cash (used in) provided by financing activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Merck&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vertex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e864-wk-Fact-637A021AF25C90A6986CB940F446EC1D"
      unitRef="usd">130575000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e883-wk-Fact-685398ED32340730119FB940F7141F3F"
      unitRef="usd">-162000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e904-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B"
      unitRef="usd">130413000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e924-wk-Fact-FA135B3F96ADD939A865B940FBD82A28"
      unitRef="usd">27283000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e943-wk-Fact-5C853DE143A994F1D350B940FEAA7444"
      unitRef="usd">-30000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e963-wk-Fact-388AA200DC25E9066B99B893800C8ED9"
      unitRef="usd">27253000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e989-wk-Fact-59CEEE167FCBD6547B49B9410449D8E3"
      unitRef="usd">157858000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1008-wk-Fact-6713A2E67AD75EBA30FDB94106F104E5"
      unitRef="usd">-192000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1028-wk-Fact-D3827E83F30C694EF76CB8937FFE759C"
      unitRef="usd">157666000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e1054-wk-Fact-B7FB2174E157D62050B8B9410C3FBD45"
      unitRef="usd">-141833000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1074-wk-Fact-BD42FA44BBAF4F91E1DAB9410F177BAA"
      unitRef="usd">192000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1093-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB"
      unitRef="usd">-141641000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e1120-wk-Fact-4993FBF2956B6C9DA5EFB941E4ACC223"
      unitRef="usd">-1820000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1140-wk-Fact-BC71E57885826C4C5206B941E7BF7FFD"
      unitRef="usd">-111000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1160-wk-Fact-156AE2DD85FA9D77014AB893801275AF"
      unitRef="usd">-1931000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e1187-wk-Fact-CDA17B8297A98D1C31CDB941EDC68020"
      unitRef="usd">-132681000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1207-wk-Fact-7B903777CCA2927DA1E9B941F084122D"
      unitRef="usd">81000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1226-wk-Fact-794A1869F8798C775B81B893800A6DA6"
      unitRef="usd">-132600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e1253-wk-Fact-438B28F55BE78C10F5C1B944B71820AB"
      unitRef="usd">-132657000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1273-wk-Fact-66CBEE88366206935F01B944BD408416"
      unitRef="usd">81000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1292-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
      unitRef="usd">-132576000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="2"
      id="d8093385e1320-wk-Fact-C2CF8B4E91552BDD8389B942500239AF"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q1YTD"
      decimals="2"
      id="d8093385e1359-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e1660-wk-Fact-438B28F55BE78C10F5C1B944B71820AB"
      unitRef="usd">-132657000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1680-wk-Fact-66CBEE88366206935F01B944BD408416"
      unitRef="usd">81000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1700-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
      unitRef="usd">-132576000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e1721-wk-Fact-44532D4E88F23FAF2614B9452424F10D"
      unitRef="usd">7328000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1740-wk-Fact-BF1302AF6D7FAC3CD674B9466EE86AAB"
      unitRef="usd">-12000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1760-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA"
      unitRef="usd">7316000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e1786-wk-Fact-3BCD33BD9E260D8D614BB94537A74935"
      unitRef="usd">-3313000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1805-wk-Fact-65AFB73CDFA8962E7DA7B94672D92CFA"
      unitRef="usd">-41000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1824-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE"
      unitRef="usd">-3354000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1869-wk-Fact-BFC011B6E00D0584ADAEB9455B5C8DF0"
      unitRef="usd">-1620000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e1888-wk-Fact-B6924E34411A34ED10EAB8B337F36C45"
      unitRef="usd">-1620000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <mrna:IncreaseDecreaseInDeferredRentCredit
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e1914-wk-Fact-CB4A3D7A5098877C3D0FB94A254ED55D"
      unitRef="usd">550000</mrna:IncreaseDecreaseInDeferredRentCredit>
    <mrna:IncreaseDecreaseInDeferredRentCredit
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1933-wk-Fact-ADB083B8162059131092B94A277A7497"
      unitRef="usd">-550000</mrna:IncreaseDecreaseInDeferredRentCredit>
    <mrna:OperatingLeaseLiabilities
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e1998-wk-Fact-05DE9855FD833447E079B94581E98E48"
      unitRef="usd">-1848000</mrna:OperatingLeaseLiabilities>
    <mrna:OperatingLeaseLiabilities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e2018-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D"
      unitRef="usd">-1848000</mrna:OperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e2045-wk-Fact-8F2C1C61E79F0B566F38B94598467915"
      unitRef="usd">484000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e2064-wk-Fact-C481BE262DBAD65A9AF8B94598545369"
      unitRef="usd">327000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e2083-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED"
      unitRef="usd">811000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e2109-wk-Fact-6BB4147743C79AD043F6B945B8053F80"
      unitRef="usd">-143927000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e2129-wk-Fact-54401B4DBB3BB8843512B945B7D722C1"
      unitRef="usd">-341000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e2149-wk-Fact-71DFE94246E5E76A1601B8938019923C"
      unitRef="usd">-144268000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e2262-wk-Fact-A5D94CE8121B38AB8CABB945DC54B57F"
      unitRef="usd">236000</mrna:ChargesToFinancingLeaseLiabilities>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e2281-wk-Fact-68DBC17D0B4E10977736B8938009AD08"
      unitRef="usd">236000</mrna:ChargesToFinancingLeaseLiabilities>
    <mrna:PaymentsForLeaseFinancingObligation
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e2307-wk-Fact-D690678D8FB8901370AEB94881C53C17"
      unitRef="usd">105000</mrna:PaymentsForLeaseFinancingObligation>
    <mrna:PaymentsForLeaseFinancingObligation
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e2327-wk-Fact-D8FB5789D54BE5537CA9B9488204A8C7"
      unitRef="usd">-105000</mrna:PaymentsForLeaseFinancingObligation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="d8093385e2372-wk-Fact-48D16BD4A46EA53F60CAB945FDE7153E"
      unitRef="usd">-48000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q1YTD_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d8093385e2392-wk-Fact-A0F15D95B9C3074D9410B945FDFA84E3"
      unitRef="usd">341000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8093385e2411-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA"
      unitRef="usd">293000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-3BB83807F9DDCC02E564B89380258F3E-0-wk-Fact-13BC02910EEE68FBD328B89380186A2D">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss includes net loss and other comprehensive (loss) income for the period. Other comprehensive (loss) income consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-21321DEA2227ECFF5F6FB8938026D219-0-wk-Fact-6D037C22BE3BCD007201B89380105C8E">&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of accumulated other comprehensive loss for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/span&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&#160;Gain on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated other comprehensive income, balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated other comprehensive loss, balance at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8093385e2526-wk-Fact-C8AC1221151F332E579EB8937FD93243"
      unitRef="usd">1804000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d8093385e2541-wk-Fact-A909D74D689741B3C39BB8937FD52DFE"
      unitRef="usd">-7931000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8093385e2567-wk-Fact-D14662EB9BEFADBFC7DEB893801721E8"
      unitRef="usd">-6127000</us-gaap:StockholdersEquity>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="FD2020Q1YTD"
      id="TextSelection-90DF67549D8561957F16B93D5F29F960-0-wk-Fact-08871AA5A37747949BD1B93DDD7936E4">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-6B32B1E16A28E7767950B8938026ADA6-0-wk-Fact-FD09E7BFEDA94A0C7347B8937FEBA9D5">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;391,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;502,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,823&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;403,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;514,757&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F106D1B45C609C54AEB7B893802646FF-0-wk-Fact-BDA58F892E6ED2EFA0C3B89380137ABC">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;391,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;502,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,823&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;403,543&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;514,757&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8093385e2758-wk-Fact-FCB7F5C18B757531C4FAB8937FEDC285"
      unitRef="usd">391720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q1"
      decimals="-3"
      id="d8093385e2777-wk-Fact-394CCC8D4C25A361E765B8937FD03929"
      unitRef="usd">502934000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8093385e2797-wk-Fact-1CA23EBD37B38E581ED0B8937FD19C30"
      unitRef="usd">1032000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2019Q1"
      decimals="-3"
      id="d8093385e2816-wk-Fact-CDF34FA761328EC14D21B8937FD34105"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8093385e2841-wk-Fact-4172F40CBA3CC26827FBB8937FDA7E59"
      unitRef="usd">10791000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2019Q1"
      decimals="-3"
      id="d8093385e2860-wk-Fact-DFF17C5DB8C7471248C6B8937FD47800"
      unitRef="usd">11823000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8093385e2893-wk-Fact-39EDF63C1C98DD365DFDB8937FF0B319"
      unitRef="usd">403543000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q1"
      decimals="-3"
      id="d8093385e2912-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE"
      unitRef="usd">514757000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F291FF24AC6B897990A4B8938026A35B-0-wk-Fact-DF4466CC6A8BC71CE0E2B8937FF4A326">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;  This standard changes how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. The amendments in this standard should be applied on a modified retrospective basis to all periods presented.&#160;We adopted this standard in the first quarter of 2020. Based on the composition of our investment portfolio and investment policy, the adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-15,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Topic 350): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). We adopted this standard in the first quarter of 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the FASB issued ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. This standard removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. This standard will be effective for us on January 1, 2021, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and disclosures upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-38C1CF2FA6113B09B040B89380261F41-0-wk-Fact-B21AAC0EBFBDEF6F7999B8937FDB2C46">Collaboration Agreements&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Merck&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vertex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contract Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,972&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contract Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;199,528&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts included in contract liabilities at the beginning of the period &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Performance obligations satisfied (or partially satisfied) in previous reporting periods &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period is first applied to the beginning contract liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Related to changes in estimated costs for our future performance obligations and estimated variable considerations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$278.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;AstraZeneca &#x2013; Strategic Alliances in Cardiovascular and Oncology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2013 Option Agreement and Services and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement, the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018. We refer to these agreements in the forms that existed prior to the 2018 amendment and restatement as the 2013 AZ Agreements. Under the 2013 AZ Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. Pursuant to the 2013 AZ Agreements, AstraZeneca was responsible for all research, development and commercialization activities, while we provided specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca&#x2019;s activities pursuant to an agreed upon services plan. Under the 2013 AZ Agreements, AstraZeneca could have requested we provide additional services, at AstraZeneca&#x2019;s expense. Subject to customary &#x201c;back-up&#x201d; supply rights granted to AstraZeneca, we exclusively manufactured (or had manufactured) mRNA for all research, development and commercialization purposes under the 2013 AZ Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2013 AZ Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of the effective date of the 2013 AZ Agreements, AstraZeneca acquired &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;forty&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates under the 2013 AZ Agreements, AstraZeneca could have elected to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca could have then exercised one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates). If AstraZeneca did not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca&#x2019;s rights to exercise an option and other rights granted under the 2013 AZ Agreements with respect to such development candidate (and related back-up candidates) would terminate, all rights to exploit such development candidate (and related back-up candidates) would be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) would be either assigned or licensed to us. Upon the earlier of termination of the 2013 AZ Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, would automatically terminate. On a target-by-target basis, we and AstraZeneca agreed to certain defined exclusivity obligations under the 2013 AZ Agreements with respect to the research, development and commercialization of mRNA medicines for such target.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$240.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Under the 2013 AZ Agreements, we were entitled to receive payments that are not related to any specific program of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$180.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the aggregate for the achievement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; technical milestones relating to toxicity, delivery, and competition criteria. We achieved the toxicity and competition milestones in the year ended December&#160;31, 2015. The delivery milestone has expired. Under the 2013 AZ &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Agreements, AstraZeneca was obligated to pay us a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; option exercise fee with respect to each development candidate (and related back-up candidates) for which it exercised an option. In addition, upon AstraZeneca&#x2019;s exercise of each option, we were eligible to receive certain payments contingent upon the achievement of specified clinical, regulatory, and commercial events. For any product candidate optioned by AstraZeneca, we were eligible to receive, per product candidate, up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments for achievement of development milestones, up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; payments for achievement of regulatory milestones, and up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$200.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; payments for achievement of commercial milestones. Additionally, under the 2013 AZ Agreements, we were entitled to receive, on a product-by-product basis, earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, subject to certain reductions, with an aggregate minimum floor.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We received from AstraZeneca under the 2013 AZ Agreements an option exercise payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the 2016 VEGF Exercise) in the year ended December&#160;31, 2016, and a clinical milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with respect to AstraZeneca&#x2019;s VEGF-A product (AZD8601) during the year ended December&#160;31, 2018, that is currently being developed in a Phase&#160;2 clinical trial in certain fields. Unless earlier terminated, the 2013 AZ Agreements would have continued until the expiration of AstraZeneca&#x2019;s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party had the right to terminate the 2013 AZ Agreements upon the other party&#x2019;s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca had the right to terminate the 2013 AZ Agreements for our material breach, then AstraZeneca could have elected, in lieu of terminating the 2013 AZ Agreements, in their entirety or with respect to such candidates, to have the 2013 AZ Agreements remain in effect, subject to reductions in certain payments we were eligible to receive and certain adjustments to AstraZeneca&#x2019;s obligations under the 2013 AZ Agreements. AstraZeneca had the right to terminate the 2013 AZ Agreements in full, without cause, upon &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-days&#x2019; prior notice to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2016 Strategic Alliance with AstraZeneca&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &#x2013;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; IL-12 &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2016, we entered into a new Strategic Drug Development Collaboration and License Agreement, which we refer to as the 2016 AZ Agreement, with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL-12 protein.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The 2016 AZ Agreement initially included research activities with respect to a second discovery program. During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. For the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement, during a defined election period that commenced as of the effective date of the 2016 AZ Agreement (for the IL-12 program) and otherwise will commence on initiation of any such new discovery program, AstraZeneca may elect to participate in the clinical development of a development candidate arising under the 2016 AZ Agreement from such program. If AstraZeneca so elects (as it has for the IL-12 program), AstraZeneca will lead clinical development activities worldwide and we will be responsible for certain activities, including being solely responsible for manufacturing activities, all in accordance with an agreed upon development plan. AstraZeneca will be responsible for funding all Phase&#160;1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan), and Phase&#160;2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan) up to a defined dollar threshold. We and AstraZeneca will equally share the costs of Phase&#160;2 clinical development activities in excess of such dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and commercialization activities and instead receive tiered royalties, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We and AstraZeneca will co-commercialize products in the United States in accordance with an agreed upon commercialization plan and budget, and on a product-by-product basis will equally share the U.S. profits or losses arising from such commercialization. Notwithstanding, on a product-by-product basis, prior to a specified stage of development of a given product, we have the right to elect not to participate in the further development and commercialization activities for such product. If we make such election, instead of participating in the U.S. profits and losses share with respect to such product, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2016 AZ Agreement, ranging from percentages in the mid-single digits to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on worldwide net sales of products, subject to certain reductions with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected to not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to tiered royalties at rates ranging from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on ex-U.S. net sales of the products, subject to certain reductions with an aggregate &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;minimum floor. Subject to customary &#x201c;back-up&#x201d; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. We and AstraZeneca have agreed to certain defined exclusivity obligations with each other under the 2016 AZ Agreement with respect to the development and commercialization of mRNA medicines for IL-12. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated, our strategic alliance under the 2016 AZ Agreement will continue on a product-by-product basis (i)&#160;until both parties cease developing and commercializing such product without the intention to resume, if we have not elected our right not to participate in further development and commercialization of such product or (ii)&#160;on a country-by-country basis, until the end of the applicable royalty term for such product in such country, if we have elected our right not to participate in further development and commercialization of such product.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Either party may terminate the 2016 AZ Agreement upon the other party&#x2019;s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2016 AZ Agreement in the event the other party challenges such party&#x2019;s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2016 AZ Agreement in full or with respect to any program for scientific, technical, regulatory or commercial reasons at any time upon &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days&#x2019; prior written notice to us. On a product-by-product basis, we have the right to terminate the 2016 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of such product for a period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;twelve&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca&#x2019;s control. On a product-by-product basis, if the 2016 AZ Agreement is terminated with respect to a given product, AstraZeneca&#x2019;s rights in such product will terminate and, to the extent we terminated for AstraZeneca&#x2019;s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing such product in the oncology field.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If we continue developing and commercializing a given product following termination of the 2016 AZ Agreement by AstraZeneca in its discretion with respect to such product, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of such product and a high-single digit percentage of the amounts received by us from a third party in consideration of a license to such third party to exploit such product, in each case, until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2016 AZ Agreement with respect to such product prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2017 Strategic Alliance with AstraZeneca &#x2013; Relaxin&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2017, we entered a new Collaboration and License Agreement, which we refer to as the 2017 AZ Agreement, under which AstraZeneca may clinically develop and commercialize a development candidate, now known as AZD7970, which is comprised of an mRNA construct for the relaxin protein designed by us and encapsulated in one of our proprietary lipid nanoparticles (LNP). We discovered and performed preclinical development activities for AZD7970 prior to the initiation of the strategic alliance with AstraZeneca under the 2017 AZ Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the 2017 AZ Agreement, we will fund and be responsible for conducting preclinical development activities for AZD7970 through completion of IND-enabling GLP toxicology studies and AstraZeneca will lead pharmacological studies, each in accordance with an agreed upon discovery program plan. During a defined election period that commences as of the effective date of the 2017 AZ Agreement, AstraZeneca may elect to participate in further development and commercialization of AZD7970. Upon such election, AstraZeneca will lead clinical development activities for AZD7970 worldwide and we will be responsible for manufacturing AZD7970, certain regulatory matters and any other development activities that we agree to perform and that are set forth in an agreed upon development plan. AstraZeneca will be responsible for funding Phase&#160;1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared), and Phase&#160;2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared) up to a defined dollar threshold. Thereafter, we and AstraZeneca will equally share the costs of Phase&#160;2 clinical development activities in excess of such defined dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and co-commercialization activities and instead receive tiered royalties as described below. If the development candidate is determined to be IND-ready, and AstraZeneca does not timely elect to participate in the clinical development of AZD7970, AstraZeneca is obligated to reimburse us for certain costs we incurred in the manufacture and development of AZD7970, since execution of the 2017 AZ Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We and AstraZeneca will co-commercialize AZD7970 in the United States in accordance with an agreed upon commercialization plan and budget, and will equally share U.S. profits or losses arising from such commercialization. Notwithstanding, prior to a specified &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;stage of development of AZD7970, we have the right to elect not to participate in the further development and commercialization activities for AZD7970. If we make such election, instead of participating in the U.S. profits and losses share with respect to AZD7970, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2017 AZ Agreement, ranging from percentages in the mid-single digits to the low 20s on worldwide net sales by AstraZeneca of AZD7970, subject to certain reductions, with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to receive tiered royalties at rates ranging from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on annual ex-U.S. net sales of AZD7970, subject to certain reductions with an aggregate minimum floor. Subject to customary &#x201c;back-up&#x201d; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. Additionally, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2017 AZ Agreement with respect to the development and commercialization of mRNA medicines for Relaxin.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated, our strategic alliance under the 2017 AZ Agreement will continue (i)&#160;until the expiration of AstraZeneca&#x2019;s election period, if it does not elect to participate in the clinical development of AZD7970, (ii)&#160;until both parties cease developing and commercializing AZD7970 without the intention to resume, if we have not elected our right not to participate in further development and commercialization of AZD7970, (iii)&#160;on a country-by-country basis, until the end of the applicable royalty term for AZD7970 in such country, if we have elected our right not to participate in further development and commercialization of AZD7970 or (iv)&#160;following completion of IND-enabling studies with respect to AZD7970, if we provide AstraZeneca with written notice that we do not reasonably believe that the product is IND-ready.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Either party may terminate the 2017 AZ Agreement upon the other party&#x2019;s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2017 AZ Agreement in the event the other party challenges the validity or enforceability of such party&#x2019;s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2017 AZ Agreement in full for scientific, technical, regulatory or commercial reasons at any time upon &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days&#x2019; prior written notice to us. We have the right to terminate the 2017 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of AZD7970 for a period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;twelve&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca&#x2019;s control. If AstraZeneca does not timely elect to participate in clinical development of AZD7970, or the Agreement is terminated, AstraZeneca&#x2019;s rights in AZD7970 will terminate and, to the extent we terminated for AstraZeneca&#x2019;s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing AZD7970 in the cardiovascular and cardiometabolic fields.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If we continue developing and commercializing AZD7970 following a termination of the 2017 AZ Agreement by AstraZeneca in its discretion, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of AZD7970 and a high-single digit percentage of the amounts received by us from a third party in consideration for a license to such third party to exploit AZD7970, in each case until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2017 AZ Agreement with respect to AZD7970 prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2013 Agreements with AstraZeneca, amended and restated in 2018 &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2018, we entered into an Amended and Restated Option Agreement and a related Amended and Restated Services and Collaboration Agreement with AstraZeneca, or the 2018 A&amp;amp;R Agreements, which amended and restated the 2013 AZ Agreements. Under the 2018 A&amp;amp;R Agreements, we granted AstraZeneca certain exclusive rights and licenses to research, develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&amp;amp;R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the 2018 A&amp;amp;R Agreements, AstraZeneca is responsible for all research, development and commercialization activities and associated costs, while we provide specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca&#x2019;s activities conducted pursuant to an agreed upon services plan. During this research and evaluation period, these research services, and manufacturing services in excess of a specified threshold, are provided at AstraZeneca&#x2019;s expense, and manufacturing services below the specified threshold are provided at no additional expense to AstraZeneca. AstraZeneca may request we provide additional research and manufacturing services, at AstraZeneca&#x2019;s expense, following the end of the research and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;evaluation period. Subject to customary &#x201c;back-up&#x201d; supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) mRNA for all research, development and commercialization purposes under the 2018 A&amp;amp;R Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2018 A&amp;amp;R Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of the effective date of the 2013 AZ Agreements, and as further reflected in the 2018 A&amp;amp;R Agreements, AstraZeneca acquired &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;forty&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates, AstraZeneca may elect to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca may then exercise one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates) in certain fields. If AstraZeneca does not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca&#x2019;s rights to exercise an option and other rights granted under the 2018 A&amp;amp;R Agreements with respect to such development candidate (and related back-up candidates) will terminate, all rights to exploit such development candidate (and related back-up candidates) will be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) will be either assigned or licensed to us. Upon the earlier of termination of the 2018 A&amp;amp;R Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, will automatically terminate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On a target-by-target basis, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2018 A&amp;amp;R Agreements with respect to the research, development and commercialization of mRNA medicines for such target in certain fields. In addition, we and AstraZeneca have agreed to certain defined exclusivity obligations with respect to the research, development and commercialization of mRNA medicines coding for the same polypeptide as any development candidate being developed under the 2018 A&amp;amp;R Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated, the 2018 A&amp;amp;R Agreements will continue until the expiration of AstraZeneca&#x2019;s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party may terminate the 2018 A&amp;amp;R Agreements upon the other party&#x2019;s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca has the right to terminate the 2018 A&amp;amp;R Agreements for our material breach, then AstraZeneca may elect, in lieu of terminating the 2018 A&amp;amp;R Agreements, in their entirety or with respect to such candidates, to have the 2018 A&amp;amp;R Agreements remain in effect, subject to reductions in certain payments we are eligible to receive and certain adjustments to AstraZeneca&#x2019;s obligations under the 2018 A&amp;amp;R Agreements. AstraZeneca may terminate the 2018 A&amp;amp;R Agreements in full, without cause, upon &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days&#x2019; prior notice to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Treatment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We applied the provisions of ASC 606 (Revenue from Contracts with Customers) in accounting for these arrangements, except for the 2017 AZ Agreement which was accounted for under ASC 808 (Collaborative Arrangements). In August 2016, AstraZeneca exercised a product option available pursuant to the 2013 AZ Agreements to obtain exclusive rights to clinically develop and commercialize the VEGF-A product (AZD8601). This option exercise is referred to as the 2016 VEGF Exercise. Pursuant to ASC 606, we determined that the 2016 VEGF Exercise and the 2017 AZ Agreement should be accounted for as separate transactions as the agreements are not interrelated or interdependent. Conversely, the 2013 Agreements, as amended by the 2018 A&amp;amp;R Agreements, and the 2016 AZ Agreement, were combined for accounting purposes and treated as a single agreement, as these agreements were negotiated in contemplation of each other. We refer to this combined transaction as the Combined 2018 AZ Agreements. We determined that all aspects of Combined 2018 AZ Agreements and the 2016 VEGF Exercise represent a transaction with a customer and therefore is accounted for in accordance with ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Combined 2018 AZ Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We identified the following performance obligations in the Combined 2018 AZ Agreements: (i) a combined performance obligation that includes a research license, research and development pool services, and manufacturing obligations related to the 2013 AZ Agreements, as amended by the 2018 A&amp;amp;R Agreements, collectively referred to as the Combined 2018 AZ Agreement Performance Obligation, (ii) preclinical development services for IL-12, (iii) preclinical development services for an oncology development target, (iv) a combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and (v) a material right to receive development and commercialization rights and manufacturing services for an oncology development target.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We concluded that the research license is not distinct from the research and development pool services or the manufacturing obligations related to the 2018 A&amp;amp;R Agreements, as AstraZeneca cannot fully exploit the value of the research license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Any supply requested by AstraZeneca in excess of the minimum quantities specified in the agreement are considered customer options and treated as separate contracts for accounting purposes. Further, we concluded that AstraZeneca cannot exploit the value of the development and commercialization license for IL-12 without receipt of supply as the development and commercialization license does not convey to AstraZeneca the right to manufacture and therefore combined the development and commercialization license and the manufacturing obligations for IL-12 into one performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the total transaction price was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$399.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million comprised of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$240.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in upfront payments pertaining to the 2013 AZ Agreements and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$159.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million of variable consideration comprised of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$38.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million of estimated reimbursement for IL-12 manufacturing obligations, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of sublicense reimbursement and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$120.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of milestone payments (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; toxicity milestone and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; competition milestone). We utilize the most likely amount method to determine the amount of reimbursement for IL-12 manufacturing obligations to be received. We determined that any sales-based royalties related to IL-12 will be recognized when the related sales occur as they were determined to relate predominately to the license granted and therefore have been excluded from the transaction price. In addition, we are eligible to receive future milestones and royalties on future commercial sales for optioned product candidates under the 2018 A&amp;amp;R Agreements and future royalties under the 2016 Agreement; however, these amounts are not considered variable consideration under the Combined 2018 Agreements as we are only eligible to receive such amounts if AstraZeneca exercises its options (including certain options that are deemed to be material rights). We have concluded that the exercise of an optioned product candidate represents a separate transaction under ASC 606. We re-evaluate the transaction price at the end of each reporting period. There was a $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million decrease to the transaction price during the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, resulting from a change in estimate of variable consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. We developed the estimated standalone selling price for the licenses included in the Combined 2018 AZ Agreement Performance Obligation and the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12 primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the performance obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The estimated standalone selling price of the material right to receive development and commercialization rights and manufacturing services for an oncology development target was developed by estimating the amount of discount that AstraZeneca would receive when exercising the option and adjusting such amount by the likelihood that the option will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the transaction price allocated to each performance obligation is as follows: (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$293.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the Combined 2018 AZ Agreement Performance Obligation, (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the preclinical development services for IL-12 performance obligation, (iii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the preclinical development services for an oncology development target performance obligation, (iv) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$88.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12, and (v) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the material right to receive development and commercialization rights and manufacturing services for an oncology development target. As part of the allocation of the transaction price to each of the performance obligations, we concluded that the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; toxicity milestone and the estimated reimbursement for IL-12 manufacturing costs can be allocated entirely to specific performance obligations because the variable payment relates specifically to our effort to satisfy the performance obligation and such allocation is consistent with the allocation objectives of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the Combined 2018 AZ Agreement Performance Obligation and the preclinical development services for IL-12 and the other oncology target performance obligations. We recognize revenue related to the amounts allocated to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL-12 based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognize revenue for the Combined 2018 AZ Agreement Performance Obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to this combined performance obligation. We also estimate the development plan, including expected demand from AstraZeneca, and the associated costs for this combined performance obligation, as we will satisfy this combined performance obligation as the manufacturing services are performed.&#160;Management has applied significant judgment in the process of developing our budget estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recognized collaboration revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from the Combined 2018 AZ Agreements. The revenue recognized for the three months ended March&#160;31, 2020 includes the amortization of deferred revenue due to the satisfaction of our performance obligation during the period, offset by a cumulative catch-up adjustment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due to changes in estimated costs for our future performance obligations. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$106.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$96.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is expected to be recognized as revenue through December&#160;31, 2029 and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is expected to be recognized as revenue at the earlier of expiration or modification of the Combined 2018 AZ Agreement. We had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$72.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$73.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from the Combined 2018 AZ Agreements, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2016 VEGF Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We concluded that the 2016 VEGF Exercise should be treated as a separate transaction for accounting purposes. We identified one performance obligation in this arrangement which is comprised of the exclusive license to develop and commercialize VEGF and the manufacturing of clinical supply. We concluded that the VEGF license is not distinct from the manufacturing obligations because AstraZeneca cannot fully exploit the value of the license without receipt of such supply. This is due to limitations inherent in the licenses conveyed wherein AstraZeneca does not have the contractual right to manufacture during the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of March 31, 2020, the total transaction price was determined to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; comprised of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in fixed payments pertaining to a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; option exercise fee and a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone achieved prior to the adoption of ASC 606, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; sublicense reimbursement and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of variable consideration related to the estimated reimbursement for clinical supply. We are eligible to receive future milestones and royalties on future commercial sales under this arrangement. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received and the amount of estimated reimbursement for clinical supply. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or AstraZeneca&#x2019;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it is recognized as revenue based on the relative completion of the underlying performance obligation. There was a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; increase to the transaction price during the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, resulting from a change in estimate of variable consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognize revenue related to the amount of the transaction price allocated to the VEGF Exercise performance obligation based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we made a cumulative catch-up adjustment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as a reduction of revenue due to changes in estimated costs for our future performance obligation associated with the 2016 VEGF Exercise. We did not recognize any collaboration revenue from the 2016 VEGF Exercise for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$56.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized as revenue through December&#160;31, 2025. We had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$43.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$41.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively, from the 2016 VEGF Exercise, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the control of the supply is expected to be transferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2017 AZ Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We concluded the 2017 AZ Agreement is under the scope of ASC 808 as we and AstraZeneca are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. Additionally, we determined the development, manufacturing and commercialization activities are not deliverables under ASC 606. As a result, the activities conducted pursuant to the development, manufacturing and commercialization activities are accounted for as a component of the related expense in the period incurred. We considered the guidance in ASC 606 by analogy in determining the appropriate treatment for the transactions between us and AstraZeneca and concluded that reimbursement for transactions in which we are considered to be principal because we control a promised good or service before transferring that good or service to the customer, are accounted for as gross revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We did &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;t recognize any revenue from the 2017 AZ Agreement for both three month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Merck &#x2013; Strategic Alliances in Infectious Diseases and Cancer Vaccines&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2015 Strategic Alliance with Merck&#160;&#x2013; Infectious Disease&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2015, we entered into a Master Collaboration and License Agreement with Merck, which was amended in each of January 2016, June 2016, and May 2019, and which we refer to, as amended, as the 2015 Merck Agreement. Pursuant to the 2015 Merck Agreement, we and Merck have agreed to research, develop, and commercialize potential mRNA medicines for the prevention of infections by RSV. As a part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to conclude the collaboration as it relates to development of potential mRNA medicines for other viruses, including mRNA-1278 for the prevention of VZV infection. Pursuant to the 2015 Merck Agreement, Merck is primarily responsible for research, development, and commercialization activities and associated costs of such research and commercialization. We are responsible for designing and manufacturing all mRNA constructs for preclinical and Phase&#160;1 and Phase&#160;2 clinical development purposes, and Merck pays us for such manufacture, and we are responsible for certain costs associated with the conduct of a Phase 1 clinical trial for an RSV vaccine product candidate (mRNA-1172). Responsibility for manufacturing mRNA constructs for late stage clinical development and commercialization purposes is to be determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The 2015 Merck Agreement includes a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year period, expected to end on January 12, 2022, during which Merck may continue to preclinically and clinically develop RSV vaccine product candidates using mRNA constructs that were initially developed during an initial &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year research period which terminated in January 2019. Merck may, prior to January 12, 2022, elect to exclusively develop and commercialize up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; RSV vaccine product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We and Merck have agreed to certain defined exclusivity obligations during the term of the 2015 Merck Agreement with respect to mRNA investigational medicines against RSV. As part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to certain expectations to the existing exclusivity obligations, pursuant to which we will no longer be restricted from researching, developing, and commercializing an mRNA investigational medicine for the prevention of a specific set of respiratory infections, including RSV, for the pediatric population.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the 2015 Merck Agreement, we received a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment. We are eligible to receive, on a product-by-product basis, up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$300.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in aggregate milestone payments upon the achievement of certain development, regulatory, and commercial milestone events. To date, we have received from Merck a clinical milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with respect to the initiation of a Phase&#160;1 clinical trial for a Merck RSV vaccine product candidate. In addition, under the terms of the 2015 Merck Agreement, we are eligible to receive an additional milestone payment unless Merck elects not to continue with further clinical development of mRNA-1172. On a product-by-product basis, we are also entitled to receive royalties on Merck&#x2019;s net sales of products at rates ranging from the mid-single digits to low teens, subject to certain reductions, with an aggregate minimum floor. Additionally, concurrent with entering into the 2015 Merck Agreement in 2015, Merck made a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equity investment in us, and concurrent with amending the 2015 Merck Agreement in January 2016, we received an upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from Merck.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated, the 2015 Merck Agreement will continue on a product-by-product and country-by-country basis for so long as royalties are payable by Merck on a given product in a given country. Either party may terminate the 2015 Merck Agreement upon the other party&#x2019;s material breach, either in its entirety or with respect to a particular program, product candidate, product or country, subject to specified notice and cure provisions. Merck may terminate the 2015 Merck Agreement in full or with respect to a particular product candidate or product upon certain advance notice to us for any reason, or earlier if Merck determines the alliance or product is no longer commercially practicable. If Merck has the right to terminate the 2015 Merck Agreement, in its entirety or with respect to a program, product candidate or product, for our material breach, then Merck may elect, in lieu of terminating the 2015 Merck &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Agreement, to have the 2015 Merck Agreement remain in effect, subject to reductions in certain payments we are eligible to receive with respect to the terminable rights. Upon a termination of the 2015 Merck Agreement with respect to a program, all licenses and other rights granted to Merck with respect to such program will terminate and the continued development and commercialization of product candidates and products will revert to us. If the 2015 Merck Agreement is terminated with respect to a given product candidate or product, all licenses and other rights granted to Merck with respect to such product candidate or product will terminate and, to the extent we terminated for Merck&#x2019;s breach, Merck will grant us licenses under select Merck technology for our continued development and commercialization of such product candidate or product. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Treatment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determined that all aspects of amended 2015 Merck Agreement represent a transaction with a customer and therefore the amended 2015 Merck Agreement is accounted for in accordance with ASC 606. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year research period was complete as of December 31, 2018 and we recognized the total transaction price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$65.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;in aggregate upfront payments and a&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;payment pertaining to achievement of a development milestone) in full as we concluded there were no unsatisfied performance obligations pertaining to the amended 2015 Merck Agreement. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) research services during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year period following the initial &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year research period during which Merck may continue to preclinically and clinically develop product candidates and (ii) clinical mRNA supply for Phase 1 and Phase 2 and/or non-cGMP mRNA supply beyond the initial &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year research period. Therefore, such options will be accounted for as a separate contract upon the customer&#x2019;s election. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Merck&#x2019;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;After completion of the initial &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year research period, and as part of the May 2019 amendment of the 2015 Merck Agreement, Merck elected to establish a new RSV vaccine product candidate and elected to conduct a Phase 1 clinical trial. We are responsible for certain costs associated with the conduct of the Phase 1 clinical trial.&#160;We determined that our obligation under the May 2019 amendment to reimburse Merck for certain costs associated with the RSV vaccine Phase 1 clinical trial represents consideration payable to a customer and is accounted for as a reduction of the transaction price. The consideration amount is determined based on the most likely method and recorded as contra-revenue as costs are incurred. The one-time payment upon election by Merck to continue developing RSV is fully constrained as it is contingent upon completion of the RSV Phase 1 clinical trial and upon decisions to be made by Merck to continue development thereafter. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. For the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; deduction to the transaction price related to reimbursements paid to Merck for RSV vaccine Phase I clinical trial costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We had no deferred revenue as of March 31, 2020 or December 31, 2019 from the amended 2015 Merck Agreement as all performance obligations under the amended 2015 were completed as of December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognized contra-revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the three months ended March 31, 2020, related to consideration payable to Merck under the May 2019 Amendment. We recognized collaboration revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the three months ended March 31, 2019, pursuant to separate agreements with Merck related to the exercise of customer options to purchase clinical mRNA supply to further develop a product candidate after the initial &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year research period. Clinical mRNA supply is recognized as collaboration revenue at a point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2016 Cancer Vaccine Strategic Alliance&#x2014;Personalized mRNA Cancer Vaccines&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck, which we refer to as the PCV Agreement, to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient&#x2019;s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient&#x2019;s immune system against her or his own cancer cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase&#160;1 and Phase&#160;2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#x2019;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna&#x2019;s manufacture and supply activities. We received an upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$200.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from Merck. In November 2017, we and Merck announced the achievement of a key milestone for the first-in-human dosing of a PCV (mRNA-4157) as a part of the alliance. The Phase&#160;1 open-label, dose escalation, multicenter clinical trial in the United States (KEYNOTE-603) is designed to assess the safety, tolerability and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with KEYTRUDA, in subjects with unresectable solid tumors.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for PCVs under the PCV Agreement and delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of PCVs by making a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; participation payment to us. If Merck exercises its election and pays the participation payment, then the parties will equally co-fund subsequent clinical development of PCVs, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. Each party may also conduct additional clinical trials for PCVs that are not included in the jointly agreed development plan and budget, in which case the non-conducting party will reimburse the conducting party for half of the total costs for such trials, plus interest, from its share of future profits resulting from sales of such PCVs, if any. Merck will lead worldwide commercialization of PCVs, subject to Moderna&#x2019;s option to co-promote PCVs in the United States, and the parties will equally share the profits or losses arising from worldwide commercialization. Until a PCV becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of such PCV, if any. Subject to customary &#x201c;back-up&#x201d; supply rights granted to Merck, we will manufacture (or have manufactured) PCVs for preclinical and clinical purposes. Manufacture of PCVs for commercial purposes will be determined by the parties in accordance with the terms of the PCV Agreement. Under the PCV Agreement, we grant certain licenses to Merck to perform its collaboration activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If Merck does not exercise its right to participate in future development and commercialization of PCVs, then Moderna will retain the exclusive right to develop and commercialize PCVs developed during the strategic alliance, subject to Merck&#x2019;s rights to receive a percentage in the high teens to the low 20s, subject to reductions of our net profits on sales of such PCVs. During a limited period following such non-exercise, Merck has the right to perform clinical studies of such PCVs in combination with KEYTRUDA, for which we agree to use reasonable efforts to supply such PCVs. During such limited period, we also have the right to perform clinical studies of PCVs in combination with KEYTRUDA, for which Merck agrees to use reasonable efforts to supply KEYTRUDA. In addition, following its non-exercise, Merck is also entitled to receive a percentage in the high teens to the low 20s, subject to reductions, of our net profits on sales of certain PCVs first developed by us following such non-exercise and reaching a specified development stage within a defined period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We and Merck have agreed to certain defined, limited exclusivity obligations with respect to the development and commercialization of PCVs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2018 Expansion of the Cancer Vaccine Strategic Alliance&#x2014;Shared Neoepitope Cancer Vaccines &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671 or V941, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events. Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCV increased to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$243.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. If Merck exercises its participation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;rights, then the parties will equally co-fund subsequent clinical development of mRNA-5671, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. If Merck declines to participate in future development and commercialization activities following the initial Phase 1 and Phase 2 clinical trials for mRNA-5671, then we will retain the rights to develop and commercialize mRNA-5671. If Merck elects to participate in future development and commercialization of mRNA-5671, Merck may also conduct additional clinical trials for mRNA-5671 that are not included in the jointly agreed development plan and budget, in which case we will reimburse Merck for half of the total development costs for such clinical trials, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. If Merck does conduct additional clinical trials for mRNA-5671, we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials. Merck will lead worldwide commercialization of mRNA-5671, subject to our option to co-promote mRNA-5671 in the United States, and the parties will equally share the operating profits or losses arising from worldwide commercialization. Until mRNA-5671 becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. Subject to &#x201c;back-up&#x201d; supply rights granted to Merck, we will manufacture (or have manufactured) mRNA-5671 and other SAVs for preclinical and clinical purposes. After Merck exercises its right to participate in future development and commercialization of mRNA-5671 and other SAVs, we will grant the applicable development and commercialization licenses and the parties are obligated to discuss responsibility for future manufacturing, giving consideration to applicable criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the PCV/SAV Agreement, for a defined period of time, either party may propose that the parties conduct additional programs for the research and development of SAVs directed to different shared neoantigens. If the parties agree to conduct any such programs, then we will be responsible for conducting and funding preclinical discovery and research activities for such SAVs, and otherwise the programs would be conducted on substantially the same terms as mRNA-5671 program. If we or Merck propose a new SAV program and the other party does not agree to conduct such program, then the PCV/SAV Agreement includes provisions allowing the proposing party to proceed with such development, at the proposing party&#x2019;s expense. If Merck is the proposing party, we will be responsible for manufacturing and supplying material for such program at Merck&#x2019;s expense. In such case, the non-proposing party will have the right to opt-in to such SAV program any time before the proposing party commits to performing Good Laboratory Practice (GLP)-toxicity studies. Until the expiration of a defined period of time following our completion of Phase&#160;1 and Phase&#160;2 clinical trials for any SAV program mutually agreed by the parties under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of such SAV by making a participation payment to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated, the PCV/SAV Agreement will continue on a program-by-program basis until Merck terminates its participation in such program. Following any such termination, we will retain the exclusive right to develop and commercialize PCVs or SAVs developed as a part of such program, subject to restrictions and certain limited rights retained by Merck.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$125.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is determined to be a premium and recorded to deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Treatment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determined that the PCV/SAV Agreement should be accounted for separately from the amended 2015 Merck Agreement, as the agreements were not negotiated in contemplation of one another and the elements within each of the agreements are not closely interrelated or interdependent on each other. We determined that all aspects of the PCV/SAV Agreement represent a transaction with a customer and therefore the PCV/SAV Agreement is accounted for in accordance with ASC 606. In addition, the equity investment in our Series H redeemable convertible preferred stock was considered together with the PCV/SAV Agreement as the transactions were executed contemporaneously in contemplation of one another. Further, the purchase price paid by Merck with respect to the investment in the Series H redeemable convertible preferred stock was not representative of fair value on the date of such purchase. As such, the incremental proceeds received in excess of the fair value of the underlying stock related to the equity investment were included in the transaction price related to the PCV/SAV Agreement and the shares of Series H redeemable convertible preferred stock purchased by Merck were recorded at their respective fair value on the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We identified the following performance obligations in the PCV/SAV Agreement: (i) a research license and research and development services, including manufacturing and supply of PCVs, during the proof of concept (POC) term for the PCV program, referred to as the PCV Performance Obligation, and (ii) research license and manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, referred to as the KRAS Performance Obligation. We concluded that the research license is not distinct from the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, as Merck cannot fully exploit the value of the license without receipt of such services and supply. Our services and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the research license has been combined with the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, into a single performance obligation. Similarly, we concluded that the research license is not distinct from the manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, as Merck cannot fully exploit the value of the license without receipt of such supply which must be provided by us. This is due to limitations inherent in the licenses conveyed wherein Merck does not have the contractual right to manufacture during the POC term. Therefore, the research license has been combined with the manufacturing and supply of mRNA-5671, during the POC term for the KRAS program, into a single performance obligation. Conversely, we concluded that the PCV Performance Obligation and the KRAS Performance Obligation are distinct from each other because Merck can fully exploit the value of each program for its intended purpose without the promises associated with the other program. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Merck participation election license related to future joint development and commercialization on a program-by-program basis, (ii) manufacturing and supply in support of certain SAV programs and/or the PCV program upon Merck election to not participate in future development and commercialization of that program and (iii) research and development services associated with certain SAV programs. Therefore, such options will be accounted for as a separate contract upon the customer&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the total transaction price was determined to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$213.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; comprised of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$200.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment pertaining to the PCV Agreement, the premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and a variable consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to a reimbursement for clinical supply. We determined there are no other components of variable consideration that should be included in the transaction price as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as additional consideration to which we could be entitled is subject to Merck&#x2019;s election to exercise a customer option that was deemed to be a marketing offer. We re-evaluate the transaction price at the end of each reporting period. During the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; increase to the transaction price from a reimbursement for clinical supply. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The transaction price was allocated to the performance obligations based on the relative estimated standalone selling price of each performance obligation. We developed the estimated standalone selling price for the license included in each of the PCV Performance Obligation and the KRAS Performance Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a development candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the PCV Performance Obligation and the KRAS Performance Obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated cost, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the transaction price allocated to each performance obligation is as follows: (i) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$206.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the PCV Performance Obligation and (ii) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; allocated to the KRAS Performance Obligation. We will recognize revenue related to amounts allocated to the PCV Performance Obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of research and development efforts. We recognize revenue related to the amounts allocated to the KRAS Performance Obligation based on the point in time upon which control of supply is transferred to Merck for each delivery of the associated supply. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recognized collaboration revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, in the condensed consolidated statements of operations, from the Merck PCV/SAV Agreement. The revenue recognized during the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; includes the amortization of deferred revenue due to the satisfaction of our performance during the period, offset by a cumulative catch-up adjustment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due to changes in estimated costs for our future performance obligations. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$81.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized as revenue through December&#160;31, 2024. We had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$81.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$83.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2019, respectively, from the Merck PCV/SAV Agreement, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Vertex &#x2013; 2016 Strategic Alliance in Cystic Fibrosis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2016, we entered into a Strategic Collaboration and License Agreement, with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex, which we refer to as the Vertex Agreement. The Vertex Agreement, which was amended in July 2019, which we refer to as the 2019 Vertex Amendment, is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional CFTR proteins.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period that was extended through March 2020, leveraging our Platform technology and mRNA delivery expertise along with Vertex&#x2019;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#x201c;back-up&#x201d; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. The parties established a joint steering committee to oversee and coordinate activities under the Vertex Agreement. We and Vertex have granted each other certain licenses under the Vertex Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Vertex Agreement, we received a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Vertex. In July 2019, Vertex elected to extend the initial &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year research period by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; pursuant to the 2019 Vertex Amendment. In March 2020, based on the promising preclinical data generated to date, Vertex extended the conduct of the initial Research Plan through the First Extended Research Term (an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-month term) by making an additional payment to us. Vertex has rights to further extend the research period for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year periods by making an additional payment to us for each &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year extension. We are eligible to receive up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$55.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments for achievement of development milestones, up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$220.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments for achievement of regulatory milestones and potentially could receive an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payment for achievement of a regulatory milestone for a second and each subsequent product under the Vertex Agreement. Vertex will also pay us tiered royalties at rates ranging from the low- to high-teens on worldwide net sales of products arising from the strategic alliance, subject to certain reductions, with an aggregate minimum floor. In connection with the strategic alliance, Vertex also made a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equity investment in us. During the term of the Vertex Agreement, we and Vertex have agreed to certain defined exclusivity obligations under the Vertex Agreement with respect to the development and commercialization of certain mRNA medicines.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated, the Vertex Agreement will continue until the expiration of all royalty terms. Vertex may terminate the Vertex Agreement for convenience upon &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;days&#x2019; prior written notice, except if termination relates to a product in a country where Vertex has received marketing approval, which, in such case, Vertex must provide &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days&#x2019; prior written notice. Either party may terminate the Vertex Agreement upon the other party&#x2019;s material breach, subject to specified notice and cure provisions. Each party may also terminate the Vertex Agreement in the event that the other party challenges the validity or enforceability of such party&#x2019;s patent rights, subject to certain exceptions, or if the other party becomes insolvent.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Treatment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, all performance obligations under the 2019 Vertex Amendment were completed and the total transaction price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, comprised of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in research and development funding related to the research and development services and supply of non-cGMP mRNA, was fully recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The First Extended Research Term represents a contract modification and is accounted for as a separate contract. Pursuant to the 2019 Vertex Amendment, we identified one performance obligation comprised of: (i) a research, development and commercialization license and (ii) research and development services, including manufacturing and supply of non-cGMP mRNA, during the 18-month First Extended Research Term. We concluded that the license is not distinct from the research and development services, including manufacturing and supply of non-cGMP mRNA. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Vertex&#x2019;s rights to extend the extended initial research period and (ii) clinical mRNA supply and/or non-cGMP mRNA supply beyond the extended initial research period. Therefore, such options will be accounted for as a separate contract upon the customer&#x2019;s election. The total transaction price was determined to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, comprised of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$31.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in research and development funding related to the research and development services and supply of non-cGMP mRNA. We utilize the most likely amount method to determine the amount of research and development funding to be received. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there were no milestones included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Vertex&#x2019;s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any sales-&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For each of the Vertex Agreement, the 2019 Vertex Amendment and the First Extended Research Term, the total transaction price was allocated entirely to a single performance obligation. We recognize revenue related to amounts allocated to the single performance obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of the research and development efforts.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recognized collaboration revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, in the condensed consolidated statements of operations, from Vertex. The revenue recognized during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; includes the amortization of the deferred revenue due to the satisfaction of our performance during the period. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized as revenue through the third quarter of 2021. We had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of March 31, 2020 and December 31, 2019, respectively, from the First Extended Research Term and the 2019 Vertex Amendment, classified as current and non-current in the condensed consolidated balance sheets based on the term of the research period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_MerckMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e587-wk-Fact-646D392203E534A7D993B8937FEEC90A"
      unitRef="usd">976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_MerckMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e606-wk-Fact-0B3484A4BAFA64DB46F4B8937FEE7FDD"
      unitRef="usd">10687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_AstraZenecaMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e626-wk-Fact-17F6BE1275DD91B32178B8937FEA4DAC"
      unitRef="usd">1270000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_AstraZenecaMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e645-wk-Fact-74D8BFD4C496081A8206B8937FE92A40"
      unitRef="usd">814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_VertexMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e670-wk-Fact-A89D2F7AC7533CB03DADB8937FE97269"
      unitRef="usd">2056000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_VertexMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e689-wk-Fact-4F27FDCCFA8E7004B2EDB8937FE92E8D"
      unitRef="usd">2614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_us-gaap_OtherCustomerMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e714-wk-Fact-78951C05862A62D12312B9042F412202"
      unitRef="usd">155000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_us-gaap_OtherCustomerMember_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e733-wk-Fact-D6EDFFB704B7261E7FCFB90431DBA447"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e763-wk-Fact-10F0573C700FD5975884B8937FECBCF1"
      unitRef="usd">4457000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember"
      decimals="-3"
      id="d8095399e782-wk-Fact-1B459A0622B6A1258B53B8937FEF27AD"
      unitRef="usd">14115000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-8F6E3BD3000261275805B893802744F7-0-wk-Fact-7FE711520D1B14027B8BB8937FEA2FA2">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contract Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,972&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contract Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;199,528&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts included in contract liabilities at the beginning of the period &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Performance obligations satisfied (or partially satisfied) in previous reporting periods &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period is first applied to the beginning contract liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Related to changes in estimated costs for our future performance obligations and estimated variable considerations. &lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8095399e1025-wk-Fact-48ADE55B44DEB2442486B8937FF376E3"
      unitRef="usd">1972000</us-gaap:ContractWithCustomerAssetNet>
    <mrna:ContractWithCustomerAssetIncreaseDuringPeriod
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8095399e1044-wk-Fact-27DA581A7B8CABC67384B8937FF18885"
      unitRef="usd">10718000</mrna:ContractWithCustomerAssetIncreaseDuringPeriod>
    <mrna:ContractWithCustomerAssetDecreaseDuringPeriod
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8095399e1064-wk-Fact-E8195B73C75A372BC6F6B8937FF13DA4"
      unitRef="usd">9370000</mrna:ContractWithCustomerAssetDecreaseDuringPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8095399e1084-wk-Fact-B828A4899FA01EBE8C7FB8937FF3093A"
      unitRef="usd">3320000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8095399e1196-wk-Fact-4C59C3B06DA5E210A32BB8937FF09974"
      unitRef="usd">199528000</us-gaap:ContractWithCustomerLiability>
    <mrna:ContractWithCustomerLiabilityIncreaseDuringPeriod
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8095399e1215-wk-Fact-B05CDA23840C03740C9DB8937FF46BE7"
      unitRef="usd">7377000</mrna:ContractWithCustomerLiabilityIncreaseDuringPeriod>
    <mrna:ContractWithCustomerLiabilityDecreaseDuringPeriod
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8095399e1235-wk-Fact-62B10A9445F6FEC54315B8937FF38E9C"
      unitRef="usd">6304000</mrna:ContractWithCustomerLiabilityDecreaseDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8095399e1255-wk-Fact-EFDA87A74015F6F4DF53B8937FF25399"
      unitRef="usd">200601000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8095399e1334-wk-Fact-C257A3F8B921D3135F13B8937FEB98A1"
      unitRef="usd">6304000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d8095399e1356-wk-Fact-32EDD6D7169019316638B9062F59B291"
      unitRef="usd">1262000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1"
      decimals="-5"
      id="d8095399e1394-wk-Fact-E32F0A224F784655402CB8937FE7AA6B"
      unitRef="usd">278800000</us-gaap:RevenueRemainingPerformanceObligation>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions
      contextRef="FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="INF"
      id="d8095399e1419-wk-Fact-DDBDF7208B30A363AEFEB8937FD5C469"
      unitRef="option">40</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions>
    <us-gaap:DeferredRevenueAdditions
      contextRef="D2013Q1Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="-5"
      id="d8095399e1428-wk-Fact-D18D008B312C52770F03B8937FE60F26"
      unitRef="usd">240000000.0</us-gaap:DeferredRevenueAdditions>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="INF"
      id="d8095399e1432-wk-Fact-D8595CCE768830509F9EB8937FEC3DF8"
      unitRef="usd">180000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones
      contextRef="FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="INF"
      id="d8095399e1436-wk-Fact-514ED0301FDA8ACFEF17B8937FD34D05"
      unitRef="milestone">3</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee
      contextRef="D2013Q1Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="-5"
      id="d8095399e1443-wk-Fact-663AC28F1028B2457C22B8937FD034A0"
      unitRef="usd">10000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_DevelopmentMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="INF"
      id="d8095399e1447-wk-Fact-855460463B89F33F8FA4B8937FDA767C"
      unitRef="usd">100000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="INF"
      id="d8095399e1451-wk-Fact-3A6FAEB780B506734E8DB8937FEB63B0"
      unitRef="usd">100000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="FI2013Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_CommercialMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="INF"
      id="d8095399e1455-wk-Fact-D1C898F2D9294CFB04D8B8937FE1A8BB"
      unitRef="usd">200000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent
      contextRef="D2013Q1Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="INF"
      id="d8095399e1459-wk-Fact-0528470DA4291F523EEFB8937FD05917"
      unitRef="number">0.12</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent>
    <us-gaap:DeferredRevenueAdditions
      contextRef="FD2016Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="-5"
      id="d8095399e1468-wk-Fact-8C6F39882D57140D1B1AB8937FE113DA"
      unitRef="usd">10000000.0</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions
      contextRef="FD2018Q4YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_VEGFAProductAZD8601Member_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="-5"
      id="d8095399e1472-wk-Fact-FCBD1BF1AC92AC5A006DB8937FCA9DCF"
      unitRef="usd">30000000.0</us-gaap:DeferredRevenueAdditions>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
      contextRef="D2013Q1Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      id="d8095399e1476-wk-Fact-E266903A4A370DB902D3B8937FE3C873">P90D</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent
      contextRef="D2016Q1Jan31az_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member"
      decimals="INF"
      id="d8095399e1509-wk-Fact-C33C9C748DA3ACA8CD9AB8937FE8690B"
      unitRef="number">0.20</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent
      contextRef="D2016Q1Jan31az_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member"
      decimals="INF"
      id="d8095399e1513-wk-Fact-F58398A9AB1BF625C735B8937FE1073D"
      unitRef="number">0.10</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent
      contextRef="D2016Q1Jan31az_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member"
      decimals="INF"
      id="d8095399e1517-wk-Fact-ED6C21CC95E2BA3B6AA9B8937FCDD786"
      unitRef="number">0.30</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
      contextRef="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2016StrategicAllianceWithAstraZenecaIL12Member"
      id="d8095399e1535-wk-Fact-404BB5F0A84143D04466B8937FD6422D">P90D</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent
      contextRef="D2017Q4Oct31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember"
      decimals="INF"
      id="d8095399e1572-wk-Fact-7D5E94E90CAF9EFC7F42B8937FCF27E9"
      unitRef="number">0.10</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent
      contextRef="D2017Q4Oct31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember"
      decimals="INF"
      id="d8095399e1576-wk-Fact-31B27E1086D2A4251EB7B8937FE30197"
      unitRef="number">0.30</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
      contextRef="D2017Q4Oct31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember"
      id="d8095399e1591-wk-Fact-161C0C3FD52DD31BF4AAB8937FE5D8F3">P90D</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions
      contextRef="FI2018Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember"
      decimals="INF"
      id="d8095399e1629-wk-Fact-58B4278961ACA99DD384B8937FED5135"
      unitRef="option">40</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
      contextRef="D2018Q2Jun30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember"
      id="d8095399e1645-wk-Fact-6A20D70245CD4EF99FF9B8937FDF0174">P90D</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="-5"
      id="d8095399e1687-wk-Fact-C8901E75D05FB4136470B8937FE6D478"
      unitRef="usd">399100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"
      decimals="-5"
      id="d8095399e1691-wk-Fact-D06EC71F8C0D0BCCCEAEB8937FCC5414"
      unitRef="usd">240000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1695-wk-Fact-2732109D8D858E673146B8937FE78146"
      unitRef="usd">159100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_EstimatedReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1699-wk-Fact-82D969DC55D8A0A8CEA3B8937FDA11EB"
      unitRef="usd">38100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_SublicenseReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1704-wk-Fact-7CEAD9B43FC0FAFAD93AB90B532A7BA6"
      unitRef="usd">1000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1708-wk-Fact-BBFF5CFA0E121EFAB2D7B8937FE1F84F"
      unitRef="usd">120000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_ToxicityMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1712-wk-Fact-73A1E84B040A8323711DB8937FD6DDB5"
      unitRef="usd">60000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_CompetitionMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1716-wk-Fact-3C1DCF20DE62930D548DB8937FDBB708"
      unitRef="usd">60000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1720-wk-Fact-7D991998C182578BB705B8937FDEDC0E"
      unitRef="usd">2700000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_Combined2018AZAgreementPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1743-wk-Fact-BA006375B8B55183A31EB8937FE23D5C"
      unitRef="usd">293200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_IL12PerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1747-wk-Fact-E673D9E2DD23120EAF6AB8937FDBC43C"
      unitRef="usd">8100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_OncologyDevelopmentTargetPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1751-wk-Fact-1A092AC54781E6958094B8937FEEBF3B"
      unitRef="usd">8100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1755-wk-Fact-6EF0AD86F675D707CAFDB8937FE5A2C3"
      unitRef="usd">88100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1760-wk-Fact-3440B26C1857FFCE9FA8B8937FCDE082"
      unitRef="usd">1600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_ToxicityMilestonesMember_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1764-wk-Fact-73A1E84B040A8323711DB8937FD6DDB5"
      unitRef="usd">60000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1792-wk-Fact-DF0639800F167A4D2B8CB8937FECCD17"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1796-wk-Fact-40E6A1B23FDA8D7CDC54B8937FD983CF"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1800-wk-Fact-715E6B3636E002D47A8EB91258C41124"
      unitRef="usd">1400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1809-wk-Fact-782F8254F50C0A051928B8937FE95171"
      unitRef="usd">106100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      decimals="-5"
      id="d8095399e1813-wk-Fact-B5AFE9DFFBE1B603CB68B8937FDF15C6"
      unitRef="usd">96400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2028-01-01"
      decimals="-5"
      id="d8095399e1817-wk-Fact-1AED75941B2F6C6AD0E9B8937FE6383F"
      unitRef="usd">9700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1821-wk-Fact-B06F1AE95F822C67F853B8937FD7E690"
      unitRef="usd">72600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember"
      decimals="-5"
      id="d8095399e1825-wk-Fact-E7121FEE29888736E0A5B8937FD88DA5"
      unitRef="usd">73700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1854-wk-Fact-4CBCF2736547EE40B840B8937FE424AC"
      unitRef="usd">60300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_FixedPaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1858-wk-Fact-F18C57600CF828D7F7C0B8937FD196FD"
      unitRef="usd">40000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_OptionExerciseFeeMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1862-wk-Fact-2E7A325E462F395B70DAB8937FE9D1DA"
      unitRef="usd">10000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1866-wk-Fact-8902D77BA883EA255A46B8937FE4F402"
      unitRef="usd">30000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_SublicenseReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1870-wk-Fact-BEAA312ECCF998D27934B9108D012A15"
      unitRef="usd">2300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1875-wk-Fact-2F0D9B6FAB0871E7A3ABB8937FDCFDC8"
      unitRef="usd">18000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="FD2020Q1YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_VariableConsiderationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1883-wk-Fact-673D6B0FB6C8F01EC6F5B8937FE6DABA"
      unitRef="usd">2400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="FD2020Q1QTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1905-wk-Fact-4192B08047CD8DB1003DB912DA6D6249"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      decimals="-5"
      id="d8095399e1917-wk-Fact-918106269F43F6E7E30DB8937FDB59A8"
      unitRef="usd">56500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1922-wk-Fact-7CE8F6CC8D0CF1848630B90E3B77988B"
      unitRef="usd">43000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_VEGFExercise2016Member"
      decimals="-5"
      id="d8095399e1926-wk-Fact-2527D24F249ABE4BE9F3B8937FE24DAE"
      unitRef="usd">41200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember"
      decimals="INF"
      id="d8095399e1953-wk-Fact-3E69DFDB4BACF95F01E7B8937FEAEFC2"
      unitRef="usd">0</us-gaap:Revenues>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates
      contextRef="I2019Q2May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="INF"
      id="d8095399e1994-wk-Fact-41F73C1C9366250586CCB8937FE330A9"
      unitRef="candidate">5</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="D2019Q2May31Merck_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="-5"
      id="d8095399e2009-wk-Fact-DE7E5C5FF2A0606B437FB8937FE4558A"
      unitRef="usd">50000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="I2019Q2May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="INF"
      id="d8095399e2013-wk-Fact-51260550C48A65FDBC05B8937FD8E3A0"
      unitRef="usd">300000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2019Q2May31Merck_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_MilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="-5"
      id="d8095399e2017-wk-Fact-47DC2CE71EF1F9F72CEBB8937FE52DB5"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="D2015Q1Jan31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="-5"
      id="d8095399e2021-wk-Fact-3E0EB87FE34BA8B8813DB8937FDA03AB"
      unitRef="usd">50000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredRevenueAdditions
      contextRef="D2016Q1Jan31az_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="-5"
      id="d8095399e2025-wk-Fact-120378EEDE8DA2FFA378B8937FCB9209"
      unitRef="usd">10000000.0</us-gaap:DeferredRevenueAdditions>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="-5"
      id="d8095399e2051-wk-Fact-890A73ED9B6A86F90FA2EF959F15405E"
      unitRef="usd">65000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="-5"
      id="d8095399e2055-wk-Fact-C7AEB3E71E310F1145E8B922DCE3D4BB"
      unitRef="usd">60000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentResearchAndDevelopmentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="-5"
      id="d8095399e2059-wk-Fact-D739219F0F687C37E489B92388B82CED"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member"
      decimals="-5"
      id="d8095399e2093-wk-Fact-CB867DB9A0052B680F32B8937FE60D86"
      unitRef="usd">-2100000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_SeparateAgreementsWithMerckMember"
      decimals="-5"
      id="d8095399e2108-wk-Fact-2A503B7C2CC4826B01B4B8937FDFBD94"
      unitRef="usd">-2100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_SeparateAgreementsWithMerckMember"
      decimals="-5"
      id="d8095399e2112-wk-Fact-1C872250E7E8E9BB0A2FB926F472CEA3"
      unitRef="usd">-500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenueAdditions
      contextRef="D2016Q2Jun30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"
      decimals="-5"
      id="d8095399e2135-wk-Fact-11084AB72BD9D3E9A9FDB8937FE88C0D"
      unitRef="usd">200000000.0</us-gaap:DeferredRevenueAdditions>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="FI2016Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"
      decimals="-5"
      id="d8095399e2144-wk-Fact-F5DF3A5439791F96A8CAB8937FEE6E20"
      unitRef="usd">250000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="I2018Q2Apr30_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2174-wk-Fact-B7994025CF5C2D92B447B8937FD038E7"
      unitRef="usd">243000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="D2018Q2Apr30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesHPreferredStockMember"
      decimals="-5"
      id="d8095399e2197-wk-Fact-F1CF7116F44F58C1E720B8937FCA406D"
      unitRef="usd">125000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RedemptionPremium
      contextRef="D2018Q2Apr30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesHPreferredStockMember"
      decimals="-5"
      id="d8095399e2201-wk-Fact-56FFDE19FD752E2DFF07B8937FE7A7B4"
      unitRef="usd">13000000.0</us-gaap:RedemptionPremium>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2233-wk-Fact-791E24C3A0A4CECF8D28B8937FEBEF5A"
      unitRef="usd">213300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2237-wk-Fact-C36EBE5BA0F0293C1ABAB8937FEA8F57"
      unitRef="usd">200000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2241-wk-Fact-5A5E76E7C4B52842BE2EB8937FE5EE3F"
      unitRef="usd">13000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ClinicalSupplyReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2245-wk-Fact-A4C1078CA1F4BBB0802EB92AF362AA72"
      unitRef="usd">300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="FD2020Q1YTD_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ClinicalSupplyReimbursementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2258-wk-Fact-DAE7FCA003F9B2DA3ED3B92D25A7040E"
      unitRef="usd">300000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_PCVPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2276-wk-Fact-5AC64EBC33C3432E0C1EB8937FE154B3"
      unitRef="usd">206300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_mrna_PerformanceObligationAxis_mrna_KRASPerformanceObligationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2280-wk-Fact-9AF5CE071E8A7F678581B8937FE6ACC7"
      unitRef="usd">7000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2297-wk-Fact-6DA4669489D8C51D0924B8937FEAFD46"
      unitRef="usd">3100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2301-wk-Fact-9BF9212ED6D2E0B67BDCB8937FD9A559"
      unitRef="usd">10200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2310-wk-Fact-0B35B33C2EE73FAA64C2B92DCBBFB24D"
      unitRef="usd">3500000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      decimals="-5"
      id="d8095399e2318-wk-Fact-5675E1E6289359354BD3B8937FE2775D"
      unitRef="usd">81000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2322-wk-Fact-17A42DA8A47E2BBB09F7B8937FDFE915"
      unitRef="usd">81000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember"
      decimals="-5"
      id="d8095399e2326-wk-Fact-C3462CD0DEDE329D4E7AB8937FCE4F22"
      unitRef="usd">83800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueAdditions
      contextRef="D2016Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2356-wk-Fact-3FFBCC956A66095209D3B8937FE8F0C7"
      unitRef="usd">20000000.0</us-gaap:DeferredRevenueAdditions>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod
      contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      id="d8095399e2368-wk-Fact-2709811FAB3D85E2B070B8937FD82581">P18M</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods
      contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="INF"
      id="d8095399e2372-wk-Fact-BDCDB61C509E8BBD4844B8937FEEFA79"
      unitRef="extension_period">2</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_DevelopmentMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="INF"
      id="d8095399e2385-wk-Fact-7548D5A448F8123AB5B3B8937FEFE66B"
      unitRef="usd">55000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="INF"
      id="d8095399e2389-wk-Fact-AA071A26EA48D3606DDBB8937FED7CED"
      unitRef="usd">220000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="I2019Q2July31_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis_mrna_RegulatoryMilestonesSubsequentProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="INF"
      id="d8095399e2393-wk-Fact-E813C2A0B11A39EFA2CAB8937FE1B112"
      unitRef="usd">3000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2397-wk-Fact-E26EFF6FB8FBA02CB86FB8937FECB8CA"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
      contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      id="d8095399e2407-wk-Fact-69C38881F7A2556F0F22B8937FE6624E">P90D</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod
      contextRef="D2019Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      id="d8095399e2411-wk-Fact-8E4B5C3131936782F640B8937FE4611A">P180D</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2430-wk-Fact-39B08D1B2F781B7874D1B8937FD619F8"
      unitRef="usd">4500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2434-wk-Fact-0FD20852246F0EC91A4BB8937FDFC810"
      unitRef="usd">2000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ResearchAndDevelopmentFundingMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2438-wk-Fact-70256660A3AAFCFF8467B8937FD5025D"
      unitRef="usd">2500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2447-wk-Fact-A461051FEDE185F1587AC3C9718895CF"
      unitRef="usd">35200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q4_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2451-wk-Fact-D4F424880D96C724CCA8C3C9AEC496E2"
      unitRef="usd">4000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q4_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_ResearchAndDevelopmentFundingMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2455-wk-Fact-CEE17C40854A0D5B71B1C3C9D7BE1055"
      unitRef="usd">31200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2484-wk-Fact-086AC0D814D425C81D9BB8937FE36039"
      unitRef="usd">2100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2488-wk-Fact-70081FACA1A4BAD7AD25B8937FD563D7"
      unitRef="usd">2600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01"
      decimals="-5"
      id="d8095399e2505-wk-Fact-99C16C4F1716A0DB8F50B8937FE049EB"
      unitRef="usd">35200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2509-wk-Fact-21D1A152215278783A15B8937FE58D66"
      unitRef="usd">4000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember"
      decimals="-5"
      id="d8095399e2513-wk-Fact-56E7C2AA87474D498AD4B8937FE7795D"
      unitRef="usd">800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-BA059394534CF5292F1FB8938027A521-0-wk-Fact-55D9EF6A637DB40587CDB8937FCFDE39">Grants&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Biomedical Advanced Research and Development Authority (BARDA)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2016, we received an award of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$125.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under Agreement No. HHSO100201600029C from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response, or ASPR within the U.S. Department of Health and Human Services, or HHS, to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; supported toxicology studies, a Phase&#160;1 clinical trial, and associated manufacturing activities. Contract options were available, for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$117.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to support an additional Phase&#160;1 study of an improved Zika vaccine candidate, Phase&#160;2 and Phase&#160;3 clinical studies, as well as large-scale manufacturing for the Zika vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; contract options had been exercised resulting in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$117.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of available funding with an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; available if the final contract option is exercised. For the three months ended March&#160;31, 2020 and 2019, we recognized revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, relating to the BARDA agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 16, 2020, we entered into a new agreement with BARDA (see Note 13).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;The Bill&#160;&amp;amp; Melinda Gates Foundation (Gates Foundation)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Gates Foundation has committed up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase&#160;1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections. Follow-on projects which could bring total potential funding under the framework agreement up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Gates Foundation certain non-exclusive licenses. In March 2019, the Gates Foundation provided an additional funding commitment up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to support a follow-on project.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$21.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been committed for funding with up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$80.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; available, if additional follow-on projects are approved. We recognized revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; relating to the Gates Foundation agreement for both of the three months ended March&#160;31, 2020 and 2019. We had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the Gates Foundation agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Defense Advanced Research Projects Agency (DARPA)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2013, DARPA awarded us up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$24.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under Agreement No.&#160;W911NF-13-1-0417, which was subsequently adjusted to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, to research and develop potential mRNA medicines as a part of DARPA&#x2019;s Autonomous Diagnostics to Enable Prevention and Therapeutics, or ADEPT, program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against chikungunya infection.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and December 31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been committed by DARPA. There was no revenue recognized for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt; or 2019, related to the DARPA agreement.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"
      decimals="-5"
      id="d8090629e460-wk-Fact-2D3BE63E535E7E138C2AB8937FF20551"
      unitRef="usd">125800000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialBaseAwardMember"
      decimals="-5"
      id="d8090629e464-wk-Fact-0FC504D995AA9ACE5568B8937FF04EED"
      unitRef="usd">8200000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember"
      decimals="-5"
      id="d8090629e468-wk-Fact-39508AE86DB5D885DF00B8937FD11D7D"
      unitRef="usd">117600000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsNumberOfContractOptionsExercised
      contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember"
      decimals="INF"
      id="d8090629e481-wk-Fact-394086F70406D62BB1C2B8937FD2DD5E"
      unitRef="contract_option">3</mrna:RevenueFromGrantsNumberOfContractOptionsExercised>
    <mrna:RevenueFromGrantsNumberOfContractOptions
      contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_ContractOptionsMember"
      decimals="INF"
      id="d8090629e485-wk-Fact-037E0A8B14A55B34BA9EB8937FD31243"
      unitRef="contract_option">4</mrna:RevenueFromGrantsNumberOfContractOptions>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"
      decimals="-5"
      id="d8090629e489-wk-Fact-B957EF90BC39C9A4D6A4B8937FF01E98"
      unitRef="usd">117300000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"
      decimals="-5"
      id="d8090629e493-wk-Fact-FD73D9D6E6DDD0162D71B8937FCC869D"
      unitRef="usd">8400000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_us-gaap_GrantMember"
      decimals="-5"
      id="d8090629e498-wk-Fact-A41528EC149D512CE73CB8937FCF7AD2"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_us-gaap_GrantMember"
      decimals="-5"
      id="d8090629e502-wk-Fact-9EB1CF828D2FD8C7791DB8937FD1B395"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="D2016Q1Jan31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialProjectMember"
      decimals="INF"
      id="d8090629e522-wk-Fact-0408ACD949BC05662851B8937FEF2307"
      unitRef="usd">20000000.0</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="D2016Q1Jan31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember"
      decimals="INF"
      id="d8090629e526-wk-Fact-F64FB11A3DEA6DD11E24B8937FD2EE2E"
      unitRef="usd">100000000.0</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="D2019Q1Mar31_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_FollowOnProjectMember"
      decimals="INF"
      id="d8090629e530-wk-Fact-83DFF95E6663EA96E736B8937FF0C043"
      unitRef="usd">1100000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_InitialProjectMember"
      decimals="INF"
      id="d8090629e541-wk-Fact-FF921234A2AE5C242BD5B8937FD88945"
      unitRef="usd">21100000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember"
      decimals="INF"
      id="d8090629e545-wk-Fact-E6D7832947E94C0B6CFEB8937FEEF997"
      unitRef="usd">80000000.0</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_us-gaap_GrantMember"
      decimals="-5"
      id="d8090629e549-wk-Fact-D0CD20AB629D48C1F971B8937FF09BAB"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember"
      decimals="-5"
      id="d8090629e553-wk-Fact-0819662646B5CDDFF492B8937FEF0006"
      unitRef="usd">1200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4_srt_MajorCustomersAxis_mrna_TheBillAndMelindaGatesFoundationMember"
      decimals="-5"
      id="d8090629e558-wk-Fact-BD51EDE10F77904850B4B8937FD6CE04"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiability>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="D2013Q4Oct31_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember"
      decimals="-5"
      id="d8090629e580-wk-Fact-CCEE8DE9E2C551DCEAB0B8937FD2D52F"
      unitRef="usd">24600000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="FD2020Q1YTD_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember"
      decimals="-5"
      id="d8090629e584-wk-Fact-27750F0903C6B3E62ABEB8937FD00755"
      unitRef="usd">19700000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="FI2020Q1_srt_MajorCustomersAxis_mrna_DefenseAdvancedResearchProjectsAgencyMember"
      decimals="-5"
      id="d8090629e599-wk-Fact-7A3FD2F5E9297FB1BC89B8937FD9BAFB"
      unitRef="usd">19700000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2CDFF80AD40914532441B8938027C02F-0-wk-Fact-E8C505CABE7302557796B8937FF4A085">Financial Instruments&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables summarize our cash and available-for-sale securities by significant investment category at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;281,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;281,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;281,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,517&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;212,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;214,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;141,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,007&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,162,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,156,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;637,634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;418,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,725,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,720,180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;391,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;825,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;502,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;225,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;225,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;225,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;117,891&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;118,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,963&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;834,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;836,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;687,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;149,122&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,259,980&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,047&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,262,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235,876&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;867,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;159,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The amortized cost and estimated fair value of marketable securities by contractual maturity at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;826,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;825,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;506,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;502,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,333,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,328,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive (loss) income, net of applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any credit losses related to available-for-sale securities for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12 months or more&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;709,128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;709,128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;724,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;724,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,822&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,822&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,979&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,979&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we held&#160;237&#160;and 19 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-FBDCAA8C618BB59945F2B8938027A7E9-0-wk-Fact-B2E3131A7C3AAB9A07A0B8937FF548EC">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables summarize our cash and available-for-sale securities by significant investment category at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;281,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;281,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;281,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,517&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;212,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;214,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;141,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,007&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,162,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,156,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;637,634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;418,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,725,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,720,180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;391,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;825,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;502,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;225,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;225,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;225,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;69,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;117,891&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;118,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,963&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;834,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;836,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;687,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;149,122&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,259,980&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,047&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,262,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235,876&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;867,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;159,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e855-wk-Fact-25F1CFA82A845B7E5C62B893800AB0E6"
      unitRef="usd">281583000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e874-wk-Fact-07DA7945DEB5DC0A7810B89380014F8E"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e894-wk-Fact-E4ABC6F9FF805E6A5996B89380181ACF"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e913-wk-Fact-BDE4CEFE47F7B47383B8B8938007F9D3"
      unitRef="usd">281583000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e932-wk-Fact-AD239BEC59494AF2D6E9B89380106A5F"
      unitRef="usd">281583000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e952-wk-Fact-0CFEA39036496F355B0CB8937FFF95A8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e971-wk-Fact-4AF473BA66A44020B68BB8938002249F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e1287-wk-Fact-F4F6F9DF2F88ED60804DB89380129CF9"
      unitRef="usd">68659000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e1306-wk-Fact-83CB8A17AC8EAE94EBFAB8938019193B"
      unitRef="usd">69000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e1325-wk-Fact-A0E300C17ACDA784473EB89380009C40"
      unitRef="usd">211000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e1346-wk-Fact-7D518748B43DEC1C7352B8938012FB5F"
      unitRef="usd">68517000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e1365-wk-Fact-BC619FC456A173512236B8937FFB8A69"
      unitRef="usd">10001000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e1385-wk-Fact-389136949C426AE16B81B8937FF824BE"
      unitRef="usd">47326000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e1404-wk-Fact-0C92265DD0C102A8D4F6B8937FFAC3EA"
      unitRef="usd">11190000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e1429-wk-Fact-FF050AF85A1FB7503A3AB8938001F6B3"
      unitRef="usd">212701000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e1448-wk-Fact-607EBD7100399A7ED63CB8938003A641"
      unitRef="usd">1327000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e1467-wk-Fact-857B7C8B97BC4D987E04B89380076D92"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e1487-wk-Fact-2A62428E733829F1A6D3B8937FF746F3"
      unitRef="usd">214028000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e1506-wk-Fact-E050E81BBB64B877FEF4B8937FF65B55"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e1526-wk-Fact-C0DB43B7EC7C6CE16EBFB89380137E84"
      unitRef="usd">141021000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e1545-wk-Fact-2082C0A0061D8886825CB8937FF81C07"
      unitRef="usd">73007000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e1570-wk-Fact-BD168117B87DF21DA45EB8938014E954"
      unitRef="usd">1162166000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e1589-wk-Fact-9676E3FA7ABBE9255876B8937FFBD480"
      unitRef="usd">1099000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e1608-wk-Fact-D4B47FC07FA79D67E4AEB89380019FA1"
      unitRef="usd">7213000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e1629-wk-Fact-40DE3322C48822F8D0CCB893800CC30B"
      unitRef="usd">1156052000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e1648-wk-Fact-F79D198872C2CDC39F13B89380189ACC"
      unitRef="usd">100136000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e1668-wk-Fact-53EE3D6F5B5A8FB43E3AB893801AFCAF"
      unitRef="usd">637634000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e1687-wk-Fact-D5199D6A2AD0434694D0B89380140F77"
      unitRef="usd">418282000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e1717-wk-Fact-1FE48B3094779A48C159B8938007B839"
      unitRef="usd">1725109000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e1736-wk-Fact-48A18A1A93D2A4348D74B893800D53E3"
      unitRef="usd">2495000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e1756-wk-Fact-2271DCB9B4D270F1A3A5B8938002C129"
      unitRef="usd">7424000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e1776-wk-Fact-BA6E3981CF4EE938DA96B89380154EC5"
      unitRef="usd">1720180000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e1795-wk-Fact-736CAF844A07F2B285D0B8937FF96511"
      unitRef="usd">391720000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e1815-wk-Fact-56100BF906C7CF159ADCB89380160556"
      unitRef="usd">825981000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e1834-wk-Fact-966D1189618411A4AA20B89380176F9C"
      unitRef="usd">502479000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e2185-wk-Fact-02A70816E7B44B4BE0D6B893800D6954"
      unitRef="usd">225874000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e2204-wk-Fact-0060FF2A19F1C8F3D54CB8938016E6A7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e2224-wk-Fact-5EB790D2E18A14CA2922B8937FFBEB78"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e2243-wk-Fact-D3FC05B895217E351444B8938001FFD7"
      unitRef="usd">225874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e2262-wk-Fact-9A7BBF2F395A71E4884AB8937FFBC673"
      unitRef="usd">225874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e2282-wk-Fact-1D8D3D8D55B1B3EBA8D8B8937FFD9B56"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="d8101936e2301-wk-Fact-BC2E47C345A3AE27D50AB8937FFAF58E"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e2617-wk-Fact-704597308BFDCB9EA629B8937FFAB60B"
      unitRef="usd">82028000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e2636-wk-Fact-D90FB9128DE834685D61B89380022364"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e2655-wk-Fact-8D94057395BABAA49E84B8938005EFA9"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e2676-wk-Fact-E8C6B6F222B03DC28CBAB8938003F2F5"
      unitRef="usd">82101000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e2695-wk-Fact-817ABF6A30A39A6CBAAEB8938017F686"
      unitRef="usd">10002000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e2715-wk-Fact-863C9F344CAE374C6199B89380186553"
      unitRef="usd">69197000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e2734-wk-Fact-79F3C33CFBFB3927F5C5B893800809E7"
      unitRef="usd">2902000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e2759-wk-Fact-E768DFEB0859516F9384B8937FFE7E5B"
      unitRef="usd">117891000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e2778-wk-Fact-303EF7022DC685175453B8937FF69E47"
      unitRef="usd">260000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e2797-wk-Fact-E67F2AFADA1C7894C01FB893800AE5EC"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e2818-wk-Fact-B92320ED99586AA96FFCB8938016BDFD"
      unitRef="usd">118149000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e2837-wk-Fact-35F969CE8F72DD17FA83B893800C7D62"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e2857-wk-Fact-B20024C471E0637F92B5B89380127554"
      unitRef="usd">110186000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e2876-wk-Fact-3B96106FD911F91D6427B8938005505F"
      unitRef="usd">7963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e2901-wk-Fact-0A56DEFE8112B9C59226B8938005B04D"
      unitRef="usd">834187000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e2920-wk-Fact-C3D9DE551542B69EC84BB89380159539"
      unitRef="usd">2708000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e2939-wk-Fact-054C8B38511708B5FF8EB893800F05B9"
      unitRef="usd">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e2960-wk-Fact-7D53B9CE3DC3B8C5999DB8938007E628"
      unitRef="usd">836863000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e2979-wk-Fact-6037D31900C1E81EFD0EB89380156FE0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e2999-wk-Fact-33B687965F45627BEE90B893801886E7"
      unitRef="usd">687741000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e3018-wk-Fact-4F2CB4B1857F6A2B9929B89380115F49"
      unitRef="usd">149122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e3048-wk-Fact-B8B8216E8652AFD15DCBB89380170209"
      unitRef="usd">1259980000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e3067-wk-Fact-6450C1E34CA9B89E4098B8938016E5E6"
      unitRef="usd">3047000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e3087-wk-Fact-E0B38E060F31302417A0B8938014482A"
      unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e3107-wk-Fact-0EB4E88DC59882067A5FB8938008AC72"
      unitRef="usd">1262987000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e3126-wk-Fact-BE547C6C4235260FA374B8937FF827A1"
      unitRef="usd">235876000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_CurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e3146-wk-Fact-A048C65F0BC55151B1F3B89380135112"
      unitRef="usd">867124000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_mrna_NoncurrentMarketableSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d8101936e3165-wk-Fact-6F9E873352429B098CA5B893801B0128"
      unitRef="usd">159987000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F37367DE059D620BF35EB8938027E0E1-0-wk-Fact-2D18BA357DF96C1DC66DB8937FF5685F">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The amortized cost and estimated fair value of marketable securities by contractual maturity at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;826,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;825,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;506,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;502,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,333,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,328,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e3318-wk-Fact-556FB9D7D35498C8BD49B8937FF1FA00"
      unitRef="usd">826449000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e3337-wk-Fact-EA71BF57AF82F2251A21B8937FF31033"
      unitRef="usd">825981000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e3357-wk-Fact-3CEA7CE0B7373C380BD8B8937FF3AF27"
      unitRef="usd">506983000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e3376-wk-Fact-DDBCDC929C459403CA41B8937FF20457"
      unitRef="usd">502479000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e3406-wk-Fact-7249B33C75C026353308B8937FF15232"
      unitRef="usd">1333432000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e3425-wk-Fact-454800A865878A0E4C76B8937FF2114B"
      unitRef="usd">1328460000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-173A98360CC71B19B6B5B8F8D9CAD1EB-0-wk-Fact-21433F9E59B0D952F2F0B8F93460C180">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12 months or more&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of March 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;709,128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;709,128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;724,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;724,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,822&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,822&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,979&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,979&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e3900-wk-Fact-9EE151A9BB9A9915524EC387AB146840"
      unitRef="usd">211000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e3920-wk-Fact-587B79CB3EBCDE6403ACC387AB09E24D"
      unitRef="usd">14883000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e3940-wk-Fact-C0D382F8E8DA68D1DA9EC387AAEF2F71"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e3959-wk-Fact-8C1EF733AD1A868F9F0FC387AB0E6847"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e3978-wk-Fact-AE67D71989B2B1D28014B8F844436586"
      unitRef="usd">211000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e3999-wk-Fact-1FF2277D78FD4CB7C3F4B8F88DDFF811"
      unitRef="usd">14883000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4019-wk-Fact-E26BE19AD4B0E690DA7EC387AAF6EA79"
      unitRef="usd">7213000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4039-wk-Fact-387029D251C6DB6DD938C387AAFB96E2"
      unitRef="usd">709128000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4099-wk-Fact-97282015C3FB0E8BC3F5B8F83F0B9FB7"
      unitRef="usd">7213000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4120-wk-Fact-E7D780478746858661CEB8F88DD54C16"
      unitRef="usd">709128000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e4150-wk-Fact-FD782B32BCA3A8C5D7EFB8F723C046D3"
      unitRef="usd">7424000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e4169-wk-Fact-BCB5ACA8948A67A020B5B8F76AB6C3B6"
      unitRef="usd">724011000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e4188-wk-Fact-DB3F4C0BF1C07B56B333B8F7C0B391EC"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e4206-wk-Fact-DAA0F47CDBE44478141EB8F80230D62E"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e4224-wk-Fact-E5BFC0AD1212FF8BC7B3B8F83FC3021C"
      unitRef="usd">7424000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101936e4244-wk-Fact-8C295F53822677A5492AB8F8901975C7"
      unitRef="usd">724011000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e4525-wk-Fact-E15E5DE103CE8860BE6AC38950C13553"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e4545-wk-Fact-6DA569617E155B81EF66C38950B55FA2"
      unitRef="usd">12822000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e4565-wk-Fact-4103520537B15DB1EBA6C38950B00FC2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e4584-wk-Fact-C99F93182603505A8035C38950BBCD13"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e4603-wk-Fact-EF5FEF4074FCBD734E3EB8F83E5450F4"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d8101936e4624-wk-Fact-055E0CD75401D44D2844B8F88EAA35DF"
      unitRef="usd">12822000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e4644-wk-Fact-D9DDF0600DC0A81C58A5C38973400B4E"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e4664-wk-Fact-AC6CFC43DACA532A8BCEC389756C4638"
      unitRef="usd">9979000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e4683-wk-Fact-E64715EB6BF38CC1215BC38977773B98"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e4703-wk-Fact-F1B441A384AFC4E93BEAC389799E43B2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e4722-wk-Fact-13700394875F1A3EBE28C3897BEDB6B4"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d8101936e4743-wk-Fact-47AA4C5EAB4A98960AA5C3897F969FB5"
      unitRef="usd">9979000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4768-wk-Fact-860B1C6948B67A1C94E2C38950A7E786"
      unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4788-wk-Fact-3AA877C677F83E12538FC38950ABE479"
      unitRef="usd">62360000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4807-wk-Fact-568EA2E451D961E3DC2AC38950A28DB7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4827-wk-Fact-F51BB7F9FB03DD7917D7C389509DF2BE"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4846-wk-Fact-4C5257905D6F007C8984B8F83FE8B357"
      unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"
      decimals="-3"
      id="d8101936e4867-wk-Fact-9EFC9776309DC1629CB4B8F88DF07271"
      unitRef="usd">62360000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101936e4898-wk-Fact-1CDBBC04DB422972FBB3B8F72067C2CD"
      unitRef="usd">40000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101936e4918-wk-Fact-BB8C55024CE72421C481B8F76A3F0E78"
      unitRef="usd">85161000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101936e4938-wk-Fact-266E67EDEAFECF920393B8F7C07638C7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101936e4957-wk-Fact-9C1DCBC0AEE2205E37F6B8F800A97878"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101936e4976-wk-Fact-84922716CF798BCD5725B8F8406FD7A7"
      unitRef="usd">40000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101936e4997-wk-Fact-90ACB519056D973A5431B8F88ECE7236"
      unitRef="usd">85161000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-831BB5788AADF090B2FDB8938027CD45-0-wk-Fact-353640447FD9C0E53A1EB8937FE9E55C">Balance Sheet Components&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consists of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,475&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tenant incentives receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest receivable on marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consists of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;109,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;108,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,985&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Internally developed software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,853&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,853&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;303,854&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;296,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(101,788&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(94,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;202,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;201,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization expense for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consists of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Compensation-related&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,428&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;External goods and services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,652&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-3896B39CF048458F8E15B893802719E6-0-wk-Fact-BC8DA6B3DE1F25139BE4B8937FDC5CF4">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consists of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,475&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tenant incentives receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest receivable on marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e598-wk-Fact-2C142E1790CE95B6E293B8937FF4A4D3"
      unitRef="usd">12410000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e617-wk-Fact-5185EB8739E384B9E424B8937FDECF91"
      unitRef="usd">8475000</us-gaap:PrepaidExpenseCurrent>
    <mrna:TenantIncentivesReceivablesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e637-wk-Fact-1ED5970E1291A496D32CB8937FF0AC59"
      unitRef="usd">3198000</mrna:TenantIncentivesReceivablesCurrent>
    <mrna:TenantIncentivesReceivablesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e656-wk-Fact-4BDE4D2408FB88F4089AB893801AFB77"
      unitRef="usd">4093000</mrna:TenantIncentivesReceivablesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e681-wk-Fact-3AC4B223BB78A902B70CB8937FF39693"
      unitRef="usd">8295000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e700-wk-Fact-E6334E6FC0F9CAFB09B5B8937FCF0068"
      unitRef="usd">6835000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e730-wk-Fact-6FD95ED13B84ACA5E3F7B8937FCE0B09"
      unitRef="usd">23903000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e749-wk-Fact-AC28DA640B65E64EC4ADB8937FEF6A5A"
      unitRef="usd">19403000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2D4E4B35B1326416AD88B8938028EC07-0-wk-Fact-C073BD1CFC46E3EB402FB8937FF29E54">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consists of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;109,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;108,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,985&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Internally developed software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,853&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,853&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;303,854&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;296,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(101,788&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(94,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;202,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;201,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="-3"
      id="d8101929e908-wk-Fact-C8D9A72FA56FF8358E4AB8937FF6A04D"
      unitRef="usd">109283000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="-3"
      id="d8101929e927-wk-Fact-B263B3BD7409F282816AB8937FDF13F5"
      unitRef="usd">108257000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d8101929e947-wk-Fact-76728C93FA18FBE3C80AB8937FE7EDAB"
      unitRef="usd">152306000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d8101929e966-wk-Fact-65A3F617F27D9B241B6DB8937FDC6644"
      unitRef="usd">152426000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember"
      decimals="-3"
      id="d8101929e991-wk-Fact-99540A21D0CACAD196DDB8937FFBE53F"
      unitRef="usd">3364000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember"
      decimals="-3"
      id="d8101929e1010-wk-Fact-B766C4D12B13DDA1DCEDB893801925C9"
      unitRef="usd">3316000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="d8101929e1035-wk-Fact-E9B1F36B11E9F231280FB8937FF5CD7D"
      unitRef="usd">12347000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="d8101929e1054-wk-Fact-3533F45AB8A993C79093B8937FF18871"
      unitRef="usd">11985000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember"
      decimals="-3"
      id="d8101929e1079-wk-Fact-79205022EECCA699377CB8937FF47C9C"
      unitRef="usd">7020000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareDevelopmentMember"
      decimals="-3"
      id="d8101929e1098-wk-Fact-7760E00CA1474C489429B8937FFD7B42"
      unitRef="usd">7020000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrna_RightOfUseAssetFinancingMember"
      decimals="-3"
      id="d8101929e1123-wk-Fact-E145848E30B5FC6A3CD3B8D2908F3B4D"
      unitRef="usd">9853000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrna_RightOfUseAssetFinancingMember"
      decimals="-3"
      id="d8101929e1142-wk-Fact-B5D63CE02D3480F5E3B8B8D2961ABF26"
      unitRef="usd">9853000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d8101929e1167-wk-Fact-CB65B56CB1F9ED6377BBB8937FFA160A"
      unitRef="usd">9681000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d8101929e1186-wk-Fact-3F49480F702F9EE9C83DB8937FFAE6DA"
      unitRef="usd">3222000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e1211-wk-Fact-60425542BD12848B6096B8938001F5EC"
      unitRef="usd">303854000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e1230-wk-Fact-7A4D9DA337001B1F18BFB8937FF04C85"
      unitRef="usd">296079000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e1255-wk-Fact-4308F8363A5B7B0C48B3B8937FF5E159"
      unitRef="usd">101788000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e1275-wk-Fact-565D44205FEE4434E6CEB8937FD77683"
      unitRef="usd">94584000</mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization>
    <mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e1307-wk-Fact-558DF1603A8CCDA85CBFB8937FCD7C33"
      unitRef="usd">202066000</mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e1326-wk-Fact-113458AB596CD8D5C17BB8937FEF297D"
      unitRef="usd">201495000</mrna:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d8101929e1354-wk-Fact-FF61343277C017291DCDB8937FF0D2FE"
      unitRef="usd">7400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q1YTD"
      decimals="-5"
      id="d8101929e1358-wk-Fact-9A7BD31CBBD1AD9A3B49B8937FE5116E"
      unitRef="usd">7300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-A60E1CDA7E17FFFAFC18B8938028FE26-0-wk-Fact-0EAF40D2D4430E581195B8937FDBE793">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consists of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Compensation-related&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,428&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;External goods and services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,652&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <mrna:AccruedPropertyAndEquipmentCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e1510-wk-Fact-9E061167754591C57B83B8937FDE0609"
      unitRef="usd">4350000</mrna:AccruedPropertyAndEquipmentCurrent>
    <mrna:AccruedPropertyAndEquipmentCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e1529-wk-Fact-93B60A4ABF6C3D11B101B8937FF3940D"
      unitRef="usd">4029000</mrna:AccruedPropertyAndEquipmentCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e1549-wk-Fact-C68AA4A58B47C2EDBAADB8937FE72CDE"
      unitRef="usd">12617000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e1568-wk-Fact-948BBAAFD976A242D5C1B8937FE81D99"
      unitRef="usd">27428000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mrna:AccruedExternalGoodsAndServicesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e1593-wk-Fact-8D42E0F8CDED26BFC428B8937FF535B3"
      unitRef="usd">38053000</mrna:AccruedExternalGoodsAndServicesCurrent>
    <mrna:AccruedExternalGoodsAndServicesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e1612-wk-Fact-B9B41D019B68FB0C521EB8937FF2D260"
      unitRef="usd">36195000</mrna:AccruedExternalGoodsAndServicesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8101929e1642-wk-Fact-A6E1BF00CB70C3CAC400B8937FDEDEFE"
      unitRef="usd">55020000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8101929e1661-wk-Fact-3481DE0A2E9AF9687BA2B8937FCF40F1"
      unitRef="usd">67652000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-D93E955B58B0D2A7EEFAB8CE51EC2D61-0-wk-Fact-FA363F8E7BC0871AF4A7B8CE68048194">Leases&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, or MTC, located in Norwood.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cambridge facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We occupy a multi-building campus in Technology Square in Cambridge, MA with a mix of offices and research laboratory space totaling approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, MA. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of additional space at 200 Technology Square including space previously occupied under a sublease which expired on December 31, 2019. We will also completely early-exit our leased space of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet at 500 Technology Square by May 2020. In addition, our current 200 Technology Square lease has been extended for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to 2029. The amendment provides an additional aggregated tenant improvement allowance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the design and construction of improvements at 200 Technology Square.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May&#160;2016, we entered into a lease agreement for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124,760&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet of office and laboratory space at 200&#160;Technology Square in Cambridge, Massachusetts. The lease commenced on September&#160;1, 2016, with the base rent subject to increases over an&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year term. We have occupied the premises in six phases from September 2016 to January&#160;2020. We have the option to extend the lease term for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;extension periods of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;each, at market-based rates. In addition to rent payments, the lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. As the amount of square footage that we lease increases over the term of the lease, we have recognized each phase&#x2019;s total rent payments on a straight-line basis over the respective lease term. The lease provides us with an initial tenant allowance of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per square foot against which costs incurred are capitalized as leasehold improvements. In December 2018, in relation to the expansion of space from the agreement entered in May 2016, we entered into sublease agreements for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,268&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet to expand our office and laboratory space at 200 Technology Square.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August&#160;2015, we entered into a facility lease agreement for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,618&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet of office and laboratory space at 500&#160;Technology Square. The lease commenced in April&#160;2016, with the base rent escalating over the&#160;six-year term of the lease. The lease provides a&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;tenant improvement allowance against which costs incurred are capitalized as leasehold improvements. The lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Moderna Technology Center North (MTC North)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2019, we entered into a new lease agreement for office and laboratory space of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet, MTC North, located Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional five-year terms. Contemporaneously, we entered into an agreement to sublease approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;64 percent&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the leased space to a third party. We have no rent obligations to the landlord for the space occupied by the third party. All sublease payments from the third party are paid directly to the landlord. The sublease can expire between May 2020 and February 2021 at the third party's option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April&#160;2017, we entered into a lease agreement for land adjacent to our MTC manufacturing facility (see MTC South below). We determined, for accounting purposes, this land lease should be accounted for separately from the lease entered in August 2016 relating to the building. The lease commenced in April 2017, with the base rent&#160;escalating over the&#160;thirty-five-year term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded to operating expenses in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Moderna Technology Center manufacturing facility (MTC South)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August&#160;2016, we entered into a lease agreement for approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Massachusetts. The lease commencement date for accounting purposes was October&#160;1, 2016. In connection with this lease, the landlord provided a tenant improvement allowance of approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$24.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;for costs associated with the design, engineering, and construction of tenant improvements for the building. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;extension periods of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to ASC 842, the MTC South lease is bifurcated into a building lease and a land lease using an estimated incremental borrowing rate as of the lease commencement date. The building lease is classified as a financing lease and the land lease is classified as an operating lease. For accounting purposes, the lease term is determined to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is the non-cancelable period of the lease and includes the optional extension periods as we are reasonably certain that we will exercise the options to extend the lease term. Upon the adoption of&#160;ASC 842 at January 1, 2019, we derecognized the assets and liabilities recorded as a result of historical build-to-suit accounting under ASC 840 and recorded financing lease liabilities and financing right-of-use asset associated with the building lease. The financing right-of-use asset is amortized on a straight-line basis to depreciation expense over the remaining lease term. We record interest expense related to the financing lease liabilities in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2019 and March 31, 2020 were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) (2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,533&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,414&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3) (4)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,488&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95,958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;108,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;147,849&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;132,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;135,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These assets are&#160;real estate assets related to the MTC South lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(5) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of the lease costs for the three months ended March 31, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financing lease costs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total financing lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental cash flow information relating to our leases for the three months ended March 31, 2020 and 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Operating cash flows used in operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,888&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Operating cash flows used in financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Right-of-use assets reduced through lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Charges to financing lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under non-cancelable operating lease agreements at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, are as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Financing Leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(remainder of the year)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;118,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;264,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;195,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;293,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(254,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Include the optional extensions in the MTC South lease term which represent a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$208.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; un-discounted future lease payments in operating leases and financing leases, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Based on an imputed interest rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-DFED948F4695C412F14EB8CEC1DEED16-0-wk-Fact-1ADDBE8FB8CB978E2AC1B8CECD83B99D">Leases&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center, or MTC, located in Norwood.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cambridge facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We occupy a multi-building campus in Technology Square in Cambridge, MA with a mix of offices and research laboratory space totaling approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, MA. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of additional space at 200 Technology Square including space previously occupied under a sublease which expired on December 31, 2019. We will also completely early-exit our leased space of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet at 500 Technology Square by May 2020. In addition, our current 200 Technology Square lease has been extended for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to 2029. The amendment provides an additional aggregated tenant improvement allowance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the design and construction of improvements at 200 Technology Square.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May&#160;2016, we entered into a lease agreement for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124,760&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet of office and laboratory space at 200&#160;Technology Square in Cambridge, Massachusetts. The lease commenced on September&#160;1, 2016, with the base rent subject to increases over an&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year term. We have occupied the premises in six phases from September 2016 to January&#160;2020. We have the option to extend the lease term for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;extension periods of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;each, at market-based rates. In addition to rent payments, the lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. As the amount of square footage that we lease increases over the term of the lease, we have recognized each phase&#x2019;s total rent payments on a straight-line basis over the respective lease term. The lease provides us with an initial tenant allowance of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per square foot against which costs incurred are capitalized as leasehold improvements. In December 2018, in relation to the expansion of space from the agreement entered in May 2016, we entered into sublease agreements for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,268&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet to expand our office and laboratory space at 200 Technology Square.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August&#160;2015, we entered into a facility lease agreement for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,618&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet of office and laboratory space at 500&#160;Technology Square. The lease commenced in April&#160;2016, with the base rent escalating over the&#160;six-year term of the lease. The lease provides a&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;tenant improvement allowance against which costs incurred are capitalized as leasehold improvements. The lease also provides that we pay our proportionate share of operating expenses and taxes during the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Moderna Technology Center North (MTC North)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2019, we entered into a new lease agreement for office and laboratory space of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet, MTC North, located Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional five-year terms. Contemporaneously, we entered into an agreement to sublease approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;64 percent&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the leased space to a third party. We have no rent obligations to the landlord for the space occupied by the third party. All sublease payments from the third party are paid directly to the landlord. The sublease can expire between May 2020 and February 2021 at the third party's option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April&#160;2017, we entered into a lease agreement for land adjacent to our MTC manufacturing facility (see MTC South below). We determined, for accounting purposes, this land lease should be accounted for separately from the lease entered in August 2016 relating to the building. The lease commenced in April 2017, with the base rent&#160;escalating over the&#160;thirty-five-year term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded to operating expenses in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Moderna Technology Center manufacturing facility (MTC South)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August&#160;2016, we entered into a lease agreement for approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Massachusetts. The lease commencement date for accounting purposes was October&#160;1, 2016. In connection with this lease, the landlord provided a tenant improvement allowance of approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$24.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;for costs associated with the design, engineering, and construction of tenant improvements for the building. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;extension periods of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to ASC 842, the MTC South lease is bifurcated into a building lease and a land lease using an estimated incremental borrowing rate as of the lease commencement date. The building lease is classified as a financing lease and the land lease is classified as an operating lease. For accounting purposes, the lease term is determined to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is the non-cancelable period of the lease and includes the optional extension periods as we are reasonably certain that we will exercise the options to extend the lease term. Upon the adoption of&#160;ASC 842 at January 1, 2019, we derecognized the assets and liabilities recorded as a result of historical build-to-suit accounting under ASC 840 and recorded financing lease liabilities and financing right-of-use asset associated with the building lease. The financing right-of-use asset is amortized on a straight-line basis to depreciation expense over the remaining lease term. We record interest expense related to the financing lease liabilities in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2019 and March 31, 2020 were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) (2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,533&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,414&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3) (4)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,488&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95,958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;108,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;147,849&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;132,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;135,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These assets are&#160;real estate assets related to the MTC South lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(5) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of the lease costs for the three months ended March 31, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financing lease costs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total financing lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental cash flow information relating to our leases for the three months ended March 31, 2020 and 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Operating cash flows used in operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,888&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Operating cash flows used in financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Right-of-use assets reduced through lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Charges to financing lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under non-cancelable operating lease agreements at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, are as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Financing Leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(remainder of the year)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;118,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;264,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;195,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;293,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(254,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Include the optional extensions in the MTC South lease term which represent a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$208.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; un-discounted future lease payments in operating leases and financing leases, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Based on an imputed interest rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits
      contextRef="FI2019Q4"
      decimals="INF"
      id="d8105074e454-wk-Fact-C9A7F4DB5624B5721D81B9778C49783F"
      unitRef="campus">2</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember"
      decimals="-3"
      id="d8105074e473-wk-Fact-BBFB57696F6D49F83FCDB978BBBF376A"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember"
      decimals="-3"
      id="d8105074e482-wk-Fact-47EFB0D17DBEAB01AB53B978DC2DFF16"
      unitRef="sqft">50000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember"
      decimals="-3"
      id="d8105074e486-wk-Fact-F7659F9B93998B537DC7B9790232E804"
      unitRef="sqft">60000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember"
      id="d8105074e490-wk-Fact-FF27812A42BCA5B4D562B9795E0BE9EC">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrna:AllowanceForTenantImprovements
      contextRef="I2019Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember"
      decimals="-5"
      id="d8105074e494-wk-Fact-87382C3907CDC69AD00AB979791313E3"
      unitRef="usd">3500000</mrna:AllowanceForTenantImprovements>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember"
      decimals="0"
      id="d8105074e504-wk-Fact-472D3F6FD57F51A6481EB97BAB5996FF"
      unitRef="sqft">124760</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember"
      id="d8105074e508-wk-Fact-3C1B3F7F8454C4316410B97BF457BC32">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember"
      decimals="INF"
      id="d8105074e512-wk-Fact-1A7F0B0871B3B7D232FDB97BD395ADBA"
      unitRef="extension_period">2</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="I2016Q2May31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember"
      id="d8105074e516-wk-Fact-725D80ACF759CC50F6ADB97C118D2EBA">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrna:LesseeOperatingLeaseTenantAllowancePricePerUnit
      contextRef="D2016Q2May_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareMember"
      decimals="INF"
      id="d8105074e520-wk-Fact-912BBA42984F6C2682C6B97C35DFF56F"
      unitRef="USD_PER_sqft">10.00</mrna:LesseeOperatingLeaseTenantAllowancePricePerUnit>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_TwoHundredTechnologySquareSubleaseAgreementsMember"
      decimals="0"
      id="d8105074e525-wk-Fact-5C24C5CA5E2B16C56329B97C9DB5F441"
      unitRef="sqft">34268</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2015Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember"
      decimals="0"
      id="d8105074e534-wk-Fact-ADD5503EEABCD68FBF14B97687C4ACDE"
      unitRef="sqft">61618</us-gaap:AreaOfRealEstateProperty>
    <mrna:AllowanceForTenantImprovements
      contextRef="I2015Q3Aug31_srt_StatementGeographicalAxis_mrna_CambridgeMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_FiveHundredTechnologySquareMember"
      decimals="-5"
      id="d8105074e538-wk-Fact-8BD021D6A71B0DDA5D16B976C12196E5"
      unitRef="usd">3100000</mrna:AllowanceForTenantImprovements>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember"
      decimals="-3"
      id="d8105074e552-wk-Fact-64BF8FC4F855C7813B79B9755A1C3DE3"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember"
      decimals="INF"
      id="d8105074e556-wk-Fact-F20EA3DC2DC1730E4E3BB9756F951510"
      unitRef="extension_period">4</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <mrna:LesseeOperatingLeasePercentageSubleased
      contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember"
      decimals="2"
      id="d8105074e560-wk-Fact-FE44C7D2CE7141565D0FB97540EE5F16"
      unitRef="number">0.64</mrna:LesseeOperatingLeasePercentageSubleased>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember"
      decimals="-3"
      id="d8105074e590-wk-Fact-51A1751B8A2C9F810846B973CF3F15EE"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <mrna:AllowanceForTenantImprovements
      contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember"
      decimals="-5"
      id="d8105074e594-wk-Fact-920944348409B6F8A45BB9740A156118"
      unitRef="usd">24200000</mrna:AllowanceForTenantImprovements>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember"
      decimals="INF"
      id="d8105074e598-wk-Fact-6CBBA739402FEA7DCBD6B973B680FE3E"
      unitRef="extension_period">2</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember"
      id="d8105074e602-wk-Fact-552F4CB43764C92D54B7B9739C3CDEA3">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="I2016Q3Aug31_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember"
      id="d8105074e611-wk-Fact-3BD65248AE1DB8931EBCB9736B9EA1D3">P35Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <mrna:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-9F376897B666C66B19ADB97D14B92AB4-0-wk-Fact-C00FC30D1A4F19AD3DFBB97D1FE3C00A">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2019 and March 31, 2020 were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) (2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100,533&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,414&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3) (4)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,488&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95,958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;108,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;147,849&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;132,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;135,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These assets are&#160;real estate assets related to the MTC South lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(5) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</mrna:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e797-wk-Fact-0DB5077D9DF77DB99501B8937FE01490"
      unitRef="usd">100533000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8105074e816-wk-Fact-78B369C60BB728FB25A9B8937FDB8A1C"
      unitRef="usd">86414000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e838-wk-Fact-F67A3056AB2D6B7F711BB970CECFCD79"
      unitRef="usd">9488000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8105074e857-wk-Fact-9EDE656BDC2C4A44C657B970D01AE253"
      unitRef="usd">9544000</us-gaap:FinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e887-wk-Fact-6C3B541DFC346B94E729B970D1219216"
      unitRef="usd">110021000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8105074e906-wk-Fact-DE27DEC2E74FE04DAC89B970D2D950C4"
      unitRef="usd">95958000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e1071-wk-Fact-23577BA4690EBEE0C7BDB970FE96051F"
      unitRef="usd">3987000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8105074e1090-wk-Fact-E4E3AED3F9B22B824DCEB9710015F001"
      unitRef="usd">3584000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e1157-wk-Fact-E301DD914DA458C31061B8937FCDE2FE"
      unitRef="usd">108919000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8105074e1176-wk-Fact-2DEF7B7076BAB361269FB8937FD01D5D"
      unitRef="usd">93675000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e1201-wk-Fact-33C005D3215430FF981AB8937FEE7C36"
      unitRef="usd">38930000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8105074e1220-wk-Fact-DDD0C8D2570F3206B9EFB8937FDEDECE"
      unitRef="usd">38689000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e1245-wk-Fact-2BADF498B4A693BEE479B97104E43E9A"
      unitRef="usd">147849000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8105074e1264-wk-Fact-DB4703C3AE43A49802A5B971065DF65A"
      unitRef="usd">132364000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiability
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e1294-wk-Fact-9BED5F4E91EABF4FCB0AB9710722945D"
      unitRef="usd">151836000</mrna:OperatingAndFinanceLeaseLiability>
    <mrna:OperatingAndFinanceLeaseLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8105074e1313-wk-Fact-315054A9EC715F1AD3FDB971083949D7"
      unitRef="usd">135948000</mrna:OperatingAndFinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-ABD5A84D1F7FAE8E86DDB98866948A1E-0-wk-Fact-4C36442126346DEE4C6AB9887555775C">&lt;div style="line-height:174%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of the lease costs for the three months ended March 31, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financing lease costs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total financing lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental cash flow information relating to our leases for the three months ended March 31, 2020 and 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Operating cash flows used in operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,888&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Operating cash flows used in financing leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Right-of-use assets reduced through lease modifications and reassessments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Charges to financing lease obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e1480-wk-Fact-1F05428C29327FD25FEDB96FD37D13D3"
      unitRef="usd">4636000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e1499-wk-Fact-F6DAF93F8FE9E7BF7B32B96FD585BDA8"
      unitRef="usd">3870000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e1565-wk-Fact-5CF83FCB82613EF3D8B7B96FD865C09D"
      unitRef="usd">73000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e1584-wk-Fact-8EFB5CC3AC419837052BB96FDA3C9E26"
      unitRef="usd">73000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e1609-wk-Fact-FA1D0C5A18A88DF0DD34B96FDBA2C409"
      unitRef="usd">1665000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e1628-wk-Fact-B86E3C11C3568FC25079B96FDD4C449F"
      unitRef="usd">1623000</us-gaap:FinanceLeaseInterestExpense>
    <mrna:FinanceLeaseCost
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e1653-wk-Fact-958F9AFF6A24F9EEAB1EB96FDEC5B5B9"
      unitRef="usd">1738000</mrna:FinanceLeaseCost>
    <mrna:FinanceLeaseCost
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e1672-wk-Fact-34F90443EA785CD7638DB96FE0AC662B"
      unitRef="usd">1696000</mrna:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e1697-wk-Fact-DF1715001598ABD83317B97009684AE7"
      unitRef="usd">1407000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e1716-wk-Fact-351A338C23342B4E2BE1B9700AED3C67"
      unitRef="usd">894000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e1905-wk-Fact-2AA8149FF9B65447599AB96F1D9B566D"
      unitRef="usd">3888000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e1925-wk-Fact-7BC81016D0AF910A2BE5B96F1F53A3BE"
      unitRef="usd">3725000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e1946-wk-Fact-65220F1883D3354D8CBBB96F20ADF85A"
      unitRef="usd">1425000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e1966-wk-Fact-DC6A9CFAEFE5152332C3B96F228B25EF"
      unitRef="usd">1387000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e2084-wk-Fact-9C1DE18E686E78026BA6B96F29D66061"
      unitRef="usd">0</mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments>
    <mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e2103-wk-Fact-749877E53B91F8218C55B96F2B4A8DC0"
      unitRef="usd">219000</mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e2128-wk-Fact-F47B320EE5811332251EB96F2BE187CB"
      unitRef="usd">16015000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e2147-wk-Fact-D8C7580A9CA2EFDBA557B96F2D3D5472"
      unitRef="usd">17416000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8105074e2265-wk-Fact-DDF96D70811E28F4720FB96F23332941"
      unitRef="usd">241000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8105074e2284-wk-Fact-1A0A974BCF4779B8856DB96F2645FDA6"
      unitRef="usd">236000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-0D3A440FB906E4259E69B96A7C3C013B-0-wk-Fact-BB77CC2D00B1FF8E8A8EB96A9F7E4EB1">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under non-cancelable operating lease agreements at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, are as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Financing Leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(remainder of the year)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;118,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;264,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;195,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;293,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(254,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Include the optional extensions in the MTC South lease term which represent a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$208.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; un-discounted future lease payments in operating leases and financing leases, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Based on an imputed interest rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-9F6B205D8E0DBA253A66B96BA115EA9E-0-wk-Fact-7C68B38FCA11C23AF00EB96BABBF4932">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under non-cancelable operating lease agreements at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, are as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Financing Leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(remainder of the year)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;118,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;264,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;195,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;293,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(254,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Include the optional extensions in the MTC South lease term which represent a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$208.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; un-discounted future lease payments in operating leases and financing leases, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Based on an imputed interest rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2402-wk-Fact-A6A8AEF4C0E40D889D9DB97FE98F4E54"
      unitRef="usd">10668000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2421-wk-Fact-F1747F1B3B140E80FCB3B980435EE8AF"
      unitRef="usd">4313000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2446-wk-Fact-1047E352A91018E178ABB96DEC855FE1"
      unitRef="usd">16266000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2465-wk-Fact-4A2270F430C973AACA21B96DEDCB2F44"
      unitRef="usd">5894000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2495-wk-Fact-74A5E239330E5F4DD1FFB96DEED5F730"
      unitRef="usd">16644000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2514-wk-Fact-859C8F335A95791691C1B96DEFFC3797"
      unitRef="usd">6054000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2544-wk-Fact-DC4A73AC258504ED0AA0B96DF0B02BFA"
      unitRef="usd">16962000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2563-wk-Fact-E0518EE7B3B8613F9A3FB96DF1F3634E"
      unitRef="usd">6219000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2593-wk-Fact-E305BE5AE96E9061F435B96DF2A64669"
      unitRef="usd">17380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2612-wk-Fact-4165B8740E890CA57B3DB96DF3FF5337"
      unitRef="usd">6387000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2642-wk-Fact-6BADF0AFE102CD6ABE8CB96DF4C559C3"
      unitRef="usd">118015000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2661-wk-Fact-22E7C54F98A4F745851FB96DF60F1582"
      unitRef="usd">264156000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2691-wk-Fact-BF61F5744848CC1C2478B96DF6ED6A7B"
      unitRef="usd">195935000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2710-wk-Fact-A5D2D2C475875E8320CCB96DF81D1683"
      unitRef="usd">293023000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2740-wk-Fact-0ACDB25FE12CC20C4446B96DF8EBD7F4"
      unitRef="usd">83018000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2760-wk-Fact-F6F9661793FF4CC9A392B96DFA67B76C"
      unitRef="usd">254093000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2796-wk-Fact-63AA2E85F637A865EDF2B96DFB1D39B8"
      unitRef="usd">112917000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8105074e2815-wk-Fact-006032B162BDA111BE0BB96DFC24D3C0"
      unitRef="usd">38930000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2020Q1_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember"
      decimals="-5"
      id="d8105074e2834-wk-Fact-943CED315E6305A4AE7FB96D490F7AE0"
      unitRef="usd">10300000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2020Q1_srt_StatementGeographicalAxis_mrna_NorwoodMassachusettsMember_us-gaap_LeaseArrangementTypeAxis_mrna_OfficeLaboratoryAndLightManufacturingSpaceMember"
      decimals="-5"
      id="d8105074e2838-wk-Fact-61CE85A0E5FF0478A245B96D7CE54704"
      unitRef="usd">208500000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <mrna:LeasesImputedInterestRate
      contextRef="FD2020Q1YTD"
      decimals="3"
      id="d8105074e2847-wk-Fact-026F5DC67CDC446D6925B96D24CFFC5A"
      unitRef="number">0.172</mrna:LeasesImputedInterestRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-41F2848F6093850D9118B89380284DD8-0-wk-Fact-BE2F143E0811D170D278B8938003DC35">Commitments and Contingencies&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Strategic Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$243.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for both periods as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and December 31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#x2019;s or director&#x2019;s lifetime.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Through the three months ended March&#160;31, 2020 and the year ended December 31, 2019, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase Commitments and Purchase Orders&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of March 31, 2020, we had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of non-cancelable purchase commitments for clinical services which are expected to be paid from 2020 to 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and December&#160;31, 2019, we had cancelable open purchase orders of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$133.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$105.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, in total under such agreements for our significant clinical operations and support. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and December&#160;31, 2019, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="FI2020Q1_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrna_PersonalizedMRNACancerVaccinesProductsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"
      decimals="-5"
      id="d8104319e476-wk-Fact-14D2BAA7826984019397B89380015BF8"
      unitRef="usd">243000000.0</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_us-gaap_PurchaseCommitmentMember"
      decimals="-5"
      id="d8104319e529-wk-Fact-D920C36B3F6AA8E7E597B8937FEFA48C"
      unitRef="usd">3900000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_mrna_ClinicalOperationsAndSupportCommitmentMember"
      decimals="-5"
      id="d8104319e543-wk-Fact-385C9DCC35D965568F78B8937FFF9E6C"
      unitRef="usd">133200000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q4_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_mrna_ClinicalOperationsAndSupportCommitmentMember"
      decimals="-5"
      id="d8104319e547-wk-Fact-E27AD696EE58CCD27649B8937FF6ECB9"
      unitRef="usd">105900000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-FB955CFA6C889870787CB89380288921-0-wk-Fact-295C9A2799C193CB3DD7B893801A9368">Shareholders' Equity&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February&#160;28, 2018 and May&#160;7,&#160;2018, the Board of Directors approved an amendment to our Certificate of Incorporation resulting in a total of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;775,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock and a total of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;509,352,795&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of redeemable convertible preferred stock being authorized, respectively. Upon completion of our IPO, our authorized capital stock consists of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,600,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock, par value&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.0001&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share, and&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock, par value&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.0001&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share, all of which shares of preferred stock are undesignated.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 11, 2018, we completed our IPO, whereby we sold&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,275,993&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock at a price of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share. The aggregate net proceeds received by us from the IPO were&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$563.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net of underwriting discounts and commissions of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$33.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and offering expenses of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;payable by us. Upon the closing of the IPO, all outstanding shares of our redeemable convertible preferred stock were converted into&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236,012,913&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of the common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 14, 2020, we sold&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,315,790&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock at a price of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share through a public equity offering. The aggregate net proceeds from the offering were&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$477.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net of underwriting discounts, commissions and estimated offering expenses. In addition, the underwriters exercised their option to purchase an additional&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,947,368&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock at the public offering price less the underwriting discount, resulting in additional net proceeds of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$71.8 million&lt;/span&gt;&lt;/span&gt;.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I2018Q1Feb28"
      decimals="INF"
      id="d8105319e461-wk-Fact-BE8345C4B2B35C1AED84B893801B21E6"
      unitRef="shares">775000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="I2018Q2May7"
      decimals="INF"
      id="d8105319e465-wk-Fact-8A816BE653BAEA3C492FB8937FF7EBF0"
      unitRef="shares">509352795</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I2018Q4Dec11"
      decimals="INF"
      id="d8105319e469-wk-Fact-D39E849CCAA9EC712948B8937FC84367"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="I2018Q4Dec11"
      decimals="INF"
      id="d8105319e473-wk-Fact-F9AB9E83BE79E2B63228B8937FF9BA35"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="I2018Q4Dec11"
      decimals="INF"
      id="d8105319e477-wk-Fact-0434DCA0086B603E16B4B8937FFB3E56"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="I2018Q4Dec11"
      decimals="INF"
      id="d8105319e482-wk-Fact-DC85316C834D4D3474DDB8937FFB75F6"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="INF"
      id="d8105319e491-wk-Fact-7AA72E57FBBB38AB1CAFB8937FC85E63"
      unitRef="shares">26275993</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="INF"
      id="d8105319e495-wk-Fact-BF7AE07AD210547A1560B8937FF827B5"
      unitRef="usdPerShare">23.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="-5"
      id="d8105319e499-wk-Fact-8F555B1D34BF18E3CAB5B8937FFE4A49"
      unitRef="usd">563000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mrna:PaymentsOfUnderwritingDiscounts
      contextRef="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="-5"
      id="d8105319e503-wk-Fact-2CCC2C1D3055194B2F3EB8937FF66413"
      unitRef="usd">33200000</mrna:PaymentsOfUnderwritingDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D2018Q4Dec11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="-5"
      id="d8105319e507-wk-Fact-D25968751A91DC4191F4B8937FF5C7EC"
      unitRef="usd">8100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="I2018Q4Dec11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
      decimals="INF"
      id="d8105319e512-wk-Fact-7B2691FE13548D93EC8AB8938003C1FF"
      unitRef="shares">236012913</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember"
      decimals="INF"
      id="d8105319e521-wk-Fact-667BEF7AA272AA53CC15B8937FF1744E"
      unitRef="shares">26315790</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember"
      decimals="INF"
      id="d8105319e525-wk-Fact-97714489A7AD1CF776FEB8937FF9F43F"
      unitRef="usdPerShare">19.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_mrna_PublicEquityOfferingMember"
      decimals="-5"
      id="d8105319e529-wk-Fact-130B4AB5F66A22E3BE89B893801C7CEB"
      unitRef="usd">477700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d8105319e533-wk-Fact-60B4A8C8DB95DC76A00EB8937FF4CC8E"
      unitRef="shares">3947368</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2020Q1Feb14_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="d8105319e537-wk-Fact-27A05DC3B117A674138BB8937FF7A22D"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-CF725775EA77EF17D12BB8938028AE5D-0-wk-Fact-83A7AC51B984925D17C8B893800BD03A">Stock-Based Compensation&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2013, we adopted the 2013 Equity Incentive Plan (the 2013 Incentive Plan) and the 2013 Unit Option and Grant Plan (the 2013 Option Plan), which provided for the grant of incentive units, non-qualified unit options, and restricted and unrestricted unit awards to our employees, officers, directors, advisors, and outside consultants. Historically, we also granted restricted stock to founders, officers, directors, and advisors outside any of the Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August&#160;2016, we adopted the 2016 Stock Option and Grant Plan (the 2016 Equity Plan), which replaced the 2013 Option Plan and the 2013 Incentive Plan. The 2016 Equity Plan and provided for the grant of incentive stock options, non-qualified stock options, restricted stock, unrestricted stock, and restricted stock units to our employees, officers, directors, consultants, and other key persons.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with the IPO, we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Plan. The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. We have initially reserved &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock for the issuance of awards under the 2018 Equity Plan. The 2018 Equity Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the outstanding number of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year period, with the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of such awards vesting following &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;twelve months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of continued employment or service. The remaining awards vests in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;twelve&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; quarterly installments over the following twelve quarters. Stock options granted under the 2016 Equity Plan expire &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had a total of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares reserved for future issuance under our Equity Plans, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares were reserved for equity awards previously granted, and&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,536,915&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.2 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;286,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,585,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,188,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(944,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,988,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.3 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;669,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,078,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.0 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;417,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected to vest at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,910,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.6 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;252,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; stock options were exercised. The total intrinsic value of options exercised was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$58.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; March 31, 2020. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$28.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Common Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have granted restricted stock unit awards generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our restricted stock unit activity during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;per Unit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding, non-vested at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,177,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,057,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25.44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(113,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(58,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding, non-vested at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,062,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, we adopted our 2018 Employee Stock Purchase Plan (ESPP), which became effective on December 5, 2018. The ESPP initially reserves and authorizes the issuance of up to a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;810,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock to participating employees. We will make one or more offerings, consisting of one or more purchase periods, each year to our employees to purchase shares under the ESPP. Offerings will usually begin every six months and will continue for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-month periods, referred to as offering periods. The purchase price at which shares are sold under the ESPP will be equal to&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of the lower of the fair market value of the shares on the first business day of the offering period or the last business day of the purchase period. Employees are generally eligible to participate through payroll deductions of between&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;to&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of their compensation and may not purchase more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock during each purchase period or&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;worth of shares of common stock in any calendar year.&#160;We began our first ESPP offering on June 1, 2019. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares sold under the ESPP during the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Valuation and Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation for options granted under our Equity Plans is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.14 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.12 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the components and classification of stock-based compensation expense for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,487&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,010&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;562&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$243.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total unrecognized compensation cost related to unvested stock-based compensation with respect to options and restricted stock granted. That cost is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.19 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="I2018Q4Nov30_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member"
      decimals="INF"
      id="d8107703e470-wk-Fact-AD59914E3E93B935117EB8937FFEAE29"
      unitRef="shares">13000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized
      contextRef="D2018Q4Nov30_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member"
      decimals="INF"
      id="d8107703e474-wk-Fact-FDBA5ACAF3093EB402C5B8937FCFBBAF"
      unitRef="number">0.04</mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="d8107703e491-wk-Fact-8DD296109F87AD4B6239B89380102D8F"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      id="d8107703e495-wk-Fact-B71827764C7E8679CD91B8937FCA5E62">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_ServiceBasedAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="d8107703e499-wk-Fact-68567C972375DC0D735AB8938003C462"
      unitRef="installment">12</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrna_StockOptionAndGrantPlan2016Member"
      id="d8107703e503-wk-Fact-47E5B5BF49416D0E400AB893800D4B51">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="d8107703e516-wk-Fact-C8059FBDF3ACD8DBEC8EB8937FD639E7"
      unitRef="shares">75000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d8107703e520-wk-Fact-57BC7CA6A3FA2CE3C803B8937FF8A590"
      unitRef="shares">47100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_mrna_StockOptionAndIncentivePlan2018Member"
      decimals="-5"
      id="d8107703e524-wk-Fact-A32FE3F45843A7055994B8937FCCDE3C"
      unitRef="shares">27900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B7363939C0D799103224B8938029800F-0-wk-Fact-098338A70E5ED90D0EDFB893800D9697">The following table summarizes our option activity during &lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;span style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,536,915&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.2 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;286,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,585,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,188,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(944,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,988,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.3 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;669,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,078,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.0 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;417,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected to vest at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,910,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.6 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;252,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d8107703e738-wk-Fact-809ED6E484387E2A3213B8938001FB6A"
      unitRef="shares">45536915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d8107703e757-wk-Fact-20369CA0EC9D0F628451B8937FF9D235"
      unitRef="usdPerShare">13.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4"
      decimals="2"
      id="d8107703e776-wk-Fact-B52090BD6631BFCF1570B89380008808"
      unitRef="usdPerShare">7.35</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q4YTD"
      id="d8107703e791-wk-Fact-32E175CE9EA6C4B2F35CB89380029156">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8107703e806-wk-Fact-CB6D20F4B94540BFD5CBB8937FF75254"
      unitRef="usd">286310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d8107703e826-wk-Fact-E5564841E0FF39A5311EB893801BF719"
      unitRef="shares">3585069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d8107703e840-wk-Fact-789D442BC744E7E175D4B8937FFFE0A6"
      unitRef="usdPerShare">25.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d8107703e859-wk-Fact-2C76027D96B5A68E2AB4B8937FF28AFA"
      unitRef="usdPerShare">13.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d8107703e915-wk-Fact-81F6CA5A895853CFDF8EB8937FFB4720"
      unitRef="shares">3188671</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d8107703e930-wk-Fact-20510793C6D98844B927B8937FFF9490"
      unitRef="usdPerShare">8.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d8107703e949-wk-Fact-0A93D85C84021374AEA0B8937FF9FC03"
      unitRef="usdPerShare">4.90</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d8107703e1005-wk-Fact-B30975C49F653C62D76CB8937FF16CF8"
      unitRef="shares">944715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d8107703e1020-wk-Fact-303ED13EE78812783057B8938000703A"
      unitRef="usdPerShare">15.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d8107703e1039-wk-Fact-E6C86D8FAD253F766BA1B8937FF2A049"
      unitRef="usdPerShare">9.68</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2020Q1"
      decimals="INF"
      id="d8107703e1095-wk-Fact-A778D9682CEE3690F53CB8937FFA9908"
      unitRef="shares">44988598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2020Q1"
      decimals="2"
      id="d8107703e1109-wk-Fact-47CD71239F6A5B10E89DB8937FFD5BF1"
      unitRef="usdPerShare">15.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="FI2020Q1"
      decimals="2"
      id="d8107703e1128-wk-Fact-501D9A8C3ED39C666F57B8937FCDBDD1"
      unitRef="usdPerShare">7.98</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2020Q1YTD"
      id="d8107703e1148-wk-Fact-9231BB98A06439230F47B8937FF527A4">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8107703e1158-wk-Fact-1CA88863354F94F4BCDFB8937FFE2F36"
      unitRef="usd">669827000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2020Q1"
      decimals="INF"
      id="d8107703e1183-wk-Fact-29D50806C2CC34CFCC9CB8938002F23A"
      unitRef="shares">22078150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2020Q1"
      decimals="2"
      id="d8107703e1197-wk-Fact-2576907F316BF2F16A29B8937FFEF8AA"
      unitRef="usdPerShare">11.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="FI2020Q1"
      decimals="2"
      id="d8107703e1216-wk-Fact-EEB986CDBD9954A7E63DB8937FF87A1E"
      unitRef="usdPerShare">5.42</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2020Q1YTD"
      id="d8107703e1236-wk-Fact-32013FE60E381A522791B8937FFA0065">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8107703e1246-wk-Fact-8D2054960E107525460BB8937FFEB97C"
      unitRef="usd">417516000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2020Q1"
      decimals="INF"
      id="d8107703e1271-wk-Fact-4E5E6FABB70DF459E6AFB8938005EEB3"
      unitRef="shares">22910448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2020Q1"
      decimals="2"
      id="d8107703e1285-wk-Fact-86169F24BA816423D648B8937FFD38A6"
      unitRef="usdPerShare">18.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue
      contextRef="FI2020Q1"
      decimals="2"
      id="d8107703e1304-wk-Fact-BE968485B141CBD5D9B0B8937FF8AF46"
      unitRef="usdPerShare">10.45</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="FD2020Q1YTD"
      id="d8107703e1324-wk-Fact-5190B314EDB53E704F57B8937FF6F102">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8107703e1334-wk-Fact-2F734174F069507FF6C7B8937FF37058"
      unitRef="usd">252311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d8107703e1374-wk-Fact-5B56D8FBBBD9734D2BE6B95DB9FCB8D6"
      unitRef="shares">3200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d8107703e1378-wk-Fact-81C863868BA3823D906BB89380199135"
      unitRef="usd">58000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d8107703e1387-wk-Fact-6CCFAB695DF4BA50D867B8937FC8996A"
      unitRef="usd">28400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-70B5C8DFB78A2A2C546FB893802991C4-0-wk-Fact-C76E1BE6F379E59006AEB8937FFD3A43">The following table summarizes our restricted stock unit activity during &lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;per Unit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding, non-vested at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,177,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,057,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25.44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(113,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(58,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding, non-vested at March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,062,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d8107703e1491-wk-Fact-B3F8355BCF94743EC0E2B893800A95BD"
      unitRef="shares">1177249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d8107703e1510-wk-Fact-56E359CFD681337CBFDDB893800A0758"
      unitRef="usdPerShare">19.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d8107703e1525-wk-Fact-A03032142BDA4C012816B89380069051"
      unitRef="shares">1057348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d8107703e1539-wk-Fact-F3CD97EB85056A84D423B893801673BC"
      unitRef="usdPerShare">25.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d8107703e1559-wk-Fact-7EE7C8805660A320DE04B8938000B501"
      unitRef="shares">113991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d8107703e1574-wk-Fact-F401E690771C74ACB13BB8938014C457"
      unitRef="usdPerShare">20.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d8107703e1594-wk-Fact-AA88DBF55BFB7FCBDDF9B89380097380"
      unitRef="shares">58514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d8107703e1609-wk-Fact-80A31DFD7B30B4495046B893800CD747"
      unitRef="usdPerShare">20.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d8107703e1629-wk-Fact-31DB587A5948223F62A4B8938016F0DE"
      unitRef="shares">2062092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d8107703e1643-wk-Fact-4BB56F7693B1958DFEADB89380150BF2"
      unitRef="usdPerShare">22.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="I2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member"
      decimals="INF"
      id="d8107703e1667-wk-Fact-751C1A66C9C6BD36E962B893800261DC"
      unitRef="shares">810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member"
      decimals="INF"
      id="d8107703e1675-wk-Fact-2B71F7267A1E6CB2355DB89380044E12"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="I2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member"
      decimals="INF"
      id="d8107703e1679-wk-Fact-1092D268B99D9FFA25F4B893801C30D3"
      unitRef="number">0.01</mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="I2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member"
      decimals="INF"
      id="d8107703e1683-wk-Fact-00727DD5CFEB42DEAFC1B8937FCE084A"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member"
      decimals="INF"
      id="d8107703e1688-wk-Fact-B5C5295E980022A1B3E7B8937FCB7B1B"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="D2018Q4Dec5_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_mrna_EmployeeStockPurchasePlan2018Member"
      decimals="-3"
      id="d8107703e1692-wk-Fact-DF364AAC36F1621BA305B8938006D4AA"
      unitRef="usd">25000</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-1E69789E09F368145A94B8938029B76F-0-wk-Fact-DF58AAEEA64E6AC38299B8937FCF926E">The weighted-average assumptions used to estimate the fair value of options granted for &lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.14 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.12 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d8107703e1943-wk-Fact-C52021C4BD08CA8978DBB8938006AE66"
      unitRef="number">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d8107703e1963-wk-Fact-B501C2629B10C7340BEFB8937FCA5B06"
      unitRef="number">0.0248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d8107703e1989-wk-Fact-2BF014FD7DCBBD330D86B8937FC9D315">P6Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d8107703e2008-wk-Fact-D99CE3D0B62F98AE9C04B8938018DAE6">P6Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d8107703e2033-wk-Fact-70C5964AB6DA388A8625B8937FCD4361"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d8107703e2053-wk-Fact-EEC7AC7BD0E324CD28A6B8937FF772E7"
      unitRef="number">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d8107703e2079-wk-Fact-9C7A74E2F7A23D9EAD6FB893800574F8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d8107703e2099-wk-Fact-F4CED1CDB669EF39BFA7B89380082455"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="FI2020Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d8107703e2130-wk-Fact-360E5D45EBD56E60D379B893800C035D"
      unitRef="usdPerShare">13.84</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="FI2019Q1_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d8107703e2149-wk-Fact-0CF41115F17048D4A708B89380141B2B"
      unitRef="usdPerShare">12.16</us-gaap:SharePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B2FD07782CBB8BB173D6B89380290CC0-0-wk-Fact-B3FF17F0ABC56AF00BD8B8938003226B">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the components and classification of stock-based compensation expense for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,487&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,010&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;562&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d8107703e2305-wk-Fact-93BE8F4A318233BC9B7DB89380177B2B"
      unitRef="usd">18018000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d8107703e2324-wk-Fact-A7820E37F85F37535637B89380114DCD"
      unitRef="usd">17487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d8107703e2344-wk-Fact-9AD0957F0D675F5ED608B893801B3718"
      unitRef="usd">1833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d8107703e2363-wk-Fact-BC11E50B1F146AF58400B893801AD118"
      unitRef="usd">1010000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-3"
      id="d8107703e2388-wk-Fact-A00675D4DEE531B24BFCB8937FD2082E"
      unitRef="usd">562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-3"
      id="d8107703e2407-wk-Fact-B838BFD549BC1E03662DB8937FC9E100"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8107703e2437-wk-Fact-7FA20B91DB9EDD84D33BB8937FC823A4"
      unitRef="usd">20413000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8107703e2456-wk-Fact-1F6399C1392C687CF797B893801BDB03"
      unitRef="usd">18497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d8107703e2481-wk-Fact-841FCAD1D87543711D51B89380128BBF"
      unitRef="usd">12036000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d8107703e2500-wk-Fact-131021C9BAF0D97B0461B8938008759D"
      unitRef="usd">10783000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d8107703e2520-wk-Fact-9B56CBD5BB77FA5F0BA9B8937FFDBA08"
      unitRef="usd">8377000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d8107703e2539-wk-Fact-A2612B8CE64A17DA9B3FB8938007F27F"
      unitRef="usd">7714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8107703e2569-wk-Fact-7FA20B91DB9EDD84D33BB8937FC823A4"
      unitRef="usd">20413000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8107703e2588-wk-Fact-1F6399C1392C687CF797B893801BDB03"
      unitRef="usd">18497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2020Q1"
      decimals="-5"
      id="d8107703e2607-wk-Fact-FF25048A13380DBC2238B8937FCB0921"
      unitRef="usd">243400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2020Q1YTD"
      id="d8107703e2611-wk-Fact-B103065911FADD975DE4B89380040303">P3Y2M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-823698E4432C3C19D50AB8938029908A-0-wk-Fact-DE0B1E4056DD76C718E7B8937FD4FD62">Income Taxes&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#x201c;more likely than not&#x201d; criterion.&#160;Realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. We continued to maintain a full valuation allowance against all of our deferred tax assets based on management&#x2019;s evaluation of all available evidence.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There were no significant income tax provisions or benefits for the three months ended March 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-C5CAB44A74EFB32599E2B893802969B5-0-wk-Fact-787EEE9BE55C2032E17AB893801843D0">Net Loss per Share &lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per share for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(124,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares used in net loss per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;353,105,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;328,809,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following common stock equivalents, presented based on amounts outstanding as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and 2019 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,988,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,271,281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,062,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,011,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,050,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54,433,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-A684FDCD44502787E84AB8938029EF8C-0-wk-Fact-EABFBAE2EA455A847EBEB89380023297">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per share for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the three months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(124,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(132,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares used in net loss per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;353,105,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;328,809,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8108495e642-wk-Fact-D74D87DA6A13D05C3CE1B893800E6618"
      unitRef="usd">-124230000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD"
      decimals="-3"
      id="d8108495e662-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
      unitRef="usd">-132576000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d8108495e729-wk-Fact-0B70C03E5259115FF9BDB893800E79A7"
      unitRef="shares">353105021</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q1YTD"
      decimals="0"
      id="d8108495e748-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52"
      unitRef="shares">328809986</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d8108495e778-wk-Fact-334C08CA9FF5FC0D8533B893800D7CE7"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q1YTD"
      decimals="2"
      id="d8108495e798-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-D7711603858B3B1FA378B893802900F9-0-wk-Fact-B2ED2DAA6F1282B6BEA6B893801494AF">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following common stock equivalents, presented based on amounts outstanding as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and 2019 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,988,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,271,281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,062,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,011,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,050,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54,433,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="d8108495e903-wk-Fact-A4F8C53D55D6967BDC97B8937FC8A6AA"
      unitRef="shares">44988598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="d8108495e917-wk-Fact-6CF37FC785D8F77710FFB8937FD086F3"
      unitRef="shares">53271281</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"
      decimals="-3"
      id="d8108495e932-wk-Fact-67844DECA70B109EB914B8BC04A2A1FD"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"
      decimals="0"
      id="d8108495e946-wk-Fact-E16E16E624FD2C60A0AFB8937FD5C033"
      unitRef="shares">150397</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="d8108495e961-wk-Fact-1BAD2E24BA8A5FD92652B8937FD3CBCC"
      unitRef="shares">2062092</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="d8108495e975-wk-Fact-5E781E798DACF4813FFCB8937FD169C4"
      unitRef="shares">1011483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d8108495e990-wk-Fact-CDECFA2D691AD5FC777EB8937FC91036"
      unitRef="shares">47050690</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q1YTD"
      decimals="0"
      id="d8108495e1004-wk-Fact-E3EEAAEC01F4BA613BF1B8937FC95C11"
      unitRef="shares">54433161</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-33930D7D4668DFEFE073B893802A7A65-0-wk-Fact-D6DD1FA159F5FE2E634BB89380151796">Subsequent Events&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#444444;"&gt;On April 16, 2020, we entered into an agreement for a commitment of up to&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#444444;"&gt;&lt;span&gt;$483 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#444444;"&gt;&#160;from the&#160;Biomedical Advanced Research and Development Authority&#160;(BARDA), a division of the&#160;Office of the Assistant&#160;Secretary for Preparedness and Response (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#555555;"&gt;ASPR&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#444444;"&gt;) within the&#160;U.S. Department of Health and Human Services&#160;(HHS), to accelerate development of our mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2). Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#444444;"&gt;On May 1, 2020, we entered into a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#444444;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt; year strategic collaboration agreement with&#160;Lonza Ltd. to enable larger scale manufacture of our mRNA vaccine candidate mRNA-1273 against the SARS-CoV-2 and additional&#160;Moderna&#160;products in the future. Under the terms of the agreement, we plan to establish manufacturing suites at Lonza&#x2019;s facilities in&#160;the United States&#160;and&#160;Switzerland&#160;for the manufacture of mRNA-1273 at both sites.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="I2020Q2April16_srt_CounterpartyNameAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="d8107804e454-wk-Fact-17A00E6A638AC690DC19B8B9639E8C5D"
      unitRef="usd">483000000</us-gaap:GrantsReceivable>
    <mrna:CollaborativeArrangementTermOfArrangement
      contextRef="D2020Q2May1_srt_CounterpartyNameAxis_mrna_LonzaLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d8107804e467-wk-Fact-EBBDEFB9AE254B2B244CEAD25D77A946">P10Y</mrna:CollaborativeArrangementTermOfArrangement>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#d8088448e3051-wk-Fact-0468755339101634CF3BB893800565B3"
          xlink:label="d8088448e3051-wk-Fact-0468755339101634CF3BB893800565B3"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl" xlink:label="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e3051-wk-Fact-0468755339101634CF3BB893800565B3"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1742-wk-Fact-06331F9217E917C083EEB89380103D9E"
          xlink:label="d8090304e1742-wk-Fact-06331F9217E917C083EEB89380103D9E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1742-wk-Fact-06331F9217E917C083EEB89380103D9E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e900-wk-Fact-13B91B25EEEA209A05DDB8937FF9A56A"
          xlink:label="d8090304e900-wk-Fact-13B91B25EEEA209A05DDB8937FF9A56A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e900-wk-Fact-13B91B25EEEA209A05DDB8937FF9A56A"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e1219-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52"
          xlink:label="d8084779e1219-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8108495e748-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52"
          xlink:label="d8108495e748-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e1219-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8108495e748-wk-Fact-14DBA92AEC1FC7B5A6F5B8938017CF52"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8093385e1160-wk-Fact-156AE2DD85FA9D77014AB893801275AF"
          xlink:label="d8093385e1160-wk-Fact-156AE2DD85FA9D77014AB893801275AF"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8084779e1016-wk-Fact-156AE2DD85FA9D77014AB893801275AF"
          xlink:label="d8084779e1016-wk-Fact-156AE2DD85FA9D77014AB893801275AF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1160-wk-Fact-156AE2DD85FA9D77014AB893801275AF"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e1016-wk-Fact-156AE2DD85FA9D77014AB893801275AF"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8086815e661-wk-Fact-16C6E45D368ABF511BFCB8937FCB92FD"
          xlink:label="d8086815e661-wk-Fact-16C6E45D368ABF511BFCB8937FCB92FD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8086815e661-wk-Fact-16C6E45D368ABF511BFCB8937FCB92FD"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2620-wk-Fact-171B54BA2BAC4D6F68F9B89380150DE5"
          xlink:label="d8088448e2620-wk-Fact-171B54BA2BAC4D6F68F9B89380150DE5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2620-wk-Fact-171B54BA2BAC4D6F68F9B89380150DE5"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8086815e786-wk-Fact-27C8D3886673A4C3D82AB8937FC91677"
          xlink:label="d8086815e786-wk-Fact-27C8D3886673A4C3D82AB8937FC91677"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8086815e786-wk-Fact-27C8D3886673A4C3D82AB8937FC91677"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8086815e701-wk-Fact-280EF1911DA26D907515B8937FE3FF22"
          xlink:label="d8086815e701-wk-Fact-280EF1911DA26D907515B8937FE3FF22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8086815e701-wk-Fact-280EF1911DA26D907515B8937FE3FF22"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2396-wk-Fact-28368F1B02540394CB54B8938018EDC2"
          xlink:label="d8088448e2396-wk-Fact-28368F1B02540394CB54B8938018EDC2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2396-wk-Fact-28368F1B02540394CB54B8938018EDC2"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8093385e2083-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED"
          xlink:label="d8093385e2083-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8090304e1222-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED"
          xlink:label="d8090304e1222-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e2083-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1222-wk-Fact-2DA8DDBE7D2698088A58B8937FF61FED"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e779-wk-Fact-2E84575AAA5FF3FC9F78B8937FF58F76"
          xlink:label="d8090304e779-wk-Fact-2E84575AAA5FF3FC9F78B8937FF58F76"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e779-wk-Fact-2E84575AAA5FF3FC9F78B8937FF58F76"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e976-wk-Fact-326EE1AA525F98E1FA63B8938009353C"
          xlink:label="d8084779e976-wk-Fact-326EE1AA525F98E1FA63B8938009353C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e976-wk-Fact-326EE1AA525F98E1FA63B8938009353C"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e856-wk-Fact-388AA200DC25E9066B99B893800C8ED9"
          xlink:label="d8084779e856-wk-Fact-388AA200DC25E9066B99B893800C8ED9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e963-wk-Fact-388AA200DC25E9066B99B893800C8ED9"
          xlink:label="d8093385e963-wk-Fact-388AA200DC25E9066B99B893800C8ED9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e856-wk-Fact-388AA200DC25E9066B99B893800C8ED9"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e963-wk-Fact-388AA200DC25E9066B99B893800C8ED9"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2508-wk-Fact-393E94D668BA5E8C9C9DB89380111236"
          xlink:label="d8088448e2508-wk-Fact-393E94D668BA5E8C9C9DB89380111236"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2508-wk-Fact-393E94D668BA5E8C9C9DB89380111236"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e3171-wk-Fact-3C6E0C87B7DA52EDD9B4B8938007040F"
          xlink:label="d8088448e3171-wk-Fact-3C6E0C87B7DA52EDD9B4B8938007040F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e3171-wk-Fact-3C6E0C87B7DA52EDD9B4B8938007040F"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e941-wk-Fact-3D792C328A7A9FAF77F0B8937FD8E780"
          xlink:label="d8090304e941-wk-Fact-3D792C328A7A9FAF77F0B8937FD8E780"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e941-wk-Fact-3D792C328A7A9FAF77F0B8937FD8E780"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8093385e1760-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA"
          xlink:label="d8093385e1760-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8090304e740-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA"
          xlink:label="d8090304e740-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1760-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e740-wk-Fact-4DBF922665C8DE8EB4BDB8938013A6FA"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1101-wk-Fact-5061953B1C2C59733B33B8937FE3BCE5"
          xlink:label="d8090304e1101-wk-Fact-5061953B1C2C59733B33B8937FE3BCE5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1101-wk-Fact-5061953B1C2C59733B33B8937FE3BCE5"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1385-wk-Fact-57606C3B8D696B7B20FBB8938013667B"
          xlink:label="d8090304e1385-wk-Fact-57606C3B8D696B7B20FBB8938013667B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1385-wk-Fact-57606C3B8D696B7B20FBB8938013667B"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e936-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB"
          xlink:label="d8084779e936-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e1093-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB"
          xlink:label="d8093385e1093-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e936-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1093-wk-Fact-5F957547B9E6E5496390B8937FFFDAEB"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e3191-wk-Fact-63A2E5079CEFCAF5726EB89380070257"
          xlink:label="d8088448e3191-wk-Fact-63A2E5079CEFCAF5726EB89380070257"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e3191-wk-Fact-63A2E5079CEFCAF5726EB89380070257"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e659-wk-Fact-66360CB5AE1A1B5E4ABEB8938010E740"
          xlink:label="d8084779e659-wk-Fact-66360CB5AE1A1B5E4ABEB8938010E740"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e659-wk-Fact-66360CB5AE1A1B5E4ABEB8938010E740"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1664-wk-Fact-68DBC17D0B4E10977736B8938009AD08"
          xlink:label="d8090304e1664-wk-Fact-68DBC17D0B4E10977736B8938009AD08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e2281-wk-Fact-68DBC17D0B4E10977736B8938009AD08"
          xlink:label="d8093385e2281-wk-Fact-68DBC17D0B4E10977736B8938009AD08"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1664-wk-Fact-68DBC17D0B4E10977736B8938009AD08"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e2281-wk-Fact-68DBC17D0B4E10977736B8938009AD08"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8093385e1824-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE"
          xlink:label="d8093385e1824-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8090304e982-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE"
          xlink:label="d8090304e982-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1824-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e982-wk-Fact-6B9E5A2D770B0E8975E6B8937FF02AFE"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e737-wk-Fact-6C01246797B7AC79E810B893800D7458"
          xlink:label="d8084779e737-wk-Fact-6C01246797B7AC79E810B893800D7458"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e737-wk-Fact-6C01246797B7AC79E810B893800D7458"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2713-wk-Fact-6E98F6850B8815FC9558B893800F1738"
          xlink:label="d8088448e2713-wk-Fact-6E98F6850B8815FC9558B893800F1738"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2713-wk-Fact-6E98F6850B8815FC9558B893800F1738"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8093385e2149-wk-Fact-71DFE94246E5E76A1601B8938019923C"
          xlink:label="d8093385e2149-wk-Fact-71DFE94246E5E76A1601B8938019923C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8090304e1262-wk-Fact-71DFE94246E5E76A1601B8938019923C"
          xlink:label="d8090304e1262-wk-Fact-71DFE94246E5E76A1601B8938019923C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e2149-wk-Fact-71DFE94246E5E76A1601B8938019923C"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1262-wk-Fact-71DFE94246E5E76A1601B8938019923C"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e1057-wk-Fact-794A1869F8798C775B81B893800A6DA6"
          xlink:label="d8084779e1057-wk-Fact-794A1869F8798C775B81B893800A6DA6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e1226-wk-Fact-794A1869F8798C775B81B893800A6DA6"
          xlink:label="d8093385e1226-wk-Fact-794A1869F8798C775B81B893800A6DA6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e1057-wk-Fact-794A1869F8798C775B81B893800A6DA6"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1226-wk-Fact-794A1869F8798C775B81B893800A6DA6"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1344-wk-Fact-7DA9A9CAD969006FD132B8937FD32083"
          xlink:label="d8090304e1344-wk-Fact-7DA9A9CAD969006FD132B8937FD32083"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1344-wk-Fact-7DA9A9CAD969006FD132B8937FD32083"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1505-wk-Fact-7ED3D5A06DA641811A58B8938000C408"
          xlink:label="d8090304e1505-wk-Fact-7ED3D5A06DA641811A58B8938000C408"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1505-wk-Fact-7ED3D5A06DA641811A58B8938000C408"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1782-wk-Fact-7EE40EC09D85242D719AB893800A84E0"
          xlink:label="d8090304e1782-wk-Fact-7EE40EC09D85242D719AB893800A84E0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1782-wk-Fact-7EE40EC09D85242D719AB893800A84E0"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2601-wk-Fact-7FE56C026237BA76D498B8938015293D"
          xlink:label="d8088448e2601-wk-Fact-7FE56C026237BA76D498B8938015293D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2601-wk-Fact-7FE56C026237BA76D498B8938015293D"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e698-wk-Fact-82B43048FBEE6F3672F2B89380094FF5"
          xlink:label="d8084779e698-wk-Fact-82B43048FBEE6F3672F2B89380094FF5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e698-wk-Fact-82B43048FBEE6F3672F2B89380094FF5"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2733-wk-Fact-8ABA793256C1005F3F19B8938017A9B2"
          xlink:label="d8088448e2733-wk-Fact-8ABA793256C1005F3F19B8938017A9B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2733-wk-Fact-8ABA793256C1005F3F19B8938017A9B2"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1061-wk-Fact-8DCA9BC49239FD042533B893800A53CF"
          xlink:label="d8090304e1061-wk-Fact-8DCA9BC49239FD042533B893800A53CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1061-wk-Fact-8DCA9BC49239FD042533B893800A53CF"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e625-wk-Fact-A1E074F942AAC9033D6DB8938016D0B6"
          xlink:label="d8084779e625-wk-Fact-A1E074F942AAC9033D6DB8938016D0B6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e625-wk-Fact-A1E074F942AAC9033D6DB8938016D0B6"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2269-wk-Fact-A79FC62A46F8E76F5CA7B893800694A3"
          xlink:label="d8088448e2269-wk-Fact-A79FC62A46F8E76F5CA7B893800694A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2269-wk-Fact-A79FC62A46F8E76F5CA7B893800694A3"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1424-wk-Fact-A9B844D9D79DFD44E64DB8937FCCC2B6"
          xlink:label="d8090304e1424-wk-Fact-A9B844D9D79DFD44E64DB8937FCCC2B6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1424-wk-Fact-A9B844D9D79DFD44E64DB8937FCCC2B6"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1827-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE"
          xlink:label="d8090304e1827-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e2912-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE"
          xlink:label="d8093385e2912-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1827-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e2912-wk-Fact-AAE1C88A4C792870D5BDB893801A0ADE"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e701-wk-Fact-AE09011276505A34815AB893800FEC64"
          xlink:label="d8090304e701-wk-Fact-AE09011276505A34815AB893800FEC64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e701-wk-Fact-AE09011276505A34815AB893800FEC64"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1142-wk-Fact-B07D7B9BE56744C316DDB893801A9D41"
          xlink:label="d8090304e1142-wk-Fact-B07D7B9BE56744C316DDB893801A9D41"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1142-wk-Fact-B07D7B9BE56744C316DDB893801A9D41"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1022-wk-Fact-B6924E34411A34ED10EAB8B337F36C45"
          xlink:label="d8090304e1022-wk-Fact-B6924E34411A34ED10EAB8B337F36C45"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e1888-wk-Fact-B6924E34411A34ED10EAB8B337F36C45"
          xlink:label="d8093385e1888-wk-Fact-B6924E34411A34ED10EAB8B337F36C45"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1022-wk-Fact-B6924E34411A34ED10EAB8B337F36C45"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1888-wk-Fact-B6924E34411A34ED10EAB8B337F36C45"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1703-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA"
          xlink:label="d8090304e1703-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e2411-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA"
          xlink:label="d8093385e2411-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1703-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e2411-wk-Fact-C17FB3F9CDB196A22183B8937FF834DA"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2289-wk-Fact-C1DDD03AE10FF9404F6AB8938012E3F3"
          xlink:label="d8088448e2289-wk-Fact-C1DDD03AE10FF9404F6AB8938012E3F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2289-wk-Fact-C1DDD03AE10FF9404F6AB8938012E3F3"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1182-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D"
          xlink:label="d8090304e1182-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e2018-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D"
          xlink:label="d8093385e2018-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1182-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e2018-wk-Fact-C3CDEF2200D3125E3053B8937FF20A9D"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8084779e1097-wk-Fact-C8FEBDCA5C3EB990D3E0B893800044E6"
          xlink:label="d8084779e1097-wk-Fact-C8FEBDCA5C3EB990D3E0B893800044E6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e1097-wk-Fact-C8FEBDCA5C3EB990D3E0B893800044E6"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1907-wk-Fact-CAA3495CF8BB8E12C464B89380044039"
          xlink:label="d8090304e1907-wk-Fact-CAA3495CF8BB8E12C464B89380044039"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1907-wk-Fact-CAA3495CF8BB8E12C464B89380044039"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2846-wk-Fact-CBF686121BE1AC6B2904B893800EF2DD"
          xlink:label="d8088448e2846-wk-Fact-CBF686121BE1AC6B2904B893800EF2DD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2846-wk-Fact-CBF686121BE1AC6B2904B893800EF2DD"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8093385e1028-wk-Fact-D3827E83F30C694EF76CB8937FFE759C"
          xlink:label="d8093385e1028-wk-Fact-D3827E83F30C694EF76CB8937FFE759C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8084779e895-wk-Fact-D3827E83F30C694EF76CB8937FFE759C"
          xlink:label="d8084779e895-wk-Fact-D3827E83F30C694EF76CB8937FFE759C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1028-wk-Fact-D3827E83F30C694EF76CB8937FFE759C"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e895-wk-Fact-D3827E83F30C694EF76CB8937FFE759C"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1625-wk-Fact-D679BA327FBD2B556510B8938006766F"
          xlink:label="d8090304e1625-wk-Fact-D679BA327FBD2B556510B8938006766F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1625-wk-Fact-D679BA327FBD2B556510B8938006766F"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e819-wk-Fact-D9F27C1A04B3019CC1E5B893801B938F"
          xlink:label="d8090304e819-wk-Fact-D9F27C1A04B3019CC1E5B893801B938F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e819-wk-Fact-D9F27C1A04B3019CC1E5B893801B938F"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1464-wk-Fact-E6AE70E1C94B7E71386EB8937FF4DA69"
          xlink:label="d8090304e1464-wk-Fact-E6AE70E1C94B7E71386EB8937FF4DA69"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1464-wk-Fact-E6AE70E1C94B7E71386EB8937FF4DA69"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8108495e798-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:label="d8108495e798-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8084779e1184-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:label="d8084779e1184-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e1359-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:label="d8093385e1359-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8108495e798-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e1184-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1359-wk-Fact-EA0CF6FE1DEAE353BBF6B8938016969F"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8090304e1586-wk-Fact-F3F6715DB4D17F67A78FB8B4C6517497"
          xlink:label="d8090304e1586-wk-Fact-F3F6715DB4D17F67A78FB8B4C6517497"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e1586-wk-Fact-F3F6715DB4D17F67A78FB8B4C6517497"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8088448e2958-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E"
          xlink:label="d8088448e2958-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8086815e741-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E"
          xlink:label="d8086815e741-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e2958-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8086815e741-wk-Fact-F62D9B7BEDD204379B1FB8937FE96B1E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8093385e904-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B"
          xlink:label="d8093385e904-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8084779e817-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B"
          xlink:label="d8084779e817-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e904-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e817-wk-Fact-FBCDFF415F3FF6E37D77B893800F4B5B"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d8086815e584-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:label="d8086815e584-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8108495e662-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:label="d8108495e662-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8084779e1143-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:label="d8084779e1143-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8090304e625-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:label="d8090304e625-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e1292-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:label="d8093385e1292-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8093385e1700-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:label="d8093385e1700-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d8088448e3071-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:label="d8088448e3071-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8086815e584-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8108495e662-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8084779e1143-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8090304e625-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1292-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8093385e1700-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d8088448e3071-wk-Fact-FFF8FCA3FE91A770C6B7B8938013792E"
          xlink:to="TextSelection-F52CAE5C0777ECA2FAF2B8A7345D2F69-0-wk-Footnote-F52CAE5C0777ECA2FAF2B8A7345D2F69_lbl"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810315968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross Unrealized Losses, Less than 12 months</a></td>
<td class="num">$ (7,424)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated Fair Value, Less than 12 months</a></td>
<td class="nump">724,011<span></span>
</td>
<td class="nump">85,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross Unrealized Losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated Fair Value, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(7,424)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">724,011<span></span>
</td>
<td class="nump">85,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross Unrealized Losses, Less than 12 months</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated Fair Value, Less than 12 months</a></td>
<td class="nump">14,883<span></span>
</td>
<td class="nump">12,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross Unrealized Losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated Fair Value, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">14,883<span></span>
</td>
<td class="nump">12,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross Unrealized Losses, Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated Fair Value, Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross Unrealized Losses, 12 months or more</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated Fair Value, 12 months or more</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross Unrealized Losses, Less than 12 months</a></td>
<td class="num">(7,213)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated Fair Value, Less than 12 months</a></td>
<td class="nump">709,128<span></span>
</td>
<td class="nump">62,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross Unrealized Losses, 12 months or more</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated Fair Value, 12 months or more</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(7,213)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">$ 709,128<span></span>
</td>
<td class="nump">$ 62,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6769244608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Timing of Satisfaction (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 278.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 106.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance period</a></td>
<td class="text">8 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 96.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 60.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance period</a></td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 56.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 213.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance period</a></td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 81.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 35.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance period</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6831822544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2016 </div>
<div>ft&#178; </div>
<div>extension_period </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>campus</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178; </div>
<div>extension_period</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>extension_period</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits', window );">Number of campuses | campus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amounts representing interest or imputed interest, operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Amounts representing interest or imputed interest, finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LeasesImputedInterestRate', window );">Imputed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember', window );">Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">35 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeasePercentageSubleased', window );">Percentage subleased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods', window );">Number of extension periods | extension_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=mrna_TwoHundredTechnologySquareMember', window );">200 Technology Square | Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="nump">124,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit', window );">Tenant allowance (in usd per sqft) | $ / ft&#178;</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods', window );">Number of extension periods | extension_period</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=mrna_TwoHundredTechnologySquareSubleaseAgreementsMember', window );">200 Technology Square, Sublease Agreements | Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=mrna_FiveHundredTechnologySquareMember', window );">500 Technology Square | Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=mrna_LandAdjacentToNorwoodMember', window );">Land adjacent to Norwood | Norwood Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">35 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=mrna_OfficeLaboratoryAndLightManufacturingSpaceMember', window );">Office, laboratory, and light manufacturing space | Norwood Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amounts representing interest or imputed interest, operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Amounts representing interest or imputed interest, finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Tenant Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LeasesImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases, Imputed Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LeasesImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Extension Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseNumberOfExtensionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeasePercentageSubleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Percentage Subleased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeasePercentageSubleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Tenant Allowance, Price Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units (items of property) under operating lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mrna_TwoHundredTechnologySquareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mrna_TwoHundredTechnologySquareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mrna_TwoHundredTechnologySquareSubleaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mrna_TwoHundredTechnologySquareSubleaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mrna_FiveHundredTechnologySquareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mrna_FiveHundredTechnologySquareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mrna_LandAdjacentToNorwoodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mrna_LandAdjacentToNorwoodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mrna_OfficeLaboratoryAndLightManufacturingSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mrna_OfficeLaboratoryAndLightManufacturingSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6627438480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are calculated as follows (in thousands, except share and per share data):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(124,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>353,105,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328,809,986</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following common stock equivalents, presented based on amounts outstanding as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and 2019 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:77%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,988,598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,271,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,062,092</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,011,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,050,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,433,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816139232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Total Consolidated Net Revenues from Strategic Collaborators</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the effects of adopting ASC 842 on our condensed consolidated financial statements for the three months ended March 31, 2019&#160;(in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 842</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Previously reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,253</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(141,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(141,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,820</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,931</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,657</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,576</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Previously reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 842 Adjustment during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,657</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,576</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(550</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(143,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(144,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charges to financing lease obligation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments on financing lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by financing activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Collaboration Revenue by Strategic Collaborator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AstraZeneca</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,270</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vertex</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total collaboration revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,115</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Balances of Receivables and Contract Liabilities</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,718</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,370</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199,528</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,304</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue recognized in the period from:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied (or partially satisfied) in previous reporting periods </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;"> We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period is first applied to the beginning contract liability.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span><span style="font-family:inherit;font-size:10pt;"> Related to changes in estimated costs for our future performance obligations and estimated variable considerations. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636075296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Options Activity</a></td>
<td class="text">The following table summarizes our option activity during <span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span><span style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(1)</sup></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,536,915</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,585,069</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,188,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(944,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,988,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.06</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669,827</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,078,150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.0 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417,516</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,910,448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.6 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Common Stock Units Activity</a></td>
<td class="text">The following table summarizes our restricted stock unit activity during <span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">per Unit</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,177,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,057,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(113,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(58,514</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,062,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted</a></td>
<td class="text">The weighted-average assumptions used to estimate the fair value of options granted for <span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.14 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.12 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividends</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the components and classification of stock-based compensation expense for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,018</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,833</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,413</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,036</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,714</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,413</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6819160848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Apr. 16, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrna_LonzaLtdMember', window );">Lonza Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_CollaborativeArrangementTermOfArrangement', window );">Term of agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_CollaborativeArrangementTermOfArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term Of Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_CollaborativeArrangementTermOfArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_LonzaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_LonzaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6828634928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedPropertyAndEquipmentCurrent', window );">Property and equipment</a></td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="nump">$ 4,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related</a></td>
<td class="nump">12,617<span></span>
</td>
<td class="nump">27,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedExternalGoodsAndServicesCurrent', window );">External goods and services</a></td>
<td class="nump">38,053<span></span>
</td>
<td class="nump">36,195<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 55,020<span></span>
</td>
<td class="nump">$ 67,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedExternalGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued External Goods And Services, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedExternalGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Property And Equipment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6815742464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 826,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">506,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,333,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">825,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">502,479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 1,328,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6830915040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Vertex &#8211; 2016 Strategic Alliance in Cystic Fibrosis (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>extension_period</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amortization of deferred revenue due to the satisfaction of our performance obligation during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,262,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,601,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,528,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod', window );">Research period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected', window );">Research extension period elected</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod', window );">Research extension period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod', window );">Payment received, research extension period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods', window );">Number of extension periods | extension_period</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity investment</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod', window );">Termination period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod', window );">Written notice period</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement | Regulatory Milestones, Subsequent Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Marketing Approval, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Number Of Extension Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Payment Received, Research Extension Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Research Extension Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Research Extension Period Elected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Research Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesSubsequentProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesSubsequentProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6872436480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 4,636<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets, financing leases</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense for financing lease liabilities</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_FinanceLeaseCost', window );">Total financing lease costs</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="num">(3,888)<span></span>
</td>
<td class="num">(3,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows used in financing leases</a></td>
<td class="num">(1,425)<span></span>
</td>
<td class="num">(1,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments', window );">Right-of-use assets reduced through lease modifications and reassessments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">16,015<span></span>
</td>
<td class="nump">17,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows provided by financing leases</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6628834336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember', window );">Purchase Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Cancelable open purchase orders</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember', window );">Clinical Operations And Support Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Cancelable open purchase orders</a></td>
<td class="nump">$ 133.2<span></span>
</td>
<td class="nump">$ 105.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6646811472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) - Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 20 days<span></span>
</td>
<td class="text">6 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Weighted average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average fair value per share (usd per share)</a></td>
<td class="nump">$ 13.84<span></span>
</td>
<td class="nump">$ 12.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6833485648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>option</div>
</th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,601,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,528,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,389,000<span></span>
</td>
<td class="nump">$ 16,025,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187,000<span></span>
</td>
<td class="nump">13,301,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions', window );">Number of options | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod', window );">Termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements | VEGF-A product (AZD8601)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent', window );">Earn-out payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member', window );">2016 AZ Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod', window );">Termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod', window );">Suspension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member', window );">2016 AZ Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent', window );">Tiered royalties at default rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent', window );">Tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member', window );">2016 AZ Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent', window );">Tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember', window );">2017 AZ Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod', window );">Termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod', window );">Suspension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember', window );">2017 AZ Agreement | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember', window );">2017 AZ Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent', window );">Tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember', window );">2017 AZ Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent', window );">Tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember', window );">2018 A&amp;R Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions', window );">Number of options | option</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod', window );">Termination period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase to the transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase to the transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase to the transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember', window );">IL12 Performance Obligation | Combined 2018 AZ Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember', window );">Variable Consideration | Combined 2018 AZ Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember', window );">Variable Consideration | 2016 VEGF Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase to the transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Number Of Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_VEGFAProductAZD8601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_VEGFAProductAZD8601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>46
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "moderna10-q3312020.htm": {
   "axisCustom": 2,
   "axisStandard": 26,
   "contextCount": 281,
   "dts": {
    "calculationLink": {
     "local": [
      "mrna-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrna-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "moderna10-q3312020.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrna-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrna-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrna-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 568,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 30,
    "http://www.modernatx.com/20200331": 13,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 48
   },
   "keyCustom": 60,
   "keyStandard": 334,
   "memberCustom": 69,
   "memberStandard": 38,
   "nsprefix": "mrna",
   "nsuri": "http://www.modernatx.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.modernatx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Description of the Business",
     "role": "http://www.modernatx.com/role/DescriptionOfBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards",
     "role": "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Collaboration Agreements",
     "role": "http://www.modernatx.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Grants",
     "role": "http://www.modernatx.com/role/Grants",
     "shortName": "Grants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Financial Instruments",
     "role": "http://www.modernatx.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Balance Sheet Components",
     "role": "http://www.modernatx.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Leases",
     "role": "http://www.modernatx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.modernatx.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Shareholders' Equity",
     "role": "http://www.modernatx.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.modernatx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134100 - Disclosure - Income Taxes",
     "role": "http://www.modernatx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137100 - Disclosure - Net Loss per Share",
     "role": "http://www.modernatx.com/role/NetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138100 - Disclosure - Subsequent Events",
     "role": "http://www.modernatx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)",
     "role": "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)",
     "role": "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.modernatx.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Leases (Tables)",
     "role": "http://www.modernatx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337301 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.modernatx.com/role/NetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - Description of the Business - Additional Information (Details)",
     "role": "http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Description of the Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details)",
     "role": "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2019Q1YTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2019Q1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails",
     "shortName": "Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD_srt_ProductOrServiceAxis_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails",
     "shortName": "Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "mrna:ContractWithCustomerAssetIncreaseDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Collaboration Agreements - Remaining Performance Obligation (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
     "shortName": "Collaboration Agreements - Remaining Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1_us-gaap_ContractWithCustomerBasisOfPricingAxis_mrna_UpfrontPaymentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PCVSAVAgreementMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
     "shortName": "Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2013Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "option",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Collaboration Agreements - Merck \u2013 Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
     "shortName": "Collaboration Agreements - Merck \u2013 Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "I2019Q2May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_MerckAgreement2015Member",
      "decimals": "INF",
      "lang": null,
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "candidate",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403407 - Disclosure - Collaboration Agreements - Vertex \u2013 2016 Strategic Alliance in Cystic Fibrosis (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
     "shortName": "Collaboration Agreements - Vertex \u2013 2016 Strategic Alliance in Cystic Fibrosis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "D2016Q3Jul31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredRevenueAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403408 - Disclosure - Collaboration Agreements - Timing of Satisfaction (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails",
     "shortName": "Collaboration Agreements - Timing of Satisfaction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_Combined2018AZAgreementsMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-04-01",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Grants (Details)",
     "role": "http://www.modernatx.com/role/GrantsDetails",
     "shortName": "Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "D2016Q3Sep30_srt_MajorCustomersAxis_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
      "decimals": "-5",
      "lang": null,
      "name": "mrna:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails",
     "shortName": "Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails",
     "shortName": "Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - Financial Instruments - Unrealized Loss Position (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails",
     "shortName": "Financial Instruments - Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)",
     "role": "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mrna:PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mrna:AccruedPropertyAndEquipmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406404 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)",
     "role": "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mrna:AccruedPropertyAndEquipmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "campus",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Leases (Details)",
     "role": "http://www.modernatx.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "campus",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Leases - Balance Sheet Information (Details)",
     "role": "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
     "shortName": "Leases - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Leases - Lease Costs (Details)",
     "role": "http://www.modernatx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407405 - Disclosure - Leases - Minimum Lease Payments (Details)",
     "role": "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
     "shortName": "Leases - Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2016Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails",
     "shortName": "Commitments and Contingencies - Strategic Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "I2018Q4Dec11",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.modernatx.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "I2018Q4Dec11",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_us-gaap_PurchaseCommitmentMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails",
     "shortName": "Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_us-gaap_PurchaseCommitmentMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428402 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2020Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428403 - Disclosure - Stock-Based Compensation - Options Activity (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428404 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428405 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails",
     "shortName": "Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
     "role": "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428406 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437402 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437403 - Disclosure - Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "D2020Q2May1_srt_CounterpartyNameAxis_mrna_LonzaLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:CollaborativeArrangementTermOfArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438401 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.modernatx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "D2020Q2May1_srt_CounterpartyNameAxis_mrna_LonzaLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:CollaborativeArrangementTermOfArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moderna10-q3312020.htm",
      "contextRef": "I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - moderna10-q3312020.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - moderna10-q3312020.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 112,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2013 Option Agreement And Services And Collaboration Agreement [Member]",
        "label": "2013 Option Agreement And Services And Collaboration Agreement [Member]",
        "terseLabel": "2013 AZ Agreements"
       }
      }
     },
     "localname": "A2013OptionAgreementAndServicesAndCollaborationAgreementMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_A2016StrategicAllianceWithAstraZenecaIL12Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2016 Strategic Alliance With AstraZeneca \u2013 IL12 [Member]",
        "label": "2016 Strategic Alliance With AstraZeneca \u2013 IL12 [Member]",
        "terseLabel": "2016 AZ Agreement"
       }
      }
     },
     "localname": "A2016StrategicAllianceWithAstraZenecaIL12Member",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2017 Strategic Alliance With AstraZeneca \u2013 Relaxin [Member]",
        "label": "2017 Strategic Alliance With AstraZeneca \u2013 Relaxin [Member]",
        "terseLabel": "2017 AZ Agreement"
       }
      }
     },
     "localname": "A2017StrategicAllianceWithAstraZenecaRelaxinMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_AccruedExternalGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued External Goods And Services, Current",
        "label": "Accrued External Goods And Services, Current",
        "terseLabel": "External goods and services"
       }
      }
     },
     "localname": "AccruedExternalGoodsAndServicesCurrent",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedPropertyAndEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Property And Equipment, Current",
        "label": "Accrued Property And Equipment, Current",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "AccruedPropertyAndEquipmentCurrent",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AllowanceForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Tenant Improvements",
        "label": "Allowance For Tenant Improvements",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "localname": "AllowanceForTenantImprovements",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended And Restated Option Agreement Related Amended And Restated Services And Collaboration Agreement With AstraZeneca [Member]",
        "label": "Amended And Restated Option Agreement Related Amended And Restated Services And Collaboration Agreement With AstraZeneca [Member]",
        "terseLabel": "2018 A&amp;R Agreements"
       }
      }
     },
     "localname": "AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Assets And Liabilities, Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrna_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biomedical Advanced Research And Development Authority [Member]",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "terseLabel": "BARDA"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cambridge, Massachusetts [Member]",
        "label": "Cambridge, Massachusetts [Member]",
        "terseLabel": "Cambridge Leases"
       }
      }
     },
     "localname": "CambridgeMassachusettsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ChangeInContractwithCustomerAssetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Contract with Customer Asset [Roll Forward]",
        "label": "Change In Contract with Customer Asset [Roll Forward]",
        "terseLabel": "Contract Assets:"
       }
      }
     },
     "localname": "ChangeInContractwithCustomerAssetRollForward",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractwithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Contract with Customer Liability [Roll Forward]",
        "label": "Change In Contract with Customer Liability [Roll Forward]",
        "terseLabel": "Contract Liabilities:"
       }
      }
     },
     "localname": "ChangeInContractwithCustomerLiabilityRollForward",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChargesToFinancingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Charges To Financing Lease Liabilities",
        "label": "Charges To Financing Lease Liabilities",
        "terseLabel": "Charges to financing lease obligation"
       }
      }
     },
     "localname": "ChargesToFinancingLeaseLiabilities",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ClinicalOperationsAndSupportCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Operations And Support Commitment [Member]",
        "label": "Clinical Operations And Support Commitment [Member]",
        "terseLabel": "Clinical Operations And Support Commitment"
       }
      }
     },
     "localname": "ClinicalOperationsAndSupportCommitmentMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ClinicalSupplyReimbursementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Supply Reimbursement [Member]",
        "label": "Clinical Supply Reimbursement [Member]",
        "terseLabel": "Clinical Supply Reimbursement"
       }
      }
     },
     "localname": "ClinicalSupplyReimbursementMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member]",
        "label": "Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member]",
        "terseLabel": "Collaboration Revenue by Strategic Collaborator"
       }
      }
     },
     "localname": "CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborationArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Arrangement [Member]",
        "label": "Collaboration Arrangement [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationArrangementMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborativeArrangementTermOfArrangement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Term Of Arrangement",
        "label": "Collaborative Arrangement, Term Of Arrangement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementTermOfArrangement",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_CollaborativeArrangementWithRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement With Related Party [Member]",
        "label": "Collaborative Arrangement With Related Party [Member]",
        "terseLabel": "Collaboration revenue from related party"
       }
      }
     },
     "localname": "CollaborativeArrangementWithRelatedPartyMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_Combined2018AZAgreementPerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Combined 2018 AZ Agreement Performance Obligation [Member]",
        "label": "Combined 2018 AZ Agreement Performance Obligation [Member]",
        "terseLabel": "Combined 2018 AZ Agreement Performance Obligation"
       }
      }
     },
     "localname": "Combined2018AZAgreementPerformanceObligationMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_Combined2018AZAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Combined 2018 AZ Agreements [Member]",
        "label": "Combined 2018 AZ Agreements [Member]",
        "terseLabel": "Combined 2018 AZ Agreements"
       }
      }
     },
     "localname": "Combined2018AZAgreementsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial Milestones [Member]",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CompetitionMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Competition Milestones [Member]",
        "label": "Competition Milestones [Member]",
        "terseLabel": "Competition Milestone"
       }
      }
     },
     "localname": "CompetitionMilestonesMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ContractOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Options",
        "label": "Contract Options [Member]",
        "terseLabel": "Contract options"
       }
      }
     },
     "localname": "ContractOptionsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ContractWithCustomerAssetDecreaseDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer Asset Decrease During Period",
        "label": "Contract With Customer Asset Decrease During Period",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDecreaseDuringPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ContractWithCustomerAssetIncreaseDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer Asset Increase During Period",
        "label": "Contract With Customer Asset Increase During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetIncreaseDuringPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer Liability Decrease During Period",
        "label": "Contract With Customer Liability Decrease During Period",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDecreaseDuringPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer Liability Increase During Period",
        "label": "Contract With Customer Liability Increase During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDuringPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_CurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current Marketable Securities [Member]",
        "label": "Current Marketable Securities [Member]",
        "terseLabel": "Current Marketable Securities"
       }
      }
     },
     "localname": "CurrentMarketableSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DefenseAdvancedResearchProjectsAgencyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defense Advanced Research Projects Agency [Member]",
        "label": "Defense Advanced Research Projects Agency [Member]",
        "terseLabel": "DARPA"
       }
      }
     },
     "localname": "DefenseAdvancedResearchProjectsAgencyMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Commercialization License And Manufacturing Obligations For IL12 [Member]",
        "label": "Development And Commercialization License And Manufacturing Obligations For IL12 [Member]",
        "terseLabel": "Development And Commercialization License And Manufacturing Obligations For IL12"
       }
      }
     },
     "localname": "DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target [Member]",
        "label": "Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target [Member]",
        "terseLabel": "Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target"
       }
      }
     },
     "localname": "DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_EmployeeStockPurchasePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2018 [Member]",
        "label": "Employee Stock Purchase Plan 2018 [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2018Member",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_EstimatedReimbursementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated Reimbursement [Member]",
        "label": "Estimated Reimbursement [Member]",
        "terseLabel": "Estimated Reimbursement"
       }
      }
     },
     "localname": "EstimatedReimbursementMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total financing lease costs"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_FiveHundredTechnologySquareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Five Hundred Technology Square [Member]",
        "label": "Five Hundred Technology Square [Member]",
        "terseLabel": "500 Technology Square"
       }
      }
     },
     "localname": "FiveHundredTechnologySquareMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_FixedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fixed Payments [Member]",
        "label": "Fixed Payments [Member]",
        "terseLabel": "Fixed Payments"
       }
      }
     },
     "localname": "FixedPaymentsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_FollowOnProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Follow-On Project [Member]",
        "label": "Follow-On Project [Member]",
        "terseLabel": "Follow-on project"
       }
      }
     },
     "localname": "FollowOnProjectMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_IL12PerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IL12 Performance Obligation [Member]",
        "label": "IL12 Performance Obligation [Member]",
        "terseLabel": "IL12 Performance Obligation"
       }
      }
     },
     "localname": "IL12PerformanceObligationMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_IncreaseDecreaseInDeferredRentCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Deferred Rent Credit",
        "label": "Increase (Decrease) In Deferred Rent Credit",
        "terseLabel": "Deferred lease obligation"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRentCredit",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Right Of Use Asset, Operating Leases",
        "label": "Increase (Decrease) In Right Of Use Asset, Operating Leases",
        "negatedTerseLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssetOperatingLeases",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_InitialBaseAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial Base Award",
        "label": "Initial Base Award [Member]",
        "terseLabel": "Initial base award"
       }
      }
     },
     "localname": "InitialBaseAwardMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_InitialProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial Project [Member]",
        "label": "Initial Project [Member]",
        "terseLabel": "Initial project"
       }
      }
     },
     "localname": "InitialProjectMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_KRASPerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "KRAS Performance Obligation [Member]",
        "label": "KRAS Performance Obligation [Member]",
        "terseLabel": "KRAS Performance Obligation"
       }
      }
     },
     "localname": "KRASPerformanceObligationMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_LandAdjacentToNorwoodMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Land Adjacent To Norwood [Member]",
        "label": "Land Adjacent To Norwood [Member]",
        "terseLabel": "Land adjacent to Norwood"
       }
      }
     },
     "localname": "LandAdjacentToNorwoodMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_LeasesImputedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Leases, Imputed Interest Rate",
        "label": "Leases, Imputed Interest Rate",
        "terseLabel": "Imputed interest rate"
       }
      }
     },
     "localname": "LeasesImputedInterestRate",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_LesseeOperatingLeaseNumberOfExtensionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Extension Periods",
        "label": "Lessee, Operating Lease, Number Of Extension Periods",
        "terseLabel": "Number of extension periods"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtensionPeriods",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_LesseeOperatingLeasePercentageSubleased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Percentage Subleased",
        "label": "Lessee, Operating Lease, Percentage Subleased",
        "terseLabel": "Percentage subleased"
       }
      }
     },
     "localname": "LesseeOperatingLeasePercentageSubleased",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_LesseeOperatingLeaseTenantAllowancePricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Tenant Allowance, Price Per Unit",
        "label": "Lessee, Operating Lease, Tenant Allowance, Price Per Unit",
        "terseLabel": "Tenant allowance (in usd per sqft)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTenantAllowancePricePerUnit",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "mrna_LonzaLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lonza Ltd [Member]",
        "label": "Lonza Ltd [Member]",
        "terseLabel": "Lonza Ltd"
       }
      }
     },
     "localname": "LonzaLtdMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MerckAgreement2015Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Merck Agreement 2015 [Member]",
        "label": "Merck Agreement 2015 [Member]",
        "terseLabel": "2015 Merck Agreement"
       }
      }
     },
     "localname": "MerckAgreement2015Member",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Merck [Member]",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payments [Member]",
        "label": "Milestone Payments [Member]",
        "terseLabel": "Milestone Payments"
       }
      }
     },
     "localname": "MilestonePaymentsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NoncurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncurrent Marketable Securities [Member]",
        "label": "Noncurrent Marketable Securities [Member]",
        "terseLabel": "Non- Current Marketable Securities"
       }
      }
     },
     "localname": "NoncurrentMarketableSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NorwoodMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Norwood, Massachusetts",
        "label": "Norwood, Massachusetts [Member]",
        "terseLabel": "Norwood Leases"
       }
      }
     },
     "localname": "NorwoodMassachusettsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OfficeLaboratoryAndLightManufacturingSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office, Laboratory, And Light Manufacturing Space [Member]",
        "label": "Office, Laboratory, And Light Manufacturing Space [Member]",
        "terseLabel": "Office, laboratory, and light manufacturing space"
       }
      }
     },
     "localname": "OfficeLaboratoryAndLightManufacturingSpaceMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OncologyDevelopmentTargetPerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Oncology Development Target Performance Obligation [Member]",
        "label": "Oncology Development Target Performance Obligation [Member]",
        "terseLabel": "Oncology Development Target Performance Obligation"
       }
      }
     },
     "localname": "OncologyDevelopmentTargetPerformanceObligationMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability",
        "label": "Operating And Finance Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiability",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability, Noncurrent",
        "label": "Operating And Finance Lease, Liability, Noncurrent",
        "totalLabel": "Total non-current lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating And Finance Lease, Right-Of-Use Asset",
        "label": "Operating And Finance Lease, Right-Of-Use Asset",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Liabilities",
        "label": "Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilities",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OptionExerciseFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Option Exercise Fee [Member]",
        "label": "Option Exercise Fee [Member]",
        "terseLabel": "Option Exercise Fee"
       }
      }
     },
     "localname": "OptionExerciseFeeMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PCVPerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PCV Performance Obligation [Member]",
        "label": "PCV Performance Obligation [Member]",
        "terseLabel": "PCV Performance Obligation"
       }
      }
     },
     "localname": "PCVPerformanceObligationMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PCVSAVAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PCVSAV Agreement [Member]",
        "label": "PCVSAV Agreement [Member]",
        "terseLabel": "PCV/SAV Agreement"
       }
      }
     },
     "localname": "PCVSAVAgreementMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PaymentsForLeaseFinancingObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Lease Financing Obligation",
        "label": "Payments For Lease Financing Obligation",
        "negatedTerseLabel": "Payments on financing lease obligation"
       }
      }
     },
     "localname": "PaymentsForLeaseFinancingObligation",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_PaymentsOfUnderwritingDiscounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Of Underwriting Discounts",
        "label": "Payments Of Underwriting Discounts",
        "terseLabel": "Underwriting discounts"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscounts",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_PerformanceObligationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Obligation [Axis]",
        "label": "Performance Obligation [Axis]",
        "terseLabel": "Performance Obligation [Axis]"
       }
      }
     },
     "localname": "PerformanceObligationAxis",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_PerformanceObligationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Performance Obligation [Axis]",
        "label": "Performance Obligation [Domain]",
        "terseLabel": "Performance Obligation [Domain]"
       }
      }
     },
     "localname": "PerformanceObligationDomain",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp And Dohme Corp [Member]",
        "label": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp And Dohme Corp [Member]",
        "terseLabel": "PCV Agreement"
       }
      }
     },
     "localname": "PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PersonalizedMRNACancerVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Personalized MRNA Cancer Vaccines Products [Member]",
        "label": "Personalized MRNA Cancer Vaccines Products [Member]",
        "terseLabel": "PCV products"
       }
      }
     },
     "localname": "PersonalizedMRNACancerVaccinesProductsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization",
        "label": "Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_PublicEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Public Equity Offering [Member]",
        "label": "Public Equity Offering [Member]",
        "terseLabel": "Public Equity Offering"
       }
      }
     },
     "localname": "PublicEquityOfferingMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RegulatoryMilestonesSubsequentProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Milestones, Subsequent Products [Member]",
        "label": "Regulatory Milestones, Subsequent Products [Member]",
        "terseLabel": "Regulatory Milestones, Subsequent Products"
       }
      }
     },
     "localname": "RegulatoryMilestonesSubsequentProductsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent",
        "terseLabel": "Earn-out payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Marketing Approval, Termination Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Marketing Approval, Termination Period",
        "terseLabel": "Written notice period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Maximum Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Maximum Amount",
        "terseLabel": "Estimated arrangement consideration",
        "verboseLabel": "Budgeted amount"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Milestone [Axis]",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Milestone [Axis]",
        "terseLabel": "Research And Development Arrangement, Contract To Perform For Others, Milestone [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Research And Development Arrangement, Contract To Perform For Others, Milestone [Axis]",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Milestone [Domain]",
        "terseLabel": "Research And Development Arrangement, Contract To Perform For Others, Milestone [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneDomain",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Extension Periods",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Extension Periods",
        "terseLabel": "Number of extension periods"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Options",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Options",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Product Candidates",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Payment Received, Research Extension Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Payment Received, Research Extension Period",
        "terseLabel": "Payment received, research extension period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Performance Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Performance Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period",
        "terseLabel": "Suspension period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Research Extension Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Research Extension Period",
        "terseLabel": "Research extension period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Research Extension Period Elected",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Research Extension Period Elected",
        "terseLabel": "Research extension period elected"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Research Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Research Period",
        "terseLabel": "Research period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent",
        "terseLabel": "Tiered royalties at default rate"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent",
        "terseLabel": "Tiered royalties"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Termination Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Termination Period",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ResearchAndDevelopmentFundingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Funding [Member]",
        "label": "Research And Development Funding [Member]",
        "terseLabel": "Research And Development Funding"
       }
      }
     },
     "localname": "ResearchAndDevelopmentFundingMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RestrictedStockAndRestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted Stock And Restricted Stock Units (RSUs) [Member]",
        "label": "Restricted Stock And Restricted Stock Units (RSU) [Member]",
        "terseLabel": "Restricted common stock units"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsRSUMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RevenueFromGrantsCurrentFundingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Current Funding Capacity",
        "label": "Revenue From Grants, Current Funding Capacity",
        "terseLabel": "Amount committed for funding"
       }
      }
     },
     "localname": "RevenueFromGrantsCurrentFundingCapacity",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsMaximumAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Maximum Award",
        "label": "Revenue From Grants, Maximum Award",
        "terseLabel": "Award amount"
       }
      }
     },
     "localname": "RevenueFromGrantsMaximumAward",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsNumberOfContractOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Number Of Contract Options",
        "label": "Revenue From Grants, Number Of Contract Options",
        "terseLabel": "Number of contract options"
       }
      }
     },
     "localname": "RevenueFromGrantsNumberOfContractOptions",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_RevenueFromGrantsNumberOfContractOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Number Of Contract Options Exercised",
        "label": "Revenue From Grants, Number Of Contract Options Exercised",
        "terseLabel": "Number of contract options exercised"
       }
      }
     },
     "localname": "RevenueFromGrantsNumberOfContractOptionsExercised",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_RevenueFromGrantsRemainingFundingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Remaining Funding Capacity",
        "label": "Revenue From Grants, Remaining Funding Capacity",
        "terseLabel": "Available funding"
       }
      }
     },
     "localname": "RevenueFromGrantsRemainingFundingCapacity",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RightOfUseAssetFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right Of Use Asset, Financing [Member]",
        "label": "Right Of Use Asset, Financing [Member]",
        "terseLabel": "Right-of-use asset, financing"
       }
      }
     },
     "localname": "RightOfUseAssetFinancingMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments",
        "label": "Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments",
        "terseLabel": "Right-of-use assets reduced through lease modifications and reassessments"
       }
      }
     },
     "localname": "RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_SeparateAgreementsWithMerckMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Separate Agreements With Merck [Member]",
        "label": "Separate Agreements With Merck [Member]",
        "terseLabel": "Separate Agreements With Merck"
       }
      }
     },
     "localname": "SeparateAgreementsWithMerckMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ServiceBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service-Based Awards [Member]",
        "label": "Service-Based Awards [Member]",
        "terseLabel": "Service-Based Awards [Member]"
       }
      }
     },
     "localname": "ServiceBasedAwardsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments",
        "terseLabel": "Number of installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum value of shares to be purchased during purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled/forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized",
        "terseLabel": "Annual percentage of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate",
        "terseLabel": "Minimum percentage of compensation through payroll deductions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_StockOptionAndGrantPlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Option And Grant Plan 2016 [Member]",
        "label": "Stock Option And Grant Plan 2016 [Member]",
        "terseLabel": "Stock Option and Grant Plan 2016"
       }
      }
     },
     "localname": "StockOptionAndGrantPlan2016Member",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_StockOptionAndIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Option And Incentive Plan 2018 [Member]",
        "label": "Stock Option And Incentive Plan 2018 [Member]",
        "terseLabel": "Stock Option And Incentive Plan 2018"
       }
      }
     },
     "localname": "StockOptionAndIncentivePlan2018Member",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic Collaboration And License Agreement, With Vertex Pharmaceuticals Incorporated, And Vertex Pharmaceuticals (Europe) Limited [Member]",
        "label": "Strategic Collaboration And License Agreement, With Vertex Pharmaceuticals Incorporated, And Vertex Pharmaceuticals (Europe) Limited [Member]",
        "terseLabel": "2019 Vertex Agreement"
       }
      }
     },
     "localname": "StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_SublicenseReimbursementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sublicense Reimbursement [Member]",
        "label": "Sublicense Reimbursement [Member]",
        "terseLabel": "Sublicense Reimbursement"
       }
      }
     },
     "localname": "SublicenseReimbursementMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_TenantIncentivesReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tenant Incentives Receivables, Current",
        "label": "Tenant Incentives Receivables, Current",
        "terseLabel": "Tenant incentives receivables"
       }
      }
     },
     "localname": "TenantIncentivesReceivablesCurrent",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_TheBillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Bill And Melinda Gates Foundation [Member]",
        "label": "The Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "The Bill &amp; Melinda Gates Foundation"
       }
      }
     },
     "localname": "TheBillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ToxicityMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Toxicity Milestones [Member]",
        "label": "Toxicity Milestones [Member]",
        "terseLabel": "Toxicity Milestone"
       }
      }
     },
     "localname": "ToxicityMilestonesMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_TwoHundredTechnologySquareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Hundred Technology Square",
        "label": "Two Hundred Technology Square [Member]",
        "terseLabel": "200 Technology Square"
       }
      }
     },
     "localname": "TwoHundredTechnologySquareMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_TwoHundredTechnologySquareSubleaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Hundred Technology Square, Sublease Agreements [Member]",
        "label": "Two Hundred Technology Square, Sublease Agreements [Member]",
        "terseLabel": "200 Technology Square, Sublease Agreements"
       }
      }
     },
     "localname": "TwoHundredTechnologySquareSubleaseAgreementsMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "US Government Agencies And Corporate Debt Securities [Member]",
        "label": "US Government Agencies And Corporate Debt Securities [Member]",
        "terseLabel": "Debt securities of U.S. government agencies and corporate entities"
       }
      }
     },
     "localname": "USGovernmentAgenciesAndCorporateDebtSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_UpfrontPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront Payment [Member]",
        "label": "Upfront Payment [Member]",
        "terseLabel": "Upfront Payment"
       }
      }
     },
     "localname": "UpfrontPaymentMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock [Member]",
        "label": "Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock [Member]",
        "terseLabel": "Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock"
       }
      }
     },
     "localname": "UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_UpfrontPaymentResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront Payment, Research And Development [Member]",
        "label": "Upfront Payment, Research And Development [Member]",
        "terseLabel": "Upfront Payment, Research And Development"
       }
      }
     },
     "localname": "UpfrontPaymentResearchAndDevelopmentMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_VEGFAProductAZD8601Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VEGF-A Product (AZD8601) [Member]",
        "label": "VEGF-A Product (AZD8601) [Member]",
        "terseLabel": "VEGF-A product (AZD8601)"
       }
      }
     },
     "localname": "VEGFAProductAZD8601Member",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_VEGFExercise2016Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VEGF Exercise 2016 [Member]",
        "label": "VEGF Exercise 2016 [Member]",
        "terseLabel": "2016 VEGF Exercise"
       }
      }
     },
     "localname": "VEGFExercise2016Member",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_VariableConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Consideration [Member]",
        "label": "Variable Consideration [Member]",
        "terseLabel": "Variable Consideration"
       }
      }
     },
     "localname": "VariableConsiderationMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_VertexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vertex [Member]",
        "label": "Vertex [Member]",
        "terseLabel": "Vertex"
       }
      }
     },
     "localname": "VertexMember",
     "nsuri": "http://www.modernatx.com/20200331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r39",
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r110",
      "r164",
      "r169",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r108",
      "r164",
      "r167",
      "r279",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r89",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement Adjustment [Member]",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r109",
      "r164",
      "r168",
      "r284",
      "r289",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Accounting Standards Update 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r18",
      "r111",
      "r112",
      "r165"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r36",
      "r86",
      "r246",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r48",
      "r51"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gain on Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r48",
      "r51",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r178",
      "r205",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office space (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r106",
      "r260",
      "r271"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r38"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r117",
      "r136"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r121",
      "r123",
      "r267"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r121",
      "r124",
      "r268"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r121",
      "r122",
      "r266"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r114",
      "r118",
      "r136"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r116",
      "r136"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r116",
      "r136"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Investments, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r179",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r26",
      "r76"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r77",
      "r82",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r76",
      "r81"
     ],
     "calculation": {
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r227"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r149",
      "r264",
      "r276"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 370,102,805 and 336,536,985 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Changes in Balances of Receivables and Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r156",
      "r158",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerBasisOfPricingAxis": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.",
        "label": "Contract with Customer, Basis of Pricing [Axis]",
        "terseLabel": "Contract with Customer, Basis of Pricing [Axis]"
       }
      }
     },
     "localname": "ContractWithCustomerBasisOfPricingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerBasisOfPricingDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.",
        "label": "Contract with Customer, Basis of Pricing [Domain]",
        "terseLabel": "Contract with Customer, Basis of Pricing [Domain]"
       }
      }
     },
     "localname": "ContractWithCustomerBasisOfPricingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r156",
      "r157",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "negatedLabel": "Decrease to the transaction price",
        "terseLabel": "Increase to the transaction price"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r156",
      "r157",
      "r165"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r156",
      "r157",
      "r165"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amortization of deferred revenue due to the satisfaction of our performance obligation during the period",
        "verboseLabel": "Amounts included in contract liabilities at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r15",
      "r16",
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Preferred stock converted into common stock (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Transition adjustment from adoption of ASU"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r128",
      "r140",
      "r143"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "negatedTerseLabel": "Gross Unrealized Losses, 12 months or more"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r128",
      "r140"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Estimated Fair Value, 12 months or more"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r128",
      "r140",
      "r143"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "negatedTerseLabel": "Gross Unrealized Losses, Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r128",
      "r140"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Estimated Fair Value, Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r125",
      "r137",
      "r143"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "negatedTotalLabel": "Gross Unrealized Losses, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r126",
      "r138"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "totalLabel": "Estimated Fair Value, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue, Additions",
        "terseLabel": "Upfront cash payments"
       }
      }
     },
     "localname": "DeferredRevenueAdditions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r74",
      "r104"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "netLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation-related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to non-vested stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of cost expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "netLabel": "Options",
        "terseLabel": "Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r226",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r226",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r231",
      "r237",
      "r244"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "mrna_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense for financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r233",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "negatedTerseLabel": "Operating cash flows used in financing leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Financing Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r230",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Finance Lease Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Financing lease liabilities, non-current",
        "verboseLabel": "Financing lease liabilities, non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.",
        "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less amounts representing interest or imputed interest",
        "terseLabel": "Amounts representing interest or imputed interest, finance lease"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r232",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash flows provided by financing leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, financing, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r231",
      "r237",
      "r244"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "mrna_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets, financing leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r139",
      "r141",
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grant commitment"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r105",
      "r217"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedTerseLabel": "Accounts receivable from related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Upfront payment"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable on marketable securities"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r62",
      "r103"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization/accretion of investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r258",
      "r269",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease, term of lease"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less amounts representing interest or imputed interest",
        "verboseLabel": "Amounts representing interest or imputed interest, operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r262",
      "r275"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "terseLabel": "Net cash provided by financing activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r52",
      "r55",
      "r59",
      "r75",
      "r96",
      "r265",
      "r277"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r238",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease obligation, non-current",
        "verboseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r234",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedTerseLabel": "Operating cash flows used in operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, operating leases",
        "verboseLabel": "Right-of-use assets, operating, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r53",
      "r56",
      "r219",
      "r220",
      "r221"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Total other comprehensive (loss) income",
        "verboseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r45",
      "r49",
      "r50",
      "r129"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Less: amounts recognized for net realized (gain) loss included in net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r45"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized (loss) gain on available-for-sale debt securities, net of tax of $0 and $540, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r42",
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale debt securities, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCustomerMember": {
     "auth_ref": [
      "r278",
      "r280",
      "r281",
      "r282",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer classified as other.",
        "label": "Other Customer [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r31"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriting option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r65",
      "r67",
      "r115"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r179",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.0001; 162,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares issued or outstanding at March 31, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r144"
     ],
     "calculation": {
      "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from equity investment"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r65",
      "r66",
      "r115"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r65",
      "r66",
      "r115"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Total consideration recorded as a result of stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock through equity plans, net"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r27",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "verboseLabel": "Furniture, fixtures and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of units (items of property) under operating lease arrangements.",
        "label": "Property Subject to or Available for Operating Lease, Number of Units",
        "terseLabel": "Number of campuses"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r13",
      "r261",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r13",
      "r261",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": {
     "auth_ref": [
      "r13",
      "r261",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Table]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentMember": {
     "auth_ref": [
      "r13",
      "r261",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.",
        "label": "Purchase Commitment [Member]",
        "terseLabel": "Purchase Commitment"
       }
      }
     },
     "localname": "PurchaseCommitmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r13",
      "r261",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Cancelable open purchase orders"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedemptionPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.",
        "label": "Redemption Premium",
        "terseLabel": "Premium recorded to deferred revenue"
       }
      }
     },
     "localname": "RedemptionPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r214",
      "r292"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1",
      "r10",
      "r81"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r12",
      "r81",
      "r290"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted common stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted common stock units",
        "verboseLabel": "Restricted Common Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r154",
      "r274"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r163",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Total collaboration revenue (contra-revenue)",
        "terseLabel": "Total revenue",
        "verboseLabel": "Total collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/GrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Grants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "verboseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r58",
      "r101",
      "r102",
      "r107"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r241",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate net proceeds from the offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares of common stock issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash and Available-for-Sale Securities by Significant Investment Category"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r178",
      "r204",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r178",
      "r204",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r88",
      "r90",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "terseLabel": "Effect of Adoption of 842 on Condensed Financial Statements",
        "verboseLabel": "Summary of Total Consolidated Net Revenues from Strategic Collaborators"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsTables",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Restricted Common Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r27",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails",
      "http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r81",
      "r259",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r179",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of Unrealized Loss on Investments"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series H preferred stock or outstanding series H preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series H Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesHPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled, forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Issued (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, non-vested at end of period (in shares)",
        "periodStartLabel": "Outstanding, non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares/Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, non-vested at end of period (usd per share)",
        "periodStartLabel": "Outstanding, non-vested at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value per Share/Unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum percentage of compensation through payroll deductions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum shares to be purchased during purchase period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Aggregate number of shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share, Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r185",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Options Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r177",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Weighted average fair value per share (usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r199",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price at which shares are sold, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Basis of Presentation and Recent Accounting Standards"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "verboseLabel": "Internally developed software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails",
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r151",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs of $1,108 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r151",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r151",
      "r154",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of options to purchase common stock, net (in shares)",
        "verboseLabel": "Stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r151",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs of $1,108"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r16",
      "r17",
      "r151",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r151",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options to purchase common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r113"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Redeemable convertible preferred stock, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r173",
      "r175",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r239",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average common shares used in net loss per share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419109&loc=SL117422543-158416"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419472&loc=d3e14931-158439"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419472&loc=SL117782755-158439"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419472&loc=SL117782768-158439"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884803&loc=SL65671395-207642"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=SL117422267-158473"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r294": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r295": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r296": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r297": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r298": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r299": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6646302144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 391,720<span></span>
</td>
<td class="nump">$ 235,876<span></span>
</td>
<td class="nump">$ 502,934<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">10,791<span></span>
</td>
<td class="nump">10,791<span></span>
</td>
<td class="nump">11,823<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 403,543<span></span>
</td>
<td class="nump">$ 247,699<span></span>
</td>
<td class="nump">$ 514,757<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">$ 670,491<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6624557632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are calculated as follows (in thousands, except share and per share data):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(124,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>353,105,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328,809,986</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following common stock equivalents, presented based on amounts outstanding as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and 2019 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:77%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,988,598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,271,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,062,092</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,011,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,050,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,433,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6828564256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 391,720<span></span>
</td>
<td class="nump">$ 235,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">825,981<span></span>
</td>
<td class="nump">867,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,617<span></span>
</td>
<td class="nump">5,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">23,903<span></span>
</td>
<td class="nump">19,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,249,936<span></span>
</td>
<td class="nump">1,128,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments, non-current</a></td>
<td class="nump">502,479<span></span>
</td>
<td class="nump">159,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">202,066<span></span>
</td>
<td class="nump">201,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">100,533<span></span>
</td>
<td class="nump">86,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">10,791<span></span>
</td>
<td class="nump">10,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,067,541<span></span>
</td>
<td class="nump">1,589,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,034<span></span>
</td>
<td class="nump">7,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">55,020<span></span>
</td>
<td class="nump">67,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">58,842<span></span>
</td>
<td class="nump">63,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">9,686<span></span>
</td>
<td class="nump">5,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">134,582<span></span>
</td>
<td class="nump">143,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">142,989<span></span>
</td>
<td class="nump">138,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation, non-current</a></td>
<td class="nump">108,919<span></span>
</td>
<td class="nump">93,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">38,930<span></span>
</td>
<td class="nump">38,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">426,667<span></span>
</td>
<td class="nump">414,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001; 162,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares issued or outstanding at March 31, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 370,102,805 and 336,536,985 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,267,648<span></span>
</td>
<td class="nump">2,669,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(6,127)<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,620,684)<span></span>
</td>
<td class="num">(1,496,454)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,640,874<span></span>
</td>
<td class="nump">1,174,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,067,541<span></span>
</td>
<td class="nump">$ 1,589,422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6818026096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gain (loss) on available-for-sale debt securities, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6627968928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Grants</a></td>
<td class="text">Grants<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Biomedical Advanced Research and Development Authority (BARDA)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2016, we received an award of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$125.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> under Agreement No. HHSO100201600029C from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response, or ASPR within the U.S. Department of Health and Human Services, or HHS, to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> supported toxicology studies, a Phase&#160;1 clinical trial, and associated manufacturing activities. Contract options were available, for </span><span style="font-family:inherit;font-size:10pt;"><span>$117.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> to support an additional Phase&#160;1 study of an improved Zika vaccine candidate, Phase&#160;2 and Phase&#160;3 clinical studies, as well as large-scale manufacturing for the Zika vaccine.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> contract options had been exercised resulting in </span><span style="font-family:inherit;font-size:10pt;"><span>$117.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of available funding with an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> available if the final contract option is exercised. For the three months ended March&#160;31, 2020 and 2019, we recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, relating to the BARDA agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 16, 2020, we entered into a new agreement with BARDA (see Note 13).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Bill&#160;&amp; Melinda Gates Foundation (Gates Foundation)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Gates Foundation has committed up to </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase&#160;1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections. Follow-on projects which could bring total potential funding under the framework agreement up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Gates Foundation certain non-exclusive licenses. In March 2019, the Gates Foundation provided an additional funding commitment up to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to support a follow-on project.  </span></div><div style="line-height:120%;padding-top:17px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$21.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been committed for funding with up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$80.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> available, if additional follow-on projects are approved. We recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to the Gates Foundation agreement for both of the three months ended March&#160;31, 2020 and 2019. We had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the Gates Foundation agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Defense Advanced Research Projects Agency (DARPA)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2013, DARPA awarded us up to </span><span style="font-family:inherit;font-size:10pt;"><span>$24.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> under Agreement No.&#160;W911NF-13-1-0417, which was subsequently adjusted to </span><span style="font-family:inherit;font-size:10pt;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, to research and develop potential mRNA medicines as a part of DARPA&#8217;s Autonomous Diagnostics to Enable Prevention and Therapeutics, or ADEPT, program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against chikungunya infection.</span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been committed by DARPA. There was no revenue recognized for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span> or 2019, related to the DARPA agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6659664832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Strategic Collaborations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$243.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for both periods as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> (see Note 3).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are not currently a party to any material legal proceedings.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification Obligations</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through the three months ended March&#160;31, 2020 and the year ended December 31, 2019, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments and Purchase Orders</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of non-cancelable purchase commitments for clinical services which are expected to be paid from 2020 to 2023.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December&#160;31, 2019, we had cancelable open purchase orders of </span><span style="font-family:inherit;font-size:10pt;"><span>$133.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$105.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in total under such agreements for our significant clinical operations and support. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December&#160;31, 2019, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810413312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2019 Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss includes net loss and other comprehensive (loss) income for the period. Other comprehensive (loss) income consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards and Recently Issued Accounting Standards</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.</span><span style="font-family:inherit;font-size:10pt;">  This standard changes how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. The amendments in this standard should be applied on a modified retrospective basis to all periods presented.&#160;We adopted this standard in the first quarter of 2020. Based on the composition of our investment portfolio and investment policy, the adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Topic 350): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.</span><span style="font-family:inherit;font-size:10pt;">&#160;This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). We adopted this standard in the first quarter of 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. This standard removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. This standard will be effective for us on January 1, 2021, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and disclosures upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6628518592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,410</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,475</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tenant incentives receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,093</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest receivable on marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,295</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,903</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,257</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture, fixtures and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,985</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internally developed software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use asset, financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,853</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,853</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303,854</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,079</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(94,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,617</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">External goods and services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,020</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,652</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001682852-20-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001682852-20-000010-xbrl.zip
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M0CAPQ:)1ND 15XY'A[A4%)#-9S7>TA3Q-_O"%AI?;<4,#@M0_=G=8O^, ]B
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M>:*GKJ8G*)EO>/2V<Z@^I #\IJ)@ED-XWI0:$DWZG48EOYI^&"5.?)[4-7E
M(^^33J<@:JA> CS:4+<)5VN05V=6%'F#!:S!(;]T.DWM.W]"]UZ *7<=<A58
M<D\:9N>O.EJGF\8YM;(^N._42_#!N_7)T<LVM$7]6'G5.11"/6 !$:UM@";H
M>T:NW+W'&/?@DR<W?D+"AUMQL_XF8;H9YY+@:[G'9[=\A/IVRKCC7S\N%)!.
MB=_)">K^<!48)D[=H7+@.6F?N2?9E*;>Q>3,0],3D9EHV%;P@DCL;ED L6:Y
M:=X7Q&97/?2D<V\_T\/'QY5+2[*S8^=0\Z?;CQ_&W+BB?E+P=]V'2'O&[0DT
M'T,Y1Z+7Z=.)$G/M)H['X#3GGR6]1_@U/(R)K:NEAB-*G X8=L1^]A>[*2Q@
M,PIEC?(K+H;P2AWQO(FZ/YNB19&3@0><#1C_51S+?8+9ZT1\:YK%-8HJ=/&F
M.AZO#K5S9WIVIO@)6U1M(V*L .?[;?'BT4<&4XOL"JX%WOH8ZNV3++AK=6CO
MO..25J'0BM/(W;,;HN)=^4QZ;D3$;'J0?]ZG.71A 1;_ETA6;6.J:_:[?DZ;
M0C^:33]?4_S1#TJJ'$1^K=JG7:>X_@)/X="!9K<+/K'YML1?0'+_DJAO7VO7
M3^<646_.,WVG92^V$+.KG)9OC,!_T5GSJ'C _FJ*J71X(Z3 .ZU-B1ZQ-RY5
M,>/M)A!>RAUBH+YB%UV^0=-!P_3A-C%'DSWD+YK'<A>X0Z>Y7<:RX/&GC>3[
M%<->)-SR%E7QLC=>L=PE2XKQLJ+G M\L-:<-G&SF0CX[S73U6\XDJYS9F6+I
MK?'3V'SOLZ$=?T#[< T_2+4MEX25= EO$_(7Z .* R?-A*:@AM;C59=\NJ/6
M([!O>2,B%..31\8N1T3G'.ZO3, _0(-SMV_?6:D;(D&_@B%T.L,; _)0+NUV
M$)?,RFV8A55%];G4+?61B1K^8^L7'?$_M-P-,O_YQH14K-[E&%H7:I-=BESX
M]I-YFJ-N.\D?_=SOXD?%Y[0%0SYEN*%.2UC^DSI2*EN7F>)V?3.1X49&)Y&(
M+Y-\ 9SSJ/!V.KBRUO2[=P"]$4/O#(>9,I< 55(92N?4#<$7 ZZ4E#'N-&)(
M$-JHR)^W^Q4]K+@*32Q^R!O1<?.+!AX[*7MI'*S)1W$R"JEZH3IV')66;K^J
M,3:G\=)"^*L1F34[BTS_WETQ'UVYB=*[N$:F.=>E8-%^X4;3N-"RGZWSOJ1-
MO,'*JV>K^F)6 E>4=5\IRV91:5=?9@:RHV)51LW576@-[>6FWI6C->Q.!U07
M;$LYINO/'Q-6W^.OBVE^>5/_/:N$F3\ARBY[J[ZCQJ93G[$>_.[X@';PQ;A3
M]OOE,@*+TF%6ZUM'ZB0?DEJ6"KMT$HQMP;0_.[_59!H&&1OU6@*QCP36C>MX
MEDW _:P,CEE+:VONVFGMB[3.CY=YDPT2A84L*U+,=;FU7#@4:HU%CE0;]$F\
M656)Z?".54LO6-$*B'Z#.?MF[LF8I 8_^NIDBLI^Q8E:/_5->*^+I32<YT?8
MU8N@9V*L"371::=^"+; F\/^8!=PN$O92\0GY,OU.2]7SEH5:+P>-)C6I<YT
MAB[,VJE(_6:'=>/A+24QXVX_-J.I",OWOWB"M_4-/I"%3TCQJRL,I=SUSV(+
MDMDVC$.YK)CXYF46YJ36VQN]?M3ZTKMF3=N!A?R&ZL5A9'8071"Q)G "(_ G
M'D9[?+&_O57O%2E8ZN*A2&X\LS,I=1?5_BI!HI1N/])0E/G6C2K-U:1[00(V
M>BC:91%\E$ZG449288GACAE!\E.HPS;-2<D^#49&JUVTYEUF<C;)^.$T]S6=
M*&AY9\VXL$C:8R2^V9R)BI=D[X1)K^ (I"@Q[4?OZUYX=^(04_[."-I\:O+E
M^(D+M;V6A)#3S8:)#%.D>)CM[.LP?L-GD1E7@1,ZO/77^L:_$6RU/R=#P.VT
MAL+!G6X+SWM.AF*,<Z-I%</ZI!OC#ILYA@@UJF?P'2JD5).% #X&1^YK\?A.
M@WOM\@WZR7_)X]EC8'O2*P9.+RQS;1,<I*IK/*58CI,.TV;)_$(]XV7"DRWP
M?WRX]=I:=^V*^!-(^V/OM M&7:@IZ*ZVONYHZ;%?4\#SS^8#Y(3D@L:#AV?E
M2=FOE#\0_5RR#/_+"M+D?AH] 1VBM\O@56)"=&:&"WG82A;'J,*[E"4O?QA[
MIACF.A5HKL>#A SBU0=))#+A3SK@$JE/E"US*L;\M:4CEX^N?]RO_P#T3'^P
M%I;!I\!,N/U%XB%V17*=YB&E.ZG(=E)YB[.W/'>+%#_7>"6YS@D.GO96WL!_
MT)-YB[,HRTRCA3NU"XK"Y1-6'0;;!4XMQ=L+VV8@#K9@J4@=H=*0AMD#BPVK
MWHK>'DX;D+!,"=5?I/=YR7(XI(T&K3AYHV*D/ ^95Y%EL%637),4WA!-I-!S
M5(**N]MUI6BV0[WK]$765/HNJ&HS\B3=W&@\Y_OH\_H)CUF1:WT6P0_4W.US
M7SREN'Y.Z4/,?7JC]B\_E!A).ZU'2C9EAE\?4Y!?'J!T<A*.WUG5CMR1LG!-
MN/52FI#7,8E_3# Z+?QQ%H#C88M_(2_^Z__A4QPSR?R?D#MQ;=/PWQ34^?09
M#PM<R:*"!E[;JC8ZBXXGFZ8YZ(?6U@://DBL3>&ROL_)H<PE<Q#M52I"M2T-
MHA%Q["K.:<^?::<8QP).HU4GU?&(^R$_2*Z1I'3=)C&)/LH@]*'CN-D 397]
M,G)B:QWS-B<N?"+Q30]GA,R-J@,E/E3LHW&A@[*ICF3]:BRPXVQ=2\4-V:](
MYD)D49E^1]DL-Z313;)##5YO2[#&F#IR>&.&R^GZ.<;XDH-CX^\Y<C2N9(+:
ML !938B3)#.4==>O2;-K4Q?Z'BRVVJO>B\>DYGAO%22?'.OL7L/N[[:[HA\N
M4E8F[/P"2=\YT &V2;6ST?-YL;KVXF6O&3'Q^UO?T*I3I<<IKPM*T<H,R;=^
M)&F(A9NLL7VDV5,D=A['VP518=A1D XYX3=*!;^2X=  ,VW1P%X)VS@@O+7'
M=CK#.$\U0%46YH!(5IZ\,7I08C/^I3(.2EA;$W\_R:>YKR$HC"2+D3U<YJR<
M'HH\_6[)7F]LN#NY[70K@S#R_B.Z=X"IJTC?-'[<$-T6YOKNA])O[V?-HXTU
MQ^XP/.-X&G.6#O$[K-A7XPU2[ *%-+/4()(25A9%##.F=%-)+$<5>E)M#==>
M'W%#1*B89PZ#HAID>G:- SE1XMGV"]Q(B>AXNY?YS7+^G@=LNB]()KY5\(M:
MQ"OW1E.*UJ:>H_R-D(\7M7VYD3*-Z02/YP)*?.(YMTH6G-5/)2K0)D@K+1D-
M?]U@'Q;#N_.K/]QN&\+\>KF"=>R!LS.$=9A$-<V0!6CF^Q<5GM(JW0X><54O
M47=FBX1@S[B&ST?!M!U@4K1LP:*V]YA&[K:49W*RF[%(4LRA::,!C8KSP#=+
M6:L/!2V#LB!Y#22K61)8: F)WWT!2\Q[#/84!7&X(+  5;X]E*\31C]0T%Z@
M(1+)#0LA=S65G!;[FE%4NK&&OW43?^[X()B#83RO-G3QR?B"W4MJN-JK&.N'
M%OJDH;;T-OXU\S\,S=-JRRDR&&I2U3];K+XH4221R3-&/T,JIBTH$'?@>AKG
M.MO]X)3>'7,:=/>NP2(B3@>7/15U,.=16."]+M$ ?0P6N$J'!8[Q<>Y^\ F&
M6@?])\WQ\@21!7+N)$E-)35?F<RKKHVQCKQSVB)VFU!'W(M EUA>Q<,<D=_,
M#1E1FH0=K)=C 8YL#-U91^PO/OC4)1J*!5;'\?I&3/71MPXB0,<ZT/*+<P<L
MT/U'_Z>(Y,)$G.*F0(0@J!/ K4K_&:[N^:VH7=+N.6 P1E@ N0->UO%7QP)?
M THAB_WF&,4[;*7T$Y"V#%0<%KA_@9L"2X*A?6-13Q9IP%N9#N9GASC&%*M+
M+*#R6@I,AN&T?Z20M'!E\N7])'7#M[/D<K)J; ,S'V/;2G E]S<A0;)& D5_
M!POTFW99E'J1.[#?4*G]KAU^XM?Z\M] /?H[Y8!UV[+BWZWU=\K]-Z[_O;C8
MM98A'11\.G5-#0@&*$5IHY-@)2-4_BEY0L="HLU_#6?_CP5A474N K9"E) _
M;VZ*(C,,'9WDS; CF[T6GO6=@_<G7A:E[W_9H]O2P577<'Q=8]HE(9L])^I/
M:LVS\GA YLE"SK/,_S0#_><>7+'('Y@I"GJ?*Q"6LE9%V-B>S;Z*-E3& J8[
M^8?_E:W][\/%"@[! M=$X$O&.&?Z,-MGD4SE=%@+Q&$:AF,'_SOA_A?#552?
MCWXKC 5V<;5_B[=!YS>0STR?+&&!#H_1 S)O?".5:\T&364 W&?%'MC<^AH)
MW/PG0^"8MLUH(WUY,03#TCSA068JUOMZ5L(AJC?I9KN$;1&9*#Y/..#%38J^
M*(<V:BVQPB(R ;3D%T/)HC[DUIG(Z>A];3:Q5L'(5Z7QSYCPHFE47\EF4;9K
MH^J63.WWNZ9TD/EAY?OEZ=E5H;//@M5J7U[TLQ3'KWGARY0]T;[,EG"X=%OH
M,L4W'?OI#/4KI9PUJ-.R=%!<X[!&M6C GPU]O#!<U7TERUSFT '^O@\M-$,5
M[8P&"#-[F#-O!]YX ]>@RVVJG W3:W.]+MH?)$:YG,0LDY^%&:B?"D/KY'L'
MRU\8SWY"JQ39,\H%K%_^J+X+W\X5'2!XD'NC/EJ&^9ENZQKA>^4LRJGEY#W0
MLDX4C;>/A P4@$^DKZ^9VT5*'A)6573R:X7)^/?E6'*^=Q.P7 9WQ5*BK:&3
M^PH*SOZEO)<_>:1O%F\L7?FN%BK_]95;:=<=!5($%6E@3[,D*D#,W-O=8,3)
M91WQKEYBI'&,Y.MXSJ&E7P&2D;.3U&J)9J1,C3OV'H+JYV:QOP@2DI:%JD96
M"0Q1=6?/:XD9J?DX<),K]7.3)'UE)"WESY00]V^)GP>(_5:&8LP8$9 .*G)O
MWL.]#:1(.+> @Z7CEU0)TKV-_GBI/-V"'8TM$H*W;6#&*BS XG"FQQ(86Q(C
MQUNK#CT7TK^06UY*Z$MA4''K>W:&M\%/!._TPDOM0MJT":D93#6SVU/;1Q3.
M>_OI7WA^*;2/H//R>A4NS/7LLN/FNV+M%G@6>4:3_Z[:9?S!]2D1IYP)KA$)
M68L)SDR]X7W2G=02+_<(&ODX;IXK;0TC#[?%/P>EW B2WY,^31CV5UMJ<ND,
M9!\Y<;FVY:MXV9DX/Y&3].IK"0G[)H5BQ_/.MZW$KIA]V7)EA$W$*C+_W7&Z
M+RO9O!B[YKRP9=6XI<$^EQZS[DY)"]OS5;Y2;]6T"W%4\D.$2*2_"%^XT D[
MV QIPO)Q9.[<M7!,SR#UZ0T!JRMV-(JYP"$"8%5VO.0LHK^##[P"LBBEV^4Z
M,\/\KY?MI+YK@[?U/YH0YOL4/,ME7)CR'N!&R.&E0D(Q/,:[TD2+3T9.=*[.
MU47]'''XRH09YYZC[;==]Q#4E-[OI2$GSR*PD5IL%UC5"<7<&DYUMY=D'=";
M?LCHE62T\YS56?75*]>XS_J*J^'^-D7^"E.P9<%O8TYK[Q<8QH300O0+Q6X>
M3',*^J"=;/ZOS\+/_4A,:$;W!@%YO_+(#(;O2"@LA&>R)-DH">Z70 Q_021*
MV;:S5+TT:S5'I+0C*W,E$\=9]5O5VK?+J9ALB>_YL-#CF$#5TH6X7+ A04-U
M$D"CZB9JYE2$IIJ2%"(:'. 9>[R!!>Y.")ZD1>3X1_5W1UK'7;M^]&1 ]7%)
MSUWJ8-?(T4J4_@J%3D<2YL;D]1%'%ZL)G$";;Q49&BLA^MKQ Z2:(]?C>E^^
MT.1E7&>>30+VN5&Y2[7'_9<J:-.LO,S\GF\+IM7Y))%PU:[QN#,+IK7G-%<'
MC!J19Z&O9ZIJG=%J.?#^(E7K;^\=MN+*A@&M^V2!B.=O$WM:Z5?T%[]G-"<M
ML"2-.C#SCDCLB8T;&N\RIAH-<5\SO2<E[/11XQH6T"#/$7"&]_7A6U<V/EM2
MM&D[8P&'OI[G8-<T?:(SZB3<6*RHZ>VH#=T=-))/CC28T?#" N8*C@WTB/5@
M7>(Z!W/Z1J'L>RM"]0-)V06V#.4^!79ZC(^T?,CMQ;Q4:ND5HIU;UMSU5U!O
MEGW*3P3HD!SQ4_ 7Q>9&45O1U6^^X25ZO113OYC>$6@OPP(V!\P[+/M-[D*3
M21\6[.H7,MDRX34/*B_+K.*)+SA#+*KAUX@/WP@ORHM7\-;#J-",?QQ.<WM9
M=T[O\J[ZB?>7U$DUO^)Q6.: *[^$?87CEF=C6H_>N6@D<!QCTU6O]-:+C3'Y
M]%OZNHV=\'*T,1YM?_V=_7Q"2\O#X%=7NX9_4,AW9S!/"L+WVSN,M/>*/E(H
M-AT_YESDNI_R?'I#Q8JC),>#J?S&5#.!=UH'A,IB[(1"2[L9*=EQEF"O7YED
MD'\D:/T]C"E60>!>W)N1GJ& (9"_.%(5NN(0\5IOE%9CG&O4LBY^QX<K=<[0
M3&)-C:6CGS/.W$4P31TCB,#;2M6/:50L=Y +C<O;A5MG%]MM,B8QU,3U*U8,
MBG+;=R9DR%[YCE9!LCY S.XX*# F@V>VJ5).#=ZEY:6TW7-\*RM6)_ F&N@S
M*+A1JP.@^9 B(8$WYW;%="R=E@^3GQO?@TA.)VZD_9BG$^\PZN<CG!0(C>F[
M==A-8#K92%5DML,A6E4YR_'%H\C0.T&KOCX"TW=X)VF+,W&<S7]R6K%-DS04
MK@(X0MI6OT,3-&HF%,!EMLF_0HM2U:8/KH>D,IMQ\<LKN#4Z,3\ZR_9JE7E.
MXE1I!V8ZCK'LT,GIM"Q4U3>H'<;,"*IS2HO>Y>62/W.R:+PET!L3QOQX6HD7
M(1V#X81O'SJHW1EU%CRPKJVN'MO,6#)^:R/QJ")E54>R<9L>N:Y*KZKD)F:<
MAV8?+T%3E6Z7NEO#QZ?TZG-CAH4J7+*"<06\CX1"0=#8=IWMC%N7V(*O(T9)
MR T+Z#@8+_)WG<[JU(Y+\<V,^@R+\7HY+U5I/EP@[YUU-=V-\=/^?F&>60!O
M/;U=ZK[QL'B-Z"+W,-#D=,CH*"T6W][(I6U:06YSSXQSLCS)5/5PPC#;<#US
MJ"[9DXB:3N;N]$5%^6-">U3[\L1B>*/'EYVD*0;$-HASLM0*I#C]!KVK#;MU
M$9_$QVTENCL:)&<,8D'Y/9D2.396]'O0,/GZ9-$G7]F'=<Y8A*V7R:E'EOW.
M#G\,K%.'<![EN=MQS1NFG*9<]5'9M4BML&7R6X_G,H?N[+/FETN?T>V3C>X8
MYH-.W_P(CSHHV9X2O.WBX>3Q8M6]@KF!)A<>M9#.Y&2V:TY/.Z*8?X1MV%AS
M3QE[+66R["2S>#9)12U=*'II-H>N4"C!]SW?(VD6O*^F(F9#'Q.VWOQ*-/,M
MIOM''^"IGTGOSY?7-26]<'W440+VO=6#(=^]<):GJE?JB%E5S(9 5?W%E6\7
MN=^F81ZK0^33\[:G-4HW1IWV/3ZP/@@UWDH\>--%SEEM-;A^4;>CZ#!P'/N.
M9<7[XAZ2?<V(\*->WBWKRM&D^^_YJ.U)5VX_V3@O?[(I[[6B"D\A,X$'#OJN
M29N!*$^E3T>V4SW3?6/*[*5<C0.2] )Z">N>-A#(PBL_G=(1"UXU G[Q_MW3
M93>S*&U6O- )Y;20:3G()8/#D1Y,LYD/TBN'E+Y\FX\%1JQAD@XG2L18X%/F
MA3L6< 83('4PSV'[?)AIND<J@3F!I'1__)'NOV/XGK68Q^IGDIY<S]\ATH*1
MSRF]?.<V^1.RG@.9\+MTV \0>/9]2F+6Z9Y.[?O]OF6".&WJOOJ,%9AP\1[5
M#*@5PX\X"-EWD?0+JQEQ"8KO?Y#BMI3Q8.ZRI1WE=[(:C7G966?&(H%I8KXY
M5(1Q08'S-O?-.&RFM_4P?9]-MHVVL0!?^9FY<ZSE%NG-KS ^<%9;713D_!8N
M5Y^2U. 4'9O2,>F$H3\V8($+ F-<Q[N]A9__+T]?_'G@?T#,;XTY-9I[6B0M
M&>_HTYS?!JP"*E0]"[BO/+PM2T\.8:C2D!3PTT[68(-+GRXU6CTB>1?]CL_S
M0=H]J6&2MH2,E*8EV F&!PM\:X3]$I8[NMH,[.PMU;WV/I X^;RSK%OASC2"
M+J]D4MKPNOQ801:38<&VMQ&DJ*6!BEB^?'S8_5"N-#VIP<,J>?4>+@FYK$8D
M>YI=ZPPE?BPFHS#IYF^-<)SJ8E*XES<WTVWGZN-:V.Y'-C,KR'MM5_ +(B8J
M?)#*,N&]^ ]3M,"4#1+ZH_ ROIZ@?AIY98&9^\+VHR&9^?=S,[/Y1IN!(_&J
MCX=8(+(22O7FU\H6C&JT]3BL 5&60%$'K?6A@6^LW"KE(8MC%F"^D%\^C2]Y
M5"U%DD6E@BCO!%%ZM^O4-56,ET["F9T_:D@@0Y)DV 03OI#?4^E+O[S=_]FZ
M2D3A9<YLNQ.W?G5-INV%N.JW^38R-85@F5S6=&55[E6"I%92IB70+1R;X5NA
MN-?NB9Q+9WTPP3OE(B*2]2U)K48N8#7!W;GLQ>/!IX6]*N0]5UL4#,*6S JQ
M $E7<5YO@;'@D7TUV#*5S_7427CTM;<%L?/]R&8+_+P-D!2.+4P.K?*]DZ1P
M,/A6,R5H':;V_>(E)I=]3LC.\:N:J@8WU:'<1YZWEL![A_P1CP'ICE33YOP<
M>X;ZLO17TO=\7HH-D&?1B)7E!(N1+)V6X]6BB%?V++6]16X@3E-/6<R2\PVP
M@-4.XRO6H0J3\SZK>)G5^!F3YWC,'SHT.&&:)[ 0):HZA$X(1>+:-6,S;0_)
MN0KC'6FC(#TOOK2H>*O$BN@*TJN#=+K$EO_C><I_<SR5/#C'VP&?[/%A@NTO
M=:=@:\0%6&"J*O/7U2RJ@?J_>ASN M82"!XI]:=8GN;V6Q13E)MA=4YW:[_!
M0TR@]O:$3;^-_A<78A.C<1 *_LF(HX1?DX)NX$XCY@L6"+S  H3)YFCG6)0!
M''1V $,8>F"!KMW\,DL=U)>E>?,.6EL]#J'A<H_:!U'":2Z%]WA^O!1OE%"N
MN5(KV[/*-HR':R)9[V$NSS!DPC#4/ A1404^6(0L5>YB@9B)/8$N,]"4=OB8
MQ[RTKC2BU]56R'DU>8^:B]"'"_[P1(^31@R/D^5[CO=;+>25>:GD0L,=+8=7
MIS5$@Z\_WA,+0"W:R9NZB>7'W6'^L^"1/^_JM.C P&(RZ6IF-@O7\I&>V<O.
M>*::H9U;S<FWX534C?_YEF*QU%1W,W/SA*2BU&*'T8-?[Y-"M2YDRK_:E=)Y
MV.E*6>)/!&61+OZS32B0]UJ+EQ.1S$CG=PH*HSX"Q>R:H$IF\9A@TUEI*TOF
M@=>>9]2FRFP(]81[-\(TN)[W]:DJ$W@0>&51R2/ L54.IL+G5GX_J@LAG+/Y
M)C44'K?8N7:#97;D6+8@RY:VD,5F+-#Z$L?'68L6:"<$J\!DNW*AV3Y$F19.
MA3N/ASP\^+OIU(77>5(^!651;J1_19LC0!%6\8I<70OL$U:QUB>5$\\_E6V2
MI)!N,EL_X\AY,SY,@ 7^F4:O&?2K?R5^9O1,Z/1PD!.LT"$+T[@6':K'=DVY
MYT9^%J4EAD$J[/+B ,U@"D'6@_\,LBPC$MCX[;WL/RU8;(15CV5K".]?A\:L
MJ2=NO IJ^/945\?S!<"NP?GLKU9O;_U_!O#?(OXD@DH:%;&ZQW+4$G@]F*]1
M3,-"3'A/;EU5DR.G"_B5BDK T/-%0[9,<0)@'F<''0?G?&:\N-+V&@O\$IS:
MQ )HH5A6+#"\ND*%9M'! IU36_XW*F)G+Q]U^DMO:&,!R5+KQJ$N]/TD8U 1
MQ%;59;6&*Q*CM9@JTC=Y!,("I E=X&/A1<@B#OQC[VY,R.S!Q=D#7!ZJ6(7\
M8O-7Q@)O-;  "G?7T7L1$P:Z!ED:A6"$8??6!\$9R1A\$8PZVCTS% MLSD/0
ME#CRR@G^&\2O(6TYR-A+LIK%L_T4G)M;=F&!8QG46RQ E( %D+C;TTC8):42
M)\X\.3A=3-GJNH]&L4#+2RS02PRFP )#];C=V<&8.Q TOPX33M&& %Q^W,(!
MU%@%_6)T@1W,BV,8NF-P#84KDAA#P8<%5K;^'KZL>^QF+A8(ZL<"\92!.(-E
MXA(J0@Z"#L+=?9HAB@6^>%Y@+D?^UB VOYMVY-_0P&T3-*2%!?"2L0 W&UH:
M"RCA0GH)=SKGN!R,*%2PQ''SO;/+BX+]9@949=>D0\0Q:T]6"'F\>F]0$9&&
M4LMC+/"[$50\D/)=TI/?C4U0WTUJ:U+(W>X)9XMS%3+QMU23<*X2O3=9/=^&
M+(EA@;6W?S*]P=^:!?0WN^?]G:%!B&H%%RQP+S8<C+ #8P%&-6%7]#$,P0PY
M5!YJAQSMPS#$.)T__,==Y!^B_-_O(+M;YC-#IQ_]MH70(JMD77ZA\H)0X[#>
M#QEQ?=VH)J:3+9^U<Q1:U>MMUF[KD_0:#<W3 R1'UY.WRX[]]&Q"&GJY ]_=
M0LIGET8WA\"(8G_#TR\NEV]]-C\>$?C)PBG%CWL+_\92YH&]6("'G^J" &>E
M[/AZ>Q3D9.PV1CT I\9:[#@.#K,5%C@Z+5\$8>Z@Y_[1$9:/RMW$ J;B5&MA
M\[B@ __M*M30DG[KGO3#"4AUH[O+Z]"9(Z=<UJOK^A:#YZ1?'A._'.(K9P,5
M0OXN.YV;=(MU6"<V55__Q5-YK'3!VWO;AP&T,RVSW>#BB5[(7'/_IP7^];%^
MDE^WZ)_?=!_VOE %72MWEE[PT<YMQ9U(A$>7&\^G#(7&U;A!4;.XWUD \%=-
MS]<@V3^_M?7[BGK?F_B?_I>)45AL4U(:*=U XGDU7FX4<D?5/*QS)E65[?#G
MD.-P^/*[@&*4VX\=AF81**V6L\UXV0W:N^L<BB.JT@*4RLP]-QHMFGD<3E/O
M!_+Z]6?*+?1X&_Y<JW.Y#C6O3/'_\5K86:$6_YHQGRVS#"?'XC]KZJ8R9M!W
MD91O5IA>PZKLIGS90XM!H4:LN4G:FG:A&<)*XV,IM]U\NRQ[36 I:,D!Z4XJ
M5C61H!/Y_LOK+FBMG/U@IKW-6)WO#E%1!*HIY&L_>C=Z\(@4.]LHZ@3O*&;^
MLRI7SC6,N>F=UOJ+8BXU<2"CSM6CS('%1/Q68L*%\DNP58C86HZ:8\3Z6N+U
MIZ+=TOM*HKLLR:'"DHP5(0E:C:..+I90<=6] LDVLMH/)4$?=4="GGSH#'=J
MYPSR=4$+.E%=G"VB!'$QOHK+!5W#N)2!"^_@_G*,M!DCN(N*>6OJNT."R7;J
M1%=QEIVX7;USDH&Q<=/ZJFITKV1;3DE#RY%"S_T&UXMFZ)XYJ;]V*:JX+72S
M0T_78 =AJNV@X'EPE2 [+CY.1ZYK>JE[H^XQI39@]'^:0_[/$;.3 472WD]0
M@ZGX[0VX<#*/.:LA,C"FGA[WS'!U@2,;"YB-0K9X@\!2?_EUU,],CM9RT\#!
M9K:P=C?[#SMNPI$9UM$F)B6\#JZBA+* &LS+J6Z(N3RF^)AO>2/7-@- ]$''
M^=L?0 F8 :XSK8,[(/"BMW$7AFU2LK^)_ZBK1BL7-:M=/?JE=EQD_VN F$J-
MM$KB_#ODR_7^YKTT2N97#N!V##'RG1+W,/?DZX9\1)62].1!5FB_9HI(J3-[
M&6'CF*PUA0.GU_D$+7.LH#)O\S?,>"6N*Z@%'^S@H@D$3S(_.B.^O#1'9E&]
MPU!Z:ZTPMCJD\Z*\S4W&2TK0] %^>;-EZ0):1%_<3I=_?B;LRY3CXB4A$(P9
M%_)-;J&Z@KI8@D1*LA-!J&9-6LML1W:NNG)DN[K:\19?O2H_-W?Y@8G#P\/1
MT?4B.[A;\GCJ-#<9?=F*!2#Z:-L_ 0&\I3O*PWS+H$C+)=RO(J^CWI8;[73!
M3]FE#OUV*91F?YYQU_+>;%GH$AH5$[FNK]2LX8#(UT=29J^8@O40B^%?0XVI
MJ*-FC4T5BNPP ?!^DK'-@"C/HQ#ROE&-Z.=,8?WF]A![0\C0'.CL!-(5NZ<E
M<G[Q%H,I1PT3]S?3C3DOC_H[X(*F'7YYTMQ4>+\^,#L7I?VU_IO'6!)1@];5
M!V-W-2@8]F+CQ5Y%DYR!W]0[?_F*!B$\,XNV'VUYG=:;7-/*5]5@N- %&K^S
M+9&O1PSZ2.*2QC_8D=IF114!:5^DWKV59[[[V'"'Y6-A_K;GGN) >T"9:4%X
M5KQ&RW;WDY9RF8JFNHDJUH8+@T8UU]5T+=VQO GAM/9?B>_L'(57B2:),DB.
M"%R_!V<G$:E9'$GZ#@5Y"-P?=6DWO9M_8:RKT"/'6A>PF_MG2_M_MR2./CX(
M"00-GPA : WL_4J^U#:/[7GP!@L\LMZ[4MJ47=(29LY_I[+C?I!"M.4MYI-8
MJMZ5AL69W7;?D+X=NU4R=JG17WZ&]^-,YH9(BS4(BMPZ>N@_O,TP5T":I5\6
MXEH6\"O(X@068 %#!6&;^U07OV"K=T!B_A8)W?$H/NV,#E31E/ZXH >[M<38
MRK@SN?2#1Z4_4^7UHKOZHNF8,WL)0:+J/Z1.=Z5R79'7-R?TNZ)*)">^;U-O
M1[G5ZT\/5 4^KP4A=T1OU2[P7N**Q?K1>N2ISK\:>.1/&(#S117, @M%S306
M6+8 T:6\7MS# GM4T,MH$[*>1BS -7#NF2AN\S.S]K![  L([F1O+2B.^!/+
MV9V9W71(NR13J1^W;O;;W?[ZZ<<*KAW3D>0Q5"@S8O6*Z2)J*8V^Y/N'*K/I
MMZ \M"# G=32T^P",-SFD'?"T5EP\_9YV'/1N0$)U&[5CXN^54Y]R#/(ORY3
M^]LHN3)!KW_QN!\3B L+6#%&XF^<.$CHT?\OE^%3_?Y1LWH@SXY>O+\"DK]T
M7+#[X6> FR!S/M,7C<$5 Y^5\E\,'K%H ,=<(LK':OFA<N8&I_&:Z(8&B"C*
M)F+:=P*3_S-KW<6NTN5<GNV2?AC2UHC4OR23Z\8 .,;3\0=7.NHT/Q;<!:'P
M1+  K7G>I0L5[L"YSK(10S_1-NCS9,P5+-"SN57V%D._&0G;,IP$(ZZ88WAC
M4?H9_#C*98,C+"U7(:A4I9HP7"3&70Q#;%;!FS]@"$:,&ECE-0A1_L>_([L[
M6(&C;C0X/B#Q.X:31C :';OP]@+,C*->.'<+@AW*_A+(^EW![-\ E"[C",E:
MX#%H!C5T?B2")L0"<4,CIL1H@2%ZR/#W$L@2 0RMK>:Z!*8U:N4>\_;2"V4:
M;^CEB2XJRK**UT0 V;O>D/-S4!/Q:: XQA]'*_$@:Q9_)^#O%0CX'R;*P@QU
M0892($LBZ/>!D5O@93/O8DQ(.J[;!WAPE,#V[Q3X-_9S/]97_OT0U'X#8-R.
MHT@]EUO@[\C,HPUS%!DNKC._UE/]?@)G0S.+IP$UAE^0TM'Q-QNKYVURYCZ4
MUH).X@NWWX[HC"-;E[JM40\HB(W<'\YRCSF=*OJ7A[FSS=*S2?(_E)ZO&M7"
MM?3"^5X7<CHKL[$_NY &\EB@TNJ";"!3L10]?9H"-J'M91HJ/$M=XQXO!2];
MW5FT#W,Y??#6ZY-HIJSB;\D8HK12?&G?N.M6<"0_XQC[DYR(?NE5%6+0V3]"
MH&G&/K+X'Z46DWR??W+W#D-!$>Q?2WOVWP89GOUOWU=,'OQ-<#FDUOP+ZD5I
M^)?9RP1G:9^WS$=Y9UF4S?_1W?XGK&,*),4"L;$X/YLV,[]D9/=9 S,J@%R+
MTCF].8ZW8E<2<BG,?R8)O?CU+1GRZ=H#:Z&-Z/-F?7(Q]5:N&D12[I6:"'1#
MFNNM"5[1\_B@G'/75:69<@(4!$%LAICU?K&_J8.02E\1NH%9U6M$*J47]O)@
M2B4RW%E]F."JO615M2^&KI-F$?(1 +X3W>\5 %@5.0<#"[<XZC1 :#W@A:+2
MC1=!SR_3]Y4PFA]FB51)^)B96YI1T*6HC=JQ,@QH8=[;:.@Q%GBG>.(CZ&@U
M%@=77[E-@EZ]]:YWO;##V"T;[!5-18;&G_0778DE]:YH='$I1H6R:QX\F>*L
MM^6JBM=*LWEO?CT>3Y1T0;.H9XT@-JB1M'S)96;AJ+72F_%1@&?[LW''?>=R
M_WOYBSLUM-MCIMK-*O70B-:GJ;*:R\'7^0TRTXB"Y.895\S?".Y?'Q92(!-.
M678 4T,LC7?BIF>$DSGR8M_-L&A:/=FPT-.Y":#6]"[0]Q$JL,Y/&*;N7,'4
M^7&G,JVU&;73IRF&5A1<-I<^\E;$!)>CZMPV _Y\B-C.[:4A<F]WLWI$!P.<
MHVCA>H83V"##1])O63"9NB1D;ZPG=LC#FFO@!1U ;/1]&13D6Q/J;[I,Q6#B
MO<!N;!+UM'[\!,4GM>W$-3>KX':9CM,5CM.UEW<X#L'XY@Y[>NE9VSQXA0BV
M% 6F] YDG2U^FFSB_?S;>T;Q7NCUVKMM&ARJ%EU=(+FUX-V,^MF.#$($1[)#
MGO%.!@=B/YT,VM3TV>N:45LT]_3(URO #57X4ZK&Z1V']U.-K,4:*U>AZ4H7
M*HU).M0J1:Q:LUVAXB[LX34Q6H+.6MPI:<ZWU?%]3TK((&^]XE&09]6P"0F!
M=+7'8U_&UM-\;G[U*[298!=K>),P^#Q;X=QUGZL .-'66K$)K5JD-D+Y[TPF
MRZV=D3F^GO4+7UBA&6E\LQ;KN:8=UV#U?LXZ)VS%YNW^:]8!-Q#]EMM6M9N/
MOER\_>TT6]#_Q=Q[AD79+&NC@TB0G*,P9%222)(X(I)$1$#)07)R2()DAB Y
MC(" @"1)DB5G!LE(SC#D(><9X@ #'-ZU]SG?>EU[K7==Y]I[G_.#'SQ7/]W5
MU55UW]W53PT+V ,;K-F]F(9HM-)#"Q:A@SL-V9;5D:MIZ;;UC0G)'\4TJE9G
M3U/BC=X]\) S+V?_^(&;X'4D@&\#1N#*AZM"[#PB37KA3'B<=+0KUWX>G845
MQ!)[#PHOD:MS[QO8*J00Z-,N8?:33F]MYAW%6.2I0G*ZK<JCM^S>I ?$5KY4
MG\;GYJG3P5Z@KC P;MVE =Y"DSX?+MEW66\*,M+/+6-E$5)F5^%.N-.MNC<U
M^$[[S9_Y5Y7\FW^ZZ2!\_<;XGQ*W_YD7W_QY7_?G@*P^Z2HI.BP"X%_DWCF
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M<Z:MH _B)20.4*1?_1IWEGS8A'?RI7$R<SQ6@*!=(--';(?\LMXB8$]R)B%
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M6*$H%<;6ABL'2=N<EE-]!1$S"G,>/BQ>\882B_AC!<JQKY/N GD87\=GD);
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M=E,O3"8:V::1E)6I=*$4FC@>Z<I]5SSQVIY.4[)T_/3Y6:^0)%.!'ZW95^S
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MHST/8J4\C3Z:O^8M2LMM\B(S(WOVK.E[C_HE#X:A<.7\&C".N12%=(JBY6X
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M;4:J=!G0MA!_;T'&M&24F<\1II *2UIL(C<R0-"0Q0,X9\.'^]<[<Q?"C_L
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M[!# E840<58MGAI@C=1?!SBF[NB#0+&J#4FTFW)YZY?N71[R?S1(N>G+J8H
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MYY$]]0D);5.^3]5\FRGRZQ+Q;UFL(/PFMF6#GW"EI.WPYT.5G@ >7U.O=0!
MLA>@32B]6D'I4]*]1-)T%Z<)AB@O6>53N]^<#E?^2&P_Y;"0FS+UR]=J#<;P
M6 1$14.B-:2CAFPT962)Q'(8<9#RE88&%%8O7/W;M*%V9T%>JQ0DC=TK/NY1
M_VNA(3^!,W#$#6!4:U9&(D,G"K(P<)6="N[K&3CZ[#H7V3<6Q+KPB_+#R0@I
M2N!%M&HU/K12B'1GL!^ESRIHYT:N;1SGKL#DL43?9,C<W5S8O!4&8A_-NMP!
M.>XLVD(3IN:?,0JQ9M;;4*DCH1F]ECQ>G77WRY8/65#Y3E @?19Q*X4YLXBZ
M[^GC1RE"(B:R^VL-M\4W=()U 5+PTA^@'L]BM'S#U-<0/I5."^+6V-OY=1'\
MI20A4K;L P_#],+<!HUBC2J'W4TH41"+L-U]G>T6NMBM08>FC1 %C/5]Y8 U
MZ<AOQ;*J  ]JG(W<M=28&@'B';H&?Y_7TLW\1 .R$R*^?J75\T/X%1^S7 1+
M/JRYUN?-V\P0P2V:U\Q&SLAR&N^U#'&ZCA\P(J]-EYD/*M?X[EFF7K%PG20'
MFSCH/ N9$N!XI[*12)G"05(44+>NVJ?$H3;LOP#$W"7?\[^^ <SXRT1(@(ZK
M8PHE_YT#"-=TR-0847#X)4G#5*O_=7:!$KNK;'O,>J?J+B/)_4<IMLR2(S*&
M6TI![P*T$71HWNP[,73[2[,S+=7-Q^ALB6NE'^Z@N?J@\U28U)I4>S<7'KG6
M]5<9PF)'[1F5;Q9*GAP[#OG\4/\Y5]+Q-2PJ^U@4NL3FV/NR-LAL6B ?,YJ>
MW%W_*G61IJ;V9PTYQ9*/\]31DH%#>4Q7:^9Q<SU,WVBNU]E F2>^O8S4_\S?
MW!E,J2HVB@=D>3R.5M>:@=&W]'\G9[M^M=#8>X6VABQ(;H:%7PG,^-C].&OA
M'#OE 6I1EE<6+5DX$A?P7\U)P[R :G(!"1F)3N\3Q)GXZ2,![Y9;]XT+T=9U
MB#U!^]99<-',#IUW%,>OCS/-T(\5*4%/ZYZ\2""X<"%:WA(;"[B-.K5#=BQ9
M))#R:SXXV<VG4!)MA.\,*RV O0@FN:L ,Q:NT.CTXV;Y,R'&NWS=<6NTXYX,
M,NR+=/4-FJ*LHI4*SB$7N< +5;9NK=^D+ES\P>28(3^)]S(FZ2GA)8Y3)B_A
MC\XXSK(Y"_U%J[I+R_ ZW9QE!MQ9F/#CHJ6Z%Z$XQ6MQL5X69*C\%7+<@GC_
M(LO=\0_K32]M:JH5F4KS\^"*JMV</ZP)<2+8 $RBUP6E%3)/D:POOB.F2KSI
MWGET!HW3PR4FS$WT/4*$Z[D8'[:\<5%U(B')ROW!2@0Z-6W%:2XO]@83AGHJ
M3R2#"](QP,^=O/Z,#GD"-P ^]_HHE[KN)S8^:\O,K;$U(TR6YD ]^!PJMQ-A
MKT7:).GO>J\?8Q^X)!XP3PV7)$S, DB9DY\5-2%ILPNZ"GU,NH^-)VH<1!O%
MWYDMY8ULP(E3/9LI;/;-<G#9CHO-EJED(2LCL;P8#A^ZWY!*[W7;';Z9\G4H
MBDOT9'US;;\?(BPI62&8<>8^<0 -?&7NDZC4,GD:J,NL?+S?0A^Y]CS^-<R(
M+=I$C4?X(XWEH+&B,TLVGU]XY\BM6;0D0BYB)>JV3=:X1HV&3;HV7A_4K0=
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M@1N/?A70]5MA98R<?$&(75WSYF&GG[NB^R:CDWYK:5=77%R=&MRYGM7<6/'
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MX>UM_C>0(;6YK2Z0B@7C03"+Z$NF95N"<YO)GB=ZV-S52\ @L F("8-V:/\
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M43RP; C]$8S!0E/R+4>'D9:KM^OGS#@_^5DN.QZ-CU]D#A!PM FI$-8>?U;
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M]DV3""[7X#?Y=R?@[T< 2%U2_YXF";2?J!7$W7@8[+**?%LG/MPP2OQI+.?
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M<];8W=X_X^?>'KOUNBHC^+'VJ-,^=\TW/0].G4,G?<,;CWTUH@\ M,'PG C
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MTIW_[XV<OGJ1(AZ@ CSMG,%3A?$$KWU&03-"/R[WX#KRC.7]7EK6]'\IA8B
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M5<G2Z\J9D$?JS\"OF >P,@XSA74RXE]G<;AK8/_;V*HXM2W"_4J/6"0_.[/
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MD8KYU;'-V\XX40O@:^#/6, >ZB6I%37MGJ*!NO%QE!6UNFELHRUHCP4X^+$
MII$&"YS>]P!._/\%Q&?USQBX!D OL0#CQFXV-V2&-6++3<5Z,CUUA3OWE52]
M_4!U,JN_1_BGM V&(1_NP<6!_(>TM=5]+HH4WMO%%ZNA01/$HE27W*)U9<ZZ
M4LO@MUD_U'-'6'J??NXJ*W[FQ.3U\I5T.CQ>!>6^P QJJM<*G?>&*'P=6!HL
M9$/L%!3B"#-A5E$=_K B_)B"U_'$NC-W1I&O]%4:/<"B.=\P[M0BS=__?-BY
MB KEL]!ITDF_S9_N8F82'AZ.SY;'P\,#/""X>JGP5=O<3$:VY?W <M:0,M1!
MWM6 G1UG9C6"5$^;!W9&-X[\N@,N,"_%/9/>6]W8O8BR:'4]M4I<'A36-Y1]
M!F^HZQ?(GUA88A^LY84XD;:'<XYI.U[F(M'Q:RJB_(*61)*ESL_RR"'JRS/&
MK%Y9C5Y#N6F-XJB_+31IT'9#7\$SF.8>NMQ,TYZ=9KSZ&8DO.3=B=*MZ(976
MLL^Z1CO$"^1H)FA&<A2O>K^D6$%! 2]J.#8VUO>ZWR4"C1),IP]?D$%%_VP+
M"S-#6 L\7E7V")*:Q#5./>EZY\[+!WY.O<RDGN0A!YX%G'-&M2X+/!!#?HFZ
MEQNC$T\SLO6;Z,L]#Z,*V!,_/&10K'](?&*S1\VKL5,DA< "OH>L#%#K-LT^
M^)U2E&YAT1*#L+;KBD0R6XYN.]_5DQ1EMB:"$&J=;P^W9K_ZR=SA.'^/UB>K
MMLUH")&\+\(8ZLZ?'K0U"A)6+>&IV'K^O-V?8#7E/D,MYY;;XEM3"]@UE/--
MO^83,>:+SGJKC07F$$.F+L0:A.&):]*4:Q)06\8ZMNLD*6!^9^_M:)<&[/#)
M=U[,KBNM&#M*?1&$,F00;1 -D_HQHJU$VEI-.78B1F.A8ID0'Q4V#Y,*-V6\
MT4K')FW@ZS AL)6Z@ 6NKAW=_Y*Z ".;TC'Z%B^Z=YZR_!]NP[3>_8^$KM-N
M8V&M'FBP,+YDF902<W16:^7,J%P@T V>%9J:S&NJE2!ST(XI6XWQ3\J9F_57
M[RY<I_6("+ ]^'BK4TK+6T"YYL[C&N'HJ4FIDEPV(9X(?B6B.%W3'GPR+OQ.
MD:)Q4,L,<_^NBXH"SF 57TL"=C@3&ATFV9[IAA,JS3GCBR2F8WJDV4:+^ KX
MX$J9LFY.^%,M]K#/&S31PE;+=K:E-R.)/M(MN;"[:.$/.L/\/#+;FE)IURF@
MMTAO*<^2-F6!S21'!@J+<MM6[AI[%78J"SZ\]3X_W]W,,&U4:1[T!CP?$0Z;
M[)@[4SS(U,^#\&Q:;FOHM!WI$X025]WGW+$SQ:.*BHFD+I&1]#<X?^]E.%_'
M<JPYY*4Z/^E)S*7GOG(FU64C1V\:0/ !KX]D>/@\7-*Y\Q).-AW<L8"ZE+T2
MPK@E<K/A:F#J_)=P4B?EH?FX/>36F]+NNW%A+VK\%)<2]7E>NY.M5426S$5.
M&HFB!& TJ;F6'J W:L97##>11C"+]:@Q01W,M^R!S[0J1Z:82']8,F.*[C#Q
M_#<B?.^S&ZA9<&G*AO%52WLF+L,X8HF<S]=)T-F^I:QF!$G)/U5*(16E")?Z
MJ7V%#7(HUL(9*.'QF5/3URG4%U;\<<L1BJDN@A)9UZAI!2'YLZ]O\J-R''T;
MBU/2]*I0<MDH)Z41$4]]"0$RZW@/BV"V(9>VZA#\X$*"N##)#3=;#8/ U4[@
M?.8]7M.?H]\\GQ]N#/*9M*$NY&26<:?D0;=J*\-[!CH79CQ=;MOY&8;9[)+/
M\BJ&M7=1C+WZYAD >#G]X>V!L:FJ#"O3GV<<&WI&U ;Z0W)S)$*%=P++WZ29
M((MWS#82#Y^X.+6%QUD(X$]%\H06EP_7WS80F'R2! K26=)M'4M9@@W*L[J
MT[  ON&7RLRV LOC"HKSKH2DF]Y"=\CGW O!\V[!A;9E$CI/8]V\G:SU)ASM
MR[:=[S5V,"T2(0NG>*W$Q;0_A3W6"=D1_CI2NS. UE<\AEU \0\^+?8;Z9F0
M\(2VTMP;!6"'YYM]VUYB-M_GQ?C/G,FY, N1BIP(0KAHTP)AUGPJ];K;40KS
M\+#+[8&157#5F-K<(MY"4W0)%Q.R['7/_=%TL9!R.MK68^7LIU\V%(JO!83:
M*#.CM3I-3^Y)&Q2-2GXX*C![IV8K9^.\*'2_VNNV1NZ@)O5PDD<!^\?D\:U=
M<_A.7$_6O+YGGHZ9$JUMVVE,1$,LKR#J N2;#YL7#Z:](5D?L3PV</C&NS27
M?*K'@=$F=##R06]#@:=!TL>]1@2F;X.RI,G1M;#%]$<7]0_7;-;EU6.UJD6F
MN4/J5DBTTBL,9[35Y_=22P&J1]L1+P>^7Y@C(8W,,MB/F1J5XX[*'Q;/FT5'
MD!6(JS[]S)R$!>YVH6\LFA89JGPQGA!-S9_,2N1E=6=^17A@_R2JK<'CL#>H
MGK5X*!^ME&>-BQ#L0N6+SQ[KE+T+O5N:2[JL:)M7RWZ;8.X53[,TXS<1/OWF
M^\AESJHSOFHL\,41H7C$>:*=9>ESO0$QO6AH-<KRJ(#QT7R4(;L\W4OGYYI#
MIW=NPI-"!)-5QPZMJA]?[G+*0^P&"N\&,Y2EFI;%-$7JZ_-,A9J,"M+R4U'O
M&SZ"]( 3;Z\Y*%W70AOC+82?V.QZR8P<4VRJ67X]T9(V*0MY'3MVXF_]8;^1
M;:;Z$H8;FD*_%"5RZ3N<V/8(5MRXQ&L].<0K(<K/N')1XZI[.BPDA:L:'KBA
M G9&S,*LV,Y3;H3Z??+Z0= X1W;?4\L\8+(W\&C"//FY@$B+O_[0C3.YS(AQ
MW?38)U_NU#N >*(_SWV9(M/1FBE&/)Y\/,SKW+B0?-OEL@B7\&:HPPNA&Y$!
M0C?9?VSE0F^,W!V,>*HWV9K"4]^W4W;F&;Q:'$AS5U*K<T"66)'^?2>MA[PQ
M0>%<-5N(\FZ(]*TA\](D;T7AD4K!&?906XJ[/WP)HA]F2XX SVFG9X?Z"-U"
MA3V9B0RJ!_/MOPQ=S"N[J\+W]8U[2,O3;\Q[<(>GY%(7335&XV.L:6.F#4")
MDGO"):) EV#'/287$=)_+X1US#'KVS#_$DV)J \]VMW:DOT\<X(!)V,^S2?;
M37<=P^NJ>^E[R 2-24>G,?A(FE+RUW ))A_JNA21P8)8,_V\YTR7XDGP8MBD
MW%=\[Y3OCF^[5,/EKH\^(LV'9H&1MT$F4R9GW-\D(P[]77?9=I%A6,!Y,8F!
M=:OAQ7PJY00J67FHH$!2OJ8UP]L]FS^A=M=F9WJ\@/UD[[&=2@F%XIA#E0G/
M &S^UBAH[5D]%OC69?RS$@3[Q.KY%=I9%#T$"[1QX3<=8(&Q9LLGE0R@=_HJ
M0R\1,5"CE77A/J^!%KP:XI6PHN7K$?125U>7&[?AH#.1M9FK2&MK/9:"/%TK
M=<O4L?@)KZ2/6P-=#"5EY*0=5?M\/Z .--)W5AD]1G$:=ED41^"' <<80KU_
MK^/S"Q89%O=%\+A^DS170__NM@BSO4I#Z9#-+C]_YL@A<0[_0B6_UDVCU<"3
M21MXR<O% GMHT%S5*-QPD=G^[,4+EAM]S_NE>V^E4G<V+L,+5H2ZJCF(NAOE
MG[SPV&]3_ONIG3BWUMURK4ZKAN$J%UL_%4#TS+-RRN/B; O, ]O;2J9O["=\
M<KPZM3QY/@7P3$(2L,";9 .<1C\\PRDK'^QG&8<82.H!ES%LSJP("S"ED7#!
M>>OOH2P6>LDE%\9%E OT?OSH/WF-/_6CFB>JMNC)NQ'C=PT6H"N;1JR#9=/$
M#Q$]@16TN"CXLA4H:+YZ,"NRN5\P9?B)9T_KO#_/A=Q7,M?7H*S-]W_<-T1$
M?*^,\<\U+C:KJ:"[M:&FG7C?/VJ]C;H/E[VI%,+Z/GEC@==Q#>A7ON(?.>?R
M]9X&Y5D5;]!\$B$EFU3@88FRBULSN1L'*UWLY%IQ.BNH DPYQ>FDZ<]3#^TO
MK5>L/D;*A<5EFN749[P@\##8_CR>]QVI1.(:X=KS=@92SY:H(3K%14^ZEOKK
M>G$INZT3)H!X%TU2_K.0!UZ'+OIR*'A@N3A(+RIJVSD/)@1Q,$B6B*_B=_AF
M_G#I.4!;),63F'QDG+3;K+>2!WJ;KV?[N$UCL'M@K6V[1,%UH]V.G^'58,)#
M@@=OGB4\HZ7>@/W-C*VZZ!M(Z8A"J_C[L)"RH$$;?O["].*ALML6@EV.CKPE
MBN'QCKX8@R_76_3Q'0'[%[HTJ25'R9!<:*!&]8#M]B$'_,ZT'M1G1DI+W(Y]
M7TS%0^DNKVVM]9LG[X@$0@Z*4$KEO:=4 @T(H5$L$*[Z%TH!&7/&!!NGI*MO
MB]"R!1.;\:=#Q9*!;6 (EXE&@,F5[,''4P$='#4Q?<_)U!;G*H/MX#AS7RJK
M%RF/5R@-F9D$E]M2G;QZ0/76U1C/@;3=LD^^,Y#@^6XUXW6RU=^6"OO-SI)G
M3:RED8C5P!WGV)$"+7$;D61J?3Y>?=E+#1\Y3FY27,VCF?[T8.E:>YL4<T.3
ME(7*J #9QP5H@20H1YFZ-</$N9]C*)K],C&O>J)H&V.^ZHXZ9:5 ^>CUPN/?
MY.$OK ?<&_P:S/6-"<?.XV9V'_G=LQB<N%S60/; 3+)X8BJ_:5LH@R9%^U*N
M =43O^^2,8;'S?9!JFB9" 6MAACP&?5"EUA<0/VPC?RM"OL$KVC2ZLUC!<*"
MWY87\>O./R,BSO/"B]%!E4,6)<),6C4JAN0.;HN^?UFOV)VG7YX[G5BO([1]
M/8SM&7VP1'"W?CD*M$"'%J -VI$T(TERC6?.70LEB\SN*X?GL L94O)X?PIZ
M'_+(YV'DRSF*3%S8];=V7CID]3\=#1918=4<16N3'F68<D75=V6&0D5#:_4#
M% >[S35;"J7=(G>BDJ\#_K2MH%*5RI"7@4LSEI5B45,;0N3;N^0M.=^BIG_<
MDC90NT<L1/VLY&4.8R4;_NNUV;_AN+(.XMT(AATQDY'5;![8T[FHD,*%KCIZ
M(/;^T2<?S1,&@HO:K#P5>-^H7W_&]/HP(V:;UH3Y" =5^LJSTTM-BZQ.#525
M1(9+>5HD<\4CW4.C\\=O)-@1K-3T_NVJNZH0+'5%*+#NH)?2 M2%6?YP0%\Y
ME/F.WN3Z@+SF)VBZD$2Q[K67$LLV4:_+'#7YZYD,=-$B@VA6>S;C\NX?%NI#
MR=?BIP6K:C[DF#BQV>/);PGGC5&(88&_>2!EI5='_"VX];5"T[_QD?L>/'\O
MVF0I(2N@/P/"\^&$==Q'BIW[9V&!?O,&8LA1TP+G6Y=$.-$"W3*B8!EN^^*.
ME=[&V!M&<O;+E^\=%?48H\Q8"7"-(8AC#,$Z#%U2E-7A2(7 #$Y(;??7G\=(
M6]QO&FKV!)E7-&C4NEET"VL/S"(ZI2]C@?31^5WTY0$L<&*F@!:*\(.ME:,\
ML< %YP:,KO8@%K"<KVU $QHO>?4>^;"5X!!G8/YI=]7SC, =+("@AT7"+!8D
M!-!70"M>@W+>?+@,)F,N]93/AP4WWD<!+!"G 6OB0G%B0HV#&A"<N&?I<BSK
MQ#V[72R %W]"]#]R8DU]C?-X+_JL]7@W5;19'S^['VWL"_TPX7CNSP%X+H0F
M3P6_QZR1/P:5.4S/8O %]LBWT IF.(,KH'L_9!=E-LR_]Z+$ G)%3;,HRLQ_
M.VWUNR4RSA1(I[' G! 6N([I;78U1E'!?IQ\"3G5Q] K-((.]-"X'/3U?6,L
MP)NGW00KE@Y>Y%,^DY!!97W93 ILXAQW[L\R4"YSL0W.CGD=U2,QX!['P+T#
M_K>M(34;B]M*;T#@5#-Q+Y/ZJ @M ?K)OD <^RYJ-: _*OS^@2X,,M>PNCJ'
M!=I'SS@9L8 T%J#&6+1H:$\T(+;.G3"!C+MH:ASE]UQ8?_][ B5P<H("X?;@
M@SWZ#*U]DDJM:FQ:B::,T#5T%)Y%*=I+CE1 (DXN3EK@^1V<V0GV%GKG'O\%
MTE$],<;'AQSM_]\_/^.:!\NG!4.3WL<#^2M#(CP=6HR>^LZ\>^+WK@!%(ZQC
MNT<ZX/'5)FW:TX(F0VB#=O!%1(C:\PJ95U^SB4@>2%;O?ELL)-KJ/1-H/+O?
M[993&60/5UFPVF>P+A7)OS!#.7PSHM?[,Q:@M&,/OT=/M";PJTIH=Z^X9XW
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MF6.FQ99!,W\,)\K]=+SLY-)(&\MCCMLHG^QQ1;U>F''J+#9_G/!Y[0<#D>L
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M+-@>@GG8>,V O8Q>3QW'FO8X2 _(OOA@E^:8^%5@URJ <EI1$?"%7;('$."
M;^3Y."#P?3@.H%;^#SFFZ?]-0\-6UFI47:CS/9C:6"VO0:Y)# Z8F2Y[L?'X
M+&$%IO%B;_,;J0M&C0^R$7;]3G!Q.59"^?)>JOQ1IS8.:->YYN],_X[JHAH
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M;@+2Y2Q^%N-8UAWQ4VAJ9&GKEYYY9[$^)^U=VCS?CT*\??NYOQL8]%-^!I,
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M>C @\I8Z4!I0W<3CNEU9!'9>>17+':9?R\NMP+%@$"ZT]$BWSUK76(A@G>"
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MY"KL=;VU+S7IT/:Q,0^:9J,U(=HBA*ROKXT4%'CA7Z3R1(#3J4E9*W;-784
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M\JJ@8E@<&C:\9H$%,C"&#<E,PH)RC&4.[J]48SM>.7[Y$,^$S^QR00J^+#R
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MJK<;H?VT0AO!L0=;QRQ[JSL)E7)Q<Z>+;^QYIQ,$>-Y_Z%N7)+1-/K\WW)7
M07?Q:<>M44@59C SK$9,5E0]<_" >,+ [),WVLQZE5W+Y)3C<*DLQ/'RIAE:
M:NI!XN/X4J/"@5T>[:Z(OD%^;7;]Q]+OAO/NE'V^O*O&D+[<@H^1K1;]N)X
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M83AR26.^Q<$2...$KY$)K04]*Y]RZZUF\ATKY$NG2WPE&F@@5D#-'G63IO2
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MQ5C6=5+>#MB,TFE06;7W!18@38W"_!K'1810-RS0PX\%WC_NN?3:@J,E&[#
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M.\C. #;\),GP?OA#,^06/SUSDY,LR7]KQ/\_&!K_RP0ZZNB$+NQ'3R47V.J
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M=;O4'3(T2?I)EJJ:?\%@U-'RY+QV54J#0#D?;3Q2)JK"3X_1'3\]-W\J_27
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M=MD&P^RN(\UY\W/IIK)D66Q^3\%LB"LW>6O0/N"-]\" 4WRWG\37?[&Z?[^
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M_C-T^A]G_R>Q_PF!2,41L6$NGS>0-X?O+*HT:L6E@B>__715/$KK[;UP&OP
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M(:8?NAB;N^-:&X?RZJDYA'M4IX*Y.P?,:HX,<"GJQ<YVBL4'^V"ONH(9;K!
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M9:]UN+S/S?V'R%ESU_BO_;[R9_W4\UG1<+]T?=YS/\$]_C]02P,$%     @
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M$L)("RK)E/HPI8D*(<]:E=(]((BXSXVA>H$D(;WAP+=PIH$Y!L( 2^D*,?!
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MMXB5R5JL"&PMHS0UHML)%J1"QDR- /(]@,RC=SX>.8"VF6 ("&K@$H[)@QH
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M6Z.309<TEJ&GYJ7R(/(R]ZEEZ.Q>PT/C<4O8"6XLT9$KXQS-PAT\ :(BWHR
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M@O1/NDSZ)[!?&D?YFS]??]%-&MY*?G<]#X!H"LW]B9>EG\GHCB33WER3%%C
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M K1S4T*;T>\U$(Y&=(@!;7PS'E%\GTM!Q7_&,VM"<QK]K^XSXT[:3^#+E'C
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MJ-EH[I>,]T"G?F,4P%S=Z^!^F%T-OJ5$3U.2%=&"Z/X(IY[YI\O'>Z"6_L4
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MPQC4P7/!SXM5*3Z[3\%H,NKY_<,+:?I*P6@HE#$S)4<J=[,Q>.D"*:^(P4\
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MV^RX%OK-_)-+D-OB*)>-B.?1A:BILKAKIG[+F=PX/+/8 VK91O=<FGB_G(U
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M=%Z7L>UHAJYH-I)57J-[O'5#D#5%,9WF0@B)"6KO/DZ>-XG*L*>9IO2*IVF
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M=]!:E6Q9!CX!+R#C?#<QO5TWK!Z-XM #.]/2LYGAMQ'Q \IP/4^=/$_=!6$
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M38#]PM6QW-=MK:T]V'/LR7!LON8YN_[)-CFVQG/SBC3^@QMEP%6YJIPDD9N
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M36?)^\MBCXTN ?[VR_WCD\\=7OF#/ZK_W1S@>D-X 9<LK^_9?;-KOW2&T-R
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M!&@D0)_E^1^EFO4HX+7MC3W0#':%V?N1#VNUS7WJ(NPTP(FF<$  6:0Q#F1
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MEES'Z<1+OMN$UZ1T:\UMD?;*SW5X^O(C?,^:W/P@),"/(A00+3&5OB_K1GF
M:*3O" W?YOMJ^</D/,FR9*++75"SLDZ^*G9@DQ*8C'"OT6%G!!^"S-Y!IGZ8
MIUOG;9@O-54HY!SX0 O)J6:5$0R0BCJG;_OBZ0V8Q7B$*7%F\?X(ZR]V,._G
MY^^7>5*)YU'K4.W4TM_^)D0^+)<A "W!C%"@=!@J$%*)A$010K[P,>;"2&RP
M\D1?9;/X#@XNUOGX_'?#M7:15T67?BL6>*,6,1G!7@/'^R)W#TF\#I<%'^%
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M&%PD;0#Z_,[RD6@RQ2(<,0YIZ),0<O-2<1&5?$0A)Y+WP$<O<-3].\GF$V,
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M29)"?;LR-_YAK4'##(F'/CQ]V6[!1:.3;IS67C"JL5%ADZR/<9U>WEK F5G
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MCDL<%V6CJVB$;3:Y<&Z1G76+/ )"$#55'8F4Q@:)D*3,9X$,%=4VQQQJHH(
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MFSY@@N$8RJ8%,1\];'IKJ,]R\/W+04"&@!R"Y_4_R?6/@2/R+ "G*P"276B
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M.S:I5SV[CKMD"OT$53_PGC1\4I<S8#EH_[1)/J'> /;L#MM,&3JEB>B\:\^
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M+/\#BPI^PDP-D1+%[)=6?Q>N:6B_'8P6PVQ%\\EMM\;M.^#+=3U5D9= K,N
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M-N<I&]Q-64YK861)ZC)*5L->6D"%NER7M!J25S_(9C8YZV<*@G-3,#3S'2\
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MZ9%O.HYA:[;G1)R0WC2U0*#4P$?^X0GN]J]K<)D!@XVB$PG):48(:%[5(!:
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MW0B7J'*.BT=#&71*@2IR7==RIU.4)$P/>Y.&)(V!=)]*E%H0#+A+.;X)L0&
M2O+40UH]A0/M& +M8MCO;XF601)A!.')$I$[C+"&KVN/EN<1+ 'M%66<%-?8
ML*=P3TR)PIX(N0"Z44Q]M4/ LFN#D"J>(!7#6-PW^DO4+0MD<T +(SAKRI.G
M[E&D-45W4"VI:-I+3(O1721VU5U1"[@.G125 Q6>2UF6P/)<93P$3C'$<X[+
M($ZE&L3&&^%4W.6"^$^L4";"O[S%!M^*2K,H"33HS* Z>XK=W'65F;%3*SV=
MX"B65B,=D01X(;LH-AI4 F"-AK)<MIH_E)28-)2F&!I%W?>#1UL2@HE6+*>8
MPU4+N"#'LF#'5P:9:8Z :[\[CJ:;=2<FQ$6Q$/T^FJMV3X,?5[+M0/NN-/97
M*_E[^.ZO)=G*/U.<#7!]?J0MI\A1]=>?/[Z[6)7?*/J<9?B?%(\9 $ _J"P(
MWE1]\SE1_[1HD9K-+0C3:PO?B)7=-7ISXH?7EN9^W47O[^P'HL0Z^Z%4T19^
M:Q1UWL:&W;DO.%8L&@H :-.XS(LS1LF_C/M\W(<#JDIF),KL9:/6I:F;&Z"5
MFFPH!G[">XOT%04[,).6#H[NJ7,G29H^)Y*SR)7&+X(_2B7*;"9B'Y,A;YK<
MW80W-1P:#8,QLS%?$CU.;"#B%?5VEP5U]YF\')'B_P/@)3)$:@N7"VAWA>?>
MLN+,7/6J!'4GG29RAYN*^)7\:'X:Z?-N.2-?MEE/]2AU==U)+2NUO4A/7$-C
M360#2W,ZY8"T)_%G>(M(=00^L?K&#PN%0Z];(]C)#;VF4@XQ:(PEX.!FY&1C
MTX$#$5>@0/R?CWS=\8K]M;DU#MET 6%W-!1V6#DD\B#DT';2-$YT/XU=VTB,
M.$TUEKM,W, ->SC'IF1G4J+&?%ZLYV=9.Y"L'3(5V>*\I42O8#W@DC8Y;E==
M?L/3/CS[P'[[[5&WA*#"XN8"_OC!6'[['F:MMVE=OUU;WTH*?97JF=.&05^-
M76@SQYR?1Z49RUG*8I'?E*N" ]*8Q3&3N#ZD:J 6"H\C$*=(<I4!X@F*T7@E
MMGP$3XI,9F4-8\68+H\2(_$/^7N:+V'@8&CQ&\&S^GL%-%O[]4_:XWOZ]40X
M'M+(KP%>QVG:D[7&6O+)+A7E#>V[(*S5'C^X;A/@LB7/O^63]8H1?"JV):[/
MQN4G'A#ECZ-O)]CF*+$NTN<*=NP^"'5S'N"3Q\P#"%23:P-3 ED!P,T9=?_0
M),=VHMQC8F/%GB;PR9B-:%+A=-&8);5^!5$&A?*!)\ID37U(IW,"'6&;L:\C
M ;@&VUL]M.[3'^? ("&$2'&$#YU,/B?JJN55KG"ZHUHJ*KZ.,-7#\US4$'">
MG/B1B,J=$8T5>;O-UA!M<3$08:5MKS(9;^8=29I!Z%9,G7?'&C,YZQ+]*"PQ
MHC!,J=\B6Z'$_#*T"\N7J]';CQ^B=QCL$!%]<(=%'$)(5I,)[J/RNA_$ZXYE
MIZC>]]HT5.E"*\,E@VN.#6'HFP:'%_2/CG<$$FW2V.'<&6I!5=&TJ(FQ0Y2<
M.(@/MRZ=%VTL GDW!EP&]I45ZX^0?UO.RH*^0T-U\?< 35VN5U3M+6602?18
M4T&I'R -JW[QVA!DUAE!]K((,O.)"#+K^1%DG UV\17Z;- J/<:I"3D@<KQ"
MWD>"^"%O@9U(Z"&.R1FL#%&ZIJ->82HD^YH5,UP3=@[0QHO$"&-\1KS)7*\>
M@HP%-J"BM9EYHR79RV@B1FD&:2JP.P9:2GTNR+3#;'4Z4SY8Y>[[R-BW*J6#
MH1&M.?$_P*-C33-9<1"L,_0 @Y:6F)7"L+TP#VYI/IS)AX!8H'EWGV/WLRHG
MW[9JR$6ZD7<;7(L>FR"3"H:E9VZ>)'H[K<AFD6HNR6XR%:&]"\[FD% -VR7"
MI-Y@':!+VY0_Z;("N"I;"U@3D9U-@D/) 5EJ"EW+%44]H1?/8$!"I)A9-B_Z
MZDB4U#[/57UGG5\9P*&1GQ,,0%P<%9^)96<1?;E+<F93QG!,;=5!B<8\X1(:
M-JD5X6HA%US]EZZBI#5:"JB5P9EP8A^?;<;95I$?9/BJK3UT&'3$JN]5GJ_I
MZ8F[D<?6>Y7AC+N1"HC)="+H!T[;F+)GE^OKB6%%9J %5I1$J1<;'DO;A$EJ
M!P/]-#[Q;JV*GI=JOLO^!LUA7E4!EVY>FH?+FC2JGT$Z#KW@,E\<F0Y963L,
MM%0S?#/2@Y#3 09>:KN'6/"^SBLAG T?KJ%+&[1?$2OZ.^76_4@!/:^P].^P
M)+)MZN%N2_MV#P&T?%@ZKK\#: ,B ?#OQX1##PYZ,"PEV1S8B>LD;F2%MN%9
M1I@8"1-B.TG,]+B$F"6X S'[>(OFO%-81E\*^#4)_T%SS:PS+W$!B,7+Q%$!
MLC^# $H2;G)8ZIKK18&>6F$8:IY&!- W@M1TC"!PC9<60-[FYS/:V)_43HVO
M3ZJT0Q[%BM>3-5M:4FR[8/-B(=QV6A52/C11R[O'DK.]7& "EXCD@+"BDR'3
MT]L36MDQV;/@E2@U:>UZ$L&^-N'O)PC&BGJ8R4[UX23%5]O#9MXP6LUDF23F
MI.5T[Z][L""$PSN<>_X:ABU;3<9! DA#33-3/S3BP$QBDRC"V+ #5[.TY"A[
M_IXUZ4&@8(PT9;AY, ;\=M*R)QZ]^-([?7>T>V\Y4:$-0SGQ1OMY/.0 ?Y"S
M70-6.[&F:,>$.B<"@ 5;\!016QV($?\]5\#UJ#NWWY/'I$4F0CGO5/#3$Z/+
MDD2@\?;+JKQB&N;B#A<.(L0,Y"0#RM^6M(2.!0LG67T[NIZ5=]W('@ZY)VR*
MG_.N84J=F>B9(V@L^9Q)0E$UK"OK,>FAAJ5EA:Q-((\DQQH9/)ZK]Q?BD1!@
M+:M&7FIU"W%P]H6"3Z*3S\%K_'C+I..HS!K+Q""6AZ\#EC$M\GS*"\754HRL
MG[VNT;L3'R<GEDWGT^1+S:W_94.IVH$$D%I&8O7&0P*YR#@9=6/0U))A^XXR
MU,%+W)3EE'^IEDA3<BPV.0)DI4PIU(.3(>$9RN/)*I,L+0 '&;LIN%TE+#:^
M&^ASR:]HQI;6CM4T]R@"TB=?<G5\X>:NI:N>'!LT/((V.7])3?-'![8G74>)
M[$2.E821:4:F91J)%ND\LJ/;5CC4W_E1CC4O!.C^H&&)]5[Q^FP_0W,.:?TI
MT<<-"A13@0>6)D\3TN0'J1TEFJLG7N"FCNO9GLZDR0FB:*_![EVD"<Z.[T2<
MW$-&N3M6[C;$(2L<93VL1<=J-;@SI\GUSJTW2"PP%E!#AP$?5;RR,#4J]<RF
MC7<S6FA><3X'Y?;S<IK/<,QS<A(S'I;^2]F]H)1VN2;G=$YLN6G3DJ#L,,2:
M6;.R&F;G<Q<,DX[2@**7DY-J,)O-V.5YR\/A^:0U$P-SNLE(;YKFS]I-_-3=
MRI29R<<:Q&I 8A\.3M5T_PE6TYTB\--6HQ4N_X?/,2B5O4X<6([C6YX?>Y&M
MQYIO6#Q3F\:6,W!X 0%K7X"+$K1"; O;+.;3+]FWX5!97:W^R?A7/U2?J:Y3
M@F*-XDAY++V^8\R\U ]XC#U%G'>2%U.IP/7#U#=T(XF=F-C-H>.&<<38@_W
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MYJZ7V+?V!;XH:V]1RJE7W=)K@H]]*D6K:$GUS!4CV.JWBP>T.D4.FZ60C[S
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M I :G%IM2&C[7U_)%*= RU0_TZ?6J9'[I%2>H-($N#A6N'@<+6 KI#!Q9FE
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MRNK5K__U#KSSG^UR]NO/&[;E\_#68M7/^=?HU\EMMF:J^SH<S&[LGW8>E4'
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M:M9DGC&J<,H@3Q&/I48$:A;7E6\9(^3P3/UB@6;W3$W023#UD[T0![74=;
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M\1'@PRN<<CO%!]Q#")TT/H1R,Z<SOYUJC,=?HA8BV 1I,T 0I03I&")!A&9
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MLKIY':AMZ'5J&^Y&;=LRBFVWX_VK;3^,(S6_GEN5P<%GSRD42_J3?9P%X_'
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MZ&-_-ED-O_3N;+O]XS+7L)9JAD4=!+*D 50FVH'3(K:$]7?/%UO\":U(?XF
M) 0308#4+!6*4&=O($!9K1)"\2I_PEOAC9<Z%Q!YOU[NK5OO@B/2TFU@%V;2
M'WK!:"%/ESD!/0N^UQ;Z?59G;V.&P#H)%@L==9,H[]/G*M5QN!:/7);>V6I#
MVV.@J&P\9,QHK;CK*8721/'8Z-A#O68"I E..@T4[8*^0WSGEOA.!AH3/*4H
M)483S!DQ$L64:)<MB:7!)D[4F@G^!?&=W>SIHZEG^7C749GK09F-(['Q@MNS
MZ^'\@> 0W-@,=CXMYEEIRU&?3"0(*D_^QFA3!8X6T>7P:CZMJSUYL7A1@::2
MCYUQJ&VOF1>^:,PXRHN9%P@&Y:XX&LQ&D3W;II.OOFB9DV"R8ED#7Y-QJOU>
M?JD=6']D279X-2R=SEETY=7%Y7'5TLR#=XU7K0KOH_1AN]12]H!]6&/.<BMY
MV57EL\T  EME9.UQ0!$1*H&^%QA,M*NUB.T9D2@8/P @[6J/RTDJ<*\04B:7
M8+H*'#6<O X^ZI)WPS)">J6,7XGXRQ3GZ*,J+%&T! 'O>EL]*2S-?,V]#=NA
MC+WH<G0?]:OZ?74@0R5XY-/^L&B+%L6#J2COH]_N)J5C,!M4<DA]*%4,ZL"P
M+EQ1%0GP.NL@;\5K^P?8O9X5E<:QJ!O<V*X\LTSS8C[RVHJ5_:VDZ3:TY+&+
MV>2BF ]G;1XH"QB4 P%5U:CJ::M<UWZEN[#YW1==OIA<7<R+:I ;Q<%E1B^9
M_]&'V(W.;EV\R+_+O+/-)D&[\H/\S@Y[6+I2*Z-=.T+]UNYA,Y%%DE)EHAQZ
MVT Q6]Q9-6&LC<F/+43E\WV;AL&W6&8)AC)+!RVSA%]79HET4V9IRRBVW4Z>
M6URYM"]X^/6*^P( RO/7;\BC59:E*VPG)->,,<.8AM(G?L4NRA<I35I5E@T
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M\YB0'O%E5#%MS/!>48(!]CY>*P#_H#+YX(<Z]?=%,<-LP*]Y/"[T5Q<A/6A
M^MSJ]V5V5:2#% 3#QL +7D/8HA7KW4N(&+5[%"1V=W,9NI:E=4S7G^082M:2
M8+:!D#4:UGLJ,=^1 86;EB,)M\V2D GJ>"N<OW$6GW#&FTG7"P_TQ>2.LLN]
MR7%S:E>:_VYN\@2=6\8XF58!>6A)[2<I:MR R;.B-NC!<E7DTD&.O!;&1<0Y
MQY)<EA<1$3)?>KP\\M"2UHHYOW%:/BH0@])Z_+E<UL>#(/:N9GEN[S.AI*=.
M&A!:F7'OX1E4W:K<^:+T"H]&::%+>!P$O[E92_;4]WWJPV&;G!/7\FC$PLIW
M8UN$+2185?7',>.I7DY0K>;HSG:O/C9]4&68;Z+2[S!.8UPD!SO&6AT(*'=M
MX7 B71+X%G%)5*D#W'?"5:?K_"35"2 '1K^%RF<[NF,4EZO2:+NG.(D?E-5%
M$>#2@((4&,WS>+!EE+V2N9386H?&-B17';*_E0E'!:26#^CJ#=G^A3?>:*?H
M>-@W) H)XY8(7!;Z(,&5:>D^B:)5C7Z^F'6JI!;A<-_T@\4*J5_/\JO**_XP
M+HIU<-2P)"PE/KZ"_,?LGJEJ1.Y? %30UQ "+XW75GN>YSE<';$%UP]]F>N'
MO="U8A"K$;IY&(6+TUKALFW'"T$>E]2A4G+F^Z02S(ACK3: ?Y'"A9Y,6#BQ
MMD XG3T\NQJF?6VD_UARQ+;5+T9XSW$/[2PYL/K%::U^N8Y#+$NX$C0PXD>.
M8T>5>.9&%ELATUNK7_LYWA<K8\0]@#)6UT P)FI51J*6-1?DGM36YNK97.P[
MD([6#.4FS/0LT,M 2)>4ALP+A5MZ.7W'#U?Z?)79QP76(ZB$O8_7#>9Z(/S?
M502T'.=RM3#S@;2TWH**II(_RT"G-;+_I=$(1-9.]OFH&(J9?$_R?EJH)"<,
M3M6%'!<BEN-Z@'AX !;#:G701K 2O@B EP:^8TO3K.B-Y?OB]5A,]<1'$"[E
M<)BI<+&/:N]:93*LYUI.C]D;V\6TSF-T")<B1W.@TEQGB)V-%@"I"9Z]I;B+
M.>0LDJW#L"Y6JZ34D2; $/,(<:3M6(0)K_+S \U:B9':+XEZ#OSL2J0<<KD*
M-H_0J%5I^OD'TH)$S501N^6Y&,]0-I9J!M=-* X;-FB% 0\CXKO<XI8M76(*
MG]A!P"/?I^[V88.'*%Q'S%WC".N(0849R'%*4ZO*0U'F&T5_58G(RLCS9'0A
M")64.PX/I>/ !CH!H5X%(C+D02.Z4# 00WU./%=8+N4!<?RJE)T7F$P^J9UM
M_,YJ="$B[X4N=ME<[$LC#+>9R4L6TN6*KL\5U:*A\6D8GWT=$A 1/_:G&;IX
MJ4F83H4:@"BHQ4)UL8RGQ1A+[&-XEZB=,WZ<WU^\\=.\@H"Z^3LP,T/S-W7C
M7SF&^"^-4-Y7K_=*1WR9^C68UP^Y46^"P)+.OX><$J1B3&W\]PQVYCI5Y53@
MBUJ:+0L+8&U70%!5.FX\4&E8\POJ:2R\,BBJV-)Y197>(U57!G=I,:^_@B98
M3%'#F#60?F(58_]?*8A3.28Q8 X$;NJPR/0*DH7Y:*D+/GR=*:'JT6]BH&3Y
MW?DG,;^N--$I8.XR+PTYNYD5TWETL;T.HFU#4?0-4&D;#3HQA\H\F0SC?A,[
M&K"["/F+:*%5^>5QU1O;0+J&DSE4+T+\TLUE\.HM0GQY;0DQ]!@*H;;%@P;$
MEZB U?R,;\D#%C<JL@X@WV/XZWBL&7:5X%NZ;U;A4JS"Y2,T5RS )FI;'[([
M':F#=^>PMO"<<97T08@S$E#J5(BN43J7!FA:2D>C!!26:3)\J!-1\6[]^&">
M4:5# C0$E?B  *.@>P'8%R=0 GIA7 ^3[VE93J@$MGY#L)K7(%5)2+,BF2=!
M:_O8Q962Q6KL*.EW7"P.,\VRH8+F40:/J=G#E^ZS_!M@6C]1Q614%G99@!26
M7E9J>7'2XF/:J>.8++&<1C_N@+LNL4(6NLQS&0<EM3)TA#*DJT$.<ZFZ*8HV
MRFQZ#RN"M\3M632+; BY!'!B9IW7"(?W 691V]@4H&HXE>/!'$KQ01R@54L(
MB"4'B-@L8;"VA%3$."U- /A0"6<Z%6X=+FX"_'D](5U"'L<LIS '/)T^'Z<Z
MBUH5VZIF4']W@J/>@T*/,?09[)P6-1 E<M7] .ME&?\['FMW40]P_R8=CY4+
M>=R\KC,(KQ[V#.]UZY4H\"27OHR8Z;+0LTSJE[XC/_(\&2W$>6P+[%?+P"['
ML,+AIR1'P(QO0$N5<W/4TP@0[ <!5EL&-!%@0], J_V. 14=;P80U#"Y@@PE
MIUAD$DE?57%;+ ^6E3FB:"N$2RMP#C1ZD.AB#3K0[''BKY'I$4.EPH7A@TI
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MI(4!D^G/AC':,N/"F-XFQB"]OD[R9-Q/C*MD>I\D8W4Y*?5'8X(*I)%=JZL
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M<21(B(Y 2*$]TX;_W#;KGG=M>CO3R2F83FRK[A%D>1ZW(\=VF4=<+H(HE&4
M!^&F%ZVO\71T 1PM$IV7BC[TDIQV(=B=2N$<:'Z[5B[YO[-BFEX_'"CA3V>D
MC2;#["%)RF2_3S,0H@!G5#;:3BEWK:WAV7E_;03)C(T/P $0%U7"7L^X3XQX
MD$U0QL34LHU[9OP8?OGTZ2=X\3;MWQI721_HE@&8@NE(=XD!5+"*6C:XBE<6
M.L\?7S-20/]4I0YB38(<")%*$XQGT]M,Y[=AFE=:%#.TGV'^[6R"=='CLDS
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M QV>7<QFCOE)?@=4YA&5=#C,^NI?'Z\_)_WL9@SK'^@>;'Y63(LGZ]IX- J
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MWE5S6S\1^!H.+<? (X:@CTVR?(IE ZJO_Y]YRKSB^JIC,^A ?27=&#K]G[C
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MZDT&,^]AS;'[!)=15)-5M! @$P:;8  -;L2GQS<ANP90UKRIG^65EM-@YBA
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M7(@R;!+?)D.47#?#E!/%@K__K=TY><OERW'[=?9VXNW G[NYRE)=?52+#ST
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MF=PM$HNSD2<B%^J$@3B>#3/)(^!3F OX,$FU9MQT/5E\C/6?K[BN2#ZBG(H
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MR2AR22-2?!ILHA#+G$3H8\N=((?O_0;B5_U)YE>I<SO5*L !KK"J48)R9I>
M]VFF/149%E3!%DA702*H_US,=W0WO#O]<G[J>^>G7SZ?FM8"OQ"6^7U:)/U
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M+L__ZF2AI]J/^*Z[C7B!6Y:.'NTP]US=O\56<S_*B!YFZVRCP!W C7DSC/I
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M(G2B !P--[J$*WT<<D&@.[WX_\EIA7C(,&/WL70PR-7$2%XM.1UV#LR,X3_
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M>4W:":N]:4*ZXB@EH#JHE;M:K:PJO6$:2SJ15H$K3K4L0T^5V*.P8GV2%?/
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M5-\F6#X-KJLY_>;TF]-O%MZ@^E:C"7R94_/_&<R;)["G6P=^J]/ Y=;HPKT
MHNKL^]U6IR&JAJA6Z&L!3M4^>C)G2^-/:?PIMQ%C^T7X4QX1V#6WD4Z#%"@A
M!1"NW6V@ B_9A-IF\C[RVP>+:((->3?DO?[DO=,!ZWD)<,3B^[#YRNQ+O@_K
ML_ U5']?4-20H6&IB1W6]TI?.9?<0*@$L$G0!%J/P2H;9,^&"_U-).>#(__P
M<!%O5$/.#3FO'3GOM([][D)9X_?=C ;IMN[TWWAFU\DS^W@ZZZ]IGDMKKCG-
M$1[.$5>Y;<_."CO[_O'A0ME;*S7:-X\)OF2+?DOO0K?E'W87LMJ:N]#<A9=T
M%UK[_M'10J[>>9NPF9;>2R;L]5GXX^C&RR2!O" -V+0QYR;H+Q(N=>0?'RRB
MPZXMWWD![&7#20HDX,E10U,-3:TX@+Y4:YK-CX._ ")\(:[#=I,D>T>2++5
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M5B98EI.0K/3Z4=XKLEQTDOL<>-N6B.0#/[!=\YH#7Z<#;RRE2;E.>XWM1)<
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M!#XN,C#L<D0/85GSG",EHV B1:5U'=U2I6RGGG6I-BPZ\4I8(]\I6>N3QZ#
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M@HV+BXQ&U"RMCTWX*(9X$\$>4KP>IRPIZ+A1H&OG^"MJ]"-AD9SZ!.H9<%?
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M+6@O UP@RLI"?I)Z68 J4##[!JSV4Z4.4HG@+30TV@-@J^B!"B8/G!CQ510
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M E7^(V40!D[PIV8E6ND+=$T3HS/8WR"[1?9 ;B5>NH^U@S"8@.IQWI HYH?
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MG:;0 JJFWC7H5AB%,<2@5?'V$:KB5QBS8+JRWAZ/7#J4NTRQC=+87.$79:(
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M;(0O" JYLNC<<.!4Q"TYERKS6/(8"6$!3-JZC'7CXB*QPHKAAE2&G*8IZK8
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MFJ E,H8Z.#NM!QY1NY*JP4QBNW'2L9/."1DE4CA;H#M2M,/H=XP$ KYGS-N
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M'Y8!I,D/W%BU-L&Z)?+!MY4E.3'9,+,T_?)U=85WAJTH/'YV.NL*@S5U*T?
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M"W)WX? %+G@3'CDGFQ^T77L%Q,$5%6X_I'LKMU1M8QQ^N"Q]7):02K[1I6E
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MP,#>+1M9_0/S\<](SC+T3G#'@A9<5V]I'H"L?@;Y@:BA6W6$34F7B&V1<V5
M!>^%5RUHVN2HEQ[[4UH!696,!L\/1W9:_)J#3Q6G0%AV[-FHSLYCBB?X<X3$
MJE#"#'H*A3LL4!9[.K5(2V65B7R#R8:#M'=9X>_5CSQ"033"CC5%&)F8M)!F
M>"_+Y8DL%QY2&L9\'(E&(MM)!V4R"?3 "/$6<<QL7':QO"=D>4+QP[(?C>,O
M/6Q %F#K\,>02NMI'^1 /I",[E$#1JEK+H;W1 S/ 9&-96@&KSS#O7K8*G6@
M3]$6S'2\8R<I]2_,R$5:)I$VDWV=R\W,U[[KAYDI&B(<OC\V&J*BDI$PK&ZE
M^$P8.]"U=JL=T7(;;)6FLBG"H+H5^7=:',28Q)P2+NZA:.C[UR\N\?036RV>
M46]NL9PL0\L %F5S))%TY+C0%,!1Z<,^#$EJ4A&WP2LJD@0QZQ2S;ND$Z[H>
M(#P$T,<8!8D\MY-6PF\CX]"^.*"*I$=EV,M <H27%?$T5L2Y\\Y3I)*,>3N(
M!O4EU?":+CQ$))">P\/&U9D/#CFLGM6E@4*"N$7V26SW<L;(LIEM*.]9^_#?
M\)C?4>GP?:B#5#JUC-G3J(6A\RDSX-YZT&) E98#)!XHSIV6+Z8UAT)IQ[C#
MI' UFR,3@1%4QWSQ/*;_$AH+]U!]XSZ&"P_9'T'SUE+]YQL9A"9"[P0_2D##
MQLM^?-.U4)?#:9:88LMJ^->FC>10A87!"A-:D<)3\X2_@+R,:0.JDEE@K20X
M_R!3RY^.^O*8!#<OPX*JC5(QZ_IY,M)@X3V+CVQXQ>D0[YT_;W=D,,)U*QLM
MWMS,?)Q9_>;B/_[VXY[[_?UE[O?]\%2_#Z0C=#Y;AHKW;SCGR?@F>,T2)_%V
M1Y-VZ1*)J<WUXOD1C^$Y.*'V(C(FKA<I>K&^#.KD ./@_:1I@-;#:A46ZEG%
MTESGB/H-=%8>!S2BX,FX;-0]U3HN#U2Y[.Y41, QL''JG_ _A:<U$#?KE)-,
M?3*!<^1Z$W&LDK5WZ/(.1^I>/8U)2<KA%"6!>TWK*NP#3'L0[D;*RG*U0A \
MK347[$M9;.LH MR=*0Y(X.#"5#D[XB#ORL8G"C_&=@LUT5:4JGPN3I<<22W?
M,L&I-G25ZMGN2BE*DA&^B1%=@_',,#*JD!RUT_C8#'HI_ S<:2JIN7(7A2V.
MS4CA-$Q=V@K@9$8GYF2]XS3;6T:L1/=XH4S[#U*FG>!(BP+)LZ_[WT6@=NPL
M_VYVM7>C43O^ !Z>ATR3XY\_-_JYZ#G#9@5_&I.<NZC$3M2])&LIPA;R\F#X
MQ[#AD?9,%8*$/DW%8K3L&38KDE7K5%9 YOQYM)(IT(/?63$U/1B763;F='57
M]+;5&3NR'CUGE%.RGJKXV4,92D+\?D=EJ9Z:<.(G)CG!7YA^[NP$4CC !Z))
MX+#H<&JB@[$I -J4PF_RP,E-CI![I U54/HNWDHD-4AMAZ? P@<%E\H%9O&T
MDEM5AK>4JSMP^NO%]VXV_1V;EQ-TFV;U)]FJ=,OCP@ Q]>]2@77PV>F&1N!6
MGI8#1EL+-?>0E"^207LF^]=BJF-'2YBBII)M1RZT79/@FAXS*F*UJH?$_MI"
M6V?I%@O.\!V> AQG&F\%#3:W)%UC>UB1T' ,*6W&3_"W/]F/\8_X^#$]PB.D
M)<F6CB83H17)'CPLXX"<B6A09NXABOB>>@/QW=*UM"O@2ZJUT,G]I*WLUU+4
M8]5Z.!D') 7^X8S7<QZ9'4'M:F+ARX::Z(1SF-?Y\Q4)'G["-3=7)#I^<5]G
MQDE]=_YQYJ(0X^G/)$KQSF=$H+["CD3?X2%A<6A<Y\(8LG1Q9AXWORKC-PV^
M GO%&)5:0=$3/'^_"T_ZK!NPMM'QY_2E+6=G(ZG$8EQ;K!PDFZ%07([NWA*2
M75K.0K]]]&W;2TZB6D8[N\$ZJ0,TA[CAC5G^'7TY!?TSCY3E4!&"2<*;/6""
MH*HT$P]'4.]:AEZWNV7#HR+<"DQ&.K+OQRY=C."E\1;G1J@HGDEKFN2/5Q0)
M%UXRD=04I.V9RR+H>V[QVP5,P-_*(24<O/1I,<WYY55X?:"$EICGNO#K ]EY
M% BQ&"/E>57)#=F6<@W$S'8+MWVQO>@2F9G_]1_6U43*(HH[:-U&)=\O\H+@
M;)$-L=78W9*$Z']VGSI C"K.L]#W6K@-'KWFF+<>&[)P-BOE2DFI:39JH'^&
MD!IHZW!U RF8.#V6->L>CWM!7;.:E*O"S#G2*4#[>O%*3)CB8N$X\Z,5@W@4
M+AUJN>H( ^E_.)*X--A_'0UVTM!RPX0*W< 08[9A?;ZXH"Z>AE$( ;:J?6A/
M5=BYPN:YMW;.Q2B>BE$<G\:[V,%3L8,0<-_6DO(@VP0PG.+OZ!Q" /3/'38.
ME)YBN$]X!"Z0S!V#1DXI/)_&1Y1;=4TUK*3]L VI4QGBK95/"BY&^%2,,&P_
M/\)<A./Z;1GRQ*B$FE!][(6)6%A-,Y9BGRM<S.>IF,_$8+@0P<FU4S^=U(RB
M,U,N)B2 $!#/:9 NMO1$;(EY'JEJ$-)VF!3Q G#ZG[(G7&SDB=J(QLM]=5/U
M/54264J2:G?;N_T0]J#R$L \'8MP30.!<\_6_P7S!MDBQDQ1N,.-?:4GN1C-
M$S0:[<-- +I>DX8JWD*F96@WCG6 !I(@)S;6+Y;T5"R)S09;#B[YV:>?.YT4
M[X'TKS20M[7160%<Q<X8-;*8#)K5+R).^A39LPS,<$]NS4HTG,]3#YMZAQ*O
M-U6,SY/" B22@FFM^]VM0,;%-PI>3/IUW-63D1N^IG5M2IN,N727V=Z>7A"/
M;2;D#Y>9D(L6W%/W;L2\5V'V3O'\982>!E<VP &%SY.\YZH"/]"*IQZ"Q[DO
MZ]$<1 2LQ]JW_SX\CO;=+X/)3\C$SE#5=?OHA!WB^IR-Y>S[>0RX]_?PC).Q
MCUG\)K#I$L\*[)K"A3DLT6'4G"'*_4!6#F8Z9SB+0JB[>HBXIA##B( WS6XX
M1E#Z['[+!8"YS"]&/!W-,BN^:P"T;>8+]W<AD\3KD+&:K<"S!#"3@KUX5F88
M,:34;<?T<PISR0:9@4LIF?"0SKP')KQ-[RK<"X,<:P^X2Y,2Z'4KN:@II_NY
MP\$I2TTP2Z.?F9M2#XJ^NC^" XO3V)? &>=?R_S+P+.ED0-[*0=@\@L2=U_=
MS5[;]2(.;>C;A/@V+A8;U G[@O8*!A0!(@)6,UP@=B5"]A%QSMB7QG6PJ<:[
M;LV6KY".R&<JPQJ  =+:BG'\G"6258.6<MU%<DNB=\)="L7=0"-3<D0<R.KH
M!@!$A!Y_W9?""5*VQY&Z".YG!S7PJ+KF+8R4!FF/S908"T2S+S"-?X+>)Z$G
MJ=9UVAHH6'J$2 KZ\I:A@R(G\M,?Y=&'D=L;#W(RONTXNI1NZ>AM\UV1NGAV
M6_$=VB"LC,C&_.FAMTXL^V??_^QH"A3-,2="CH\R+<HC@4TU5?#PYHGA<1!D
M$WN!$_KC8[B2.2ROSD*>@O5Z E5DGLB*=^;^>'3&1Q$A2FA(G)$QGK%W0$.^
M!Q@,'ALR\&>^@J\PZE3;R*2)NAVR(@(.8[,?\/!O=Z"Y&*O*^#SWO#6X45X
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M34O1:HLE?;U*UUC7SZQJOPALA9=,X<V@"!Q72Q]T;DI*Z[NN<YA9N@H9Y"#
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M?2OSCG5?\ ^'6YH"II&GVXZ><4*< ^Z)X3!Y>$R.T5--,-=4F+ZE]]22%=[
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M'7V[0DY\"&9^/6O/=P^B-9??2ESE'T!*^WY TU?6JE\(:Y51BGNZ<B HNZV
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M'_-VZXYKT:@\&2.53>.E8/]J0L_%A%0S"GTBQX2E*"CN[ O,9&-^ZVH@S\5
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MRD2?N 8DFE T6K(AHCEF11'64 6*2[#9WC=]I_#Z$Y?^\1+<.7CL5+D=GVC
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MKE^ 5?;P;J$(TY3 XJ$&+.6RA]%^?QU&>[_#:.]W0\EX$VB:].1J9CTH&>5
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MF'^\#F'^K(<PU1T92[;'\22>&A<6^QDP!ZVISJ!#K#J==_TQEIY:_S*XZ
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MJX=N?H.HIA^W$D'4\=OK8FSXI6DHI")M_.O7--?\B3).H0W'!Z,4WG*/8$M
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MC'E ^E"!;F=.+_U<.TBJ:*<HIB:*.OLI_3*T&9W&F?8+3<E)WE066!4VGD[
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M\MU'?,7SKY?:U%I$+H%O$^E'0PO;L[TT6_WF=9;F,TT>=YC!/:VGM(-I9TR
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M$6/EF8XH*T?R+<H%J#M!6QOZZ-QSTK.2HS:]7I@RG@D/6< ^ID70IUS(\#@
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MMT'$#@\.AN+=/ZYX]P\R@6*#YU>8+89,("Y5;#7)W<6*DS]SMU(V3?MF%)B
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MMP"</T+JO;5/MFWS1VADZT-;*60L"?OWZ*!W7D]1>X/-JW+(4_07LTMQ? S
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MR1#?/V"Q1P_!&J&GB(^GHO*"A_.QX>MYZG;-W;RDNC&(<3V)@3EO\)S/0?R
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MZ+2U;JJWWS2K+%V,2SQWFSF)HO!8PP =TUX!TT]GR^:M3LU .8H*.X$&JDD
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M)Z8_9&CH*35\NJV?H#_ZEIU6ML& G:G&"E;S$DX3=F[CK<F<*%61BYW6;O>
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M(XN]<,[/.CU).Q;M3CO>&%5=Z5QY56?\4J"+91>W(>]^/PM)LQ;+#0NZD,8
M;;K<>4BP2I4<]$%ET /\CXI9]?9N4HSF=<M$BR6;P7G&#V];08.>*]7CWMAG
M!43*YKHPR9<='9R9\!VB#S4XQL9HTO70^W:Y*6=WFMX=:T1)@<NZP?![ZSIU
M)H)'6O9&3 \D"?3,$T\0/F/%F5E#0C"'03 +E#2"/;CMV(--(51MF1P9N!X(
M>O="N6;QE.+YBOB;5 2/%Z[)4,9QKZM9@!<DL(2._DC#[XEY4KWTV+.X<FE_
ME8S6",!U;OJ;S/ J=()'=%ADKJM:%767/>XKLT]%2\8[^W5' M.\NFLCE-J(
MM7W(^VEAY1+0.7<(^%F21:2RE>SB@H7UFV<FA?AV%[4B2><%O%+B5A7RCU*4
M>75?>48G@5F/3 M!HWG$J43%^D.KIGKY2,7/PW.5:Y--4?0EYY'!N<:V/0ND
MHHOO;,:E_6\_ULA.!JZ"6Y8>R#PY]HTN4KZEX>10(A$I5?=EG@M-0NM+!7>/
M74V2M2F;Y[I:-PYT]!;/;TG$ )8_'"**-9]#0^*.7T9Q)BM]TM>K:5]G=351
M:Z]72=((>V1[9B#*.!\2R3_:7'LLEO(0G[$'W\*$OY6%8,9@&5G9B= ,\.^@
M>=K^H9T%OFY/T4JRC#!(4&(N[+/![9>A6%1;88E@F;G?,_](".EKY7(Q()X\
M.%P7QB93\9:%P18M@UR$YV$3P"LR_E?KL7O7N<RX(.O\#30KW$IP7UZ%_ ?C
M/GZ^@T#YM:J'PVD[L^@XS" /AZ[I*5[<30^4P:6>N/MW_)WA:^O(M<;F-C3?
M. J\FL+K\NKCW"*G0,URD%Q[QWHEFZ7R.27.%@:@K9H'2;:A6:A_*X$<+8H,
M.HD$'N@HS[L:Z9  <S,M.4C##B2^DCP&X+&PP1]E^NX;INLKIBR[RC3V<WA0
MM-(*0.CQ05Z*]'C@=E;N^#*,\6:H_3 R%HAV-"@GHW@U&.,4*49R7B)-%Z\>
M]2:K:,:4]R;K=?:]V6YQ?+QP_P7&#\SK5.;U))_^]3+@W^3C&,%[3X9'FFJ,
M;FM?F!0\F_U])79DGM:-K8%8]$;OZ_Y.U!K/FXBYE?BFN\;3C,/VWG>FUXQ/
MNE7]IA%?1K>.YY!^/H0=U/1"_59LC770<'EV,3X*R4"GAR9?HNM4*!ZS/1GD
MSIQ-SU!P0?B*EC?!A[)7]5EK8ZXU*H(0FY^*_B@^LM()3YM=>B%DX2"P#'6E
M[/A?OK7[_R >+%T9S(I2QJZ9]\TB)(0]#D"Q QS6^$Z^+84'N'EX >G9S"*%
M7"9FQG9Z7M)#^9L$JZ+?)0X#XVL2+!\4$5%M^VJ';XGLD-^47FC#9;)="$*E
M7VS,<:SSDMG2.J5_^;@W4>*9X8\-ORTX^;RT-(PRUHZ?AYCUI^[*$R[]=^GB
MK?BYONV)HY$,A/><]LMV)Y?/_T"$K6F3ULO/[8?MJV Q[F;!F[)OD)UYAO,E
M>5$6KJ>K-/MC+S7C0P#<+L&[N+("[%NA_L;CYPV\@KPNVGY=?0:EK*'/,J,&
MX]D@<0T]!"OIHNGK<\7>;\;.;*OL?5[,*:\V^QWB4W@O9(N.Z<0/W5&B8V/:
M@W03059O?TU?DW0U:G #UVV\X#DTDH9__X&Z#5[2E$IY801)[Y"A@JM?! 3F
M=I:F"@]:C3M%Q9_D:]1?HL\^/A]Z*O=6^KG(^9!_<>L:,?.X9C5G7^WS:^4'
M!=M]/EAX=<B]C@$(D17+G7K)08&N\%Z ]\\P;L$\H;7%$_3QXI"/\I4/[['U
M4%3+[_FA^3\U]75AS]C8ALQ)UPAD(R6FN^&\],[Y1"],SP]VZWVF4!ICM314
MAE2%*SDW_2Z/9O-BKX^03(.4FF89&>4_DKLC86*K\ZVV11[^JN-\/8IDIJ:=
M1 'B7,'V3Z6^/S]_,)%H*CC"X[;G0[)E/ XZ+_I"SR1J5#NU^<;%KSRV-I)4
M;F8Z&:6*%"M$CIO"2\Z+Y[PXH*OO,^=N,E.%74+8?88#GFDD>=*),W&S:LQB
M &U'9M/E@8_GO*P80+-B(B=F2Z\YI&0.[[DFR-PRU.)'7$YD2YZGWCV<E(KB
MJ/?!6!X]U,P72 W-5ROI2ODS3G$HY%S4S<%SB!L])#EE%;;.CSNS7<D16^KA
MNZPRS@3*->*NI294LFKK:GT]\2CR5NJ'Y%,/7P)DJ&2$V.MKQ2CF^#Q[O?J#
MIK+37A_AV)#J;G:%6^_H?@]N,O731V37/+&_%D4.K:M-K$XXNKI('R3$VK68
M#0LKE/#!NA^^NE>>S>'>%4JEP5RLUM1JN7"V 2]KBPHFF[?S G4'N<Z<%\'?
M(QK9]GLX4F3%?FP_?^B2P(ZJH]OEMG@)%_.3$K)P S/8I%/ZG6JGWZ4KY7U
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MC^QYBL"KH+PI@Z"NA<L]'R(4G11I\D0(5+K*4'.%&^PSSS$SOBJGO=;" A6
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M[VA?,&)C)]G&QN!JWG>1G=/Y/OQ7]#(R0PC$4^XSYO.N^70MX*B4B[_%1G9
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MA>=L/3*7HJM$+V#MRB75V;ER9.OSM#MDKKY8&&UO!%[5RVEEZ_'A1YIZ@'J
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M-*"9=\W@/*6+(KO*+M5%I:K/VSD-FD]?'@[&+I%KU$;$N_7F".=X!\R@5&T
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M].N::L.O$*';A%*/,C2OWB*XPVHTM&KPP?Y%3*PR9)(&Y_:RXDF]<5"AOTX
MBRO$_1$@?X?'[!A1EB).DTNGY7E1O2AQV5+=D.R[R9SRC:UT1:<]/[?/C(E<
M3;8=TB]=&CP<E/7VA_Q)908Y8Z^=EV&9I20S%2(/%,L._9#JRRW]MB-^.) 9
M8[C1NYP ^P1S 32?TI=J):J"^)O'RS\I;M7PHIE7,1KSY>&!!!N\@T*O<[[=
MJ@U14ZGK0ET_\2?+J[>X_ZAHB&*<;[ZMG3:T?R:##BQI/+\[8E_B;NBA W,
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M5&20%;G1Q<;_.FF$.HF>U?53D2/TIP<41B@?*TW=OY1K]DQ?9'  JYUOKIT
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MZ^=4UB_!>%L.-AZWK:*G>89X4LYEQ4!,,P071Z"UU[^?:Y2M^VV-[9:-G5X
MO?\L<ZJW*$TB_4QVW+&IH;G*UQ13/L*!(RUXLA%$5G68D9CGL47UW V CVCF
M+M&BL?!9?3SN6N8&X$NR!BY+PP= (3B2^!M Z"WIWP V=%"W<)\/Q]8T5]2C
M%+1CQFIOC3Q_(1FP8"B F/M%]/;(BLL-8.H,<GQ*<WW"P:!=:L%I9_KL0,HT
M9 U>-O^_?%U/G,0-@/=8S+>HU@^^XA$?W&CY-N P>2HH2+#PK>_++4V0E(/*
MQ@/13WSG\:S+N=F6?L/,3^%$6*OF%M64O1U8HMX>VY:!>PN-R&85!_ KU0GY
M&?\-8+#0_@;P;> &T*9MK-1<>8E*FIKW$)M:F_IH%XRD^];4V<GE'1)IP1QY
M= -X,^8Y:WR[MH_[8MICH95UVCUO;\QD&A%LSQ0+S_5-I_N8H[ L>X\J?,52
M*C(=& CZ.H2GL48N(2GJ\(!O7&.(],#G? ^J-;W%8IJZ?MTE4N72=7&I=0$
M'QGE[:[.WP#.7N8(7*(OX G:H/D/C> C+A\=K'LN3NT@MCW(5WC28N8ENIJ
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M/>\C-*K9(F:<11^8W.=I5QG7E*KPV.>0+-.1Z_[,HT5?$,V9<7V$!/6QS*A
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M_'" :)M#@+ZH:M1)LGF!Q6^-[WO3L[!'LVW>G[U\Z]*V<&!O<'W?WOQ*1LT
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M?<$4Q=['-= ;T^E5F[J"_PYP )5QF&+$&WA"T4G7%!TOMQOD<1*0C4:-&T
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M^?I+&2N'JQL5V&4#E:[ #TB^%5534R*R-[CXS7)5PI]Q_=-, \S92XY)4M=
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MU,O<['F:WA3*6F:E$0,5M R $GT03SC&B&2]B<-3=S^X^:73/#3RK[=9;&D
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M7',4H/S>*#_\0M('540O0LORX)0>?[PBDQ56BH&FL!IJJ+()JY%ZCA'#B\<
MKG]2ZO$>BRE)15:A<;^T*EPTPFM_WB8?O_I%>1):)D-EW64GC:^.@] _?;K_
MR_IFXUI>K>].$T^85AKR']_4-Q9GF>PZGCW1\"<'IL_QDY(+UOV!=G4W7$ZJ
M>4KL[63J=M7YPZE0;"P-<*GHBZ)/R. -N@ [;+C]'GY[>_75!O_QB3?)U'8!
M=]E9F1VU7],GA-]_/&S_!(R-%R2;M(CX@[9\?DZ]7$(>Z)CN6VH0H([,G"HC
M% 6'NG3??+^OH+UN.<'1[/S3]/I>;TAN\7Z!G%'2M]EIND/[^#1*1+"3]]&P
MHJC'ZF;JWM0_3THQ8CBU._!?!F)9<MC$<,GI4%:$>>-8B_T/BY:Q''_VK$8:
MX$[Y1<@/HG)[?01A_$NSXRF:Z4WA0'\]=0RKWH4I%80AE1<1&^!+Y>D$7R#K
M;/^B-:1BJ_KTVY'9B?T6YF?N6;SEIN3>R9)3WQFVO#64_\!__V$/@=&*D'<;
M=M$Y)J43[^;Z0O<KLO'A2CRYZPW)?T$M/';WJ+#64_ S,:^GL67E^@F?#\!O
MP'.:?1K#W<&=*_1,/]R8"Q#$Y"OBSQ<8%F/]2" TT^:(!"]'D45 ]YHRH.)=
M\G0B%GC(%#9J\#?HCN^/?Q(RWO048S/>W2KA<N?Z<6G*XZWI=U)?%R=59DQ@
MSRGBP<2LE+6^G*79"9OA["#_(?$N03!:"G3']6: 9?L-LIT$2G\L4GP:Y/-4
MOF'9D^3/7[\7_TD2=V&=L''RUL;*?C719&4%NHVAJQA?D3>N0.^6@W'0)M&F
M,MY].'6-BSB[T4R]M8>-_.1C&0K2C>RI^V1_5N1.+R]5\N_=0[G\*1GWW1AC
M7A[MQ#)!N294F=V0&MMU-L.0RE6/7=V&AJB!.?.UA%<?[XOMR[67?DC4V@;\
MN.$V>2>R"\XI^"D$Z-5S8]:%$[WNYU>>0YFT_9"\PVB@<+BK2S+<VP%&9O/$
M74T9%=/G)1Y\'=[74XK MYZJ5#BUO=,B&&)N! SL2W-SI%O@U#ZJO-]F&91C
MQ!6U*B""9K6Q,R=W'+(9KU6MHP-/L4I!&M39K;/54SK)&H7L_?^/*8C):=UC
MW#+FW\.'#Q2X2EB6]E:57=0/^_H+VYL^2 7?I0$JHBGK399,O99?1RS4##\&
M%AERW^W/7/P0_[^/>M,'KCN,% ,J+#&B1^I#2,@5ALV+X.UL=&]C^FIS*+<M
M24??;-9Z4>7QE)?Z\&7P5\D//*+L&AJC#$?13@%ZSWX*1!)>Z&JB8EO"'K '
MS2_'!P%JU9Z82S_[([<45<B:]_H=9M=M)A@(LS]YP7""\"A6]1F^U,<>OZNI
MSGE0>I(ANOK%3Z;G>N*#IT/2XT_5G[#8B?QVHUXAA=G$PFI";#U%/PBREF9U
M^BS[])]7XC<A92U8WX"([5K5F"OD>ZP^/@D?$/'7P8I*(92O3-\:7AUSG+U3
MF1G!OIR.:D<S!:AWB9J,Z4(,&DRF[R^7MPN<7TNR^YK'4[^I%L38<7:KQHW!
M..]4-NU/B0<-H/CU/5OHNR>A_?=JRGUJ]-7T[_V_C]F5^8&<I!@BNR:G'FHL
M%H$'&K7;JJVSGZ!I /=9R,H'2_TR$6]KV5@'>"(EH2/,ZN>W8&W;$T-'-Y>#
M;6[=V>YW!@]$B!A@A7#1IT>M;0M]7+\[V Y8*)=VJ+6VW;<K$&X^AZ?'WL+P
M8Y4><"_*3H6;X3S@'6.!S,Y?G2;T;!$Y2@3._A FC.K?I $$E*M"M,JD4XL2
M6/K]Q?=_Z/<\"J8"%RR\-7]V[FRSLCE4;HO A_ X,RS0)$LS_$E*):K([X0&
MR,9*VJ&_**4NK9SY@%CES T*SS:@5\IH )"$1L>)]GJCE<F9P^D^ZCB3"%X;
MKBDNQ]N;<(>XWM%9L]'IU+^V-GIJ%(PM"IV6/)OC3K148VM6*^[G%TM^Z1WX
M[O$V>"717Y#NJK1'A@\G?#*X$"^YGO$$5^[HFOP]C-^>F#//Z&_YOI.BNK6N
M5*9NGGAI2HN+#W3_^SS3<'YRLI ;&;UESRV)DT":^I/$YEIH@'F6<B5#JQ2=
ML%<%Q=E[>\.P"S;+]#; 71S&4Z%W[9GCMEP5%W:^OT1516%'#J=#Q694W3-,
M2]RW0[5RU"5]LY$H,@WPM4!N46E*;V@7-T*A+E9\R5'+Z]XQ&_0'/1F8-:,!
MPIW%S;!IGXWO)&( )J%'+0SEV<^UQTV5+NA[D[.Q^C[!".M/Z?E-=@-J^1I7
M:(!_E-8]O^%J2O&P+;6SNS$+6L&/%#T\&H+0)#_I)9OZ44=7-UZ05"2S[]U.
MYT,B#:#D$BK2\6[BC[N37W.K^_/]@_AC#1=LQ"5\[O]L_7KI8Z'T-_@ED$CY
M&_GJ.^>TL".)Z5446^)$\<+9KK/U@=0Q2.VD16-8XI&+^6=C_40MNL&4B6(>
MC>!Y@-U=67?HGAC?=)':ZQ\K;==]32BTR1V[62=._"]Y.F(4Z%M*AH&;*-LZ
M7=X;3Q4'6_MV:0"1N&:"5Y]XW;#;M&'#3D^GZXXEY<Q%J%G$L_0/BAL_U'AW
MQ8WOOAV$\-^]4Z8*TWYTBRXRY;^[B[+*I/)0:ZWZRS<I:MP;?FND97(^_X0?
MO:KQ9Y91+5*]3?0A0ZK&Z<=J630=Q9--^L9I@#H8O_K6BY]_$5B' 'R>_GYW
M'C QJM=-QWA<V5J9Y:<ED!Q4#Q0';B-L1BA23O:"F0L5%9 'S@-+\ U]%^J3
M84DK1->B)/J@&Y1UL/%AA%!NE,.Y(^8T2P.DDK/TV%U <SJ)2BDT (P<NKC1
MRE%3E8J_Z=[2O.E4KQ 7&NDREAZ 7W1V3+"+53>?><\XFKX,^:RHAO3,=U:%
MO*<!^L9RWWEN7H<1NU@IBM9/'>&VHQ527S3X^$+JC4Z%Z'XW5%@P4 &;T"+;
MGKB2=QNTM=K52DIV<'*UYAU;LFX&MKD4]0%-#X]OL>LW*RW&<WB7;ZJJ5[K7
MR7N>+?#&T #42KQU; LB)=:YBFNANDXE4^A2WLS8M1S"3<W:U-^USKXZ><.W
M!0XD2(>4:FT0-;2S 40F]<T!]]SC%SX!)X_T,6*/G3S2U4\JU_8V+/Q3QZ9"
M+KJ6+-6%!_6(A /3*E[,!J!M%N>F</_6>9"=Y0Y>8WZN@Z\+ZT B&H/U4/(U
MQ]PK$U0%E +CD/?(Q&J2Q9S7F7IVRL>S2^[0^VV!$I9ON$,'FKQD9V]\"X?-
M><E2*G>-ISN4A0D:\F,_&W4S?*N&25Y*W! :P*R"7HN(YO^LG T[_XM2Y?>&
M[J"[U=8CSQ-8CC+8Q?)?5B0W3WC)$-!_?^\=?Y2TO5(LS2%>/KLC0%X![_'_
MICP6\:O,)TAZ5>J(!")MS\+;J0(CBED>+T[WNXJ>P>@FGP8 4UL\^VX4GDWW
MD&'9'091PT+C]8T1 TH'O0F@LCH1/@@;1N+[X:DS<L;?>"IL4U?+8R%8%O>G
M'A<LXY^%@L*7+)[,6#H3F'=YFNU_" A1&%Z?U20OCYK2G5W? ;#Y^._OTVO5
M)0>^?G6L0++CVR>X:!AQ<S8^\JWDT=Q7<B+QX#XY0[D5%ZXB&'4W(<I<1>H0
M?MBO:3M( R">[_NV:.SV<62P4KFZCRE;#-L> 45R_CC"9,CGXR"7_NB,^K=+
M.,62&R=-Y\SPBQ]\NI6DAUW7-M"W7T ?%-3MU69Z!5;OMF0TS4CO#B-G;"PV
M*N.ES?!_K[%]!=^S1+O=#Y1B.$;O4WJ/LT]NV4X&%9;T$]<F7X'WV\?#2"CZ
M\HW<..&)2PMC:(RD:WAL'_1U,2J*8R'*>2S)5D;WEYL**1U2Z6J1*B/C.?$,
MMI)5WP>%S;M>:M0Z,-3SVD4O'IY^L6HJ\'.QV4Q)#UI=]8ENO;Q\QFC1J\S7
M.*IL+=:N%4DYAB_'T^/7I+Q9XM7K:0I2V:90:^" REYFN3]>0E V7BD[Q9$Y
MG94.Y79)ZCNUCZ01T .0;77;O@8-,(Z(%I4>U]--^2L@@GNS? 8Q-+GUL41@
M_EK^F.Y:E.2I]$151EK0)7SW/JS@SK?'5 IJYYBB]J;#Q'7D0;I"P)_$QNZP
M,KE?[.%'_=Y&-$!\\)O#B7A*3;T"G$I7<%9(9/N[GKNI+^HS]+_!!DW:67*C
ME&K6*$*V_>OHP;UKKZELTC!.-8$('NDY:W6/D]>/PS:[\Z@]8U+9OE?:'-UA
M*W,C);SAZ#/?OZI7_0B?%V/M589>O&0*!97U%A$*8/=SZ;!\',F?VMG+[1YN
MGX\\D6K,\_^ZCR%(^5\LP[FDI#L$[U38O_>;^W7SD&?K<K/;T:KX^HEO=_ZL
M8G^KE2KU NP$B].Y1G;3D[;U4GCXJM3(])//;M7ID7Q0+[99O_!- Z>II@!P
MOTO9B1))+$=N*_E;K!F.AL<P(FK?MV%R[/_K05V1]D:;&%5+"V0&77KSR?"M
MI)$]1(-SQY+_?\<6P)R>IA+N_SG5H.#6T[[Z(F"==YS]SNO6*8DA6PF\.> S
MNX*:/9[J 91\[9^IEM\;:_#9>'J[$JS5/7OF327**>I_:YP5D_R/^LKG+2?C
MI7H.E]Z'?LD9]S3YN&(;CVNHE4_>1#M]"D=WH/MWR?SY<9(14II#^FPOA6/.
MD8QDIL+KTMQ'9F<TW)B(B:9,8 DKCR-,3(A6-[RPXX<%BM)LFS6\-/I 5KD3
M*B65VG[Z4(QCUZJI?GR7D6 MSHH<.K>QK:=4EKY M#"J[1S5.HIOI@%Z0NE&
M723^2X=!&J)9HF#&-2GNZB^N>=4=##WBB,6PA8MC%*-GV4+82;=X\&2ZYR3G
M4 8);8OP]SLB6+17JMQ0O1'SR+/8&/BOL+;)#KBB.^Z[IA>YQ?%XNU4K*"T=
M''&(8YDFR[MEFB0<3Z E0BU+**YZ="21]D[6DM.=;5V@>[I_]:VH#4OX\QU-
MX3M%3+TMKV+(B:'2%9H4UVP:X--2)_0^.41N8>WCQ0U8*5Q4?/.Z%^P?Z+>*
M(+:?7%&5:RLK\8%O6H_1O6L_$MENZ#%X<>.Z1*]HP;?K]GO*<-D<XWH0J2^'
MOY>(@[5.R X=?."G[(?C.[[LBADBALN_E#[S0.LO-O8#.QJ=(O 4Q)/NVU**
M-[DI_43W(H)DK?1RVRNJG'Q\U3 X&$M)),H>>?"0T#OEO*P_W?&G6[G@KV>7
M$*+G%VPB<P>/FCXOCTGQ^4NMYLZYKHV>_W5"/*YHTULI*+(3_&Z\XK->H ?*
M]T&7S5(FZ+PP^/C_Y(.C ,\SE^X$#0]9C<>TWG6VN?P!.LX/"05=-YN.'=&&
MG+\RX=1 #3&0SE,OY'/)$IJ#Y,KL@NZ.X!T;&M)$\8L&@X]BV(VN+:?O3R-<
MS4D=GJ(1'_<W>&^://0N8ZVS_"&?_^\AX_@!=2,;UY9^W%GV&4FQ6],;9O_T
M]0W'MGKHU?Z94U\:P#_!)M7C L=C-3>/&RI77=CY8Y^6?O@+4#"8.6(K=DSO
M*AG;;7ZU,6Q GR^F<&WEVWL#60NB#T05=.HL71W6XLRGF\1W( CGJATK@Z'G
M!&&C+'.Y_MF6:3X3UD26!P6%W]O>CI1\97-B\]GJDDIV:!N$: -\ SFC:D7B
MH^?XD]J#%!' R+?YAN4NXG#B)R#Q4O"^G/)<V&KU(@W Z<(K/^:X!_OT6HBQ
MK]15?#^EYV\N*W:0/[ZHA&?M$^5_>^^BAFM^-S<%1.C(B/+S5F :P&?N'XN\
MUTM4'%^8194=#\[;]J*SZ"HF3 .@X#KK$V;3&WXOS*>>UAW]O1LG^_6E\(?W
M#! U=HU!Z>6=8R:AO"+!@G]NK\1+^ <9-+ST4F-JBU 3!;#IJP'8I> 4J H-
M8,U)'I7Z?WX/,S0PL\5,&V4ZL46%_&[COU5X_@/S[V5]S5+6=P_?G&.*V)30
MH2.BB7)M@894?IMZ9P*WS)3\1:[!+4NVF)S1LJL?'ZO=E05%3C7US$M'J49G
MW,H>5CM\.8E9QA7X)2"SW.__*W/#P38D&_X9*3LL>1HKL\CX65+MY<^Y2[N+
MCX+B8C1:Z38:)[4QI'[ORW6?%X#\B-[>A60^QI77!O"=M0322VJRI,BJ):5C
M=YGJ)#GV44Z@V\Q7ED=NBXR-RS1D#8-68Z[6+=SZ\^E\C>\Q,/)B[;9;/R)3
MG[>T^2QX7)1@^((@G;Q@#@H1Y*D=*_&XFU"^<QTUQ==V]<O'QS,?P;.8H#U^
M@L*21S27Y48C<W=60DVSM$M^\,[W>8.6J-K!@+C%J5V+[X-L20J:_>#D*[^U
M\ZK46,Z_9Y*,43+W3K XMKF;]N["N\G$ ,ZK#E_C3U;3^ E=(5/H<\KW2>ER
MNR&ZBVHCKSSF!H\0VN9Z@)6H!]=?GL/5NE%8ASU";I;WO7(J:9FM*+LS+C'(
MQ\XQ-H1GG<';:;XFO[>A(U6![J3?\^,L%MLD@Z:4RS>%KGQ>8Y54Z66_(38F
M0"D8SYQ?CF-*GREWX^@LM]OJW>?L,T/\4/R><^<]Y/A[XI]02.W;F'DGA(5$
M<#B;_O/_Y:W5&&67$&SG8MW1!&,KU)E"\9G:6PFW+?,4D2:+48'M?T ;-,!8
MF476W^KJ1,CB>AZVR53MV8I0EY]M D:M^*E!L#6ZL[^NNV!1SEV^ZTVV!0W0
M'$0#Z%LF:VA4GC)$W:,[/9Q"]FFL:K&UEN^]JAJP' U@#G( +CU#!RJ(?BU!
MVT/2;=EJ41D;)^S(M-JMP<IGFM6?5P,Y2?'':FX8;@QWKM!_F8I_A4449+?=
MQH0BV(./!4>QK@B596^/UXH]3>B]HI:'T(/9B+Z3ICL&!4')RH)GYC ;NTV+
M'U7_R(X/-$)OW*<Z3:45;*A/3JVN-$]/*A_016+"H,W#([],1S*C"-;"'[IZ
MQ-:=OFNPR'IDIM"+"SACL)U<B8@NX\<_-,(>ZA11@$^"\1:W^6ZF.8']!);A
M>Z7.!8,EOQ^,9BPS/G0I6@':&NJ%EQ\.F\QRK\X3'9?A)27,M7@:X(2LW,]*
M Z1XGBT1)<?K6V85Z=Z1SWH3#)O;MPS!V6X]M<PRF,*P@@;O+KSZ['"F5%J"
M0F/!XSU'(MXTP*.ET^5@^,%A68+EY(;^\MO/_GZ*\.XR+:1 C,' 93$<5IWS
MH. VW8S6'L"PD0IN%B;[MMA)OT$(:F1I\L(K)8@W47(:;S"N9S7SO!C6A(U?
M,$\J.&O?:6Z.AWRF_TTVOI^N(^&J+G4<@QD*<J"BP9/Q6Q2O(*@15HJ.*2>P
MC/MCGE8UB[GTM543 >-[C24RZ\3*#_;12:2O:_#\)F-0A.Y%AE>>Y3:U(\0K
M_&XQH1R(_K,<2<<*L7LC.;MA*90M<62-PD,O"UV]M;.O#H(G)J7:\AH075L<
M55TOL]15JI\JRDG]!VVH(E4@?&^X/-W7YISQ)!?=NH<S:H]* 4G4YL?=L)58
M%#"-!B!B87A=%^+32><O3D"5^]/VP#W6P8-"5/@.$6!IC%U-D/_N1N"&T5E5
MN"]+8V&$X*11Z6USZM'G2'48=N%FB6 +>R3>*Q].7CY[XI)#T"LJ]<Q_L\^F
M) :ZUGFRA)YWIB-JN\3"W M+<AE%YW1\<#S3J*B+4R;$>4JMOSM(2YH?,I S
MIX>W'9UZJ.*%49MDARVP8WWC?+/L($+$VJK;-]<AL$Z3K.RP7)(+Z(FL*-Z/
MF&T@ \/I&DUA.BU23T[7?=8']RP?K%(&#R6W8.<W2JF^2[K%.K,[^8(4JF3&
M.F[&P-K@M+.!L)IU)ULW?; $,BEJ+WI" T2X-#013"H[.>I.) 6I%GIS#G Z
M;;):NOH7;GB2/;E>J5"N%U.?IIU5'< PM9DCL)H.%ZKO'P);7BYNE\*X25WB
M!4?^M/Y=M<5Y;%$3EE4E9X894EDZJ(C"/*\>?C7I[,9>Y;\_*@9MK35T1_AB
M<VIL7S6@V].G[CR7L9GMDZ4!W(Z0*^:]+5IXSH,AF.U=+5 XA[MODX@M^ET^
M#>"K;']B;(LO*ZMX=$CF\DOT^/K?*,@K8_.=T9M_5"(AC]S!6;*N$KHT &_=
M36T%2?C="B?]ECOXC;(SV-W5@],(F--F*IQ "*KK.>OS'%PSF";YM<_L!E".
M-VWLF^CN37>?&(QL$9".IOZ:&87OQ6'$^V?_'&L,P:^0C8H?[/R8W@5M4%4\
M1$Z2^A'.1R(U@UR89_'P%6,T2JP"O=2GEXQQ?D#FI.,(>;3I, N4\U&:%RX!
MBY6@WA#(B+:TC,[;+ NG;/1Z..N"[I=16U6@VTX3OJXX$JG%T@C<YMY,]15%
M1[R]Y[:O/O[$/S###W;M6S_=H\]J/DK%QAW1 $P0DH;%4L;TQ@YLDM&%:JSX
MI:E83GF?!@BC/D4EG^E(;'%#TYNXW_P%4:KCD\A,)33 Y0O'5F;.(\\5M 1_
MH\^"T*YYD^;S7>Y1':3//91^R]=,3_082RKB+(;GM$"@ ]BR=?[)1.?I162Q
MMW=0G3,-H(B/!&?INBZ$*L^BFM57]0K6%+Y0Y(V.N8GA%?ZSZI!<'LQA*6SO
M:[]O5UR6(C6>7DO6RS%>T%S(X"[,4WD19]LY96PV*EQLS /@8DM\_C4GD,=>
M'_M]WD1FDMB$(Z8^GLBA<J5Z0]%+3P-,L-^51I-L>K8D,J'&J)H2T$<@%+[:
MN^KAH+S4%10B6B7C6J(@<*6)N/'BC+YRR-95Z="C>*V@IP]J>^8R45L;@97N
M8'K6^OF'H5BMB"5K1O3W'!H@]!<X&6QO49@([X%E(_>Y/ZWBR;?LVU?Q82ZF
MU3:\K68*-_>!9R[8ZA&$#W':XX)G<.D^M*C%OF_)]9\54?YZ=-)I'>$F90,^
MI7R77N=(SD]5&D!4#"ZX#URPEMS3AK?T.<WNDC9],8RR6_?[-O'D31]?=;K+
M&3G\<U:X(_29RC/I\=O;'+P7/8?S+G'EO%&RQ5[/BAS![9>E*+,/U^Q?]=.O
MI@&"()G4VJ$^/85>*GP/]GLD\9/R0]0ZVI2JQD'XECKC+&_=M>LACDD%KL).
M1G';.-9-'(%8K%;X'SGGKM  NQ6X#XC3_J<CNM&AV#_2E4=/ZO5/QF6\"2#M
M@ZO2K+,N(X>LD^V61-DS"8VZ&.BE A(-8.N)U3(JH>(U5K%TXYA[&GVD?'EX
M>_G X0O2:=.QT6V9R@/6GCEG_QS RA8*J)#=S'X\%E SC/<)L,Q')7K *A@A
MG08LD5Z;,4";L5TI9:HV4!ATN@Q[;F)0(IS>,^,K=*"P6 92VP5W0#J'L*UW
MU^7E'MX_@<A A*>/8^%ZLL OY6B2=K,.TC-WW=;N_6$C]AJN\^[:?K]/.B3"
M!W&5Y>>$JCONX*^8+?5$D5I;9+[IB/]9@PZ'I!TGG;&C.0;XJ>SXG=H( D>3
M=TA1DJO;:3'TTS7TUXHDC;V!U 72T<;1X^D[+QLKK,[,]F'R([E9,2Y+(F/Q
M @4[1Q:@AC=L?S&^\M6U(%;G(%FPVZ@H_C/UEL YM%C-G:%/I<IF(M7J48L%
MI )'GW[>V"+<EE=8S'3[4ZC /E@X'J^L,$8#8"W- J W*88R64+ "(U5!I$L
M&F"2F(>P5*7H#>[@]A0B7I::?V:ZJ*7$X"V/Z41>6\_/;XSQ[L^\Y 8+ZCP)
M:3Y/E$I7IHN&\\]0F&7K&(OA-?K20N]#X+*:3SHXO":6X=^?(PC\=UB?VG/T
M(B:)/#):\9P=%.7NT>.%;-FB 1(S&PC(+U([DJ"K/1=TA[>,/40]MZKEP!\D
M(W]QKZ('/S?K*'0&36[D]<:OZRF_(K+C]+5G,<1CR-E4>F16!?48UHX!YY"N
M_+NW,U8U<L_<-'^8Y0GD=*-*8\&:@<U0\22YU"15R5P.+/.N\*"IB&WS8=I_
M^R4R*A7G)GQATOS!D)O^J6IY1*PBIQ(5N/,@;NY2MXV6F7 Q4>#PA[/T]A>7
MNAR8:\%4R^Q*IU\=X6I-5;TQT, UK)6$?%#I<\3+/+P\OC.*=RUD$+4[?N0)
M'U'ZDE]%LO1'SG85!XP;N;UV4,@;6>BU> ;-=#\A9)/I;FX\SJ:X0/%M Z?;
M*@V G\NN0OV)6,),K<45!H,9S,DFK^JT*N9RS%+'^PR4[8G ]UN6V2PD5_N%
MX*)1P11=6XO4-%^1CL;G2UQ69T,GI^.F'DP6W5]5;ZA>L'<1<*&SX?MS?PWS
M#3KMLIH23'EVY&7?[*OL4H9I +;&$Q'0/8&KFACM@#M7B3]\V(J42K)?Z.N2
M431 M4[-#98@@(50.9 K *>UIPP_0N@MV<NP6F(.="2"A(_Q@RK9NOP61J6F
MZ47:,DF3_-J+*WQ?5M+&A+YRO+;[IYA'2VIE*O(+$18U/LX-^K3LRG.9)344
M>5U]UVR!*+M+B;R?0'+J!+,76L)OD!LY(Y_PBG(\X#/'O'!4?!D,#2LYQ#_I
MG5;[&='=/:=@:6;ZUK.SG@D\&"25@$>^2M[$&Z!P7-#$5*IV\^]FD05=F;9T
M10OW5/>[J/@4=R2__VNE'AI@RP<1%#%3.=M0O6%H.+&W:93EW)C,,SW[,S>#
MCQ,CVR4?]CAO:SA*Z)_[R2J_K)A2<LW>S61&!4F(*T0H"9T;U=?L:]#<^/>*
MH3D-@%D&$H=@6:9J$S^<I.S^[W3>QC_W<A/B_B_&_CNJB>CM]X9'$;%!+#2E
M1 2D"4CO!$6Z]-X5E!8!Z9VH*$@-17KO($UJZ"@MTJ5+[RVAUQ!2GGC?Y[SG
M=Y_UKF<]?^RLF;5FLO=<>\]U?;Z[#75&34Q;4D,WUP=!IU=N$=JL-&8?XS1R
M/MSQT;*WR_EP[_T<0AJK,^I).=,T6D3V 1.V\%>6;7_H*[*/T1!LU>",M7TH
MSO'7'XE2\&PL*'3,V9H4FXPMI:W;?!.KN$EMH 07!F-4<#Q%]A_(V"KOW9')
M8RQ$D7N7U94M#T6F!,;G(%^+)N>;Q##AC_]VQG*01X$XLJ^CGLF0:W0Y&=>.
MUQ*!KR;Y&V%O&NI':WBN)W#RYKIF'_[R3/-X=>V)'^.E^9;,=FP:PH*^KK')
M]?![55-,'XU5 S9-G]*ZPV!:\\-@S&MP/-2I\@N3QGB,<1(VXSH'^KDY;VNB
M2T$']R_^=)=&W9%IL$#H-_RE\P -F<V_?ME\(FNQQ[2(A&6(A&.X8B]%BN^+
M!E8WWX\CC0SFJM.[TUS+\2]=.5_O; =0NG;(4S)G%OM/G)Y6SX3S*#)V@=/R
MJGV;\.LR/D@G]^/4K]ON"'NFW"B)=9MWT33^$Q(K;>)D#5D&$I9?Z70Q*<;;
M\=,0D+%J]!S]>9Q6DSB7/?WNU6=N?]Z0#5?2P(.<I'F$!G]7FZ$4N?CYI.N2
ME1)4C"Y72%TU9(H:3;.I5V-2TCYX,GWKE)EEQ!_BF.US,"=?-)=4SGRHY";<
M=#G]9S"#Z9\?>Q:1UF6:):97" MM$S.O*(G M9VP+H8[OV3=ZY&+#OQN:L(U
M#,MV_M;+G 1D3@_[-QU8Z1B?Z,PCD/(*PRK'W%?F\3Z,[K-Q?_X5Z!LB\#D,
M;9R>9\01F9PBZ'HKTSMMYV6L]^I'<ZIL\N,XA<*_,R@3V6PV';. UCW+V+72
M984GM@F7;[T5O+PSJ+$";^I.[&"BW#Y.#3#8!7-C=]D?T4H\S=YP\HL-M/*+
MV]%TM?BZ^\:J).;%FZHCC9P:H?^:D'I]^KKT#>Z6E7O@;VV!&A"JXY&F2D'_
M[VL!PC1A]E_7C6\&TC#"#@1;J69_46@J.B1X,BLC(I;T7F>.DO!/71__1T%6
MO:WX8L"<R:PI+:%*:[.-5G9Y62WAJ2DS+,RB[[@0R?C O'5V9>S,6G_ZQ"I"
MZ?*VI<7)C?.(KI_G;:UX4H0_=Z_[G>$GZ[BPMJDF'&O&OP?>GMA '(@\3.MB
M[GMCZMVVD9>NV2HU9IH;6<VV((;@.,K=44Y#7ETG'#>/'QY7)HHBG"V1V(O/
M7]146L53UBW/M\2>'=/8V%TZKW#R)@(9KQ9A)ZAOD['*@3YU\-WLKN?9&JJL
MR@'/G0CN/G4W3FNL81T$\'K?BMXG<BY[IY&5Q@A0Y]@]2[-^6;^O.XD7E90[
M)%UW@JJ^SDC96T+"G?RA38EL4R>*:1*I5CO209)_Y7OSZK2=X-WY$TIKG/IV
M":T'!S,<@@SV? P$WSE1V@1'A3O/50)C*NS*Z"#!"F+;]JQ.%S1=/823_E0'
M[ZY.""JAMQ]6);B0_[*$+U_QLS7>%'O1.[RN.% 7+](!&U(KF):MWW3P>3C.
M!!OAWSG>;&NZQAC(@;,?8% C-&EG:.I_\=2ETZR*V+U@BT6<%?K#3DHRC+YZ
MQ!.!>W;M AC#DT,N%>?L[HMR)YLQFW\?T+ EL?2#%N<B:6BU^K Y->FZ2[=)
M7I'@(>T%MEWF+"M#7K!">H,\V-*=S"X4F*R?O/0S*_N:LF#>?'%&>\I#!%Y.
M_B-9K;:0[=1T>:V4@Q!]G_<0E@'C0^G!'V9#)",Q7,XSM4_<-7Z><<@T#C;*
MG#*X(,G<$\K?96U5V\JT"7ZS[G;+?8&V*8C3OBG8N/$V$7 P('SSH7L;Z)>T
M9'E*F^WG!SMW##ST<UXY+,WGAB_#8HF 8"WMBR;GD[-A4ZHE@%!KHGP\ONY7
MS&<Z%TK0?Y3.#6X,UCWF.!\[F"<G O  6<WR/[61WQ#V^.U,=,,M,0.2)$66
MI[-F[KU#HG633R0"UYJU0%B[*8+>GI1VW.Y,%]W%3N::\KL]4K@U]JR$*X_4
M&$Y9KL;B>L><__(7$ %3?RV8)PT2K2V;6BCGYB:6LG \8>'@O*WW%H_O)P7.
M9IP.;T8B=$P^\W0&TC_B3@12>-9W:7>_YH[5]!G,7/%+@@UQGN-0FCMJ#?5!
MFG'X+8UI-R@M+8F$2*K04P2RI(*O(3D"75L7_M99T&#4FYH-2W8B0$5WQ+"*
MF@3[>CLFCHC,PDP@2V#CAH;&^GHB\*:.[K PH$0W$6^>YD)ZFG."WD(5*B[@
MXO<B<TP!+)WV<VM?8@6.X:;&).^S/..95TAG>ME2,7#_6-6\Z0P1*$T1/YA*
MNM&3J%EGAJ_6C2%AG?TG>&_VD3_$%J?=0 0^RCA?TY].%VZK8'-\X,&^+]?"
M$?HDOBY7>@?_-SKE]7A%X?*">C2L5L@1S\UVP)Y3/J.F%MIR1>"5#A& .L01
M@:(15=">^D-P(4W%.+IO.;YU[7QV$C7>.I'IBD/B4XT:2=;VH,S)^%.P0E+G
MD60=3W][F9N9F6>J,"XGKT'/F&QJ:\';7-;8]522@SV90^("',ZHI$H?*G(%
MZ"3BFN/Q3O]F(Z".)Y$BF#8,^7C5CU$Y9[YK CC'#S A;3/O0K6Z072--:G9
M_G)>TU9:DA%D;(ZI&1BK&;FGZL%$H;(E$W%+BL5\H5!DF'[X4Q418+73S:VA
MSM\L([RQW(\70=*:O)V;O'C91'>TGKKN'7:TVP%]U5HEX(D7+RK ?,DM>?=Q
MO1FV.].N@G?1)@+MNB46+M9+Z$\@I4:7VS@X9O0TQO(63+=,JYA)GQU\ #FR
M#R2'8Q3WG-I6SHSKW_OFU]^!'V'TPYVO;1FTB4T9V.Z.WCW'@<#YMN<6?*UH
MT<R"BHL;;US.5W4U/SE5P%;9*Q;,HK:NWV'!2>3.J&^FMP%.*B8>L>:Y1. 2
M.R8U\4%&>BZR#IH*56"ZDVYX2!/I<L"@9"S=9.U2I(;O,U*!E',/)'XXYF&D
M^1%ELSL:]QA&AMPR?6_:!:57ME*.NZ@LTL8:2*;A_AH=?VM=(\"2>TD/]6S9
M7(T@+4Q3(S]B>BY !*+V[4'!_@K%1T7>GV=8T+29S LXOR#S  47+_*<W0R[
M)4MC>DZ\W8\)KJ[I2''DFA=F85]B!A+R@+TFX]T?%9B8#]\JG^;8>]":.4U+
M*:W+UYVEJ&O(%Y'/X;\-9!:B:ABD]\:6G+%KR9#CVU")UD>FYBZ%6RE1.7,1
M6OYMF43 )"$X-C^J$RWRN/D4YRZ)XHDF3!V8$P&<[Z;!*<_4'L<<]M8#S6TP
MC<-]NL"'80.@?6,YT"KR:GH_H; /IQH#'R0"6/7!EB3N!"L:)1THG=9!W9?\
MC9T'^?6OQZV=!4(6&T02VFYM\]'+YOO!OB-<7-Y[$N0S)^I(;_7US6D+RKID
M1P:J*.M;"\GKD?*)%* PG<0<M0,O7 0$8ZPUS]2H$5/L$%*-I/I+DJRYHX<%
M^*;N:00V_"83+>MP^9LCLT"S0*LF@2TU.4*U(K@]IVUG?8V@MB^>N\BDI+=A
M?"!RTIOQ8]KJ"M8EC:"?78"3V-]-#H:_#+.'M+DDJ\BVB2JM\N3GA#]Z&]79
MXUH\Y4E2>49A]!-SSQ^5VN5>TGL%:L_/>SNG*E[P_G]^2[)'<J3<1>YFO>W]
M]802"PM3^Q_)N[M6_R8M"'W6QJ2LG(#"L=PO'6N*RD\N!O]L[2?</[.>F;6)
M'VRD5\5D+OYJZUL_57(SQB*_"O\;P,/&;XMJ>PJ)D[<&%4-4E_L#90^<Y_TL
MK_U%D'QB#]@BB @PB?@I892R_IH%E)_;3#H/\;H5*[]E(P*-WK@CM3_;V'+F
MD(L!T]8_9YD+^Q5Q@<'NF7=/+*FEGBWNW%7[?52#\EKL<I+YB5K(/BTTQ7%F
MFM>KM=&CA="NQ;-U6G$TW\&O!#(KF,\K7KPP&M:FYB[Z^6_BH\ZPTQ(^9[/<
MC)$&(K-&<F*D6D/H\/RU/VTT_VYJ/-,%=:9O[[I!KHVY4:G ^M2B5BEV=75W
M/F=8^=^649=O<#%(>:^..\KKU0YOSZ,(ZSQ2[A<C_4MZ@8\_=O.I*W)OU^H[
MUTJ9\TV8IC:LU"&^OEV+__0=[@H=*F]]8H&)\GF"NY>K5JI<"'40>]@%O7_2
M\\NYD'DJ9W2):;#%@^DL4B34HV%LU_2:2M2(T":UM==DQ-F ^@5S;U\\^4!4
M)L>9%\G5(7QA,P/^OW=;V1P(0@VQR)\)S.ZOZ]3*+;E,O?&>EP61^[AKZ[4X
MKOVJ(86QJY4EYFK+H-MBC[%',> :Z+#<SM8,$T]U;>VG[FDI/SN=:ZSFQ8PD
MU><+2.K5F#;0"%$928HK7XC+8'LMEQ,W2YN#5>CCTA9'_6O-R'I$^!&^W/"'
M"EJYEQ/". $.,N'?JPLQ$0]@%I0B6GPN<E0%*H_[75("!-]]6_[ >$V&RMZ!
M7F\UXU/!?W]LI*":%']_0] Y1$ R^#]/Y! L.=$_M&/?<QK<$J12>$J;,L*=
M]L!#(/?6U)8<Z']]PN12Z4?L9+(=+\G9\W=%*BF^OZ=^<#D5+31E<__HWL$J
MX:9%IH7?0>JSAO%FT<:H%(%2NVK>DVSM!':?M\P-9.*[>C?DE0(/2H>%70'4
MSQ*R/T'3/Q[NMY35KGX>$#Z0*JFY2\/2N]\4)?;4XF<L-XP<4S#3G4$_>A+^
M7+HIJ4/0=E=\Z1O^VJ,Z_\HV+U_?FSH%"*<S$_-^ES05!%?F'ED,-FR%)6.=
ML+P^+?Z68L#>ZD/GREF_K&UT3&1,6O15+T;#K-OTKR+"PK?1"(9,YX*CL(1R
M'4_Q=,N..@(8X^92^,S!1,H(-R1HU&T<=-5+8E=#764I\[9"+H;VOOZ#Y;?)
M.UEU\#TU+M>[(MC5  J1,8L.*!N_,YO#</W4PVX5"DQ@0?.,UI^]YIO?G[^S
M23E6O[(PY7GXN=.K_^Y3+P$MH^=O'@HPU"'<5+:*)AH?Q&Z*F1S[!H>0G\Z$
MOE&:K/5.?!\K)\_[S9A 3D^Y'6"T4CON$0GIJ(/8M]6']4[):@TAA_6\9-OK
M W2[Y9<J@E>@36KJ%"\1YB5\E8&1TH.N*G<Z6M+_QB+38E7*Y=L1)G4MI>;>
MN9V"R;B?5^,+FB^1-\*&%'>O'Z/1YD8F5,T-VB),M;9>'@>/#Y>\[ .9&Q*H
M)A]\+G&(W*5>.SC1-IH$4S<_<YARY'GY2K+4RTES7<_ HLS-Q;=_5'F ,"0'
MN;'!MX3N"J 6Q'+Y]1U)R.3*W%3!K.2K/ TQKDU]X>JRT7#W%Z81OU "R*"'
M'7<?-7YY'*R00,>0H/R7YI7?)YZUB_K&\;8KWKOHI?FL>G[1(%98WM3)';()
MHQ KR7C&.WMF]1&UIBGP63T'+]FX6)3X4?T.=L(_Y;-?Z-W+R,CY3-4$<<<3
M->_RK'C;3V] #!7<>A&?N"6$1W+7M&0_-;.+, V7%O?Z";9-(R\I!J"XG*CV
MDA)$WAD), J_N0A3JFP"N[,P=Y?,0*J^8BM\: QL>>)UA#8YW\8T%I.<TCW=
M<]\(V&&/,I9,?Z [ESI3I E\9I _7OQG^-5>;6:_?NC%;<@<=<YX*L:,"/RT
M+RN=53I;C@==U SMK!'$8F#S\L828P'J!E0YT^SQ58'#*B?=7$3@=4QEX]V%
MO8;OX65R T0 K J9IR\D G;R'&I)\!4B,%F$7T&?@U#C!@>\O''\^\\SS1[$
M_8ZCOWC.>:P;5H#@G&.7)VF>2,Y4+Y4XPKD(\Z FK#_SM6Q7157A@1FH3]A'
MM(\(\!IEOBV2GK4^0\F&P=H3!]&I_0%DL"_\UJM!J*/ME\//.[YDJ+H^#\MU
M3*TD91ZC+[UJ#:^#K13BN.YG<:RW$('?MCBN"XXUO'_(B0\1,"0"CS VEDW0
MNP%&.O@<-U(.CBO@/0-[Z+N(>=BJ:&Y )HYP[_CKN)\$3.SDC.[?/2I$("8@
MS_-B$D5QP<W]6'2'4'5J>VH65KQN%(70@?W4I<Y91CICT;G'8+R#3/Q9X@;!
M&EO:EM=WZ9WON>Y+V(-H]5LP+TUGJUY(F>Z%PD>G1-= ZD_F$&FCN1X23$%6
MU+7#T!@0JF)HEPA\LB",Q'BK>:^ =U1SDJ;S%HXF)B 89EB\P='.Z9I[>,+Q
M.:6XN=N7/[,D)9 %4VU5/HG#W< V'N%N5Q2+'3@(%%[$)!#B[UD@.4QGBF'H
M6,?BKIT-68-P^,M&^);FA4W5@I=F,$1]) @7R3R8J+?07_&:O(WP+2P)$1UA
MO*"YNX+C?J%(?UACV:U$TF^I@4T<RMNYV 3AB1 S@E2?>!7LBPK!*N4+>\WM
M<6YH7N 9%F2Y(T($]&VA3C)#&%W"4$G/6?EB.*&A );T/1):).H_YRM^,,;F
M(( -^U+ZVOF$P!J7N3M8!$F'#CGF1.I9#U=\,\4-9^/A7AS8.1T20)M-.I\4
MY?_9)I$FO*3'<G(PZ9+QB'TCG:QG"1NAJ9P,QJ+]U9_#N8=[8_;WF)_QF8AV
MHA+_-[5.;Z>ATKI^)<MY9T)!,HF?9#\ZR'W.=E;.8L7J":#F'WS^2%/J!)NJ
MZ\$K&,.[#%PB3+<F([MA'DX P8//U:^R40=&;8,W;U,$[R>SS9*4Y1G%^.N?
MN"-ECQ;7%8+,,>0)S-?G)UZ\&++TN,GMHNSN01LZ:PK/!:D3Z8&-;X8%$5+,
M^$G,F)5I0RHZW\I1(HY:J;I+S/)P5+/:\E1>@) #QRAYA&=BSB?7F$N<;VN.
M/?#*7/:I-X5>@RS8<!P+!X1TC@;@54<6" T*343@.34H17M:"]X#&8Y@OC2Z
M^FK2S7Q!S'*A7_.PR[)N/P-N#^?7^! SKS /.]@>!V,4:U7:)C&?5K9NO8;$
M9&&8K\-65G3&^$ 7;@>X(NKO#?;2\N<<1 "8FX,6(C^]KM-\^9E&<:7+1*'.
M"R5ZSA33 1XI[EIDNBN44&MO.J%B1'J6-HK@XQ+G$U^/'[(%#S77[5%NL&K>
MV<P>_O'D6)S\L'8=4AC!B_^;;073XLK<3U5S(0+,OK3YD%QI/Y*.:31:BJ*9
M>? $NIE[.5,Q>^?IP71J($GZL$697IB2#(,2-O63\V5([@C\$*1.&#SP6,#.
M&?3^9I[8WV,E8,$3C:4C?R!EKCCJY59#W*XK;/_SO#D,N?>U]OID8_N\%B1$
M1*2M(_W&XP7VZCD5_-::%>PYN?N8]FMI3]:W4K[VYT;9]EE;">(7,E]JV&!W
M.[,(WB7'J7;"@RH:NEYQ]35)73?5GCVR28BCK@'^JZ.*,T_B=Q? RR)^/S_K
MJ MX5(=ZOJCO-Z#1]])L;NZ70VNU:C%NP,TDI M$.26@712>+/0A8;@Z#O,1
M/A$SJG;3HFT_:R''UE+A_<)^I<?-7>',&R@OZYK$AW(A!Q)Y,P=D1@1>H6?A
M?^_G@P?4Z23;JE%(3%6$S)N*,YZVG[LE#(8'"2%90:<[.M-7F:P72*IX+R8.
M:RA%!&ZT.ZJE.W>F9.2!C')AC_^MVKZ/%S!]H-E10;F9;S*C@A#D5WE\U8!B
MC'80<L,$/K58C/-@).FITM9SV.%C'G^#!S%<2W@*[8FH]^R'N"+87FY:X$-=
MD\EEBJ_B"1N:^^--'D:&0TF@"I[S.^;[E^2 5U2?$M)#3GKUVCXJ\$OX#1V<
MP0YUOU1CY/-JT&ZE9A;0,VN"B>5+57A.T.C?.//(J%3[_)\LU;7!(W>(P).E
MB$>$YZ6C;%;U7;02T&7TLGN)Z*13)GL5([V8?(I)%!].[]N@7"ZK^)Z"@O2/
M&<51]4>=X3T^]-SP8N&K%2_47L:H6=/\AH+IFGGSQ!+Q>8C1C<L,-$*TLA_@
MB2>E;1@-?]-E2&('@<:/TS1_O6K>"#C[^V^,IMPWND] Q^P(SN;7-V<967'8
ML.E2;+;> +_CK[J_$&P67J8AX?3L9VT=?CL/^]H77,Y#WGH?;?'0G,!UH# ^
M9EL6E7[Q-?#SRCI8"]3BWDCQ\1A\<T?2)M'9\2$12.CR(@6D@#I-M&+IZ-0K
M.]C=W*(+!6/8HL[D+KQ_'13:[+("2I0?UNVHXQVY,%S7D3&07?C*.E]8B1&Q
M=G-/;&4?<\*I^S;#:R6,#/%_?VWMI/D99O,X:=G;F]9GV.JDK+5WZ5C.85I=
M \]F1PX?U=8&]\X]1 2+/XQP5%[6^I[[Y])(?DY8[F]'Q+_=8P$#_ST)=,J/
MAFFAB81_7TDH_7@4-88"_O>\OO^=WL3Z0--L"D<7^AL_K(";+=>Y'VMU7+$I
MK+SDM B\\ODWBC!;(IF@'>63AU TBQ5(B4GB[!&GYKEZG^)1TA<2*=\WS[-"
MIND-5[[M06OEO1PX>N,WALI6) =XJ?4$0HXD!J7^7)G=F$X9+LWT<=,HAVAB
MJI?*U$S4^>[O=?4G"AEW/9E6GS4X'*#%'R"E.A]Y,INE\3#NB ]RDD6/F/FS
M8+(?Q[#<QEAV#MI46;>;FA\T0E[-6J.RW$70,Q]^<ERM;[N[9<+1S7\#Y:O:
M\]#.7+<_]OJCA)&5/N/;.^]+KQG3L0Z'I3%^C-L/0=*9C%AX6W>^45B>NW4N
MQHTDR%K33PEB/PG$[8(8OK#L^IH+.K:+<IU]6,Y4$& \EJQMIC+/C56Y]-#E
M/+.X8(&DZQU-:YNQSRU,Q1[S?#TK/EZ,,)1?>[PS0R=;7ZAS?SEE/3('%<A[
MIR/':%H^K[M!>4<;- V.50'N?2$[*I/L/J ++3VV_,K\J+;A'AM(6"<\ZTN<
MRQ<R%F0!7>;I][F,I@+4+?*Z;$<A\)*QXM[O(TO;SQ'6S[EEHB2D>F+-%:+5
MK2SD)\.VV"*J%L-ZFD.*RJNH3%"RM>$>().MW45TE]6<?,0?UE&(+1&X+3UM
M?AHDM+JUS;P .>JJ_GBLV^4[X W^>?@']ZSAV9FE>C1BZ8DWP:;EL%6)B?S&
M(<)<H]'I@'XX&'6IP,<O$$TCB^=V4#3O5? IYTKE$E9HU;OHJ_<MXQXLZWX?
M0"ETEH!!#J;C%51?N/$I7]&#5KVU'[^ZS"VJY]QR%[%(R2S/(2 K W^4,O*-
M")C34IPEYG-P@,.?QVHN/4H8'/[K5 MG/@@+5J=02RUK!!4H6&A5W4*RLSX)
M'Z=]AAU=]_M6R-G$)7(D2 26[OU@^R:83>+)K;;]L"\D0O.3))%-5UN9/=U7
M1DEAFSQ]2D*Y]?EZ;/JQR.EX[FERQ#Q3LV6#;P4!:Y7KR*$+ST+$;78^F)^1
M/'[K7-0E4I!\Z3')]34Z-(S,"28\*HPCM"I)GS9^-DOEX" DO^2B[!Q>Z:]J
ME4?1@[=,T47DXN[NV+!O%L]A:UDX[]SI9ULN%_8>(>MN\GH(1N7ISS!M#7--
M393S+BFD>R\WPA(4MCN.BN8'K\L>"V1^#_LC6TE5"=T@!=7VJ-/!EXX3;T]7
M4])-Z+I%?"A6PEH>AUKSSR-TS\-*Y^E&9\3#;2_J"3D?+TSX2RS9A+8/>D:-
M8.U:D#(9]Y:%(^IZB(H#[7X:^)=P^,EZ=ER[(T[LQL(>%WCB4T-QRW?354M"
M%PQ[;8X(+/3*9R5THR^ZP2<CI&BZ1-\$WQ7F(%SY.6JJ,I:SR>8$64O#$-S#
MJK;T WZ/.U,I+O@>'H1D)Q*!,N7Y^W5.M\[88).:A-JW(JW%=/OS).BWI<1S
ME;D4(2-'%I!P(S+0QDO_>%\]R\GL4G\>JXXK_4IX=^&2)9FG'A]3T:RP2&O8
M.U)SG?XV3,)\-6W23R%?RWLC:P.$[(A<!U;G3V#?O1$8UO"<@6<I@!>V-A;(
MA\2.E2SMB&@$(NF6A8QOEBQ$>Z(DK6&M79J'Q<'%)6*<V#<9?2PDX+31R& M
M)0*T#GSAA<B1W@4"G@S/[5Z%@#,\#(7-R?&P[C1N7#&>_BTT. 7!'K<Y3=)\
ME#33@$RE@=;M!-Q1,NMM^^P$F^DB[0]/98JA-R],C17/:\P[\*E?LFM;C'T(
M[3#<-<O]K,R2L=W_NG*'YD/KPS'/HVP-4,T'(J"J>,"._4&9;6Z-3Q@ZSI(M
M,>S;LUQWIS:$D("2=YH(]%,=$ZAA[9I>1$".9Z_W [;,8B&," AEY33L853Y
M(9MD 43 ?P36KD]2#G(,>Q?K'_$&%6_/*HXDN7E28326Y.?^$'_->N1Q0468
MA^(O9J9&G!EH2P%Y(CF7.-_6OU54;H?)U"<"V:X;! )\OP!^%UK:P'P_;D9,
M%:)>8R9;:$B*0I?AY^DR-*0#1^_X1-:.XIW4&I+M-'<T:6A6%&IU]]Z+X^WJ
M"<6R57 ".?A(,H4G_L(V@FTFG$F4=<&O$KEJ+]UVOQ>TYY[DZD?!%AC\$6_8
MHHPG JL>[H;<[@MTRK.H">U;L"OW"5;_>L/W0FW,U)8#TF!]4B\(25FR9:!:
M$\BY$!&8T:@*6VU;NC[&+I':B8W[-P$RM8^@&$>@:<D+.L,6E+QW"5HW(\'G
M6""2"E%VID"HDVRPB:*98RV%HCHOZ?%)J^>9; R,/UF1C93<.!RP5MIOZ^B=
MR:N-=4.S[>&OE?SQII-#= ]PD\3.I,("[D@Q=^T7TD<%%XLWID1V6E*9;@26
MD("CW&$(]_$[QW)!)*O5! _Z:)3V=)4("/+D(?X<H\U\) -*Q8E QOOO1(#%
MD.9Y$8EN/F@7N2VNU$I C-G/E4[$%S :)VH1 ?!VWXB&32=0K)37PQ$8U'L>
MC=<(??T&)._FTD8$GHE,:RN$G'S7QG J;?03 =- "CI\^(K:+I_(A12YC,'@
M# SU$SP1C1.)/2(\MV ;KZ!P5VFNP3643\08.OL^@>S<." PY6Y1MS%8'DA(
M67X)?%#C2 2F%NSB)'A=6&5AEUVP!H3,_+];T+J1WIND]^JEE1[A>84.#47*
M$S?]+L,RG#$"];=&'YJN.C@$L6O\!,)N/;1<ASY&(^<9:X:22Z<RL1N<,#R%
M\)T;- [^MYV'A0)3!L)6G&3Y,3:T,S2SD\[XOXX+'$>7LYU#W2S$<&K-_*5S
M48/[YW8P9KM&*5K3\+E1Z*3F(-)#.2NJH-X9HRSM%C" ""[=ICZ&]F41@9QH
MF"JDRC^@"%8Q*3PG8%I4C1 DV3\ CE9=P0;!#[C;(:<G1. XP[KQ^X.HA@+[
M5_A&PL0H^&CZK3PVA50G2X8#,%(MP.ZASE::7?K6%&&+TN,SH,\$FM%]Q6^)
MH+ER\[RA10V(J@BX\I?\RO<U CVA"GK(THII6?*C/5QN\=MJ4K"]*0&1_P#:
MT =U@NXXS-JU4C5S+G@ZJG22,3=I6OZ<A%KG3]E#ZP8'YX=]'3^Q/\/>J%7,
MQ7939>YO'L'"- _A_.M#$$?69=I:(@ VF4C/?C&GTTW&\_'$>=/^-4:LP%RU
M&IH2G+M\'0G92KQU.P!8#1 RQ[/:VB--/$$[TB_TBZ;!2RJ0-ECGX(B_6+X=
M%T)CM*STPBGX86E@83$.JAKCALBHB7QHT"4TD+:F?:0^=QY54/,Z2KE0^]FE
M_UA-_"]=!BB>A=TDOR_#)?VKR=G7Y3Z],!#V*UA)U43ADB+%Y80/_RU,_CNQ
MU'L: (Q4M;;J5I.W[TWV6VYH5P6CA'3_1IC_I" CG2K3KOFP'M'=[[I3F% _
M:#^F>UM;@?H69T[)K,!"Q(%<.+4N"WONE=%->L/0+2) B=,NF+<72Z0S"2XI
M?%Q;9-:3)33-YMGJ7GU.IXSZODOSACW7AYYP]M#F:>%TBH)ND$:>5*8H!K3$
M__4XP**K7)K_E,F8[\F:YMV @KG6 6?F=&K!&5SYF_,\)09]5<9=CH\9UEV0
MZH2F,HR[I;T%-?S%9,T,@YK/*_NR-P\&>J480J=4O-<,>].&:C.C4<!]['J8
M69%__SG=SU/#A=NXF]:%FDM^,J9:(XX>E"(U4,^HL2VQ6.5@ANI;558/Z[\Y
M?8AC=GEPZ9OE\\S%7 <"-W3'\EG-N(6C<<HZ:J,O;JCF@54GV54)3B=J\!-X
M,]F=GR+#_EH8=;^ $HZ(YGOO&S4C>2FDEYF>41CE,UU_^.K>-DC.4'[)MCM2
M;)DN.7_^Q30X_-UA8B/O9-^C'ZB>S.86O%)@9\5CJ1.E=&_0$CC4O8W)&Z8[
M\:Z6BV_'NI95.VI%\Y W6TTD<F=>GL$\;IT"/RWV;=YFY^>J859?%NZU/2-R
MI8(LST=*OYG.NY/J9^;.Z[B]CQ;QR@.U*B(&CS?Z"(_WG3LW_4V+C"V]JW_%
M!=3?_+OJ?,W\B^>-.^WPG9?%]/=7U^OQMHL5D;M5 \NPZZS@Y9#VLS#8\3H4
MM4#O_5;:N+ [IN]41G4*-R.5);365K];F,WTJT(&T>S9%*<^YDCX5=(IQ%["
MS @;4H8?9)\P1H70'-=SC9:07_=7&T@;;?22]83_A-$TLPMJOEZ)!&N'TM-5
MQBDU?#%W^ZWC;$06100&6Z#MK;R(@X>B.>O+'881@4<:K1W@[\QBH'QG5(J3
MVT<SR-=FL:M9N0//V>23UB-VW&6_SY6,1U#+WF.8W>9C"2CLUV+ QW59S2OT
ME/L.=9GLADF'+_";U%G0&LJ:_V3>R T,+@SI,@QD&\L:J9%Y9']B&E1+:\/
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M GOUJ@X#Q^<OXI<3N!Q-:)\7,H0\N9'A\ELVRX"^=.CK_H^-"O-\-'-D06*
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MBK2B>+ERM=3;N2-A.O'SRS.3M[4;,\)])14U)G\['BAQ\M9Z+2*2!-JS%8"
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M;P(>SQ#NLN;.JE&F&C\\<B+_19E4]V&P)(V+HE"#TSA04KB!R<MC9-KQNND
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M";0H&4GF9X7(1UN!;)5M[G=G!@NZ7_6E?XS21A;V7\XT[QCY[C"=1^?)XH&
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MXN=M50,?77[CJ<_L7'*5DU)S#YA<OP<$^S,U-H_SD.GJ]#U>Y.^]!W@*4*%
M)%'XSTN[=A P1JD:<6?:?>8N8;+5IXU<Z#5$A/KR["EMYDR;G_A%Y[T]$(;Q
MCW_ $LKUW\YFQ4NQ*3GMB#V'!/D1X:Q8*6/^/$I?IYAR.)%-3U%-LQ$LY0VO
M$6P2 OE,<;S[G2&63FLH2-G<H5VPY?UY@KO6PN'LBYTOV).<]!"!7Y42^^:F
M(*=&Y++,^/ =YY9QE&Q\DI\@^-TU:<B@AMQB&?OE8I&L@T,.J/N UM!%F197
MQE YSC>\W8J,JTYN*79'XDK1.\@SJHL=8^=HEW.7\)M;0:MC'1WQ@C;L-\9^
M;ZD+2=^;7TO[0[3:W4XB[]]R%O5A8PCPV/')[R,:KORU1=*"\<V3U,]/5!4,
M?* QB3@=Q3A/+DDG6/?L]GDLW4R]"$JVZ:@H08^<JB><B?U&Y59S/^X:X0OS
MK; 'Y[<FIF1;:8/2XR<ZKM-PE8ZE_,[S,[@=PQ0Z.F>I'G<=#8>MF!T:A=TJ
MNM><BU*,T[_ .DB9SQ1_TOTZ%[/VUF7 T9#NL!1ZN-JEOITR[.)>4/9,AKC#
MU UCS>3QTA-S^@EL?Y*0CH^7[X6+!R,*=25.I'/NO.=S/UZS0C.OYZUU[:DK
MLC$3"_WM2.N19:X-%^,7C XEU<HH\W-Z.[9N=@KM*?[AKM_1DEG7OW8V]47C
MEM*8B-JFMPMYE8E?4ASV21_Z02<+C0N;ZUX/:RBDICK0Z>!CQ;6NO9"C__S+
ML+;G:K7=NY*)(=9\P5_G///U;$40A<XIP$W8HZP(27@)5C^\"#&/TKJRMZCE
M^MH7XCF>Q:!%$[XN_VO)#*#$O%?+1Z#.#7]7[8UW0?A=?FO6WZ?W8%_4-/3P
M\)<QC5*\Q8&(R<R$KI=KA1 I0U:+C1B+P!"IY\ILJR.HJH:O/NZ"39.UA$;[
MNW5X0WK_8WR\10&JY]6=-D"B[",7-LB2G=IX'.7'[*(^$O!/-D>:XU22^*\?
MT!P;Y*D.F:56L:+RYCQMU'NK&PQ$DYU(=M269?N;E[.E3GM*Z7:EQVZY7G?P
MI0S]/A,J]CPPJ]:3' YACM>*T7,_5\O?)\"XK)_:T)>%K!Y?G[T9SXKS4E>K
M5S0::#"8SH&-5/EMR'Y?YJC*-,RVFY_7;;B-;4XQRLO+VEF@KHS/JSAR.^NX
MRQY'V*U]1A:3TJ @=S&+B3J!1)=CRJ%0Z98OR\KS/<YA,'5E:@Y=+(FN\:\_
MKQ10.]Q!KO4L[LT$8V>AU?21"LOU3SJ+N5E\VX*$AQW)[5BK/G$LE"@N\8SI
MJ8Y51<B768PYC(YZEK)VUA<FAVIIG1 3S,G1KE+&'XZ?E%QSFQ/W-.0@&>IT
M\R:J[1%TB*9JT0HO+56FF+BL^-(:*P/N]-.:_:F9Y5S?=Q.^P!+=EC!A:1NO
MY=T$2_.&1IB"1Y5?^%;G&*9&_'1 71\;CNF6X;/+T%S/782"2:+[V*R=!:P9
M9FG&4>,N]^-,IK7U#)V<]$2,P)/RF,)$\3DCHIJ'<'A>F4M0^O$DD_C"'GY
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M,HX:02]=DEA>NWVB2V=' ;B:K&@@S]8] ./,=*6);F52FG=3^4GN>/ )'Z%
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M?.(;D/]B67R.#.VFJ6@J3)1'UT8K@]9'D53A93&PRHC[PF35?\(\DO]7!&_
MON#::1F$2"<>I"Q ^M2CHHK-*PH]('\.;ZCI=5?!A<I7-;=/52,<L=(L/Y@#
MY-%B,0Q%F(\]I^#;P1L5H[Q5FC"]6>70O.OYN;L7&HXI4]4+%PU^$#]W+0/6
MS%--"#S)[LR*?6TD*ODNW<XD5LK]A24(M\XUNLN1S/X)&K\PCP]1FQY40;]F
MJE'>+Y^"#@?7&CCCGN# $/LV-#,4C0-@ZM[_.?QS^+5V7P;.I7+I9:#^#5O5
M/> PW*J\_*0L>34^">!(K:(DS[_^"> ^1'!V#PAQX,8FDODY6G4G.0>:%D\X
M+!Y\9BN-R2F_MJ2]IT^3N!&7J]9LZED:FE/MT6#%?&US_/MV+-3)DRDFB)RP
M::%,VN9UV>(]X+DKOKJ:=(P4S6/UD;@U]>+3U274L#+>3!O[6?.Z8+I3+X 8
M5)"LSR?J3!W.?A.)#5#\=PG,_VS33Y_%B#_/2HJU7SK[SVPG*I>=_BBS?3Y>
M!LX[:94F!A3+_V":) %G_+EY\I2WN)8HIVI,"!5&EP='KN(2*?CO4Z7_SU*G
MH1;S=!R="O+E'A9HW%7_\)D]:5W)J+$D6-]BF=XQ /*$)6708SF4_YLS5LQV
M=QJ08NF'?NY4('-0L<3=82C#/"KK&,+;0AR1]DZIXRY("<IF<<"^)J'J=;)V
M<;ZYU&(_>=PJT@60?NTR;UE&,-[,;@,"1O$4S(P;>H+ERQMK:R-*5=X?D//:
M9[W&#<<:"N>&'(_T\&N"ML#+EC:6B)R^Y0:>(]WQ%VU"/!/$T[R[+DX;9%%4
M_*JDM?!8I:7';SQ4'2M%Z,*.A:+"*.E'A;69K$FQ.*Q&9JU,SB<.QMSB$HFX
MQ(?PY(8RGC[Y;0KLS?[4 57V.*K?[YI2;4EM+[Z+J[D.O_8=6=RP^?[QAE:7
MAN,SX<I3-9)+(.]8)]$SK@G+,NZHE<BZU^T/UO4P8AKX,D)JSV2$1XLW0Z=&
M+Y Q[1>Q;PF10YS2P;F_<;]E"U&C@M.2;E[M6(+--QR<TN(":YES?GIM)W[-
ML%?H,96/ V,=?_ Z_FYE([2H4S54=?HCR9#*./WASCW '%J3*0IA\5C.J^-U
MJ)!.X"+&LZ>*?P7Y?&(GK"V1>_L^8$C^"/L@/%7A,,Z;H$W*RXTMCW0 ;S5B
MI/^85L)E(ZB=X2J8T_GIP]@..I0T$\EZ>[S[JK\_6A$5,>Z)#!V7*B!)?996
M'5L(A9_O>3-=1O9_W\-(UKGVZ,!F[L2=,]@"-4-*&AI(/E;4R8]2RV)V/FUM
M)7Y<RK17T%GCZD&:8K5%#0N7IWJ%&ABD?]I3QE?#)TIU&5;O-K%*>T$4/"ZG
M\3.")-%^@CZHZ_ECKMU.5T[#8LDBXL@O+Z<\]"&^4Q30'9@_V9$_9,6RA$PE
M>%"NE#:2MQV'(58CC9R1F&KI5%@[%&*\J8=9QX:@G3'0&G)HO"8O<LK679BR
MFFZ^>[ZSNG2]2[I1;N%6R/=[#ZKEY/AU!_8C,_:-!O\:NK\\?RO!H"=D:6#6
M9H$D94@E?/MZSIKM=>2L]?;-*]WG&GS]PHUI1Q=."Y6(%BLO$%P)]OV=[J,2
M#[E]-L>/+YA+=(7$UI/<*4X0*H;(D<AFHO'3HWQ:*R=S.SOR*!=D8;8$V9LK
ML?6L(T3&V:%2J1%W)MTB\M%.(G+V$J)4N&IRE96XO V^:SADV08_.> !OO2$
MR8=H&EW&P&+PAQZ+3CMJ)E-KSA\G8,X/ON'?:)P0?JNYPC*09*:M.JA1C.IT
M:>;/\WO.UWF2YYE0&:YERD=(UM=JK<DRM4-9[['N3DT:&<L6=U4BLN\8FSO,
MP=_;ZX<ZE$FMM6L$N9'D8_MY/NF)7ZH<GXK:9=:4(I4!SY,&](\7O>,.5>VU
MZQ<-7$^KH="&+QQ01CC^J!9,D7OJH&E(5V^(0T*+I823;-Q=+-[6TUO&QB:_
M=:8?<+%2 /(T9LT*YJMCB<GZ,?-&#HU\DV?!4ZR=U8U;G=O0()R>Z<D]0$?V
MO8]WRIU=G]3)MKRKD*ZIIRN]\I5E38?_*YN^,Z$ !#[3@]C:^F"?\CLQT-F&
M2J\$"4:@H>Q*!*&/4%X0RLDK>@?^$QH$TK\ZC3)/8Z$^":8=$:E,4W0]J7@B
MZV5_)"!$5I]&0+6&MR6!FK"]%O'SJ#MC+T<-9.5BQ)[43QV>9K_&Y?-9KT=&
MOM Z>6*@K\B"C+V].-U_BR/A)>FR&0U56H9R.14E1Y?/5)ZE*$78H) ",S%6
MK$P [8X2 .X?[R _FK%O5E7Q;<-T4"R99\<0>+A'2M!,]$+_S=4Z3=G/4X*U
M94=^VT?(,C*C">3'I!(W6\VFDC*3_!#AUX2QQ2)=TV6"FQ5^(G>[F5EAN\)]
M<_\9=2PVM-9*\=ZOJPM#N0<HDK,"=+-^FAWEI31*6C2(G;81TISP$X"42>7
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M%V3'-M3V4W;YDH>D[-7X7G[LA70E7R('DU+X8%VD8@=*FJTQ0K\LC$U8=66
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MVM#',<&ASI1-U3#+'"ABLQ;#NU6_*Q3L\3U7ZUI7+.KX08?S'N_[66F@Q.4
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M$*>G^?S^<#."2/\H AGHDA\A:(D>A>\R5S'7'4HW88H?DZ=9]^&(^UO74PS
MOKZOV&'.@-E&E[2>7&88PTJ&F62,Z"6LZ.<+ M^?;$_1O\^-SX"_N++2:]G)
M3#Z-W;Q()=C_Z&G,YKS!GQPF"]%0';\>N_AB:"?*UI":N69ZQ/-R>W?'/R1F
M3]"U&.&$AZ1).Z4Y!H(B<B+J%C@"!\6X+B>P!O6XGCV.2)?;K\- VYY+:;)9
MP;90_A6B60MP9]/UK[4]9"21<F4BBT+^O,8TE11Z(;M[#]BE2VI2W!4+O5XO
M15^9.1(Z,,C/2"LK&X4JKBJBZ0"L,RC(>MKEGX_ZURU-,0W?<>W.SIUMJ_*T
MP/)[_81P=E-2J;U4QWH>W)IUMY'RI)'2=Y+CTCHTY/7F62E73RM-<&N7K-2!
M5LKS[#0/L?[3724-^]73(A!^%>.5X6+N8XIV=#,_9K6>'\$[C&Q41&^8S9=9
M8=ZG.\P%1IA;"U0&,SQ'5;7W (A0RQJ.T:8LS^?>V;2,[] =;S(T4R^69_<
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M$8WFGW8-E*IMB$)N!5^/#>N]6_:0:RSOWE?$U^AS?0N3)2\/S6&G,W-W?";
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M@(5)UNG9V8<A. C_FE]M9K:++5,('.$# 3'DJ,W=3_]?4$L#!!0    ( 'J
MIU "8\ G$(P  +7Y   2    ;6]D97)N86QO9V]A,#0N:G!G[+T'0!-+US"\
MH?<JO44Z2$OH2)$.TKL@(I"$3@(A-%%0+ @H2)<N*BI%D(X4L5!$$!6D"2B"
MB" @2"_"EP2Q7+WW:??]_O?Y/T:3G3ESYIPSI\TN.]G=ZML:!N@.ZNCK " 0
MB/ ^X7T V)H6Z#%U0V%0?FXH'["TA!2@H*%O1$0$X(HY)\@.(.00T/V'1P(
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M LN"0H(V@A&"58(?A%B%](6."14(#0I3"ZL)^PI?%7XI0B*B(.(IDBGR7)1
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MKJZNB">KKBTOI:.E*:<(D8-H*,K+[9#]8>@O9+?WC3EY_8#C[X^E+:L%E5+
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M'H&$!?\IJ9^0?J5F;(I-0WZJD&\COP)^Q31R"L)U6;@?0_SS^_:QNE0*5(5
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MQLT'3<T]6.I<N!><X[A_?_<7*0D9.3&(D C'W!O_PG%"+$-"4C):>BK*;>8
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MDC\!A:?M?6]")Y=7[_-5+_,AVO/_U7Q9VA+03=#ZXRQ,^;*U$'UGV'%B^>M
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M\ZK7+O16-NN6PW$%R?.3CN_G'.;)P8I,_I3I8^':(\*4J*GD9-VY!\^&FY^
M2ISJWO_/WX'^_UW:I99F,O=JE+(U@#5& R7(W9C#^%7G((!'147'=)%+K6B1
M%D@'35Z%++42\.K7?YAEPK:N.8Q7.K9?%KR'+[B2KAZG%H4G#=5B+?N-M4:O
M.UB6),<)-^NL]:DZ&8Q"BFPX+2283^$9=&@M(1E'R<$T^I.!W@WQH/*+F. -
MWIM-AO]PQ);*7L3?3P 6'^F'9WKG1,1*Q%Y6@\C;9. =DY.>D[MD /-FY2>
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M28UFTP./IJ_KE9\%O$4IYV-V0-<!Y8:?@)?^Y0;[B]2W1^*99S?AOD\ [B=
MN%=KB]B7R.-LP_KE$S#=)7)_T3+-F=HI/T=NU@C#847H&BQX7Z*G&FU%02_B
M%D/]A9+?SPSI.-H^IR(JE]$L'AQ-(8:RBB,0W$I39KCI1]W!O+MGU9,]&='Q
MMQ-O35D;!.=,-$5EL\N%5 %WE+=[M<;#\_6])Z&MD^W:E".Y-L&^%,! Y)]>
M%M\%Y'R0M["90)HB5"*73JRDC)^-SS=7.$F:3^89:I"2K,,%BFKCUHE68DM
MF7\=<Z#7 K"0?8U6!A80FP.@7>8UB=OFI*,I7HN./>(04QSHWC_^Z*7R-IK>
M'VV8?'_C$[1&-O7Q"M4Y0CNS,TIO'*4T*K8;A_DQJG)8YR_9S4(:JHS=AT<'
M\^6Y;$)@[SV>(OA#003M91_Z)5"Z9]#N+G Y=];-WVCL*G#1L ]RLCSJV18Y
MH\@M3'>#*G(D53_[T0XB37QY>8\P6(<RX$&T3&]HFVS6[NR6TWZ($>\U&_!:
MS)$A'AMMDJ#J/FOOE-&#]5)7X-Y>.0Y"<0\;0TCE\3'Q$.9OP5W+^L5'R*X
MU NW3OY-!?Q94IB<9L34/>,*SI8@H_H9!&^AI. )J^Z*V]AP>=XFARJ-\$<V
MH46WN84J??[[!!4R48? H1E; &:/*CJ\:,V<]SCF-ON%S.8D]H<' \$>G&RV
MFI%6*%579(1JS"BZ]DA,CX[YGV;I)(YRJN*1@@V= K-Y!S&22VWF<EL[8WYS
M5WC%Z4!G_<KTE!GN$X@%\/B+'@:53!0-_X#QXA*]?+ ETK3H.5G1",_TV6DZ
MCYN9M3UQ;MRH_8I_JFG]E+1ODRZJ8G>K6;*,J]LB@KXO&ER<U2H.->TD$E6
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MBL1YHM''RU+LM5^BS3>M?E%Q@I4;.?P=4.F@V2!]Z[$ &Y-(M8-[\HS7)S'
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M*)*<:>1DR#Y[/J9_/02>N;G #OKMI_\'4$L#!!0    ( 'J IU HB(]!C"$
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M99/F'I207&#*" 8+&#%72.F0*M-3#+XW89I2[D1LE(38SZRD<YG X7E5WA2
M@[>WZ:ZMC^/%C33CR\6=<)N7\9MWDI,0O68.V+?P E,C.3):9ZE"*S;1& ;_
MCMV=/F8 E0/.S'#[SJ4+P<\J+'VLZ^FL+E1<2N?:N N]I6V.(]:9\!(I@3'*
M9+HO(H, 1G@:<?#*2MKB&,HPB.QKFI_M57<OS$. :$9K.G*S2:FM;I!;PG!0
MS* L, %OH\#P7BJ.,N6<I2K28(X^H>X <&DEP;W/SYU>F>HRU%_+>]8>+6&N
MMFH-6^;!@P0(S1"G.B*)@0]I@U[4EO89DUF+I<%A@KN>D="?*(=2&VL$]'%\
M P:^I7^THI.D0#.CL$2&>H.D)PH"*:,1R(!'XTED;0I##*->7KY_U,W,',*T
M?3:3Q8GE68F$V_N\(3,:I;L^UQYW;F@)]^X_#PRB="(<(A%41Y!,(M#W#&DG
MB,?"8B-;J,N#^EFMX;+!< XI\,$ NV#C:WGBX,VOPMICT)M0V;@3F OEH\06
M*4[ O/@(;@=S# 6.N?9,2BZ.MX[WT-CK4ZP' ]CF,@^[H&QS3[FR@I@@(E*1
M@(,4<$ 8@T52D8>,R$BC;E&4A?W84.M<M@<)+H'P37IY&^!V["KWQ%/L8@#W
MAX'[0[E!X!!)1'GFJ"&4!MOBCHYA]A$.8%=[DNV!XY+[5)TV<<F*3G(7L,^L
M9,B 7D?6:8LR'=*I2:P5"1SB]A:E%(8)=E]^7-+-S R(T8?S<)MA^/!<'DB&
M72 AU6E3**@0D%(6(Y8%Y8%3XMN<&CMHG-!Z^IZCI)7@A@+"Q96IPELSVYZ\
M3A7[UI6>VMP@C]AJKZA %GX!OJ)'W,.?FFINE-!*Z:-?'!D(&IU)<"B,+)>P
M@M]'H5FQLEV:Y\&&2+DRR!M*D&291]I3A9CGZ:P4AG>F1<K%05=LN\9/3_(<
M"DUSSS%%%W,%"5);IOPLOBOJ61)CNN*B"M?%]'H#N/;H+7?P)HD(BEA;"1&R
MS%)*),>(4(A@M I*B!;+7?R@@6#78!M&OD-A[Q=3C)-!/AO/8XQ'"RA-5K::
M=9!# "RYT0%E L0.LJ!(IU/"-@8<)<52M4&8^*$0UIM(AU-H3P./YT6S-VJP
M[<USK&UF.3$H"I.*:HN O"1I>4_&&+FD"K<PC_*' E1/ CTF.#VNP=X27(\[
MR[43$OMHD6<0I@A"-1*&10B0%==:2$Y<B\I\V;\=U%J+]W# 6Y1R?[<H@[&R
MI/M.X&O28>ZCLU[&#"D6#<+8460]*'[IA$MWX?A6H:3ZP0'8DXCWSO-Y3N&3
M@K>/CS"NS?K9M9_<&R(\ 0\A,/ 5+$Y;$A9D.R^NG'%&9(O%*OU#P&@HR1[>
M=BX.Q.UE*A=M\TQ3(J4%EH4D2(@0(:2)'CFCK  GE!O6IJH%_I$6*?J0YD%1
M].00W:Y >M(<8N0,8F30NT8K@PQH7405HT@1:KUP$.WX-LGV/]1:>D\"/1R<
M-AZTVPE9&WO*531$"P5$^50[D\ET] O,/+>>1I@(T2ZOZX=:E>]?MGN[4*N+
M/&S(D%[;()<9SAP+Z5X![!'/,HP,EVYANFGR_5KL%9,?8IV]<Q$>3M',?/X'
M5O8T7VM[R7WF U6*H1@,1S)D#E&G0,8Q!&T,XZS5=:X'S7#I7\%T*=>#G:I]
M=))UN=[N<F;!\"=:GU?^;5"">4.K7(#\F: 8$0=!#S::(*P)11GV$AP-HJAL
ME,OUGWR.CC.'NIJS%YK T:30]7G:L(.YF4RJPDXG*?SZ6LY/P&_ 2LN><Q&P
ML]B#9:3"(9-N^9,T*N2LQI$10Z1I@:Z!SLOTA*[A97MH//XV!JLW*OX5_/\M
M1RDM;VG?[SZS\Z0J:OCJ'?PYOIRG]350VWT-F0=XQ[T2 F;8<91Y#9,K4H$N
MJ@/C/&*FCUX_#HJTAB@_P,0<&OZ)NR_!C4Q=%[%P<RSX_S^=YU:DK.>3L]./
MBU3GL[ATN^7^^&\]9NZ#(5Q:AJ07&*1+!,J<$DAR@@6)A-O88MMYH-,YQ_@&
M'&)JCC-$.*)"/(M0K!P?+FXYK!_?V[+$@M"$ZWF5_"GH] =QOPVQK!9O!F [
MU)^+<0EXO_TXGH0JU"FY['$O\YKMG\/D*B7^WZ6H;5G6&(H*"-^)Y#I8)#*I
MD6;,HTPKBJBAQAL=#&USN>%@:_O[(NSYPL<12WXPQ^!NG:?1^[WBZ5QYBXE/
MZ\PP&TA0%E&Z/Q@I8[GQGAM*VZS=#H*JH\7"NKK*K>0_%+:^A)LPGFY<U;U[
M).=4 /=,HT@T1X9F&O',..0]UBXJK:,]_IBF[>P\N_II;^$,KCX6"3V-E,?=
ML[F0"F?.!8B7* ,_-G@8(GH4,-718"]#=ORG[+N>]2[$--P;7@<8*QV#? =@
M'96SI.@%X1M?^PWM\A"I<3HHA+&,R'*9(<84Z$JC7 B.VQ".OH!VRUE\?A]W
MI_(:[&!#&(,81ND4D+\NQD4]24*Y"=L1LJ5E+A27Z3PU"B[E2*<+SY0V'E&O
M+'4AD[2C ATO!B/=2^Q01Z_N7*J-8=/J)GDZSF^43_DVX&+Y: SRRD-LH VU
MRG$7<(O:!L/@XJ5XHQU.PJ#KH+^6X_*QT=ZNCS8WS#/#C,X81E13,/@:!\3A
ME4HW 5M.1$:%//IB!R\%=IU/Q8"),'/!+4A]"QH[;KPR=TV+7$KIC([ HXH$
M[ 1)549 JS-)*4V7A\HVMP0,5YZJTZ6<+L1T%(O1SV^!/.P"]'-ZAEP=OPG5
MN;D,O8[R+M2N*K[-CPZ_G=;%.*S-$NIQQ(=[YC^.0=->+\[23TPQZI>:19W5
M-"ZXC=-'B]:##;@XP)UP.+,D[^M)<9VP^,$4U>R:X[/XV51_A-D^V,/>T]O;
MNY38J1DMBA_>;I;: !<(/2D3E8I#+6TB+[/ZUM3%IG637;O*::8Y-M8A["Q'
MP< /%4 +^L@-=]@F,WBX?9?-!;0>BE>F_.9B?#8._P]"WT=<[B"KW3O/J53:
M$N61PTJAJ#U&2C"6;J9R,L,L,'?T]PWT"YFG5SD=0N9#^6Q-F3N)X $#;U^O
MJG)Z>?4! N_$9MTU<!N-DP>GB4B7WE@L7:I"!^YONE*+Q.@Y(Y8$?O0EYX\2
MPWV)_]C@? %AU2C<&U.PPAU@]WFGN<.>,FX(PLQ",$@Q14%+@12\^)B)Z#!O
MM(QW1*;JWEOIVDS==YQ[E6$E9)R7T74,U*5A@"\(=KR@@A)ICOX>\Z% TX6Q
M:B/Y8WNSUVFP+F&[=8Q<&FH$<0H9E2Y^BQ"4<^\(\C0$"[)DY/B7:8\<P7U,
MPA#+(ZM"PXLT)=7M_%*ZM,.Q5@9O;R^*R_$L>3$M2]^M.)Z"U"_+ZC]AX8L)
M"Y^PX]ST>CJK6/-+5=;U0ZIVRM&>KTMOSD;NI/]<1VNB=A9QJ2)B5A.D7:0(
M8A<J">C_C'5S)46?"Z\']:R'DONA[&Y3_M*B=Y^X?=1_;B@S5NET(IP'F#SX
MC1C%D60Q6HX#UVWVI_X- L*AQ'X<[F*C2WZ:=I$'(:GCRB(6M$;4B6PN"L>L
M(EA(*U0+9V^8S=$C6HUH)=E#>7!?$SO#[RD\?C'/R[K8OJ4R1.7J1^!Y,MNK
M:=[P(N[376X]AYZP03(&F9* %')1*PA&'->,X\RZ1I[,(22TR$THIVOF]U.H
MZZ]79DSH9WCR:I,2ZW:@//,TZG3O/(/("H$.L(AD 3@TR@:705A%6BR\#K,R
MTS^<GE4./_ <#&5TVS%ZQ^!9]:D<7X:J-U0_'2B'*8V!1IO2$A4X+\JCS-&(
MK,-22(*-ET=_B\(+0W4'<W <J%[-WI(#O>7(40>]YYQG5/.@4.3!(@J>-Q+$
M""1Q-,!35(XWPN\Q:H6GZJ\KR;8<%V0.+FAF<<H!!2=8&8R"] *IC"DM1+2>
MMJG!=+0ZHQ7V>C6,[6?H.#3*KJISJ#=BR[AY%!CL20S@B#B/C 4[XC0UR#/"
M%*4XTZ[%L9;CM:+'\T9T/T-#A-._5*;O=+SY$$-D&BXEC_<ZSN.JW3T.\=:,
MS-B%BZN0TID;9FVVJ;9Y,O;SE8[PJ ;DJ@*MS1KF%FLJI%0PJE>(8YHNG1 !
M614R8K7VS#6Z@;;G(Z:/J3Z=5ML*A6ULF%M-(%"$\91P%$4-KC6C B,J#;?$
M,GC7C_;<>A\3N^X8:E?2:U]G=AV?OY9CMQ8-NW:19\H)08A#&=@G9!P6H/]3
M+F(26CK01+-XK&:Z1UP,(,?!#ZWO */&;7-/5-3@*2#)N4<Z: H_E$:4N.@)
M(^#['&UR5K^3W$S#M!+E4!#:70\U;)DS27U&/4,B:(Z"-1:IJ"3*A,?2*9>%
MP%^V^ND(/MT+LG,+]>3"DEVMTY/FN8O<\D@Y4@1S9 7AB*E,+M0V"\$<<LOF
M\>N\G?5&[7+O(O,1>WCG1:IM'F$"B?!(,:.MT_!M/-H-E?XF=Z,F;2_"0VC1
MYH#9)$6I:28=.#76@0"%=A@\&Z:0L#%3T6F?M;E(X(#:LTNX="O (99 YJ'V
M$.L3\Y%F/U,NQY8Q][ 5R\)?<R9HY7.Y8E(&IP@RA&*P8BR Y^[TG:U4\'8W
M\BL'?Y4;WL?=L(<\2.NX] 3%X#(D+4L)U!D(P_A,2*5EUN8>O@$L0KN9;?XN
MMY3:(8S 71V)[?4X-K3*#3<JI,1Z&H)$AD:&O)(612RLUPI8-2WJ7 Y@!'I#
M2'M)#:?M/Q?CXGIZ/?OCW-S.TKD.G;BU,N:X)V[CV9EM37.A!!$0F(!SYF"B
MO<E0-"R5:]+:" (!BSG@)O5&\K^$:U/ %%1G\4-1P\2G@R;[RF)E9[F0E/#9
M D F()#+ @6_)"ID1"1!B<S)T&)5;ICMY&XAT"0<[EJF!UU>69)4(O_KGV6+
MUVW10ZXQ5]'S#!'F'+"?ZE5EWJ.@O&!195;K;BKI_)"X:B7(HP(3#-A&>]_W
MD3N>@B2AD=<0:(?@(.1FZ386(H)GP7HO6MQ-,$RR^^$!M:<HCPE2'\KIWC9P
MJ8N<*^,R'Q/O254K"P+/6$261DXD_!:S%FDCP]QE=W! [2G)H\)3<=-60Z4N
M<D>)DSI2Y!C52!-+4:3<(.V#-<%C*F0+/(E_$SSM)\ECP=/L;'@'H'K43ZZP
M\0HS PZD98BF$K8&Y(Q %I+S(##Q+=;JY8^/K+;B' I>*;,TA#7[M\W"X:9=
MY,11YXF(2!J= 2WPFR54(N*QP9G $O3XX<+B1FSL&A[OWVDR<=9%$%3&LI1;
M21U21CGD,BZ8]MC29F?\#QDF]P.-\H R/K;W<GOXO&-/N;:88PL*,7+F0##"
M(RQBAF2F(R/:4VL;I1 >,HP^'MRU$NQ1@FU+>+US7SF-.(!%Y(C'M"*.M48A
M@IED#AO+P??BOD4ACF'"[.,#W)ZB/4;(;0F_=^TJ)\%G@D#(**).HI$1<1*2
M:%3&'$0!UK1P;H<)PX\.<'M*]BCQMCF2VK6K'%P*'RB)R!CO$#.@\Y73$GG!
M7>3IU$R;D^3#A.G'A[?])'ML>&L:ON_57VXY(0'"640--H@):5& %Q19CZ6:
MF8!FB2:'#../"GEMQ3O<GOL 55I^#9/9D;Q075R9JM^R_D_&2H5Y7+I"JQA-
M)\$_^?;Q)<NGY?5U.5Z^^6"([+,G)"T1D>Y=N#&CA*CWW]UH"F/.;FEY&.HL
MKN;K '0/ */9.,/=D?%\N"'$.IMY0&VJ*W6=,G8>Y= -..2OIII?)G8XKL]F
M=V74)P[(.*CXOX0:%(6;S#Z]>SU!JRS]]=NXF!P!I:L_7>1^'8ZL(;3#RH%_
MG_D=P9_<@,6^3$F2T^LYJGZ#)[^6=Q>.+-TWLD#=['QT\(/(;&KK\,]INM[Q
MIO=K6)X.-@R#BUJ^LSIY9_&\"C6,/?<3Q_Y+</#7B7/E-!WFO[R8F+$WE3].
MHA*\RO'\FJ2E:@*S*\K2=V T 'V@..?GWH]9ON]C#&X";/AR<2W12>TDEF?C
ME1=$W5?;>[@IZIBY.P>Z7=&WVMF3./BB!%F.BH4CEZI<IW]+3M^L^;WA@>\.
MG0J[@L;'!#ZC>.G)#3%KJWYS2EPJ(8*1I$$A9BE&./,$<2VD%EAP[QJ=_^E/
M9LE3>#*UDU-PKVX!$-OJ[S=JGQ,?,H6=0UKB#'EC&,(VW23+G%(F:)[)HZ^\
M-" *RF%D/-0:TF.I;*^2L?+Y7)*H&=$&26-2X6(:4<P\1I$3A;72$A@\]OV\
MPV&H*YD>!C.-CK&O:Y([%3WU2B"318^\LA'1+&8H6A:B,-&Y-B<PA]F8.Q;D
MM!+K$*N&^SH\6T/ !<GIAX4P[N]_^5]02P,$%     @ >H"G4-,_: )19@
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M^'QB!53.<>@0H-!I@#AVY9R4\ .M6M=<1-_+NC5P7H?@![7E#T3>K9DYGKJ
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M&($,6\R%XU90BLH1*TDJU:4]1X6',UE!6T6S7?GOM=L<:Y(0"(B'V"(OA*<
M,"+X9M0N:)5RF ;%MD1Q5+*-4+H4&0_*W#8TT7:KU^X<62U=]T!/B5&*24N
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M&51$68F)(9)Y55XI<4L'&&[7XKU8MV#U9F.(U^?S)_?GA^P*+Y]-+#;>V6B
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MCGE, <($8V6CFPT6$"NDI$*5JHI<:@A/T#V=T SH\&UP 2D RFSF+HV!]<T
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M]#N&K,OXINM%NEAA\/<LORW2A[M5\/7^*,:]SR>:4J*,9D'G-0( 2YPKD9-
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M[BPZ\!/[Q$^;XI;Q_:'8EM7J4Y-OF_?Y=;%N873?]F5;W)S^BO5V^^ ;&$.
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MT]'+T>C'X2,?\A_L5_!;OEU==9=9U%>[IF[R-G)L;C]6ZW56;=E?+D 4TR0
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M.#](*(V%WGB=UI+N'9;%3='.D%9RXCF11#Z9-,>?F"">T\ ]-L.7!%VBZ8+
MJ:'7#BE39,OC*W@4,L0K3^R%>J:#[+J>!, P"'V""<T\$K1-T R!$+N>%R1I
MP/4.C<SW:I:> 8K4M6="]/#)C"YFQ$2%DQ0M"G+$P 6]D.')#G600EY-[R52
M(W^XW16A)$9Q&+B$>FF $S>@T=B&2R.N:^#EOMG4Z)>Z1DN0)"$%T,"/I ;,
M<HW6 Q:>UP%!MJQ2 E'LI[5 B@%>-?CT)=\6[&:9%:[N[HM-W94KN_V_G[?Y
M9OFEN-H4PX&TQ$VBD! /1 #["$(7!<F ( P(%<H35+:KN_C3XW%:0&(BHI1;
M/HF9BU8Q >I0OF77F*V<#_F/_KG.;8OOMF _OW&.*)_ILF@!(B]HF YWV*%P
M6BRK]'=FU>KX^5LU7G-(,@CCE!(088 "M\W<1GT.(8ZX#BKH:->0.K: 5*NC
M +>JU%$/K9K4L05KK3KNB9RDCN+N>"GJ*&&9L#K*LL>U'65X):0#T#4Z7J>5
M@LB+L)>U\U8_06Z(XL ;VHK<#/!O7)1N0;/B#;C>=L#Z<XU2]^'),WA9[<R1
M)ZAKL_,FL&?$"']R6T3D>.3;$'+.['/[/R;39,%VC^DV5"H[CEB&2N_NU]6/
MHOC45,O?^VWKX_6P:8PH],,D ^VWMZS0=-3\* M]H0ORY5O1K,6")S#49#]G
MV;B0ZTQGT([,1H$=E>J^-6'$#"W%T$,P2WWB^EY*DSA%-!Q;0A1QW7 \Y?LU
MCQ+ZZ<,'L<F9%$E\DS#=_(@E)2,:IX,STW3J!"6\4B)(H(4B(FK!)?F08H/[
M_9FVX_R2W_5OKK83*9C$)(@R@F+?)1'R\=!$'">9D&((?;%FJ6!8' 9&:ME<
MC"(^O=#&CIA0<!.CY^V9(Q(N2(,45W9H@ASTQP_/R-LOJ@+#JAP@7AQF&. X
M2!*"",9DWPB-(-<-8Y)?;4X)Y%ZB$B1*3 TT<"2M!_.\1O6 " Y-$&3,+E40
M!7]&%Z0XX"N''F8O<+-ZUQJW:<JO!6NX=6"Z?U+5QVT*$@0P<RF)TB1#X5Z2
M4H]KMXW"YG072KN4ND?IM#"=/4ZG&ST,J4C=3PW%/,53X^P*5E(YB)6JK*IA
M6*3,:IQIR9JK$L8Y:[ \G)PMR"HEU(;JK%J#*FV=3SI8=(< AT;C<3L#]2+J
M@39IA<0'&4E0!,=&HP3)!@J9IDP&B;P=6?T3\>.HBJ7E2XI6X>"@F]&)@>$1
MF=.#@A2KT@%!-[N*@H$PRS*!X 07?$%@"HG6!8!)QIP7_^D<<0G_@V+EA[9[
M?<GKQ_$&^!C2+"-!2MFS9$$2!.G8K!<@P"W]*AK3O3#QH/HN($I*B.00>],<
M3EJ\&/%-FP0HH59 \4U3+*?Y"JCF$WT..L[)ODHF+1!^I>94FGJ<DOW$A\V=
MZ,?A(\/>SVX3R7A!8?>W-=PU7ZIM^<]BM4AA"MO928((3E(O\+(@&,^()1!X
MH8)=QQK1:0XO<'B-I' V^PMJZPZCD^]!=A<-EG6]R]LNZ?RQW P?^9.2[<PZ
M7<M7,;?;JX+SFZ.MT<?6'.^/=JY_.">W4#.;]M>XMCVAM\LY&&;%'FIYOUQ8
M YBO#]BQC#"C_7R[MHUY@J\^Q0GR^C%(N-GL\O6'8LM*:?EM<74#5ZN2_>-\
M_00X)2E(8Q@@FF0$$.HB0$;@<1!RA2Z+X.J.91U6YWX/EDE8OH?[-*Z)E'BL
M()"K^&8%4MT!#ET.<.AB@!LZRL%4=F7YP5B!L&=M1Q&I)UJ!V$!-TJ:.PUG>
M-.&:LR52J_J%!;-MRPBIK!W#AF;\W7^&&R!:"\IJY;&ER(@FD9NY((MQ$GL
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MH">KP(JYXM4T4M;+=57OMOWC;_O; S[V=Y-U:=R3F^WJS\7W!K74_+[P(X]
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M2U ,"4RR: @B41M98K&I[82&M,]O#]B<<N/<#^A$)[93J.2=W1IB472*^Y#
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M-M[E.04,*KG<>>'"!"<ACMW80VU@;/]_3,<V_=A+U*S1\;=GV2*=^=M^!1-
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M8J-?V_]\SJ_7;5Q)O2A+DCA+O<"G-,. 8 HQ#2!-0>")'2B0:4#S].N R>E
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M._Y4!;-[9%\&\F. \;&\7U:;&WEC6E%M5\OU?Y7+9A'E/O=Y1GG.$.8%C:*
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M\,HK<S.O5UT=]IE7'.@W^+*Q_/M#N=F>2$DNQBEAG"!">1X5-$EH$?3V4!K
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M>-=7C^1[M5U$),$$4YHRWT^HG_N\G[>6+R#EH!X")G8<5V3/KN<8P'E_2GC
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M1>S! 671B$5%#1R+0.#P=.#NB&MHE4O6Z_JO=K%+MA%D37E3[3S9OV0J!;S
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M:G?']MM=?5\V@_$?A\8,<9)3EF&?$E;0-.0H9(/I*(I!O?JL&'3\3O'RMA1
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MNF32YX3SC!1Q& >L8#2FPU;;/,HBK-2HQ(HAQU(NX9EKN3&;"F(^)I$P-;_
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MH!E7SL[(N"%8^L3-0Y(,\->V7B%%63F3L@7._3B&.<D2<?MB@$.0Q8.A$(5
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M?#V533=(O=,F>N(.D-.!_%"O^5LJ>73<><#D]'$.L5*3S@&QV) ;,(NV\EV
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M6-ITZ.S3=LM<:>S[+Y?-OER]JXK/U;K=T'GQX8&/ <TACBF-<A($7&?S? #
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MP?^A_%*)-<_-[M?BL5Q GX9Y'N ,16E.":!\EM.;0=P^4Q, Q8>/(P)'4)Y
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MA0%*M=>8&;CA*T-)3O(>WL/U(.+[_$+L:G&L9UBGZ--#NPQ+P:RC7"L+PO%
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M8ODB47/SP#+(V854QFQ"T,_WF,:8>LYX73V8%8$A,6E?S#MUP)RL-4 F# 0
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M(RP!U\H((Q42T"NK*IJLE)<4>M06JAKD[\F8V3X'OYC$O,C[P5*C:P8)=\!
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MXNYN,/UV=?.QG _&,=ZC'"^KK([>Y?,UM<L:5UL23I33V:7FE'92&&J(UY)
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M4B-^H.X0&=7( .ZU ,IZ$;9(P"J#6<&P?UZ64==J($I+/#\#ZNK'J>SNE*G
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M=X,#!G'(**"<1+E99Q*^ZS%K[T3.J>(@SZ/;6:.:QKE;;KT*Q2MFQ=^C:1K
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MT<9)E =H1HS54Q?V;$%O/A>@)TA0B@1&0"H)@$"RZE_Z3:=WDUWG]3A5X$U
MV-7:\*_1?)(\A.IH)3\]&P26)IK56#G&K(P$-M158Z)YE5$&>;78R#J0"V-7
MU'AU.3'ZL>^*\? +@<0-44D(H_FDHRD5AUEMBA (*7,TCOJWBW)#DEFJ-Y+B
M&"^$*XU VJ>>L>WRS:Q.?9QZ#824(90Y@HF,OR(FXJYIJ]%;@'+\1>M?/UXH
MH5J!^&Q]Y)4NO?A4W*[&$<V'>;FZ?UAW\D-Y.[F;C->"6JC9[:?XPU0?ZJ"_
M0VZ[@5(@XBI,4+03#3140%GI8Y!"DD.Q05Y YNL['4/>U9KV:E@W7Y>CR2P=
MZ+E_Q@\I(O8GU^HZ"UU&JR%J"DI3[[RS.H+#(+8[G"S(BMH8Y-5F(\M>=X#W
ML=E^G$]FX\FWT;2&DG;PO> QM- S3PB@1'&MH:Z,% BPS<K<=/)=Y<6PJTE,
MNSSO_S"9I6+H+W3+2SWYY\HA3#AC@E ->,H\L<F="HV7HMZ15!=V5+6N3(K%
M#O)5G5I[IS03+)>:<$2, ]19KPA%=H-&U-Y,5K6"X=\6U*9"K=S@C2 \"(^7
M:AB; L"WR9''3Q;CT?3_%:.W8I#S&PW$17/!2FV=@<)Z30@R6@H@D(LV+,]Q
MY!L@#]LAT"E>,$U*8U"<C<BE(7SYN\PEZE-+ 3I!A;-,,RJT-TA6^;:C"*"C
M.=FJ!W@7-AQVGBV"05(R?OAX<N83V@K2&8FM!%0JSZP1/&YG%2::H)RK_@'>
MK@V/EF<(88C$].4J>U=_UE0P!EL-:2K9"+A7QD2S9HL(Q!#G7/8,,#YQ<+0\
M0P:#9.7D>U.K96HJ$.(I$X K*#$6DB'@T0X1H*XL%]_P6'FZ#(;&2G47Y=8@
M-5^T%Z"@E*0TN9I)9!$'#( *&PUYCB4^P-C*0?$S1Q!#(VD#O S"2@ZT(8)(
MYJFRQM)*I8&&9UW$#[!XTZ"H>"+V@V!?9P%2%$B.F3!)@5&,2X&8K+ !V.=<
M.M2_;.WZ/K]_>C8DCW[<D>K<LNZ[T -Q!A+A&(16"X04DT3OQI>7:&6 -ZB=
M$*T9J/L,OCOY/J9^(X$1")E1&'E-A:;6.\JV*"!@^)6=,S9T&],:OKV&>)Y[
M!W-Z8X$8+#EB2 CF4W"9Q="O3_LQ1#X::]=U]](&7>J$?38I@T$PL]9-2\T6
M F'86@8X$2E!  ."Q@U@"[4#^,I6OKXY>#;P@R+>D?N4VFV$:-9[8CSR@CN1
MJL.;".P6 T9L3K3[ .]1AD*^,Z ?$OV.W)K4;2) JRBV1@F,(536*D&J"8BE
M$3F'+0.\+1D(^<Y ?E#<.WP 7;>)P+%".JH;PCK(E!.,J^H\'@/"<\I$#/!.
M9"C<.QWYH7"O[@W(2>T$QQ2E'C@/HM[KN7"25$>>F'N54U]M@#<? V!A#OQ#
MH6(&^P)PABK.33JPU$H2QFEU>"6,YCD."@.\WQ@ X4Y$_+IS:PDL(#6&F6CR
M(V2]<:CR9!/*Z6YR5G9]B]$7"1N20J^,/)5YR7U78J^EUD@!Q)%*P22;L4D.
M>(Y),<![B[ZH=2+,7<;KK(L575YH#M0FVF&*2<RX1)   -4:4(0H%?62L=8,
M*-[$GJXKBNX8L[D$76/W):*E8U/_?J/S)[T?=[Y($QIW/ P\8!H*KWPU)B7U
ME=1DS!5HV3ZTW;E*;+-U'"72D3>"3*5R@=9,R;B@4,>9J]!C7L,<C[ !GHEG
M4J=9,'O=[S^,4FGCY8_:!#JAE8"Q5"BJ/31=M4/&F"*VP@'!K 1- SSK;HA4
M[0$\" >NDPEW1FL!0B*!D2"* $BIG+($5+@H:G)RQ0[PG+NQU:QMH+M12_\L
MEN_+Q>)C,?_\$/'K33-UH_DLXKCK2 T===\KP7L!!5> "@<(CU8C940+2>(?
M &3UBN%T,\HZ4WKO.P%XQZ 32C+(K45*4".J<4J8519J@!ILOKC+=H#M9:+J
MT6(RCJJXG4Q3>NI7?ZN6R_GDZVJY7G]*4SX^EK//RSBTAW(:6^X]1423LYU@
MB 0'F$G"C;+&(P&TT/%?2!41M4H9M3/**)1WLRC (HEF5\GU+7ELI'D<A#-;
M#-9KH2Q#A"B'G6$J77)M,&( 9>F6)Z\47=2OR"=+V0?P7>F<+T93EVY!1)4%
M.<X%!,)1Q8 #KAH+@OC*BCRW+O%###L1ZZYX\WI:O=J$;I8/Q=Q.%N-IN5C-
M:YTSGMEBD!YK +WFFB/#L=*<\PH?Z/V5G< TOIQU WM7M/R?(N6&*VY5W%I&
M][L25^N1W:R6B^5H=AM'^VJ0!UAY7H/!8R.1-QPQ$:>_]LRQ2AJ,()=5F^<2
M=MG&653V():!K*7GKYF!&B,58C3N/(I"QGTT9[;CY1!D93X=X$%BUVOCB?#V
M8AP^TU'<?U:3[Z-INF]U_XRGJVC?^8BA&4W'J^GZ4S=W;]N0UV0C(N^  5)*
M@@".=KW5QFT,>KH^BNO/1OP\?BAN5]/BYD[-EI/;)(G)]^)S,4X'B)/BI=#*
M5(MJ*[2?3B^2>GH FV8_%* &AC /,?/$:<*%=K9"E'B8XQHX0&,@GUCE@*31
MU1:7.33]X^T&U#^30T9KBU\-0#"7JNQR2X$2T;KC$E<X.Y650&F K.^+I.50
M!=KOQ/ES]%C8,L4HGLS^IU<#Y513IY-/N])&,TJ4WHX8*6=R7- &2.%!<*<6
MG\\646<&R^.W:?FC*-9JY<VZP.:'(EE@AQ2R?>\$2H6R EHJ#>5.&TJTJL9H
MD,X)<!FDK=R<T%^;*PU!W!6-/A51=9J,H[VQ[O%1"KWY?  ,048E$( )["PB
M&)EJ;(+4JQ)Z.>=_K9&G"7![(LY?L\ER\>GS7Z<2Z.5[01ON@"8$. @ED1Y2
M72&'%3,Y&MT #TNZ(E(6R!=BGKROJDNW9XOL/A$D5 0J[X'!C!@KA8:D0E!B
ME),)9(#KW748'N=*[T+X?S3XJI'VH_ (@I"2B!NS&CHG=B<LV&F?DW_D^NR5
M,RC7+.?/$EHO9^0]1^(T>;H=]U8ML1,X;==8$$;%UET-J+B;US+IVS[=/G*K
M4MO!^<P6@S%,,*LD\%YXSKSC&%<8 9EE, QP&<FGRM[SZC9A[VKG:TZ_.(FQ
M37TL:(N XY(#QYP@46Z>F I5)$2.T3) ;;!%,O<DD6XVO'47MSYJZ1KX*5ZY
M^]UN_?DZ>]R+!X-D'"F)H*4170&TE0QN8,7<6%KKEK&E)>29 ^"FTW^6R^+)
MVZ76RE"WC0 0$Y!Y(#53S+-HO@!7X0"LOS[/HC-I\'JBMP1P7_.W=Y>,,Z<Q
M<(*A%'4G5/PUF2)0:DD,@,AYC6HI7RU-X]771=P!1O,?-_--IS\4RX?R]MWL
M>[%8%L7G4=HFUCS2/WY^N'KLJ/-%@Y\)D@I)N=& Q)T/:F0D0A6:TII.KTXZ
MV/W/I-+KI: _"72FU>YZ_6PP1YPE]KX3#%0^N;D!8;%E B@N835&P]65>?OW
M0X^]',T31F>$>^IEND*XN?LR'\T6<99&<1]U5#C^<N"880$,HDAR 8WT!I'M
MJ#UW_LHR=#0@_==\:AKBKHCU[N/-T6N]W3/!$\P41%&#4PP#"J*>J*HQ*&^N
MC28-"K5L!M+CM-B3Z^?CZNMT,MXLH3=W$>9H7.\5_)$W@K62&F2!5,J3.&XE
M!*OZS!S+L9$&>"C2 @V:!;BKM>(FVJ-J.BV7*:=83;>DO>\$K;&#C'A#(UJ1
M],X:LQLCRCHF'J [0(MK25,0=Z;+1'D5J:]F.EHL:BK/^]X)3A#L.5%QLE "
MB? 2[=9/R6%.9H8AKD6#4)X;$D97A'O>S:/*\L\/!RN(0""NPI@S$&<G]L1O
M1H6!]ZS3D/X.*)8OW;)A2#LCRE,PU]&-[:=G@Y206@P!CE.'&$>D Z(:$X'7
MYNZ=(]37_,B$LM=3G_<U?-,.OQBBFB>TL4QB0V4*<>08[$9+2<XIXQ UH4%L
M84U*I(?E:7UAL5"K"-Q\\M^#,<P'W@J*8H4@T0XB*PP50O+=C"4Z*PWW )>L
MIH2^?_G*!+@K(GTI'K^5\XC#9DJ=0*8C;P8EH8K+/Y00.,@U\\JX[7BATO3*
M@@5:(E2S(/>P.GT<S6_F:SWR]E^CZ:IXG?+P\"JU[^U %'&86FU9<FS7SBA=
M328H(+ZR$F7MKU8- =T5P3Y6 CIU!SS\8I"IVJYGD"OK(Z &6EXA";4!+(-6
M)R=E[<+CHR5B-8IR/YPZ8]VJUT!@'C-'N;=,>X%2P2NZFU$.LIS$OP,L,M8)
MPQK"NH\;W.?9E!;O%HM5$:V?9P?"->]RCS43,$!:0:,YQ9I;9 GAJ$("6I'C
M6## HF(ML:Y%Q'O@WL?Y9%QG7=OW2B#6.2R\9(Q0J; A$./M")%$+.<*^/2Z
M85? J1QT>^"/*6<1D'4J]G+VJ1@7D^_%[<WIB]?Q=@) B&.MO=?,K7U0F:O
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M"VHXW_EY2.EPEL?=[[O:X4AN\(<N.S^DE-'Y1>JW[6%K&Z<P1S\:#%-68"8
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M7I[O#7,5.+&/05E$HS'F4B';E,7*L53"=B-#X$!.3IAK"M+]9=: =OES^6O
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MH8JI.*TU(5)H1#8[!Z+&VIQ==H"Q__WLLEU+J2MFOYTQ)>79GBT.G98>?"\
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M=F5L;W!M96YT<&EP96QI;F4N:G!G4$L! A0#%     @ >H"G4#E^(O<F"
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M;F%L;V=O83 T+FIP9U!+ 0(4 Q0    ( 'J IU EW?64XQ<  ,P/ 0 1
M          "  2SG!P!M<FYA+3(P,C P,S,Q+GAS9%!+ 0(4 Q0    ( 'J
MIU HB(]!C"$  (MH 0 5              "  3[_!P!M<FYA+3(P,C P,S,Q
M7V-A;"YX;6Q02P$"% ,4    " !Z@*=0TS]H E%F  ! $P4 %0
M    @ ']( @ ;7)N82TR,#(P,#,S,5]D968N>&UL4$L! A0#%     @ >H"G
M4$.0O0$L[   S3(- !4              ( !@8<( &UR;F$M,C R,# S,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( 'J IU">4>M:5YP  ,L-"  5
M  "  >!S"0!M<FYA+3(P,C P,S,Q7W!R92YX;6Q02P4&      P #  = P
&:A *

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6632855456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 12,410<span></span>
</td>
<td class="nump">$ 8,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_TenantIncentivesReceivablesCurrent', window );">Tenant incentives receivables</a></td>
<td class="nump">3,198<span></span>
</td>
<td class="nump">4,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable on marketable securities</a></td>
<td class="nump">8,295<span></span>
</td>
<td class="nump">6,835<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 23,903<span></span>
</td>
<td class="nump">$ 19,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_TenantIncentivesReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Incentives Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_TenantIncentivesReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6830010144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grants (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>contract_option</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,601,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,528,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Initial base award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Contract options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsNumberOfContractOptionsExercised', window );">Number of contract options exercised | contract_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsNumberOfContractOptions', window );">Number of contract options | contract_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember', window );">The Bill &amp; Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember', window );">The Bill &amp; Melinda Gates Foundation | Initial project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember', window );">The Bill &amp; Melinda Gates Foundation | Follow-on project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember', window );">The Bill &amp; Melinda Gates Foundation | Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember', window );">DARPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="nump">19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsCurrentFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Current Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsCurrentFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsNumberOfContractOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Number Of Contract Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsNumberOfContractOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsNumberOfContractOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Number Of Contract Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsNumberOfContractOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsRemainingFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Remaining Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsRemainingFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialBaseAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialBaseAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_FollowOnProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_FollowOnProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6635949296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (124,230)<span></span>
</td>
<td colspan="2" class="num">$ (132,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used in net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">353,105,021<span></span>
</td>
<td colspan="2" class="nump">328,809,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (usd per share)</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td colspan="2" class="num">$ (0.40)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763187680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Strategic Collaborations (Details) - PCV Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Budgeted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Budgeted amount</a></td>
<td class="nump">$ 243.0<span></span>
</td>
<td class="nump">$ 243.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645089840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">45,536,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,585,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(3,188,671)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(944,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">44,988,598<span></span>
</td>
<td class="nump">45,536,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">$ 13.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">25.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">8.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (usd per share)</a></td>
<td class="nump">15.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">15.06<span></span>
</td>
<td class="nump">$ 13.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">7.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">13.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (usd per share)</a></td>
<td class="nump">4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue', window );">Cancelled/forfeited (usd per share)</a></td>
<td class="nump">9.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="nump">$ 7.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Outstanding and Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable (in shares)</a></td>
<td class="nump">22,078,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Exercisable (usd per share)</a></td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)</a></td>
<td class="nump">$ 5.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 669,827<span></span>
</td>
<td class="nump">$ 286,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 417,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options (in shares)</a></td>
<td class="nump">22,910,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share (usd per share)</a></td>
<td class="nump">$ 18.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value per Share</a></td>
<td class="nump">$ 10.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 252,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>281</ContextCount>
  <ElementCount>394</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>112</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Grants</Role>
      <ShortName>Grants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2137100 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2138100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/CollaborationAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/FinancialInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/BalanceSheetComponents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2337301 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/NetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails</Role>
      <ShortName>Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails</Role>
      <ShortName>Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Collaboration Agreements - Remaining Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails</Role>
      <ShortName>Collaboration Agreements - Remaining Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails</Role>
      <ShortName>Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Collaboration Agreements - Merck ??? Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails</Role>
      <ShortName>Collaboration Agreements - Merck ??? Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Collaboration Agreements - Vertex ??? 2016 Strategic Alliance in Cystic Fibrosis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails</Role>
      <ShortName>Collaboration Agreements - Vertex ??? 2016 Strategic Alliance in Cystic Fibrosis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403408 - Disclosure - Collaboration Agreements - Timing of Satisfaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails</Role>
      <ShortName>Collaboration Agreements - Timing of Satisfaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantsDetails</Role>
      <ShortName>Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Grants</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails</Role>
      <ShortName>Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails</Role>
      <ShortName>Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Financial Instruments - Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsUnrealizedLossPositionDetails</Role>
      <ShortName>Financial Instruments - Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/LeasesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Leases - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Leases - Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails</Role>
      <ShortName>Commitments and Contingencies - Strategic Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/ShareholdersEquity</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAndPurchaseOrdersDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Stock-Based Compensation - Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2428404 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2428405 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2428406 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2437402 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2437403 - Disclosure - Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2438401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="moderna10-q3312020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - moderna10-q3312020.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - moderna10-q3312020.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="moderna10-q3312020.htm">moderna10-q3312020.htm</File>
    <File>exhibit3113312020.htm</File>
    <File>exhibit3123312020.htm</File>
    <File>exhibit3213312020.htm</File>
    <File>mrna-20200331.xsd</File>
    <File>mrna-20200331_cal.xml</File>
    <File>mrna-20200331_def.xml</File>
    <File>mrna-20200331_lab.xml</File>
    <File>mrna-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>developmentpipeline.jpg</File>
    <File>modernacellmap.jpg</File>
    <File>modernalogoa04.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6829228480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 8,389<span></span>
</td>
<td colspan="2" class="nump">$ 16,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">115,137<span></span>
</td>
<td colspan="2" class="nump">130,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">24,114<span></span>
</td>
<td colspan="2" class="nump">27,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">139,251<span></span>
</td>
<td colspan="2" class="nump">157,666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(130,862)<span></span>
</td>
<td colspan="2" class="num">(141,641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7,852<span></span>
</td>
<td colspan="2" class="nump">10,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1,154)<span></span>
</td>
<td colspan="2" class="num">(1,931)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(124,164)<span></span>
</td>
<td colspan="2" class="num">(132,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">66<span></span>
</td>
<td colspan="2" class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (124,230)<span></span>
</td>
<td colspan="2" class="num">$ (132,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (usd per share)</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td colspan="2" class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used in net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">353,105,021<span></span>
</td>
<td colspan="2" class="nump">328,809,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 3,187<span></span>
</td>
<td colspan="2" class="nump">$ 13,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborativeArrangementWithRelatedPartyMember', window );">Collaboration revenue from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,270<span></span>
</td>
<td colspan="2" class="nump">814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 3,932<span></span>
</td>
<td colspan="2" class="nump">$ 1,910<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborativeArrangementWithRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborativeArrangementWithRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645371392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Plans</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2013, we adopted the 2013 Equity Incentive Plan (the 2013 Incentive Plan) and the 2013 Unit Option and Grant Plan (the 2013 Option Plan), which provided for the grant of incentive units, non-qualified unit options, and restricted and unrestricted unit awards to our employees, officers, directors, advisors, and outside consultants. Historically, we also granted restricted stock to founders, officers, directors, and advisors outside any of the Plans.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2016, we adopted the 2016 Stock Option and Grant Plan (the 2016 Equity Plan), which replaced the 2013 Option Plan and the 2013 Incentive Plan. The 2016 Equity Plan and provided for the grant of incentive stock options, non-qualified stock options, restricted stock, unrestricted stock, and restricted stock units to our employees, officers, directors, consultants, and other key persons.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the IPO, we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Plan. The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. We have initially reserved </span><span style="font-family:inherit;font-size:10pt;"><span>13,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock for the issuance of awards under the 2018 Equity Plan. The 2018 Equity Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by </span><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding number of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year period, with the first </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> of such awards vesting following </span><span style="font-family:inherit;font-size:10pt;"><span>twelve months</span></span><span style="font-family:inherit;font-size:10pt;"> of continued employment or service. The remaining awards vests in </span><span style="font-family:inherit;font-size:10pt;"><span>twelve</span></span><span style="font-family:inherit;font-size:10pt;"> quarterly installments over the following twelve quarters. Stock options granted under the 2016 Equity Plan expire </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a total of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>75.0 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares reserved for future issuance under our Equity Plans, of which </span><span style="font-family:inherit;font-size:10pt;"><span>47.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares were reserved for equity awards previously granted, and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>27.9 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span><span style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(1)</sup></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,536,915</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,585,069</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,188,671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(944,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,988,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.06</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669,827</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,078,150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.0 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417,516</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,910,448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.6 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______</span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> stock options were exercised. The total intrinsic value of options exercised was </span><span style="font-family:inherit;font-size:10pt;"><span>$58.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> March 31, 2020. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$28.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Common Stock Units</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have granted restricted stock unit awards generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our restricted stock unit activity during </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">per Unit</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,177,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,057,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(113,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(58,514</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,062,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Employee Stock Purchase Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, we adopted our 2018 Employee Stock Purchase Plan (ESPP), which became effective on December 5, 2018. The ESPP initially reserves and authorizes the issuance of up to a total of </span><span style="font-family:inherit;font-size:10pt;"><span>810,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock to participating employees. We will make one or more offerings, consisting of one or more purchase periods, each year to our employees to purchase shares under the ESPP. Offerings will usually begin every six months and will continue for </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month periods, referred to as offering periods. The purchase price at which shares are sold under the ESPP will be equal to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the lower of the fair market value of the shares on the first business day of the offering period or the last business day of the purchase period. Employees are generally eligible to participate through payroll deductions of between&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of their compensation and may not purchase more than </span><span style="font-family:inherit;font-size:10pt;"><span>3,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock during each purchase period or&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$25,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;worth of shares of common stock in any calendar year.&#160;We began our first ESPP offering on June 1, 2019. There were </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> shares sold under the ESPP during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation and Stock-Based Compensation Expense</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation for options granted under our Equity Plans is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.14 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.12 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividends</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the components and classification of stock-based compensation expense for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,018</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted common stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,833</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,413</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,036</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,714</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,413</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$243.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to unvested stock-based compensation with respect to options and restricted stock granted. That cost is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>3.19 years</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6618265104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Basis of Presentation and Recent Accounting Standards</a></td>
<td class="text">Summary of Basis of Presentation and Recent Accounting Standards<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2019 Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Accounting Policies</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are consistent with those described in our 2019 Form 10-K, except as noted within the&#160;&#8220;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</span><span style="font-family:inherit;font-size:10pt;">&#8221;&#160;section below.&#160;&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective on December 31, 2019, we lost our emerging growth company (EGC) status which accelerated the requirement of ASC 842 (Lease Accounting) adoption. As a result, we adjusted our previously reported consolidated financial statements effective January 1, 2019 in our 2019 Form 10-K, and amendments to previously filed Forms 10-Q were not required. Accordingly, our prior period condensed consolidated financial statements and information, as presented herein, have been restated to conform to the new standard. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the effects of adopting ASC 842 on our condensed consolidated financial statements for the three months ended March 31, 2019&#160;(in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 842</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Previously reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,253</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(141,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(141,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,820</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,931</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,657</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,576</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Previously reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 842 Adjustment during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As adjusted</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,657</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(132,576</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets, operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(550</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(143,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(144,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charges to financing lease obligation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments on financing lease obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by financing activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss includes net loss and other comprehensive (loss) income for the period. Other comprehensive (loss) income consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized&#160;Gain on Available-for-Sale Debt Securities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income, balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,804</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss, balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,720</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, non-current </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,823</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;statements of cash flows</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403,543</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>514,757</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.</span><span style="font-family:inherit;font-size:10pt;">  This standard changes how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. The amendments in this standard should be applied on a modified retrospective basis to all periods presented.&#160;We adopted this standard in the first quarter of 2020. Based on the composition of our investment portfolio and investment policy, the adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Topic 350): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.</span><span style="font-family:inherit;font-size:10pt;">&#160;This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). We adopted this standard in the first quarter of 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. This standard removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. This standard will be effective for us on January 1, 2021, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and disclosures upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645952320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prepaid Expenses and Other Current Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,410</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,475</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tenant incentives receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,093</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest receivable on marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,295</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,903</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,257</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture, fixtures and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer equipment and software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,985</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internally developed software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use asset, financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,853</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,853</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303,854</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,079</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(94,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense for </span><span style="font-family:inherit;font-size:10pt;">the three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$7.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities, as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consists of the following (in&#160;thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,617</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">External goods and services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,020</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,652</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810122512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 1,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6825403680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerAssetRollForward', window );"><strong>Contract Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Beginning balance</a></td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerAssetIncreaseDuringPeriod', window );">Additions</a></td>
<td class="nump">10,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerAssetDecreaseDuringPeriod', window );">Deductions</a></td>
<td class="num">(9,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Ending balance</a></td>
<td class="nump">3,320<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Contract Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">199,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod', window );">Additions</a></td>
<td class="nump">7,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod', window );">Deductions</a></td>
<td class="num">(6,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">200,601<span></span>
</td>
<td class="nump">199,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in contract liabilities at the beginning of the period</a></td>
<td class="nump">$ 6,304<span></span>
</td>
<td class="nump">$ 1,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerAssetDecreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Asset Decrease During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerAssetDecreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerAssetIncreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Asset Increase During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerAssetIncreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Liability Decrease During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Liability Increase During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6828379648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 115,137<span></span>
</td>
<td class="nump">$ 130,413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">24,114<span></span>
</td>
<td class="nump">27,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">139,251<span></span>
</td>
<td class="nump">157,666<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(130,862)<span></span>
</td>
<td class="num">(141,641)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(1,931)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(124,164)<span></span>
</td>
<td class="num">(132,600)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (124,230)<span></span>
</td>
<td class="num">$ (132,576)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (usd per share)</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 7,449<span></span>
</td>
<td class="nump">$ 7,316<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(4,305)<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases', window );">Right-of-use assets, operating leases</a></td>
<td class="num">(14,119)<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">15,244<span></span>
</td>
<td class="num">(1,848)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">5,732<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(106,191)<span></span>
</td>
<td class="num">(144,268)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChargesToFinancingLeaseLiabilities', window );">Charges to financing lease obligation</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">$ 578,053<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,575<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,858<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,833)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,820)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,681)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (132,657)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,328<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,313<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_IncreaseDecreaseInDeferredRentCredit', window );">Deferred lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,927)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PaymentsForLeaseFinancingObligation', window );">Payments on financing lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases', window );">Right-of-use assets, operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_IncreaseDecreaseInDeferredRentCredit', window );">Deferred lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(550)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,848)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(341)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChargesToFinancingLeaseLiabilities', window );">Charges to financing lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PaymentsForLeaseFinancingObligation', window );">Payments on financing lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChargesToFinancingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges To Financing Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChargesToFinancingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_IncreaseDecreaseInDeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Deferred Rent Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_IncreaseDecreaseInDeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Right Of Use Asset, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PaymentsForLeaseFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Lease Financing Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PaymentsForLeaseFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NQZ8_?V'QM?!&4+O^Y"?@%02P,$%     @ >8"G4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M<VAE970Q+GAM;'U786^;,!3\*X@?,/"S2=(JB=1FFC9IDZI.VS[3Q$E0 6=
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M];=S>]\,[=SPT)G3V*HF4[^\_@M02P,$%     @ >8"G4 65W;QL!   )!4
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MR"HN0V6\L[(;+;K1W T0-R>)N>K&HPF>R"I!9AV@EMT8T8WA;LCC6QG6C;%
MLJ 21*5"V8D5G5CN1!$GEG4"UA-1Q45*.=F($XTX;D03(X[U@2J4U E70=!7
MJALO7O3BN1=#O'C>R_7,GZS\1'3C)(A. G=BB9/ .T$=@B*Z2M !>E]F$A=*
M&4TE=\385 IIB=H%2BBN Q."S^0-9& )W)&GCH"G3HDEG<M*U($.)N-()B<@
M=Q2H(Q1RHS2*9K.@\U9#[J')* ;.8D=9?-;<&G*!TN^GLEL_,HR!T]A1&@/G
M+#B6U)(JJ)P;&<; :>PHC8&3-J6/,YK-#Q>"\4%CYK4'&<M@V>KK,@@#F:?
M@>HH4$%@92*4IF/B,E>&,F-'1BIPICK*5."\- D<M!P09-99DYM@&:S R>HH
M68$CTWBO6:'%958IR,P/REQ%SE5'N8J<E\%Z^DH(*E/:3/*@S%3D3'64J<A9
M"4H;3Z='TFD%D&$J9JI1SE2ZGJQ08*K&X.FZ(^F4#SG*HPQ5Y%#U%*HHT=('
M8(ZX+BW@+F=(IBIRJM+B=86<EVGDBKYBHLSZ3/V/,E>1<Y4FQPH%7*9*@=H1
M5"KW,2,#%7FA2VO8%?(B5J.UM+ZI)!UH"QD"H0QHY(#V%-"2QE W'VING<AL
M1L\6&Y_YN$*9ILAIZAF]."99VGTDN?WDE"FJ.$4]Y9;B?%3T"4N:3,FE9((J
M3E#*H97B9%28EC+MJ1VA++4V%169IZ1DABK.T, ^R3D;/Z7,9A,D(#3[*:$R
M&P0<H+3<7"D.QD]@4^E%7Y5*5.I@M<FYDBFJ.$4#I982JDZK2T\+K$H2@M,^
M5QPHF:2*DS10>)TU-[LD8H4J".4*M;C:KAKW#_^HNY?MOI\]ML/0[J;]J>>V
M'6)JM/R<&MW$>GVY:.+S,)ZZ=-Z=]NU.%T-[..])%I>-T>7_4$L#!!0    (
M 'F IU!]GZ'(10(  ,0'   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
MC97;CILP%$5_!?$!L8%PBPA2DZIJI5:*IFK[[! GH#&8VDZ8_GUMPR PGB1Y
MP+>]SUF'&#OK*'OE)<;">:M)P[=N*42[ 8 7):X17]$6-W+E3%F-A!RR"^ M
MP^BD334!/H01J%'5N'FFYPXLS^A5D*K!!^;P:UTC]F^'">VVKN>^3[Q4EU*H
M"9!G+;K@GUC\:@],CL 8Y535N.$5;1R&SUOWD[?9>U 9M.)WA3L^Z3NJE".E
MKVKP[;1UH2+"!!="A4"RN>$])D1%DAQ_AZ#NF%,9I_WWZ%]T\;*8(^)X3\F?
MZB3*K9NXS@F?T96(%]I]Q4-!H>L,U7_'-TRD7)'(' 4E7#^=XLH%K8<H$J5&
M;WU;-;KM^I4H'FQV@S\8_-'@K>\:@L$0& ;0D^E2/R.!\HS1SF']O]4BM2F\
M32!?9J$F];O3:[):+F=O>;K.P$W%&22[7N)/)/Y<L5\JPF24 )E_A/"M$+[V
M!U.(T.X/K/Y ^]=3?V04T4MB+6FT!*X@A)Y1R4/9C&9MI5DO:6*#II>$DS1>
M)#\]]3. GE'.F$(K4[AD2@RF<)')9+FGF#%$5H9HR9 :#-%#AGN*&4-L98@7
M#)[YRG?Q<UOEH6R&DUAQ$@N.D6>76'8 A-;-\I1TAI5:L5(+EO'-[])%KB"&
M4I; T*"R*(,H#*(T^> CE]>"]:B"%JS /*S@TUPVZ0=@8'*<JOOM!V*7JN'.
MD0IY,NOS\TRIP#(L7,F I;Q2QP'!9Z&ZL>RS_E[I!X*VPYT)QHL[_P]02P,$
M%     @ >8"G4,EG[.0&!   >A$  !@   !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6R56-F.XS80_!5![SMB-W7#-C"VL$B !!ALD.198],'5H<C:<:;OP]U
MC&*3I<7NBRVUJIO59;)H:G6KFZ_M6:G.^5865;MVSUUW33VOW9]5F;=/]555
M^LFQ;LJ\T[?-R6NOC<H/0U)9>"Q$Z)7YI7(WJR'VTFQ6]5M77"KUTCCM6UGF
MS;];5=2WM4ON1^#+Y73N^H"W65WSD_I#=7]>7QI]Y\U5#I=25>VEKIQ&'=?N
M,Z491WW"@/CKHF[MW;73M_):UU_[FU\/:U?TC%2A]EU?(M=?[VJGBJ*OI'G\
M,Q5UYS'[Q/OKC^J?A^9U,Z]YJW9U\??ET)W7;NPZ!W7,WXKN2WW[14T-!:XS
M=?^;>E>%AO=,]!C[NFB'3V?_UG9U.5715,K\V_A]J8;OVU3_(PTG\)3 <T(0
M?3=!3@ER3B#_NPG^E.#/"0/>&SL9I,GR+M^LFOKF-..O>\W[242IK\7?]\%!
MZ^&95J?5T?<-"7_EO?>%)LQVQ/ ]9D9XNOH\!*,AMFRE\^, .QM!(GC$9 @3
M8AH2=BJ' O*A0(0+^+" /Q3P'PK$AE0C)APPU8")99P8[=H@"@4'F$L N02@
MF007"&&!T&Z&A-',B GN>5) ,C+: 3 I?)*83@3I1( .&70B:QSVB8S)N@.H
MB(,%,C$D$P,RQI3=QJ#IA .#\P[ @B@,%R9N NDD@(XTZ"36.)_TCQ"'YDI#
M.)]"?V%!D\"F(0 ERS6$-584!R8A@-(S.>(%/@LF1H!/8/(AT#L%YOR!L$0N
M"00M[YD8$ I-0@Q&XO[7,"DAH.10B 52V !) E*124I:8X6AR<?&?&)_@0OV
M4@)F2J:9DFV4O4 LA4D( 27KE;9 "ILJ!8!48I(:0?']6.))!B8E"%L2"7LT
M 9-FTZ3)ME\92+U_"C;-"$$YCD62Q$M"8;<F8->\M$*PQU+\X]LQ85\D8(S6
MACR![J>&I-C<P@"*I!1+?W.P*S)P15XP,L9&QO3CJC"V'@;68ZG"MJ,01^:R
M JB8%J8P8\]AX#F\L!DSM@KV?T(3O+ 9+&Q;D\">*8FT_JK:*$IHP8C97->/
M3_'B8K"XA+EW()!EP=[=(:!4S6DX7[7.OGZKNF'XN_!\B'OF_A1AQ+?Z<$<@
MOI-I)E'<3S,?Q8,T"U \3+,0Q:,TBU \3K,8Q9,T2U"<A&Y P"=]:[ W8OT$
MJ:$W0/T$]DVZ<8*=DVZ=8.^DFR?8/>GV"?9/6@"""I"6@* &K#5@J 'W9W>H
M 6L-&&K 6@.&&K#6@*$&K#5@I,$S:PT8::!G^L=[!>__.3R^E?@];TZ7JG5>
MZTX?CX=3[+&N.Z47B'C2Z_2L\L-\4ZACUU]&^KH9WP:,-UU]G=YT>//KELU_
M4$L#!!0    ( 'F IU"*Q2(UE (  )4(   8    >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL?5;;CILP%/P5Q'O7V-Q1$BD)JEJIE:*MVCY[$R=!"YC:3K+]
M^]J&4-:<[$NPASGC&4-\6-RX>)5GQI3WUM2M7/IGI;H"(;D_LX;*)]ZQ5M\Y
M<M%0I:?BA&0G&#W8HJ9&) @2U-"J]5<+B^W$:L$OJJY:MA.>O#0-%7\WK.:W
MI8_]._!<G<[* &BUZ.B)_6#J9[<3>H9&E4/5L%96O/4$.R[]-2Y*; LLXU?%
M;G(R]DR4%\Y?S>3K8>D'QA&KV5X9":HO5[9E=6V4M(\_@Z@_KFD*I^.[^F<;
M7H=YH9)M>?V[.JCSTL]\[\".]%*K9W[[PH9 L>\-Z;^Q*ZLUW3C1:^QY+>VO
MM[](Q9M!15MIZ%M_K5I[O0WZ]S*X@ P%9"R(TP\+PJ$@' MP]&%!-!1$8X'E
MHSZ)W9J2*KI:"'[S1/]T.VI>(EQ$>O/W!K1[;>_IW9$:O:XPB1?H:H0&SJ;G
MD"EG9""M/BY!H"4V9%9.WB^PG3-PX)@H(4X"VPC!I*$5"-\E?2 0@0*1%8BF
M CASMJKG));36LXG3"(2!DYBB!>2.'U@* 8-Q4"B%!9(0(%DGHBXB7I./'6:
M)MC-,V?A/,A@+RGH)06\Y(Z7=.XE)-BQ,B>%L(\,])'-?;A/;Y,!>Y*'KI$Y
M"^?XP3\G![WD@!=GE4T.ODDX<=V O"!)8M@0#AQ'[^\^.$SPW/#D3SJ<)@")
M1(X+-#F_&B9.MC5(;\\OK;++3^"Q_ZR).0 =?&/Z$H!OPZ(,(3PJR@C"XZ*,
M(3PIR@3"TZ),(3PKR@S"\Z+, 7R- QT@ ).-+1?]WZ.^87^GXE2UTGOA2G<.
M>\ ?.5=,/X#@2;^29_V-,$YJ=E1FF.JQZ!ME/U&\&SX"T/@ELOH'4$L#!!0
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M%K-K,0)-DIHTEKPIP9H2C"D@^3UB](DI4")&BKME=,4DQW>A+B%(&4((*F%
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MFZ:O%1_I%X7J:UT]G2ZV]7,__/3ZNSV>]A\O^N8P_9.1G/Y.N?D/4$L#!!0
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M-L8#2DEN<(5:?&"S(Z'VP?R$MAW7;'2\Z:87Q.9G7/P&4$L#!!0    ( 'F
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M6;38S%()!=H)HXF%.J>WV\,Q#?$QX+> P2W.)%1R-N8I&-^KG&Z"()!0^L#
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M8+,AH7;AN/=G,X[9:#CLIA_$YF]<O %02P,$%     @ >8"G4(*8IM&S 0
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M^NF-F^OI+4\+J_JY3<GRKRC^ E!+ P04    " !Y@*=0=\%1@;8!  #2 P
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MW^/93F,V&=[T\P]BRS<N_@!02P,$%     @ >8"G4-5/>I^S 0  T@,  !D
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M!NC-22TDI]J8LL%JD$ K%\09)F&88$Z[/B@RY[O((A.C9ET/%XG4R#F5O\_
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MNM9":#"E! _F5%OS'JT!@UK;;6KV<I[*.=!B6!X<LKYZQ6]02P,$%     @
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MSJ.-$2HEBP%F*M:";&H./,8)AFP@9 ,@"P+Y:F,F6*060A/$P"J5A@(&_D*
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MH5/3O=1-HMJ\.X*[CF2G_G81#%><U5]02P,$%     @ >8"G4,$P)3QS @
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MM*>'*C1.0# !#0G40P+S2<8U)AMB3E<9UBV8.A7L1H%N+$Z@80(=+M3 !"9
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M!H2]$)(K_?Z=.JVC&F/[1<[W4K]&ZKUJ9[EV(<6IFU.]?EA>_@502P,$%
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M*3L(=1G(ZZ(^8ZEO!#_K\R.G.<1:_@-02P,$%     @ >8"G4$:]+@VA!0
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M0JOH31)3B"L2,201 Q)<(Q$;(5") )2M1!)()0%4M""KY+82,6$3)3*#;&:
M38@=,!^+B'][_S*+#K$;.G@ 78T\&4."4)&%#)8C1C?T\  :AV%!DG"=#8!1
M0F0AA.6-F?IFMO$ FFJA2<@U$2QN#*F;WLK,U"V#R!3DF@C6-8:$36]G9NH6
MJA> LM4+UC>&!$YO:&;J%ZP7 )NH%ZQU#(F=+2>L42SYCY[&PL),93%Z>CV
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M^ZH_;_</C3P.WQ*\RP>-Y5]02P,$%     @ >8"G4/ H;)<  @  =04  !D
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MB^&<'R:*]^,=)IHN4IO_4$L#!!0    ( 'F IU!J[XK@K@(  )D*   9
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MF\_@\\/07NSWA?3^D6/S+U!+ P04    " !Y@*=0%LMVC6\"  #2!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6QUE=N.FS 0AE\%<5_ YAP1I&2K
MJI5:*=IJVVN'. $M8&H[R?;M:QM""0PW8)N9_YNQ&4]V9_Q=E)1*ZZ.I6[&U
M2RF[C>N*HJ0-$0[K:*N^G!EOB%13?G%%QRDY&:>F=K'G16Y#JM;.,[-VX'G&
MKK*N6GK@EK@V#>%_][1F]ZV-[,?":W4II5YP\ZPC%_J3RK?NP-7,'55.54-;
M4;'6XO2\M7=HLT>!=C 6ORIZ%Y.QI5,Y,O:N)]].6]O3$=&:%E)+$/6ZT1=:
MUUI)Q?%G$+5'IG:<CA_J7TSR*IDC$?2%U;^KDRRW=F);)WHFUUJ^LOM7.B04
MVM:0_7=ZH[4RUY$H1L%J89Y6<162-8.*"J4A'_V[:LW[/N@_W& '/#C@T<$W
M#FX/,I%_)I+D&6=WB_>;WQ%]QFB#U=X4>M%LA?FF@A=J]99'"<[<FQ8:;/:]
M#9[8H-'"5>HC D.(/5ZX1XD/"_A@C+X1\)\$ E@@  4"(Q \"82S)'N;T-BT
M?9(HCG&0PJ 0!(4 *)J!PB7("V,_2&!0!((B !3/0-$"] DA/TU7#B\&03$
M2F:@> D*DQ"M'%$"<A* D\XXR8*#O0A[*89!*0A*ES]3ZL$"R(-+QEO&.MG4
MH69ZHV1ZS*GCK>P]6BE.!) 6U3F4,)KN2^@$*]N/P"+=(0R@_#D* RC/B5>J
M&<'EC'P %<Q1/HB:_.3/*+CP$5#YZ;SR!Z/I46'LH'D]NI,KM:'\8IJ)L IV
M;4TGFZR.#6N'S97\W[SO=C\(OU2ML(Y,JHO=7+]GQB15T7B.^K]+U6#'24W/
M4@]C->9]E^DGDG5#!W7'-I[_ U!+ P04    " !Y@*=0X2FLYSP"   2!P
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M]5P,77I8*-Z-+Q"9GL'B#U!+ P04    " !Y@*=0U-\O[YL"  #%"0  &0
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M6)M0Z#IM]M_8E14:;I3H/?:\D/;J["]2\;)ET5)*^M;<\\K>;RW_/0P.\-L
MOPO0>_\O@+0!Y#T@L,DWRFRJGZBBRTSPFR.:MU53\U'@9Z+-W)M%ZYU]IK.5
M>O6ZC%&:>5=#U&+6#<;O87"'\#1[MX4/;;'V1^'^QPTV8P1&(;P% ;,@EH#T
ML\ ()@A @L 2!!\(\,"&!A-93-7D@0),!KF,43@)TA@6$X)BPI$8/)5-!!)$
M\^V(08)XAAT-)NPGZB,2#>P 4"A.""PF <4D@!T3'V *$J3S[< (KA(TPY 6
MU,\U(7$\, 1 Q3$.)N1,%"T>R8G(% 58E"OL/V *7'28S#&%C#^ !.%DZ H
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M/ISOPT2R;KRZT'1_YO\ 4$L#!!0    ( 'F IU#<8Z(X8 (  *X'   9
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;)55VXZ;,!#]%<0'++YP79%(2:JJ
ME5HIVJK;9X<X 2U@:CMA^_>U#6$)F"I]"?9PYLR<$^Q)6\;?1$ZI=-ZKLA8K
M-Y>R>?8\D>6T(N*)-;16;TZ,5T2J+3][HN&4'$U257H(@-"K2%&[Z]3$]GR=
MLHLLBYKNN2,N547XGRTM6;MRH7L+O!3G7.J MTX;<J8_J/S9[+G:>0/+L:AH
M+0I6.YR>5NX&/N\@U@D&\5K05HS6CI9R8.Q-;[X>5R[0'=&29E)3$/6XTATM
M2\VD^OC=D[I#39TX7M_8/QOQ2LR!"+ICY:_B*/.5&[O.D9[(I90OK/U">T&!
MZ_3JO]$K+15<=Z)J9*P4YM?)+D*RJF=1K53DO7L6M7FV/?\MS9Z ^@0T)*C:
M_TK ?0+^2/"-^*XS(_43D62=<M8ZO/NW&J(_"OB,E9F9#AKOS#NE5JCH=1W!
M*/6NFJC';#L,&F'@@/ 4^U "V4ILT2P=W1?8S1$0!/82V*H"&P)\IR*V$_A6
M M\0^'<$R<2&#A,83&TP?@0"$"9@(F<.#'P?8Q@NV!986PKF+2%@)PBM!.'C
MID16@N@!4Z*Y*7X2QT$23TR9 P.,(HCB!5-B:TNQQ90%@L1*D#QN"@3V$P,>
ML*4'C>5.OQ(+! 8 )]%"-POG%UJZ00L4UO.Y@>@_/+&?/X@?\03/!",0(I!,
MKP,+$ ((_1A/FO)&MUQ%^=D,!.%D[%)+?9^,HL/0V2!]2T[B6SV,S.WY0=--
MLN^$GXM:. <FU1UL;LH38Y*J/L&3ZC!7PW/8E/0D]3)2:]Y-D&XC6=-/1V\8
MT>N_4$L#!!0    ( 'F IU#(I;$_U@$  -<$   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;(U4VX[;(!#]%8L/6.)[-K(M=5-5K=1*T59MGXD]CM%R
M<8'$V[\O8*^;I*CJBV&&,V?.P4 U2?6B!P 3O7(F=(T&8\8=QKH=@!/]($<0
M=J67BA-C0W7">E1 .E_$&4XVFP)S0@5J*I\[J*:29\.H@(.*])ESHGX] 9-3
MC6+TEGBFI\&X!&ZJD9S@*YAOXT'9"*\L'>4@-)4B4M#7Z%V\VY<.[P'?*4SZ
M:AXY)T<I7USPJ:O1Q@D"!JUQ#,0.%]@#8X[(ROBY<**UI2N\GK^Q?_#>K9<C
MT;"7[ ?MS%"C+8HZZ,F9F6<Y?83%3XZBQ?QGN "S<*?$]F@ET_X;M6=M)%]8
MK!1.7N>1"C].\TH9+V7A@F0I2-:"./UG0;H4I'\*,F]^5N:MOB>&-)624Z3F
MGS42=R;B76HWLW5)OW=^S;K5-GMIRB2I\,41+9BG&9/<8-);S#Z$R58,MAI6
M(4E02.()LAN"/$R0!@E23Y#>$!1A@BQ(D 44E'=;\3<FSQ[#3?)@DSS09!LF
M*(($Q?_;+(,$94#!X]W?G#&%QPB/R;;I71-\=<3<E?]"U(D*'1VEL:?5GZE>
M2@.6;_-@;0_VE5D#!KUQT]+.U7S7YL#(<7E&\/J6-;\!4$L#!!0    ( 'F
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M"/XQWP)NEK=!%/=N3H/K;+&K8/;VY5ZOX:CK;;GX,0PV:14\I*M=%IP,S@:
MPL$&KCZ1F];X5;K,B[O@^FE]4ZY:X/OPK@5 M83@XM/B/BV DOD0_]W\^O6\
M13($^.>[JL)+RS>5IH>#W+5(X5_:U%'?&2 X0,7RAPS)1JJ&W'/!X4(!LMR5
M50MX;],*=C%?+#)X"IY9\O,=8UVOT]4J^&I7PW6HN]9WL<ZJ.]S8UU7YN+T'
M/%EOTJ(ULQKR/H,A]S\C)WS-)WQ-K"-XO]L"]A9X@BU> &1Q2:3QS2IM?:OI
MYIN\1M3\2P8H\P8^;&UH+]65MX6&>]__<]2U(1B@@I<O@<U]"OZ4M3:.B#N>
MQM-1W,)VP1][\5T,I-^/XG[26L3Y^W>O+]Y=7[P.X+?K]V\O7\\_PA]?S=_.
MWYU?!-??7%Q\O 8>_=WUZZ!W<AJ<!'D1?+PO=S6 N[7)U]E"<>6H32UDM6E=
M9]OZ59O:U?<!#!HL\)?L'[L<KBX\WYKDLGC(ZNW:]Q7@+C*+.JBR10;OWZQ:
M</ \$MQ6Y1K^7A'. ]%HTY6K*MND^3+(/H'T4P/&X4++[3W<IH6SK>:+'V"I
M5;[ @7%?+;)3(M'=/X2UWS HRJ*_\-]QH/U W@"C<&T(OPV^ Z]DK4<_Y'?W
MVWYYV]_5F<P:!OAV2E1HE:5UF^0TMK)W+>\)--8#'7OC_?N_4_BRRM.;? 4R
M3=9&&GV:F_2IX[1!Z%K:8[1Q]C:#B9:   ]9T9;0WCNGO&<@]RR?,>-^2+JG
M$I0WJ_Q.1*0]K[W)B[18F->LY3SSX [N>,\#2*QS1EV^VB#1PYHR6!G<H=Z[
M$J26Z6GC+=0[7M6;=)']Y^] L:BSZB'[W1^#%O]%#G!?KD"PK/_G_S^-H\F7
MA/7;IQ:6P.T5B'<)!E\&T3@.X3?\3Q22(-UM[\LJ_R>\E]8H>X 0OKC76@?M
M""A>AG*,IGI? O#4 'E=(_*!7%8:!A6DVZ,&>J9H SL(Q[S^S["'9#((HT$<
M3@<C>B1)QN$(_IM-1XW-$2&T=W?T+"'@?[W)2'A9M2@N"*:DQ@""(>7M ]M9
MI)L<$,YSQW?K'1-O(<D@0539/5!JE(MZJ[*N3X%OP<<^ J%?7F:@*^2M*\%8
M7G>BV\%;0=L__OWC6'+O*L7K>9]M0;]9G0*+/@F^Z%"E23T@006.1B@#BBNE
M:(K=RO">F]/;U4LC3S<O<?O-%D(>^P8CVK%/E]VB8-<-.K 3][6#V_ ^[M^#
M]]%]&_!CQO5'^.?;BW> %>_?!.^O+C[,/U[" T>+;98QI4UW_A:UL.(#\ZT6
MG67,[^*CFI$I(:KU/D@8&1$.O#!+&&95D@S3?.[KK,A09,;'TN4Z+\CT@'3$
MOZ*R-75;,07%GL1 >;8L/'(8Z%H@ W50$N:<,H%7ZJ));K+;LLIDC&";?FHO
MAI3X&B\F/!KT;F"WM_F6EG>Z]\5W&;#KLJV,J<\-DH?!35KG"P9TOMHA^3MP
M#7[(4&A$BO\ $ )%<2'8RV@+DN02D:PX;JY<O>BY;JM5>B-FH"YD\CYTA!S_
M-5FH.@9% 9=>W98HJ:"%$W^=7Y\'TV%\%EQG("PO%JR>(C:1_!*W[%E'7=/S
M]]]>?;CX!IZ[_/XB>/O^^OCKZI#S<X?773)V=!/T]X<89.M2?E=46;HB"4(>
MO$MA=0#V]"'-5RAU]P%4_1JT-;BT-]N@9LL(BYH9K1+0%?\Y85'@9#0<[.?^
M;[.Z?A6D:ZVJE7<%+0%O!(YIUH2K.664@QVL=DL7#SLHPG/E!!?,OH%?>NIM
M1GX<%ECG0@<BRS_R7.! 7K2!ZX_OS__TS?NWKR\^7/]'</'G[RX__N7H)1/L
M.Y@@B?-[A, K% (OB^#\L!#(..Z>V%O/B=GOO/;+?E^E*Q"6,I39;[*[O"CP
MV@,B;]C28Y$Q?,0V?[3,R0>&.O0ZW.R*-+D>/$:_(:H&MA8$YT$"9?"W#T >
M@S=E]9A6RQ8)^![(G,Q=62J])8OL(\^'WV[9N3YEU2*OR7I;;HBU(EG=[(#3
MXX86CA2$]W;/],\>S*LV]H$C\:J16Q,3.?YZK=/JQVQ+AB-SH_:<=H8:4A?*
M[!6].@=YQHO/1-OG#G7H=9!E%EFV%.%JL[M9@210WH+H+N.T3Q\^1'&99EV4
M]984RI,(]-'I/LSXO#-]AO-LVXN//$^/S_+%I+G)78Y6!.*!T/2]TH>?_'1+
M'^HXNN3PXYCH_/J;X,W;]S\<+S(9Y8.<)=XK.U_^?2=V5B0I*'2 G@RW7(NT
M\"G^3@9J)>^6GI%;,M3K#%@1Z-PDK9+6LD:'SS^]E&=N??<%R)M51J\ALG9;
MODFW@*>6>;TI:Y1P +F\!N$6R,EYA<*3V&'I\7U&USW&<+\EMVG#W&,Q9-Z]
MYX%WQQR WX2^_YDK82%$!(ZB\2[%6:=;>>Z% Z"@]HQW[>4>=](MT.5'@,48
MDO> [C.0WOUCZF<;@P7;^ZK<W=V+*2W8 (&MO7P?T+Q"-(<[?-NPC1N3>B?$
M-JB2HV9Q\V2]W@T1?#'7$MO2EMC8=])T<M')5?N=1>='OQFZO/HI2UM>W.<,
MYC"KUE;15X##6-@$SQ\#I2-PV-'ITH:WATGI,2Z>>E'E&T5&@<1T^JW?5W=I
M(<0W!!VBJ,M5OC2$^PH=$L4V56,9:ZKFB_6^X*+NE01.C$S06X ,K]3C,'C,
MMP!A&'NAEX2FS]U-G2_SM"*=+BV>R/:NQGG,0KCJ(?H?<"+QJY\&CRFIRA)L
MPZ!]G:U2T!8RY"'_M5L]!7%, MWX+/@!X Q?X!#U;K& I<* 1#W$'@972N8,
MWKX]AW7 6:SSK74F3X%835!_7\,7NP*>IR%AVEJ!0L)8;LUJ8!I81'(6O-]5
M@"&PZGP#L,X^ 5VDH >@,CF0A;P&#KV@S8 LY8W$@=/4\33!MW.]KS18K/("
MI2,@*6C7NLG+K7E9+1QO,",W4)?'X(Y,D/H<,>J*(^)P4;!#4";A4 /6,U!I
M +!EP&>KX,.[>=!;P\_3$"&7KY&V,'A7\#+?!1@',>DLP >M\7#!RZS.[PHV
M4RUSD"NV]/)-N7P2QP)@2;9:L6)4E<L= @B##/!3T'>K$$8$4*1%1LA1(WDB
MDUD%.\]1H[H'*-ZG#P@=9,CI)@-P+_#A#1G/:)O*,$FXB4O8P.OP%4 29DXE
M7"H-;JHR!5Q%8T^U6^/^0$HA%[.<*ZC@9&R[V>6K)8DQ["C<@30'XSP@Y2<!
MQ1@2T\UFE<.2"3[U J"U@,TL,P1A]128 PSI\75:[&[A0NZ0(X5"SO$T=S6M
M?)%N%*:R-EGO"/DV:97"-5S!+JKR!L3#8)-O8)*"T!01P3)3PRC%DFYFK;%+
MOL:I+$ RG7T TD6G>DL7ZA9O.^Y802<$Y%COBK(/<JCLI:(Q]??I;EO2,YE$
M3E3+O'Q(ZP6>LCT.7#>0U3 >;L4$ELZL!."3Y1R8Q2)8:)MJ6<$&KC&.#.E$
MMF%B^)@Q2L!'.W:\ !I2>!UL7<G(N/6YSP4H[Z/#$$EVT^G&FM?9.(;KMUKA
MM2(0HHBYV(I!%C$BHSN#*W"F=T51(V[2B@B^>,IH>:^SC&,^=H ,V1D06\34
M7&\11LN1R&PSO@4((SWZ(ZS-\'5K 0#5G+"VH$,L#'S+XJYTN2#NH-YM,.2+
MGM#H7XG[ _"XVMWA\2U*PF8Z6T6D+(3#@[VM4CC"':(V(X%VHEP4=[D@QD6*
M4:FO+53E+V&F_ [-:8V!0B%W3-W2 -=Z"URG9"UDFQ%KVJ%O5KAVB$#"T-.2
M&$,9W*W*&_B>9=DZ]/AJ%!#HH)>@6I5;Z[R%P#I0=@W]6EXV9*=!+7?%BBA0
M@0QGFZ_P?(6%W>Y6*R;N*R!]7N@R+MULT?I397>(KR4>Q@:I!SR*6(6!C/#/
M&ETZ:)':54H,8H$2UZ26 [AV2RO(LA]QAP>&%FZ^=TC"6 .S]KU 61D-9FC)
MXO-4N,RDMSFRD*0@19M7S8RE "1<P4@5//&05T"@B'WUHWB2  ][O,\!V8 !
M2\"(7 4%4) DTQ4L%.0\8!A9H2",X2_I)E^NGEC9!K6U():&4PKR $(MLW6^
MT-24%D]TV[G\MP O5MIO=Q4ID#@(#>\<*(D9L%*#,'J_Q;*#U@!BUG!6#S)H
MD7W:!E$,)XZQZ6?!QWNX;GH%1!\J%%Y%8)(%T^6$V>U5I\:V?0OB$*,IO5.C
M[I?7]VK-'6\]EM5J^0A:B8\*H/<++E!]GV^8(J<(X]UJ2RA#ZRPRD2"W*0.C
ML2+B62ZI4H!96FY2GHXY)CYSQY&>PE>>SH+OU-6##1QQK;MN,Q"[VP >K!I(
MSXH&SVVM2BF&*=Z!&WA&43.EGI(\^8!+$=U1*:PPDX:EI<?4XI6^V5J?A<$=
MHD9!1Z6 EE85FE0D8L\P6) D<A9E6"1!RDCB2$,Z62*)S&]V6NF ]:(;HS$T
MW8IU^@37"L@;,36\22E:QUO(!=O-4%YGX@Q$\%Y9;.ZJ3-06=#BG#R  T%!9
MM6;= 9@@K%Q1K]LT7YEY)"3'-[PU<"KT__$^PZ@UP+ML2:>(JR>9 E]RN"E(
M<BDP%8QK!4$S!4V_K)@CJJMYG[6(=9O:(0%MDVB@LG=5NF8(WH XESU8W-ZO
MH/,.+ N</]*);M8-LAE43%"(Q[UE?#P[H5$4,D7+^'M&:K8/;[=DG=AZJ [?
M$_S<-HO@B+=:&ZVU-GH6?)4MTAV[3&BP'0 )Y<PJKW]4W'$!3!Q(/H<K@8:'
MQLI,Q,3-?0J:S8(DUZ8 \LB$V> ?Z =P87G96U #T0)1B2>7I0>6GBSS(7R/
MF('_YK>:/ $0U9CIXIZ."(\1%XEL$X 'NH<([6?!!5 0>9N4.GE3DQLA,1;L
MR"\J<+.)#-D;<-F:R6E410GE)B,/NYI^E34O1NL!VK\#HQH4B=8>R'.K*"S.
MC\H.>FH1-(^>FZZO0H/R >:@&0PUQ!4>%1_Q#8F_"U8;X8QV+9+9BF.XWJV!
M2)$4\A6N!7]Q[!\L;BX0R2405W(8BB5H(EW1V?C,%0B3% /:;2KYJ;/O>>N*
M#0DB/KI&'F#H;I ' !SP@9V<J$&QX] RPO@N'5,3/0X>8HV2%*B&3/!(%-J@
M(;TRMJUJ29>9+MUW9]=G@KXHJ<+7H(=E2V4#PY5MS#9Z7\_G5Z=&,UX0DE2[
M5:9,>B1D$GXH8XLV+;.*H+)8*&:W)D&^=WUQ?BK:*1#W?&WMM5(Y*R%! U@6
M6^N05Z M/*OX*5+[:V4C*)$WB>J.MGM P'E1H"+!.3!X"=Z@+A0-^G_2>AO:
M+]$(F7FB2(,>_=0OG8*T P"GZ,",-5@'^DA.#(3N=CG#'#!EG:5,K>E=)8I*
MH-^6518_]#W'Q+."[$.80X8MXABWY:[0WWK0%C.I3,I:;WY]SJ?JQ?#O-HB!
M^-1WI^I8C4'2?RE*G*3W9G[]U2E*KWDM)QG4]^5N170"DSE%G?T[< :CSY*E
MY"#JR[FZQT*2\E$OD[G7-E@RXX7O;&LGG#*IXH!G^HZA$2Y=&*'TAMVM]HW+
MT#)9**/GPK[Y(*@RC[P A6A-Y_6#6#S6Z9+$<OD8Q_[[;GDG8L M&6[8P&.%
M+"%0#98_AW8H1< A0X2]H+0A!=-&!6$1* ]C*"M93]%>H99JL[,%7G;DWS8.
M*S)<6B_I"#JZ"BR92P066TFJCC!-S=%#*TJ1;6U(3D@6]@=?A))RPD(6R"J@
MGAMKZ JVV\>_EN)?9+F-7#?V;I%X $*#*DW[Q-549!AD3;X ;:\B QML$.#%
M22F[M8HB08K]:,F#I=R%NA3I3=NL%WFUV*U1;UIDS*%%N:+ELD+,T8/W&9\1
MD;)U^B,"W4*=FW*W%?MC5=$Q4T0R#>-WQ@ICJ8B<T4W-5V0X(#>_A+"28%\#
M;!89JZAH?=HQ.:95JKU:($+Q B@/4CY%O6%@'L\&,AH&+=7;1AHDZKL-&8"$
MM<FM@(/:=]E#O#4H)^*Z"9[()BPL!-%*Q6H#8$1=0P?!L@Y?C*(*XZS!T>11
M[41O:V*AWS]EH[K"7X077T<2.%:K\I&%="8%2Q6XCK=#(;0-5)^<A(?HV $\
MEUBY=1GVQCE!!_ < J3X+N@B6::4#N:_S<2.*K/9O\7EE^3INC$4T.4':"]$
M5HD\$4D;JQK"%]&-$0^^%.ENA5G*)7%5+TNCIZ,OT8U!6X8+7#Z"1L!T^8'@
M[DD^>:0P3C'PJC15,5XHEM*[^!KX;TU)N7*O4RL]EB\^67N4K4:"A8/>6S(1
MFP4#&U]RP%K;')-2Y$FFM,+L :G4ZLDPD<-'ENG=_E<*\A3(S4H^Z@ _1Z%(
M;JRXBO3$M_D*LW_AZ1H?_S,L4E,<VN[RC+96(6=!]R0O/$>C"D<T/9??Y86X
MS_#V DYL6&:'5X F9'D16DR\\L=ILZ+\&-2"&4SY;DN\?T2(D(JC%(%Z1?Y/
M,= 1W)C@TOG @^H,R^>S[B-O#HJMA.L2KJ1O@PZ:#V"2]/05; $'LBMA- =2
MJ[WRX(T=TH1(I_#,DXMA_ 9-DGD21,D@'$U&\%LO&L?!J7PTC)*@.Q4CB"=A
M/$V"7C* -_"/41)TY6,$T6@23D=3F&"&$^"?X_$X\.5EP#/#*)PF"3X'3].?
MXV$$?[9S,.#;<!KC"GI1%-$_X2S!7^QL##O%PB'H\'@2A^,IO@ _^*\!#J=S
M*OBST<1Z8C09VT^80TVW;-@S*KP)99$H.F^VQ.!LB'.2>S?^4O]]&#F\2"$(
M8Y C6.X4JU;WUX\MEA-+[^[$AL )PN#$AL+>T+=@$B8Q'CJ>.?P>C8.#P65!
M L\E 9PW_#(:!D?E,FO0 :8 -O!/G8?;# ,*1J-!T,,?!N9[8MC,N0"N#:>,
M9/Q+*YPM&$Z'01)/ $Y1<%0L&^)W$LYB!&\O&3(.#X=A/,8)?.%9P5&Q3GK5
M<3*F_Z[2)V,'[GZM%PU&>//@IQI![Z,G&SD]&# 5] @^N)]XEGB"]1L?V?D=
MM8G(M-+PNW,Y-%5FW#X+#B;!*)F&^,+.C007D9P]R\(B++/PF="X17OYY-4#
MK967X? X[1S+ZP4\:PP('<S'8CD<$=>82ZG;:Q#'U5/I@3Q9O<;C13\R:"!_
MK5U^!HS+BI__6O*%YDY>RC7:7U^C.\6R1#7F.)3:RZ<5*DU?HM$;!B)@5N%T
M,/2>.E/PB;"$0]/AT\YDC>4"X1N'$=U4JU@"%;;X(=.F#4281HB='E.=^M'!
M>3I,.3<.#T5$PB-"\IZ'9SCA+1ZW5[92EYZEV^:RGK&G_6M2L*)Z8Z++@E"G
M1, MBQBW8N1?9^*.$L-,?5\^%B_<=0O)O9$NA'2=U4P 29)9%$X(74:#&%!O
M:&,+/1^%@R36Y'5?X0V@P^%D%@41BCE*OGH&J'\2.$Z"X2 )1\,$MQ(-PPG(
M ,?I;)<895AD%&'(!A2T2*J: O/K[X)WY1E]VX^2,#A'I]*6^ *RCH_E!B2D
M)![#$7P+_&EG]"_W2;0F:S']TFCW8OE4FD*PD!AX (;H?F06YY4335SPN%9
MT1J51Z,$6.8:\:4)"<GM:=\@>:W0G&C*SZ MHDR%K]QGJV5_6_8EFORIG;EG
MUJ?<9$HG4UD+E"I)<5;:]-#> I (#I1("W8'*0'0-46IBT3;$UN2T1H);VQ
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MF!E'F5%HG> E)S?$[$>DL-1].#-A1TRK*9;"A.)0:$QH)TI9>]0&'\L[L+'
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M=36[<*Y8JN4W-3T5P0-!H,:,% *BH? @A.223[L@WXQ.[FUIB\\'CO+[M.!
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M"2_@?PL7X#[,.>@*3+EKF]<C>-S1_O=W!KJI.8>C;U^44#GY^5R!8ASYR<[
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M9NH"*_)<"95!A(NMF\L\\&RD/PB5K98TR#!PVL'!$@B=#8Z3;VH.)'85(-7
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M-]?EDJ,T=4TS%.-@UIK9L4G8FGE'Y0*NO/#LT^(>/;Y2KJ>;K8 ^.H@ &R?
MY\9:Z_5OY?P>JY20S-+$6"LA/AY&09Q@4)+4&.)*;PV3$XMN#0&XN5"[R&HK
M'C,\E.SR)D?+1_ 7M&^TG/[(: PQL#ZDL7LL=2VE8O\]NYQ8-(#;.^58ERAA
M6Q; ,!Z/@U&(5Q$^B?&3,;!_S&VC3Q+\9#:.X1,\/?ADB"!/I@/X).$T(3AL
M2IW!9"@\DG@\Q/0X(1$=8(Q0G@#U(@9FCM-0%+=IBRB53<6;SF2*<TYVHKGQ
M9[TIO!Y1_%0\XC@^EH6NI#2J3E!J8Q!*-S$(%"26L(A@,?-+'5+J4UTT VIJ
MF*1*,6]WZK,2+,2+E+@!5?%@:CF$=T4?^U8J0QSC8@-X/B+A$6WK9G@6 N:K
M5"5]%VUP5F*7CB9G\>^#5NCIN2[7H/H'2I%Y#'M^UL/!:]CCBM..NN.9]@]Q
MK1N>.WT,:RG]Y/9$7SBM#E.K$*9HGB91&Q/$N<B?UD&]G0=\I6/M:D[S6N?T
MXUJNSK]OM&J$3[ZXGMN?DM+V+:BX/_Z$=>U=EBWXX8JDXK4)V+(<%JH85*-0
MC-3) ,5R>9>12*M]PB?Q,+'J9>@B%9:B?VS8GZD]A*6'WF9WN"#=*IF"W%3]
M:I$/L2J#:8&*^3JZ*NR*7C>=ELG?NLS6A>9;5DW=FDX.#2%;TYKF-8"-@D?A
M'SJ;7-Y_LIRBF-3%3@>=NX8%ILNG3 06W;GR@7&/"O!5:!ZJI:<@D1L>C*+!
MU'!!SN4<0(8).=20H^ZHK;OTH--MX%/0&#!TG.1>VUZ6-S:=&SE*)C7E],W<
M^C,,B</P/F,<Q")PRY2T>7=D)]A.&CI8DINEWI!?F14?\2FAP0?W1(9),0,J
M8#OV5^4DQ;-6E/U)BEK_?8<F94PL"%'AH$(5#-%TC?$*W&L7D[I6:;ZFAZ1$
MI84F8:!-LZ;6&+VI&Q,L\!RY9P,2W(>\7*E:EYS]U[<KANXT:5(AA1\MO\%Q
MLJSBZO)$Z^I(7,52^DWAW6.7"X&IE;NF4BK<\W.*=E)"8FFN$X.,%2#L"HY(
M0,9E]$&5>M[%UJG.(&\]9^J U&)J92Z%5T)?E64W%9E'=<J.UUCZ7<I)ZNVH
MA2 1K3 S@/:#:C*\"IHC-R!=$!%L<B+]Q7OLQE9[,[KT.9PD9S.[+EW3>JK&
M6EB3$+4P1;XDM%C:[%*#L(UN@G<C_LYFC&32BB;R367"<.QR^>+W$!^GRF)4
M,;ZF>KH54:@6:1VPWH$QQW&LM*Y8N#3%]1R6%;;;,4J98)5-CN1>DFQ,[PYV
MI11 7@GGI81(F3/RTU^KE9*J/*YI>'$)M-M$+%LP4?T]B6):O;"D?KA=F<OZ
M]A9I/W5:P4I Y6/!]$05J.3(9)\X8F]45LI 7=MMWK5,B"'>O/@P0!6 FC64
MIA@M)S@)M<\KRKZB+"=68';;5?IDA9CH;MR,J"M5Y?BX[#*-^JZ.5!@$+/G>
MD$2<)*VB4X.1=66:B6<H>I,\O?.!4$>MN[1G+R*>*9M94P$!07G%'%XY?YC"
ME$BW4+ETT90B/IR2!U:%,[Q_Z=$%:3!'HMZMJ2A3%CR2CYYN $%4A=%;?28H
M3)4G5=N0^!Y1503K74SO@"%VQ &E'AM@:.>_>W9JDI:2<(VQ0QB)!.?['U)7
MJ/F,5!OJEOQ]@V Q2Q.+,0VYMCT;WY^"22AA<[C4KTJIW_I:26.F\IXO+-Q*
M-,6W0/>3]$TV0%E51BU5;C(9H6>;O=NX7D)G/'"L%;LM%S^*+U&_,1K,PF04
MAY/9R'H#KAN 797A?L"E$%O0_2%X+&Y!EG)YX']BB(>KW)&O2T*OA='@UBZO
MWG-,M'E3Q8[)P':"312.>4=[=D45^87=GF!,Y"#BJ$A\FKDKELUI#]+8T:%Q
M5@0SOEN=@Q"Q1!Q6#4BIYJF^35&DT.(QTW'I2P.81S1?W&#MZZ#&X+EX',9P
MK+-9TGFD6ZK *<603X#)JJ#0>QU=J(/!R>(M\J3*/.0 IYT5O 0K8=GC9#2V
MU2=M,*<[^HBIA]B$3JP#*L\8Z$NMNT6=M&AIB9?8B2?ALL8F#A%(!"$?K<KR
MF:)^3L$WMVJ5<BA&XK. Q(K(49@LC7[H >6&CQ.TYZ$YQH8\F_@-],\<&A -
M+4%+'5\2C>!^==](]_BBF7-\1@L&:H>%Z<G5@:W2!(I[SU<?J(8YG^IP,G'J
M ^X]U= Y4K?D3NLL&ZD/.+<>%=FK*97,3-_$<6AB[J8Q).$,:W)A ' G_)@7
M$'3T@ABB*R[%D/FW%C8HJ9G5@2(>RR0R59!;K '7T6<SEIVIYV4A$FER)7EC
M5H.R?<RG8P;%AZY  :W;12<?)<P@TQV;$O7&I4H_IG>#GO[>_>)4ZW?TY7<%
M:+_O3>=<*B??'$&^I]>55U'')2GEG@N]8BZ)GF\'@XN?E$H'W7+N3ZX+;H<J
MW6L+9ZL*_*/4J#^@IZ5$HS!2;>Y0SLRF263YD-?:.(*4!"5JY$" &"G),=_H
M^ D)6Z7 9=5EP)J>$9+#81'?.N>D\$J>5T])A8Z8P-!QMKO5M8]S'!!F'#B2
ML8TF^DA HL023];I6@?G'KN+$TQQFN/2&\<<,P-)'ZE[W(TOF[ -W>.6SQI8
MP6,0-AV+!-9QAU:Z]X_9$U+BNI33:(?A"1-JG\RT?3(=5V[JG [G5SZ8K L-
M;><YD+T6V"[6-"D6%DGAA?D:*[ER8)]6FR@,U-O3&+D]PU P D%&Y^L<M[L
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MP@0H#5#>X3#XG@?I1:!)SV9(;@&C)XF7U(ZPG\*0'P%*NV=!3?H&I![^F\5
MZ<X ^GP$8KF1\]51#G0FEPU;B6.($2/&@2%Z%]=75]HFYK.J:+"-0LL@@Z^U
M30U, +5?JV[9$U2DFI8.I]%>=QUY:"NIB4UV=F7),A6.R/N.)=)596%E Q?#
MEC3208IF/:3-[1()%[(%@5.8&U8SQSPO*S4B'(+B#-MQ\J2\J%W-<0)DAL#H
M,DP;R3\I[$8PT7-*%>$$;WB@3T^8535ZTAO[/C_ IV$VPW1QZSKIJ&(6>F/<
M16NQ5&L#TY$VBL"5-B'+7@W!5HT+2R>[P?1,]#LL4VW1;2Q;-4U?I1W/-T[G
M3",Q;\;0++LEK<$4XS;:I$\5T"?01)><ETLXIGA*]'M\;S10N\X;9AB.VWPB
M-[]>$J$/&1N2?:@KA(W+Y[C;P>V?Q.2K1@L>E^KN&(9J=#^AJ))A7!\A*.$^
M8%;*>>@,=CI1#6<T>NT W74]L(_<XBBCL!TUF0\IGD60ST@H-L#J=M1(1LNU
M9>5P0&V: 3<5XJ8FV,B+Y61@BC$ =>G'_O4"N'VF*D#0C< 'UN4R6_%M>53<
M(Q7N07$=,C?E:V#^JHHN:8MSS66^(/'%S3=XI1F:5DV.3E6BI6!N2/UCGRHV
MNJ'C$7I3?Q_$9\#+?F])V:CCC,^ 3XDP?Q8I/40_\T!QDV37'N'+X]@>89FC
M@1?4'YU,\GOK-[T?!6(+@L:W>R(J#=8(/@/1PB=-.&*AE3%&!C1)M59ABJX1
MS4&OGU!T]7D)2JVSP=U-*27BA')C0":PI+>&/3>G7*QIDJ ( JH@W<@10%Z!
M5N4]QJ (10F//9Q-W.[5=N@YU5\><(;D()Q,D^!K)I[BA<-L$ K*1W8_#9/)
M))B JCCLG*FS7[!JH48AYT,[O%+%AEEIW UK=^WT7MT5(B1U'B>9 27:AHMT
MV*E.#8%3[BE>_G2K:WPTXC6MM8GUL44FC&DT.8/SY>O2EN-:\5>7U%HC^(@E
MFKJ_.RX!PQ[+Z6%IFD>B.;XC0UYAO]Z[BD"#5W1,[T(B/;A<4?5D*6.UHXV9
M3BFFMXS4HB+K+@WC7XD*[[.'IA+QG*AG4_6L2!<JFWQ'\>DX/M7F,ZZ.QF&B
MR$4RK-XQ'Q9\SH)1<U[[?>S_5V'&K<7:5.$0?EJ[>1_OM6(J[W,!?4V/?(>R
M+#/NUK*F>IITM>/!ER16<'5\EB[@$?HJ^C)84/0(Q7M^<"= YNB;)%<=>#+J
MY*H,N'3UU;OF\+G!MG2 P0<E@81.,U^+^&QBG7>%1+N2)&+,Z10+"PR(XG1A
M?!"\'MI -%D"'%#6M8<;E1BU3HN48T1TXD.C-3/Z!;7!-B/.)'9\6^AQ&A/2
M/<+93.EBE,MN $2W^8ORCUL7'W/#WU(C!66$;(5=2HN;X$J;*;OO?GLXS!W+
M%TSS\Q5ECF'DSDH]Q&SVA?*):QWSLD!TSRVRS58F$D>1_+5,M^GQ2;SOL-$4
MYI^\HI1ZVL():-SQ,(P3[J?1P^3_T02;B+S.BI+<?_A\2]A03%4T-<G ;4,F
MI,H9+OR241)&@Q'56,#&8=,!=E\;FT7M?1L6.4"S[BG_1HU 7*G&8?A6([Y0
M23KD?%09@1(V;'NH.S.V3 H\]8:F,!3E)5)GJ<A2-[*D6V">-[NM:9=AUJO,
M: JA5!)9#BOC CYH0-AQ:'M><2H"U97A:&G3>0C[7/5I%2!VM)K)T4Y<'YEE
MC88#BB=1&$^C3D%*=_\;#<)D=DC@,H87%+HB$-$2[(,Y@)?'LT$P&H;#),%6
M+JVP--U_.+B@_+&##^R+<6L]^UX59,/@)QU6V5TSD++?[?AV;7 YP2UI.Z-"
MBJ_RDCH> P-O=W;F$'@C1\[9J(/UR+Z:?W@]/PW1:9PSY51J^WO.&I._YM3$
M&*GM=8;^:I0E<(W4G@.V0$H_SO.!.H !VO2"^?75![@S*-^)69R:^KS&-_2F
MO@$>N.4E?D-M[Z]5IDOOFV^N3T,NUXV6.=*!&IV3D=U0NV?5E7B!-XO\J#WJ
M*A_%D^14,RD*7BFQE>6BK,HB?<BK'4QT/?]PW3\OO^_'IRIS9*N]^P( J^D[
MP8P-+MCBG+]FH*MUZ;EQ^6_@:6[LOL,8YO=< 3'JQ ,0[ML(A798,JE\Q95X
M;U42ME'8/V14XW!N*B%=2P(A[/$*VR&"M';:[F33-=X5-]19L?!WKDN >,)!
MR2&P0+$^+9ZX!E.Z6^;2@=!71,0(G%9I(98!U3@(6*HWL,WL3F<;03DRIS1Z
M0'+7*&U10L0A ZI=HLOLJO?U?'[%8:%6C[QJM]+5^.^$T&HTL/JPXA,7JJ#"
MN0XK!G2Z.#^5/$F4]-8^X5J;,Z7.2TK&3\D %&5()XJ57#ATE?.F$>GG18%V
MO@\9M^8NT*FT!L3I_\D1D[NR&(,>_=0OG7(K0C)0DJ>&+ZR&/J*E@=#=+F>8
M ^* E,^9'O2N"D,0L_&655$_]#W'I,A$09ASO27%@ 267:&_]> W@-\4R0AZ
M\^MS/E7O5?ANP_1A?OW=J3I6TW3;^PJ'Y/3>S*^_.I7&!'R25GU/T!9HB7"N
M?P>9VHVL/(SZ<J[NL:C:.H=?-N44SN7R4(DXSIRK\V5.G3RYTBNAI;YCH%#7
MDIU+[TAU'_O&9=C?M% M,Q8V(0!ZR9XWU8K/>*S6V%0UTQ_CV'_?+>\DS9/=
M$J(76IEAI60MJ*J<1],.Y4!TR!!A+Y%<M*\6=R5^2"76F.ZJ[JMV#IJ3=XG:
M&G%5&X>%E'(/%;4_R^;1Z#K/Z0-5EU5'I1N$?D4F[+2<A+H0!06/UQDH:<!H
M'IA>4RN:%3E/60=C2S.EF-F[1>)A5=4S*<T</%SH&%?8(,"+^VUI$ZNJ'Z@[
MM8D!1@H-VB%TB[Q:[-8H1"Q4@43VL]9&(:7Z"_B-U(1%#T_Z(P+=0IT;##%D
M2=CI&]=MHC#&!6X[FH*X^H04+:725R1%<>!A#;!99&["GUJEVJL%(BN33U%O
M5='7 ?)9<&TIK [24&8 *O6Y8FUR*^IL[V4/\=:@,H_K)GB6;ID_U]#MA%"%
M+T91A7'6X#D52I4$VR86^BN;V:B>Z72%RFM@*(LNHT)31P\^K5>OJ,K!?_YN
M(U[,W_WQATR3QX8+FXH8J6)FJN09?!:V.ZLW;)'T/8*NP+J^QH!C*@=R$\5V
M542K5LC^(FMNP453A.HL\-1QL5H HU%A_Q.D).KBH5IM-*D">WH*-]3%,^EL
MN.\-.P'2:DI)$CG?4RZ:(.=L=9\\$[OUHKU\4H^ E2FMU>C;NO',DDVP1JHX
M#M"MN5J6(!:SX9K/Q3OO%1F,0 Y/2BB"[\&7C7XI+D%.IB$)!F03CA&&5ZZ_
M"]Z59_1M'Y.GSKFULG3-[7TL-_DB2.(QULITRZFY3Z)<J4G0I;GG(@/I^B0L
M!(/(4#X&S'U)0.:5<]D I[DST74J%ZY'MPBWRKYG;,SM:2ETBKJU6XTFL1!)
M*LB$(?%8$U8U^ 2ZX;26#:WU*9>Y5$,1UFU:4EM$J+T%N.@Z4)T*MRE9QF5*
M6GW$[36Z'0D)L %IE8L7>9]*Q'(-.#));Z5A.:*GKA7KO0K<1E6G\MC3Y+:/
MWVFN@-%=NHB5=M-)$VE1N+V=:$G<M+\ &>E)#-!6>6!W':H1.!?(, H0MB-?
M;!5).$[V6VJ72S/=;.J_(?A-'[NE7(+26U#D02W&IJ_+<LD)*H4T;Y4O5.O+
M/DJ]UZKEI;I0H\$IEFT%66IMU?JQ+C"BT>5:U60DF)Q3_9M+51F"C.WGJW*W
ME*:<^)J=6$E^KTL,4E/!]RK>M7DI!:UKT\R$<D/=Z1N]3ZCN,/%]%&ZY="#K
M"[AIM ;J/I\]NFZE,#F[(!%WL1>>FW:]SQ:1[/2%:&IYE3;6E5AG( =)G-\O
M@'?'4/S@#1GMJ)M[2?^&U'[%T9++HMR)/8G]5(*X$C].N(PGQ$*K)A_9EMZ_
M 7JA K@$LIR\8^JG(\28IKB)=&@ HTQCDYZ#.]P!_5J&CJ2OLL$4T&Z))M/N
M9;&UWK(C?S^!R&$FI7OV<Q$!N^G3K),,S/I1' :..U:N]&2(5_H:+TU^^Z00
MKGFC[1?;MW!=HBRLBY.1DX5T)S81:7$GI$#:5#S3R'OLHI_*EF19_W7V+49^
M*I,,\3"L(RH%&3XA$Q1+F;5F6_YN+EF'DNDSHN8X=2O[+HXDB8<:$9K[ILN[
MG:E"<J:(G'+VJ;M;H@7,.F[WHJ)^Q2WG7F80L/!!DIIDC>W"*C_9POJ1A)&6
M??6"G=<PW-RB1U@BGZB_VH^1LZ[U%GQ6UD9,36U"=-EY3;.Q*DS3(?N0DOPO
M@.&1[D8T*'I]B<_U(&)M=EGME<GRT6:A^?+O.]6:?EYC6Y\=Q9:8.JY*4WVU
M-XHF&82CR8C<D..8''SX$8;&[ FHB2?4AKM''DS\8Z0*-7O:RD2C23@=36&"
M64R9&I-P/!ZSRY?- Z944B\:<IP0/ =/TY_C(48FLW8E@ZIR].$T'E"IX2CB
MBL.S!'^AH6^RVY(Z+9'CFV>RKSK[7;&C]FD /_BO 0ZG?:+\V6AB/<%^VK;7
M]!@'H\^SJKRIRK5GO*N'D,.+%((P!CG:@?\=V&)IXXZC6D/@!&'0\%;OZP<^
M"9,8#QW/?$*MU??TKQ>5)Z&2P4-L<IZ,.IH*M K2:J]H. 9LX)^OE8FD57QY
M-!H$/?QA8+ZOJ8 ^%\"UX921C']AA+2?'4Z'H$E. $X1P9 L%>UBVQ:D ;^3
M<!8C>'O)D'%XR'T1[>++UAO'59C6A;"3,?UW9;6SW/-:+QI0+A7\5"/H??1D
M(Z<F3 CD**\UIT?PP?W$L^287 J3A:)),-YO99C3-D1?E=W2X[@W)I!GE5YW
MJOL"T>3989>^ L 8H6&\^E1*%YM73"0B<3S%D$)X[Z] ?Q8IH&4\&0!F8-(%
M7-5/Z)T?P>&$8_B(42D:C1KQD&XM804.K*P]'&$QZ6@81M'(9^(R_0?F5@\$
MGL<U@;'$YF.O;A\#NY>"SS:F;5%'AN3LKTS^G;&.?4WV#U!B52!4'V;I7Z>
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M?S1%D=G\U^+2Y]]_<3W_WFSWX / EK_;P$6'WX3%O^"5$&GQ.M^M$?5*C!:
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M:TPW00X97L-,'&WL')7AP^1(_IW3?;LUX!._U1!"N=]4;B$^5?*2O(,5/@@
M44WZ]Y46F$I9"AVXS3;(4;3R8UC%XO%YX>,%.+U%56)L7L0,"2K7PJ1VJA/
MX**-D,?)93EKUNX50'AVYR6)<\J89[OAF;(J>"&P*<TC$MLT+4K!F_(#+P#[
M[%0YQXC>(#Q+"!^#XLG8$.+1TMFJZ1'[M6I=5NV:]2%!I>IEBJ")#^43](ZI
ML3")_Z&T!AH/DWC1L8B8]&*D 3$I]:P['B9Q'<Z@8/+31G/K"EXN+;2IC6Q6
MI:UM8$@&?,-"#$^9V"^KT%LC<BY%%ZF#$G@0OT ^NTJ.7(!68S%=_@I7YSWW
MFM49W /N$.,S\Q!-WA7&#&"$OA2-+NAOX<T$?=2N-<OYLM9B&)[Q](L^P+S(
M82;>E^\A\.7;>E\^0(H9N/'7A_W'C0;J0[K>+%O#:,'P7_1P?S.[(Z>G0<B%
M2P.W)]!J03H-I,^W7D?4/U'Q?VL Q2_:F*/6OD-@Q?)H=F<#-1Q64H8!CIUF
MD\9 0F+O(;S3+<<[QBDRZC3]H)[;L+/#3AWPH S$!?V'NQW '75VKR(H%Q09
M6, I.((VZP]#N..TW\5E?!5!,J^KK:._V5$P93ZBW,H(@*!50]<!YDIY$3K.
MXN@-JY]T"!5@MQ6;\O5!,)I$KO5F6>#+X>?6"9\N0OF^+->-DCPKF%NR$FPR
M"](7#2<(8P,G@*"<\[PT[B[B0WWK\NNM!_A8T/J%WM7^3L?LC!@1JW5+$:H8
MP9N"K@;!<Z%SRY_IVG&.8>^%G*2H;H+.>:H-3U5GF_,9AB-X1,AM&"2!" !
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MZ#.$SX:C[WNI6]BI[YIF__?_ 5!+ P04    " !Y@*=08E=I:U@"  !>#
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M4QC7GO,BO]',_QR_NT@S/X.Z.13%A6N[EI>*^_;J&"_?>)[]!%!+ P04
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ME\^K_Y\N4_]$A'E%>?X-4$L#!!0    ( 'F IU#>GY_G\@$   8F   3
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M1Y1U/.:=:?K?DCQ9N_Z<S\:_?RW> %!+ 0(4 Q0    ( 'F IU ?(\\#P
M !,"   +              "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M 'F IU GZ(<.@@   +$    0              "  >D   !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ >8"G4#TNF^;O    *P(  !$
M ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ >8"G4)E<G",0
M!@  G"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !Y@*=09%I"FC0#   [#P  &               @ 'X"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ >8"G4 65W;QL
M!   )!4  !@              ( !8@P  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( 'F IU!]GZ'(10(  ,0'   8              "
M 001  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !Y@*=0
MR6?LY 8$  !Z$0  &               @ %_$P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ >8"G4(K%(C64 @  E0@  !@
M     ( !NQ<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M 'F IU#HS_T*V0$  &$$   8              "  84:  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " !Y@*=0HAGMFJ<$  "7%0  &
M            @ &4'   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ >8"G4#YKC*:[ 0  U0,  !@              ( !<2$  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( 'F IU"C/<"Z5P4  %H9
M   8              "  6(C  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " !Y@*=07%0,"K(!  #2 P  &0              @ 'O*
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( 'F IU#%$=!4
MM $  -(#   9              "  =@J  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ >8"G4+_%Q_"U 0  T@,  !D
M ( !PRP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !Y
M@*=07 _H^K4!  #2 P  &0              @ &O+@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( 'F IU""F*;1LP$  -(#   9
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M970Q."YX;6Q02P$"% ,4    " !Y@*=087)LQK4!  #2 P  &0
M    @ $[.@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M 'F IU 0Y"(2M0$  -(#   9              "  2<\  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ >8"G4/C67D&Q 0  T@,  !D
M             ( !$SX  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " !Y@*=0RW"-,[4!  #2 P  &0              @ '[/P  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( 'F IU >?C=-Y $
M   %   9              "  >=!  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ >8"G4*;NHE+A 0   04  !D              ( !
M D0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !Y@*=0
MLJ:#S\8!   W!   &0              @ $:1@  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( 'F IU"%0F1$SP$  )P$   9
M      "  1=(  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ >8"G4)#[& '. 0  G 0  !D              ( !'4H  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !Y@*=0N15=/]\!   !!0
M&0              @ $B3   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( 'F IU#R9.N;W $   $%   9              "  3A.  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ >8"G4,'/$P3#
M 0  -P0  !D              ( !2U   'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " !Y@*=0 F9M*;<!  #7 P  &0
M@ %%4@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( 'F
MIU![H5G@L04  %0>   9              "  3-4  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ >8"G4%/9Z(H( P  VPL  !D
M         ( !&UH  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " !Y@*=0,#7^L*T"  #N"   &0              @ %:70  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( 'F IU#!,"4\<P(  *H(
M   9              "  3Y@  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ >8"G4!\=F3=X @  0P@  !D              ( !Z&(
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !Y@*=0E6()
M MP$   D'P  &0              @ &790  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( 'F IU W 4C.) 8  # E   9
M  "  :IJ  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M>8"G4!KE+=88!0  LAL  !D              ( !!7$  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " !Y@*=0)?M\S&P#   X#P  &0
M            @ %4=@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( 'F IU#*-WQ;$ ,  $\.   9              "  ?=Y  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ >8"G4$)FE^O5 P
MT!(  !D              ( !/GT  'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " !Y@*=01KTN#:$%  ##(0  &0              @ %*
M@0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( 'F IU!L
M;1+^!@(  *@%   9              "  2*'  !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ >8"G4$!>9\]U P  W!   !D
M     ( !7XD  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'F IU!=.2K89 (  +8'   9              "
M 0*:  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ >8"G
M4$ Y#ZVJ @  5 D  !D              ( !G9P  'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " !Y@*=0:N^*X*X"  "9"@  &0
M        @ %^GP  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( 'F IU!O*/[+V@$   P%   9              "  6.B  !X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ >8"G4+9BJY5+!   [Q,
M !D              ( !=*0  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " !Y@*=0YP<!4]H!  #\!   &0              @ 'VJ
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( 'F IU!QWN%Z
M80,  $<0   9              "  0>K  !X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ >8"G4&OFMZO2 P  \!   !D
M ( !GZX  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !Y
M@*=0%LMVC6\"  #2!P  &0              @ &HL@  >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( 'F IU#A*:SG/ (  !('   9
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M970V,RYX;6Q02P$"% ,4    " !Y@*=0L%;K='4"   X"   &0
M    @ '7P0  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M 'F IU#C\RTHLGP  #<8 @ 4              "  8/$  !X;"]S:&%R9613
M=')I;F=S+GAM;%!+ 0(4 Q0    ( 'F IU!B5VEK6 (  %X,   -
M      "  6=! 0!X;"]S='EL97,N>&UL4$L! A0#%     @ >8"G4-I7HTSQ
M!   9RH   \              ( !ZD,! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( 'F IU"WT,(/* (  *4F   :              "  0A) 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( 'F IU#>GY_G\@$
M  8F   3              "  6A+ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !) $D \1,  (M- 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6759288448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 10,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">16,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">16,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">16,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">17,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">118,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">195,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="num">(83,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">112,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">4,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">5,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">6,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">6,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">6,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">264,156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">293,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="num">(254,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 38,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810743344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 05, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Total consideration recorded as a result of stock option exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to non-vested stock-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of cost expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member', window );">Stock Option And Incentive Plan 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized', window );">Annual percentage of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember', window );">Service-Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Stock Option and Grant Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares)</a></td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price at which shares are sold, percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Minimum percentage of compensation through payroll deductions</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of compensation through payroll deductions</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum shares to be purchased during purchase period (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum value of shares to be purchased during purchase period | $</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Service-Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Service-Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionAndGrantPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionAndGrantPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_EmployeeStockPurchasePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_EmployeeStockPurchasePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6625687184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business</a></td>
<td class="text">Description of the Business<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a clinical stage biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since inception, we have incurred significant net losses. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$1.62 billion</span></span><span style="font-family:inherit;font-size:10pt;">. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, we anticipate that our expenses will increase significantly in connection with our ongoing activities to support our platform research, drug discovery and clinical development, infrastructure and Research Engine and Early Development Engine, digital infrastructure, creation of a portfolio of intellectual property, expansion into global markets, and administrative support.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not expect to generate significant revenue from sales of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for any of our investigational medicines, we expect to incur significant commercialization expenses. Our investigational vaccine against the novel coronavirus (mRNA-1273), which is currently in clinical trials, has been developed rapidly to respond to the global pandemic. We are expending significant efforts to further the rapid development of this potential vaccine and expect to continue to do so over the next 12 months. These efforts will require the expenditure of significant additional funds and the establishment of significant additional worldwide infrastructure and partnerships. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from potential mRNA medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs. We believe that our cash, cash equivalents, and investments as of&#160;</span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of our financial statements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our medicines, including mRNA-1273, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6647118416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Investments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize our cash and available-for-sale securities by significant investment category at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,659</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214,028</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,021</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,007</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,162,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,099</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,213</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,156,052</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>637,634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>418,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,725,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,720,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>825,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,902</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,149</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>834,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>836,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>687,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149,122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,259,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,262,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235,876</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>867,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amortized cost and estimated fair value of marketable securities by contractual maturity at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>826,449</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>825,981</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>506,983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,479</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,333,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,328,460</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive (loss) income, net of applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any credit losses related to available-for-sale securities for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 months or more</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,213</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>709,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>709,128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>724,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>724,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,822</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,822</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we held&#160;237&#160;and 19 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821119088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (124,230)<span></span>
</td>
<td colspan="2" class="num">$ (132,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">20,413<span></span>
</td>
<td colspan="2" class="nump">18,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,449<span></span>
</td>
<td colspan="2" class="nump">7,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization/accretion of investments</a></td>
<td class="nump">515<span></span>
</td>
<td colspan="2" class="num">(1,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">137<span></span>
</td>
<td colspan="2" class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(585)<span></span>
</td>
<td colspan="2" class="nump">6,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from related party</a></td>
<td class="num">(1,346)<span></span>
</td>
<td colspan="2" class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(4,305)<span></span>
</td>
<td colspan="2" class="nump">3,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases', window );">Right-of-use assets, operating leases</a></td>
<td class="num">(14,119)<span></span>
</td>
<td colspan="2" class="nump">1,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,331<span></span>
</td>
<td colspan="2" class="nump">1,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(12,953)<span></span>
</td>
<td colspan="2" class="num">(32,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(474)<span></span>
</td>
<td colspan="2" class="num">(15,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">15,244<span></span>
</td>
<td colspan="2" class="num">(1,848)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">5,732<span></span>
</td>
<td colspan="2" class="nump">811<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(106,191)<span></span>
</td>
<td colspan="2" class="num">(144,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(621,257)<span></span>
</td>
<td colspan="2" class="num">(429,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">269,733<span></span>
</td>
<td colspan="2" class="nump">403,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">41,729<span></span>
</td>
<td colspan="2" class="nump">21,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,223)<span></span>
</td>
<td colspan="2" class="num">(7,595)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(316,018)<span></span>
</td>
<td colspan="2" class="num">(11,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">549,455<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock through equity plans, net</a></td>
<td class="nump">28,357<span></span>
</td>
<td colspan="2" class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChargesToFinancingLeaseLiabilities', window );">Charges to financing lease obligation</a></td>
<td class="nump">241<span></span>
</td>
<td colspan="2" class="nump">236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">578,053<span></span>
</td>
<td colspan="2" class="nump">293<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">155,844<span></span>
</td>
<td colspan="2" class="num">(155,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">247,699<span></span>
</td>
<td colspan="2" class="nump">670,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">403,543<span></span>
</td>
<td colspan="2" class="nump">514,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 6,610<span></span>
</td>
<td colspan="2" class="nump">$ 14,127<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChargesToFinancingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges To Financing Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChargesToFinancingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Right Of Use Asset, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6822492128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Moderna, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3467528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Technology Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">714-6500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,223,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6819329472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (124,230)<span></span>
</td>
<td colspan="2" class="num">$ (132,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale debt securities, net of tax of $0 and $540, respectively</a></td>
<td class="num">(7,610)<span></span>
</td>
<td colspan="2" class="nump">1,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: amounts recognized for net realized (gain) loss included in net loss</a></td>
<td class="num">(321)<span></span>
</td>
<td colspan="2" class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive (loss) income</a></td>
<td class="num">(7,931)<span></span>
</td>
<td colspan="2" class="nump">1,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (132,161)<span></span>
</td>
<td colspan="2" class="num">$ (130,665)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816191168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February&#160;28, 2018 and May&#160;7,&#160;2018, the Board of Directors approved an amendment to our Certificate of Incorporation resulting in a total of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>775,000,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock and a total of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>509,352,795</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of redeemable convertible preferred stock being authorized, respectively. Upon completion of our IPO, our authorized capital stock consists of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>1,600,000,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock, par value&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$0.0001</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share, and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>162,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock, par value&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$0.0001</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share, all of which shares of preferred stock are undesignated.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 11, 2018, we completed our IPO, whereby we sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>26,275,993</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$23.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share. The aggregate net proceeds received by us from the IPO were&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$563.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$33.2 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;payable by us. Upon the closing of the IPO, all outstanding shares of our redeemable convertible preferred stock were converted into&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>236,012,913</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of the common stock. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On February 14, 2020, we sold&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>26,315,790</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock at a price of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$19.00</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share through a public equity offering. The aggregate net proceeds from the offering were&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$477.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of underwriting discounts, commissions and estimated offering expenses. In addition, the underwriters exercised their option to purchase an additional&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>3,947,368</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock at the public offering price less the underwriting discount, resulting in additional net proceeds of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$71.8 million</span></span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6829594448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Remaining Performance Obligation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 278.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">213.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | Clinical Supply Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | PCV Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">206.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember', window );">PCV/SAV Agreement | KRAS Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">60.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise | Fixed Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise | Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise | Variable Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise | Sublicense Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member', window );">2016 VEGF Exercise | Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">399.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">240.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">106.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Variable Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">159.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Estimated Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Sublicense Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Milestone Payments | Toxicity Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Milestone Payments | Competition Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Combined 2018 AZ Agreement Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">293.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | IL12 Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Oncology Development Target Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Development And Commercialization License And Manufacturing Obligations For IL12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">88.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember', window );">Combined 2018 AZ Agreements | Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">$ 35.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember', window );">2019 Vertex Agreement | Research And Development Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 31.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ClinicalSupplyReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ClinicalSupplyReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PerformanceObligationAxis=mrna_PCVPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PerformanceObligationAxis=mrna_PCVPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PerformanceObligationAxis=mrna_KRASPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PerformanceObligationAxis=mrna_KRASPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_FixedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_FixedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_OptionExerciseFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_OptionExerciseFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_SublicenseReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_SublicenseReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_EstimatedReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_EstimatedReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_ToxicityMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_ToxicityMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CompetitionMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CompetitionMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PerformanceObligationAxis=mrna_Combined2018AZAgreementPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PerformanceObligationAxis=mrna_Combined2018AZAgreementPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PerformanceObligationAxis=mrna_OncologyDevelopmentTargetPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PerformanceObligationAxis=mrna_OncologyDevelopmentTargetPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ResearchAndDevelopmentFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ResearchAndDevelopmentFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816279792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,640,874<span></span>
</td>
<td class="nump">$ 1,442,325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,174,810<span></span>
</td>
<td class="nump">$ 1,530,241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(7,931)<span></span>
</td>
<td class="nump">1,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">1,640,874<span></span>
</td>
<td class="nump">1,442,325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="num">(6,127)<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,804<span></span>
</td>
<td class="num">$ (1,320)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(7,931)<span></span>
</td>
<td class="nump">1,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="num">(6,127)<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gain on Available-for-Sale Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">$ (7,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810135168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#444444;">On April 16, 2020, we entered into an agreement for a commitment of up to&#160;</span><span style="font-family:inherit;font-size:10pt;color:#444444;"><span>$483 million</span></span><span style="font-family:inherit;font-size:10pt;color:#444444;">&#160;from the&#160;Biomedical Advanced Research and Development Authority&#160;(BARDA), a division of the&#160;Office of the Assistant&#160;Secretary for Preparedness and Response (</span><span style="font-family:inherit;font-size:10pt;color:#555555;">ASPR</span><span style="font-family:inherit;font-size:10pt;color:#444444;">) within the&#160;U.S. Department of Health and Human Services&#160;(HHS), to accelerate development of our mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2). Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;color:#444444;">On May 1, 2020, we entered into a </span><span style="font-family:inherit;font-size:10pt;color:#444444;"><span>10</span></span> year strategic collaboration agreement with&#160;Lonza Ltd. to enable larger scale manufacture of our mRNA vaccine candidate mRNA-1273 against the SARS-CoV-2 and additional&#160;Moderna&#160;products in the future. Under the terms of the agreement, we plan to establish manufacturing suites at Lonza&#8217;s facilities in&#160;the United States&#160;and&#160;Switzerland&#160;for the manufacture of mRNA-1273 at both sites.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6816285072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash and Available-for-Sale Securities by Significant Investment Category</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize our cash and available-for-sale securities by significant investment category at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,659</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214,028</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,021</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,007</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,162,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,099</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,213</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,156,052</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>637,634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>418,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,725,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,720,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>825,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,902</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,149</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>834,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>836,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>687,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149,122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,259,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,262,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235,876</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>867,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amortized cost and estimated fair value of marketable securities by contractual maturity at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>826,449</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>825,981</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>506,983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>502,479</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,333,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,328,460</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Unrealized Loss on Investments</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 months or more</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,213</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>709,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>709,128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>724,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>724,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,822</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,822</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6623912992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 303,854<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(101,788)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(94,584)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">202,066<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">201,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,449<span></span>
</td>
<td colspan="2" class="nump">$ 7,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">109,283<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">108,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">152,306<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">152,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">3,364<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">3,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">12,347<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">11,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internally developed software</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">7,020<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">7,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_RightOfUseAssetFinancingMember', window );">Right-of-use asset, financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">9,853<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">9,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 9,681<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,222<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family:inherit;font-size:10pt;">Restated to conform to ASC 842. See accompanying Note 2.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_RightOfUseAssetFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_RightOfUseAssetFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6830059408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,333,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,725,109<span></span>
</td>
<td class="nump">$ 1,259,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">3,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7,424)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,720,180<span></span>
</td>
<td class="nump">1,262,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">391,720<span></span>
</td>
<td class="nump">235,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">825,981<span></span>
</td>
<td class="nump">867,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">502,479<span></span>
</td>
<td class="nump">159,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">281,583<span></span>
</td>
<td class="nump">225,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">281,583<span></span>
</td>
<td class="nump">225,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">281,583<span></span>
</td>
<td class="nump">225,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">68,659<span></span>
</td>
<td class="nump">82,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">68,517<span></span>
</td>
<td class="nump">82,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,001<span></span>
</td>
<td class="nump">10,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">47,326<span></span>
</td>
<td class="nump">69,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,190<span></span>
</td>
<td class="nump">2,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">212,701<span></span>
</td>
<td class="nump">117,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">214,028<span></span>
</td>
<td class="nump">118,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">141,021<span></span>
</td>
<td class="nump">110,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">73,007<span></span>
</td>
<td class="nump">7,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,162,166<span></span>
</td>
<td class="nump">834,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7,213)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,156,052<span></span>
</td>
<td class="nump">836,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">100,136<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">637,634<span></span>
</td>
<td class="nump">687,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 418,282<span></span>
</td>
<td class="nump">$ 149,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761210400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 20,413<span></span>
</td>
<td class="nump">$ 18,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">12,036<span></span>
</td>
<td class="nump">10,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">8,377<span></span>
</td>
<td class="nump">7,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">18,018<span></span>
</td>
<td class="nump">17,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember', window );">Restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
